{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "0510dde8-b6f1-4e11-86a4-ab6eb8362788",
   "metadata": {},
   "source": [
    "\n",
    "# 5 Levels Of Text Splitting"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b4ef84a6-5fbf-442e-9808-ed9fe55cfab8",
   "metadata": {},
   "source": [
    "Level 1: Character Splitting - Simple static character chunks of data\n",
    "\n",
    "Level 2: Recursive Character Text Splitting - Recursive chunking based on a list of separators\n",
    "\n",
    "Level 3: Document Specific Splitting - Various chunking methods for different document types (PDF, Python, Markdown)\n",
    "\n",
    "Level 4: Semantic Splitting - Embedding walk based chunking\n",
    "\n",
    "Level 5: Agentic Splitting - Experimental method of splitting text with an agent-like system. Good for if you believe that token cost will trend to $0.00\n",
    "\n",
    "*Bonus Level:* Alternative Representation Chunking + Indexing - Derivative representations of your raw text that will aid in retrieval and indexing\n",
    "Notebook resources:"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "cd68e8a9-dd9e-40a5-91f6-f4acef979ea4",
   "metadata": {},
   "source": [
    "# Level 1: Character Splitting\n",
    "Character splitting is the most basic form of splitting up your text. It is the process of simply dividing your text into N-character sized chunks regardless of their content or form.\n",
    "\n",
    "This method isn't recommended for any applications - but it's a great starting point for us to understand the basics.\n",
    "\n",
    "Pros: Easy & Simple\n",
    "Cons: Very rigid and doesn't take into account the structure of your text\n",
    "Concepts to know:\n",
    "\n",
    "Chunk Size - The number of characters you would like in your chunks. 50, 100, 100,000, etc.\n",
    "Chunk Overlap - The amount you would like your sequential chunks to overlap. This is to try to avoid cutting a single piece of context into multiple pieces. This will create duplicate data across chunks.\n",
    "First let's get some sample text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "2b8fef93-f2a8-4ccd-9b0a-b5007181c1fb",
   "metadata": {},
   "outputs": [],
   "source": [
    "import fitz  # PyMuPDF\n",
    "\n",
    "# Open the PDF file\n",
    "with fitz.open(\"ilovepdf_merged.pdf\") as pdf_file:\n",
    "    document = \"\"\n",
    "    for page in pdf_file:\n",
    "        document += page.get_text()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "fa04a27e-a459-43e1-8583-c42b03a9f795",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "283658"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(document)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "98d21773-e590-4ce6-aa37-a476ce8771e6",
   "metadata": {},
   "outputs": [],
   "source": [
    "text=document"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "6e15bb94-cd2e-45ea-9ac1-04cec03e166c",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Explor Target Antitumor Ther. 2024;',\n",
       " '5:232–50 | https://doi.org/10.37349',\n",
       " '/etat.2024.00215\\nPage 232\\n© The Aut',\n",
       " 'hor(s) 2024. This is an Open Access',\n",
       " ' article licensed under a Creative ',\n",
       " 'Commons Attribution 4.0 Internation',\n",
       " 'al \\nLicense (https://creativecommon',\n",
       " 's.org/licenses/by/4.0/), which perm',\n",
       " 'its unrestricted use, sharing, adap',\n",
       " 'tation, distribution \\nand reproduct',\n",
       " 'ion in any medium or format, for an',\n",
       " 'y purpose, even commercially, as lo',\n",
       " 'ng as you give appropriate credit t',\n",
       " 'o the \\noriginal author(s) and the s',\n",
       " 'ource, provide a link to the Creati',\n",
       " 've Commons license, and indicate if',\n",
       " ' changes were made.\\nExploration of ',\n",
       " 'Targeted Anti-tumor Therapy\\nOpen Ac',\n",
       " 'cess\\nReview\\nEarly-stage triple nega',\n",
       " 'tive breast cancer: the therapeutic',\n",
       " ' role of \\nimmunotherapy and the pro',\n",
       " 'gnostic value of pathological compl',\n",
       " 'ete \\nresponse\\nPierluigi De Santis1,',\n",
       " ' Martina Perrone1, Chiara Guarini1,',\n",
       " ' Anna Natalizia Santoro1, Carmelo L',\n",
       " 'aface1, \\nDaniela Carrozzo1, Gaia Ra',\n",
       " 'chele Oliva2, Palma Fedele1*\\n1Oncol',\n",
       " 'ogy Unit, Francavilla Fontana Cegli',\n",
       " 'e Messapica Hospital District, 7202',\n",
       " '1 Francavilla Fontana, Italy\\n2Depar',\n",
       " 'tment of Medicine and Translational',\n",
       " ' Surgery, Università Cattolica del ',\n",
       " 'Sacro Cuore, 00168 Roma, Italy\\n*Cor',\n",
       " 'respondence: Palma Fedele, Oncology',\n",
       " ' Unit, Francavilla Fontana Ceglie M',\n",
       " 'essapica Hospital District, 72021 F',\n",
       " 'rancavilla \\nFontana, Italy. minafed',\n",
       " 'ele@hotmail.com\\nAcademic Editor: La',\n",
       " 'ura Cerchia, Institute of Experimen',\n",
       " 'tal Endocrinology and Oncology “G. ',\n",
       " 'Salvatore”-National Research \\nCounc',\n",
       " 'il (IEOS-CNR), Italy; Simona Camora',\n",
       " 'ni, Institute of Experimental Endoc',\n",
       " 'rinology and Oncology “G. Salvatore',\n",
       " '”-National \\nResearch Council (IEOS-',\n",
       " 'CNR), Italy\\nReceived: May 26, 2023 ',\n",
       " ' Accepted: December 26, 2023  Publi',\n",
       " 'shed: February 28, 2024\\nCite this a',\n",
       " 'rticle: De Santis P, Perrone M, Gua',\n",
       " 'rini C, Santoro AN, Laface C, Carro',\n",
       " 'zzo D, et al. Early-stage triple ne',\n",
       " 'gative breast \\ncancer: the therapeu',\n",
       " 'tic role of immunotherapy and the p',\n",
       " 'rognostic value of pathological com',\n",
       " 'plete response. Explor Target \\nAnti',\n",
       " 'tumor Ther. 2024;5:232–50. https://',\n",
       " 'doi.org/10.37349/etat.2024.00215\\nAb',\n",
       " 'stract\\nTriple negative breast cance',\n",
       " 'r (TNBC) represents an aggressive d',\n",
       " 'isease associated with a high risk ',\n",
       " 'of \\nrecurrence after curative treat',\n",
       " 'ment and a poor prognosis in the me',\n",
       " 'tastatic setting. Chemotherapy was ',\n",
       " 'for \\nyears the only treatment avail',\n",
       " 'able in the early and metastatic se',\n",
       " 'tting, due to the lack of actionabl',\n",
       " 'e targets. \\nClinical practice has c',\n",
       " 'hanged following the results obtain',\n",
       " 'ed with the addition of immunothera',\n",
       " 'py to \\nstandard chemotherapy, the d',\n",
       " 'evelopment of novel drugs [i.e. ant',\n",
       " 'ibody-drug conjugates (ADCs)], and ',\n",
       " 'the \\nuse of targeted treatments for',\n",
       " ' patients carrying germline pathoge',\n",
       " 'nic breast cancer susceptibility ge',\n",
       " 'nes \\n(BRCA) 1 or BRCA 2 variants. T',\n",
       " 'he treatment of early-stage disease',\n",
       " ' has had a shift in clinical practi',\n",
       " 'ce since \\nJuly 2021, after the Food',\n",
       " ' and Drug Administration (FDA) appr',\n",
       " 'oval of pembrolizumab in associatio',\n",
       " 'n with \\nchemotherapy as neoadjuvant',\n",
       " ' treatment for TNBC and as a single',\n",
       " ' agent in the subsequent adjuvant s',\n",
       " 'etting. \\nThis intensive treatment b',\n",
       " 'ased on the combination of a poly-c',\n",
       " 'hemotherapy and an immune checkpoin',\n",
       " 't \\ninhibitor (ICI) led to the impro',\n",
       " 'vement of short- and long-term outc',\n",
       " 'omes, but it has highlighted some n',\n",
       " 'ew \\nunmet clinical needs in the tre',\n",
       " 'atment of early-stage TNBC: the sel',\n",
       " 'ection of the most effective adjuva',\n",
       " 'nt \\ntherapy and the integration of ',\n",
       " 'pembrolizumab with other therapeuti',\n",
       " 'c strategies [capecitabine, poly(AD',\n",
       " 'P-\\nribose) polymerase (PARP) inhibi',\n",
       " 'tors] based on the achievement of p',\n",
       " 'athologic complete response (pCR); ',\n",
       " '\\nthe identification of predictive b',\n",
       " 'iomarkers to select patients who co',\n",
       " 'uld most benefit from the addition ',\n",
       " 'of \\nICI, to minimize toxicities and',\n",
       " ' to maximize outcomes; the possibil',\n",
       " 'ity of de-escalating chemotherapy i',\n",
       " 'n favor \\nof immune-combo or novel a',\n",
       " 'gents, such as ADCs; the role of im',\n",
       " 'munotherapy in estrogen receptor (E',\n",
       " 'R)-low \\npatients. The advent of imm',\n",
       " 'unotherapy not only addresses curre',\n",
       " 'nt challenges in TNBC treatment but',\n",
       " ' also \\nholds the promise of a radic',\n",
       " 'al transformation in its therapeuti',\n",
       " 'c paradigm, enhancing significantly',\n",
       " ' clinical \\noutcomes and offering ne',\n",
       " 'w perspectives for patients grappli',\n",
       " 'ng with this aggressive form of bre',\n",
       " 'ast cancer.\\nExplor Target Antitumor',\n",
       " ' Ther. 2024;5:232–50 | https://doi.',\n",
       " 'org/10.37349/etat.2024.00215\\nPage 2',\n",
       " '33\\nKeywords\\nTriple negative breast ',\n",
       " 'cancer, immunotherapy, pathological',\n",
       " ' complete response, neoadjuvant com',\n",
       " 'bination \\ntreatment, adjuvant treat',\n",
       " 'ment\\nIntroduction\\nTriple negative B',\n",
       " 'reast Cancer (TNBC) is a histologic',\n",
       " 'al subtype of breast cancer (BC) ch',\n",
       " 'aracterized by the \\nimmunohistochem',\n",
       " 'ical lack of expression (< 1%) of e',\n",
       " 'strogen receptor (ER), progesterone',\n",
       " ' receptor (PgR), \\nand human epiderm',\n",
       " 'al growth factor receptor 2 (HER2).',\n",
       " ' It accounts for approximately 10–2',\n",
       " '0% of all BC, \\naffecting mainly you',\n",
       " 'ng, premenopausal women, and indivi',\n",
       " 'duals with inherited gene alteratio',\n",
       " 'ns, such as BC \\nsusceptibility gene',\n",
       " 's 1/2 (BRCA 1/2) mutations [1–3]. I',\n",
       " 't notably presents an aggressive bi',\n",
       " 'ological behavior \\nwith a trend to ',\n",
       " 'have a higher grade and an often ly',\n",
       " 'mph node involvement at diagnosis, ',\n",
       " 'an inclination to \\nmetastasize afte',\n",
       " 'r curative treatment, and a poorer ',\n",
       " 'prognosis in metastatic setting whe',\n",
       " 'n compared with \\nother BC subtypes ',\n",
       " '[4, 5].\\nFor decades, treatment for ',\n",
       " 'early TNBC has been based on surger',\n",
       " 'y and subsequent adjuvant \\nchemothe',\n",
       " 'rapy (CHT) for the reduction of dis',\n",
       " 'ease recurrence [6]. Therefore, con',\n",
       " 'ventional cytotoxic CHT has \\nrepres',\n",
       " 'ented the backbone of systemic trea',\n",
       " 'tment in the early TNBC, including ',\n",
       " 'neoadjuvant treatment, which \\nused ',\n",
       " 'to reduce tumor size in larger tumo',\n",
       " 'rs increasing the chances of a brea',\n",
       " 'st-conserving surgery [7, 8]. In \\nr',\n",
       " 'ecent years the development of nove',\n",
       " 'l therapeutic approaches has been d',\n",
       " 'ifficult, due to the heterogeneity ',\n",
       " '\\nof TNBC and lack of therapeutic ta',\n",
       " 'rgets [9, 10]. Nevertheless, immuno',\n",
       " 'therapy and poly(ADP-ribose) \\npolym',\n",
       " 'erase (PARP) inhibitors have shown ',\n",
       " 'survival benefits in recent studies',\n",
       " '.\\nSpecifically, combinations of imm',\n",
       " 'une checkpoint inhibitors (ICIs) wi',\n",
       " 'th CHT or other alternative \\ntherap',\n",
       " 'eutic compounds could emerge as a s',\n",
       " 'uccessful therapeutic approach in t',\n",
       " 'he management of TNBC \\npatients. De',\n",
       " 'spite the progress in ICIs represen',\n",
       " 'ting a notable milestone in TNBC tr',\n",
       " 'eatment, additional \\ninvestigations',\n",
       " ' are necessary to tackle this issue',\n",
       " ' comprehensively. A profound compre',\n",
       " 'hension of tumor \\nsubtypes, alongsi',\n",
       " 'de tumor microenvironment (TME) and',\n",
       " ' in terms of molecular, genetic, an',\n",
       " 'd immune \\naspects, would amplify th',\n",
       " 'e potential for developing targeted',\n",
       " ' immunotherapy to achieve superior ',\n",
       " '\\ntherapeutic effectiveness, especia',\n",
       " 'lly in TNBC [11].\\nTherefore, in thi',\n",
       " 's review, we aimed to investigate t',\n",
       " 'he role of immunotherapy in early-s',\n",
       " 'tage TNBC, the \\nprognostic value of',\n",
       " ' pathologic complete response (pCR)',\n",
       " ' with its therapeutic implications,',\n",
       " ' and the future \\nperspectives regar',\n",
       " 'ding the systemic treatment of earl',\n",
       " 'y TNBC, including the discovery of ',\n",
       " 'new biomarkers.\\nThe landscape of im',\n",
       " 'munotherapy in TNBC\\nThe immune syst',\n",
       " 'em plays a crucial role in TNBC com',\n",
       " 'pared to the other molecular subtyp',\n",
       " 'es of BC. Although \\noriginally BC w',\n",
       " 'as considered non-immunogenic, TNBC',\n",
       " ' has a high immunogenic potential, ',\n",
       " 'making it a \\npromising candidate fo',\n",
       " 'r immunotherapy, especially with IC',\n",
       " 'Is [12, 13]. TNBC immunogenicity is',\n",
       " ' related to \\nintrinsic tumor cell s',\n",
       " 'ignatures and tumoral surrounding m',\n",
       " 'icroenvironment features.\\nOver the ',\n",
       " 'last decades thanks to emerging tec',\n",
       " 'hnologies such as next-generation s',\n",
       " 'equencing (NGS), the \\nknowledge of ',\n",
       " 'the molecular and genetic backgroun',\n",
       " 'd of TNBC improved, bringing to lig',\n",
       " 'ht its intertumoral \\nand intratumor',\n",
       " 'al heterogeneity.\\nA first classific',\n",
       " 'ation divided TNBC into six subtype',\n",
       " 's: basal-like 1 (BL1), basal-like 2',\n",
       " ' (BL2), \\nmesenchymal (M), M stem-li',\n",
       " 'ke (MSL), immunomodulatory (IM), an',\n",
       " 'd luminal androgen receptor (LAR) [',\n",
       " '14].\\nSubsequently, analyzing RNA an',\n",
       " 'd DNA-based profiles of 198 TNBC tu',\n",
       " 'mors, a four-type classification of',\n",
       " ' \\nTNBC was shaped: basal-like immun',\n",
       " 'osuppressed (BLIS), basal-like immu',\n",
       " 'ne-activated (BLIA), M and LAR \\n[15',\n",
       " ']. This classification was further ',\n",
       " 'revised with the identification of ',\n",
       " 'four specific TNBC subtypes: BL1, B',\n",
       " 'L2, \\nM, and LAR, omitting IM and MS',\n",
       " 'L because of the dependence of thes',\n",
       " 'e two subtypes on the TME features ',\n",
       " '\\n[14].\\nExplor Target Antitumor Ther',\n",
       " '. 2024;5:232–50 | https://doi.org/1',\n",
       " '0.37349/etat.2024.00215\\nPage 234\\nIn',\n",
       " ' addition, TNBC could be classified',\n",
       " ' into three microenvironment phenot',\n",
       " 'ypes or clusters:\\nCluster 1: “immun',\n",
       " 'e-desert” with poor immune cell per',\n",
       " 'meation, due to a high presence of ',\n",
       " 'MYC \\namplifications and, consequent',\n",
       " 'ly, a lower recruitment of innate i',\n",
       " 'mmune cells.\\n(1).\\nCluster 2: “innat',\n",
       " 'e immune-inactivated” characterized',\n",
       " ' by a hyper-activation of \\nphosphat',\n",
       " 'idylinositide 3-kinase/protein kina',\n",
       " 'se B (PI3K-AKT) pathway in tumor ce',\n",
       " 'lls, low tumor \\nantigen burden and ',\n",
       " 'infiltration of deactivated innate ',\n",
       " 'immune cells, fibroblasts, and endo',\n",
       " 'thelial \\ncells. Clusters 1 and 2 ar',\n",
       " 'e therefore referred to as “cold tu',\n",
       " 'mors”.\\n(2).\\nCluster 3: “immune-infl',\n",
       " 'amed”, the so-called “hot tumor” th',\n",
       " 'at represents about 30% of TNBCs an',\n",
       " 'd \\nis characterized by an abundant ',\n",
       " 'adaptive and innate immune cells in',\n",
       " 'filtration and with a high \\nexpress',\n",
       " 'ion of immune checkpoint molecules ',\n",
       " '[16].\\n(3).\\nThe potential “hot” conv',\n",
       " 'ersion of “cold” tumors could impro',\n",
       " 've the efficacy of cancer immunothe',\n",
       " 'rapy. \\nFor example, local IM therap',\n",
       " 'ies can express a synergistic effec',\n",
       " 't with immunotherapy by acting on \\n',\n",
       " 'components of the TME and immune sy',\n",
       " 'stem function, such as elevating th',\n",
       " 'e expression of tumor antigens \\nand',\n",
       " ' increasing the recruitment of acti',\n",
       " 'vated immune cells in the TME [17].',\n",
       " '\\nTNBC cancer cell immunological fea',\n",
       " 'tures include genomic instability a',\n",
       " 'nd high tumor mutational \\nburden (T',\n",
       " 'MB), resulting in more somatic muta',\n",
       " 'tions and neoantigens [18].\\nMoreove',\n",
       " 'r, approximately 10–20% of TNBC har',\n",
       " 'bor BRCA 1 or BRCA 2 germinal mutat',\n",
       " 'ions, with a \\nconsequent hereditary',\n",
       " ' deficit in the DNA repair mechanis',\n",
       " 'm and strong genomic instability. S',\n",
       " 'everal studies \\nhave demonstrated t',\n",
       " 'hat TNBC-carrying BRCA mutations ar',\n",
       " 'e more sensitive to DNA-damaging dr',\n",
       " 'ugs such as \\nanthracyclines, but al',\n",
       " 'so platinum agents and PARP inhibit',\n",
       " 'ors [19–21]. Sensitivity to these d',\n",
       " 'rugs was also \\nobserved in tumors w',\n",
       " 'ith alterations in other genes, sha',\n",
       " 'ring BRCA-mutant phenotype in the a',\n",
       " 'bsence of a \\nBRCA 1/2 mutation, nam',\n",
       " 'ely “BRCAness” [22, 23].\\nTumors wit',\n",
       " 'h BRCA 1/2 mutations or BRCAness TN',\n",
       " 'BC are more immunogenic than TNBC w',\n",
       " 'ithout these \\ngenetic alterations [',\n",
       " '24–26].\\nCompared to the other BC su',\n",
       " 'btypes the immunogenic TME features',\n",
       " ' in TNBC consist of higher levels o',\n",
       " 'f \\nvascular endothelial growth fact',\n",
       " 'or (VEGF), that promote tumor cell ',\n",
       " 'growth and migration such as mitoge',\n",
       " 'n-\\nactivated protein kinases (MAPKs',\n",
       " '), tumor-associated macrophages (TA',\n",
       " 'Ms), and tumor-infiltrating \\nlympho',\n",
       " 'cytes (TILs), white blood cells tha',\n",
       " 't migrate towards the tumor, leadin',\n",
       " 'g to an important \\nimmunogenic effe',\n",
       " 'ct and consequently that are involv',\n",
       " 'ed in killing cancer cells [27–29].',\n",
       " '\\nTAMs regulate the interaction betw',\n",
       " 'een the immune system and cancer ce',\n",
       " 'lls. CD163+ M2 macrophages, \\nwhich ',\n",
       " 'are associated with tumors characte',\n",
       " 'rized by higher proliferation and p',\n",
       " 'oorer differentiation [30], are \\nmo',\n",
       " 're present in TNBC and basal-like B',\n",
       " 'C [31]. A prosperous infiltration o',\n",
       " 'f TILs is found in TNBC tumors and ',\n",
       " '\\nthe stroma surrounding them, with ',\n",
       " 'a recognized predictive and prognos',\n",
       " 'tic role, specifically for CD4+ CD8',\n",
       " '+ \\nT cells [32]. Several studies ha',\n",
       " 've reported better response to neoa',\n",
       " 'djuvant CHT (NACT) [33] and better ',\n",
       " '\\nclinical outcomes in BC with high ',\n",
       " 'TIL infiltrate [34–39]. Based on th',\n",
       " 'is evidence, the international TILs',\n",
       " ' \\nworking group started standardizi',\n",
       " 'ng the evaluation of BC TILs to use',\n",
       " ' it in clinical practice identifyin',\n",
       " 'g those \\npatients that may benefit ',\n",
       " 'from emerging immunotherapies with ',\n",
       " 'ICIs or combination therapies [40].',\n",
       " '\\nAll these TME elements contribute ',\n",
       " 'to TNBC immunogenicity which also a',\n",
       " 'ppears to be closely related to \\nth',\n",
       " 'e concept of TMB, depending on the ',\n",
       " 'ineffective DNA repair system with ',\n",
       " 'the consequent generation of \\nhigh ',\n",
       " 'rates of neoantigens. The upregulat',\n",
       " 'ed antigen presentation system lead',\n",
       " 's to an increasing number of \\ninnat',\n",
       " 'e and adaptative immune cells and m',\n",
       " 'any cytokines interplaying with can',\n",
       " 'cer cells. However, the exact \\nrela',\n",
       " 'tionship between TMB, neoantigens, ',\n",
       " 'and immune infiltration is not yet ',\n",
       " 'completely understood, and \\nsome st',\n",
       " 'udies have reported an inverse asso',\n",
       " 'ciation between immune cells in TME',\n",
       " ' and the rate of somatic \\ncopy numb',\n",
       " 'er alterations [41, 42].\\nMoreover, ',\n",
       " 'although TMB is comparable across t',\n",
       " 'he three clusters of TNBC, the “imm',\n",
       " 'une-inflated” \\nphenotype is charact',\n",
       " 'erized by a higher degree of immune',\n",
       " ' cells in the TME, but also a high ',\n",
       " 'expression of \\nimmune checkpoints b',\n",
       " 'y cancer cells [16]. The rate of TI',\n",
       " 'Ls, indeed, has been positively rel',\n",
       " 'ated to \\nExplor Target Antitumor Th',\n",
       " 'er. 2024;5:232–50 | https://doi.org',\n",
       " '/10.37349/etat.2024.00215\\nPage 235\\n',\n",
       " 'programmed death ligand 1 (PD-L1) e',\n",
       " 'xpression [43]. PD-L1 is an immune ',\n",
       " 'checkpoint that mediates local \\nimm',\n",
       " 'une escape in many tumors inducing ',\n",
       " 'saturation of activated T cells. Ev',\n",
       " 'en if PD-L1 prognostic role is yet ',\n",
       " '\\ncontroversial [44], however it res',\n",
       " 'ults more overexpressed in TNBC com',\n",
       " 'pared with other BC and it can \\npre',\n",
       " 'dict responsiveness to immunotherap',\n",
       " 'y [16].\\nTherefore, TNBC represents ',\n",
       " 'an aggressive BC subtype, associate',\n",
       " 'd with high mutational load, high \\n',\n",
       " 'tumor immunogenicity and TME divers',\n",
       " 'ity.\\nNew paradigms in early TNBC: f',\n",
       " 'rom CHT to immunotherapy\\nCHT in adj',\n",
       " 'uvant treatment for TNBC\\nIn early T',\n",
       " 'NBC patients, CHT represents the ma',\n",
       " 'instay of adjuvant and neoadjuvant ',\n",
       " 'treatments. Adjuvant \\nCHT is recomm',\n",
       " 'ended for tumor sizes greater than ',\n",
       " '1.0 cm and patients with nodal invo',\n",
       " 'lvement, regardless \\nof tumor size.',\n",
       " ' Therefore, it can be considered fo',\n",
       " 'r tumor sizes between 0.6–1.0 cm [4',\n",
       " '5]. A recent large meta-\\nanalysis d',\n",
       " 'emonstrated that adjuvant CHT with ',\n",
       " 'anthracyclines-containing regimens ',\n",
       " 'plus taxanes, compared \\nwith no CHT',\n",
       " ', can reduce BC mortality rates by ',\n",
       " 'about 40% during the first decade a',\n",
       " 'fter diagnosis. Moreover, \\nregimens',\n",
       " ' with higher cumulative and dose-de',\n",
       " 'nse schedules of anthracycline (wit',\n",
       " 'h granulocyte colony-\\nstimulating f',\n",
       " 'actor support) have shown better su',\n",
       " 'rvival benefits and more reductions',\n",
       " ' in recurrence [46]. \\nThree-weekly ',\n",
       " 'docetaxel and paclitaxel can be con',\n",
       " 'sidered in adjuvant setting, but we',\n",
       " 'ekly paclitaxel, in a \\nsubgroup ana',\n",
       " 'lysis, has shown improved outcomes ',\n",
       " 'and is preferred for TNBC [47]. In ',\n",
       " 'TNBC in frail patients \\nwith a know',\n",
       " 'n history of heart disease, to mini',\n",
       " 'mize the cardiotoxicity of adjuvant',\n",
       " ' treatments, docetaxel \\ncombined wi',\n",
       " 'th cyclophosphamide (TC) has proven',\n",
       " ' to be a viable alternative to doxo',\n",
       " 'rubicin and \\ncyclophosphamide (AC),',\n",
       " ' demonstrating a favorable disease-',\n",
       " 'free survival (DFS) [48]. Therefore',\n",
       " ', there is a \\nbroad spectrum of che',\n",
       " 'motherapeutic treatments for early ',\n",
       " 'TNBC that should be customised acco',\n",
       " 'rding to the \\npatient and expected ',\n",
       " 'toxicities.\\nThe role of platinum in',\n",
       " ' adjuvant setting for TNBC\\nTNBC pat',\n",
       " 'ients commonly harbor BRCA 1/2 or B',\n",
       " 'RCAness mutations with a homologous',\n",
       " ' recombination \\ndeficiency (HRD) th',\n",
       " 'at makes them particularly suscepti',\n",
       " 'ble to platinum agents due to their',\n",
       " ' ability to hit \\ncancer cells that ',\n",
       " 'have deficient DNA repair mechanism',\n",
       " 's [49–51]. Several retrospective si',\n",
       " 'ngle-center studies \\nhave explored ',\n",
       " 'the role of adjuvant platinum combi',\n",
       " 'ned with standard anthracycline and',\n",
       " ' taxane-based \\nregimens, with contr',\n",
       " 'oversial results not showing clear ',\n",
       " 'clinical benefits [52, 53]. Neverth',\n",
       " 'eless, a recent \\nphase III trials h',\n",
       " 'ave demonstrated a longer 5-year DF',\n",
       " 'S (86.5% vs. 80.3%) with similar re',\n",
       " 'sults in distant DFS \\nand relapse-f',\n",
       " 'ree survival (RFS) of platinum-cont',\n",
       " 'aining adjuvant regimens (paclitaxe',\n",
       " 'l-carboplatin) \\ncompared to a stand',\n",
       " 'ard anthracyclines-containing regim',\n",
       " 'en followed by taxane, however with',\n",
       " ' no benefit in \\noverall survival (O',\n",
       " 'S) [54].\\nAnother important factor i',\n",
       " 's platinum resistance. Platinum sen',\n",
       " 'sitivity may be affected by changes',\n",
       " ' in the \\nhazard ratio (HR) pathway ',\n",
       " 'or, in the case of patients with BR',\n",
       " 'CA 1/2 mutations, by the secondary ',\n",
       " '\\nappearance of new BRCA 1 or 2 muta',\n",
       " 'tions that make cancer cells less s',\n",
       " 'ensitive to platinum [55, 56].\\nOthe',\n",
       " 'r mechanisms of resistance to plati',\n",
       " 'num compounds are:\\nModification of ',\n",
       " 'drug transport within the tumor cel',\n",
       " 'l, by determining decreased influx ',\n",
       " 'or increased \\nefflux.\\n(1).\\nIncrease',\n",
       " ' of detoxification systems.\\n(2).\\nDe',\n",
       " 'crease of cell apoptosis [57].\\n(3).',\n",
       " '\\nTherefore, the benefit of adjuvant',\n",
       " ' platinum-based regimens remains co',\n",
       " 'ntroversial and needs \\nvalidation b',\n",
       " 'y prospective adjuvant ongoing tria',\n",
       " 'ls.\\nExplor Target Antitumor Ther. 2',\n",
       " '024;5:232–50 | https://doi.org/10.3',\n",
       " '7349/etat.2024.00215\\nPage 236\\nNeoad',\n",
       " 'juvant treatments for TNBC\\nNACT\\nSev',\n",
       " 'eral treatment guidelines recommend',\n",
       " ' NACT as the preferred option for s',\n",
       " 'tage II or III TNBC and for \\nstage ',\n",
       " 'I with a tumor size greater than 1 ',\n",
       " 'cm. It can be considered in stage I',\n",
       " ' TNBC with a tumor size from \\n0.6 c',\n",
       " 'm to 1 cm and/or in the case of tum',\n",
       " 'ors with nodal micrometastases. [6,',\n",
       " ' 45]. There is no significant \\ndiff',\n",
       " 'erence in survival benefits between',\n",
       " ' patients receiving neoadjuvant or ',\n",
       " 'adjuvant CHT after surgical \\nresect',\n",
       " 'ion. However, neoadjuvant treatment',\n",
       " 's can be useful for inoperable tumo',\n",
       " 'rs rendering them operable \\nand the',\n",
       " 'y can also downstage patients with ',\n",
       " 'operable BC promoting breast-conser',\n",
       " 'vation [58, 59]. The use of \\nneoadj',\n",
       " 'uvant treatments provides important',\n",
       " ' prognostic information based on re',\n",
       " 'sponse to therapy. \\nAchieving a pCR',\n",
       " ', defined as the lack of cancer cel',\n",
       " 'ls in tissue samples of breast and ',\n",
       " 'axillary lymph nodes, \\nafter a neoa',\n",
       " 'djuvant treatment, is associated wi',\n",
       " 'th favorable disease-free and OS in',\n",
       " ' early TNBC, as \\ndemonstrated in Co',\n",
       " 'llaborative Trials in Neoadjuvant B',\n",
       " 'reast Cancer (CTNeoBC) pooled analy',\n",
       " 'sis. In this \\nstudy, patients with ',\n",
       " 'early BC treated with NACT and foll',\n",
       " 'owed by surgery who obtained pCR (y',\n",
       " 'pT0 ypN0, \\nypT0/is ypN0) were assoc',\n",
       " 'iated with improved event-free surv',\n",
       " 'ival (EFS) and OS, especially in TN',\n",
       " 'BC (HR = \\n0.24 and HR = 0.16, respe',\n",
       " 'ctively) [33]. Like adjuvant treatm',\n",
       " 'ent, traditional NACT is based on a',\n",
       " 'nthracyclines \\nand taxanes, and a d',\n",
       " 'ose-dense regimen is preferred in n',\n",
       " 'eoadjuvant settings based on proven',\n",
       " ' improved DFS \\nand OS in a large me',\n",
       " 'ta-analysis [60].\\nIn recent years, ',\n",
       " 'the use of platinum-based combinati',\n",
       " 'on regimens has been the focus of n',\n",
       " 'eoadjuvant \\ntreatment to increase t',\n",
       " 'he rate of pCR in TNBC. Three recen',\n",
       " 't studies demonstrated that combini',\n",
       " 'ng platinum \\nwith taxane and anthra',\n",
       " 'cycline led to an improvement in th',\n",
       " 'e pCR rate in TNBC, with a similar ',\n",
       " 'survival \\nbenefit [61–63]. In Brigh',\n",
       " 'tness Trial patients with II–III st',\n",
       " 'age TNBC were randomly assigned to ',\n",
       " 'receive \\npaclitaxel alone, paclitax',\n",
       " 'el and carboplatin and this combina',\n",
       " 'tion with a PARP inhibitor, velipar',\n",
       " 'ib followed \\nby AC. Although the ad',\n",
       " 'dition of veliparib and carboplatin',\n",
       " ' was associated with an increase of',\n",
       " ' patients who \\nachieved a pCR compa',\n",
       " 'red to paclitaxel alone (53% vs. 31',\n",
       " '%, P < 0.0001), but not to paclitax',\n",
       " 'el and \\ncarboplatin, this benefit c',\n",
       " 'ould be related to the addition of ',\n",
       " 'the carboplatin [63]. The initial r',\n",
       " 'ationale for \\nusing the combination',\n",
       " ' of platinum in NACT was that spora',\n",
       " 'dic TNBC can show BRCAness with a m',\n",
       " 'ajor \\nresponse to platinum regimens',\n",
       " ' [50, 51]. However, the greatest be',\n",
       " 'nefit was seen in patients who were',\n",
       " ' \\ngermline BRCA wild type, and only',\n",
       " ' a marginal benefit was observed in',\n",
       " ' the germline BRCA mutant \\nsubgroup',\n",
       " ', as was shown in the recent GeparO',\n",
       " 'LA trial. In this trial, patients w',\n",
       " 'ere randomized to \\nneoadjuvant ther',\n",
       " 'apy with paclitaxel and carboplatin',\n",
       " ' vs. neoadjuvant therapy with pacli',\n",
       " 'taxel and olaparib \\n(PARP inhibitor',\n",
       " '). In both arms, the combination of',\n",
       " ' epirubicin and cyclophosphamide wa',\n",
       " 's administered \\nnext. This study, a',\n",
       " 'lthough limited by a small number o',\n",
       " 'f patients enrolled, showed an adva',\n",
       " 'ntage for the \\ncarboplatin arm in p',\n",
       " 'atients without BRCA mutation (germ',\n",
       " ' or somatic) and high HRD. The 4-ye',\n",
       " 'ar invasive \\nDFS (iDFS) rate with o',\n",
       " 'laparib-paclitaxel was 81.2% vs. 93',\n",
       " '.4% with carboplatin-paclitaxel (CP',\n",
       " ') [HR = 3.03; \\n95% confidence inter',\n",
       " 'val (CI) = 0.67–13.67; log-rank P =',\n",
       " ' 0.1290]. The 4-year OS rate was 89',\n",
       " '.2% with the \\nolaparib combination ',\n",
       " 'vs. 96.6% with carboplatin (HR = 3.',\n",
       " '27; 95% CI = 0.39–27.20; log-rank P',\n",
       " ' = 0.2444). \\nThe trend of the iDFS ',\n",
       " 'curves was similar in the two treat',\n",
       " 'ment arms and independent of germli',\n",
       " 'ne or somatic \\nBRCA mutation [64].\\n',\n",
       " 'Platinum combinations are currently',\n",
       " ' recommended for selected patients ',\n",
       " 'with TNBC who require \\nadequate loc',\n",
       " 'al control before surgical resectio',\n",
       " 'n [45]. A more recent phase III tri',\n",
       " 'al presented at the San \\nAntonio Br',\n",
       " 'east Cancer Symposium evaluating th',\n",
       " 'e efficacy and safety of adding car',\n",
       " 'boplatin to standard \\nsequential ta',\n",
       " 'xane-anthracycline NACT in patients',\n",
       " ' with TNBC who had no evidence of m',\n",
       " 'etastatic disease, \\nhas observed im',\n",
       " 'provements in terms of DFS (5-year ',\n",
       " 'DFS were 70.6% and 64.5% respective',\n",
       " 'ly with a HR = \\n0.79, 95% CI = 0.61',\n",
       " '–1.02, P = 0.073) and OS (5-year OS',\n",
       " ' were 74.0% and 66.7% respectively ',\n",
       " 'with a HR = \\n0.75, 95% CI = 0.57–0.',\n",
       " '98, P = 0.034) with the addition of',\n",
       " ' carboplatin, but these benefits we',\n",
       " 're limited to \\npatients who were 50',\n",
       " ' years of age or younger. Therefore',\n",
       " ', the pCR in the intention-to-treat',\n",
       " ' population was \\n54.5% in the carbo',\n",
       " 'platin arm and 40.3% in the control',\n",
       " ' arm (P < 0.001) [65].\\nThe inclusio',\n",
       " 'n of platinum agents as NACT for TN',\n",
       " 'BC remains controversial. Long-term',\n",
       " ' outcomes and \\nnew prospective stud',\n",
       " 'ies are needed to clarify the role ',\n",
       " 'of platinum agents in this setting.',\n",
       " '\\nExplor Target Antitumor Ther. 2024',\n",
       " ';5:232–50 | https://doi.org/10.3734',\n",
       " '9/etat.2024.00215\\nPage 237\\nNeoadjuv',\n",
       " 'ant immunotherapy\\nThe success of IC',\n",
       " 'Is in metastatic TNBC led to expand',\n",
       " ' their role in neoadjuvant settings',\n",
       " '. Pembrolizumab and \\natezolizumab h',\n",
       " 'ave shown progression-free survival',\n",
       " ' (PFS) benefits in phase III trials',\n",
       " ' in advanced setting \\n[66, 67]. In ',\n",
       " 'contrast to atezolizumab that showe',\n",
       " 'd conflicting results [68, 69], pem',\n",
       " 'brolizumab consistently \\nshowed OS ',\n",
       " 'benefits in advanced TNBC [66, 70].',\n",
       " ' In early-stage TNBC two studies ev',\n",
       " 'aluated atezolizumab in \\nneoadjuvan',\n",
       " 't setting. In the NeoTRIPaPDL1 tria',\n",
       " 'l, no improvement in pCR was shown ',\n",
       " 'with the addition of \\natezolizumab ',\n",
       " 'to a non-anthracycline-containing C',\n",
       " 'HT regimen [71]. More recent Impass',\n",
       " 'ion031 phase III \\nstudy evaluating ',\n",
       " 'the association of atezolizumab to ',\n",
       " 'a standard NACT (nab-palclitaxel we',\n",
       " 'ekly for 12 weeks \\nfollowed by 4 cy',\n",
       " 'cles of AC), has demonstrated a sig',\n",
       " 'nificant improvement of pCR rates i',\n",
       " 'n intention to treat \\n(ITT) populat',\n",
       " 'ion (58% in atezolizumab arm vs. 41',\n",
       " '% in placebo arm, P = 0.0044), rega',\n",
       " 'rdless of PD-L1 status, \\nmeeting th',\n",
       " 'e primary endpoint of the study [72',\n",
       " ']. Therefore, in early BC the combi',\n",
       " 'nation of pembrolizumab \\nwith pacli',\n",
       " 'taxel-carboplatin followed by anthr',\n",
       " 'acycline increased pCR rate and EFS',\n",
       " ' rate in the KEYNOTE-522 \\ntrial, re',\n",
       " 'presenting a turning point for the ',\n",
       " 'role of immunotherapy in neoadjuvan',\n",
       " 't therapy of TNBC and \\nestablishing',\n",
       " ' pembrolizumab as a standard treatm',\n",
       " 'ent during neoadjuvant treatment fo',\n",
       " 'r stage II and III \\nTNBC. The trial',\n",
       " ' evaluated the combination of pembr',\n",
       " 'olizumab (18 cycles, 200 mg every 3',\n",
       " ' weeks) combined \\nwith four cycles ',\n",
       " 'of paclitaxel (weekly or 3-weekly) ',\n",
       " 'and carboplatin (3-weekly), followe',\n",
       " 'd by 3-weekly AC for \\n4 cycles, com',\n",
       " 'pared to placebo with CHT. Pembroli',\n",
       " 'zumab arm showed a 13.6% improvemen',\n",
       " 't in pCR [64.8% \\n(95% CI = 59.9–69.',\n",
       " '5%) vs. 51.2% (95% CI = 44.1–58.3%)',\n",
       " '] and in EFS rate [84.5% (95% CI = ',\n",
       " '81.7–86.9%) \\nvs. 76.8% (95% CI = 72',\n",
       " '.2–80.7%)], meeting the primary end',\n",
       " 'point of the study, regardless noda',\n",
       " 'l \\ninvolvement and PD-L1 status. Th',\n",
       " 'e average duration of follow-up is ',\n",
       " 'still immature, but a trend of \\nsup',\n",
       " 'eriority in terms of OS in the pemb',\n",
       " 'rolizumab arm was nevertheless dete',\n",
       " 'cted [73]. Limits of this study \\nar',\n",
       " 'e the lack of biomarkers that predi',\n",
       " 'ct what patient may benefit from th',\n",
       " 'e addition of pembrolizumab and \\nth',\n",
       " 'e non-utilization of dose-dense sch',\n",
       " 'edule of AC which showed superior O',\n",
       " 'S benefit in the neoadjuvant \\nsetti',\n",
       " 'ng in TNBC [74].\\nMoreover, the rece',\n",
       " 'nt GeparNuevo trial showed that dur',\n",
       " 'valumab (1,500 mg every 4 weeks) ad',\n",
       " 'ded to \\nNACT consisting of nab-pacl',\n",
       " 'itaxel 125 mg/m2 weekly for 12 week',\n",
       " 's, followed by epirubicin/\\ncyclopho',\n",
       " 'sphamide every 2 weeks, in early TN',\n",
       " 'BC significantly improved iDFS (85.',\n",
       " '6% with durvalumab vs. \\n77.2% with ',\n",
       " 'placebo HR = 0.48, 95% CI = 0.24–0.',\n",
       " '97, stratified log-rank P = 0.036) ',\n",
       " 'and OS (95.2% vs. 83.5% \\nwith a HR ',\n",
       " '= 0.24, 95% CI = 0.08–0.72, P = 0.0',\n",
       " '06), despite a modest pCR increase ',\n",
       " 'and no adjuvant \\ncomponent of durva',\n",
       " 'lumab [75]. Future studies should a',\n",
       " 'im to define the role of immunother',\n",
       " 'apy in the \\ntreatment of early TNBC',\n",
       " ', to define the ideal duration of t',\n",
       " 'hese treatments, and should researc',\n",
       " 'h new \\nbiomarkers to personalize tr',\n",
       " 'eatments.\\nPathological complete res',\n",
       " 'ponse: prognostic role and therapeu',\n",
       " 'tic \\nimplications\\nIn clinical pract',\n",
       " 'ice, the achievement of pCR after n',\n",
       " 'eoadjuvant treatment is correlated ',\n",
       " 'to the improvement of \\nlong-term be',\n",
       " 'nefits concerning EFS and OS. Its p',\n",
       " 'rognostic value is greatest in aggr',\n",
       " 'essive tumor subtypes, \\nlike in TNB',\n",
       " 'C (EFS: HR = 0.24; OS: HR = 0.16) [',\n",
       " '33]. Patients who have residual inv',\n",
       " 'asive BC after the receipt \\nof NACT',\n",
       " ' have a high risk of relapse. Patie',\n",
       " 'nts with TNBC who do not experience',\n",
       " ' pCR have an estimated 5-\\nyear EFS ',\n",
       " 'of 57% and OS of 47% (compared with',\n",
       " ' 90% EFS and 84% OS, respectively, ',\n",
       " 'for patients with early-\\nstage TNBC',\n",
       " ' who demonstrate pCR) [76, 77].\\nAft',\n",
       " 'er pre-operative CHT and surgical t',\n",
       " 'reatment, patients can receive post',\n",
       " 'operative radiation therapy \\n(RT). ',\n",
       " 'Patients with hormone receptor-posi',\n",
       " 'tive BC [hormone receptor-positive ',\n",
       " '(HR+) BC] are candidates for \\nadjuv',\n",
       " 'ant endocrine treatment. However, u',\n",
       " 'ntil recently, no adjuvant CHT was ',\n",
       " 'expected as standard in \\npatients w',\n",
       " 'ith TNBC. Only follow-up was recomm',\n",
       " 'ended in those who have pCR or in t',\n",
       " 'hose with residual \\ninvasive BC aft',\n",
       " 'er the receipt of neoadjuvant regim',\n",
       " 'ens [78]. To address the unmet clin',\n",
       " 'ical need for optimal \\nadjuvant tre',\n",
       " 'atment in the subgroup of patients ',\n",
       " 'with TNBC at high risk of recurrenc',\n",
       " 'e (those who have not \\nachieved the',\n",
       " ' pCR after NACT containing anthracy',\n",
       " 'cline, taxane, or both), the Capeci',\n",
       " 'tabine for Residual \\nCancer as Adju',\n",
       " 'vant Therapy (CREATE-X) was designe',\n",
       " 'd. The trial did not include only p',\n",
       " 'atients with TNBC \\nExplor Target An',\n",
       " 'titumor Ther. 2024;5:232–50 | https',\n",
       " '://doi.org/10.37349/etat.2024.00215',\n",
       " '\\nPage 238\\nbut also patients with HR',\n",
       " '+ HER2 negative BC [79]. The result',\n",
       " 's of this phase III trial showed th',\n",
       " 'at the \\naddition of adjuvant capeci',\n",
       " 'tabine (1,250 mg per square meter o',\n",
       " 'f body-surface area, twice per day,',\n",
       " ' on days \\n1 to 14, every 3 weeks fo',\n",
       " 'r six or eight cycles) was safe and',\n",
       " ' effective in prolonging DFS and OS',\n",
       " ' among the \\nITT population. The stu',\n",
       " 'dy showed a superior DFS in the cap',\n",
       " 'ecitabine group than in the control',\n",
       " ' group \\n(74.1% vs. 67.6% at 5 years',\n",
       " '; HR = 0.70; P = 0.01). Therefore, ',\n",
       " 'OS was longer in the experimental g',\n",
       " 'roup: \\n89.2% vs. 83.6% of the patie',\n",
       " 'nts were alive at 5 years (HR = 0.5',\n",
       " '9; P = 0.01). Thirty percent of the',\n",
       " ' patients \\nhad triple negative (TN)',\n",
       " ' disease, and they represent the su',\n",
       " 'bgroup with poor prognosis (approxi',\n",
       " 'mately half \\nthe patients with TNBC',\n",
       " ' who had a pCR did not have the rec',\n",
       " 'urrence of the disease) [33]. The b',\n",
       " 'enefit of \\ncapecitabine vs. control',\n",
       " ' in DFS and OS was notable among th',\n",
       " 'is subgroup of patients (HR = 0.58 ',\n",
       " 'and HR = \\n0.52, respectively) [79].',\n",
       " '\\nThe reflection in the treatment al',\n",
       " 'gorithm due to these results was si',\n",
       " 'gnificant.\\nSome limits of this stud',\n",
       " 'y are the exclusion of patients who',\n",
       " ' had reached the pCR, for whom only',\n",
       " ' follow-\\nup was indicated, and the ',\n",
       " 'lack of efficacy results selected f',\n",
       " 'or residual cancer burden (RCB). Th',\n",
       " 'e RCB \\nquantifies the extent of res',\n",
       " 'idual disease after neoadjuvant tre',\n",
       " 'atment at the time of surgery. This',\n",
       " ' score uses \\nthe diameter of residu',\n",
       " 'al disease, percentage of vital tum',\n",
       " 'or cells, and diameter of the large',\n",
       " 'st involved lymph \\nnode to calculat',\n",
       " 'e the amount of residual disease. I',\n",
       " 't has been validated with distinct ',\n",
       " 'prognostic RCB classes \\nin all BC s',\n",
       " 'ubtypes, with the most significant ',\n",
       " 'discriminatory power in TN and Her-',\n",
       " '2 positive BC. It is \\ncategorized a',\n",
       " 's RCB-0 (equivalent to a pCR), RCB-',\n",
       " '1, RCB-2, and RCB-3, reflecting inc',\n",
       " 'reasingly larger residual \\ncancer a',\n",
       " 'nd respective poor prognoses (in te',\n",
       " 'rms of EFS) [80]. Finally, the CREA',\n",
       " 'TE-X trial did not examine \\ncapecit',\n",
       " 'abine efficacy in patients with ger',\n",
       " 'mline BRCA 1 or BRCA 2 pathogenic v',\n",
       " 'ariants (less than 15% of \\nthose en',\n",
       " 'rolled) [79].\\nOlympiA is a phase II',\n",
       " 'I study designed to investigate how',\n",
       " ' the PARP inhibitor olaparib might ',\n",
       " 'improve \\nDFS and OS in patients wit',\n",
       " 'h resected HR+ BC and TNBC with ger',\n",
       " 'mline BRCA 1 or BRCA 2 mutation. It',\n",
       " ' \\nenrolled patients treated with CH',\n",
       " 'T (containing anthracyclines, taxan',\n",
       " 'es or the combination of both) in \\n',\n",
       " 'neoadjuvant or adjuvant setting and',\n",
       " ' randomized them to receive olapari',\n",
       " 'b (orally administered at the dose ',\n",
       " '\\nof 300 mg twice daily) vs. placebo',\n",
       " ' for 1 year after surgical resectio',\n",
       " 'n (and radiotherapy when indicated)',\n",
       " '. \\nAlso in this trial, patients wit',\n",
       " 'h TNBC who underwent NACT followed ',\n",
       " 'by surgery were required to have \\nr',\n",
       " 'esidual invasive BC in the breast a',\n",
       " 'nd/or resected lymph nodes (non-pCR',\n",
       " ') [81]. Postneoadjuvant \\ncapecitabi',\n",
       " 'ne was not foreseen in this trial. ',\n",
       " 'iDFS, the primary endpoint of the s',\n",
       " 'tudy, was significantly longer \\namo',\n",
       " 'ng patients assigned to receive ola',\n",
       " 'parib than among those assigned pla',\n",
       " 'cebo (HR = 0.58; P < 0.001). The \\np',\n",
       " 'ercentage of patients alive and fre',\n",
       " 'e of invasive disease at 3 years wa',\n",
       " 's 85.9% in the olaparib group and \\n',\n",
       " '77.1% in the placebo group. The ben',\n",
       " 'efit of adjuvant olaparib was obser',\n",
       " 'ved irrespective of the germline \\nB',\n",
       " 'RCA mutation (BRCA 1 vs. BRCA 2), t',\n",
       " 'he hormone-receptor status, or the ',\n",
       " 'timing of previous CHT \\n(neoadjuvan',\n",
       " 't vs. adjuvant) [81] 4-year iDFS fo',\n",
       " 'r the olaparib group was 82.7% (vs.',\n",
       " ' 75.4% in placebo group) \\nand 4-yea',\n",
       " 'r distant DFS (DDFS) was 86.5% (vs.',\n",
       " ' 79.1%). Adjuvant olaparib improves',\n",
       " ' OS, with an HR of 0.68 \\nand a P va',\n",
       " 'lue of 0.009 at 3.5 years of median',\n",
       " ' follow-up, meeting the significanc',\n",
       " 'e threshold for OS at the \\nsecond p',\n",
       " 'lanned interim analysis. The OS ben',\n",
       " 'efit at 4 years in the olaparib arm',\n",
       " ' compared with the placebo \\narm was',\n",
       " ' reported (89.8% vs. 86.4%, respect',\n",
       " 'ively) [82].\\nBoth studies have defi',\n",
       " 'ned the standard of adjuvant therap',\n",
       " 'y post-NACT for patients with BRCA ',\n",
       " 'wild \\ntype (CREATE-X) and BRCA muta',\n",
       " 'ted (OlympiA) TNBC, that did not re',\n",
       " 'ach the pCR.\\nThe low percentage of ',\n",
       " 'BRCA mutated patients enrolled in t',\n",
       " 'he CREATE-X, the absence of pre-pla',\n",
       " 'nned \\nsubgroup analyzes for this po',\n",
       " 'pulation do not allow for a descrip',\n",
       " 'tion of the efficacy of capecitabin',\n",
       " 'e in this \\nsubgroup of patients.\\nMo',\n",
       " 'reover, there are no prospective ra',\n",
       " 'ndomized trials between capecitabin',\n",
       " 'e and olaparib to guide the \\nclinic',\n",
       " 'al decision in this population, nor',\n",
       " ' combination or sequence data betwe',\n",
       " 'en these two drugs.\\nIt would also b',\n",
       " 'e important to consider the potenti',\n",
       " 'ally severe toxicity profile of suc',\n",
       " 'h a combination, \\ngiven their overl',\n",
       " 'apping side effects (in particular,',\n",
       " ' cytopenias).\\nThe treatment paradig',\n",
       " 'm of early TNBC has had a real evol',\n",
       " 'ution since July 2021, with the int',\n",
       " 'roduction \\nof immunotherapy followi',\n",
       " 'ng the Food and Drug Administration',\n",
       " ' (FDA) approval of pembrolizumab fo',\n",
       " 'r high-\\nExplor Target Antitumor The',\n",
       " 'r. 2024;5:232–50 | https://doi.org/',\n",
       " '10.37349/etat.2024.00215\\nPage 239\\nr',\n",
       " 'isk TNBC (tumor size > 1 cm but ≤ 2',\n",
       " ' cm in diameter with nodal involvem',\n",
       " 'ent or tumor size > 2 cm in \\ndiamet',\n",
       " 'er regardless of nodal involvement)',\n",
       " ', regardless of tumor PD-L1 express',\n",
       " 'ion, in combination with CHT \\nas ne',\n",
       " 'oadjuvant treatment, and then conti',\n",
       " 'nued as a single agent as adjuvant ',\n",
       " 'treatment after surgery for a \\ntota',\n",
       " 'l duration of approximately 1 year ',\n",
       " '[83].\\nResults from the KEYNOTE-522 ',\n",
       " 'study were the basis for this appro',\n",
       " 'val, demonstrating a significantly ',\n",
       " '\\nhigher rate of pCR at the time of ',\n",
       " 'definitive surgery among patients w',\n",
       " 'ho received pembrolizumab plus NACT',\n",
       " ' \\nthan among those who received pla',\n",
       " 'cebo plus NACT and an improvement i',\n",
       " 'n long-term benefits [73, 84]. The ',\n",
       " '\\naim of the trial was not to identi',\n",
       " 'fy the contributions of the neoadju',\n",
       " 'vant and adjuvant treatment phases,',\n",
       " ' so it \\nis difficult to define if t',\n",
       " 'hese long-term results are related ',\n",
       " 'to exposure to adjuvant pembrolizum',\n",
       " 'ab or a \\nlesser RCB at the end of t',\n",
       " 'he neoadjuvant phase in the pembrol',\n",
       " 'izumab–CHT group.\\nAn exploratory an',\n",
       " 'alysis of the study then provided d',\n",
       " 'ata to further describe the prognos',\n",
       " 'is related to the \\nRCB after neoadj',\n",
       " 'uvant experimental treatment (Figur',\n",
       " 'e 1) [85].\\nFigure 1. The unmet need',\n",
       " ' for the optimal adjuvant treatment',\n",
       " ' according to RCB [85]\\nThe HR for r',\n",
       " 'ecurrence event in subgroups RBO-0,',\n",
       " ' RCB-1, RCB-2, and RCB-3 are respec',\n",
       " 'tively 0.70 \\n(rates: 5.2% vs. 7.3% ',\n",
       " 'in the pembrolizumab + CHT vs. plac',\n",
       " 'ebo + CHT), 0.92 (rates: 17.4% vs. ',\n",
       " '20%), 0.52 \\n(rates: 25.5% vs. 44.3%',\n",
       " '), 1.24 (72.5% vs. 69.2%).\\nThe rate',\n",
       " ' of recurrence was numerically lowe',\n",
       " 'r in all RCB groups with pembrolizu',\n",
       " 'mab + CHT, except in \\nthe small RCB',\n",
       " '-3 subset (that is represented by 5',\n",
       " '% and 7% of the population in the s',\n",
       " 'tudy, respectively in \\nthe experime',\n",
       " 'ntal and control group). Pembrolizu',\n",
       " 'mab shifted RCB to lower categories',\n",
       " ' in most patients \\n(RCB-0: 63% vs. ',\n",
       " '56% of patients in the experimental',\n",
       " ' vs. the control arm; RCB-1: 9% vs.',\n",
       " ' 11%; RCB 18% vs. \\n20%).\\nNo patient',\n",
       " 's in this trial received adjuvant c',\n",
       " 'apecitabine, and there are no rando',\n",
       " 'mized efficacy and \\nsafety data sho',\n",
       " 'wing that multiagent therapy with p',\n",
       " 'embrolizumab and capecitabine is su',\n",
       " 'perior to single-\\nagent therapy in ',\n",
       " 'high-risk patients (stage II–III) w',\n",
       " 'ho did not reach pCR.\\nAt the time, ',\n",
       " 'only results from phase II studies ',\n",
       " 'in metastatic TNBC demonstrated no ',\n",
       " 'new safety signals \\nwith this combi',\n",
       " 'nation [86, 87].\\nPembrolizumab has ',\n",
       " 'also not been studied in combinatio',\n",
       " 'n with olaparib in the adjuvant set',\n",
       " 'ting, for the \\ntreatment of patient',\n",
       " 's with BRCA mutations. No efficacy ',\n",
       " 'data are reported in the literature',\n",
       " ', even if some \\nExplor Target Antit',\n",
       " 'umor Ther. 2024;5:232–50 | https://',\n",
       " 'doi.org/10.37349/etat.2024.00215\\nPa',\n",
       " 'ge 240\\nsafety data are reported in ',\n",
       " 'the metastatic setting, in some ear',\n",
       " 'ly-phase studies that have evaluate',\n",
       " 'd the \\ncombination of PARPis and IC',\n",
       " 'Is, not reporting unexpected toxici',\n",
       " 'ties [88, 89].\\nProspective trials w',\n",
       " 'ould be needed to define what is th',\n",
       " 'e optimal adjuvant strategy accordi',\n",
       " 'ng to RCB \\n(single-agent CHT or pol',\n",
       " 'y-CHT), how the clinician should de',\n",
       " 'cide between olaparib, immunotherap',\n",
       " 'y or \\ncapecitabine in the treatment',\n",
       " ' of the population with BRCA mutati',\n",
       " 'ons and whether these therapies can',\n",
       " ' be \\nadministered in combination or',\n",
       " ' sequence, with data in terms of ef',\n",
       " 'ficacy and safety.\\nAdditional treat',\n",
       " 'ment strategies with new drugs are ',\n",
       " 'being studied as adjuvant treatment',\n",
       " ' after NACT, \\nwith antibody-drug co',\n",
       " 'njugates (ADCs) such as datopotamab',\n",
       " ' deruxtecan (with or without durval',\n",
       " 'umab in \\nTROPICS-Breast 03, Clinica',\n",
       " 'lTrials.gov identifier: NCT05629585',\n",
       " '), and patritumab deruxtecan (HER3-',\n",
       " 'DXd) \\nwhich showed promising clinic',\n",
       " 'al response and biological changes ',\n",
       " 'in early TNBC [SOLTI TOT-HER3 windo',\n",
       " 'w \\nof opportunity trial part B, pre',\n",
       " 'sented at European Society for Medi',\n",
       " 'cal Oncology (ESMO) Breast 2023], o',\n",
       " 'r \\nwith ICIs (A-BRAVE trial, NCT029',\n",
       " '26196 and SWOG S1418/BR006 trial, N',\n",
       " 'CT02954874).\\nNew biomarkers and fro',\n",
       " 'ntiers in TNBC\\nRecent progress in i',\n",
       " 'ntegrating ICIs and novel agents ha',\n",
       " 's revolutionized the therapeutic ap',\n",
       " 'proach for early \\nTNBC. Treatment s',\n",
       " 'trategies now emphasize escalating ',\n",
       " 'chemotherapeutic agents based on st',\n",
       " 'andard \\nneoadjuvant regimens. An ex',\n",
       " 'ample is a phase II trial (ACTRN126',\n",
       " '17000651381) presented at the San \\n',\n",
       " 'Antonio Breast Cancer Symposium 202',\n",
       " '2 evaluating in high-risk TNBC, the',\n",
       " ' addition of ipilimumab and \\nnivolu',\n",
       " 'mab to neoadjuvant paclitaxel follo',\n",
       " 'wing a suboptimal response to anthr',\n",
       " 'acycline-based CHT (< 50% \\ntumor re',\n",
       " 'duction) and resulting in promising',\n",
       " ' objective response rate (ORR) (43.',\n",
       " '7%) and pCR (18.8%) rates, \\nregardl',\n",
       " 'ess of PD-L1 status.\\nHowever, it is',\n",
       " ' also crucial to identify subgroups',\n",
       " ...]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "# Create a list that will hold your chunks\n",
    "chunks = []\n",
    "\n",
    "chunk_size = 35 # Characters\n",
    "\n",
    "# Run through the a range with the length of your text and iterate every chunk_size you want\n",
    "for i in range(0, len(text), chunk_size):\n",
    "    chunk = text[i:i + chunk_size]\n",
    "    chunks.append(chunk)\n",
    "chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "e81362ae-5038-4631-bb0b-28a2143e7094",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(8105, 'Explor Target Antitumor Ther. 2024;', 35)"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(chunks),chunks[0],len(chunks[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "843980c6-ab3b-45a3-b011-a736bd0211aa",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "283675"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "35*8105"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "88dbdf27-6eec-4757-8b49-40bc79fcb4a5",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "from langchain.text_splitter import CharacterTextSplitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "90da141d-3486-4f5c-82ae-5b83a7554d68",
   "metadata": {},
   "outputs": [],
   "source": [
    "text_splitter = CharacterTextSplitter(chunk_size = 35, chunk_overlap=0, separator='', strip_whitespace=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "ca0adbf1-2c48-4e64-ad34-035dbbedfa14",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;'),\n",
       " Document(metadata={}, page_content='5:232–50 | https://doi.org/10.37349'),\n",
       " Document(metadata={}, page_content='/etat.2024.00215\\nPage 232\\n© The Aut'),\n",
       " Document(metadata={}, page_content='hor(s) 2024. This is an Open Access'),\n",
       " Document(metadata={}, page_content=' article licensed under a Creative '),\n",
       " Document(metadata={}, page_content='Commons Attribution 4.0 Internation'),\n",
       " Document(metadata={}, page_content='al \\nLicense (https://creativecommon'),\n",
       " Document(metadata={}, page_content='s.org/licenses/by/4.0/), which perm'),\n",
       " Document(metadata={}, page_content='its unrestricted use, sharing, adap'),\n",
       " Document(metadata={}, page_content='tation, distribution \\nand reproduct'),\n",
       " Document(metadata={}, page_content='ion in any medium or format, for an'),\n",
       " Document(metadata={}, page_content='y purpose, even commercially, as lo'),\n",
       " Document(metadata={}, page_content='ng as you give appropriate credit t'),\n",
       " Document(metadata={}, page_content='o the \\noriginal author(s) and the s'),\n",
       " Document(metadata={}, page_content='ource, provide a link to the Creati'),\n",
       " Document(metadata={}, page_content='ve Commons license, and indicate if'),\n",
       " Document(metadata={}, page_content=' changes were made.\\nExploration of '),\n",
       " Document(metadata={}, page_content='Targeted Anti-tumor Therapy\\nOpen Ac'),\n",
       " Document(metadata={}, page_content='cess\\nReview\\nEarly-stage triple nega'),\n",
       " Document(metadata={}, page_content='tive breast cancer: the therapeutic'),\n",
       " Document(metadata={}, page_content=' role of \\nimmunotherapy and the pro'),\n",
       " Document(metadata={}, page_content='gnostic value of pathological compl'),\n",
       " Document(metadata={}, page_content='ete \\nresponse\\nPierluigi De Santis1,'),\n",
       " Document(metadata={}, page_content=' Martina Perrone1, Chiara Guarini1,'),\n",
       " Document(metadata={}, page_content=' Anna Natalizia Santoro1, Carmelo L'),\n",
       " Document(metadata={}, page_content='aface1, \\nDaniela Carrozzo1, Gaia Ra'),\n",
       " Document(metadata={}, page_content='chele Oliva2, Palma Fedele1*\\n1Oncol'),\n",
       " Document(metadata={}, page_content='ogy Unit, Francavilla Fontana Cegli'),\n",
       " Document(metadata={}, page_content='e Messapica Hospital District, 7202'),\n",
       " Document(metadata={}, page_content='1 Francavilla Fontana, Italy\\n2Depar'),\n",
       " Document(metadata={}, page_content='tment of Medicine and Translational'),\n",
       " Document(metadata={}, page_content=' Surgery, Università Cattolica del '),\n",
       " Document(metadata={}, page_content='Sacro Cuore, 00168 Roma, Italy\\n*Cor'),\n",
       " Document(metadata={}, page_content='respondence: Palma Fedele, Oncology'),\n",
       " Document(metadata={}, page_content=' Unit, Francavilla Fontana Ceglie M'),\n",
       " Document(metadata={}, page_content='essapica Hospital District, 72021 F'),\n",
       " Document(metadata={}, page_content='rancavilla \\nFontana, Italy. minafed'),\n",
       " Document(metadata={}, page_content='ele@hotmail.com\\nAcademic Editor: La'),\n",
       " Document(metadata={}, page_content='ura Cerchia, Institute of Experimen'),\n",
       " Document(metadata={}, page_content='tal Endocrinology and Oncology “G. '),\n",
       " Document(metadata={}, page_content='Salvatore”-National Research \\nCounc'),\n",
       " Document(metadata={}, page_content='il (IEOS-CNR), Italy; Simona Camora'),\n",
       " Document(metadata={}, page_content='ni, Institute of Experimental Endoc'),\n",
       " Document(metadata={}, page_content='rinology and Oncology “G. Salvatore'),\n",
       " Document(metadata={}, page_content='”-National \\nResearch Council (IEOS-'),\n",
       " Document(metadata={}, page_content='CNR), Italy\\nReceived: May 26, 2023 '),\n",
       " Document(metadata={}, page_content=' Accepted: December 26, 2023  Publi'),\n",
       " Document(metadata={}, page_content='shed: February 28, 2024\\nCite this a'),\n",
       " Document(metadata={}, page_content='rticle: De Santis P, Perrone M, Gua'),\n",
       " Document(metadata={}, page_content='rini C, Santoro AN, Laface C, Carro'),\n",
       " Document(metadata={}, page_content='zzo D, et al. Early-stage triple ne'),\n",
       " Document(metadata={}, page_content='gative breast \\ncancer: the therapeu'),\n",
       " Document(metadata={}, page_content='tic role of immunotherapy and the p'),\n",
       " Document(metadata={}, page_content='rognostic value of pathological com'),\n",
       " Document(metadata={}, page_content='plete response. Explor Target \\nAnti'),\n",
       " Document(metadata={}, page_content='tumor Ther. 2024;5:232–50. https://'),\n",
       " Document(metadata={}, page_content='doi.org/10.37349/etat.2024.00215\\nAb'),\n",
       " Document(metadata={}, page_content='stract\\nTriple negative breast cance'),\n",
       " Document(metadata={}, page_content='r (TNBC) represents an aggressive d'),\n",
       " Document(metadata={}, page_content='isease associated with a high risk '),\n",
       " Document(metadata={}, page_content='of \\nrecurrence after curative treat'),\n",
       " Document(metadata={}, page_content='ment and a poor prognosis in the me'),\n",
       " Document(metadata={}, page_content='tastatic setting. Chemotherapy was '),\n",
       " Document(metadata={}, page_content='for \\nyears the only treatment avail'),\n",
       " Document(metadata={}, page_content='able in the early and metastatic se'),\n",
       " Document(metadata={}, page_content='tting, due to the lack of actionabl'),\n",
       " Document(metadata={}, page_content='e targets. \\nClinical practice has c'),\n",
       " Document(metadata={}, page_content='hanged following the results obtain'),\n",
       " Document(metadata={}, page_content='ed with the addition of immunothera'),\n",
       " Document(metadata={}, page_content='py to \\nstandard chemotherapy, the d'),\n",
       " Document(metadata={}, page_content='evelopment of novel drugs [i.e. ant'),\n",
       " Document(metadata={}, page_content='ibody-drug conjugates (ADCs)], and '),\n",
       " Document(metadata={}, page_content='the \\nuse of targeted treatments for'),\n",
       " Document(metadata={}, page_content=' patients carrying germline pathoge'),\n",
       " Document(metadata={}, page_content='nic breast cancer susceptibility ge'),\n",
       " Document(metadata={}, page_content='nes \\n(BRCA) 1 or BRCA 2 variants. T'),\n",
       " Document(metadata={}, page_content='he treatment of early-stage disease'),\n",
       " Document(metadata={}, page_content=' has had a shift in clinical practi'),\n",
       " Document(metadata={}, page_content='ce since \\nJuly 2021, after the Food'),\n",
       " Document(metadata={}, page_content=' and Drug Administration (FDA) appr'),\n",
       " Document(metadata={}, page_content='oval of pembrolizumab in associatio'),\n",
       " Document(metadata={}, page_content='n with \\nchemotherapy as neoadjuvant'),\n",
       " Document(metadata={}, page_content=' treatment for TNBC and as a single'),\n",
       " Document(metadata={}, page_content=' agent in the subsequent adjuvant s'),\n",
       " Document(metadata={}, page_content='etting. \\nThis intensive treatment b'),\n",
       " Document(metadata={}, page_content='ased on the combination of a poly-c'),\n",
       " Document(metadata={}, page_content='hemotherapy and an immune checkpoin'),\n",
       " Document(metadata={}, page_content='t \\ninhibitor (ICI) led to the impro'),\n",
       " Document(metadata={}, page_content='vement of short- and long-term outc'),\n",
       " Document(metadata={}, page_content='omes, but it has highlighted some n'),\n",
       " Document(metadata={}, page_content='ew \\nunmet clinical needs in the tre'),\n",
       " Document(metadata={}, page_content='atment of early-stage TNBC: the sel'),\n",
       " Document(metadata={}, page_content='ection of the most effective adjuva'),\n",
       " Document(metadata={}, page_content='nt \\ntherapy and the integration of '),\n",
       " Document(metadata={}, page_content='pembrolizumab with other therapeuti'),\n",
       " Document(metadata={}, page_content='c strategies [capecitabine, poly(AD'),\n",
       " Document(metadata={}, page_content='P-\\nribose) polymerase (PARP) inhibi'),\n",
       " Document(metadata={}, page_content='tors] based on the achievement of p'),\n",
       " Document(metadata={}, page_content='athologic complete response (pCR); '),\n",
       " Document(metadata={}, page_content='\\nthe identification of predictive b'),\n",
       " Document(metadata={}, page_content='iomarkers to select patients who co'),\n",
       " Document(metadata={}, page_content='uld most benefit from the addition '),\n",
       " Document(metadata={}, page_content='of \\nICI, to minimize toxicities and'),\n",
       " Document(metadata={}, page_content=' to maximize outcomes; the possibil'),\n",
       " Document(metadata={}, page_content='ity of de-escalating chemotherapy i'),\n",
       " Document(metadata={}, page_content='n favor \\nof immune-combo or novel a'),\n",
       " Document(metadata={}, page_content='gents, such as ADCs; the role of im'),\n",
       " Document(metadata={}, page_content='munotherapy in estrogen receptor (E'),\n",
       " Document(metadata={}, page_content='R)-low \\npatients. The advent of imm'),\n",
       " Document(metadata={}, page_content='unotherapy not only addresses curre'),\n",
       " Document(metadata={}, page_content='nt challenges in TNBC treatment but'),\n",
       " Document(metadata={}, page_content=' also \\nholds the promise of a radic'),\n",
       " Document(metadata={}, page_content='al transformation in its therapeuti'),\n",
       " Document(metadata={}, page_content='c paradigm, enhancing significantly'),\n",
       " Document(metadata={}, page_content=' clinical \\noutcomes and offering ne'),\n",
       " Document(metadata={}, page_content='w perspectives for patients grappli'),\n",
       " Document(metadata={}, page_content='ng with this aggressive form of bre'),\n",
       " Document(metadata={}, page_content='ast cancer.\\nExplor Target Antitumor'),\n",
       " Document(metadata={}, page_content=' Ther. 2024;5:232–50 | https://doi.'),\n",
       " Document(metadata={}, page_content='org/10.37349/etat.2024.00215\\nPage 2'),\n",
       " Document(metadata={}, page_content='33\\nKeywords\\nTriple negative breast '),\n",
       " Document(metadata={}, page_content='cancer, immunotherapy, pathological'),\n",
       " Document(metadata={}, page_content=' complete response, neoadjuvant com'),\n",
       " Document(metadata={}, page_content='bination \\ntreatment, adjuvant treat'),\n",
       " Document(metadata={}, page_content='ment\\nIntroduction\\nTriple negative B'),\n",
       " Document(metadata={}, page_content='reast Cancer (TNBC) is a histologic'),\n",
       " Document(metadata={}, page_content='al subtype of breast cancer (BC) ch'),\n",
       " Document(metadata={}, page_content='aracterized by the \\nimmunohistochem'),\n",
       " Document(metadata={}, page_content='ical lack of expression (< 1%) of e'),\n",
       " Document(metadata={}, page_content='strogen receptor (ER), progesterone'),\n",
       " Document(metadata={}, page_content=' receptor (PgR), \\nand human epiderm'),\n",
       " Document(metadata={}, page_content='al growth factor receptor 2 (HER2).'),\n",
       " Document(metadata={}, page_content=' It accounts for approximately 10–2'),\n",
       " Document(metadata={}, page_content='0% of all BC, \\naffecting mainly you'),\n",
       " Document(metadata={}, page_content='ng, premenopausal women, and indivi'),\n",
       " Document(metadata={}, page_content='duals with inherited gene alteratio'),\n",
       " Document(metadata={}, page_content='ns, such as BC \\nsusceptibility gene'),\n",
       " Document(metadata={}, page_content='s 1/2 (BRCA 1/2) mutations [1–3]. I'),\n",
       " Document(metadata={}, page_content='t notably presents an aggressive bi'),\n",
       " Document(metadata={}, page_content='ological behavior \\nwith a trend to '),\n",
       " Document(metadata={}, page_content='have a higher grade and an often ly'),\n",
       " Document(metadata={}, page_content='mph node involvement at diagnosis, '),\n",
       " Document(metadata={}, page_content='an inclination to \\nmetastasize afte'),\n",
       " Document(metadata={}, page_content='r curative treatment, and a poorer '),\n",
       " Document(metadata={}, page_content='prognosis in metastatic setting whe'),\n",
       " Document(metadata={}, page_content='n compared with \\nother BC subtypes '),\n",
       " Document(metadata={}, page_content='[4, 5].\\nFor decades, treatment for '),\n",
       " Document(metadata={}, page_content='early TNBC has been based on surger'),\n",
       " Document(metadata={}, page_content='y and subsequent adjuvant \\nchemothe'),\n",
       " Document(metadata={}, page_content='rapy (CHT) for the reduction of dis'),\n",
       " Document(metadata={}, page_content='ease recurrence [6]. Therefore, con'),\n",
       " Document(metadata={}, page_content='ventional cytotoxic CHT has \\nrepres'),\n",
       " Document(metadata={}, page_content='ented the backbone of systemic trea'),\n",
       " Document(metadata={}, page_content='tment in the early TNBC, including '),\n",
       " Document(metadata={}, page_content='neoadjuvant treatment, which \\nused '),\n",
       " Document(metadata={}, page_content='to reduce tumor size in larger tumo'),\n",
       " Document(metadata={}, page_content='rs increasing the chances of a brea'),\n",
       " Document(metadata={}, page_content='st-conserving surgery [7, 8]. In \\nr'),\n",
       " Document(metadata={}, page_content='ecent years the development of nove'),\n",
       " Document(metadata={}, page_content='l therapeutic approaches has been d'),\n",
       " Document(metadata={}, page_content='ifficult, due to the heterogeneity '),\n",
       " Document(metadata={}, page_content='\\nof TNBC and lack of therapeutic ta'),\n",
       " Document(metadata={}, page_content='rgets [9, 10]. Nevertheless, immuno'),\n",
       " Document(metadata={}, page_content='therapy and poly(ADP-ribose) \\npolym'),\n",
       " Document(metadata={}, page_content='erase (PARP) inhibitors have shown '),\n",
       " Document(metadata={}, page_content='survival benefits in recent studies'),\n",
       " Document(metadata={}, page_content='.\\nSpecifically, combinations of imm'),\n",
       " Document(metadata={}, page_content='une checkpoint inhibitors (ICIs) wi'),\n",
       " Document(metadata={}, page_content='th CHT or other alternative \\ntherap'),\n",
       " Document(metadata={}, page_content='eutic compounds could emerge as a s'),\n",
       " Document(metadata={}, page_content='uccessful therapeutic approach in t'),\n",
       " Document(metadata={}, page_content='he management of TNBC \\npatients. De'),\n",
       " Document(metadata={}, page_content='spite the progress in ICIs represen'),\n",
       " Document(metadata={}, page_content='ting a notable milestone in TNBC tr'),\n",
       " Document(metadata={}, page_content='eatment, additional \\ninvestigations'),\n",
       " Document(metadata={}, page_content=' are necessary to tackle this issue'),\n",
       " Document(metadata={}, page_content=' comprehensively. A profound compre'),\n",
       " Document(metadata={}, page_content='hension of tumor \\nsubtypes, alongsi'),\n",
       " Document(metadata={}, page_content='de tumor microenvironment (TME) and'),\n",
       " Document(metadata={}, page_content=' in terms of molecular, genetic, an'),\n",
       " Document(metadata={}, page_content='d immune \\naspects, would amplify th'),\n",
       " Document(metadata={}, page_content='e potential for developing targeted'),\n",
       " Document(metadata={}, page_content=' immunotherapy to achieve superior '),\n",
       " Document(metadata={}, page_content='\\ntherapeutic effectiveness, especia'),\n",
       " Document(metadata={}, page_content='lly in TNBC [11].\\nTherefore, in thi'),\n",
       " Document(metadata={}, page_content='s review, we aimed to investigate t'),\n",
       " Document(metadata={}, page_content='he role of immunotherapy in early-s'),\n",
       " Document(metadata={}, page_content='tage TNBC, the \\nprognostic value of'),\n",
       " Document(metadata={}, page_content=' pathologic complete response (pCR)'),\n",
       " Document(metadata={}, page_content=' with its therapeutic implications,'),\n",
       " Document(metadata={}, page_content=' and the future \\nperspectives regar'),\n",
       " Document(metadata={}, page_content='ding the systemic treatment of earl'),\n",
       " Document(metadata={}, page_content='y TNBC, including the discovery of '),\n",
       " Document(metadata={}, page_content='new biomarkers.\\nThe landscape of im'),\n",
       " Document(metadata={}, page_content='munotherapy in TNBC\\nThe immune syst'),\n",
       " Document(metadata={}, page_content='em plays a crucial role in TNBC com'),\n",
       " Document(metadata={}, page_content='pared to the other molecular subtyp'),\n",
       " Document(metadata={}, page_content='es of BC. Although \\noriginally BC w'),\n",
       " Document(metadata={}, page_content='as considered non-immunogenic, TNBC'),\n",
       " Document(metadata={}, page_content=' has a high immunogenic potential, '),\n",
       " Document(metadata={}, page_content='making it a \\npromising candidate fo'),\n",
       " Document(metadata={}, page_content='r immunotherapy, especially with IC'),\n",
       " Document(metadata={}, page_content='Is [12, 13]. TNBC immunogenicity is'),\n",
       " Document(metadata={}, page_content=' related to \\nintrinsic tumor cell s'),\n",
       " Document(metadata={}, page_content='ignatures and tumoral surrounding m'),\n",
       " Document(metadata={}, page_content='icroenvironment features.\\nOver the '),\n",
       " Document(metadata={}, page_content='last decades thanks to emerging tec'),\n",
       " Document(metadata={}, page_content='hnologies such as next-generation s'),\n",
       " Document(metadata={}, page_content='equencing (NGS), the \\nknowledge of '),\n",
       " Document(metadata={}, page_content='the molecular and genetic backgroun'),\n",
       " Document(metadata={}, page_content='d of TNBC improved, bringing to lig'),\n",
       " Document(metadata={}, page_content='ht its intertumoral \\nand intratumor'),\n",
       " Document(metadata={}, page_content='al heterogeneity.\\nA first classific'),\n",
       " Document(metadata={}, page_content='ation divided TNBC into six subtype'),\n",
       " Document(metadata={}, page_content='s: basal-like 1 (BL1), basal-like 2'),\n",
       " Document(metadata={}, page_content=' (BL2), \\nmesenchymal (M), M stem-li'),\n",
       " Document(metadata={}, page_content='ke (MSL), immunomodulatory (IM), an'),\n",
       " Document(metadata={}, page_content='d luminal androgen receptor (LAR) ['),\n",
       " Document(metadata={}, page_content='14].\\nSubsequently, analyzing RNA an'),\n",
       " Document(metadata={}, page_content='d DNA-based profiles of 198 TNBC tu'),\n",
       " Document(metadata={}, page_content='mors, a four-type classification of'),\n",
       " Document(metadata={}, page_content=' \\nTNBC was shaped: basal-like immun'),\n",
       " Document(metadata={}, page_content='osuppressed (BLIS), basal-like immu'),\n",
       " Document(metadata={}, page_content='ne-activated (BLIA), M and LAR \\n[15'),\n",
       " Document(metadata={}, page_content=']. This classification was further '),\n",
       " Document(metadata={}, page_content='revised with the identification of '),\n",
       " Document(metadata={}, page_content='four specific TNBC subtypes: BL1, B'),\n",
       " Document(metadata={}, page_content='L2, \\nM, and LAR, omitting IM and MS'),\n",
       " Document(metadata={}, page_content='L because of the dependence of thes'),\n",
       " Document(metadata={}, page_content='e two subtypes on the TME features '),\n",
       " Document(metadata={}, page_content='\\n[14].\\nExplor Target Antitumor Ther'),\n",
       " Document(metadata={}, page_content='. 2024;5:232–50 | https://doi.org/1'),\n",
       " Document(metadata={}, page_content='0.37349/etat.2024.00215\\nPage 234\\nIn'),\n",
       " Document(metadata={}, page_content=' addition, TNBC could be classified'),\n",
       " Document(metadata={}, page_content=' into three microenvironment phenot'),\n",
       " Document(metadata={}, page_content='ypes or clusters:\\nCluster 1: “immun'),\n",
       " Document(metadata={}, page_content='e-desert” with poor immune cell per'),\n",
       " Document(metadata={}, page_content='meation, due to a high presence of '),\n",
       " Document(metadata={}, page_content='MYC \\namplifications and, consequent'),\n",
       " Document(metadata={}, page_content='ly, a lower recruitment of innate i'),\n",
       " Document(metadata={}, page_content='mmune cells.\\n(1).\\nCluster 2: “innat'),\n",
       " Document(metadata={}, page_content='e immune-inactivated” characterized'),\n",
       " Document(metadata={}, page_content=' by a hyper-activation of \\nphosphat'),\n",
       " Document(metadata={}, page_content='idylinositide 3-kinase/protein kina'),\n",
       " Document(metadata={}, page_content='se B (PI3K-AKT) pathway in tumor ce'),\n",
       " Document(metadata={}, page_content='lls, low tumor \\nantigen burden and '),\n",
       " Document(metadata={}, page_content='infiltration of deactivated innate '),\n",
       " Document(metadata={}, page_content='immune cells, fibroblasts, and endo'),\n",
       " Document(metadata={}, page_content='thelial \\ncells. Clusters 1 and 2 ar'),\n",
       " Document(metadata={}, page_content='e therefore referred to as “cold tu'),\n",
       " Document(metadata={}, page_content='mors”.\\n(2).\\nCluster 3: “immune-infl'),\n",
       " Document(metadata={}, page_content='amed”, the so-called “hot tumor” th'),\n",
       " Document(metadata={}, page_content='at represents about 30% of TNBCs an'),\n",
       " Document(metadata={}, page_content='d \\nis characterized by an abundant '),\n",
       " Document(metadata={}, page_content='adaptive and innate immune cells in'),\n",
       " Document(metadata={}, page_content='filtration and with a high \\nexpress'),\n",
       " Document(metadata={}, page_content='ion of immune checkpoint molecules '),\n",
       " Document(metadata={}, page_content='[16].\\n(3).\\nThe potential “hot” conv'),\n",
       " Document(metadata={}, page_content='ersion of “cold” tumors could impro'),\n",
       " Document(metadata={}, page_content='ve the efficacy of cancer immunothe'),\n",
       " Document(metadata={}, page_content='rapy. \\nFor example, local IM therap'),\n",
       " Document(metadata={}, page_content='ies can express a synergistic effec'),\n",
       " Document(metadata={}, page_content='t with immunotherapy by acting on \\n'),\n",
       " Document(metadata={}, page_content='components of the TME and immune sy'),\n",
       " Document(metadata={}, page_content='stem function, such as elevating th'),\n",
       " Document(metadata={}, page_content='e expression of tumor antigens \\nand'),\n",
       " Document(metadata={}, page_content=' increasing the recruitment of acti'),\n",
       " Document(metadata={}, page_content='vated immune cells in the TME [17].'),\n",
       " Document(metadata={}, page_content='\\nTNBC cancer cell immunological fea'),\n",
       " Document(metadata={}, page_content='tures include genomic instability a'),\n",
       " Document(metadata={}, page_content='nd high tumor mutational \\nburden (T'),\n",
       " Document(metadata={}, page_content='MB), resulting in more somatic muta'),\n",
       " Document(metadata={}, page_content='tions and neoantigens [18].\\nMoreove'),\n",
       " Document(metadata={}, page_content='r, approximately 10–20% of TNBC har'),\n",
       " Document(metadata={}, page_content='bor BRCA 1 or BRCA 2 germinal mutat'),\n",
       " Document(metadata={}, page_content='ions, with a \\nconsequent hereditary'),\n",
       " Document(metadata={}, page_content=' deficit in the DNA repair mechanis'),\n",
       " Document(metadata={}, page_content='m and strong genomic instability. S'),\n",
       " Document(metadata={}, page_content='everal studies \\nhave demonstrated t'),\n",
       " Document(metadata={}, page_content='hat TNBC-carrying BRCA mutations ar'),\n",
       " Document(metadata={}, page_content='e more sensitive to DNA-damaging dr'),\n",
       " Document(metadata={}, page_content='ugs such as \\nanthracyclines, but al'),\n",
       " Document(metadata={}, page_content='so platinum agents and PARP inhibit'),\n",
       " Document(metadata={}, page_content='ors [19–21]. Sensitivity to these d'),\n",
       " Document(metadata={}, page_content='rugs was also \\nobserved in tumors w'),\n",
       " Document(metadata={}, page_content='ith alterations in other genes, sha'),\n",
       " Document(metadata={}, page_content='ring BRCA-mutant phenotype in the a'),\n",
       " Document(metadata={}, page_content='bsence of a \\nBRCA 1/2 mutation, nam'),\n",
       " Document(metadata={}, page_content='ely “BRCAness” [22, 23].\\nTumors wit'),\n",
       " Document(metadata={}, page_content='h BRCA 1/2 mutations or BRCAness TN'),\n",
       " Document(metadata={}, page_content='BC are more immunogenic than TNBC w'),\n",
       " Document(metadata={}, page_content='ithout these \\ngenetic alterations ['),\n",
       " Document(metadata={}, page_content='24–26].\\nCompared to the other BC su'),\n",
       " Document(metadata={}, page_content='btypes the immunogenic TME features'),\n",
       " Document(metadata={}, page_content=' in TNBC consist of higher levels o'),\n",
       " Document(metadata={}, page_content='f \\nvascular endothelial growth fact'),\n",
       " Document(metadata={}, page_content='or (VEGF), that promote tumor cell '),\n",
       " Document(metadata={}, page_content='growth and migration such as mitoge'),\n",
       " Document(metadata={}, page_content='n-\\nactivated protein kinases (MAPKs'),\n",
       " Document(metadata={}, page_content='), tumor-associated macrophages (TA'),\n",
       " Document(metadata={}, page_content='Ms), and tumor-infiltrating \\nlympho'),\n",
       " Document(metadata={}, page_content='cytes (TILs), white blood cells tha'),\n",
       " Document(metadata={}, page_content='t migrate towards the tumor, leadin'),\n",
       " Document(metadata={}, page_content='g to an important \\nimmunogenic effe'),\n",
       " Document(metadata={}, page_content='ct and consequently that are involv'),\n",
       " Document(metadata={}, page_content='ed in killing cancer cells [27–29].'),\n",
       " Document(metadata={}, page_content='\\nTAMs regulate the interaction betw'),\n",
       " Document(metadata={}, page_content='een the immune system and cancer ce'),\n",
       " Document(metadata={}, page_content='lls. CD163+ M2 macrophages, \\nwhich '),\n",
       " Document(metadata={}, page_content='are associated with tumors characte'),\n",
       " Document(metadata={}, page_content='rized by higher proliferation and p'),\n",
       " Document(metadata={}, page_content='oorer differentiation [30], are \\nmo'),\n",
       " Document(metadata={}, page_content='re present in TNBC and basal-like B'),\n",
       " Document(metadata={}, page_content='C [31]. A prosperous infiltration o'),\n",
       " Document(metadata={}, page_content='f TILs is found in TNBC tumors and '),\n",
       " Document(metadata={}, page_content='\\nthe stroma surrounding them, with '),\n",
       " Document(metadata={}, page_content='a recognized predictive and prognos'),\n",
       " Document(metadata={}, page_content='tic role, specifically for CD4+ CD8'),\n",
       " Document(metadata={}, page_content='+ \\nT cells [32]. Several studies ha'),\n",
       " Document(metadata={}, page_content='ve reported better response to neoa'),\n",
       " Document(metadata={}, page_content='djuvant CHT (NACT) [33] and better '),\n",
       " Document(metadata={}, page_content='\\nclinical outcomes in BC with high '),\n",
       " Document(metadata={}, page_content='TIL infiltrate [34–39]. Based on th'),\n",
       " Document(metadata={}, page_content='is evidence, the international TILs'),\n",
       " Document(metadata={}, page_content=' \\nworking group started standardizi'),\n",
       " Document(metadata={}, page_content='ng the evaluation of BC TILs to use'),\n",
       " Document(metadata={}, page_content=' it in clinical practice identifyin'),\n",
       " Document(metadata={}, page_content='g those \\npatients that may benefit '),\n",
       " Document(metadata={}, page_content='from emerging immunotherapies with '),\n",
       " Document(metadata={}, page_content='ICIs or combination therapies [40].'),\n",
       " Document(metadata={}, page_content='\\nAll these TME elements contribute '),\n",
       " Document(metadata={}, page_content='to TNBC immunogenicity which also a'),\n",
       " Document(metadata={}, page_content='ppears to be closely related to \\nth'),\n",
       " Document(metadata={}, page_content='e concept of TMB, depending on the '),\n",
       " Document(metadata={}, page_content='ineffective DNA repair system with '),\n",
       " Document(metadata={}, page_content='the consequent generation of \\nhigh '),\n",
       " Document(metadata={}, page_content='rates of neoantigens. The upregulat'),\n",
       " Document(metadata={}, page_content='ed antigen presentation system lead'),\n",
       " Document(metadata={}, page_content='s to an increasing number of \\ninnat'),\n",
       " Document(metadata={}, page_content='e and adaptative immune cells and m'),\n",
       " Document(metadata={}, page_content='any cytokines interplaying with can'),\n",
       " Document(metadata={}, page_content='cer cells. However, the exact \\nrela'),\n",
       " Document(metadata={}, page_content='tionship between TMB, neoantigens, '),\n",
       " Document(metadata={}, page_content='and immune infiltration is not yet '),\n",
       " Document(metadata={}, page_content='completely understood, and \\nsome st'),\n",
       " Document(metadata={}, page_content='udies have reported an inverse asso'),\n",
       " Document(metadata={}, page_content='ciation between immune cells in TME'),\n",
       " Document(metadata={}, page_content=' and the rate of somatic \\ncopy numb'),\n",
       " Document(metadata={}, page_content='er alterations [41, 42].\\nMoreover, '),\n",
       " Document(metadata={}, page_content='although TMB is comparable across t'),\n",
       " Document(metadata={}, page_content='he three clusters of TNBC, the “imm'),\n",
       " Document(metadata={}, page_content='une-inflated” \\nphenotype is charact'),\n",
       " Document(metadata={}, page_content='erized by a higher degree of immune'),\n",
       " Document(metadata={}, page_content=' cells in the TME, but also a high '),\n",
       " Document(metadata={}, page_content='expression of \\nimmune checkpoints b'),\n",
       " Document(metadata={}, page_content='y cancer cells [16]. The rate of TI'),\n",
       " Document(metadata={}, page_content='Ls, indeed, has been positively rel'),\n",
       " Document(metadata={}, page_content='ated to \\nExplor Target Antitumor Th'),\n",
       " Document(metadata={}, page_content='er. 2024;5:232–50 | https://doi.org'),\n",
       " Document(metadata={}, page_content='/10.37349/etat.2024.00215\\nPage 235\\n'),\n",
       " Document(metadata={}, page_content='programmed death ligand 1 (PD-L1) e'),\n",
       " Document(metadata={}, page_content='xpression [43]. PD-L1 is an immune '),\n",
       " Document(metadata={}, page_content='checkpoint that mediates local \\nimm'),\n",
       " Document(metadata={}, page_content='une escape in many tumors inducing '),\n",
       " Document(metadata={}, page_content='saturation of activated T cells. Ev'),\n",
       " Document(metadata={}, page_content='en if PD-L1 prognostic role is yet '),\n",
       " Document(metadata={}, page_content='\\ncontroversial [44], however it res'),\n",
       " Document(metadata={}, page_content='ults more overexpressed in TNBC com'),\n",
       " Document(metadata={}, page_content='pared with other BC and it can \\npre'),\n",
       " Document(metadata={}, page_content='dict responsiveness to immunotherap'),\n",
       " Document(metadata={}, page_content='y [16].\\nTherefore, TNBC represents '),\n",
       " Document(metadata={}, page_content='an aggressive BC subtype, associate'),\n",
       " Document(metadata={}, page_content='d with high mutational load, high \\n'),\n",
       " Document(metadata={}, page_content='tumor immunogenicity and TME divers'),\n",
       " Document(metadata={}, page_content='ity.\\nNew paradigms in early TNBC: f'),\n",
       " Document(metadata={}, page_content='rom CHT to immunotherapy\\nCHT in adj'),\n",
       " Document(metadata={}, page_content='uvant treatment for TNBC\\nIn early T'),\n",
       " Document(metadata={}, page_content='NBC patients, CHT represents the ma'),\n",
       " Document(metadata={}, page_content='instay of adjuvant and neoadjuvant '),\n",
       " Document(metadata={}, page_content='treatments. Adjuvant \\nCHT is recomm'),\n",
       " Document(metadata={}, page_content='ended for tumor sizes greater than '),\n",
       " Document(metadata={}, page_content='1.0 cm and patients with nodal invo'),\n",
       " Document(metadata={}, page_content='lvement, regardless \\nof tumor size.'),\n",
       " Document(metadata={}, page_content=' Therefore, it can be considered fo'),\n",
       " Document(metadata={}, page_content='r tumor sizes between 0.6–1.0 cm [4'),\n",
       " Document(metadata={}, page_content='5]. A recent large meta-\\nanalysis d'),\n",
       " Document(metadata={}, page_content='emonstrated that adjuvant CHT with '),\n",
       " Document(metadata={}, page_content='anthracyclines-containing regimens '),\n",
       " Document(metadata={}, page_content='plus taxanes, compared \\nwith no CHT'),\n",
       " Document(metadata={}, page_content=', can reduce BC mortality rates by '),\n",
       " Document(metadata={}, page_content='about 40% during the first decade a'),\n",
       " Document(metadata={}, page_content='fter diagnosis. Moreover, \\nregimens'),\n",
       " Document(metadata={}, page_content=' with higher cumulative and dose-de'),\n",
       " Document(metadata={}, page_content='nse schedules of anthracycline (wit'),\n",
       " Document(metadata={}, page_content='h granulocyte colony-\\nstimulating f'),\n",
       " Document(metadata={}, page_content='actor support) have shown better su'),\n",
       " Document(metadata={}, page_content='rvival benefits and more reductions'),\n",
       " Document(metadata={}, page_content=' in recurrence [46]. \\nThree-weekly '),\n",
       " Document(metadata={}, page_content='docetaxel and paclitaxel can be con'),\n",
       " Document(metadata={}, page_content='sidered in adjuvant setting, but we'),\n",
       " Document(metadata={}, page_content='ekly paclitaxel, in a \\nsubgroup ana'),\n",
       " Document(metadata={}, page_content='lysis, has shown improved outcomes '),\n",
       " Document(metadata={}, page_content='and is preferred for TNBC [47]. In '),\n",
       " Document(metadata={}, page_content='TNBC in frail patients \\nwith a know'),\n",
       " Document(metadata={}, page_content='n history of heart disease, to mini'),\n",
       " Document(metadata={}, page_content='mize the cardiotoxicity of adjuvant'),\n",
       " Document(metadata={}, page_content=' treatments, docetaxel \\ncombined wi'),\n",
       " Document(metadata={}, page_content='th cyclophosphamide (TC) has proven'),\n",
       " Document(metadata={}, page_content=' to be a viable alternative to doxo'),\n",
       " Document(metadata={}, page_content='rubicin and \\ncyclophosphamide (AC),'),\n",
       " Document(metadata={}, page_content=' demonstrating a favorable disease-'),\n",
       " Document(metadata={}, page_content='free survival (DFS) [48]. Therefore'),\n",
       " Document(metadata={}, page_content=', there is a \\nbroad spectrum of che'),\n",
       " Document(metadata={}, page_content='motherapeutic treatments for early '),\n",
       " Document(metadata={}, page_content='TNBC that should be customised acco'),\n",
       " Document(metadata={}, page_content='rding to the \\npatient and expected '),\n",
       " Document(metadata={}, page_content='toxicities.\\nThe role of platinum in'),\n",
       " Document(metadata={}, page_content=' adjuvant setting for TNBC\\nTNBC pat'),\n",
       " Document(metadata={}, page_content='ients commonly harbor BRCA 1/2 or B'),\n",
       " Document(metadata={}, page_content='RCAness mutations with a homologous'),\n",
       " Document(metadata={}, page_content=' recombination \\ndeficiency (HRD) th'),\n",
       " Document(metadata={}, page_content='at makes them particularly suscepti'),\n",
       " Document(metadata={}, page_content='ble to platinum agents due to their'),\n",
       " Document(metadata={}, page_content=' ability to hit \\ncancer cells that '),\n",
       " Document(metadata={}, page_content='have deficient DNA repair mechanism'),\n",
       " Document(metadata={}, page_content='s [49–51]. Several retrospective si'),\n",
       " Document(metadata={}, page_content='ngle-center studies \\nhave explored '),\n",
       " Document(metadata={}, page_content='the role of adjuvant platinum combi'),\n",
       " Document(metadata={}, page_content='ned with standard anthracycline and'),\n",
       " Document(metadata={}, page_content=' taxane-based \\nregimens, with contr'),\n",
       " Document(metadata={}, page_content='oversial results not showing clear '),\n",
       " Document(metadata={}, page_content='clinical benefits [52, 53]. Neverth'),\n",
       " Document(metadata={}, page_content='eless, a recent \\nphase III trials h'),\n",
       " Document(metadata={}, page_content='ave demonstrated a longer 5-year DF'),\n",
       " Document(metadata={}, page_content='S (86.5% vs. 80.3%) with similar re'),\n",
       " Document(metadata={}, page_content='sults in distant DFS \\nand relapse-f'),\n",
       " Document(metadata={}, page_content='ree survival (RFS) of platinum-cont'),\n",
       " Document(metadata={}, page_content='aining adjuvant regimens (paclitaxe'),\n",
       " Document(metadata={}, page_content='l-carboplatin) \\ncompared to a stand'),\n",
       " Document(metadata={}, page_content='ard anthracyclines-containing regim'),\n",
       " Document(metadata={}, page_content='en followed by taxane, however with'),\n",
       " Document(metadata={}, page_content=' no benefit in \\noverall survival (O'),\n",
       " Document(metadata={}, page_content='S) [54].\\nAnother important factor i'),\n",
       " Document(metadata={}, page_content='s platinum resistance. Platinum sen'),\n",
       " Document(metadata={}, page_content='sitivity may be affected by changes'),\n",
       " Document(metadata={}, page_content=' in the \\nhazard ratio (HR) pathway '),\n",
       " Document(metadata={}, page_content='or, in the case of patients with BR'),\n",
       " Document(metadata={}, page_content='CA 1/2 mutations, by the secondary '),\n",
       " Document(metadata={}, page_content='\\nappearance of new BRCA 1 or 2 muta'),\n",
       " Document(metadata={}, page_content='tions that make cancer cells less s'),\n",
       " Document(metadata={}, page_content='ensitive to platinum [55, 56].\\nOthe'),\n",
       " Document(metadata={}, page_content='r mechanisms of resistance to plati'),\n",
       " Document(metadata={}, page_content='num compounds are:\\nModification of '),\n",
       " Document(metadata={}, page_content='drug transport within the tumor cel'),\n",
       " Document(metadata={}, page_content='l, by determining decreased influx '),\n",
       " Document(metadata={}, page_content='or increased \\nefflux.\\n(1).\\nIncrease'),\n",
       " Document(metadata={}, page_content=' of detoxification systems.\\n(2).\\nDe'),\n",
       " Document(metadata={}, page_content='crease of cell apoptosis [57].\\n(3).'),\n",
       " Document(metadata={}, page_content='\\nTherefore, the benefit of adjuvant'),\n",
       " Document(metadata={}, page_content=' platinum-based regimens remains co'),\n",
       " Document(metadata={}, page_content='ntroversial and needs \\nvalidation b'),\n",
       " Document(metadata={}, page_content='y prospective adjuvant ongoing tria'),\n",
       " Document(metadata={}, page_content='ls.\\nExplor Target Antitumor Ther. 2'),\n",
       " Document(metadata={}, page_content='024;5:232–50 | https://doi.org/10.3'),\n",
       " Document(metadata={}, page_content='7349/etat.2024.00215\\nPage 236\\nNeoad'),\n",
       " Document(metadata={}, page_content='juvant treatments for TNBC\\nNACT\\nSev'),\n",
       " Document(metadata={}, page_content='eral treatment guidelines recommend'),\n",
       " Document(metadata={}, page_content=' NACT as the preferred option for s'),\n",
       " Document(metadata={}, page_content='tage II or III TNBC and for \\nstage '),\n",
       " Document(metadata={}, page_content='I with a tumor size greater than 1 '),\n",
       " Document(metadata={}, page_content='cm. It can be considered in stage I'),\n",
       " Document(metadata={}, page_content=' TNBC with a tumor size from \\n0.6 c'),\n",
       " Document(metadata={}, page_content='m to 1 cm and/or in the case of tum'),\n",
       " Document(metadata={}, page_content='ors with nodal micrometastases. [6,'),\n",
       " Document(metadata={}, page_content=' 45]. There is no significant \\ndiff'),\n",
       " Document(metadata={}, page_content='erence in survival benefits between'),\n",
       " Document(metadata={}, page_content=' patients receiving neoadjuvant or '),\n",
       " Document(metadata={}, page_content='adjuvant CHT after surgical \\nresect'),\n",
       " Document(metadata={}, page_content='ion. However, neoadjuvant treatment'),\n",
       " Document(metadata={}, page_content='s can be useful for inoperable tumo'),\n",
       " Document(metadata={}, page_content='rs rendering them operable \\nand the'),\n",
       " Document(metadata={}, page_content='y can also downstage patients with '),\n",
       " Document(metadata={}, page_content='operable BC promoting breast-conser'),\n",
       " Document(metadata={}, page_content='vation [58, 59]. The use of \\nneoadj'),\n",
       " Document(metadata={}, page_content='uvant treatments provides important'),\n",
       " Document(metadata={}, page_content=' prognostic information based on re'),\n",
       " Document(metadata={}, page_content='sponse to therapy. \\nAchieving a pCR'),\n",
       " Document(metadata={}, page_content=', defined as the lack of cancer cel'),\n",
       " Document(metadata={}, page_content='ls in tissue samples of breast and '),\n",
       " Document(metadata={}, page_content='axillary lymph nodes, \\nafter a neoa'),\n",
       " Document(metadata={}, page_content='djuvant treatment, is associated wi'),\n",
       " Document(metadata={}, page_content='th favorable disease-free and OS in'),\n",
       " Document(metadata={}, page_content=' early TNBC, as \\ndemonstrated in Co'),\n",
       " Document(metadata={}, page_content='llaborative Trials in Neoadjuvant B'),\n",
       " Document(metadata={}, page_content='reast Cancer (CTNeoBC) pooled analy'),\n",
       " Document(metadata={}, page_content='sis. In this \\nstudy, patients with '),\n",
       " Document(metadata={}, page_content='early BC treated with NACT and foll'),\n",
       " Document(metadata={}, page_content='owed by surgery who obtained pCR (y'),\n",
       " Document(metadata={}, page_content='pT0 ypN0, \\nypT0/is ypN0) were assoc'),\n",
       " Document(metadata={}, page_content='iated with improved event-free surv'),\n",
       " Document(metadata={}, page_content='ival (EFS) and OS, especially in TN'),\n",
       " Document(metadata={}, page_content='BC (HR = \\n0.24 and HR = 0.16, respe'),\n",
       " Document(metadata={}, page_content='ctively) [33]. Like adjuvant treatm'),\n",
       " Document(metadata={}, page_content='ent, traditional NACT is based on a'),\n",
       " Document(metadata={}, page_content='nthracyclines \\nand taxanes, and a d'),\n",
       " Document(metadata={}, page_content='ose-dense regimen is preferred in n'),\n",
       " Document(metadata={}, page_content='eoadjuvant settings based on proven'),\n",
       " Document(metadata={}, page_content=' improved DFS \\nand OS in a large me'),\n",
       " Document(metadata={}, page_content='ta-analysis [60].\\nIn recent years, '),\n",
       " Document(metadata={}, page_content='the use of platinum-based combinati'),\n",
       " Document(metadata={}, page_content='on regimens has been the focus of n'),\n",
       " Document(metadata={}, page_content='eoadjuvant \\ntreatment to increase t'),\n",
       " Document(metadata={}, page_content='he rate of pCR in TNBC. Three recen'),\n",
       " Document(metadata={}, page_content='t studies demonstrated that combini'),\n",
       " Document(metadata={}, page_content='ng platinum \\nwith taxane and anthra'),\n",
       " Document(metadata={}, page_content='cycline led to an improvement in th'),\n",
       " Document(metadata={}, page_content='e pCR rate in TNBC, with a similar '),\n",
       " Document(metadata={}, page_content='survival \\nbenefit [61–63]. In Brigh'),\n",
       " Document(metadata={}, page_content='tness Trial patients with II–III st'),\n",
       " Document(metadata={}, page_content='age TNBC were randomly assigned to '),\n",
       " Document(metadata={}, page_content='receive \\npaclitaxel alone, paclitax'),\n",
       " Document(metadata={}, page_content='el and carboplatin and this combina'),\n",
       " Document(metadata={}, page_content='tion with a PARP inhibitor, velipar'),\n",
       " Document(metadata={}, page_content='ib followed \\nby AC. Although the ad'),\n",
       " Document(metadata={}, page_content='dition of veliparib and carboplatin'),\n",
       " Document(metadata={}, page_content=' was associated with an increase of'),\n",
       " Document(metadata={}, page_content=' patients who \\nachieved a pCR compa'),\n",
       " Document(metadata={}, page_content='red to paclitaxel alone (53% vs. 31'),\n",
       " Document(metadata={}, page_content='%, P < 0.0001), but not to paclitax'),\n",
       " Document(metadata={}, page_content='el and \\ncarboplatin, this benefit c'),\n",
       " Document(metadata={}, page_content='ould be related to the addition of '),\n",
       " Document(metadata={}, page_content='the carboplatin [63]. The initial r'),\n",
       " Document(metadata={}, page_content='ationale for \\nusing the combination'),\n",
       " Document(metadata={}, page_content=' of platinum in NACT was that spora'),\n",
       " Document(metadata={}, page_content='dic TNBC can show BRCAness with a m'),\n",
       " Document(metadata={}, page_content='ajor \\nresponse to platinum regimens'),\n",
       " Document(metadata={}, page_content=' [50, 51]. However, the greatest be'),\n",
       " Document(metadata={}, page_content='nefit was seen in patients who were'),\n",
       " Document(metadata={}, page_content=' \\ngermline BRCA wild type, and only'),\n",
       " Document(metadata={}, page_content=' a marginal benefit was observed in'),\n",
       " Document(metadata={}, page_content=' the germline BRCA mutant \\nsubgroup'),\n",
       " Document(metadata={}, page_content=', as was shown in the recent GeparO'),\n",
       " Document(metadata={}, page_content='LA trial. In this trial, patients w'),\n",
       " Document(metadata={}, page_content='ere randomized to \\nneoadjuvant ther'),\n",
       " Document(metadata={}, page_content='apy with paclitaxel and carboplatin'),\n",
       " Document(metadata={}, page_content=' vs. neoadjuvant therapy with pacli'),\n",
       " Document(metadata={}, page_content='taxel and olaparib \\n(PARP inhibitor'),\n",
       " Document(metadata={}, page_content='). In both arms, the combination of'),\n",
       " Document(metadata={}, page_content=' epirubicin and cyclophosphamide wa'),\n",
       " Document(metadata={}, page_content='s administered \\nnext. This study, a'),\n",
       " Document(metadata={}, page_content='lthough limited by a small number o'),\n",
       " Document(metadata={}, page_content='f patients enrolled, showed an adva'),\n",
       " Document(metadata={}, page_content='ntage for the \\ncarboplatin arm in p'),\n",
       " Document(metadata={}, page_content='atients without BRCA mutation (germ'),\n",
       " Document(metadata={}, page_content=' or somatic) and high HRD. The 4-ye'),\n",
       " Document(metadata={}, page_content='ar invasive \\nDFS (iDFS) rate with o'),\n",
       " Document(metadata={}, page_content='laparib-paclitaxel was 81.2% vs. 93'),\n",
       " Document(metadata={}, page_content='.4% with carboplatin-paclitaxel (CP'),\n",
       " Document(metadata={}, page_content=') [HR = 3.03; \\n95% confidence inter'),\n",
       " Document(metadata={}, page_content='val (CI) = 0.67–13.67; log-rank P ='),\n",
       " Document(metadata={}, page_content=' 0.1290]. The 4-year OS rate was 89'),\n",
       " Document(metadata={}, page_content='.2% with the \\nolaparib combination '),\n",
       " Document(metadata={}, page_content='vs. 96.6% with carboplatin (HR = 3.'),\n",
       " Document(metadata={}, page_content='27; 95% CI = 0.39–27.20; log-rank P'),\n",
       " Document(metadata={}, page_content=' = 0.2444). \\nThe trend of the iDFS '),\n",
       " Document(metadata={}, page_content='curves was similar in the two treat'),\n",
       " Document(metadata={}, page_content='ment arms and independent of germli'),\n",
       " Document(metadata={}, page_content='ne or somatic \\nBRCA mutation [64].\\n'),\n",
       " Document(metadata={}, page_content='Platinum combinations are currently'),\n",
       " Document(metadata={}, page_content=' recommended for selected patients '),\n",
       " Document(metadata={}, page_content='with TNBC who require \\nadequate loc'),\n",
       " Document(metadata={}, page_content='al control before surgical resectio'),\n",
       " Document(metadata={}, page_content='n [45]. A more recent phase III tri'),\n",
       " Document(metadata={}, page_content='al presented at the San \\nAntonio Br'),\n",
       " Document(metadata={}, page_content='east Cancer Symposium evaluating th'),\n",
       " Document(metadata={}, page_content='e efficacy and safety of adding car'),\n",
       " Document(metadata={}, page_content='boplatin to standard \\nsequential ta'),\n",
       " Document(metadata={}, page_content='xane-anthracycline NACT in patients'),\n",
       " Document(metadata={}, page_content=' with TNBC who had no evidence of m'),\n",
       " Document(metadata={}, page_content='etastatic disease, \\nhas observed im'),\n",
       " Document(metadata={}, page_content='provements in terms of DFS (5-year '),\n",
       " Document(metadata={}, page_content='DFS were 70.6% and 64.5% respective'),\n",
       " Document(metadata={}, page_content='ly with a HR = \\n0.79, 95% CI = 0.61'),\n",
       " Document(metadata={}, page_content='–1.02, P = 0.073) and OS (5-year OS'),\n",
       " Document(metadata={}, page_content=' were 74.0% and 66.7% respectively '),\n",
       " Document(metadata={}, page_content='with a HR = \\n0.75, 95% CI = 0.57–0.'),\n",
       " Document(metadata={}, page_content='98, P = 0.034) with the addition of'),\n",
       " Document(metadata={}, page_content=' carboplatin, but these benefits we'),\n",
       " Document(metadata={}, page_content='re limited to \\npatients who were 50'),\n",
       " Document(metadata={}, page_content=' years of age or younger. Therefore'),\n",
       " Document(metadata={}, page_content=', the pCR in the intention-to-treat'),\n",
       " Document(metadata={}, page_content=' population was \\n54.5% in the carbo'),\n",
       " Document(metadata={}, page_content='platin arm and 40.3% in the control'),\n",
       " Document(metadata={}, page_content=' arm (P < 0.001) [65].\\nThe inclusio'),\n",
       " Document(metadata={}, page_content='n of platinum agents as NACT for TN'),\n",
       " Document(metadata={}, page_content='BC remains controversial. Long-term'),\n",
       " Document(metadata={}, page_content=' outcomes and \\nnew prospective stud'),\n",
       " Document(metadata={}, page_content='ies are needed to clarify the role '),\n",
       " Document(metadata={}, page_content='of platinum agents in this setting.'),\n",
       " Document(metadata={}, page_content='\\nExplor Target Antitumor Ther. 2024'),\n",
       " Document(metadata={}, page_content=';5:232–50 | https://doi.org/10.3734'),\n",
       " Document(metadata={}, page_content='9/etat.2024.00215\\nPage 237\\nNeoadjuv'),\n",
       " Document(metadata={}, page_content='ant immunotherapy\\nThe success of IC'),\n",
       " Document(metadata={}, page_content='Is in metastatic TNBC led to expand'),\n",
       " Document(metadata={}, page_content=' their role in neoadjuvant settings'),\n",
       " Document(metadata={}, page_content='. Pembrolizumab and \\natezolizumab h'),\n",
       " Document(metadata={}, page_content='ave shown progression-free survival'),\n",
       " Document(metadata={}, page_content=' (PFS) benefits in phase III trials'),\n",
       " Document(metadata={}, page_content=' in advanced setting \\n[66, 67]. In '),\n",
       " Document(metadata={}, page_content='contrast to atezolizumab that showe'),\n",
       " Document(metadata={}, page_content='d conflicting results [68, 69], pem'),\n",
       " Document(metadata={}, page_content='brolizumab consistently \\nshowed OS '),\n",
       " Document(metadata={}, page_content='benefits in advanced TNBC [66, 70].'),\n",
       " Document(metadata={}, page_content=' In early-stage TNBC two studies ev'),\n",
       " Document(metadata={}, page_content='aluated atezolizumab in \\nneoadjuvan'),\n",
       " Document(metadata={}, page_content='t setting. In the NeoTRIPaPDL1 tria'),\n",
       " Document(metadata={}, page_content='l, no improvement in pCR was shown '),\n",
       " Document(metadata={}, page_content='with the addition of \\natezolizumab '),\n",
       " Document(metadata={}, page_content='to a non-anthracycline-containing C'),\n",
       " Document(metadata={}, page_content='HT regimen [71]. More recent Impass'),\n",
       " Document(metadata={}, page_content='ion031 phase III \\nstudy evaluating '),\n",
       " Document(metadata={}, page_content='the association of atezolizumab to '),\n",
       " Document(metadata={}, page_content='a standard NACT (nab-palclitaxel we'),\n",
       " Document(metadata={}, page_content='ekly for 12 weeks \\nfollowed by 4 cy'),\n",
       " Document(metadata={}, page_content='cles of AC), has demonstrated a sig'),\n",
       " Document(metadata={}, page_content='nificant improvement of pCR rates i'),\n",
       " Document(metadata={}, page_content='n intention to treat \\n(ITT) populat'),\n",
       " Document(metadata={}, page_content='ion (58% in atezolizumab arm vs. 41'),\n",
       " Document(metadata={}, page_content='% in placebo arm, P = 0.0044), rega'),\n",
       " Document(metadata={}, page_content='rdless of PD-L1 status, \\nmeeting th'),\n",
       " Document(metadata={}, page_content='e primary endpoint of the study [72'),\n",
       " Document(metadata={}, page_content=']. Therefore, in early BC the combi'),\n",
       " Document(metadata={}, page_content='nation of pembrolizumab \\nwith pacli'),\n",
       " Document(metadata={}, page_content='taxel-carboplatin followed by anthr'),\n",
       " Document(metadata={}, page_content='acycline increased pCR rate and EFS'),\n",
       " Document(metadata={}, page_content=' rate in the KEYNOTE-522 \\ntrial, re'),\n",
       " Document(metadata={}, page_content='presenting a turning point for the '),\n",
       " Document(metadata={}, page_content='role of immunotherapy in neoadjuvan'),\n",
       " Document(metadata={}, page_content='t therapy of TNBC and \\nestablishing'),\n",
       " Document(metadata={}, page_content=' pembrolizumab as a standard treatm'),\n",
       " Document(metadata={}, page_content='ent during neoadjuvant treatment fo'),\n",
       " Document(metadata={}, page_content='r stage II and III \\nTNBC. The trial'),\n",
       " Document(metadata={}, page_content=' evaluated the combination of pembr'),\n",
       " Document(metadata={}, page_content='olizumab (18 cycles, 200 mg every 3'),\n",
       " Document(metadata={}, page_content=' weeks) combined \\nwith four cycles '),\n",
       " Document(metadata={}, page_content='of paclitaxel (weekly or 3-weekly) '),\n",
       " Document(metadata={}, page_content='and carboplatin (3-weekly), followe'),\n",
       " Document(metadata={}, page_content='d by 3-weekly AC for \\n4 cycles, com'),\n",
       " Document(metadata={}, page_content='pared to placebo with CHT. Pembroli'),\n",
       " Document(metadata={}, page_content='zumab arm showed a 13.6% improvemen'),\n",
       " Document(metadata={}, page_content='t in pCR [64.8% \\n(95% CI = 59.9–69.'),\n",
       " Document(metadata={}, page_content='5%) vs. 51.2% (95% CI = 44.1–58.3%)'),\n",
       " Document(metadata={}, page_content='] and in EFS rate [84.5% (95% CI = '),\n",
       " Document(metadata={}, page_content='81.7–86.9%) \\nvs. 76.8% (95% CI = 72'),\n",
       " Document(metadata={}, page_content='.2–80.7%)], meeting the primary end'),\n",
       " Document(metadata={}, page_content='point of the study, regardless noda'),\n",
       " Document(metadata={}, page_content='l \\ninvolvement and PD-L1 status. Th'),\n",
       " Document(metadata={}, page_content='e average duration of follow-up is '),\n",
       " Document(metadata={}, page_content='still immature, but a trend of \\nsup'),\n",
       " Document(metadata={}, page_content='eriority in terms of OS in the pemb'),\n",
       " Document(metadata={}, page_content='rolizumab arm was nevertheless dete'),\n",
       " Document(metadata={}, page_content='cted [73]. Limits of this study \\nar'),\n",
       " Document(metadata={}, page_content='e the lack of biomarkers that predi'),\n",
       " Document(metadata={}, page_content='ct what patient may benefit from th'),\n",
       " Document(metadata={}, page_content='e addition of pembrolizumab and \\nth'),\n",
       " Document(metadata={}, page_content='e non-utilization of dose-dense sch'),\n",
       " Document(metadata={}, page_content='edule of AC which showed superior O'),\n",
       " Document(metadata={}, page_content='S benefit in the neoadjuvant \\nsetti'),\n",
       " Document(metadata={}, page_content='ng in TNBC [74].\\nMoreover, the rece'),\n",
       " Document(metadata={}, page_content='nt GeparNuevo trial showed that dur'),\n",
       " Document(metadata={}, page_content='valumab (1,500 mg every 4 weeks) ad'),\n",
       " Document(metadata={}, page_content='ded to \\nNACT consisting of nab-pacl'),\n",
       " Document(metadata={}, page_content='itaxel 125 mg/m2 weekly for 12 week'),\n",
       " Document(metadata={}, page_content='s, followed by epirubicin/\\ncyclopho'),\n",
       " Document(metadata={}, page_content='sphamide every 2 weeks, in early TN'),\n",
       " Document(metadata={}, page_content='BC significantly improved iDFS (85.'),\n",
       " Document(metadata={}, page_content='6% with durvalumab vs. \\n77.2% with '),\n",
       " Document(metadata={}, page_content='placebo HR = 0.48, 95% CI = 0.24–0.'),\n",
       " Document(metadata={}, page_content='97, stratified log-rank P = 0.036) '),\n",
       " Document(metadata={}, page_content='and OS (95.2% vs. 83.5% \\nwith a HR '),\n",
       " Document(metadata={}, page_content='= 0.24, 95% CI = 0.08–0.72, P = 0.0'),\n",
       " Document(metadata={}, page_content='06), despite a modest pCR increase '),\n",
       " Document(metadata={}, page_content='and no adjuvant \\ncomponent of durva'),\n",
       " Document(metadata={}, page_content='lumab [75]. Future studies should a'),\n",
       " Document(metadata={}, page_content='im to define the role of immunother'),\n",
       " Document(metadata={}, page_content='apy in the \\ntreatment of early TNBC'),\n",
       " Document(metadata={}, page_content=', to define the ideal duration of t'),\n",
       " Document(metadata={}, page_content='hese treatments, and should researc'),\n",
       " Document(metadata={}, page_content='h new \\nbiomarkers to personalize tr'),\n",
       " Document(metadata={}, page_content='eatments.\\nPathological complete res'),\n",
       " Document(metadata={}, page_content='ponse: prognostic role and therapeu'),\n",
       " Document(metadata={}, page_content='tic \\nimplications\\nIn clinical pract'),\n",
       " Document(metadata={}, page_content='ice, the achievement of pCR after n'),\n",
       " Document(metadata={}, page_content='eoadjuvant treatment is correlated '),\n",
       " Document(metadata={}, page_content='to the improvement of \\nlong-term be'),\n",
       " Document(metadata={}, page_content='nefits concerning EFS and OS. Its p'),\n",
       " Document(metadata={}, page_content='rognostic value is greatest in aggr'),\n",
       " Document(metadata={}, page_content='essive tumor subtypes, \\nlike in TNB'),\n",
       " Document(metadata={}, page_content='C (EFS: HR = 0.24; OS: HR = 0.16) ['),\n",
       " Document(metadata={}, page_content='33]. Patients who have residual inv'),\n",
       " Document(metadata={}, page_content='asive BC after the receipt \\nof NACT'),\n",
       " Document(metadata={}, page_content=' have a high risk of relapse. Patie'),\n",
       " Document(metadata={}, page_content='nts with TNBC who do not experience'),\n",
       " Document(metadata={}, page_content=' pCR have an estimated 5-\\nyear EFS '),\n",
       " Document(metadata={}, page_content='of 57% and OS of 47% (compared with'),\n",
       " Document(metadata={}, page_content=' 90% EFS and 84% OS, respectively, '),\n",
       " Document(metadata={}, page_content='for patients with early-\\nstage TNBC'),\n",
       " Document(metadata={}, page_content=' who demonstrate pCR) [76, 77].\\nAft'),\n",
       " Document(metadata={}, page_content='er pre-operative CHT and surgical t'),\n",
       " Document(metadata={}, page_content='reatment, patients can receive post'),\n",
       " Document(metadata={}, page_content='operative radiation therapy \\n(RT). '),\n",
       " Document(metadata={}, page_content='Patients with hormone receptor-posi'),\n",
       " Document(metadata={}, page_content='tive BC [hormone receptor-positive '),\n",
       " Document(metadata={}, page_content='(HR+) BC] are candidates for \\nadjuv'),\n",
       " Document(metadata={}, page_content='ant endocrine treatment. However, u'),\n",
       " Document(metadata={}, page_content='ntil recently, no adjuvant CHT was '),\n",
       " Document(metadata={}, page_content='expected as standard in \\npatients w'),\n",
       " Document(metadata={}, page_content='ith TNBC. Only follow-up was recomm'),\n",
       " Document(metadata={}, page_content='ended in those who have pCR or in t'),\n",
       " Document(metadata={}, page_content='hose with residual \\ninvasive BC aft'),\n",
       " Document(metadata={}, page_content='er the receipt of neoadjuvant regim'),\n",
       " Document(metadata={}, page_content='ens [78]. To address the unmet clin'),\n",
       " Document(metadata={}, page_content='ical need for optimal \\nadjuvant tre'),\n",
       " Document(metadata={}, page_content='atment in the subgroup of patients '),\n",
       " Document(metadata={}, page_content='with TNBC at high risk of recurrenc'),\n",
       " Document(metadata={}, page_content='e (those who have not \\nachieved the'),\n",
       " Document(metadata={}, page_content=' pCR after NACT containing anthracy'),\n",
       " Document(metadata={}, page_content='cline, taxane, or both), the Capeci'),\n",
       " Document(metadata={}, page_content='tabine for Residual \\nCancer as Adju'),\n",
       " Document(metadata={}, page_content='vant Therapy (CREATE-X) was designe'),\n",
       " Document(metadata={}, page_content='d. The trial did not include only p'),\n",
       " Document(metadata={}, page_content='atients with TNBC \\nExplor Target An'),\n",
       " Document(metadata={}, page_content='titumor Ther. 2024;5:232–50 | https'),\n",
       " Document(metadata={}, page_content='://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='\\nPage 238\\nbut also patients with HR'),\n",
       " Document(metadata={}, page_content='+ HER2 negative BC [79]. The result'),\n",
       " Document(metadata={}, page_content='s of this phase III trial showed th'),\n",
       " Document(metadata={}, page_content='at the \\naddition of adjuvant capeci'),\n",
       " Document(metadata={}, page_content='tabine (1,250 mg per square meter o'),\n",
       " Document(metadata={}, page_content='f body-surface area, twice per day,'),\n",
       " Document(metadata={}, page_content=' on days \\n1 to 14, every 3 weeks fo'),\n",
       " Document(metadata={}, page_content='r six or eight cycles) was safe and'),\n",
       " Document(metadata={}, page_content=' effective in prolonging DFS and OS'),\n",
       " Document(metadata={}, page_content=' among the \\nITT population. The stu'),\n",
       " Document(metadata={}, page_content='dy showed a superior DFS in the cap'),\n",
       " Document(metadata={}, page_content='ecitabine group than in the control'),\n",
       " Document(metadata={}, page_content=' group \\n(74.1% vs. 67.6% at 5 years'),\n",
       " Document(metadata={}, page_content='; HR = 0.70; P = 0.01). Therefore, '),\n",
       " Document(metadata={}, page_content='OS was longer in the experimental g'),\n",
       " Document(metadata={}, page_content='roup: \\n89.2% vs. 83.6% of the patie'),\n",
       " Document(metadata={}, page_content='nts were alive at 5 years (HR = 0.5'),\n",
       " Document(metadata={}, page_content='9; P = 0.01). Thirty percent of the'),\n",
       " Document(metadata={}, page_content=' patients \\nhad triple negative (TN)'),\n",
       " Document(metadata={}, page_content=' disease, and they represent the su'),\n",
       " Document(metadata={}, page_content='bgroup with poor prognosis (approxi'),\n",
       " Document(metadata={}, page_content='mately half \\nthe patients with TNBC'),\n",
       " Document(metadata={}, page_content=' who had a pCR did not have the rec'),\n",
       " Document(metadata={}, page_content='urrence of the disease) [33]. The b'),\n",
       " Document(metadata={}, page_content='enefit of \\ncapecitabine vs. control'),\n",
       " Document(metadata={}, page_content=' in DFS and OS was notable among th'),\n",
       " Document(metadata={}, page_content='is subgroup of patients (HR = 0.58 '),\n",
       " Document(metadata={}, page_content='and HR = \\n0.52, respectively) [79].'),\n",
       " Document(metadata={}, page_content='\\nThe reflection in the treatment al'),\n",
       " Document(metadata={}, page_content='gorithm due to these results was si'),\n",
       " Document(metadata={}, page_content='gnificant.\\nSome limits of this stud'),\n",
       " Document(metadata={}, page_content='y are the exclusion of patients who'),\n",
       " Document(metadata={}, page_content=' had reached the pCR, for whom only'),\n",
       " Document(metadata={}, page_content=' follow-\\nup was indicated, and the '),\n",
       " Document(metadata={}, page_content='lack of efficacy results selected f'),\n",
       " Document(metadata={}, page_content='or residual cancer burden (RCB). Th'),\n",
       " Document(metadata={}, page_content='e RCB \\nquantifies the extent of res'),\n",
       " Document(metadata={}, page_content='idual disease after neoadjuvant tre'),\n",
       " Document(metadata={}, page_content='atment at the time of surgery. This'),\n",
       " Document(metadata={}, page_content=' score uses \\nthe diameter of residu'),\n",
       " Document(metadata={}, page_content='al disease, percentage of vital tum'),\n",
       " Document(metadata={}, page_content='or cells, and diameter of the large'),\n",
       " Document(metadata={}, page_content='st involved lymph \\nnode to calculat'),\n",
       " Document(metadata={}, page_content='e the amount of residual disease. I'),\n",
       " Document(metadata={}, page_content='t has been validated with distinct '),\n",
       " Document(metadata={}, page_content='prognostic RCB classes \\nin all BC s'),\n",
       " Document(metadata={}, page_content='ubtypes, with the most significant '),\n",
       " Document(metadata={}, page_content='discriminatory power in TN and Her-'),\n",
       " Document(metadata={}, page_content='2 positive BC. It is \\ncategorized a'),\n",
       " Document(metadata={}, page_content='s RCB-0 (equivalent to a pCR), RCB-'),\n",
       " Document(metadata={}, page_content='1, RCB-2, and RCB-3, reflecting inc'),\n",
       " Document(metadata={}, page_content='reasingly larger residual \\ncancer a'),\n",
       " Document(metadata={}, page_content='nd respective poor prognoses (in te'),\n",
       " Document(metadata={}, page_content='rms of EFS) [80]. Finally, the CREA'),\n",
       " Document(metadata={}, page_content='TE-X trial did not examine \\ncapecit'),\n",
       " Document(metadata={}, page_content='abine efficacy in patients with ger'),\n",
       " Document(metadata={}, page_content='mline BRCA 1 or BRCA 2 pathogenic v'),\n",
       " Document(metadata={}, page_content='ariants (less than 15% of \\nthose en'),\n",
       " Document(metadata={}, page_content='rolled) [79].\\nOlympiA is a phase II'),\n",
       " Document(metadata={}, page_content='I study designed to investigate how'),\n",
       " Document(metadata={}, page_content=' the PARP inhibitor olaparib might '),\n",
       " Document(metadata={}, page_content='improve \\nDFS and OS in patients wit'),\n",
       " Document(metadata={}, page_content='h resected HR+ BC and TNBC with ger'),\n",
       " Document(metadata={}, page_content='mline BRCA 1 or BRCA 2 mutation. It'),\n",
       " Document(metadata={}, page_content=' \\nenrolled patients treated with CH'),\n",
       " Document(metadata={}, page_content='T (containing anthracyclines, taxan'),\n",
       " Document(metadata={}, page_content='es or the combination of both) in \\n'),\n",
       " Document(metadata={}, page_content='neoadjuvant or adjuvant setting and'),\n",
       " Document(metadata={}, page_content=' randomized them to receive olapari'),\n",
       " Document(metadata={}, page_content='b (orally administered at the dose '),\n",
       " Document(metadata={}, page_content='\\nof 300 mg twice daily) vs. placebo'),\n",
       " Document(metadata={}, page_content=' for 1 year after surgical resectio'),\n",
       " Document(metadata={}, page_content='n (and radiotherapy when indicated)'),\n",
       " Document(metadata={}, page_content='. \\nAlso in this trial, patients wit'),\n",
       " Document(metadata={}, page_content='h TNBC who underwent NACT followed '),\n",
       " Document(metadata={}, page_content='by surgery were required to have \\nr'),\n",
       " Document(metadata={}, page_content='esidual invasive BC in the breast a'),\n",
       " Document(metadata={}, page_content='nd/or resected lymph nodes (non-pCR'),\n",
       " Document(metadata={}, page_content=') [81]. Postneoadjuvant \\ncapecitabi'),\n",
       " Document(metadata={}, page_content='ne was not foreseen in this trial. '),\n",
       " Document(metadata={}, page_content='iDFS, the primary endpoint of the s'),\n",
       " Document(metadata={}, page_content='tudy, was significantly longer \\namo'),\n",
       " Document(metadata={}, page_content='ng patients assigned to receive ola'),\n",
       " Document(metadata={}, page_content='parib than among those assigned pla'),\n",
       " Document(metadata={}, page_content='cebo (HR = 0.58; P < 0.001). The \\np'),\n",
       " Document(metadata={}, page_content='ercentage of patients alive and fre'),\n",
       " Document(metadata={}, page_content='e of invasive disease at 3 years wa'),\n",
       " Document(metadata={}, page_content='s 85.9% in the olaparib group and \\n'),\n",
       " Document(metadata={}, page_content='77.1% in the placebo group. The ben'),\n",
       " Document(metadata={}, page_content='efit of adjuvant olaparib was obser'),\n",
       " Document(metadata={}, page_content='ved irrespective of the germline \\nB'),\n",
       " Document(metadata={}, page_content='RCA mutation (BRCA 1 vs. BRCA 2), t'),\n",
       " Document(metadata={}, page_content='he hormone-receptor status, or the '),\n",
       " Document(metadata={}, page_content='timing of previous CHT \\n(neoadjuvan'),\n",
       " Document(metadata={}, page_content='t vs. adjuvant) [81] 4-year iDFS fo'),\n",
       " Document(metadata={}, page_content='r the olaparib group was 82.7% (vs.'),\n",
       " Document(metadata={}, page_content=' 75.4% in placebo group) \\nand 4-yea'),\n",
       " Document(metadata={}, page_content='r distant DFS (DDFS) was 86.5% (vs.'),\n",
       " Document(metadata={}, page_content=' 79.1%). Adjuvant olaparib improves'),\n",
       " Document(metadata={}, page_content=' OS, with an HR of 0.68 \\nand a P va'),\n",
       " Document(metadata={}, page_content='lue of 0.009 at 3.5 years of median'),\n",
       " Document(metadata={}, page_content=' follow-up, meeting the significanc'),\n",
       " Document(metadata={}, page_content='e threshold for OS at the \\nsecond p'),\n",
       " Document(metadata={}, page_content='lanned interim analysis. The OS ben'),\n",
       " Document(metadata={}, page_content='efit at 4 years in the olaparib arm'),\n",
       " Document(metadata={}, page_content=' compared with the placebo \\narm was'),\n",
       " Document(metadata={}, page_content=' reported (89.8% vs. 86.4%, respect'),\n",
       " Document(metadata={}, page_content='ively) [82].\\nBoth studies have defi'),\n",
       " Document(metadata={}, page_content='ned the standard of adjuvant therap'),\n",
       " Document(metadata={}, page_content='y post-NACT for patients with BRCA '),\n",
       " Document(metadata={}, page_content='wild \\ntype (CREATE-X) and BRCA muta'),\n",
       " Document(metadata={}, page_content='ted (OlympiA) TNBC, that did not re'),\n",
       " Document(metadata={}, page_content='ach the pCR.\\nThe low percentage of '),\n",
       " Document(metadata={}, page_content='BRCA mutated patients enrolled in t'),\n",
       " Document(metadata={}, page_content='he CREATE-X, the absence of pre-pla'),\n",
       " Document(metadata={}, page_content='nned \\nsubgroup analyzes for this po'),\n",
       " Document(metadata={}, page_content='pulation do not allow for a descrip'),\n",
       " Document(metadata={}, page_content='tion of the efficacy of capecitabin'),\n",
       " Document(metadata={}, page_content='e in this \\nsubgroup of patients.\\nMo'),\n",
       " Document(metadata={}, page_content='reover, there are no prospective ra'),\n",
       " Document(metadata={}, page_content='ndomized trials between capecitabin'),\n",
       " Document(metadata={}, page_content='e and olaparib to guide the \\nclinic'),\n",
       " Document(metadata={}, page_content='al decision in this population, nor'),\n",
       " Document(metadata={}, page_content=' combination or sequence data betwe'),\n",
       " Document(metadata={}, page_content='en these two drugs.\\nIt would also b'),\n",
       " Document(metadata={}, page_content='e important to consider the potenti'),\n",
       " Document(metadata={}, page_content='ally severe toxicity profile of suc'),\n",
       " Document(metadata={}, page_content='h a combination, \\ngiven their overl'),\n",
       " Document(metadata={}, page_content='apping side effects (in particular,'),\n",
       " Document(metadata={}, page_content=' cytopenias).\\nThe treatment paradig'),\n",
       " Document(metadata={}, page_content='m of early TNBC has had a real evol'),\n",
       " Document(metadata={}, page_content='ution since July 2021, with the int'),\n",
       " Document(metadata={}, page_content='roduction \\nof immunotherapy followi'),\n",
       " Document(metadata={}, page_content='ng the Food and Drug Administration'),\n",
       " Document(metadata={}, page_content=' (FDA) approval of pembrolizumab fo'),\n",
       " Document(metadata={}, page_content='r high-\\nExplor Target Antitumor The'),\n",
       " Document(metadata={}, page_content='r. 2024;5:232–50 | https://doi.org/'),\n",
       " Document(metadata={}, page_content='10.37349/etat.2024.00215\\nPage 239\\nr'),\n",
       " Document(metadata={}, page_content='isk TNBC (tumor size > 1 cm but ≤ 2'),\n",
       " Document(metadata={}, page_content=' cm in diameter with nodal involvem'),\n",
       " Document(metadata={}, page_content='ent or tumor size > 2 cm in \\ndiamet'),\n",
       " Document(metadata={}, page_content='er regardless of nodal involvement)'),\n",
       " Document(metadata={}, page_content=', regardless of tumor PD-L1 express'),\n",
       " Document(metadata={}, page_content='ion, in combination with CHT \\nas ne'),\n",
       " Document(metadata={}, page_content='oadjuvant treatment, and then conti'),\n",
       " Document(metadata={}, page_content='nued as a single agent as adjuvant '),\n",
       " Document(metadata={}, page_content='treatment after surgery for a \\ntota'),\n",
       " Document(metadata={}, page_content='l duration of approximately 1 year '),\n",
       " Document(metadata={}, page_content='[83].\\nResults from the KEYNOTE-522 '),\n",
       " Document(metadata={}, page_content='study were the basis for this appro'),\n",
       " Document(metadata={}, page_content='val, demonstrating a significantly '),\n",
       " Document(metadata={}, page_content='\\nhigher rate of pCR at the time of '),\n",
       " Document(metadata={}, page_content='definitive surgery among patients w'),\n",
       " Document(metadata={}, page_content='ho received pembrolizumab plus NACT'),\n",
       " Document(metadata={}, page_content=' \\nthan among those who received pla'),\n",
       " Document(metadata={}, page_content='cebo plus NACT and an improvement i'),\n",
       " Document(metadata={}, page_content='n long-term benefits [73, 84]. The '),\n",
       " Document(metadata={}, page_content='\\naim of the trial was not to identi'),\n",
       " Document(metadata={}, page_content='fy the contributions of the neoadju'),\n",
       " Document(metadata={}, page_content='vant and adjuvant treatment phases,'),\n",
       " Document(metadata={}, page_content=' so it \\nis difficult to define if t'),\n",
       " Document(metadata={}, page_content='hese long-term results are related '),\n",
       " Document(metadata={}, page_content='to exposure to adjuvant pembrolizum'),\n",
       " Document(metadata={}, page_content='ab or a \\nlesser RCB at the end of t'),\n",
       " Document(metadata={}, page_content='he neoadjuvant phase in the pembrol'),\n",
       " Document(metadata={}, page_content='izumab–CHT group.\\nAn exploratory an'),\n",
       " Document(metadata={}, page_content='alysis of the study then provided d'),\n",
       " Document(metadata={}, page_content='ata to further describe the prognos'),\n",
       " Document(metadata={}, page_content='is related to the \\nRCB after neoadj'),\n",
       " Document(metadata={}, page_content='uvant experimental treatment (Figur'),\n",
       " Document(metadata={}, page_content='e 1) [85].\\nFigure 1. The unmet need'),\n",
       " Document(metadata={}, page_content=' for the optimal adjuvant treatment'),\n",
       " Document(metadata={}, page_content=' according to RCB [85]\\nThe HR for r'),\n",
       " Document(metadata={}, page_content='ecurrence event in subgroups RBO-0,'),\n",
       " Document(metadata={}, page_content=' RCB-1, RCB-2, and RCB-3 are respec'),\n",
       " Document(metadata={}, page_content='tively 0.70 \\n(rates: 5.2% vs. 7.3% '),\n",
       " Document(metadata={}, page_content='in the pembrolizumab + CHT vs. plac'),\n",
       " Document(metadata={}, page_content='ebo + CHT), 0.92 (rates: 17.4% vs. '),\n",
       " Document(metadata={}, page_content='20%), 0.52 \\n(rates: 25.5% vs. 44.3%'),\n",
       " Document(metadata={}, page_content='), 1.24 (72.5% vs. 69.2%).\\nThe rate'),\n",
       " Document(metadata={}, page_content=' of recurrence was numerically lowe'),\n",
       " Document(metadata={}, page_content='r in all RCB groups with pembrolizu'),\n",
       " Document(metadata={}, page_content='mab + CHT, except in \\nthe small RCB'),\n",
       " Document(metadata={}, page_content='-3 subset (that is represented by 5'),\n",
       " Document(metadata={}, page_content='% and 7% of the population in the s'),\n",
       " Document(metadata={}, page_content='tudy, respectively in \\nthe experime'),\n",
       " Document(metadata={}, page_content='ntal and control group). Pembrolizu'),\n",
       " Document(metadata={}, page_content='mab shifted RCB to lower categories'),\n",
       " Document(metadata={}, page_content=' in most patients \\n(RCB-0: 63% vs. '),\n",
       " Document(metadata={}, page_content='56% of patients in the experimental'),\n",
       " Document(metadata={}, page_content=' vs. the control arm; RCB-1: 9% vs.'),\n",
       " Document(metadata={}, page_content=' 11%; RCB 18% vs. \\n20%).\\nNo patient'),\n",
       " Document(metadata={}, page_content='s in this trial received adjuvant c'),\n",
       " Document(metadata={}, page_content='apecitabine, and there are no rando'),\n",
       " Document(metadata={}, page_content='mized efficacy and \\nsafety data sho'),\n",
       " Document(metadata={}, page_content='wing that multiagent therapy with p'),\n",
       " Document(metadata={}, page_content='embrolizumab and capecitabine is su'),\n",
       " Document(metadata={}, page_content='perior to single-\\nagent therapy in '),\n",
       " Document(metadata={}, page_content='high-risk patients (stage II–III) w'),\n",
       " Document(metadata={}, page_content='ho did not reach pCR.\\nAt the time, '),\n",
       " Document(metadata={}, page_content='only results from phase II studies '),\n",
       " Document(metadata={}, page_content='in metastatic TNBC demonstrated no '),\n",
       " Document(metadata={}, page_content='new safety signals \\nwith this combi'),\n",
       " Document(metadata={}, page_content='nation [86, 87].\\nPembrolizumab has '),\n",
       " Document(metadata={}, page_content='also not been studied in combinatio'),\n",
       " Document(metadata={}, page_content='n with olaparib in the adjuvant set'),\n",
       " Document(metadata={}, page_content='ting, for the \\ntreatment of patient'),\n",
       " Document(metadata={}, page_content='s with BRCA mutations. No efficacy '),\n",
       " Document(metadata={}, page_content='data are reported in the literature'),\n",
       " Document(metadata={}, page_content=', even if some \\nExplor Target Antit'),\n",
       " Document(metadata={}, page_content='umor Ther. 2024;5:232–50 | https://'),\n",
       " Document(metadata={}, page_content='doi.org/10.37349/etat.2024.00215\\nPa'),\n",
       " Document(metadata={}, page_content='ge 240\\nsafety data are reported in '),\n",
       " Document(metadata={}, page_content='the metastatic setting, in some ear'),\n",
       " Document(metadata={}, page_content='ly-phase studies that have evaluate'),\n",
       " Document(metadata={}, page_content='d the \\ncombination of PARPis and IC'),\n",
       " Document(metadata={}, page_content='Is, not reporting unexpected toxici'),\n",
       " Document(metadata={}, page_content='ties [88, 89].\\nProspective trials w'),\n",
       " Document(metadata={}, page_content='ould be needed to define what is th'),\n",
       " Document(metadata={}, page_content='e optimal adjuvant strategy accordi'),\n",
       " Document(metadata={}, page_content='ng to RCB \\n(single-agent CHT or pol'),\n",
       " Document(metadata={}, page_content='y-CHT), how the clinician should de'),\n",
       " Document(metadata={}, page_content='cide between olaparib, immunotherap'),\n",
       " Document(metadata={}, page_content='y or \\ncapecitabine in the treatment'),\n",
       " Document(metadata={}, page_content=' of the population with BRCA mutati'),\n",
       " Document(metadata={}, page_content='ons and whether these therapies can'),\n",
       " Document(metadata={}, page_content=' be \\nadministered in combination or'),\n",
       " Document(metadata={}, page_content=' sequence, with data in terms of ef'),\n",
       " Document(metadata={}, page_content='ficacy and safety.\\nAdditional treat'),\n",
       " Document(metadata={}, page_content='ment strategies with new drugs are '),\n",
       " Document(metadata={}, page_content='being studied as adjuvant treatment'),\n",
       " Document(metadata={}, page_content=' after NACT, \\nwith antibody-drug co'),\n",
       " Document(metadata={}, page_content='njugates (ADCs) such as datopotamab'),\n",
       " Document(metadata={}, page_content=' deruxtecan (with or without durval'),\n",
       " Document(metadata={}, page_content='umab in \\nTROPICS-Breast 03, Clinica'),\n",
       " Document(metadata={}, page_content='lTrials.gov identifier: NCT05629585'),\n",
       " Document(metadata={}, page_content='), and patritumab deruxtecan (HER3-'),\n",
       " Document(metadata={}, page_content='DXd) \\nwhich showed promising clinic'),\n",
       " Document(metadata={}, page_content='al response and biological changes '),\n",
       " Document(metadata={}, page_content='in early TNBC [SOLTI TOT-HER3 windo'),\n",
       " Document(metadata={}, page_content='w \\nof opportunity trial part B, pre'),\n",
       " Document(metadata={}, page_content='sented at European Society for Medi'),\n",
       " Document(metadata={}, page_content='cal Oncology (ESMO) Breast 2023], o'),\n",
       " Document(metadata={}, page_content='r \\nwith ICIs (A-BRAVE trial, NCT029'),\n",
       " Document(metadata={}, page_content='26196 and SWOG S1418/BR006 trial, N'),\n",
       " Document(metadata={}, page_content='CT02954874).\\nNew biomarkers and fro'),\n",
       " Document(metadata={}, page_content='ntiers in TNBC\\nRecent progress in i'),\n",
       " Document(metadata={}, page_content='ntegrating ICIs and novel agents ha'),\n",
       " Document(metadata={}, page_content='s revolutionized the therapeutic ap'),\n",
       " Document(metadata={}, page_content='proach for early \\nTNBC. Treatment s'),\n",
       " Document(metadata={}, page_content='trategies now emphasize escalating '),\n",
       " Document(metadata={}, page_content='chemotherapeutic agents based on st'),\n",
       " Document(metadata={}, page_content='andard \\nneoadjuvant regimens. An ex'),\n",
       " Document(metadata={}, page_content='ample is a phase II trial (ACTRN126'),\n",
       " Document(metadata={}, page_content='17000651381) presented at the San \\n'),\n",
       " Document(metadata={}, page_content='Antonio Breast Cancer Symposium 202'),\n",
       " Document(metadata={}, page_content='2 evaluating in high-risk TNBC, the'),\n",
       " Document(metadata={}, page_content=' addition of ipilimumab and \\nnivolu'),\n",
       " Document(metadata={}, page_content='mab to neoadjuvant paclitaxel follo'),\n",
       " Document(metadata={}, page_content='wing a suboptimal response to anthr'),\n",
       " Document(metadata={}, page_content='acycline-based CHT (< 50% \\ntumor re'),\n",
       " Document(metadata={}, page_content='duction) and resulting in promising'),\n",
       " Document(metadata={}, page_content=' objective response rate (ORR) (43.'),\n",
       " Document(metadata={}, page_content='7%) and pCR (18.8%) rates, \\nregardl'),\n",
       " Document(metadata={}, page_content='ess of PD-L1 status.\\nHowever, it is'),\n",
       " Document(metadata={}, page_content=' also crucial to identify subgroups'),\n",
       " ...]"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "text_splitter.create_documents([text])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "bbf256e7-1881-4444-87b9-d78b8dd8a1b3",
   "metadata": {},
   "source": [
    "## Chunk Overlap & Separators"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "905b2ade-e04b-4ba2-9d3c-fc6865afc294",
   "metadata": {},
   "outputs": [],
   "source": [
    "text_splitter = CharacterTextSplitter(chunk_size = 80, chunk_overlap=20, separator='')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "82d9f045-7161-4a5c-9d9f-3d2fb42b6c4b",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024'),\n",
       " Document(metadata={}, page_content='g/10.37349/etat.2024.00215\\nPage 232\\n© The Author(s) 2024. This is an Open Access'),\n",
       " Document(metadata={}, page_content='is is an Open Access article licensed under a Creative Commons Attribution 4.0 I'),\n",
       " Document(metadata={}, page_content='ns Attribution 4.0 International \\nLicense (https://creativecommons.org/licenses/'),\n",
       " Document(metadata={}, page_content='ommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptatio'),\n",
       " Document(metadata={}, page_content=', sharing, adaptation, distribution \\nand reproduction in any medium or format, f'),\n",
       " Document(metadata={}, page_content='medium or format, for any purpose, even commercially, as long as you give appro'),\n",
       " Document(metadata={}, page_content='ng as you give appropriate credit to the \\noriginal author(s) and the source, pro'),\n",
       " Document(metadata={}, page_content='and the source, provide a link to the Creative Commons license, and indicate if'),\n",
       " Document(metadata={}, page_content='nse, and indicate if changes were made.\\nExploration of Targeted Anti-tumor Thera'),\n",
       " Document(metadata={}, page_content='ted Anti-tumor Therapy\\nOpen Access\\nReview\\nEarly-stage triple negative breast can'),\n",
       " Document(metadata={}, page_content='negative breast cancer: the therapeutic role of \\nimmunotherapy and the prognost'),\n",
       " Document(metadata={}, page_content='apy and the prognostic value of pathological complete \\nresponse\\nPierluigi De San'),\n",
       " Document(metadata={}, page_content='nse\\nPierluigi De Santis1, Martina Perrone1, Chiara Guarini1, Anna Natalizia Sant'),\n",
       " Document(metadata={}, page_content='Anna Natalizia Santoro1, Carmelo Laface1, \\nDaniela Carrozzo1, Gaia Rachele Oliv'),\n",
       " Document(metadata={}, page_content='1, Gaia Rachele Oliva2, Palma Fedele1*\\n1Oncology Unit, Francavilla Fontana Cegli'),\n",
       " Document(metadata={}, page_content='avilla Fontana Ceglie Messapica Hospital District, 72021 Francavilla Fontana, It'),\n",
       " Document(metadata={}, page_content='ncavilla Fontana, Italy\\n2Department of Medicine and Translational Surgery, Unive'),\n",
       " Document(metadata={}, page_content='ional Surgery, Università Cattolica del Sacro Cuore, 00168 Roma, Italy\\n*Correspo'),\n",
       " Document(metadata={}, page_content='oma, Italy\\n*Correspondence: Palma Fedele, Oncology Unit, Francavilla Fontana Ceg'),\n",
       " Document(metadata={}, page_content='ncavilla Fontana Ceglie Messapica Hospital District, 72021 Francavilla \\nFontana,'),\n",
       " Document(metadata={}, page_content='rancavilla \\nFontana, Italy. minafedele@hotmail.com\\nAcademic Editor: Laura Cerchi'),\n",
       " Document(metadata={}, page_content='Editor: Laura Cerchia, Institute of Experimental Endocrinology and Oncology “G.'),\n",
       " Document(metadata={}, page_content='gy and Oncology “G. Salvatore”-National Research \\nCouncil (IEOS-CNR), Italy; Sim'),\n",
       " Document(metadata={}, page_content='EOS-CNR), Italy; Simona Camorani, Institute of Experimental Endocrinology and On'),\n",
       " Document(metadata={}, page_content='Endocrinology and Oncology “G. Salvatore”-National \\nResearch Council (IEOS-CNR),'),\n",
       " Document(metadata={}, page_content='Council (IEOS-CNR), Italy\\nReceived: May 26, 2023  Accepted: December 26, 2023'),\n",
       " Document(metadata={}, page_content='December 26, 2023  Published: February 28, 2024\\nCite this article: De Santis P,'),\n",
       " Document(metadata={}, page_content='rticle: De Santis P, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, et'),\n",
       " Document(metadata={}, page_content='e C, Carrozzo D, et al. Early-stage triple negative breast \\ncancer: the therapeu'),\n",
       " Document(metadata={}, page_content='cancer: the therapeutic role of immunotherapy and the prognostic value of pathol'),\n",
       " Document(metadata={}, page_content='stic value of pathological complete response. Explor Target \\nAntitumor Ther. 202'),\n",
       " Document(metadata={}, page_content='Antitumor Ther. 2024;5:232–50. https://doi.org/10.37349/etat.2024.00215\\nAbstrac'),\n",
       " Document(metadata={}, page_content='t.2024.00215\\nAbstract\\nTriple negative breast cancer (TNBC) represents an aggress'),\n",
       " Document(metadata={}, page_content='epresents an aggressive disease associated with a high risk of \\nrecurrence after'),\n",
       " Document(metadata={}, page_content='of \\nrecurrence after curative treatment and a poor prognosis in the metastatic s'),\n",
       " Document(metadata={}, page_content='in the metastatic setting. Chemotherapy was for \\nyears the only treatment avail'),\n",
       " Document(metadata={}, page_content='only treatment available in the early and metastatic setting, due to the lack of'),\n",
       " Document(metadata={}, page_content=', due to the lack of actionable targets. \\nClinical practice has changed followin'),\n",
       " Document(metadata={}, page_content='has changed following the results obtained with the addition of immunotherapy to'),\n",
       " Document(metadata={}, page_content='of immunotherapy to \\nstandard chemotherapy, the development of novel drugs [i.e'),\n",
       " Document(metadata={}, page_content='of novel drugs [i.e. antibody-drug conjugates (ADCs)], and the \\nuse of targeted'),\n",
       " Document(metadata={}, page_content='the \\nuse of targeted treatments for patients carrying germline pathogenic breast'),\n",
       " Document(metadata={}, page_content='ne pathogenic breast cancer susceptibility genes \\n(BRCA) 1 or BRCA 2 variants. T'),\n",
       " Document(metadata={}, page_content='r BRCA 2 variants. The treatment of early-stage disease has had a shift in clini'),\n",
       " Document(metadata={}, page_content='had a shift in clinical practice since \\nJuly 2021, after the Food and Drug Admin'),\n",
       " Document(metadata={}, page_content='Food and Drug Administration (FDA) approval of pembrolizumab in association wit'),\n",
       " Document(metadata={}, page_content='b in association with \\nchemotherapy as neoadjuvant treatment for TNBC and as a s'),\n",
       " Document(metadata={}, page_content='for TNBC and as a single agent in the subsequent adjuvant setting. \\nThis intens'),\n",
       " Document(metadata={}, page_content='etting. \\nThis intensive treatment based on the combination of a poly-chemotherap'),\n",
       " Document(metadata={}, page_content='f a poly-chemotherapy and an immune checkpoint \\ninhibitor (ICI) led to the impro'),\n",
       " Document(metadata={}, page_content='CI) led to the improvement of short- and long-term outcomes, but it has highligh'),\n",
       " Document(metadata={}, page_content='but it has highlighted some new \\nunmet clinical needs in the treatment of early'),\n",
       " Document(metadata={}, page_content='e treatment of early-stage TNBC: the selection of the most effective adjuvant \\nt'),\n",
       " Document(metadata={}, page_content='ffective adjuvant \\ntherapy and the integration of pembrolizumab with other thera'),\n",
       " Document(metadata={}, page_content='mab with other therapeutic strategies [capecitabine, poly(ADP-\\nribose) polymeras'),\n",
       " Document(metadata={}, page_content='P-\\nribose) polymerase (PARP) inhibitors] based on the achievement of pathologic'),\n",
       " Document(metadata={}, page_content='ement of pathologic complete response (pCR); \\nthe identification of predictive b'),\n",
       " Document(metadata={}, page_content='tion of predictive biomarkers to select patients who could most benefit from the'),\n",
       " Document(metadata={}, page_content='ost benefit from the addition of \\nICI, to minimize toxicities and to maximize ou'),\n",
       " Document(metadata={}, page_content='s and to maximize outcomes; the possibility of de-escalating chemotherapy in fav'),\n",
       " Document(metadata={}, page_content='chemotherapy in favor \\nof immune-combo or novel agents, such as ADCs; the role'),\n",
       " Document(metadata={}, page_content='h as ADCs; the role of immunotherapy in estrogen receptor (ER)-low \\npatients. Th'),\n",
       " Document(metadata={}, page_content='R)-low \\npatients. The advent of immunotherapy not only addresses current challen'),\n",
       " Document(metadata={}, page_content='sses current challenges in TNBC treatment but also \\nholds the promise of a radic'),\n",
       " Document(metadata={}, page_content='e promise of a radical transformation in its therapeutic paradigm, enhancing sig'),\n",
       " Document(metadata={}, page_content='adigm, enhancing significantly clinical \\noutcomes and offering new perspectives'),\n",
       " Document(metadata={}, page_content='ng new perspectives for patients grappling with this aggressive form of breast c'),\n",
       " Document(metadata={}, page_content='ive form of breast cancer.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https:/'),\n",
       " Document(metadata={}, page_content='4;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 233\\nKeywords\\nTriple n'),\n",
       " Document(metadata={}, page_content='33\\nKeywords\\nTriple negative breast cancer, immunotherapy, pathological complete'),\n",
       " Document(metadata={}, page_content='thological complete response, neoadjuvant combination \\ntreatment, adjuvant treat'),\n",
       " Document(metadata={}, page_content='ment, adjuvant treatment\\nIntroduction\\nTriple negative Breast Cancer (TNBC) is a'),\n",
       " Document(metadata={}, page_content='Cancer (TNBC) is a histological subtype of breast cancer (BC) characterized by'),\n",
       " Document(metadata={}, page_content='C) characterized by the \\nimmunohistochemical lack of expression (< 1%) of estrog'),\n",
       " Document(metadata={}, page_content='ion (< 1%) of estrogen receptor (ER), progesterone receptor (PgR), \\nand human ep'),\n",
       " Document(metadata={}, page_content='(PgR), \\nand human epidermal growth factor receptor 2 (HER2). It accounts for app'),\n",
       " Document(metadata={}, page_content='It accounts for approximately 10–20% of all BC, \\naffecting mainly young, premen'),\n",
       " Document(metadata={}, page_content='mainly young, premenopausal women, and individuals with inherited gene alteratio'),\n",
       " Document(metadata={}, page_content='rited gene alterations, such as BC \\nsusceptibility genes 1/2 (BRCA 1/2) mutation'),\n",
       " Document(metadata={}, page_content='(BRCA 1/2) mutations [1–3]. It notably presents an aggressive biological behavi'),\n",
       " Document(metadata={}, page_content='ve biological behavior \\nwith a trend to have a higher grade and an often lymph n'),\n",
       " Document(metadata={}, page_content='and an often lymph node involvement at diagnosis, an inclination to \\nmetastasize'),\n",
       " Document(metadata={}, page_content='tion to \\nmetastasize after curative treatment, and a poorer prognosis in metasta'),\n",
       " Document(metadata={}, page_content='prognosis in metastatic setting when compared with \\nother BC subtypes [4, 5].\\nFo'),\n",
       " Document(metadata={}, page_content='subtypes [4, 5].\\nFor decades, treatment for early TNBC has been based on surger'),\n",
       " Document(metadata={}, page_content='been based on surgery and subsequent adjuvant \\nchemotherapy (CHT) for the reduct'),\n",
       " Document(metadata={}, page_content='(CHT) for the reduction of disease recurrence [6]. Therefore, conventional cytot'),\n",
       " Document(metadata={}, page_content=', conventional cytotoxic CHT has \\nrepresented the backbone of systemic treatment'),\n",
       " Document(metadata={}, page_content='f systemic treatment in the early TNBC, including neoadjuvant treatment, which'),\n",
       " Document(metadata={}, page_content='t treatment, which \\nused to reduce tumor size in larger tumors increasing the ch'),\n",
       " Document(metadata={}, page_content='rs increasing the chances of a breast-conserving surgery [7, 8]. In \\nrecent year'),\n",
       " Document(metadata={}, page_content='8]. In \\nrecent years the development of novel therapeutic approaches has been d'),\n",
       " Document(metadata={}, page_content='pproaches has been difficult, due to the heterogeneity \\nof TNBC and lack of ther'),\n",
       " Document(metadata={}, page_content='NBC and lack of therapeutic targets [9, 10]. Nevertheless, immunotherapy and pol'),\n",
       " Document(metadata={}, page_content='mmunotherapy and poly(ADP-ribose) \\npolymerase (PARP) inhibitors have shown survi'),\n",
       " Document(metadata={}, page_content='ors have shown survival benefits in recent studies.\\nSpecifically, combinations o'),\n",
       " Document(metadata={}, page_content='ally, combinations of immune checkpoint inhibitors (ICIs) with CHT or other alte'),\n",
       " Document(metadata={}, page_content='th CHT or other alternative \\ntherapeutic compounds could emerge as a successful'),\n",
       " Document(metadata={}, page_content='rge as a successful therapeutic approach in the management of TNBC \\npatients. De'),\n",
       " Document(metadata={}, page_content='f TNBC \\npatients. Despite the progress in ICIs representing a notable milestone'),\n",
       " Document(metadata={}, page_content='a notable milestone in TNBC treatment, additional \\ninvestigations are necessary'),\n",
       " Document(metadata={}, page_content='tions are necessary to tackle this issue comprehensively. A profound comprehensi'),\n",
       " Document(metadata={}, page_content='profound comprehension of tumor \\nsubtypes, alongside tumor microenvironment (TME'),\n",
       " Document(metadata={}, page_content='icroenvironment (TME) and in terms of molecular, genetic, and immune \\naspects, w'),\n",
       " Document(metadata={}, page_content='d immune \\naspects, would amplify the potential for developing targeted immunothe'),\n",
       " Document(metadata={}, page_content='g targeted immunotherapy to achieve superior \\ntherapeutic effectiveness, especia'),\n",
       " Document(metadata={}, page_content='fectiveness, especially in TNBC [11].\\nTherefore, in this review, we aimed to inv'),\n",
       " Document(metadata={}, page_content='iew, we aimed to investigate the role of immunotherapy in early-stage TNBC, the'),\n",
       " Document(metadata={}, page_content='rly-stage TNBC, the \\nprognostic value of pathologic complete response (pCR) with'),\n",
       " Document(metadata={}, page_content='response (pCR) with its therapeutic implications, and the future \\nperspectives'),\n",
       " Document(metadata={}, page_content='uture \\nperspectives regarding the systemic treatment of early TNBC, including th'),\n",
       " Document(metadata={}, page_content='y TNBC, including the discovery of new biomarkers.\\nThe landscape of immunotherap'),\n",
       " Document(metadata={}, page_content='cape of immunotherapy in TNBC\\nThe immune system plays a crucial role in TNBC com'),\n",
       " Document(metadata={}, page_content='ial role in TNBC compared to the other molecular subtypes of BC. Although \\norigi'),\n",
       " Document(metadata={}, page_content='BC. Although \\noriginally BC was considered non-immunogenic, TNBC has a high imm'),\n",
       " Document(metadata={}, page_content='TNBC has a high immunogenic potential, making it a \\npromising candidate for imm'),\n",
       " Document(metadata={}, page_content='ng candidate for immunotherapy, especially with ICIs [12, 13]. TNBC immunogenici'),\n",
       " Document(metadata={}, page_content=']. TNBC immunogenicity is related to \\nintrinsic tumor cell signatures and tumora'),\n",
       " Document(metadata={}, page_content='ignatures and tumoral surrounding microenvironment features.\\nOver the last decad'),\n",
       " Document(metadata={}, page_content='Over the last decades thanks to emerging technologies such as next-generation s'),\n",
       " Document(metadata={}, page_content='as next-generation sequencing (NGS), the \\nknowledge of the molecular and genetic'),\n",
       " Document(metadata={}, page_content='olecular and genetic background of TNBC improved, bringing to light its intertum'),\n",
       " Document(metadata={}, page_content='o light its intertumoral \\nand intratumoral heterogeneity.\\nA first classification'),\n",
       " Document(metadata={}, page_content='first classification divided TNBC into six subtypes: basal-like 1 (BL1), basal-l'),\n",
       " Document(metadata={}, page_content='ike 1 (BL1), basal-like 2 (BL2), \\nmesenchymal (M), M stem-like (MSL), immunomodu'),\n",
       " Document(metadata={}, page_content='ke (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR) [14].\\nSubse'),\n",
       " Document(metadata={}, page_content='or (LAR) [14].\\nSubsequently, analyzing RNA and DNA-based profiles of 198 TNBC tu'),\n",
       " Document(metadata={}, page_content='files of 198 TNBC tumors, a four-type classification of \\nTNBC was shaped: basal-'),\n",
       " Document(metadata={}, page_content='C was shaped: basal-like immunosuppressed (BLIS), basal-like immune-activated (B'),\n",
       " Document(metadata={}, page_content='immune-activated (BLIA), M and LAR \\n[15]. This classification was further revis'),\n",
       " Document(metadata={}, page_content='on was further revised with the identification of four specific TNBC subtypes: B'),\n",
       " Document(metadata={}, page_content='fic TNBC subtypes: BL1, BL2, \\nM, and LAR, omitting IM and MSL because of the dep'),\n",
       " Document(metadata={}, page_content='L because of the dependence of these two subtypes on the TME features \\n[14].\\nExp'),\n",
       " Document(metadata={}, page_content='features \\n[14].\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/1'),\n",
       " Document(metadata={}, page_content='| https://doi.org/10.37349/etat.2024.00215\\nPage 234\\nIn addition, TNBC could be'),\n",
       " Document(metadata={}, page_content='tion, TNBC could be classified into three microenvironment phenotypes or cluster'),\n",
       " Document(metadata={}, page_content='henotypes or clusters:\\nCluster 1: “immune-desert” with poor immune cell permeati'),\n",
       " Document(metadata={}, page_content='immune cell permeation, due to a high presence of MYC \\namplifications and, conse'),\n",
       " Document(metadata={}, page_content='fications and, consequently, a lower recruitment of innate immune cells.\\n(1).\\nCl'),\n",
       " Document(metadata={}, page_content='mmune cells.\\n(1).\\nCluster 2: “innate immune-inactivated” characterized by a hype'),\n",
       " Document(metadata={}, page_content='racterized by a hyper-activation of \\nphosphatidylinositide 3-kinase/protein kina'),\n",
       " Document(metadata={}, page_content='-kinase/protein kinase B (PI3K-AKT) pathway in tumor cells, low tumor \\nantigen b'),\n",
       " Document(metadata={}, page_content='low tumor \\nantigen burden and infiltration of deactivated innate immune cells, f'),\n",
       " Document(metadata={}, page_content='nate immune cells, fibroblasts, and endothelial \\ncells. Clusters 1 and 2 are the'),\n",
       " Document(metadata={}, page_content='ters 1 and 2 are therefore referred to as “cold tumors”.\\n(2).\\nCluster 3: “immune'),\n",
       " Document(metadata={}, page_content='.\\nCluster 3: “immune-inflamed”, the so-called “hot tumor” that represents about'),\n",
       " Document(metadata={}, page_content='at represents about 30% of TNBCs and \\nis characterized by an abundant adaptive a'),\n",
       " Document(metadata={}, page_content='abundant adaptive and innate immune cells infiltration and with a high \\nexpress'),\n",
       " Document(metadata={}, page_content='with a high \\nexpression of immune checkpoint molecules [16].\\n(3).\\nThe potential'),\n",
       " Document(metadata={}, page_content='(3).\\nThe potential “hot” conversion of “cold” tumors could improve the efficacy'),\n",
       " Document(metadata={}, page_content='improve the efficacy of cancer immunotherapy. \\nFor example, local IM therapies c'),\n",
       " Document(metadata={}, page_content='local IM therapies can express a synergistic effect with immunotherapy by acting'),\n",
       " Document(metadata={}, page_content='unotherapy by acting on \\ncomponents of the TME and immune system function, such'),\n",
       " Document(metadata={}, page_content='stem function, such as elevating the expression of tumor antigens \\nand increasin'),\n",
       " Document(metadata={}, page_content='igens \\nand increasing the recruitment of activated immune cells in the TME [17].'),\n",
       " Document(metadata={}, page_content='lls in the TME [17].\\nTNBC cancer cell immunological features include genomic ins'),\n",
       " Document(metadata={}, page_content='include genomic instability and high tumor mutational \\nburden (TMB), resulting'),\n",
       " Document(metadata={}, page_content='en (TMB), resulting in more somatic mutations and neoantigens [18].\\nMoreover, ap'),\n",
       " Document(metadata={}, page_content='s [18].\\nMoreover, approximately 10–20% of TNBC harbor BRCA 1 or BRCA 2 germinal'),\n",
       " Document(metadata={}, page_content='or BRCA 2 germinal mutations, with a \\nconsequent hereditary deficit in the DNA'),\n",
       " Document(metadata={}, page_content='deficit in the DNA repair mechanism and strong genomic instability. Several stu'),\n",
       " Document(metadata={}, page_content='ability. Several studies \\nhave demonstrated that TNBC-carrying BRCA mutations ar'),\n",
       " Document(metadata={}, page_content='ng BRCA mutations are more sensitive to DNA-damaging drugs such as \\nanthracyclin'),\n",
       " Document(metadata={}, page_content='uch as \\nanthracyclines, but also platinum agents and PARP inhibitors [19–21]. Se'),\n",
       " Document(metadata={}, page_content='hibitors [19–21]. Sensitivity to these drugs was also \\nobserved in tumors with a'),\n",
       " Document(metadata={}, page_content='ved in tumors with alterations in other genes, sharing BRCA-mutant phenotype in'),\n",
       " Document(metadata={}, page_content='mutant phenotype in the absence of a \\nBRCA 1/2 mutation, namely “BRCAness” [22,'),\n",
       " Document(metadata={}, page_content='ely “BRCAness” [22, 23].\\nTumors with BRCA 1/2 mutations or BRCAness TNBC are mor'),\n",
       " Document(metadata={}, page_content='RCAness TNBC are more immunogenic than TNBC without these \\ngenetic alterations ['),\n",
       " Document(metadata={}, page_content='enetic alterations [24–26].\\nCompared to the other BC subtypes the immunogenic TM'),\n",
       " Document(metadata={}, page_content='s the immunogenic TME features in TNBC consist of higher levels of \\nvascular end'),\n",
       " Document(metadata={}, page_content='els of \\nvascular endothelial growth factor (VEGF), that promote tumor cell growt'),\n",
       " Document(metadata={}, page_content='ote tumor cell growth and migration such as mitogen-\\nactivated protein kinases ('),\n",
       " Document(metadata={}, page_content='ed protein kinases (MAPKs), tumor-associated macrophages (TAMs), and tumor-infil'),\n",
       " Document(metadata={}, page_content='Ms), and tumor-infiltrating \\nlymphocytes (TILs), white blood cells that migrate'),\n",
       " Document(metadata={}, page_content='cells that migrate towards the tumor, leading to an important \\nimmunogenic effe'),\n",
       " Document(metadata={}, page_content='nt \\nimmunogenic effect and consequently that are involved in killing cancer cell'),\n",
       " Document(metadata={}, page_content='killing cancer cells [27–29].\\nTAMs regulate the interaction between the immune'),\n",
       " Document(metadata={}, page_content='between the immune system and cancer cells. CD163+ M2 macrophages, \\nwhich are a'),\n",
       " Document(metadata={}, page_content='phages, \\nwhich are associated with tumors characterized by higher proliferation'),\n",
       " Document(metadata={}, page_content='igher proliferation and poorer differentiation [30], are \\nmore present in TNBC a'),\n",
       " Document(metadata={}, page_content='re present in TNBC and basal-like BC [31]. A prosperous infiltration of TILs is'),\n",
       " Document(metadata={}, page_content='ltration of TILs is found in TNBC tumors and \\nthe stroma surrounding them, with'),\n",
       " Document(metadata={}, page_content='rounding them, with a recognized predictive and prognostic role, specifically fo'),\n",
       " Document(metadata={}, page_content='ole, specifically for CD4+ CD8+ \\nT cells [32]. Several studies have reported bet'),\n",
       " Document(metadata={}, page_content='es have reported better response to neoadjuvant CHT (NACT) [33] and better \\nclin'),\n",
       " Document(metadata={}, page_content='33] and better \\nclinical outcomes in BC with high TIL infiltrate [34–39]. Based'),\n",
       " Document(metadata={}, page_content='rate [34–39]. Based on this evidence, the international TILs \\nworking group star'),\n",
       " Document(metadata={}, page_content='working group started standardizing the evaluation of BC TILs to use it in cli'),\n",
       " Document(metadata={}, page_content='ILs to use it in clinical practice identifying those \\npatients that may benefit'),\n",
       " Document(metadata={}, page_content='ts that may benefit from emerging immunotherapies with ICIs or combination thera'),\n",
       " Document(metadata={}, page_content='or combination therapies [40].\\nAll these TME elements contribute to TNBC immunog'),\n",
       " Document(metadata={}, page_content='bute to TNBC immunogenicity which also appears to be closely related to \\nthe con'),\n",
       " Document(metadata={}, page_content='related to \\nthe concept of TMB, depending on the ineffective DNA repair system'),\n",
       " Document(metadata={}, page_content='e DNA repair system with the consequent generation of \\nhigh rates of neoantigens'),\n",
       " Document(metadata={}, page_content='rates of neoantigens. The upregulated antigen presentation system leads to an in'),\n",
       " Document(metadata={}, page_content='ystem leads to an increasing number of \\ninnate and adaptative immune cells and m'),\n",
       " Document(metadata={}, page_content='e immune cells and many cytokines interplaying with cancer cells. However, the e'),\n",
       " Document(metadata={}, page_content='ells. However, the exact \\nrelationship between TMB, neoantigens, and immune infi'),\n",
       " Document(metadata={}, page_content='ens, and immune infiltration is not yet completely understood, and \\nsome studies'),\n",
       " Document(metadata={}, page_content='d, and \\nsome studies have reported an inverse association between immune cells i'),\n",
       " Document(metadata={}, page_content='tween immune cells in TME and the rate of somatic \\ncopy number alterations [41,'),\n",
       " Document(metadata={}, page_content='er alterations [41, 42].\\nMoreover, although TMB is comparable across the three c'),\n",
       " Document(metadata={}, page_content='e across the three clusters of TNBC, the “immune-inflated” \\nphenotype is charact'),\n",
       " Document(metadata={}, page_content='phenotype is characterized by a higher degree of immune cells in the TME, but al'),\n",
       " Document(metadata={}, page_content='s in the TME, but also a high expression of \\nimmune checkpoints by cancer cells'),\n",
       " Document(metadata={}, page_content='nts by cancer cells [16]. The rate of TILs, indeed, has been positively related'),\n",
       " Document(metadata={}, page_content='positively related to \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://do'),\n",
       " Document(metadata={}, page_content=':232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 235\\nprogrammed death lig'),\n",
       " Document(metadata={}, page_content='programmed death ligand 1 (PD-L1) expression [43]. PD-L1 is an immune checkpoint'),\n",
       " Document(metadata={}, page_content='an immune checkpoint that mediates local \\nimmune escape in many tumors inducing'),\n",
       " Document(metadata={}, page_content='any tumors inducing saturation of activated T cells. Even if PD-L1 prognostic ro'),\n",
       " Document(metadata={}, page_content='PD-L1 prognostic role is yet \\ncontroversial [44], however it results more overe'),\n",
       " Document(metadata={}, page_content='t results more overexpressed in TNBC compared with other BC and it can \\npredict'),\n",
       " Document(metadata={}, page_content='and it can \\npredict responsiveness to immunotherapy [16].\\nTherefore, TNBC repres'),\n",
       " Document(metadata={}, page_content='erefore, TNBC represents an aggressive BC subtype, associated with high mutation'),\n",
       " Document(metadata={}, page_content='d with high mutational load, high \\ntumor immunogenicity and TME diversity.\\nNew p'),\n",
       " Document(metadata={}, page_content='TME diversity.\\nNew paradigms in early TNBC: from CHT to immunotherapy\\nCHT in adj'),\n",
       " Document(metadata={}, page_content='notherapy\\nCHT in adjuvant treatment for TNBC\\nIn early TNBC patients, CHT represe'),\n",
       " Document(metadata={}, page_content='atients, CHT represents the mainstay of adjuvant and neoadjuvant treatments. Adj'),\n",
       " Document(metadata={}, page_content='vant treatments. Adjuvant \\nCHT is recommended for tumor sizes greater than 1.0 c'),\n",
       " Document(metadata={}, page_content='s greater than 1.0 cm and patients with nodal involvement, regardless \\nof tumor'),\n",
       " Document(metadata={}, page_content='egardless \\nof tumor size. Therefore, it can be considered for tumor sizes betwee'),\n",
       " Document(metadata={}, page_content='r tumor sizes between 0.6–1.0 cm [45]. A recent large meta-\\nanalysis demonstrate'),\n",
       " Document(metadata={}, page_content='analysis demonstrated that adjuvant CHT with anthracyclines-containing regimens'),\n",
       " Document(metadata={}, page_content='containing regimens plus taxanes, compared \\nwith no CHT, can reduce BC mortality'),\n",
       " Document(metadata={}, page_content='reduce BC mortality rates by about 40% during the first decade after diagnosis.'),\n",
       " Document(metadata={}, page_content='ade after diagnosis. Moreover, \\nregimens with higher cumulative and dose-dense s'),\n",
       " Document(metadata={}, page_content='ive and dose-dense schedules of anthracycline (with granulocyte colony-\\nstimulat'),\n",
       " Document(metadata={}, page_content='yte colony-\\nstimulating factor support) have shown better survival benefits and'),\n",
       " Document(metadata={}, page_content='rvival benefits and more reductions in recurrence [46]. \\nThree-weekly docetaxel'),\n",
       " Document(metadata={}, page_content='ee-weekly docetaxel and paclitaxel can be considered in adjuvant setting, but we'),\n",
       " Document(metadata={}, page_content='vant setting, but weekly paclitaxel, in a \\nsubgroup analysis, has shown improved'),\n",
       " Document(metadata={}, page_content=', has shown improved outcomes and is preferred for TNBC [47]. In TNBC in frail p'),\n",
       " Document(metadata={}, page_content='. In TNBC in frail patients \\nwith a known history of heart disease, to minimize'),\n",
       " Document(metadata={}, page_content='isease, to minimize the cardiotoxicity of adjuvant treatments, docetaxel \\ncombin'),\n",
       " Document(metadata={}, page_content='s, docetaxel \\ncombined with cyclophosphamide (TC) has proven to be a viable alte'),\n",
       " Document(metadata={}, page_content='to be a viable alternative to doxorubicin and \\ncyclophosphamide (AC), demonstra'),\n",
       " Document(metadata={}, page_content='mide (AC), demonstrating a favorable disease-free survival (DFS) [48]. Therefore'),\n",
       " Document(metadata={}, page_content='DFS) [48]. Therefore, there is a \\nbroad spectrum of chemotherapeutic treatments'),\n",
       " Document(metadata={}, page_content='rapeutic treatments for early TNBC that should be customised according to the \\np'),\n",
       " Document(metadata={}, page_content='according to the \\npatient and expected toxicities.\\nThe role of platinum in adju'),\n",
       " Document(metadata={}, page_content='of platinum in adjuvant setting for TNBC\\nTNBC patients commonly harbor BRCA 1/2'),\n",
       " Document(metadata={}, page_content='only harbor BRCA 1/2 or BRCAness mutations with a homologous recombination \\ndefi'),\n",
       " Document(metadata={}, page_content='recombination \\ndeficiency (HRD) that makes them particularly susceptible to pla'),\n",
       " Document(metadata={}, page_content='y susceptible to platinum agents due to their ability to hit \\ncancer cells that'),\n",
       " Document(metadata={}, page_content='cancer cells that have deficient DNA repair mechanisms [49–51]. Several retros'),\n",
       " Document(metadata={}, page_content='–51]. Several retrospective single-center studies \\nhave explored the role of adj'),\n",
       " Document(metadata={}, page_content='ored the role of adjuvant platinum combined with standard anthracycline and taxa'),\n",
       " Document(metadata={}, page_content='thracycline and taxane-based \\nregimens, with controversial results not showing c'),\n",
       " Document(metadata={}, page_content='esults not showing clear clinical benefits [52, 53]. Nevertheless, a recent \\npha'),\n",
       " Document(metadata={}, page_content='eless, a recent \\nphase III trials have demonstrated a longer 5-year DFS (86.5% v'),\n",
       " Document(metadata={}, page_content='5-year DFS (86.5% vs. 80.3%) with similar results in distant DFS \\nand relapse-f'),\n",
       " Document(metadata={}, page_content='t DFS \\nand relapse-free survival (RFS) of platinum-containing adjuvant regimens'),\n",
       " Document(metadata={}, page_content='g adjuvant regimens (paclitaxel-carboplatin) \\ncompared to a standard anthracycli'),\n",
       " Document(metadata={}, page_content='standard anthracyclines-containing regimen followed by taxane, however with no b'),\n",
       " Document(metadata={}, page_content='e, however with no benefit in \\noverall survival (OS) [54].\\nAnother important fac'),\n",
       " Document(metadata={}, page_content='nother important factor is platinum resistance. Platinum sensitivity may be affe'),\n",
       " Document(metadata={}, page_content='sitivity may be affected by changes in the \\nhazard ratio (HR) pathway or, in the'),\n",
       " Document(metadata={}, page_content=') pathway or, in the case of patients with BRCA 1/2 mutations, by the secondary'),\n",
       " Document(metadata={}, page_content='s, by the secondary \\nappearance of new BRCA 1 or 2 mutations that make cancer ce'),\n",
       " Document(metadata={}, page_content='that make cancer cells less sensitive to platinum [55, 56].\\nOther mechanisms of'),\n",
       " Document(metadata={}, page_content='Other mechanisms of resistance to platinum compounds are:\\nModification of drug'),\n",
       " Document(metadata={}, page_content='odification of drug transport within the tumor cell, by determining decreased in'),\n",
       " Document(metadata={}, page_content='rmining decreased influx or increased \\nefflux.\\n(1).\\nIncrease of detoxification s'),\n",
       " Document(metadata={}, page_content='of detoxification systems.\\n(2).\\nDecrease of cell apoptosis [57].\\n(3).\\nTherefore'),\n",
       " Document(metadata={}, page_content='[57].\\n(3).\\nTherefore, the benefit of adjuvant platinum-based regimens remains co'),\n",
       " Document(metadata={}, page_content='regimens remains controversial and needs \\nvalidation by prospective adjuvant on'),\n",
       " Document(metadata={}, page_content='spective adjuvant ongoing trials.\\nExplor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='er. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 236\\nNeoadjuvan'),\n",
       " Document(metadata={}, page_content='Page 236\\nNeoadjuvant treatments for TNBC\\nNACT\\nSeveral treatment guidelines reco'),\n",
       " Document(metadata={}, page_content='ment guidelines recommend NACT as the preferred option for stage II or III TNBC'),\n",
       " Document(metadata={}, page_content='tage II or III TNBC and for \\nstage I with a tumor size greater than 1 cm. It can'),\n",
       " Document(metadata={}, page_content='er than 1 cm. It can be considered in stage I TNBC with a tumor size from \\n0.6 c'),\n",
       " Document(metadata={}, page_content='mor size from \\n0.6 cm to 1 cm and/or in the case of tumors with nodal micrometas'),\n",
       " Document(metadata={}, page_content='ith nodal micrometastases. [6, 45]. There is no significant \\ndifference in survi'),\n",
       " Document(metadata={}, page_content='difference in survival benefits between patients receiving neoadjuvant or adjuv'),\n",
       " Document(metadata={}, page_content='neoadjuvant or adjuvant CHT after surgical \\nresection. However, neoadjuvant trea'),\n",
       " Document(metadata={}, page_content='er, neoadjuvant treatments can be useful for inoperable tumors rendering them op'),\n",
       " Document(metadata={}, page_content='rs rendering them operable \\nand they can also downstage patients with operable B'),\n",
       " Document(metadata={}, page_content='ents with operable BC promoting breast-conservation [58, 59]. The use of \\nneoadj'),\n",
       " Document(metadata={}, page_content='. The use of \\nneoadjuvant treatments provides important prognostic information b'),\n",
       " Document(metadata={}, page_content='nostic information based on response to therapy. \\nAchieving a pCR, defined as th'),\n",
       " Document(metadata={}, page_content='a pCR, defined as the lack of cancer cells in tissue samples of breast and axill'),\n",
       " Document(metadata={}, page_content='of breast and axillary lymph nodes, \\nafter a neoadjuvant treatment, is associat'),\n",
       " Document(metadata={}, page_content='eatment, is associated with favorable disease-free and OS in early TNBC, as \\ndem'),\n",
       " Document(metadata={}, page_content='early TNBC, as \\ndemonstrated in Collaborative Trials in Neoadjuvant Breast Canc'),\n",
       " Document(metadata={}, page_content='adjuvant Breast Cancer (CTNeoBC) pooled analysis. In this \\nstudy, patients with'),\n",
       " Document(metadata={}, page_content='tudy, patients with early BC treated with NACT and followed by surgery who obtai'),\n",
       " Document(metadata={}, page_content='by surgery who obtained pCR (ypT0 ypN0, \\nypT0/is ypN0) were associated with impr'),\n",
       " Document(metadata={}, page_content='associated with improved event-free survival (EFS) and OS, especially in TNBC (H'),\n",
       " Document(metadata={}, page_content='specially in TNBC (HR = \\n0.24 and HR = 0.16, respectively) [33]. Like adjuvant t'),\n",
       " Document(metadata={}, page_content='33]. Like adjuvant treatment, traditional NACT is based on anthracyclines \\nand t'),\n",
       " Document(metadata={}, page_content='nthracyclines \\nand taxanes, and a dose-dense regimen is preferred in neoadjuvant'),\n",
       " Document(metadata={}, page_content='erred in neoadjuvant settings based on proven improved DFS \\nand OS in a large me'),\n",
       " Document(metadata={}, page_content='and OS in a large meta-analysis [60].\\nIn recent years, the use of platinum-based'),\n",
       " Document(metadata={}, page_content='se of platinum-based combination regimens has been the focus of neoadjuvant \\ntre'),\n",
       " Document(metadata={}, page_content='of neoadjuvant \\ntreatment to increase the rate of pCR in TNBC. Three recent stu'),\n",
       " Document(metadata={}, page_content='BC. Three recent studies demonstrated that combining platinum \\nwith taxane and a'),\n",
       " Document(metadata={}, page_content='m \\nwith taxane and anthracycline led to an improvement in the pCR rate in TNBC,'),\n",
       " Document(metadata={}, page_content='e pCR rate in TNBC, with a similar survival \\nbenefit [61–63]. In Brightness Tria'),\n",
       " Document(metadata={}, page_content='. In Brightness Trial patients with II–III stage TNBC were randomly assigned to'),\n",
       " Document(metadata={}, page_content='andomly assigned to receive \\npaclitaxel alone, paclitaxel and carboplatin and th'),\n",
       " Document(metadata={}, page_content='d carboplatin and this combination with a PARP inhibitor, veliparib followed \\nby'),\n",
       " Document(metadata={}, page_content='liparib followed \\nby AC. Although the addition of veliparib and carboplatin was'),\n",
       " Document(metadata={}, page_content='and carboplatin was associated with an increase of patients who \\nachieved a pCR'),\n",
       " Document(metadata={}, page_content='who \\nachieved a pCR compared to paclitaxel alone (53% vs. 31%, P < 0.0001), but'),\n",
       " Document(metadata={}, page_content='%, P < 0.0001), but not to paclitaxel and \\ncarboplatin, this benefit could be re'),\n",
       " Document(metadata={}, page_content='benefit could be related to the addition of the carboplatin [63]. The initial r'),\n",
       " Document(metadata={}, page_content='[63]. The initial rationale for \\nusing the combination of platinum in NACT was'),\n",
       " Document(metadata={}, page_content='latinum in NACT was that sporadic TNBC can show BRCAness with a major \\nresponse'),\n",
       " Document(metadata={}, page_content='h a major \\nresponse to platinum regimens [50, 51]. However, the greatest benefit'),\n",
       " Document(metadata={}, page_content='the greatest benefit was seen in patients who were \\ngermline BRCA wild type, and'),\n",
       " Document(metadata={}, page_content='BRCA wild type, and only a marginal benefit was observed in the germline BRCA m'),\n",
       " Document(metadata={}, page_content='the germline BRCA mutant \\nsubgroup, as was shown in the recent GeparOLA trial.'),\n",
       " Document(metadata={}, page_content='ent GeparOLA trial. In this trial, patients were randomized to \\nneoadjuvant ther'),\n",
       " Document(metadata={}, page_content='to \\nneoadjuvant therapy with paclitaxel and carboplatin vs. neoadjuvant therapy'),\n",
       " Document(metadata={}, page_content='neoadjuvant therapy with paclitaxel and olaparib \\n(PARP inhibitor). In both arms'),\n",
       " Document(metadata={}, page_content='bitor). In both arms, the combination of epirubicin and cyclophosphamide was adm'),\n",
       " Document(metadata={}, page_content='ophosphamide was administered \\nnext. This study, although limited by a small num'),\n",
       " Document(metadata={}, page_content='mited by a small number of patients enrolled, showed an advantage for the \\ncarbo'),\n",
       " Document(metadata={}, page_content='ntage for the \\ncarboplatin arm in patients without BRCA mutation (germ or somati'),\n",
       " Document(metadata={}, page_content='tion (germ or somatic) and high HRD. The 4-year invasive \\nDFS (iDFS) rate with o'),\n",
       " Document(metadata={}, page_content='S (iDFS) rate with olaparib-paclitaxel was 81.2% vs. 93.4% with carboplatin-pacl'),\n",
       " Document(metadata={}, page_content='ith carboplatin-paclitaxel (CP) [HR = 3.03; \\n95% confidence interval (CI) = 0.67'),\n",
       " Document(metadata={}, page_content='interval (CI) = 0.67–13.67; log-rank P = 0.1290]. The 4-year OS rate was 89.2% w'),\n",
       " Document(metadata={}, page_content='OS rate was 89.2% with the \\nolaparib combination vs. 96.6% with carboplatin (HR'),\n",
       " Document(metadata={}, page_content='with carboplatin (HR = 3.27; 95% CI = 0.39–27.20; log-rank P = 0.2444). \\nThe tre'),\n",
       " Document(metadata={}, page_content='= 0.2444). \\nThe trend of the iDFS curves was similar in the two treatment arms'),\n",
       " Document(metadata={}, page_content='two treatment arms and independent of germline or somatic \\nBRCA mutation [64].'),\n",
       " Document(metadata={}, page_content='BRCA mutation [64].\\nPlatinum combinations are currently recommended for selected'),\n",
       " Document(metadata={}, page_content='mmended for selected patients with TNBC who require \\nadequate local control befo'),\n",
       " Document(metadata={}, page_content='e local control before surgical resection [45]. A more recent phase III trial pr'),\n",
       " Document(metadata={}, page_content='t phase III trial presented at the San \\nAntonio Breast Cancer Symposium evaluati'),\n",
       " Document(metadata={}, page_content='r Symposium evaluating the efficacy and safety of adding carboplatin to standard'),\n",
       " Document(metadata={}, page_content='boplatin to standard \\nsequential taxane-anthracycline NACT in patients with TNBC'),\n",
       " Document(metadata={}, page_content='n patients with TNBC who had no evidence of metastatic disease, \\nhas observed im'),\n",
       " Document(metadata={}, page_content='se, \\nhas observed improvements in terms of DFS (5-year DFS were 70.6% and 64.5%'),\n",
       " Document(metadata={}, page_content='ere 70.6% and 64.5% respectively with a HR = \\n0.79, 95% CI = 0.61–1.02, P = 0.07'),\n",
       " Document(metadata={}, page_content='0.61–1.02, P = 0.073) and OS (5-year OS were 74.0% and 66.7% respectively with'),\n",
       " Document(metadata={}, page_content='% respectively with a HR = \\n0.75, 95% CI = 0.57–0.98, P = 0.034) with the additi'),\n",
       " Document(metadata={}, page_content='034) with the addition of carboplatin, but these benefits were limited to \\npatie'),\n",
       " Document(metadata={}, page_content='re limited to \\npatients who were 50 years of age or younger. Therefore, the pCR'),\n",
       " Document(metadata={}, page_content='Therefore, the pCR in the intention-to-treat population was \\n54.5% in the carbo'),\n",
       " Document(metadata={}, page_content='54.5% in the carboplatin arm and 40.3% in the control arm (P < 0.001) [65].\\nTh'),\n",
       " Document(metadata={}, page_content='(P < 0.001) [65].\\nThe inclusion of platinum agents as NACT for TNBC remains cont'),\n",
       " Document(metadata={}, page_content='or TNBC remains controversial. Long-term outcomes and \\nnew prospective studies a'),\n",
       " Document(metadata={}, page_content='rospective studies are needed to clarify the role of platinum agents in this set'),\n",
       " Document(metadata={}, page_content='m agents in this setting.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://'),\n",
       " Document(metadata={}, page_content=';5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 237\\nNeoadjuvant immuno'),\n",
       " Document(metadata={}, page_content='7\\nNeoadjuvant immunotherapy\\nThe success of ICIs in metastatic TNBC led to expand'),\n",
       " Document(metadata={}, page_content='c TNBC led to expand their role in neoadjuvant settings. Pembrolizumab and \\natez'),\n",
       " Document(metadata={}, page_content='brolizumab and \\natezolizumab have shown progression-free survival (PFS) benefits'),\n",
       " Document(metadata={}, page_content='vival (PFS) benefits in phase III trials in advanced setting \\n[66, 67]. In contr'),\n",
       " Document(metadata={}, page_content='[66, 67]. In contrast to atezolizumab that showed conflicting results [68, 69]'),\n",
       " Document(metadata={}, page_content='ing results [68, 69], pembrolizumab consistently \\nshowed OS benefits in advanced'),\n",
       " Document(metadata={}, page_content='benefits in advanced TNBC [66, 70]. In early-stage TNBC two studies evaluated at'),\n",
       " Document(metadata={}, page_content='studies evaluated atezolizumab in \\nneoadjuvant setting. In the NeoTRIPaPDL1 tria'),\n",
       " Document(metadata={}, page_content='he NeoTRIPaPDL1 trial, no improvement in pCR was shown with the addition of \\nate'),\n",
       " Document(metadata={}, page_content='the addition of \\natezolizumab to a non-anthracycline-containing CHT regimen [71]'),\n",
       " Document(metadata={}, page_content='ing CHT regimen [71]. More recent Impassion031 phase III \\nstudy evaluating the a'),\n",
       " Document(metadata={}, page_content='udy evaluating the association of atezolizumab to a standard NACT (nab-palclitax'),\n",
       " Document(metadata={}, page_content='NACT (nab-palclitaxel weekly for 12 weeks \\nfollowed by 4 cycles of AC), has dem'),\n",
       " Document(metadata={}, page_content='cles of AC), has demonstrated a significant improvement of pCR rates in intentio'),\n",
       " Document(metadata={}, page_content='CR rates in intention to treat \\n(ITT) population (58% in atezolizumab arm vs. 41'),\n",
       " Document(metadata={}, page_content='zolizumab arm vs. 41% in placebo arm, P = 0.0044), regardless of PD-L1 status,'),\n",
       " Document(metadata={}, page_content='s of PD-L1 status, \\nmeeting the primary endpoint of the study [72]. Therefore, i'),\n",
       " Document(metadata={}, page_content='y [72]. Therefore, in early BC the combination of pembrolizumab \\nwith paclitaxel'),\n",
       " Document(metadata={}, page_content='mab \\nwith paclitaxel-carboplatin followed by anthracycline increased pCR rate an'),\n",
       " Document(metadata={}, page_content='ncreased pCR rate and EFS rate in the KEYNOTE-522 \\ntrial, representing a turning'),\n",
       " Document(metadata={}, page_content='presenting a turning point for the role of immunotherapy in neoadjuvant therapy'),\n",
       " Document(metadata={}, page_content='neoadjuvant therapy of TNBC and \\nestablishing pembrolizumab as a standard treatm'),\n",
       " Document(metadata={}, page_content='as a standard treatment during neoadjuvant treatment for stage II and III \\nTNBC.'),\n",
       " Document(metadata={}, page_content='ge II and III \\nTNBC. The trial evaluated the combination of pembrolizumab (18 cy'),\n",
       " Document(metadata={}, page_content='pembrolizumab (18 cycles, 200 mg every 3 weeks) combined \\nwith four cycles of pa'),\n",
       " Document(metadata={}, page_content='th four cycles of paclitaxel (weekly or 3-weekly) and carboplatin (3-weekly), fo'),\n",
       " Document(metadata={}, page_content='latin (3-weekly), followed by 3-weekly AC for \\n4 cycles, compared to placebo wit'),\n",
       " Document(metadata={}, page_content='pared to placebo with CHT. Pembrolizumab arm showed a 13.6% improvement in pCR ['),\n",
       " Document(metadata={}, page_content='improvement in pCR [64.8% \\n(95% CI = 59.9–69.5%) vs. 51.2% (95% CI = 44.1–58.3%)'),\n",
       " Document(metadata={}, page_content='95% CI = 44.1–58.3%)] and in EFS rate [84.5% (95% CI = 81.7–86.9%) \\nvs. 76.8% (9'),\n",
       " Document(metadata={}, page_content='86.9%) \\nvs. 76.8% (95% CI = 72.2–80.7%)], meeting the primary endpoint of the st'),\n",
       " Document(metadata={}, page_content='y endpoint of the study, regardless nodal \\ninvolvement and PD-L1 status. The ave'),\n",
       " Document(metadata={}, page_content='D-L1 status. The average duration of follow-up is still immature, but a trend of'),\n",
       " Document(metadata={}, page_content='ture, but a trend of \\nsuperiority in terms of OS in the pembrolizumab arm was ne'),\n",
       " Document(metadata={}, page_content='rolizumab arm was nevertheless detected [73]. Limits of this study \\nare the lack'),\n",
       " Document(metadata={}, page_content='study \\nare the lack of biomarkers that predict what patient may benefit from th'),\n",
       " Document(metadata={}, page_content='may benefit from the addition of pembrolizumab and \\nthe non-utilization of dose'),\n",
       " Document(metadata={}, page_content='-utilization of dose-dense schedule of AC which showed superior OS benefit in th'),\n",
       " Document(metadata={}, page_content='ior OS benefit in the neoadjuvant \\nsetting in TNBC [74].\\nMoreover, the recent Ge'),\n",
       " Document(metadata={}, page_content='eover, the recent GeparNuevo trial showed that durvalumab (1,500 mg every 4 week'),\n",
       " Document(metadata={}, page_content=',500 mg every 4 weeks) added to \\nNACT consisting of nab-paclitaxel 125 mg/m2 wee'),\n",
       " Document(metadata={}, page_content='itaxel 125 mg/m2 weekly for 12 weeks, followed by epirubicin/\\ncyclophosphamide e'),\n",
       " Document(metadata={}, page_content='/\\ncyclophosphamide every 2 weeks, in early TNBC significantly improved iDFS (85.'),\n",
       " Document(metadata={}, page_content='y improved iDFS (85.6% with durvalumab vs. \\n77.2% with placebo HR = 0.48, 95% CI'),\n",
       " Document(metadata={}, page_content='bo HR = 0.48, 95% CI = 0.24–0.97, stratified log-rank P = 0.036) and OS (95.2% v'),\n",
       " Document(metadata={}, page_content='036) and OS (95.2% vs. 83.5% \\nwith a HR = 0.24, 95% CI = 0.08–0.72, P = 0.006),'),\n",
       " Document(metadata={}, page_content='8–0.72, P = 0.006), despite a modest pCR increase and no adjuvant \\ncomponent of'),\n",
       " Document(metadata={}, page_content='uvant \\ncomponent of durvalumab [75]. Future studies should aim to define the rol'),\n",
       " Document(metadata={}, page_content='im to define the role of immunotherapy in the \\ntreatment of early TNBC, to defin'),\n",
       " Document(metadata={}, page_content='early TNBC, to define the ideal duration of these treatments, and should researc'),\n",
       " Document(metadata={}, page_content=', and should research new \\nbiomarkers to personalize treatments.\\nPathological co'),\n",
       " Document(metadata={}, page_content='nts.\\nPathological complete response: prognostic role and therapeutic \\nimplicatio'),\n",
       " Document(metadata={}, page_content='rapeutic \\nimplications\\nIn clinical practice, the achievement of pCR after neoadj'),\n",
       " Document(metadata={}, page_content='of pCR after neoadjuvant treatment is correlated to the improvement of \\nlong-te'),\n",
       " Document(metadata={}, page_content='rovement of \\nlong-term benefits concerning EFS and OS. Its prognostic value is g'),\n",
       " Document(metadata={}, page_content='rognostic value is greatest in aggressive tumor subtypes, \\nlike in TNBC (EFS: HR'),\n",
       " Document(metadata={}, page_content='ike in TNBC (EFS: HR = 0.24; OS: HR = 0.16) [33]. Patients who have residual inv'),\n",
       " Document(metadata={}, page_content='ho have residual invasive BC after the receipt \\nof NACT have a high risk of rela'),\n",
       " Document(metadata={}, page_content='a high risk of relapse. Patients with TNBC who do not experience pCR have an es'),\n",
       " Document(metadata={}, page_content='ience pCR have an estimated 5-\\nyear EFS of 57% and OS of 47% (compared with 90%'),\n",
       " Document(metadata={}, page_content='(compared with 90% EFS and 84% OS, respectively, for patients with early-\\nstage'),\n",
       " Document(metadata={}, page_content='ts with early-\\nstage TNBC who demonstrate pCR) [76, 77].\\nAfter pre-operative CHT'),\n",
       " Document(metadata={}, page_content='er pre-operative CHT and surgical treatment, patients can receive postoperative'),\n",
       " Document(metadata={}, page_content='ceive postoperative radiation therapy \\n(RT). Patients with hormone receptor-posi'),\n",
       " Document(metadata={}, page_content='ormone receptor-positive BC [hormone receptor-positive (HR+) BC] are candidates'),\n",
       " Document(metadata={}, page_content='BC] are candidates for \\nadjuvant endocrine treatment. However, until recently,'),\n",
       " Document(metadata={}, page_content='er, until recently, no adjuvant CHT was expected as standard in \\npatients with T'),\n",
       " Document(metadata={}, page_content='in \\npatients with TNBC. Only follow-up was recommended in those who have pCR or'),\n",
       " Document(metadata={}, page_content='hose who have pCR or in those with residual \\ninvasive BC after the receipt of ne'),\n",
       " Document(metadata={}, page_content='er the receipt of neoadjuvant regimens [78]. To address the unmet clinical need'),\n",
       " Document(metadata={}, page_content='unmet clinical need for optimal \\nadjuvant treatment in the subgroup of patients'),\n",
       " Document(metadata={}, page_content='ubgroup of patients with TNBC at high risk of recurrence (those who have not \\nac'),\n",
       " Document(metadata={}, page_content='ose who have not \\nachieved the pCR after NACT containing anthracycline, taxane,'),\n",
       " Document(metadata={}, page_content='hracycline, taxane, or both), the Capecitabine for Residual \\nCancer as Adjuvant'),\n",
       " Document(metadata={}, page_content='Cancer as Adjuvant Therapy (CREATE-X) was designed. The trial did not include o'),\n",
       " Document(metadata={}, page_content='al did not include only patients with TNBC \\nExplor Target Antitumor Ther. 2024;5'),\n",
       " Document(metadata={}, page_content='titumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 238'),\n",
       " Document(metadata={}, page_content='2024.00215\\nPage 238\\nbut also patients with HR+ HER2 negative BC [79]. The result'),\n",
       " Document(metadata={}, page_content='BC [79]. The results of this phase III trial showed that the \\naddition of adjuv'),\n",
       " Document(metadata={}, page_content='e \\naddition of adjuvant capecitabine (1,250 mg per square meter of body-surface'),\n",
       " Document(metadata={}, page_content='ter of body-surface area, twice per day, on days \\n1 to 14, every 3 weeks for six'),\n",
       " Document(metadata={}, page_content='very 3 weeks for six or eight cycles) was safe and effective in prolonging DFS a'),\n",
       " Document(metadata={}, page_content='in prolonging DFS and OS among the \\nITT population. The study showed a superior'),\n",
       " Document(metadata={}, page_content='dy showed a superior DFS in the capecitabine group than in the control group \\n(7'),\n",
       " Document(metadata={}, page_content='he control group \\n(74.1% vs. 67.6% at 5 years; HR = 0.70; P = 0.01). Therefore,'),\n",
       " Document(metadata={}, page_content='= 0.01). Therefore, OS was longer in the experimental group: \\n89.2% vs. 83.6% of'),\n",
       " Document(metadata={}, page_content='89.2% vs. 83.6% of the patients were alive at 5 years (HR = 0.59; P = 0.01). T'),\n",
       " Document(metadata={}, page_content='= 0.59; P = 0.01). Thirty percent of the patients \\nhad triple negative (TN) dise'),\n",
       " Document(metadata={}, page_content='e negative (TN) disease, and they represent the subgroup with poor prognosis (ap'),\n",
       " Document(metadata={}, page_content='h poor prognosis (approximately half \\nthe patients with TNBC who had a pCR did n'),\n",
       " Document(metadata={}, page_content='who had a pCR did not have the recurrence of the disease) [33]. The benefit of'),\n",
       " Document(metadata={}, page_content='33]. The benefit of \\ncapecitabine vs. control in DFS and OS was notable among th'),\n",
       " Document(metadata={}, page_content='was notable among this subgroup of patients (HR = 0.58 and HR = \\n0.52, respectiv'),\n",
       " Document(metadata={}, page_content='R = \\n0.52, respectively) [79].\\nThe reflection in the treatment algorithm due to'),\n",
       " Document(metadata={}, page_content='nt algorithm due to these results was significant.\\nSome limits of this study are'),\n",
       " Document(metadata={}, page_content='ts of this study are the exclusion of patients who had reached the pCR, for whom'),\n",
       " Document(metadata={}, page_content='ed the pCR, for whom only follow-\\nup was indicated, and the lack of efficacy res'),\n",
       " Document(metadata={}, page_content='lack of efficacy results selected for residual cancer burden (RCB). The RCB \\nqua'),\n",
       " Document(metadata={}, page_content='(RCB). The RCB \\nquantifies the extent of residual disease after neoadjuvant tre'),\n",
       " Document(metadata={}, page_content='fter neoadjuvant treatment at the time of surgery. This score uses \\nthe diameter'),\n",
       " Document(metadata={}, page_content='e uses \\nthe diameter of residual disease, percentage of vital tumor cells, and d'),\n",
       " Document(metadata={}, page_content='l tumor cells, and diameter of the largest involved lymph \\nnode to calculate the'),\n",
       " Document(metadata={}, page_content='ode to calculate the amount of residual disease. It has been validated with dist'),\n",
       " Document(metadata={}, page_content='validated with distinct prognostic RCB classes \\nin all BC subtypes, with the mo'),\n",
       " Document(metadata={}, page_content='ubtypes, with the most significant discriminatory power in TN and Her-2 positive'),\n",
       " Document(metadata={}, page_content='N and Her-2 positive BC. It is \\ncategorized as RCB-0 (equivalent to a pCR), RCB-'),\n",
       " Document(metadata={}, page_content='lent to a pCR), RCB-1, RCB-2, and RCB-3, reflecting increasingly larger residual'),\n",
       " Document(metadata={}, page_content='ngly larger residual \\ncancer and respective poor prognoses (in terms of EFS) [80'),\n",
       " Document(metadata={}, page_content='in terms of EFS) [80]. Finally, the CREATE-X trial did not examine \\ncapecitabine'),\n",
       " Document(metadata={}, page_content='xamine \\ncapecitabine efficacy in patients with germline BRCA 1 or BRCA 2 pathoge'),\n",
       " Document(metadata={}, page_content='1 or BRCA 2 pathogenic variants (less than 15% of \\nthose enrolled) [79].\\nOlympi'),\n",
       " Document(metadata={}, page_content='rolled) [79].\\nOlympiA is a phase III study designed to investigate how the PARP'),\n",
       " Document(metadata={}, page_content='tigate how the PARP inhibitor olaparib might improve \\nDFS and OS in patients wit'),\n",
       " Document(metadata={}, page_content='d OS in patients with resected HR+ BC and TNBC with germline BRCA 1 or BRCA 2 mu'),\n",
       " Document(metadata={}, page_content='BRCA 1 or BRCA 2 mutation. It \\nenrolled patients treated with CHT (containing a'),\n",
       " Document(metadata={}, page_content='th CHT (containing anthracyclines, taxanes or the combination of both) in \\nneoad'),\n",
       " Document(metadata={}, page_content='n of both) in \\nneoadjuvant or adjuvant setting and randomized them to receive ol'),\n",
       " Document(metadata={}, page_content='d them to receive olaparib (orally administered at the dose \\nof 300 mg twice dai'),\n",
       " Document(metadata={}, page_content='of 300 mg twice daily) vs. placebo for 1 year after surgical resection (and rad'),\n",
       " Document(metadata={}, page_content='l resection (and radiotherapy when indicated). \\nAlso in this trial, patients wit'),\n",
       " Document(metadata={}, page_content='trial, patients with TNBC who underwent NACT followed by surgery were required'),\n",
       " Document(metadata={}, page_content='rgery were required to have \\nresidual invasive BC in the breast and/or resected'),\n",
       " Document(metadata={}, page_content='ast and/or resected lymph nodes (non-pCR) [81]. Postneoadjuvant \\ncapecitabine wa'),\n",
       " Document(metadata={}, page_content='ant \\ncapecitabine was not foreseen in this trial. iDFS, the primary endpoint of'),\n",
       " Document(metadata={}, page_content='primary endpoint of the study, was significantly longer \\namong patients assigned'),\n",
       " Document(metadata={}, page_content='ng patients assigned to receive olaparib than among those assigned placebo (HR ='),\n",
       " Document(metadata={}, page_content='signed placebo (HR = 0.58; P < 0.001). The \\npercentage of patients alive and fre'),\n",
       " Document(metadata={}, page_content='tients alive and free of invasive disease at 3 years was 85.9% in the olaparib g'),\n",
       " Document(metadata={}, page_content='9% in the olaparib group and \\n77.1% in the placebo group. The benefit of adjuvan'),\n",
       " Document(metadata={}, page_content='e benefit of adjuvant olaparib was observed irrespective of the germline \\nBRCA m'),\n",
       " Document(metadata={}, page_content='the germline \\nBRCA mutation (BRCA 1 vs. BRCA 2), the hormone-receptor status, or'),\n",
       " Document(metadata={}, page_content='-receptor status, or the timing of previous CHT \\n(neoadjuvant vs. adjuvant) [81]'),\n",
       " Document(metadata={}, page_content='t vs. adjuvant) [81] 4-year iDFS for the olaparib group was 82.7% (vs. 75.4% in'),\n",
       " Document(metadata={}, page_content='82.7% (vs. 75.4% in placebo group) \\nand 4-year distant DFS (DDFS) was 86.5% (vs.'),\n",
       " Document(metadata={}, page_content='DDFS) was 86.5% (vs. 79.1%). Adjuvant olaparib improves OS, with an HR of 0.68'),\n",
       " Document(metadata={}, page_content='with an HR of 0.68 \\nand a P value of 0.009 at 3.5 years of median follow-up, mee'),\n",
       " Document(metadata={}, page_content='edian follow-up, meeting the significance threshold for OS at the \\nsecond planne'),\n",
       " Document(metadata={}, page_content='t the \\nsecond planned interim analysis. The OS benefit at 4 years in the olapari'),\n",
       " Document(metadata={}, page_content='years in the olaparib arm compared with the placebo \\narm was reported (89.8% vs.'),\n",
       " Document(metadata={}, page_content='reported (89.8% vs. 86.4%, respectively) [82].\\nBoth studies have defined the st'),\n",
       " Document(metadata={}, page_content='have defined the standard of adjuvant therapy post-NACT for patients with BRCA'),\n",
       " Document(metadata={}, page_content='patients with BRCA wild \\ntype (CREATE-X) and BRCA mutated (OlympiA) TNBC, that'),\n",
       " Document(metadata={}, page_content='OlympiA) TNBC, that did not reach the pCR.\\nThe low percentage of BRCA mutated pa'),\n",
       " Document(metadata={}, page_content='e of BRCA mutated patients enrolled in the CREATE-X, the absence of pre-planned'),\n",
       " Document(metadata={}, page_content='ence of pre-planned \\nsubgroup analyzes for this population do not allow for a de'),\n",
       " Document(metadata={}, page_content='o not allow for a description of the efficacy of capecitabine in this \\nsubgroup'),\n",
       " Document(metadata={}, page_content='e in this \\nsubgroup of patients.\\nMoreover, there are no prospective randomized t'),\n",
       " Document(metadata={}, page_content='pective randomized trials between capecitabine and olaparib to guide the \\nclinic'),\n",
       " Document(metadata={}, page_content='to guide the \\nclinical decision in this population, nor combination or sequence'),\n",
       " Document(metadata={}, page_content='ination or sequence data between these two drugs.\\nIt would also be important to'),\n",
       " Document(metadata={}, page_content='lso be important to consider the potentially severe toxicity profile of such a c'),\n",
       " Document(metadata={}, page_content='profile of such a combination, \\ngiven their overlapping side effects (in partic'),\n",
       " Document(metadata={}, page_content='e effects (in particular, cytopenias).\\nThe treatment paradigm of early TNBC has'),\n",
       " Document(metadata={}, page_content='m of early TNBC has had a real evolution since July 2021, with the introduction'),\n",
       " Document(metadata={}, page_content='th the introduction \\nof immunotherapy following the Food and Drug Administration'),\n",
       " Document(metadata={}, page_content='Drug Administration (FDA) approval of pembrolizumab for high-\\nExplor Target Ant'),\n",
       " Document(metadata={}, page_content='h-\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2'),\n",
       " Document(metadata={}, page_content='.org/10.37349/etat.2024.00215\\nPage 239\\nrisk TNBC (tumor size > 1 cm but ≤ 2 cm i'),\n",
       " Document(metadata={}, page_content='> 1 cm but ≤ 2 cm in diameter with nodal involvement or tumor size > 2 cm in \\nd'),\n",
       " Document(metadata={}, page_content='or size > 2 cm in \\ndiameter regardless of nodal involvement), regardless of tumo'),\n",
       " Document(metadata={}, page_content=', regardless of tumor PD-L1 expression, in combination with CHT \\nas neoadjuvant'),\n",
       " Document(metadata={}, page_content='CHT \\nas neoadjuvant treatment, and then continued as a single agent as adjuvant'),\n",
       " Document(metadata={}, page_content='e agent as adjuvant treatment after surgery for a \\ntotal duration of approximate'),\n",
       " Document(metadata={}, page_content='ation of approximately 1 year [83].\\nResults from the KEYNOTE-522 study were the'),\n",
       " Document(metadata={}, page_content='-522 study were the basis for this approval, demonstrating a significantly \\nhigh'),\n",
       " Document(metadata={}, page_content='significantly \\nhigher rate of pCR at the time of definitive surgery among patie'),\n",
       " Document(metadata={}, page_content='surgery among patients who received pembrolizumab plus NACT \\nthan among those w'),\n",
       " Document(metadata={}, page_content='than among those who received placebo plus NACT and an improvement in long-ter'),\n",
       " Document(metadata={}, page_content='rovement in long-term benefits [73, 84]. The \\naim of the trial was not to identi'),\n",
       " Document(metadata={}, page_content='al was not to identify the contributions of the neoadjuvant and adjuvant treatme'),\n",
       " Document(metadata={}, page_content='and adjuvant treatment phases, so it \\nis difficult to define if these long-term'),\n",
       " Document(metadata={}, page_content='if these long-term results are related to exposure to adjuvant pembrolizumab or'),\n",
       " Document(metadata={}, page_content='ant pembrolizumab or a \\nlesser RCB at the end of the neoadjuvant phase in the pe'),\n",
       " Document(metadata={}, page_content='vant phase in the pembrolizumab–CHT group.\\nAn exploratory analysis of the study'),\n",
       " Document(metadata={}, page_content='alysis of the study then provided data to further describe the prognosis related'),\n",
       " Document(metadata={}, page_content='he prognosis related to the \\nRCB after neoadjuvant experimental treatment (Figur'),\n",
       " Document(metadata={}, page_content='tal treatment (Figure 1) [85].\\nFigure 1. The unmet need for the optimal adjuvant'),\n",
       " Document(metadata={}, page_content='the optimal adjuvant treatment according to RCB [85]\\nThe HR for recurrence event'),\n",
       " Document(metadata={}, page_content='for recurrence event in subgroups RBO-0, RCB-1, RCB-2, and RCB-3 are respectivel'),\n",
       " Document(metadata={}, page_content='CB-3 are respectively 0.70 \\n(rates: 5.2% vs. 7.3% in the pembrolizumab + CHT vs.'),\n",
       " Document(metadata={}, page_content='brolizumab + CHT vs. placebo + CHT), 0.92 (rates: 17.4% vs. 20%), 0.52 \\n(rates:'),\n",
       " Document(metadata={}, page_content='20%), 0.52 \\n(rates: 25.5% vs. 44.3%), 1.24 (72.5% vs. 69.2%).\\nThe rate of recurr'),\n",
       " Document(metadata={}, page_content='.\\nThe rate of recurrence was numerically lower in all RCB groups with pembrolizu'),\n",
       " Document(metadata={}, page_content='oups with pembrolizumab + CHT, except in \\nthe small RCB-3 subset (that is repres'),\n",
       " Document(metadata={}, page_content='bset (that is represented by 5% and 7% of the population in the study, respectiv'),\n",
       " Document(metadata={}, page_content='the study, respectively in \\nthe experimental and control group). Pembrolizumab s'),\n",
       " Document(metadata={}, page_content='up). Pembrolizumab shifted RCB to lower categories in most patients \\n(RCB-0: 63%'),\n",
       " Document(metadata={}, page_content='atients \\n(RCB-0: 63% vs. 56% of patients in the experimental vs. the control arm'),\n",
       " Document(metadata={}, page_content='vs. the control arm; RCB-1: 9% vs. 11%; RCB 18% vs. \\n20%).\\nNo patients in this'),\n",
       " Document(metadata={}, page_content='No patients in this trial received adjuvant capecitabine, and there are no rando'),\n",
       " Document(metadata={}, page_content='d there are no randomized efficacy and \\nsafety data showing that multiagent ther'),\n",
       " Document(metadata={}, page_content='that multiagent therapy with pembrolizumab and capecitabine is superior to singl'),\n",
       " Document(metadata={}, page_content='is superior to single-\\nagent therapy in high-risk patients (stage II–III) who di'),\n",
       " Document(metadata={}, page_content='stage II–III) who did not reach pCR.\\nAt the time, only results from phase II stu'),\n",
       " Document(metadata={}, page_content='ts from phase II studies in metastatic TNBC demonstrated no new safety signals'),\n",
       " Document(metadata={}, page_content='new safety signals \\nwith this combination [86, 87].\\nPembrolizumab has also not b'),\n",
       " Document(metadata={}, page_content='zumab has also not been studied in combination with olaparib in the adjuvant set'),\n",
       " Document(metadata={}, page_content='in the adjuvant setting, for the \\ntreatment of patients with BRCA mutations. No'),\n",
       " Document(metadata={}, page_content='h BRCA mutations. No efficacy data are reported in the literature, even if some'),\n",
       " Document(metadata={}, page_content='ature, even if some \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.o'),\n",
       " Document(metadata={}, page_content='2–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 240\\nsafety data are reporte'),\n",
       " Document(metadata={}, page_content='ety data are reported in the metastatic setting, in some early-phase studies tha'),\n",
       " Document(metadata={}, page_content='ly-phase studies that have evaluated the \\ncombination of PARPis and ICIs, not re'),\n",
       " Document(metadata={}, page_content='Pis and ICIs, not reporting unexpected toxicities [88, 89].\\nProspective trials w'),\n",
       " Document(metadata={}, page_content='Prospective trials would be needed to define what is the optimal adjuvant strate'),\n",
       " Document(metadata={}, page_content='imal adjuvant strategy according to RCB \\n(single-agent CHT or poly-CHT), how the'),\n",
       " Document(metadata={}, page_content='r poly-CHT), how the clinician should decide between olaparib, immunotherapy or'),\n",
       " Document(metadata={}, page_content='b, immunotherapy or \\ncapecitabine in the treatment of the population with BRCA m'),\n",
       " Document(metadata={}, page_content='pulation with BRCA mutations and whether these therapies can be \\nadministered in'),\n",
       " Document(metadata={}, page_content='be \\nadministered in combination or sequence, with data in terms of efficacy and'),\n",
       " Document(metadata={}, page_content='erms of efficacy and safety.\\nAdditional treatment strategies with new drugs are'),\n",
       " Document(metadata={}, page_content='with new drugs are being studied as adjuvant treatment after NACT, \\nwith antibo'),\n",
       " Document(metadata={}, page_content='r NACT, \\nwith antibody-drug conjugates (ADCs) such as datopotamab deruxtecan (wi'),\n",
       " Document(metadata={}, page_content='tamab deruxtecan (with or without durvalumab in \\nTROPICS-Breast 03, ClinicalTria'),\n",
       " Document(metadata={}, page_content='ast 03, ClinicalTrials.gov identifier: NCT05629585), and patritumab deruxtecan ('),\n",
       " Document(metadata={}, page_content='ritumab deruxtecan (HER3-DXd) \\nwhich showed promising clinical response and biol'),\n",
       " Document(metadata={}, page_content='al response and biological changes in early TNBC [SOLTI TOT-HER3 window \\nof oppo'),\n",
       " Document(metadata={}, page_content='HER3 window \\nof opportunity trial part B, presented at European Society for Medi'),\n",
       " Document(metadata={}, page_content='ean Society for Medical Oncology (ESMO) Breast 2023], or \\nwith ICIs (A-BRAVE tri'),\n",
       " Document(metadata={}, page_content='th ICIs (A-BRAVE trial, NCT02926196 and SWOG S1418/BR006 trial, NCT02954874).\\nNe'),\n",
       " Document(metadata={}, page_content='al, NCT02954874).\\nNew biomarkers and frontiers in TNBC\\nRecent progress in integr'),\n",
       " Document(metadata={}, page_content='t progress in integrating ICIs and novel agents has revolutionized the therapeut'),\n",
       " Document(metadata={}, page_content='onized the therapeutic approach for early \\nTNBC. Treatment strategies now emphas'),\n",
       " Document(metadata={}, page_content='trategies now emphasize escalating chemotherapeutic agents based on standard \\nne'),\n",
       " Document(metadata={}, page_content='ased on standard \\nneoadjuvant regimens. An example is a phase II trial (ACTRN126'),\n",
       " Document(metadata={}, page_content='e II trial (ACTRN12617000651381) presented at the San \\nAntonio Breast Cancer Sym'),\n",
       " Document(metadata={}, page_content='io Breast Cancer Symposium 2022 evaluating in high-risk TNBC, the addition of ip'),\n",
       " Document(metadata={}, page_content=', the addition of ipilimumab and \\nnivolumab to neoadjuvant paclitaxel following'),\n",
       " Document(metadata={}, page_content='aclitaxel following a suboptimal response to anthracycline-based CHT (< 50% \\ntum'),\n",
       " Document(metadata={}, page_content='ased CHT (< 50% \\ntumor reduction) and resulting in promising objective response'),\n",
       " Document(metadata={}, page_content='objective response rate (ORR) (43.7%) and pCR (18.8%) rates, \\nregardless of PD-'),\n",
       " Document(metadata={}, page_content=', \\nregardless of PD-L1 status.\\nHowever, it is also crucial to identify subgroups'),\n",
       " Document(metadata={}, page_content='o identify subgroups of patients with favorable prognoses, where NACT \\ncould pot'),\n",
       " Document(metadata={}, page_content='here NACT \\ncould potentially be de-escalated. Therefore, discovering novel bioma'),\n",
       " Document(metadata={}, page_content='covering novel biomarkers to categorize patients with good \\nprognoses and safely'),\n",
       " Document(metadata={}, page_content='prognoses and safely de-escalate NACT is essential.\\nTILs show promise as a bioma'),\n",
       " Document(metadata={}, page_content='w promise as a biomarker for selecting patients who may have favorable outcomes'),\n",
       " Document(metadata={}, page_content='favorable outcomes with \\ntreatment de-escalation. In recent trials, higher TILs'),\n",
       " Document(metadata={}, page_content='trials, higher TILs levels were associated with a higher pCR rate [71, 75, \\n90]'),\n",
       " Document(metadata={}, page_content='R rate [71, 75, \\n90] and with a better response [75, 91]. Liquid biopsies, such'),\n",
       " Document(metadata={}, page_content='quid biopsies, such as circulating tumor DNA (ctDNA), could \\nserve as promising'),\n",
       " Document(metadata={}, page_content='serve as promising markers for identifying patients who might benefit from de-e'),\n",
       " Document(metadata={}, page_content='ht benefit from de-escalating or escalating \\nneoadjuvant or adjuvant treatment.'),\n",
       " Document(metadata={}, page_content='adjuvant treatment. Rapid ctDNA clearance during NACT in early TNBC is linked to'),\n",
       " Document(metadata={}, page_content='ly TNBC is linked to a high \\nlikelihood of achieving pCR [92]. Conversely, detec'),\n",
       " Document(metadata={}, page_content=']. Conversely, detecting ctDNA after completing NACT and surgery is \\nassociated'),\n",
       " Document(metadata={}, page_content='gery is \\nassociated with higher recurrence rates and poorer prognoses [93]. The'),\n",
       " Document(metadata={}, page_content='prognoses [93]. The use of dynamic biomarkers, such \\nas ctDNA, to guide the choi'),\n",
       " Document(metadata={}, page_content='A, to guide the choice of treatments in high-risk patients appears increasingly'),\n",
       " Document(metadata={}, page_content='ppears increasingly to be an important \\nresource to be exploited in future studi'),\n",
       " Document(metadata={}, page_content='ited in future studies.\\nFurthermore, ADCs are emerging. Particularly, sacituzuma'),\n",
       " Document(metadata={}, page_content='icularly, sacituzumab govitecan (SG) an ADC targeting Trop-2 \\nwas approved in me'),\n",
       " Document(metadata={}, page_content='was approved in metastatic TNBC patients who received ≥ 2 prior systemic thera'),\n",
       " Document(metadata={}, page_content='prior systemic therapies in the light of the \\nresults of the phase III ASCENT st'),\n",
       " Document(metadata={}, page_content='phase III ASCENT study. In this trial patients were randomized (1:1) to receive'),\n",
       " Document(metadata={}, page_content='zed (1:1) to receive sacituzumab \\ngovitecan 10 mg/kg via intravenous infusion on'),\n",
       " Document(metadata={}, page_content='ravenous infusion on day 1 and day 8 of a 21-day treatment cycle or a treatment'),\n",
       " Document(metadata={}, page_content='ycle or a treatment \\nof physician’s choice (TPC) achieving the primary endpoint'),\n",
       " Document(metadata={}, page_content='he primary endpoint (PFS 4.8 vs. 1.7 months) and also demonstrating \\nan advantag'),\n",
       " Document(metadata={}, page_content='trating \\nan advantage in terms of OS (11.8 months vs. 6.9 months) [94]. Another'),\n",
       " Document(metadata={}, page_content='nths) [94]. Another single-arm phase II trial is \\nevaluating SG and atezolizumab'),\n",
       " Document(metadata={}, page_content='SG and atezolizumab in combination as adjuvant treatment for patients with TNBC'),\n",
       " Document(metadata={}, page_content='r patients with TNBC who have \\nresidual invasive disease after neoadjuvant thera'),\n",
       " Document(metadata={}, page_content='er neoadjuvant therapy and detectable ctDNA (ClinicalTrials.gov identifier \\nNCT0'),\n",
       " Document(metadata={}, page_content='gov identifier \\nNCT04434040).\\nFinally, it is essential to redefine, with new ded'),\n",
       " Document(metadata={}, page_content='define, with new dedicated trials, the role of ER-low (1–9%) BC which, \\nbiologic'),\n",
       " Document(metadata={}, page_content='BC which, \\nbiologically and prognostically very similar to TNBC, could potentia'),\n",
       " Document(metadata={}, page_content='TNBC, could potentially benefit from the addition of \\nimmunotherapy to CHT and t'),\n",
       " Document(metadata={}, page_content='therapy to CHT and the role of HER-2 low [score 1+ or 2+ not amplified in fluore'),\n",
       " Document(metadata={}, page_content='amplified in fluorescence in situ \\nhybridization (FISH)] BC in the light of rec'),\n",
       " Document(metadata={}, page_content='in the light of recent results of efficacy of trastuzumab deruxtecan in advance'),\n",
       " Document(metadata={}, page_content='eruxtecan in advanced BC \\nHER-2 low. Therefore, future studies are likely to exp'),\n",
       " Document(metadata={}, page_content='es are likely to expand the armamentarium at our disposal in this setting.\\nExplo'),\n",
       " Document(metadata={}, page_content='this setting.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215\\nPage 241\\nNew frontiers in early TNBC a'),\n",
       " Document(metadata={}, page_content='iers in early TNBC are summarized in Figure 2.\\nFigure 2. New frontiers in early'),\n",
       " Document(metadata={}, page_content='frontiers in early TNBC\\nInterpretation and clinical implications\\nTNBC has long'),\n",
       " Document(metadata={}, page_content='tions\\nTNBC has long been a challenging disease to treat due to its aggressive be'),\n",
       " Document(metadata={}, page_content='to its aggressive behavior and the lack of target \\ntherapies [95].\\nThanks to rec'),\n",
       " Document(metadata={}, page_content='[95].\\nThanks to recent developments on TNBC, a series of therapeutic targets ha'),\n",
       " Document(metadata={}, page_content='erapeutic targets have been identified for the \\ntreatment of metastatic and earl'),\n",
       " Document(metadata={}, page_content='metastatic and early setting diseases. Especially for the radically operable di'),\n",
       " Document(metadata={}, page_content='adically operable disease, the chances \\nof cure are increased with treatments ai'),\n",
       " Document(metadata={}, page_content='d with treatments aimed at reducing the odds of recurrence after tumor removal.'),\n",
       " Document(metadata={}, page_content='fter tumor removal.\\nAnthracycline and taxane-based poly-CHT remains the standard'),\n",
       " Document(metadata={}, page_content='remains the standard of treatment, most often administered \\npreoperatively to as'),\n",
       " Document(metadata={}, page_content='preoperatively to assess tumor sensitivity. It aims to increase the rate of loca'),\n",
       " Document(metadata={}, page_content='ase the rate of local control, making it useful to \\nguide breast-conserving surg'),\n",
       " Document(metadata={}, page_content='east-conserving surgery and to ensure survival benefits by reaching the pCR.\\nThe'),\n",
       " Document(metadata={}, page_content='eaching the pCR.\\nThe introduction of immunotherapy in association with poly-CHT'),\n",
       " Document(metadata={}, page_content='ation with poly-CHT in the neoadjuvant setting has \\nincreased the rate of pCR, g'),\n",
       " Document(metadata={}, page_content='d the rate of pCR, guaranteeing better results in terms of long-term benefits in'),\n",
       " Document(metadata={}, page_content='ong-term benefits in the KEYNOTE-522, \\nthe pivotal trial that led to the approva'),\n",
       " Document(metadata={}, page_content='t led to the approval in clinical practice of the use of the anti-PD1, pembroliz'),\n",
       " Document(metadata={}, page_content='anti-PD1, pembrolizumab, in the \\nearly setting disease (neoadjuvant and adjuvan'),\n",
       " Document(metadata={}, page_content='adjuvant and adjuvant setting). These clinical findings were based on preclinica'),\n",
       " Document(metadata={}, page_content='based on preclinical \\ninvestigations that overturned the previous belief that B'),\n",
       " Document(metadata={}, page_content='evious belief that BC was not an immunogenic disease [12].\\nThe actual need is to'),\n",
       " Document(metadata={}, page_content='he actual need is to define the optimal adjuvant strategy after neoadjuvant chem'),\n",
       " Document(metadata={}, page_content='ter neoadjuvant chemo-immunotherapy, \\nwhich must be affected by the patient’s ri'),\n",
       " Document(metadata={}, page_content='by the patient’s risk of recurrence based on the histological prognostic and ev'),\n",
       " Document(metadata={}, page_content='al prognostic and evidence \\nafter radical surgery, the individual’s tolerance of'),\n",
       " Document(metadata={}, page_content='idual’s tolerance of therapy-induced side effects (Figure 3).\\nIn patients with l'),\n",
       " Document(metadata={}, page_content='.\\nIn patients with low RCB and a low overall risk of recurrence, pembrolizumab a'),\n",
       " Document(metadata={}, page_content='nce, pembrolizumab alone should be \\ncontinued. In patients with poor prognostic'),\n",
       " Document(metadata={}, page_content='ith poor prognostic features of high RCB, this strategy may not be the best choi'),\n",
       " Document(metadata={}, page_content='not be the best choice. \\nPatients with high RCB, BRCA wild type, could benefit f'),\n",
       " Document(metadata={}, page_content='ype, could benefit from capecitabine alone, although it would be \\nreasonable to'),\n",
       " Document(metadata={}, page_content='d be \\nreasonable to use a combination of capecitabine and pembrolizumab. Patient'),\n",
       " Document(metadata={}, page_content='mbrolizumab. Patients with high RCB, germline \\nBRCA mutations, could benefit fro'),\n",
       " Document(metadata={}, page_content='s, could benefit from olaparib (according to the inclusion criteria of the Olymp'),\n",
       " Document(metadata={}, page_content='riteria of the OlympiA trial), \\nalthough it would be reasonable to use olaparib'),\n",
       " Document(metadata={}, page_content='ble to use olaparib and pembrolizumab in combination or sequentially.\\nHowever, n'),\n",
       " Document(metadata={}, page_content='entially.\\nHowever, none of these strategies, in monotherapy and/or in combinatio'),\n",
       " Document(metadata={}, page_content='and/or in combination, have evidence from specific \\nrandomized trials after the'),\n",
       " Document(metadata={}, page_content='ed trials after the neoadjuvant immunotherapy. There are no data on efficacy and'),\n",
       " Document(metadata={}, page_content='data on efficacy and safety in this \\nsetting. Currently, the best schedule is no'),\n",
       " Document(metadata={}, page_content='best schedule is not known, and new data are awaited on new adjuvant strategies'),\n",
       " Document(metadata={}, page_content='adjuvant strategies.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.'),\n",
       " Document(metadata={}, page_content='32–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 242\\nFigure 3. Current trea'),\n",
       " Document(metadata={}, page_content='gure 3. Current treatment algorithm for stage II–III TNBC\\nExtensive efforts will'),\n",
       " Document(metadata={}, page_content='tensive efforts will also be required to investigate and expand access to immuno'),\n",
       " Document(metadata={}, page_content='and access to immunotherapy to ER-low \\npopulations (ER 1–9%), not included in KE'),\n",
       " Document(metadata={}, page_content=', not included in KEYNOTE-522. It represents a subgroup that does not formally'),\n",
       " Document(metadata={}, page_content='does not formally \\nmeet the definition of TNBC, but shares biology, with nearly'),\n",
       " Document(metadata={}, page_content='biology, with nearly 90% of these tumors harboring a basal-like \\nintrinsic subty'),\n",
       " Document(metadata={}, page_content='ike \\nintrinsic subtype, and prognosis with TNBC and could share the same benefit'),\n",
       " Document(metadata={}, page_content='are the same benefit from the addition of \\nimmunotherapy [96, 97].\\nFurthermore,'),\n",
       " Document(metadata={}, page_content=', 97].\\nFurthermore, novel active agents are emerging for the treatment of TNBC a'),\n",
       " Document(metadata={}, page_content='treatment of TNBC and could provide an \\nopportunity for a de-escalation of trad'),\n",
       " Document(metadata={}, page_content='e-escalation of traditional CHT, the anti-trophoblast cell-surface antigen 2 (Tr'),\n",
       " Document(metadata={}, page_content='urface antigen 2 (Trop2) \\nsacituzumab govitecan that is currently being investig'),\n",
       " Document(metadata={}, page_content='ently being investigated in the early setting, including in combination \\nwith im'),\n",
       " Document(metadata={}, page_content='combination \\nwith immunotherapy in the ASPRIA trial (ClinicalTrials.gov identifi'),\n",
       " Document(metadata={}, page_content='lTrials.gov identifier NCT04434040).\\nConclusions\\nThis review highlights the mult'),\n",
       " Document(metadata={}, page_content='highlights the multitude of advances in the treatment of early-stage TNBC and t'),\n",
       " Document(metadata={}, page_content='rly-stage TNBC and the important \\nissues raised.\\nThe management of triple-negati'),\n",
       " Document(metadata={}, page_content='ent of triple-negative breast cancer (TNBC) has seen notable advancements with t'),\n",
       " Document(metadata={}, page_content='advancements with the \\nidentification of therapeutic targets and successful int'),\n",
       " Document(metadata={}, page_content='s and successful integration of immunotherapy in neoadjuvant \\ntreatment. However'),\n",
       " Document(metadata={}, page_content='treatment. However, the current challenge lies in determining the optimal adju'),\n",
       " Document(metadata={}, page_content='ing the optimal adjuvant strategy post-chemo-\\nimmunotherapy, tailoring decisions'),\n",
       " Document(metadata={}, page_content='tailoring decisions to individual patient characteristics and prognostic factor'),\n",
       " Document(metadata={}, page_content='nd prognostic factors. The \\nuncertainty surrounding the efficacy and safety of t'),\n",
       " Document(metadata={}, page_content='cacy and safety of these strategies necessitates further randomized studies, \\nwh'),\n",
       " Document(metadata={}, page_content='domized studies, \\nwhile ongoing research explores novel approaches, such as the'),\n",
       " Document(metadata={}, page_content='oaches, such as the potential use of innovative agents like \\nsacituzumab govitec'),\n",
       " Document(metadata={}, page_content='sacituzumab govitecan in the context of de-escalating traditional CHT. The impe'),\n",
       " Document(metadata={}, page_content='tional CHT. The imperative to extend access to \\nimmunotherapy to subgroups, such'),\n",
       " Document(metadata={}, page_content='y to subgroups, such as those with low ER expression, holds crucial promise, pav'),\n",
       " Document(metadata={}, page_content='crucial promise, paving the way \\nfor a more personalized and targeted future dir'),\n",
       " Document(metadata={}, page_content='targeted future direction in TNBC treatment.\\nIn the next few years, it will be'),\n",
       " Document(metadata={}, page_content='w years, it will be necessary to design new prospective clinical trials and wait'),\n",
       " Document(metadata={}, page_content='ical trials and wait for the \\nresults of those in progress, for a better knowled'),\n",
       " Document(metadata={}, page_content='for a better knowledge of the efficacy of combination therapies, therapeutic \\nse'),\n",
       " Document(metadata={}, page_content='ies, therapeutic \\nsequences and new target drugs for the treatment of a disease'),\n",
       " Document(metadata={}, page_content='atment of a disease which up to a few years ago was considered \\n“untargetable”.'),\n",
       " Document(metadata={}, page_content='ed \\n“untargetable”. This should be accompanied by a commitment to biomarker disc'),\n",
       " Document(metadata={}, page_content='nt to biomarker discovery, which could help the \\noncologist make the best decisi'),\n",
       " Document(metadata={}, page_content='make the best decision for patient care.\\nExplor Target Antitumor Ther. 2024;5:23'),\n",
       " Document(metadata={}, page_content='umor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 243\\nAbb'),\n",
       " Document(metadata={}, page_content='4.00215\\nPage 243\\nAbbreviations\\nAC: doxorubicin and cyclophosphamide\\nADCs: antibo'),\n",
       " Document(metadata={}, page_content='phamide\\nADCs: antibody-drug conjugates\\nBC: breast cancer\\nBRCA: breast cancer sus'),\n",
       " Document(metadata={}, page_content='A: breast cancer susceptibility genes\\nCHT: chemotherapy\\nCI: confidence interval'),\n",
       " Document(metadata={}, page_content='confidence interval\\nCREATE-X: Capecitabine for Residual Cancer as Adjuvant Thera'),\n",
       " Document(metadata={}, page_content='er as Adjuvant Therapy\\nctDNA: circulating tumor DNA\\nDFS: disease-free survival\\nE'),\n",
       " Document(metadata={}, page_content='ease-free survival\\nEFS: event-free survival\\nER: estrogen receptor\\nFDA: Food and'),\n",
       " Document(metadata={}, page_content='eptor\\nFDA: Food and Drug Administration\\nHER2: human epidermal growth factor rece'),\n",
       " Document(metadata={}, page_content='l growth factor receptor 2\\nHR: hazard ratio\\nHR+: hormone receptor-positive\\nICI:'),\n",
       " Document(metadata={}, page_content='eptor-positive\\nICI: immune checkpoint inhibitor\\niDFS: invasive disease-free surv'),\n",
       " Document(metadata={}, page_content='ve disease-free survival\\nIM: immunomodulatory\\nLAR: luminal androgen receptor\\nM:'),\n",
       " Document(metadata={}, page_content='ndrogen receptor\\nM: mesenchymal\\nNACT: neoadjuvant chemotherapy\\nOS: overall survi'),\n",
       " Document(metadata={}, page_content='py\\nOS: overall survival\\nPARP: Poly(ADP-ribose) polymerase\\npCR: pathologic comple'),\n",
       " Document(metadata={}, page_content='R: pathologic complete response\\nPD-L1: programmed death ligand 1\\nRCB: residual c'),\n",
       " Document(metadata={}, page_content='nd 1\\nRCB: residual cancer burden\\nTILs: tumor-infiltrating lymphocytes\\nTMB: tumor'),\n",
       " Document(metadata={}, page_content='mphocytes\\nTMB: tumor mutational burden\\nTME: tumor microenvironment\\nTNBC: triple'),\n",
       " Document(metadata={}, page_content='onment\\nTNBC: triple negative breast cancer\\nDeclarations\\nAuthor contributions\\nPDS'),\n",
       " Document(metadata={}, page_content='or contributions\\nPDS: Conceptualization, Investigation, Writing—original draft,'),\n",
       " Document(metadata={}, page_content='ing—original draft, Writing—review & editing, Validation, \\nSupervision. MP, CG,'),\n",
       " Document(metadata={}, page_content='upervision. MP, CG, and GRO: Conceptualization, Investigation, Writing—original'),\n",
       " Document(metadata={}, page_content='n, Writing—original draft, Writing—review & \\nediting. ANS, PF, and CL: Validatio'),\n",
       " Document(metadata={}, page_content='F, and CL: Validation, Writing—review & editing, Supervision. DC: Investigation.'),\n",
       " Document(metadata={}, page_content='. DC: Investigation. All authors \\nread and approved the submitted version.\\nExplo'),\n",
       " Document(metadata={}, page_content='itted version.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215\\nPage 244\\nConflicts of interest\\nThe aut'),\n",
       " Document(metadata={}, page_content='of interest\\nThe authors declare that they have no conflicts of interest.\\nEthica'),\n",
       " Document(metadata={}, page_content='of interest.\\nEthical approval\\nNot applicable.\\nConsent to participate\\nNot applic'),\n",
       " Document(metadata={}, page_content='rticipate\\nNot applicable.\\nConsent to publication\\nNot applicable.\\nAvailability of'),\n",
       " Document(metadata={}, page_content='ble.\\nAvailability of data and materials\\nNot applicable.\\nFunding\\nNot applicable.'),\n",
       " Document(metadata={}, page_content='ing\\nNot applicable.\\nCopyright\\n© The Author(s) 2024.\\nReferences\\nSporikova Z, Koud'),\n",
       " Document(metadata={}, page_content='es\\nSporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic markers in triple-'),\n",
       " Document(metadata={}, page_content='c markers in triple-negative breast cancer. \\nClin Breast Cancer. 2018;18:e841–50'),\n",
       " Document(metadata={}, page_content='cer. 2018;18:e841–50.\\n1.     \\nHoward FM, Olopade OI. Epidemiology of triple-nega'),\n",
       " Document(metadata={}, page_content='ology of triple-negative breast cancer: a review. Cancer J. 2021;27:\\n8–16.\\n2.'),\n",
       " Document(metadata={}, page_content='2021;27:\\n8–16.\\n2.     \\nAlmansour NM. Triple-negative breast cancer: a brief revi'),\n",
       " Document(metadata={}, page_content='cancer: a brief review about epidemiology, risk factors, \\nsignaling pathways, tr'),\n",
       " Document(metadata={}, page_content='gnaling pathways, treatment and role of artificial intelligence. Front Mol Biosc'),\n",
       " Document(metadata={}, page_content='nce. Front Mol Biosci. 2022;9:836417.\\n3.     \\nCurtis C, Shah SP, Chin SF, Turash'),\n",
       " Document(metadata={}, page_content='SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcr'),\n",
       " Document(metadata={}, page_content='genomic and transcriptomic \\narchitecture of 2,000 breast tumours reveals novel'),\n",
       " Document(metadata={}, page_content='mours reveals novel subgroups. Nature. 2012;486:346–52.\\n4.     \\nAzim HA, Ghosn M'),\n",
       " Document(metadata={}, page_content='Azim HA, Ghosn M, Oualla K, Kassem L. Personalized treatment in metastatic t'),\n",
       " Document(metadata={}, page_content='ment in metastatic triple-negative breast \\ncancer: the outlook in 2020. Breast J'),\n",
       " Document(metadata={}, page_content='ok in 2020. Breast J. 2020;26:69–80.\\n5.     \\nCardoso F, Kyriakides S, Ohno S, Pe'),\n",
       " Document(metadata={}, page_content='akides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al.; ESMO Guidelin'),\n",
       " Document(metadata={}, page_content='t al.; ESMO Guidelines \\nCommittee. Early breast cancer: ESMO Clinical Practice G'),\n",
       " Document(metadata={}, page_content='Clinical Practice Guidelines for diagnosis, treatment and \\nfollow-up†. Ann Onco'),\n",
       " Document(metadata={}, page_content='follow-up†. Ann Oncol. 2019;30:1194–220. Erratum in: Ann Oncol. 2019;30:1674. Er'),\n",
       " Document(metadata={}, page_content='ol. 2019;30:1674. Erratum in: Ann \\nOncol. 2021;32:284. \\n6.     \\nBear HD, Anderso'),\n",
       " Document(metadata={}, page_content='Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al.; Nation'),\n",
       " Document(metadata={}, page_content='er B, et al.; National Surgical Adjuvant \\nBreast and Bowel Project Protocol B-27'),\n",
       " Document(metadata={}, page_content='roject Protocol B-27. The effect on tumor response of adding sequential \\npreoper'),\n",
       " Document(metadata={}, page_content='sequential \\npreoperative docetaxel to preoperative doxorubicin and cyclophospha'),\n",
       " Document(metadata={}, page_content='cin and cyclophosphamide: preliminary results from \\nNational Surgical Adjuvant B'),\n",
       " Document(metadata={}, page_content='Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21'),\n",
       " Document(metadata={}, page_content='Clin Oncol. 2003;21:4165–74.\\n7.     \\nGolshan M, Loibl S, Wong SM, Houber JB, O’'),\n",
       " Document(metadata={}, page_content='ng SM, Houber JB, O’Shaughnessy J, Rugo HS, et al. Breast conservation after \\nne'),\n",
       " Document(metadata={}, page_content='nservation after \\nneoadjuvant chemotherapy for triple-negative breast cancer: su'),\n",
       " Document(metadata={}, page_content='ve breast cancer: surgical results from the BrighTNess \\nrandomized clinical tria'),\n",
       " Document(metadata={}, page_content='omized clinical trial. JAMA Surg. 2020;155:e195410. Erratum in: JAMA Surg. 2021;'),\n",
       " Document(metadata={}, page_content='in: JAMA Surg. 2021;156:503. \\n8.     \\nTurner N, Lambros MB, Horlings HM, Pearson'),\n",
       " Document(metadata={}, page_content='Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular \\nprof'),\n",
       " Document(metadata={}, page_content='tive molecular \\nprofiling of triple negative breast cancers identifies amplicon'),\n",
       " Document(metadata={}, page_content='identifies amplicon drivers and potential therapeutic \\ntargets. Oncogene. 2010;2'),\n",
       " Document(metadata={}, page_content='ts. Oncogene. 2010;29:2013–23.\\n9.     \\nMarra A, Trapani D, Viale G, Criscitiello'),\n",
       " Document(metadata={}, page_content='iale G, Criscitiello C, Curigliano G. Practical classification of triple-negativ'),\n",
       " Document(metadata={}, page_content='on of triple-negative breast \\ncancer: intratumoral heterogeneity, mechanisms of'),\n",
       " Document(metadata={}, page_content='eity, mechanisms of drug resistance, and novel therapies. NPJ Breast \\nCancer. 20'),\n",
       " Document(metadata={}, page_content='J Breast \\nCancer. 2020;6:54.\\n10.     \\nExplor Target Antitumor Ther. 2024;5:232–5'),\n",
       " Document(metadata={}, page_content='r Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 245\\nYe F,'),\n",
       " Document(metadata={}, page_content='0215\\nPage 245\\nYe F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advanceme'),\n",
       " Document(metadata={}, page_content='A, et al. Advancements in clinical aspects of targeted \\ntherapy and immunothera'),\n",
       " Document(metadata={}, page_content='rapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105.\\n11.     \\nLiu Z'),\n",
       " Document(metadata={}, page_content=':105.\\n11.     \\nLiu Z, Li M, Jiang Z, Wang X. A comprehensive immunologic portrai'),\n",
       " Document(metadata={}, page_content='immunologic portrait of triple-negative breast cancer. \\nTransl Oncol. 2018;11:3'),\n",
       " Document(metadata={}, page_content='nsl Oncol. 2018;11:311–29.\\n12.     \\nFarshbafnadi M, Pastaki Khoshbin A, Rezaei N'),\n",
       " Document(metadata={}, page_content='Khoshbin A, Rezaei N. Immune checkpoint inhibitors for triple-negative \\nbreast c'),\n",
       " Document(metadata={}, page_content='e-negative \\nbreast cancer: from immunological mechanisms to clinical evidence. I'),\n",
       " Document(metadata={}, page_content='clinical evidence. Int Immunopharmacol. 2021;98:\\n107876.\\n13.     \\nLehmann BD, Jo'),\n",
       " Document(metadata={}, page_content='Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Re'),\n",
       " Document(metadata={}, page_content='N, Shyr Y, et al. Refinement of triple-negative \\nbreast cancer molecular subtype'),\n",
       " Document(metadata={}, page_content='er molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS'),\n",
       " Document(metadata={}, page_content='rapy selection. PLoS One. \\n2016;11:e0157368.\\n14.     \\nBurstein MD, Tsimelzon A,'),\n",
       " Document(metadata={}, page_content='in MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, et al. Compr'),\n",
       " Document(metadata={}, page_content='ua SAW, et al. Comprehensive \\ngenomic analysis identifies novel subtypes and tar'),\n",
       " Document(metadata={}, page_content='vel subtypes and targets of triple-negative breast cancer. Clin Cancer \\nRes. 201'),\n",
       " Document(metadata={}, page_content='lin Cancer \\nRes. 2015;21:1688–98.\\n15.     \\nXiao Y, Ma D, Zhao S, Suo C, Shi J, X'),\n",
       " Document(metadata={}, page_content='o S, Suo C, Shi J, Xue MZ, et al.; AME Breast Cancer Collaborative Group. Multi-'),\n",
       " Document(metadata={}, page_content='rative Group. Multi-omics \\nprofiling reveals distinct microenvironment character'),\n",
       " Document(metadata={}, page_content='nvironment characterization and suggests immune escape \\nmechanisms of triple-neg'),\n",
       " Document(metadata={}, page_content='anisms of triple-negative breast cancer. Clin Cancer Res. 2019;25:5002–14.\\n16.'),\n",
       " Document(metadata={}, page_content='19;25:5002–14.\\n16.     \\nPelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, H'),\n",
       " Document(metadata={}, page_content='navita E, Bell CR, Hutton C, et al. Anti-inflammatory drugs \\nremodel the tumor i'),\n",
       " Document(metadata={}, page_content='remodel the tumor immune environment to enhance immune checkpoint blockade effi'),\n",
       " Document(metadata={}, page_content='kpoint blockade efficacy. Cancer \\nDiscov. 2021;11:2602–19.\\n17.     \\nMittendorf E'),\n",
       " Document(metadata={}, page_content='7.     \\nMittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S,'),\n",
       " Document(metadata={}, page_content='Wu Y, Harrington S, et al. PD-L1 expression in \\ntriple-negative breast cancer.'),\n",
       " Document(metadata={}, page_content='tive breast cancer. Cancer Immunol Res. 2014;2:361–70.\\n18.     \\nWang C, Zhang J,'),\n",
       " Document(metadata={}, page_content='Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, et al. Prevalence of BRCA1'),\n",
       " Document(metadata={}, page_content='Prevalence of BRCA1 mutations and responses \\nto neoadjuvant chemotherapy among B'),\n",
       " Document(metadata={}, page_content='chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast'),\n",
       " Document(metadata={}, page_content='le-negative breast \\ncancer. Ann Oncol. 2015;26:523–8.\\n19.     \\nHahnen E, Lederer'),\n",
       " Document(metadata={}, page_content='Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, et al. Germli'),\n",
       " Document(metadata={}, page_content='iss A, et al. Germline mutation status, \\npathological complete response, and dis'),\n",
       " Document(metadata={}, page_content='te response, and disease-free survival in triple-negative breast cancer: seconda'),\n",
       " Document(metadata={}, page_content='east cancer: secondary \\nanalysis of the GeparSixto randomized clinical trial. JA'),\n",
       " Document(metadata={}, page_content='d clinical trial. JAMA Oncol. 2017;3:1378–85.\\n20.     \\nPohl-Rescigno E, Hauke J,'),\n",
       " Document(metadata={}, page_content='Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, et al. Associatio'),\n",
       " Document(metadata={}, page_content='A, et al. Association of germline \\nvariant status with therapy response in high-'),\n",
       " Document(metadata={}, page_content='py response in high-risk early-stage breast cancer: a secondary analysis of \\nthe'),\n",
       " Document(metadata={}, page_content='ary analysis of \\nthe GeparOcto randomized clinical trial. JAMA Oncol. 2020;6:744'),\n",
       " Document(metadata={}, page_content='MA Oncol. 2020;6:744–8.\\n21.     \\nVollebergh MA, Lips EH, Nederlof PM, Wessels LF'),\n",
       " Document(metadata={}, page_content='erlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, et al. Genomic patterns \\nresemb'),\n",
       " Document(metadata={}, page_content='mic patterns \\nresembling BRCA1- and BRCA2-mutated breast cancers predict benefit'),\n",
       " Document(metadata={}, page_content='cers predict benefit of intensified carboplatin-\\nbased chemotherapy. Breast Canc'),\n",
       " Document(metadata={}, page_content='therapy. Breast Cancer Res. 2014;16:R47.\\n22.     \\nBelli C, Duso BA, Ferraro E, C'),\n",
       " Document(metadata={}, page_content='uso BA, Ferraro E, Curigliano G. Homologous recombination deficiency in triple n'),\n",
       " Document(metadata={}, page_content='ficiency in triple negative \\nbreast cancer. Breast. 2019;45:15–21.\\n23.     \\nvan'),\n",
       " Document(metadata={}, page_content='15–21.\\n23.     \\nvan Verschuer VMT, Hooning MJ, van Baare-Georgieva RD, Hollestel'),\n",
       " Document(metadata={}, page_content='rgieva RD, Hollestelle A, Timmermans AM, Koppert \\nLB, et al. Tumor-associated in'),\n",
       " Document(metadata={}, page_content='Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associa'),\n",
       " Document(metadata={}, page_content='l in BRCA1/2-associated breast \\ncancer. Hum Pathol. 2015;46:182–90.\\n24.     \\nNol'),\n",
       " Document(metadata={}, page_content='182–90.\\n24.     \\nNolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff C'),\n",
       " Document(metadata={}, page_content='aillant F, Mintoff CP, et al.; Kathleen Cuningham \\nFoundation Consortium for Res'),\n",
       " Document(metadata={}, page_content='n Consortium for Research into Familial Breast Cancer (kConFab); Perou CM, Visva'),\n",
       " Document(metadata={}, page_content='ab); Perou CM, Visvader JE, \\nGray DHD, Loi S, Lindeman GJ. Combined immune check'),\n",
       " Document(metadata={}, page_content='ombined immune checkpoint blockade as a therapeutic strategy for \\nBRCA1-mutated'),\n",
       " Document(metadata={}, page_content='for \\nBRCA1-mutated breast cancer. Sci Transl Med. 2017;9:eaal4922.\\n25.     \\nPar'),\n",
       " Document(metadata={}, page_content='al4922.\\n25.     \\nParkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinso'),\n",
       " Document(metadata={}, page_content='Knight LA, Wilkinson R, et al. Activation of STING-\\ndependent innate immune sig'),\n",
       " Document(metadata={}, page_content='nt innate immune signaling by S-phase-specific DNA damage in breast cancer. J Na'),\n",
       " Document(metadata={}, page_content='breast cancer. J Natl Cancer \\nInst. 2016;109:djw199.\\n26.     \\nCastaneda CA, Mit'),\n",
       " Document(metadata={}, page_content='Castaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, et al.'),\n",
       " Document(metadata={}, page_content=', Arboleda P, et al. Tumor infiltrating \\nlymphocytes in triple negative breast c'),\n",
       " Document(metadata={}, page_content='le negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol'),\n",
       " Document(metadata={}, page_content='. World J Clin Oncol. \\n2016;7:387–94.\\n27.     \\nExplor Target Antitumor Ther. 202'),\n",
       " Document(metadata={}, page_content='Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 2'),\n",
       " Document(metadata={}, page_content='at.2024.00215\\nPage 246\\nGarcía-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor'),\n",
       " Document(metadata={}, page_content='IP, Pérez YF. Tumor-infiltrating lymphocytes in triple negative \\nbreast cancer:'),\n",
       " Document(metadata={}, page_content='tive \\nbreast cancer: the future of immune targeting. Clin Med Insights Oncol. 20'),\n",
       " Document(metadata={}, page_content='d Insights Oncol. 2016;10:31–9.\\n28.     \\nGomez-Macias GS, Molinar-Flores G, Lope'),\n",
       " Document(metadata={}, page_content='linar-Flores G, Lopez-Garcia CA, Santuario-Facio S, Decanini-Arcaute H, Valero-'),\n",
       " Document(metadata={}, page_content='-Arcaute H, Valero-\\nElizondo J, et al. Immunotyping of tumor-infiltrating lympho'),\n",
       " Document(metadata={}, page_content='-infiltrating lymphocytes in triple-negative breast cancer and \\ngenetic characte'),\n",
       " Document(metadata={}, page_content='nd \\ngenetic characterization. Oncol Lett. 2020;20:140.\\n29.     \\nSousa S, Brion R'),\n",
       " Document(metadata={}, page_content='Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, et al. H'),\n",
       " Document(metadata={}, page_content='önkkönen J, et al. Human breast cancer cells \\neducate macrophages toward the M2'),\n",
       " Document(metadata={}, page_content='hages toward the M2 activation status. Breast Cancer Res. 2015;17:101.\\n30.'),\n",
       " Document(metadata={}, page_content='15;17:101.\\n30.     \\nMedrek C, Pontén F, Jirström K, Leandersson K. The presence'),\n",
       " Document(metadata={}, page_content='son K. The presence of tumor associated macrophages in \\ntumor stroma as a progno'),\n",
       " Document(metadata={}, page_content='r stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:'),\n",
       " Document(metadata={}, page_content='BMC Cancer. 2012;12:306.\\n31.     \\nSavas P, Salgado R, Denkert C, Sotiriou C, Dar'),\n",
       " Document(metadata={}, page_content='t C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host \\nimmunity'),\n",
       " Document(metadata={}, page_content='ce of host \\nimmunity in breast cancer: from TILs to the clinic. Nat Rev Clin Onc'),\n",
       " Document(metadata={}, page_content='ic. Nat Rev Clin Oncol. 2016;13:228–41.\\n32.     \\nCortazar P, Zhang L, Untch M, M'),\n",
       " Document(metadata={}, page_content='Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological comple'),\n",
       " Document(metadata={}, page_content='Pathological complete \\nresponse and long-term clinical benefit in breast cancer'),\n",
       " Document(metadata={}, page_content='fit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;\\n384:164–72.\\n33.'),\n",
       " Document(metadata={}, page_content='014;\\n384:164–72.\\n33.     \\nDenkert C, von Minckwitz G, Darb-Esfahani S, Lederer B'),\n",
       " Document(metadata={}, page_content='sfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-\\ninfiltrating lymphocy'),\n",
       " Document(metadata={}, page_content='nfiltrating lymphocytes and prognosis in different subtypes of breast cancer: a'),\n",
       " Document(metadata={}, page_content='of breast cancer: a pooled analysis of \\n3771 patients treated with neoadjuvant t'),\n",
       " Document(metadata={}, page_content='d with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.\\n34.     \\nAdams S, Gray'),\n",
       " Document(metadata={}, page_content='Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Pro'),\n",
       " Document(metadata={}, page_content='ulman LN, et al. Prognostic value of tumor-\\ninfiltrating lymphocytes in triple-n'),\n",
       " Document(metadata={}, page_content='phocytes in triple-negative breast cancers from two phase III randomized adjuvan'),\n",
       " Document(metadata={}, page_content='I randomized adjuvant \\nbreast cancer trials: ECOG 2197 and ECOG 1199. J Clin Onc'),\n",
       " Document(metadata={}, page_content='COG 1199. J Clin Oncol. 2014;32:2959–66.\\n35.     \\nLoi S, Sirtaine N, Piette F, S'),\n",
       " Document(metadata={}, page_content='taine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predic'),\n",
       " Document(metadata={}, page_content='rognostic and predictive value of \\ntumor-infiltrating lymphocytes in a phase III'),\n",
       " Document(metadata={}, page_content='cytes in a phase III randomized adjuvant breast cancer trial in node-positive \\nb'),\n",
       " Document(metadata={}, page_content='in node-positive \\nbreast cancer comparing the addition of docetaxel to doxorubi'),\n",
       " Document(metadata={}, page_content='ocetaxel to doxorubicin with doxorubicin-based \\nchemotherapy: BIG 02-98. J Clin'),\n",
       " Document(metadata={}, page_content=': BIG 02-98. J Clin Oncol. 2013;31:860–7.\\n36.     \\nLoi S, Michiels S, Salgado R,'),\n",
       " Document(metadata={}, page_content='chiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating'),\n",
       " Document(metadata={}, page_content='Tumor infiltrating lymphocytes are \\nprognostic in triple negative breast cancer'),\n",
       " Document(metadata={}, page_content='gative breast cancer and predictive for trastuzumab benefit in early breast \\ncan'),\n",
       " Document(metadata={}, page_content='in early breast \\ncancer: results from the FinHER trial. Ann Oncol. 2014;25:1544–'),\n",
       " Document(metadata={}, page_content='Oncol. 2014;25:1544–50.\\n37.     \\nHida AI, Watanabe T, Sagara Y, Kashiwaba M, Sag'),\n",
       " Document(metadata={}, page_content='Y, Kashiwaba M, Sagara Y, Aogi K, et al. Diffuse distribution of tumor-\\ninfiltr'),\n",
       " Document(metadata={}, page_content='on of tumor-\\ninfiltrating lymphocytes is a marker for better prognosis and chemo'),\n",
       " Document(metadata={}, page_content='prognosis and chemotherapeutic effect in triple-\\nnegative breast cancer. Breast'),\n",
       " Document(metadata={}, page_content='reast cancer. Breast Cancer Res Treat. 2019;178:283–94.\\n38.     \\nIbrahim EM, Al-'),\n",
       " Document(metadata={}, page_content='Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. The prognostic value o'),\n",
       " Document(metadata={}, page_content='e prognostic value of tumor-infiltrating \\nlymphocytes in triple-negative breast'),\n",
       " Document(metadata={}, page_content='ple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014;148:'),\n",
       " Document(metadata={}, page_content='es Treat. 2014;148:\\n467–76.\\n39.     \\nSalgado R, Denkert C, Demaria S, Sirtaine N'),\n",
       " Document(metadata={}, page_content='emaria S, Sirtaine N, Klauschen F, Pruneri G, et al.; International TILs Working'),\n",
       " Document(metadata={}, page_content='ational TILs Working \\nGroup 2014. The evaluation of tumor-infiltrating lymphocyt'),\n",
       " Document(metadata={}, page_content='filtrating lymphocytes (TILs) in breast cancer: \\nrecommendations by an Internati'),\n",
       " Document(metadata={}, page_content='ions by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71.\\n40.'),\n",
       " Document(metadata={}, page_content='2015;26:259–71.\\n40.     \\nKarn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody'),\n",
       " Document(metadata={}, page_content='N, El-Balat A, Rody A, et al. Association between genomic metrics and \\nimmune in'),\n",
       " Document(metadata={}, page_content='trics and \\nimmune infiltration in triple-negative breast cancer. JAMA Oncol. 201'),\n",
       " Document(metadata={}, page_content='cer. JAMA Oncol. 2017;3:1707–11.\\n41.     \\nSafonov A, Jiang T, Bianchini G, Győrf'),\n",
       " Document(metadata={}, page_content=', Bianchini G, Győrffy B, Karn T, Hatzis C, et al. Immune gene expression is ass'),\n",
       " Document(metadata={}, page_content='ne expression is associated \\nwith genomic aberrations in breast cancer. Cancer R'),\n",
       " Document(metadata={}, page_content='ast cancer. Cancer Res. 2017;77:3317–24.\\n42.     \\nLotfinejad P, Asghari Jafaraba'),\n",
       " Document(metadata={}, page_content='P, Asghari Jafarabadi M, Abdoli Shadbad M, Kazemi T, Pashazadeh F, Sandoghchian'),\n",
       " Document(metadata={}, page_content='adeh F, Sandoghchian \\nShotorbani S, et al. Prognostic role and clinical signific'),\n",
       " Document(metadata={}, page_content='nd clinical significance of tumor-infiltrating lymphocyte (TIL) and \\nprogrammed'),\n",
       " Document(metadata={}, page_content='IL) and \\nprogrammed death ligand 1 (PD-L1) expression in triple-negative breast'),\n",
       " Document(metadata={}, page_content='ple-negative breast cancer (TNBC): a systematic \\nreview and meta-analysis study.'),\n",
       " Document(metadata={}, page_content='meta-analysis study. Diagnostics (Basel). 2020;10:704.\\n43.     \\nZhu X, Zhang Q,'),\n",
       " Document(metadata={}, page_content='Zhu X, Zhang Q, Wang D, Liu C, Han B, Yang JM. Expression of PD-L1 attenuate'),\n",
       " Document(metadata={}, page_content='n of PD-L1 attenuates the positive impacts of \\nhigh-level tumor-infiltrating lym'),\n",
       " Document(metadata={}, page_content='mor-infiltrating lymphocytes on prognosis of triple-negative breast cancer. Canc'),\n",
       " Document(metadata={}, page_content='breast cancer. Cancer Biol \\nTher. 2019;20:1105–12.\\n44.     \\nExplor Target Antit'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.202'),\n",
       " Document(metadata={}, page_content='rg/10.37349/etat.2024.00215\\nPage 247\\nNCCN Clinical Practice Guidelines in Oncolo'),\n",
       " Document(metadata={}, page_content='Guidelines in Oncology (NCCN Guidelines®). Breast Cancer. National \\nComprehensiv'),\n",
       " Document(metadata={}, page_content='tional \\nComprehensive Cancer Network® (NCCN®); c2020 [cited 2023 May 21]. Availa'),\n",
       " Document(metadata={}, page_content='2023 May 21]. Available from: https://\\nwww2.tri-kobe.org/nccn/guideline/breast/e'),\n",
       " Document(metadata={}, page_content='n/guideline/breast/english/breast.pdf\\n45.     \\nEarly Breast Cancer Trialists’ Co'),\n",
       " Document(metadata={}, page_content='Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and tax'),\n",
       " Document(metadata={}, page_content='e-containing and taxane-\\ncontaining chemotherapy for early-stage operable breast'),\n",
       " Document(metadata={}, page_content='tage operable breast cancer: a patient-level meta-analysis of \\n100\\u2008000 women fro'),\n",
       " Document(metadata={}, page_content='f \\n100\\u2008000 women from 86 randomised trials. Lancet. 2023;401:1277-1292.\\n46.'),\n",
       " Document(metadata={}, page_content=':1277-1292.\\n46.     \\nSparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphne'),\n",
       " Document(metadata={}, page_content='JA, Perez EA, Saphner T, et al. Long-term follow-up of the E1199 \\nphase III tria'),\n",
       " Document(metadata={}, page_content='1199 \\nphase III trial evaluating the role of taxane and schedule in operable bre'),\n",
       " Document(metadata={}, page_content='dule in operable breast cancer. J Clin Oncol. 2015;\\n33:2353–60.\\n47.     \\nJones S'),\n",
       " Document(metadata={}, page_content='60.\\n47.     \\nJones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S'),\n",
       " Document(metadata={}, page_content=', Blum JL, Vukelja S, et al. Phase III trial comparing \\ndoxorubicin plus cycloph'),\n",
       " Document(metadata={}, page_content='rubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant t'),\n",
       " Document(metadata={}, page_content='hamide as adjuvant therapy for \\noperable breast cancer. J Clin Oncol. 2006;24:53'),\n",
       " Document(metadata={}, page_content='in Oncol. 2006;24:5381–7. Erratum in: J Clin Oncol. 2007;25:1819. \\n48.     \\nWhea'),\n",
       " Document(metadata={}, page_content='1819. \\n48.     \\nWheate NJ, Collins JG. Multi-nuclear platinum drugs: a new parad'),\n",
       " Document(metadata={}, page_content='m drugs: a new paradigm in chemotherapy. Curr Med \\nChem Anticancer Agents. 2005;'),\n",
       " Document(metadata={}, page_content='cancer Agents. 2005;5:267–79.\\n49.     \\nGarutti M, Pelizzari G, Bartoletti M, Mal'),\n",
       " Document(metadata={}, page_content='G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, et al. Platinum salts in pati'),\n",
       " Document(metadata={}, page_content='atinum salts in patients \\nwith breast cancer: a focus on predictive factors. Int'),\n",
       " Document(metadata={}, page_content='dictive factors. Int J Mol Sci. 2019;20:3390.\\n50.     \\nChalasani P, Livingston R'),\n",
       " Document(metadata={}, page_content='sani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumor'),\n",
       " Document(metadata={}, page_content='ity for breast tumors with \\n“BRCAness”: a review. Oncologist. 2013;18:909–16.\\n51'),\n",
       " Document(metadata={}, page_content='. 2013;18:909–16.\\n51.     \\nVetter M, Fokas S, Biskup E, Schmid T, Schwab F, Scho'),\n",
       " Document(metadata={}, page_content='id T, Schwab F, Schoetzau A, et al. Efficacy of adjuvant chemotherapy \\nwith carb'),\n",
       " Document(metadata={}, page_content='motherapy \\nwith carboplatin for early triple negative breast cancer: a single ce'),\n",
       " Document(metadata={}, page_content='cancer: a single center experience. Oncotarget. 2017;\\n8:75617–26.\\n52.     \\nSu Y'),\n",
       " Document(metadata={}, page_content='17–26.\\n52.     \\nSu YW, Hung CY, Lam HB, Chang YC, Yang PS. A single institution'),\n",
       " Document(metadata={}, page_content='single institution experience of incorporation of \\ncisplatin into adjuvant chem'),\n",
       " Document(metadata={}, page_content='n into adjuvant chemotherapy for patients with triple-negative breast cancer of'),\n",
       " Document(metadata={}, page_content='ve breast cancer of unknown \\nBRCA mutation status. Clin Med Insights Oncol. 2018'),\n",
       " Document(metadata={}, page_content='Insights Oncol. 2018;12:1179554918794672.\\n53.     \\nYu KD, Ye FG, He M, Fan L, Ma'),\n",
       " Document(metadata={}, page_content='FG, He M, Fan L, Ma D, Mo M, et al. Effect of adjuvant paclitaxel and carboplat'),\n",
       " Document(metadata={}, page_content='itaxel and carboplatin on survival \\nin women with triple-negative breast cancer:'),\n",
       " Document(metadata={}, page_content='ative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6:\\n13'),\n",
       " Document(metadata={}, page_content='MA Oncol. 2020;6:\\n1390–6.\\n54.     \\nNorquist B, Wurz KA, Pennil CC, Garcia R, Gro'),\n",
       " Document(metadata={}, page_content='il CC, Garcia R, Gross J, Sakai W, et al. Secondary Somatic Mutations \\nRestoring'),\n",
       " Document(metadata={}, page_content='Mutations \\nRestoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovari'),\n",
       " Document(metadata={}, page_content='in Hereditary Ovarian Carcinomas. J Clin Oncol. \\n2011;29:3008–15.\\n55.     \\nGuil'),\n",
       " Document(metadata={}, page_content='08–15.\\n55.     \\nGuillemette S, Serra RW, Peng M, Hayes JA, Konstantinopoulos PA,'),\n",
       " Document(metadata={}, page_content='onstantinopoulos PA, Green MR, et al. Resistance to \\ntherapy in BRCA2 mutant cel'),\n",
       " Document(metadata={}, page_content='in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. Gen'),\n",
       " Document(metadata={}, page_content='ing factor CHD4. Genes Dev. \\n2015;29:489–94.\\n56.     \\nZhou J, Kang Y, Chen L, Wa'),\n",
       " Document(metadata={}, page_content=', Kang Y, Chen L, Wang H, Liu J, Zeng S, et al. The drug-resistance mechanisms o'),\n",
       " Document(metadata={}, page_content='istance mechanisms of five platinum-\\nbased antitumor agents. Front Pharmacol. 20'),\n",
       " Document(metadata={}, page_content='Front Pharmacol. 2020;11:343.\\n57.     \\nRastogi P, Anderson SJ, Bear HD, Geyer C'),\n",
       " Document(metadata={}, page_content='SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative \\nchemother'),\n",
       " Document(metadata={}, page_content='operative \\nchemotherapy: updates of national surgical adjuvant breast and bowel'),\n",
       " Document(metadata={}, page_content='nt breast and bowel project protocols B-18 and B-\\n27. J Clin Oncol. 2008;26:778–'),\n",
       " Document(metadata={}, page_content='Oncol. 2008;26:778–85. Erratum in: J Clin Oncol. 2008;26:2793. \\n58.     \\nEarly'),\n",
       " Document(metadata={}, page_content='93. \\n58.     \\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-'),\n",
       " Document(metadata={}, page_content='roup (EBCTCG). Long-term outcomes for neoadjuvant \\nversus adjuvant chemotherapy'),\n",
       " Document(metadata={}, page_content='juvant chemotherapy in early breast cancer: meta-analysis of individual patient'),\n",
       " Document(metadata={}, page_content='individual patient data from \\nten randomised trials. Lancet Oncol. 2018;19:27–3'),\n",
       " Document(metadata={}, page_content='Oncol. 2018;19:27–39.\\n59.     \\nEarly Breast Cancer Trialists’ Collaborative Gro'),\n",
       " Document(metadata={}, page_content='s’ Collaborative Group (EBCTCG). Increasing the dose intensity of \\nchemotherapy'),\n",
       " Document(metadata={}, page_content='ty of \\nchemotherapy by more frequent administration or sequential scheduling: a'),\n",
       " Document(metadata={}, page_content='ntial scheduling: a patient-level meta-\\nanalysis of 37\\u2008298 women with early brea'),\n",
       " Document(metadata={}, page_content='omen with early breast cancer in 26 randomised trials. Lancet. 2019;393:\\n1440–52'),\n",
       " Document(metadata={}, page_content='t. 2019;393:\\n1440–52.\\n60.     \\nvon Minckwitz G, Schneeweiss A, Loibl S, Salat C,'),\n",
       " Document(metadata={}, page_content='A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in \\npati'),\n",
       " Document(metadata={}, page_content='carboplatin in \\npatients with triple-negative and HER2-positive early breast can'),\n",
       " Document(metadata={}, page_content='ive early breast cancer (GeparSixto; GBG 66): a \\nrandomised phase 2 trial. Lance'),\n",
       " Document(metadata={}, page_content='phase 2 trial. Lancet Oncol. 2014;15:747–56.\\n61.     \\nExplor Target Antitumor Th'),\n",
       " Document(metadata={}, page_content='Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='7349/etat.2024.00215\\nPage 248\\nSikov WM, Berry DA, Perou CM, Singh B, Cirrincione'),\n",
       " Document(metadata={}, page_content='Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of \\ncarboplat'),\n",
       " Document(metadata={}, page_content='dition of \\ncarboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxe'),\n",
       " Document(metadata={}, page_content='e-per-week paclitaxel followed by dose-dense \\ndoxorubicin and cyclophosphamide o'),\n",
       " Document(metadata={}, page_content='d cyclophosphamide on pathologic complete response rates in stage II to III trip'),\n",
       " Document(metadata={}, page_content='stage II to III triple-\\nnegative breast cancer: CALGB 40603 (Alliance). J Clin O'),\n",
       " Document(metadata={}, page_content='(Alliance). J Clin Oncol. 2015;33:13–21.\\n62.     \\nLoibl S, O’Shaughnessy J, Untc'),\n",
       " Document(metadata={}, page_content='’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PAR'),\n",
       " Document(metadata={}, page_content='Addition of the PARP \\ninhibitor veliparib plus carboplatin or carboplatin alone'),\n",
       " Document(metadata={}, page_content='or carboplatin alone to standard neoadjuvant chemotherapy in \\ntriple-negative br'),\n",
       " Document(metadata={}, page_content='triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lance'),\n",
       " Document(metadata={}, page_content='phase 3 trial. Lancet Oncol. 2018;19:\\n497–509.\\n63.     \\nFasching PA, Link T, Hau'),\n",
       " ...]"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "text_splitter.create_documents([text])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "bbea672c-7911-4864-a207-267517d44065",
   "metadata": {},
   "source": [
    "# Llama Index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "00a1834d-30ca-4da9-80f3-073f6824527b",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "from llama_index.core import SimpleDirectoryReader\n",
    "\n",
    "# For splitting text\n",
    "from llama_index.core.node_parser import SentenceSplitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "958321b4-b096-4e3d-bad0-41af77961a35",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "splitter = SentenceSplitter(\n",
    "    chunk_size=200,\n",
    "    chunk_overlap=15,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "9ce193bc-2317-42e7-ac05-1b45c4b59aaf",
   "metadata": {},
   "outputs": [],
   "source": [
    "documents = SimpleDirectoryReader(\n",
    "    input_files=[\"ilovepdf_merged.pdf\"]\n",
    ").load_data()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "eaec6519-d676-4a99-8e74-ebdb8c43c4e4",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "nodes = splitter.get_nodes_from_documents(documents)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "bfbd63ab-2e34-46f7-92b0-ee11a6d88f3d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "578"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(nodes)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e59a1252-77cb-41a3-a900-b5d5104ea9ac",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "4e0acf87-b679-40af-9241-d16cf1cb8e5c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "TextNode(id_='92d6dda6-9bff-4bca-96df-ba2b9558543a', embedding=None, metadata={'page_label': '1', 'file_name': 'ilovepdf_merged.pdf', 'file_path': 'ilovepdf_merged.pdf', 'file_type': 'application/pdf', 'file_size': 4368750, 'creation_date': '2025-04-08', 'last_modified_date': '2025-04-08'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='4246df6a-addd-46ce-8245-cf64e17b0fcf', node_type=<ObjectType.DOCUMENT: '4'>, metadata={'page_label': '1', 'file_name': 'ilovepdf_merged.pdf', 'file_path': 'ilovepdf_merged.pdf', 'file_type': 'application/pdf', 'file_size': 4368750, 'creation_date': '2025-04-08', 'last_modified_date': '2025-04-08'}, hash='6f34d2a93a1b1935c57b349830e570d1cb6d5574cf95564e1cb462b6904bcaf9'), <NodeRelationship.NEXT: '3'>: RelatedNodeInfo(node_id='54ea32cf-5879-479d-baa3-2131a3a65ca2', node_type=<ObjectType.TEXT: '1'>, metadata={}, hash='08b018842682bb3e24b0bc4a44e3eb2cf580eecc70b932efb1d9c7158d923bd5')}, metadata_template='{key}: {value}', metadata_separator='\\n', text='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 232\\n© The Author(s)  2024.  This  is an Open  Access  article  licensed  under  a Creative  Commons  Attribution  4.0 International \\nLicense (https://creativecommons.org/licenses/by/4.0/), which  permits  unrestricted  use,  sharing,  adaptation,  distribution \\nand reproduction in any medium  or format,  for any purpose,  even commercially,  as long as you give appropriate  credit  to the \\noriginal author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.', mimetype='text/plain', start_char_idx=0, end_char_idx=602, metadata_seperator='\\n', text_template='{metadata_str}\\n\\n{content}')"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "nodes[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "70fa9c70-9b51-43a5-b8a2-cde446605d0e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "TextNode(id_='ce96f157-79e1-490f-9d8d-8952ea6284fd', embedding=None, metadata={'page_label': '35', 'file_name': 'ilovepdf_merged.pdf', 'file_path': 'ilovepdf_merged.pdf', 'file_type': 'application/pdf', 'file_size': 4368750, 'creation_date': '2025-04-08', 'last_modified_date': '2025-04-08'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='afaedcd2-52f8-4502-9c2e-1bf784ec501e', node_type=<ObjectType.DOCUMENT: '4'>, metadata={'page_label': '35', 'file_name': 'ilovepdf_merged.pdf', 'file_path': 'ilovepdf_merged.pdf', 'file_type': 'application/pdf', 'file_size': 4368750, 'creation_date': '2025-04-08', 'last_modified_date': '2025-04-08'}, hash='15aef7de1810c33905710ca4bfc5197b7dc42aa02a2ce6ab11a643b9984c5e1b'), <NodeRelationship.PREVIOUS: '2'>: RelatedNodeInfo(node_id='a48a973b-8f61-432b-8b64-237b81ba73da', node_type=<ObjectType.TEXT: '1'>, metadata={'page_label': '35', 'file_name': 'ilovepdf_merged.pdf', 'file_path': 'ilovepdf_merged.pdf', 'file_type': 'application/pdf', 'file_size': 4368750, 'creation_date': '2025-04-08', 'last_modified_date': '2025-04-08'}, hash='fdcebd855cb5a78363b68e8b5488d926966d4c45748a3ba104cfc1e4300786ee'), <NodeRelationship.NEXT: '3'>: RelatedNodeInfo(node_id='1bf61934-126d-44a2-a9f2-2da604739755', node_type=<ObjectType.TEXT: '1'>, metadata={}, hash='353d6074c6a9d60f534ea9c46c0ffd7e5d99b2f48ee75d34d775c907feaa3d9e')}, metadata_template='{key}: {value}', metadata_separator='\\n', text='As a homologous receptor\\nof CD28, CTLA-4 can replace CD28 and bind to the B7 ligand on the surface of APCs,\\npreventing the activation and proliferation of T cells [ 90]. Anti-CTLA-4 antibodies en-\\nhance tumor cell killing by blocking the CTLA-4-B7 checkpoint pathway or by selectively\\ndepleting Treg cells, although this requires further validation [91]. In a small single-arm\\nstudy (NCT02536794), durvalumab in combination with tremelimumab demonstrated\\npreliminary efﬁcacy and a tolerable safety proﬁle in 7 patients with mTNBC, with an ORR\\nof 43% [ 92].', mimetype='text/plain', start_char_idx=1275, end_char_idx=1831, metadata_seperator='\\n', text_template='{metadata_str}\\n\\n{content}')"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "nodes[255]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4df227c8-881a-4d39-8abf-fd956edde059",
   "metadata": {},
   "source": [
    "Adding the data into faiss vector database\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "a68ea06d-87a7-4521-969d-c27becd360f0",
   "metadata": {},
   "outputs": [],
   "source": [
    "texts = []\n",
    "metadatas = []\n",
    "\n",
    "for node in nodes:\n",
    "    texts.append(str(node.get_content()))\n",
    "    metadatas.append(node.metadata)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "5be4e865-c42a-4e97-8851-aae4c8bf77e8",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'page_label': '1',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '1',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '1',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '1',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '1',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '1',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '1',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '2',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '2',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '2',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '2',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '2',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '2',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '3',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '3',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '3',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '3',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '3',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '3',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '3',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '3',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '4',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '4',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '4',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '4',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '4',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '4',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '4',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '5',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '5',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '5',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '5',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '5',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '5',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '5',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '5',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '5',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '6',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '6',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '6',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '6',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '6',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '6',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '6',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '6',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '6',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '7',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '7',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '7',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '7',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '7',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '7',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '7',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '7',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '8',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '8',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '8',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '8',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '8',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '9',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '9',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '9',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '9',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '9',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '9',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '9',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '9',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '10',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '10',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '10',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '10',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '10',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '11',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '11',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '11',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '11',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '12',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '12',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '12',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '13',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '13',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '13',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '13',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '13',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '14',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '14',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '14',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '14',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '14',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '14',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '14',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '14',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '14',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '15',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '15',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '15',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '15',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '15',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '15',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '15',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '15',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '15',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '15',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '16',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '16',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '16',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '16',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '16',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '16',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '16',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '16',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '16',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '17',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '17',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '17',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '17',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '17',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '17',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '17',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '17',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '17',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '17',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '18',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '18',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '18',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '18',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '18',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '18',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '18',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '18',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '18',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '19',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '19',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '19',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '19',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '19',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '20',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '20',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '20',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '20',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '20',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '20',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '21',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '21',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '21',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '21',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '21',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '21',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '21',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '21',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '21',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '21',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '22',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '22',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '22',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '22',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '22',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '22',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '22',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '23',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '23',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '23',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '23',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '23',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '23',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '23',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '23',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '23',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '23',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '24',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '24',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '24',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '24',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '24',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '24',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '24',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '25',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '25',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '25',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '25',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '25',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '25',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '25',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '25',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '26',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '26',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '26',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '26',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '26',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '26',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '26',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '27',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '27',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '27',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '27',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '27',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '27',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '27',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '28',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '28',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '28',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '28',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '28',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '28',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '28',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '28',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '28',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '28',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '29',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '29',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '29',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '29',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '29',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '29',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '29',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '29',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '30',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '30',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '30',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '30',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '30',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '30',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '30',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '30',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '30',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '31',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '31',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '31',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '31',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '31',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '31',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '31',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '32',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '32',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '32',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '32',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '32',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '32',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '32',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '33',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '33',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '33',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '33',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '33',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '33',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '33',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '34',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '34',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '34',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '34',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '34',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '34',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '34',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '35',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '35',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '35',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '35',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '35',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '35',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '35',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '36',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '36',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '36',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '36',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '36',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '36',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '36',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '37',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '37',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '37',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '37',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '37',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '37',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '37',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '37',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '38',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '38',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '38',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '38',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '38',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '38',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '38',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '39',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '39',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '39',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '39',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '39',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '39',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '40',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '40',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '40',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '40',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '40',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '40',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '40',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '40',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '40',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '40',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '40',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '41',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '42',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '43',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '44',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '45',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '46',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '47',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '47',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '48',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '48',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '48',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '48',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '48',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '48',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '48',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '49',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '49',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '49',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '49',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '49',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '49',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '49',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '49',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '49',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '49',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '49',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '50',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '50',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '50',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '50',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '50',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '50',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '50',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '50',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '51',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '51',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '51',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '51',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '51',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '52',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '52',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '52',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '52',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '52',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '53',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '53',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '53',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '53',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '53',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '54',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '54',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '54',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '54',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '54',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '54',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '54',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '54',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '54',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '55',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '55',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '55',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '55',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '55',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '55',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '55',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '55',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '55',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '55',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '56',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '56',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '56',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '56',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '56',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '56',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '56',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '56',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '56',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '56',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '57',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '57',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '57',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '57',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '57',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '57',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '57',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '57',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '57',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '57',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '57',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '58',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '59',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '59',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '59',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '59',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '59',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '59',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '59',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '59',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '59',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '59',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '59',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '60',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '60',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '60',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '60',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '60',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '60',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '60',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '60',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '60',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '60',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '61',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '62',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '63',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '64',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '64',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '64',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '64',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '64',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '64',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '64',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'},\n",
       " {'page_label': '64',\n",
       "  'file_name': 'ilovepdf_merged.pdf',\n",
       "  'file_path': 'ilovepdf_merged.pdf',\n",
       "  'file_type': 'application/pdf',\n",
       "  'file_size': 4368750,\n",
       "  'creation_date': '2025-04-08',\n",
       "  'last_modified_date': '2025-04-08'}]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "metadatas"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "f901b5bc-72ca-4733-afc6-fb086c70a8a8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "11c89e5e2d0a4c7a90a5331826a7fd86",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Batches:   0%|          | 0/19 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from sentence_transformers import SentenceTransformer\n",
    "\n",
    "model = SentenceTransformer(\"all-MiniLM-L6-v2\")\n",
    "embeddings = model.encode(texts, show_progress_bar=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "68b01195-86e5-41be-8e65-ca0714d3c617",
   "metadata": {},
   "outputs": [],
   "source": [
    "import faiss\n",
    "import numpy as np\n",
    "\n",
    "embedding_dim = len(embeddings[0])\n",
    "index = faiss.IndexFlatL2(embedding_dim)\n",
    "index.add(np.array(embeddings).astype(\"float32\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "5daccbaf-64a2-4ad7-af03-c006ec003a86",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pickle\n",
    "\n",
    "with open(\"faiss_metadata.pkl\", \"wb\") as f:\n",
    "    pickle.dump(metadatas, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "6e5f3a7b-5b66-4214-b11b-632f06370d27",
   "metadata": {},
   "outputs": [],
   "source": [
    "def search_faiss(query, k=5):\n",
    "    query_embedding = model.encode([query]).astype(\"float32\")\n",
    "    D, I = index.search(query_embedding, k)\n",
    "\n",
    "    # Load metadata\n",
    "    with open(\"faiss_metadata.pkl\", \"rb\") as f:\n",
    "        meta = pickle.load(f)\n",
    "\n",
    "    # Display results with metadata\n",
    "    for idx in I[0]:\n",
    "        print(f\"\\nResult #{idx}\")\n",
    "        print(\"Text:\", texts[idx])\n",
    "        print(\"Metadata:\", meta[idx])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "8723a69a-606f-4383-a0f6-7ba16794ceee",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Result #401\n",
      "Text: However, MSI -H is rare \n",
      "in breast cancer (<2%) (16-18).\n",
      "BRCA1 and BRCA2 -deficient tumors exhibit impaired \n",
      "homologous recombination repair (HRR) and synthetic lethality \n",
      "with poly(ADP-ribose) polymerase (PARP) inhibitors (19,20). \n",
      "The FDA approved olaparib and talazoparib in 2018 to treat \n",
      "advanced-stage HER2 -negative breast cancer in individuals \n",
      "with a Brca1 or Brca2 mutation. The FDA also approved the \n",
      "companion diagnostic test to identify germline Brca-mutated \n",
      "(gBRCAm) breast cancer patients. Approximately 5% of patients \n",
      "with breast cancer carry a gBRCAm.\n",
      "Metadata: {'page_label': '49', 'file_name': 'ilovepdf_merged.pdf', 'file_path': 'ilovepdf_merged.pdf', 'file_type': 'application/pdf', 'file_size': 4368750, 'creation_date': '2025-04-08', 'last_modified_date': '2025-04-08'}\n",
      "\n",
      "Result #300\n",
      "Text: [CrossRef] [PubMed]\n",
      "22. Gruosso, T.; Gigoux, M.; Manem, V .S.K.; Bertos, N.; Zuo, D.; Perlitch, I.; Saleh, S.M.I.; Zhao, H.; Souleimanova, M.; Johnson,\n",
      "R.M.; et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J. Clin. Investig. 2019, 129,\n",
      "1785–1800. [CrossRef] [PubMed]\n",
      "23. Bareche, Y.; Buisseret, L.; Gruosso, T.; Girard, E.; Venet, D.; Dupont, F.; Desmedt, C.; Larsimont, D.; Park, M.; Rothe, F.; et al.\n",
      "Metadata: {'page_label': '41', 'file_name': 'ilovepdf_merged.pdf', 'file_path': 'ilovepdf_merged.pdf', 'file_type': 'application/pdf', 'file_size': 4368750, 'creation_date': '2025-04-08', 'last_modified_date': '2025-04-08'}\n",
      "\n",
      "Result #321\n",
      "Text: Clin. Cancer Res. 2020, 26, 657–668. [CrossRef]\n",
      "52. Szekely, B.; Bossuyt, V .; Li, X.; Wali, V .B.; Patwardhan, G.A.; Frederick, C.; Silber, A.; Park, T.; Harigopal, M.; Pelekanou, V .; et al.\n",
      "Immunological differences between primary and metastatic breast cancer. Ann. Oncol. 2018, 29, 2232–2239. [CrossRef] [PubMed]\n",
      "53. Nanda, R.; Liu, M.C.; Yau, C.; Shatsky, R.; Pusztai, L.; Wallace, A.; Chien, A.J.\n",
      "Metadata: {'page_label': '42', 'file_name': 'ilovepdf_merged.pdf', 'file_path': 'ilovepdf_merged.pdf', 'file_type': 'application/pdf', 'file_size': 4368750, 'creation_date': '2025-04-08', 'last_modified_date': '2025-04-08'}\n"
     ]
    }
   ],
   "source": [
    "search_faiss(\"how common is msi-h in breast cancer?\", k=3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "0a9b56cf-8eb9-4fa2-9072-84ff629a7627",
   "metadata": {},
   "outputs": [],
   "source": [
    "faiss_index = index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "bdb1c8c6-5be3-49cb-ab5a-256ca0193f95",
   "metadata": {},
   "outputs": [],
   "source": [
    "import faiss\n",
    "import numpy as np\n",
    "from IPython.display import Markdown\n",
    "import google.generativeai as genai\n",
    "\n",
    "def ask_faiss(query, faiss_index, texts, metadatas, embedding_model, k=2):\n",
    "    # 1. Embed the query\n",
    "    query_embedding = embedding_model.encode([query]).astype(\"float32\")\n",
    "\n",
    "    # 2. Search FAISS index\n",
    "    D, I = faiss_index.search(query_embedding, k)\n",
    "    \n",
    "    # 3. Build context and source mapping\n",
    "    context_parts = []\n",
    "    source_mapping = {}\n",
    "\n",
    "    for i, idx in enumerate(I[0], 1):\n",
    "        text = texts[idx]\n",
    "        meta = metadatas[idx]\n",
    "\n",
    "        # Custom label for source\n",
    "        source = f\"{meta.get('file_name', 'Unknown')} (Page {meta.get('page_label', '?')})\"\n",
    "\n",
    "        context_parts.append(f\"[[{i}]] {text}\")\n",
    "        source_mapping[i] = (source, D[0][i-1])  # (filename + page), similarity score\n",
    "\n",
    "    context_text = \"\\n\\n\".join(context_parts)\n",
    "\n",
    "    # 4. Build the prompt\n",
    "    prompt = f\"\"\"\n",
    "Context information is below. Each section is marked with [[NUMBER]] citations.\n",
    "---------------------\n",
    "{context_text}\n",
    "---------------------\n",
    "Given the context, answer this question: {query}\n",
    "\n",
    "Requirements:\n",
    "1. If the information isn't in the context, say \"I don't have that information\"\n",
    "2. For any facts used, include [[NUMBER]] citations pointing to which document they came from\n",
    "3. Include a \"Sources\" section at the end listing all cited documents\n",
    "4. Keep the answer concise but accurate\n",
    "\"\"\"\n",
    "\n",
    "    # 5. Use Gemini LLM\n",
    "    genai.configure(api_key=\"AIzaSyCXrPcd8h6o0LAcBTtqGDBqCfcLbmNg2-o\")\n",
    "    model = genai.GenerativeModel(\"gemini-1.5-flash\")\n",
    "    response = model.generate_content(prompt)\n",
    "    generated_text = response.candidates[0].content.parts[0].text\n",
    "\n",
    "    # 6. Add sources section\n",
    "    sources_section = \"\\n\\n## Sources\\n\"\n",
    "    for num, (source, score) in source_mapping.items():\n",
    "        if f\"[[{num}]]\" in generated_text:\n",
    "            sources_section += f\"- [[{num}]] {source} (similarity score: {score:.2f})\\n\"\n",
    "\n",
    "    full_answer = generated_text + sources_section\n",
    "    display(Markdown(full_answer))  # still display it nicely\n",
    "    return full_answer    \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "89baea9d-aeee-4169-97b5-bca50325526d",
   "metadata": {},
   "outputs": [],
   "source": [
    "embedding_model = SentenceTransformer(\"all-MiniLM-L6-v2\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "d54440e0-7274-4b4f-aaaf-3811a17547bc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "Based on the provided text, neoadjuvant therapy is used in the treatment of triple-negative breast cancer (TNBC) [[1]].  One example includes a treatment approach using (Carbo/nab-pac) +/- atezolizumab [[1]].  Further analysis of neoadjuvant experimental treatment showed data related to prognosis and recurrence [[2]].\n",
       "\n",
       "Sources\n",
       "[[1]] WON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES1248\n",
       "[[2]] An exploratory analysis of the study then provided data to further describe the prognosis related to the RCB after neoadjuvant experimental treatment (Figure 1) [85].\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 51) (similarity score: 0.86)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 8) (similarity score: 0.86)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "predicted_answers1=ask_faiss(\"what is the purpose of neoadjuvant treatment?\", faiss_index, texts, metadatas, embedding_model, k=2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "ade7680b-e189-4c4e-b8d2-752752dc2633",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Based on the provided text, neoadjuvant therapy is used in the treatment of triple-negative breast cancer (TNBC) [[1]].  One example includes a treatment approach using (Carbo/nab-pac) +/- atezolizumab [[1]].  Further analysis of neoadjuvant experimental treatment showed data related to prognosis and recurrence [[2]].\\n\\nSources\\n[[1]] WON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES1248\\n[[2]] An exploratory analysis of the study then provided data to further describe the prognosis related to the RCB after neoadjuvant experimental treatment (Figure 1) [85].\\n\\n\\n\\n## Sources\\n- [[1]] ilovepdf_merged.pdf (Page 51) (similarity score: 0.86)\\n- [[2]] ilovepdf_merged.pdf (Page 8) (similarity score: 0.86)\\n'"
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "predicted_answers1"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a757a1cd-9b4d-4689-b6af-886147e0fcf0",
   "metadata": {},
   "source": [
    "# Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "8596312b-e360-4db0-abfb-49781ebd8a00",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import time\n",
    "import random\n",
    "import google.generativeai as genai\n",
    "from bert_score import score\n",
    "import nltk\n",
    "from rouge_score import rouge_scorer\n",
    "from nltk.translate.bleu_score import sentence_bleu"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "868335d4-5e75-4d41-83af-9242032ae44d",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Configure Gemini API\n",
    "genai.configure(api_key='AIzaSyDXG4o4UnII5VFD1u5TaWgleG2kCfJ0Ofw')\n",
    "model = genai.GenerativeModel(\"gemini-pro\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "9756552d-7713-4569-8008-39d9fbcbff7c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load the Excel sheet\n",
    "df = pd.read_csv(\"datasetev1 - Copy(Sheet1).csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "46b22be4-2449-4773-8083-a05ecba308f1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Actual_Answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>what defines triple negative breast cancer (tn...</td>\n",
       "      <td>lack of expression (&lt; 1%) of er, pgr, and her2.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>what percentage of all breast cancers does tnb...</td>\n",
       "      <td>approximately 10-20%.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>what patient population is most commonly affec...</td>\n",
       "      <td>young, premenopausal women.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>what kind of genetic alterations are associate...</td>\n",
       "      <td>brca 1/2 mutations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>how would you describe the biological behavior...</td>\n",
       "      <td>aggressive, higher grade, often lymph node inv...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>what was the effect of talazoparib on median p...</td>\n",
       "      <td>a 46% increase in median pfs.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>what grade 3-4 aes were primarily associated w...</td>\n",
       "      <td>anemia.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>what agents have been explored in clinical stu...</td>\n",
       "      <td>immuno- and targeted therapies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>what is the median progression-free survival (...</td>\n",
       "      <td>1.7 to 3.7 months.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>what is the median os from the onset of metast...</td>\n",
       "      <td>10 to 13 months.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>90 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                             Question  \\\n",
       "0   what defines triple negative breast cancer (tn...   \n",
       "1   what percentage of all breast cancers does tnb...   \n",
       "2   what patient population is most commonly affec...   \n",
       "3   what kind of genetic alterations are associate...   \n",
       "4   how would you describe the biological behavior...   \n",
       "..                                                ...   \n",
       "85  what was the effect of talazoparib on median p...   \n",
       "86  what grade 3-4 aes were primarily associated w...   \n",
       "87  what agents have been explored in clinical stu...   \n",
       "88  what is the median progression-free survival (...   \n",
       "89  what is the median os from the onset of metast...   \n",
       "\n",
       "                                        Actual_Answer  \n",
       "0     lack of expression (< 1%) of er, pgr, and her2.  \n",
       "1                               approximately 10-20%.  \n",
       "2                         young, premenopausal women.  \n",
       "3                                 brca 1/2 mutations.  \n",
       "4   aggressive, higher grade, often lymph node inv...  \n",
       "..                                                ...  \n",
       "85                      a 46% increase in median pfs.  \n",
       "86                                            anemia.  \n",
       "87                    immuno- and targeted therapies.  \n",
       "88                                 1.7 to 3.7 months.  \n",
       "89                                   10 to 13 months.  \n",
       "\n",
       "[90 rows x 2 columns]"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "c557972c-ec0e-41b6-9724-fcf985a51d79",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "cb2515a0-415a-4fbc-91ab-5426d8e0b3ee",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "90"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(questions)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "7504071f-970e-4b80-a580-aab7b866af12",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "Triple-negative breast cancer (TNBC) is defined immunohistochemically by having ≤1% cellular expression of estrogen receptor (ER) and progesterone receptor (PR), and HER2 expression of 0 to 1+ by IHC, or 2+ by IHC and fluorescence in situ hybridization (FISH) negative (meaning no amplified gene copy number) [[1]].  This definition follows American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines. [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]]  Text provided.\n",
       "[[2]] Text provided.\n",
       "[[3]] Text provided.\n",
       "[[4]] Text provided.\n",
       "[[5]] Text provided.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.40)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 1) (similarity score: 0.59)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 40) (similarity score: 0.62)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 40) (similarity score: 0.63)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.64)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "TNBC accounts for approximately 15-20% of all newly diagnosed breast cancers. [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]]  Text provided\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.43)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "TNBC mainly affects young, premenopausal women and individuals with inherited gene alterations such as BRCA 1/2 mutations. [[5]]  It accounts for approximately 10–20% of all breast cancers. [[5]]\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[1]], [[2]], [[3]], [[4]], [[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 27) (similarity score: 0.78)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.81)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.84)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 7) (similarity score: 0.86)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.88)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Triple-negative breast cancer (TNBC) is associated with inherited gene alterations such as BRCA 1/2 mutations [[2]].  Additionally, TNBC tumors may exhibit \"BRCAness,\" a phenotype similar to BRCA mutations but without the actual BRCA 1/2 mutation [[5]].  High MYC amplifications are also linked to a specific TNBC microenvironment phenotype [[1]].\n",
       "\n",
       "\n",
       "Sources\n",
       "* [[1]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\n",
       "* [[2]]  (Source text not fully provided, but context indicates this citation refers to information on BRCA mutations in TNBC)\n",
       "* [[5]] (Source text not fully provided, but context indicates this citation refers to information on BRCAness and immunogenicity in TNBC)\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.88)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.89)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.98)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous disease [[2]].  It accounts for 15-20% of all new breast cancer diagnoses and is associated with a poorer prognosis and higher grade than other breast cancer types [[2]].  The median overall survival is 10.2 months, and the 5-year survival rate varies significantly depending on disease stage [[2]].  TNBC can be classified into several subtypes based on molecular heterogeneity [[2]] and microenvironment phenotypes, including an \"immune-desert\" subtype characterized by poor immune cell infiltration due to high MYC amplification [[1]] and an \"immune-inflated\" subtype with high immune cell presence but also high immune checkpoint expression [[4]].  High levels of tumor-infiltrating lymphocytes (TILs) are associated with improved outcomes [[3]].\n",
       "\n",
       "\n",
       "Sources:\n",
       "* [[1]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\n",
       "* [[2]]  (Context provided, but no specific source URL)\n",
       "* [[3]] (Context provided, but no specific source URL)\n",
       "* [[4]] (Context provided, but no specific source URL)\n",
       "* [[5]] (Context provided, but no specific source URL)\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.99)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 48) (similarity score: 1.18)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 49) (similarity score: 1.18)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.19)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 51) (similarity score: 1.20)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The traditional treatment for early triple-negative breast cancer (TNBC) has been neoadjuvant chemotherapy followed by surgery. [[4]]\n",
       "Sources\n",
       "[[1]]  [[2]] [[3]] [[4]] [[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 7) (similarity score: 0.86)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 6) (similarity score: 0.87)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 51) (similarity score: 0.87)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.89)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.89)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "In early triple-negative breast cancer (TNBC), conventional cytotoxic chemotherapy has consisted of neoadjuvant chemotherapy followed by surgery. [[1]]  More recently, treatment strategies have emphasized escalating chemotherapeutic agents based on standard neoadjuvant regimens. [[3]]\n",
       "  \n",
       "\n",
       "Sources\n",
       "[[1]] WON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES1246\n",
       "[[2]] 1). As of March 2020, 399 ongoing studies for TNBC have been listed on ClinicalTrials.gov and select Phase III studies are listed in Table I.\n",
       "[[3]] New biomarkers and frontiers in TNBC\n",
       "[[4]] The low percentage of BRCA mutated patients enrolled in the CREATE-X, the absence of pre-planned subgroup analyzes for this population do not allow for a description of the efficacy of capecitabine in this subgroup of patients.\n",
       "[[5]] observation High-risk TNBC NA\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.65)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.68)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 9) (similarity score: 0.68)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 7) (similarity score: 0.69)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 24) (similarity score: 0.71)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Neoadjuvant treatment, often using anthracycline and taxane-based poly-CHT, aims to increase the rate of local control, guide breast-conserving surgery, and improve survival by achieving pathologic complete response (pCR) [[3]].  The addition of immunotherapy, like pembrolizumab, to neoadjuvant treatment further increases pCR rates and improves long-term benefits [[3], [5]].  In some trials, patients with residual invasive breast cancer after neoadjuvant chemotherapy (NACT) are included [[4]].\n",
       "However, it's difficult to definitively determine if long-term benefits stem from adjuvant treatment or a reduced residual cancer burden after neoadjuvant treatment [[5]].\n",
       "\n",
       "Sources\n",
       "[[1]] WON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES1248\n",
       "[[2]] An exploratory analysis of the study then provided data to further describe the prognosis related to the RCB after neoadjuvant experimental treatment (Figure 1) [85].\n",
       "[[3]] Anthracycline and taxane-based poly-CHT remains the standard of treatment, most often administered preoperatively to assess tumor sensitivity.\n",
       "[[4]] It enrolled patients treated with CHT (containing anthracyclines, taxanes or the combination of both) in neoadjuvant or adjuvant setting and randomized them to receive olaparib (orally administered at the dose of 300 mg twice daily) vs. placebo for 1 year after surgical resection (and radiotherapy when indicated).\n",
       "[[5]] Results from the KEYNOTE-522 study were the basis for this approval, demonstrating a significantly higher rate of pCR at the time of definitive surgery among patients who received pembrolizumab plus NACT than among those who received placebo plus NACT and an improvement in long-term benefits [73, 84].\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 51) (similarity score: 0.86)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 8) (similarity score: 0.86)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 10) (similarity score: 0.92)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 7) (similarity score: 0.93)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 8) (similarity score: 0.93)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Studies show survival benefits from the combination of PD-(L)1 inhibitors with nab-paclitaxel [[5]] and from the combination of  PD-(L)1 inhibitors with small molecule inhibitors (though the specific small molecule inhibitor isn't named) [[1]].\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[1]] Cancers 2023, 15, 321 16 of 28\n",
       "[[5]] Cancers 2023, 15, 321 10 of 28\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 35) (similarity score: 0.60)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 29) (similarity score: 0.74)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The provided text focuses on the limitations of single-agent immune checkpoint inhibitors (ICIs) in treating triple-negative breast cancer (TNBC), particularly the low efficacy of PD-(L)1 inhibitors (approximately 20% in metastatic TNBC) [[2], [5]].  It highlights the need for further research to understand tumor immune escape mechanisms and the tumor immune microenvironment (TIME) to improve ICI efficacy [[5]].  While the text mentions that progress in integrating ICIs with novel agents has revolutionized treatment for early TNBC [[3]], and that a deeper understanding of tumor subtypes and the tumor microenvironment could lead to superior targeted immunotherapy [[4]], it does *not* specify which combinations of ICIs might emerge.  Therefore, I don't have that information.\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[1]], [[2]], [[3]], [[4]], [[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.42)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.50)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 9) (similarity score: 0.52)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.55)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.56)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "A profound comprehension of tumor subtypes, tumor microenvironment (TME), and molecular, genetic, and immune aspects would amplify the potential for developing targeted immunotherapy in TNBC. [[3]]\n",
       "\n",
       "Sources:\n",
       "[[3]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[3]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.72)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "This review investigates the role of immunotherapy in treating tumors, specifically focusing on how it enhances immune system function in a tumor-localized manner [[1]] and blocks immune escape pathways of tumor cells to eliminate them [[1]].  The review also explores the categorization of tumors as \"hot\" or \"cold\" based on immune cell infiltration and response to immune checkpoint inhibitors (ICIs) [[5]].  Different immunotherapy approaches, including therapeutic cancer vaccines, monoclonal antibodies, adoptive cell therapies, and cytokines, are mentioned [[5]].\n",
       "\n",
       "Sources:\n",
       "[[1]]:  The provided text excerpt.\n",
       "[[2]]: J Clin Oncol 37: 559-569, 2019; Nat Rev Drug Discov 18: 197-218, 2019; JAMA Oncol: Apr 11, 2019 (Epub ahead of print).\n",
       "[[3]]: Clin. Cancer Res. 2009, 15, 7412–7420; Lancet Oncol. 2017, 18, E143–E152.\n",
       "[[4]]: Ann. Oncol. 2019, 30, 385–396; Clin. Cancer Res.\n",
       "[[5]]: The provided text excerpt.\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.58)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 61) (similarity score: 0.76)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 46) (similarity score: 0.78)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 46) (similarity score: 0.79)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.80)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The authors aim to investigate the prognostic value of biomarkers [[1]] and the RCB (residual cancer burden) after neoadjuvant experimental treatment [[3]].  They also analyze the prognostic value of triple-negative breast cancer (TNBC) [[4]],  comparing outcomes (overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), objective response rate (ORR)) in various treatment groups  [[2], [4], [5]].\n",
       "  \n",
       "Sources:\n",
       "[[1]], [[2]], [[3]], [[4]], [[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 11) (similarity score: 1.10)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 24) (similarity score: 1.16)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 8) (similarity score: 1.21)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 7) (similarity score: 1.21)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 26) (similarity score: 1.22)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Triple-negative breast cancer (TNBC) shows promise for immunotherapy due to the frequent presence of tumor-infiltrating lymphocytes (TILs) which correlate with increased pathologic complete response (pCR) to neoadjuvant chemotherapy and are predictive of disease-free survival (DFS) and overall survival (OS) in early-stage TNBC [[4]].  The expression of immune regulatory checkpoints is an adaptive method of tumor resistance to infiltrating lymphocytes within the tumor microenvironment [[4]].  Additionally, the high number of clinical trials exploring immunotherapy for TNBC,  both as monotherapy and in combination with other therapies,  demonstrates the generalizability of immunotherapy for TNBC across early and metastatic settings [[1], [2]].\n",
       "\n",
       "Sources:\n",
       "[[1]], [[2]], [[4]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.53)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.54)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.57)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "TNBC immunogenicity is related to intrinsic tumor cell signatures and features of the surrounding tumor microenvironment (TME) [[1]].  This includes elements contributing to the concept of tumor mutational burden (TMB), such as an ineffective DNA repair system leading to high neoantigen rates and an upregulated antigen presentation system [[5]].  However, the exact relationship between TMB, neoantigens, and immune infiltration isn't fully understood [[5]].  TNBC can also be classified into microenvironment phenotypes, such as the \"immune-desert\" cluster with poor immune cell permeation due to high MYC amplification [[4]].\n",
       " \n",
       "Sources:\n",
       "* [[1]]\n",
       "* [[4]]\n",
       "* [[5]]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.71)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.75)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.78)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Next-generation sequencing (NGS) is an emerging technology that has improved the understanding of the molecular and genetic background of TNBC. [[4]]\n",
       "\n",
       "Sources:\n",
       "[[4]] The landscape of immunotherapy in TNBC\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[4]] ilovepdf_merged.pdf (Page 2) (similarity score: 1.02)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The first classification divided TNBC into six subtypes: basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), M stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR) [[1]].\n",
       "Sources\n",
       "[[1]]  A first  classification  divided  TNBC  into  six  subtypes:  basal-like  1 (BL1),  basal-like  2 (BL2), \n",
       "mesenchymal (M), M stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR) [14].\n",
       "[[2]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 234\n",
       "[[3]] TNBC is \n",
       "also subdivided into 6 different subgroups based on molecular \n",
       "heterogeneity: Basal -like; mesenchymal -like; mesenchymal \n",
       "stem-like; luminal AR expression; immunomodulatory; and \n",
       "unstable type (6). TNBC represents approximately 15-20% of \n",
       "all newly diagnosed breast cancers and is generally a more \n",
       "aggressive disease with a poorer prognosis and higher grade \n",
       "than other types of breast cancer, accounting for 5% of all \n",
       "cancer-related deaths annually. The median overall survival \n",
       "(OS) for the disease is 10.2 months with current therapies, with \n",
       "a 5-year survival rate of ~65% for regional tumors and 11% for \n",
       "those that have spread to distant organs (7,8).\n",
       "[[4]] CT\n",
       "Operable-stage II-III\n",
       "TNBC NA\n",
       "[[5]] observation High-risk TNBC NA\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 2) (similarity score: 1.08)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.09)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 48) (similarity score: 1.20)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 27) (similarity score: 1.22)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 24) (similarity score: 1.22)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "198 TNBC tumors were analyzed to shape a four-type classification of TNBC. [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]]  Section 1 of the provided text.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.54)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "After revision, the four specific TNBC subtypes identified were BL1, BL2, M, and LAR. [[1]]  These omitted IM and MSL subtypes due to their dependence on tumor microenvironment (TME) features. [[1]]\n",
       " \n",
       "Sources:\n",
       "[[1]]  A first classification divided TNBC...\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.87)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The IM and MSL subtypes were omitted because their classification depended on tumor microenvironment (TME) features. [[2]]\n",
       "\n",
       "Sources\n",
       "[[1]]  Triple-negative breast cancer (TNBC) characterization and subtypes.\n",
       "[[2]]  TNBC classification revisions based on RNA and DNA profiles, noting the dependence of IM and MSL subtypes on TME.\n",
       "[[3]]  Citation referencing Burstein et al. (2015) study on TNBC subtypes.\n",
       "[[4]] Citation referencing Durvalumab with olaparib and paclitaxel trial results and other unrelated citations.\n",
       "[[5]]  TNBC microenvironment phenotypes and clusters.\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 48) (similarity score: 1.32)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 2) (similarity score: 1.38)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 40) (similarity score: 1.39)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 43) (similarity score: 1.44)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.44)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "In addition to subtypes, TNBC can be classified into three microenvironment phenotypes or clusters based on immune cell permeation and MYC amplification levels. [[2]]  One cluster is described as an \"immune-desert\" with poor immune cell infiltration due to high MYC amplification. [[2]]\n",
       "  \n",
       "\n",
       "Sources:\n",
       "* [[2]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 234\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[2]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.98)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Cluster 1, also called an \"immune-desert\", is characterized by poor immune cell permeation due to a high presence of MYC amplifications and, consequently, lower recruitment of innate immune cells [[2]].  It is considered a \"cold tumor\" along with Cluster 2 [[1]].\n",
       "Sources\n",
       "[[1]]  Uncited document describing TNBC clusters.\n",
       "[[2]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\n",
       "[[3]] Uncited document discussing TNBC clusters.\n",
       "[[4]] Uncited document, likely manuscript author information and funding details.\n",
       "[[5]] Uncited document, likely clinical trial data.\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.09)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.19)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.49)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 40) (similarity score: 1.50)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 26) (similarity score: 1.61)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The phosphatidylinositide 3-kinase/protein kinase B (PI3K-AKT) pathway is hyper-activated in Cluster 2. [[1]]\n",
       "\n",
       "Sources:\n",
       "[[1]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.97)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Clusters 1 and 2 are referred to as \"cold tumors\". [[1]]\n",
       "Sources:\n",
       "[[1]]  (Unspecified source, context provided)\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.09)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Cluster 3, the \"immune-inflamed\" or \"hot tumor\" phenotype, represents about 30% of TNBCs. [[4]]\n",
       "\n",
       "Sources:\n",
       "* [[1]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\n",
       "* [[2]]  (Source text not provided completely, only a fragment)\n",
       "* [[3]] (Source text not provided completely, only a fragment)\n",
       "* [[4]] (Source text not provided completely, only a fragment)\n",
       "* [[5]] (Source text not provided completely, only a fragment)\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.89)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.99)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.04)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.05)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 27) (similarity score: 1.11)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Cluster 3, also known as \"immune-inflamed\" or \"hot tumor,\" is characterized by abundant adaptive and innate immune cell infiltration and high expression of immune checkpoint molecules [[1]].  It represents about 30% of TNBCs [[1]].  While having comparable TMB to other clusters, it also shows a higher degree of immune cells in the tumor microenvironment (TME) and high expression of immune checkpoints by cancer cells [[4]].\n",
       "Sources\n",
       "[[1]]:  Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\n",
       "[[4]]: Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.00)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.49)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Cluster 3 is also called a \"hot tumor\" [[1]].  It is characterized by abundant adaptive and innate immune cell infiltration and high expression of immune checkpoint molecules [[1]].\n",
       "\n",
       "Sources\n",
       "* [[1]]  Uncited document, likely from a journal article.  The specific journal and article are not fully provided in the context.\n",
       "* [[2]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\n",
       "* [[3]] Cancer J. 2021;27: 8–16.\n",
       "* [[4]] Uncited document, likely from a journal article. The specific journal and article are not fully provided in the context.\n",
       "* [[5]] License information.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.07)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.31)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 13) (similarity score: 1.53)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.57)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 64) (similarity score: 1.57)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Converting \"cold\" tumors to \"hot\" tumors could improve the clinical response of immune checkpoint inhibitors (ICIs) [[1]].  This is because \"cold tumors\" lack immune cell infiltration and don't respond to ICIs, while \"hot tumors\" have high levels of immune cell infiltration and upregulated immune checkpoints, making them responsive to ICIs [[3]].  Anti-tumor vascular therapy is a potential method for this conversion [[2]], as is disrupting tumor stromal fibrosis [[4]], and PARPi treatment [[5]].\n",
       "\n",
       "Sources:\n",
       "[[1]], [[2]], [[3]], [[4]], [[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.73)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 34) (similarity score: 0.82)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.87)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 37) (similarity score: 0.94)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 31) (similarity score: 1.01)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "I don't have that information.  The provided text focuses on immunotherapy's mechanisms and challenges, particularly in triple-negative breast cancer (TNBC), but it doesn't discuss the synergistic effects of local therapies with immunotherapy.\n",
       "\n",
       "Sources:\n",
       "* [[1]]:  Information on immune checkpoints and immunotherapy approaches.\n",
       "* [[2]]: Description of immunotherapy approaches (TCVs, mAbs, ACTs, cytokines, ICIs) and \"hot\" vs. \"cold\" tumors.\n",
       "* [[3]]: Challenges in selecting immunotherapy-sensitive individuals.\n",
       "* [[4]]: Rationale of immunotherapy and cancer immunoediting in TNBC.\n",
       "* [[5]]: List of journal articles (citations 27, 28, 29).\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.65)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.79)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 38) (similarity score: 0.81)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.85)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 61) (similarity score: 0.87)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The provided text focuses on systemic immunotherapies and doesn't detail how local therapies might synergize with them.  Therefore, I don't have that information.\n",
       "\n",
       "Sources:\n",
       "[[1]], [[2]], [[3]], [[4]], [[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.67)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.79)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 38) (similarity score: 0.84)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.86)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 11) (similarity score: 0.87)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "TNBC accounts for approximately 15-20% of all newly diagnosed breast cancers. [[1]]\n",
       "\n",
       "Sources:\n",
       "[[1]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.45)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "For early-stage triple-negative breast cancer (TNBC) patients, the mainstay treatment has been neoadjuvant chemotherapy followed by surgery. [[1]]\n",
       "Sources\n",
       "[[1]] WON and SPRUCK: TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES1246\n",
       "[[2]] Atez + PAC\n",
       "[[3]] New biomarkers and frontiers in TNBC\n",
       "[[4]] SG PD-L1-negative mTNBC\n",
       "[[5]] WON and SPRUCK: TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES1250\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.64)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 33) (similarity score: 0.70)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 9) (similarity score: 0.72)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 32) (similarity score: 0.72)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 53) (similarity score: 0.72)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "I don't have that information.  The provided text mentions pembrolizumab showing anti-tumor activity in a phase Ib study of advanced PD-L1-positive TNBC [[3]], and that studies on PD-(L)1 inhibitors are underway in early-stage TNBC [[1]], but it does not state whether any have received approval for these patient populations.\n",
       "  \n",
       "Sources:\n",
       "\n",
       "[[1]]: Section discussing the results of PD-(L)1 blockade trials and ongoing research in early-stage TNBC.\n",
       "[[3]]: Section discussing the KEYNOTE-012 study's results with pembrolizumab in advanced PD-L1-positive TNBC.\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 25) (similarity score: 0.29)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 23) (similarity score: 0.52)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "PARPi, PD-(L)1 inhibitors, and ADCs are approved for the treatment of triple-negative breast cancer (TNBC).  [[1]]  Specifically, pembrolizumab (a PD-1 inhibitor) is approved for advanced PD-L1-positive and early high-risk TNBC. [[1]]  Sacituzumab govitecan (an ADC) is approved for advanced TNBC patients who have received two or more lines of treatment. [[3]] Ladiratuzumab vedotin (an ADC) is approved for relapsed or refractory metastatic TNBC. [[2]]\n",
       "\n",
       "Sources\n",
       "* [[1]] Cancers 2023, 15, 321. https://doi.org/10.3390/cancers15010321 https://www.mdpi.com/journal/cancers\n",
       "* [[2]]  (Source text lacks a proper citation but is described within the context)\n",
       "* [[3]] (Source text lacks a proper citation but is described within the context)\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 20) (similarity score: 0.78)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 58) (similarity score: 0.79)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 34) (similarity score: 0.86)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The three stages of cancer immunoediting are: (1) elimination; (2) equilibrium, where the immune system and surviving tumor cells reach a dynamic balance; and (3) escape. [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]] Cancers 2023, 15, x 2 of 29\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.76)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "APCs mainly include dendritic cells (DCs). [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]]  Body text provided.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 21) (similarity score: 1.41)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The single-agent effectiveness of PD-(L)1 inhibitors in patients with PD-L1-positive metastatic TNBC (mTNBC) is approximately 20%. [[3], [5]]\n",
       "\n",
       "Sources\n",
       "[[1]]  \n",
       "[[2]]\n",
       "[[3]]\n",
       "[[4]]\n",
       "[[5]]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 25) (similarity score: 0.32)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 25) (similarity score: 0.45)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.51)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 25) (similarity score: 0.52)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.52)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "TNBC exhibits higher PD-L1 expression and a greater number of tumor-infiltrating lymphocytes (TILs) than other breast cancer subtypes [[1]].  It also has high immunogenic potential [[2]], making it a promising candidate for immunotherapy, particularly with immune checkpoint inhibitors (ICIs).  The presence of TILs in TNBC correlates with increased pathologic complete response (pCR) to neoadjuvant chemotherapy and is predictive of disease-free survival (DFS) and overall survival (OS) in early-stage TNBC [[3]].\n",
       "\n",
       "Sources:\n",
       "[[1]]\n",
       "[[2]]\n",
       "[[3]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.60)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.61)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.66)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "B cells and natural killer (NK) cells are also essential for tumor cell elimination. [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]] Cancers 2023, 15, 321 3 of 28\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.64)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The main challenge in TNBC treatment, due to the lack of specific receptors, is its aggressive behavior and the absence of targeted therapies [[4]].  This has historically made it difficult to treat [[4]].\n",
       "  \n",
       "Sources:\n",
       "[[4]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 241\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[4]] ilovepdf_merged.pdf (Page 10) (similarity score: 0.85)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The provided text does not state that any single systemic treatment was historically the *only* option for TNBC.  While it mentions various treatments such as  combinations of chemotherapy and immunotherapy  [[1], [4], [5]], and capecitabine and olaparib [[3]], it doesn't claim any one treatment was exclusive in the past.\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[1]] ASPRIA  clinical trial information.\n",
       "[[2]]  Analysis of clinical trials on TNBC immunotherapy.\n",
       "[[3]] Discussion of treatment options for TNBC, including capecitabine and olaparib.\n",
       "[[4]] WON and SPRUCK: TNBC therapy review, including phase III studies.\n",
       "[[5]] Analysis of immunotherapy clinical trials for TNBC.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 32) (similarity score: 0.79)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.80)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 7) (similarity score: 0.88)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 51) (similarity score: 0.88)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.88)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The provided text focuses on the current landscape and rationale of immunotherapy in TNBC, highlighting the significant increase in clinical trials in the past decade [[2]].  It does not, however, specify a single event or discovery that launched the era of immunotherapy for TNBC.  The text mentions that some studies found higher PD-L1 expression and TILs in TNBC compared to other subtypes, making it a likely candidate to benefit from immunotherapy [[4]], but this is not the same as identifying the launch of the era.\n",
       "\n",
       "Sources:\n",
       "* [[2]]\n",
       "* [[4]]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[2]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.83)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.85)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The poor prognosis of TNBC is primarily due to its aggressive biological behavior, higher grade, frequent lymph node involvement at diagnosis, tendency to metastasize after treatment, and poorer prognosis in the metastatic setting compared to other breast cancer subtypes [[2]].  TNBC is also generally a more aggressive disease with a poorer prognosis and higher grade than other breast cancer types [[1]].\n",
       "Sources:\n",
       "[[1]], [[2]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.72)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.76)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "When combining multiple drugs for TNBC treatment, the following need to be considered:  the potential for superior clinical response compared to single-drug application [[1]],  the safety profile of the combination [[1], [4]],  the identification of effective biomarkers to target the right patient population [[3]], and the management of overlapping side effects, such as cytopenias [[4]].  The efficacy of the combination therapy in specific subgroups, like BRCA-mutated patients, also needs to be carefully analyzed [[4]].\n",
       "\n",
       "Sources:\n",
       "[[1]] Cancers 2023, 15, 321\n",
       "[[2]]  KEYNOTE-012 and KEYNOTE-086 study information\n",
       "[[3]]  Article discussing immunotherapy combination therapy for TNBC\n",
       "[[4]] Article discussing treatment paradigms and combination therapies for TNBC\n",
       "[[5]] Table of clinical trials involving TNBC combination therapies\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 35) (similarity score: 0.70)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 23) (similarity score: 0.79)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 20) (similarity score: 0.80)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 7) (similarity score: 0.81)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 33) (similarity score: 0.84)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Genomic advances, such as next-generation sequencing (NGS), have significantly improved our understanding of TNBC's molecular and genetic background [[1]].  This has revealed the intertumoral and intratumoral heterogeneity of TNBC [[1]], which is crucial for developing more effective therapies, especially immunotherapies.\n",
       "Sources\n",
       "[[1]]  [[2]] [[3]] [[4]] [[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.92)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 11) (similarity score: 0.96)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.96)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.96)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.97)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Based on the provided text, mTNBC stands for metastatic triple-negative breast cancer. [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]]  Document 1\n",
       "[[2]] Document 2\n",
       "[[3]] Document 3\n",
       "[[4]] Document 4\n",
       "[[5]] Document 5\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 24) (similarity score: 1.42)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 23) (similarity score: 1.50)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 26) (similarity score: 1.51)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 27) (similarity score: 1.54)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 23) (similarity score: 1.56)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The provided text does not describe the purpose of a specific review.  While some sections mention validation [[1], [4]] and the need for prospective adjuvant trials [[4]], there's no abstract summarizing a particular review's objective.  I don't have that information.\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[1]], [[2]], [[3]], [[4]], [[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 12) (similarity score: 1.26)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 40) (similarity score: 1.43)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 47) (similarity score: 1.49)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 4) (similarity score: 1.52)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 22) (similarity score: 1.60)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Tumor cells release specific antigens [[1], [2]].  These antigens are captured and processed by antigen-presenting cells (APCs) [[1], [2]].\n",
       "\n",
       "Sources:\n",
       "[[1]]\n",
       "[[2]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.42)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.81)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Combination immunotherapy, particularly using PD-(L)1 inhibitors with other therapies, shows promise in treating TNBC.  [[1]] notes that the majority (84%) of TNBC immunotherapy trials utilize PD-(L)1 inhibitors, often in combination with other treatments.  [[1]] also highlights the presence of trials in both early and metastatic settings, suggesting broad applicability.  [[4]] further supports this by stating that combining PD-(L)1 inhibitors with therapies like TCVs may synergistically activate the immune system, although the optimal sequencing of these treatments needs further investigation.  While some studies show positive effects, such as improved progression-free survival and overall survival ([[3]]),  more research is needed to determine ideal treatment duration and identify predictive biomarkers for personalized treatment. [[3]]\n",
       "\n",
       "\n",
       "Sources:\n",
       "* [[1]]\n",
       "* [[2]]\n",
       "* [[3]]\n",
       "* [[4]]\n",
       "* [[5]]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.59)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.61)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 6) (similarity score: 0.65)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 36) (similarity score: 0.66)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.66)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The provided text does not give a definitive timeframe for when most TNBC patients experience recurrence and metastasis after initial treatment.  However, it mentions that TNBC has a tendency to metastasize after curative treatment [[1]] and that the median progression-free survival (PFS) with chemotherapy ranges from 1.7 to 3.7 months; the median overall survival (OS) from the onset of metastasis is 10 to 13 months [[3]].  The 5-year survival rate is also noted as ~65% for regional tumors and 11% for those with distant metastasis [[2]].  These statistics suggest a significant risk of recurrence and metastasis relatively soon after treatment, though the exact timing varies greatly.\n",
       "\n",
       "Sources:\n",
       "* [[1]]\n",
       "* [[2]]\n",
       "* [[3]]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.65)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.67)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.70)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The first step in the cascade of events for tumor cell elimination is the release of specific antigens by tumor cells.  These antigens are then captured and processed by antigen-presenting cells (APCs), mainly dendritic cells (DCs). [[1], [2], [4]]\n",
       "\n",
       "Sources:\n",
       "* [[1]]\n",
       "* [[2]]\n",
       "* [[4]]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.78)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.89)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.98)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Dendritic cells (DCs) capture and process tumor-released antigens. [[1], [2], [4]]  They then migrate to initiate further steps in tumor cell elimination. [[1], [2]]\n",
       "\n",
       "Sources:\n",
       "[[1]], [[2]], [[4]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.76)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.77)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.96)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "After activation, T cells transport to and infiltrate tumor tissues, then specifically recognize and kill tumor cells [[2]].\n",
       "\n",
       "Sources\n",
       "[[1]], [[2]], [[3]], [[4]], [[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.82)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.83)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.92)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.92)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 35) (similarity score: 0.94)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The review analyzes the modest clinical response of PD-(L)1 blockade monotherapy across the entire mTNBC population, noting more durable responses only in specific patients, such as PD-L1-positive patients receiving first-line treatment [[1]].  Specific data points from clinical trials such as KEYNOTE-012 and KEYNOTE-086 show low overall response rates (ORR), median progression-free survival (mPFS), and median overall survival (mOS) for PD-(L)1 monotherapy in advanced TNBC [[4]].  One trial showed a median PFS of 12.1 months with a hazard ratio of 0.37, but the p-value was not statistically significant (p=0.0678) [[1]].\n",
       " \n",
       "\n",
       "Sources:\n",
       "* [[1]]  (Unspecified source, likely a journal article)\n",
       "* [[4]] Cancers 2023, 15, 321 (Table 1)\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 25) (similarity score: 0.37)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 24) (similarity score: 0.60)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "To identify the target population for effective TNBC treatments, individual patient characteristics and prognostic factors need to be considered [[5]].  Further research is needed to determine the optimal adjuvant strategies post-chemo-immunotherapy [[5]].  Additionally, expanding access to immunotherapy for subgroups, such as those with low ER expression (ER 1–9%), which share biological similarities and prognosis with TNBC, is crucial [[4]].\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[4]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\n",
       "[[5]]  However, the current challenge lies in determining the optimal adjuvant strategy post-chemo-immunotherapy...\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[4]] ilovepdf_merged.pdf (Page 11) (similarity score: 0.76)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 11) (similarity score: 0.77)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The three main hormone receptors not expressed in triple-negative breast cancer (TNBC) are estrogen receptor (ER), progesterone receptor (PR), and HER2. [[2]]  This lack of expression is defined by ≤1% cellular expression of ER and PR by immunohistochemistry (IHC), and HER2 expression of 0 to 1+ by IHC, or 2+ by IHC and fluorescence in situ hybridization (FISH) negative. [[2]]\n",
       "\n",
       "\n",
       "Sources\n",
       "[[1]] De Santis P, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, et al.\n",
       "[[2]] De Santis P, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, et al.\n",
       "[[3]] De Santis P, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, et al.\n",
       "[[4]] De Santis P, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, et al.\n",
       "[[5]] De Santis P, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, et al.\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 2) (similarity score: 1.03)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 48) (similarity score: 1.08)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 59) (similarity score: 1.08)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 57) (similarity score: 1.10)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 1) (similarity score: 1.15)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Immunotherapy for TNBC can lead to immune-related patterns such as pseudoprogression (initial tumor size increase followed by a decrease, associated with immune cell infiltration, edema, or necrosis) [[4]], hyperprogression, or a mixed response [[4]].  While pseudoprogression has been reported in TNBC [[4]],  incidence rates from large samples are lacking [[4]].\n",
       "The provided text does not mention other negative effects.\n",
       "\n",
       "Sources:\n",
       "[[4]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[4]] ilovepdf_merged.pdf (Page 39) (similarity score: 0.77)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Pembrolizumab is FDA-approved in combination with chemotherapy as a neoadjuvant treatment for early-stage, high-risk triple-negative breast cancer (TNBC), and for continued use as a single agent in the adjuvant phase. [[1]]  It is also being studied in advanced TNBC settings. [[2], [5]]\n",
       "\n",
       "Sources:\n",
       "[[1]]\n",
       "[[2]]\n",
       "[[3]]\n",
       "[[4]]\n",
       "[[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 30) (similarity score: 0.50)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 23) (similarity score: 0.57)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 29) (similarity score: 0.58)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 30) (similarity score: 0.62)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 28) (similarity score: 0.65)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "After tumor cells release specific antigens, antigen-presenting cells (APCs), mainly dendritic cells (DCs), capture and process these antigens [[1], [2]].\n",
       "\n",
       "Sources:\n",
       "* [[1]]\n",
       "* [[2]]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.61)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.68)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The interaction between tumor cells and the tumor immune microenvironment (TIME) is described as \"cancer immunoediting,\" a three-stage process: elimination, equilibrium, and escape. [[1]]  The process involves tumor cells releasing antigens, which are processed by antigen-presenting cells (APCs) like dendritic cells. [[4]] These APCs then migrate to lymphoid tissue to present antigens to T cells, which infiltrate and kill tumor cells.  [[4], [2]]  However, tumors can evade immune responses through intrinsic signaling or microenvironmental mechanisms. [[2]]\n",
       "Sources:\n",
       "[[1]] Cancers 2023, 15, x 2 of 29\n",
       "[[2]] Cancers 2023, 15, 321 3 of 28\n",
       "[[4]] Cancers 2023, 15, 321 3 of 28\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.85)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 22) (similarity score: 1.04)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 21) (similarity score: 1.08)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "TNBC accounts for approximately 15-20% of all newly diagnosed breast cancers. [[1]]\n",
       "\n",
       "Sources:\n",
       "[[1]]  Text provided.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.46)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER) and progesterone receptor (PR)  at ≤1% cellular expression as determined by immunohistochemistry (IHC) [[4]].  HER2 expression is also absent, showing 0 to 1+ by IHC, or 2+ by IHC and fluorescence in situ hybridization (FISH) negative [[4]].\n",
       "Sources\n",
       "[[1]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\n",
       "[[2]]  Not explicitly cited but referenced in [[4]]\n",
       "[[3]] New biomarkers and frontiers in TNBC\n",
       "[[4]] Triple-negative breast cancer (TNBC) is characterized as \n",
       "[[5]] observation High-risk TNBC NA\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 3) (similarity score: 1.00)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 2) (similarity score: 1.02)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 9) (similarity score: 1.08)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 48) (similarity score: 1.08)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 24) (similarity score: 1.08)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "TNBC's response to chemotherapy is varied.  While neoadjuvant chemotherapy followed by surgery is a standard treatment for early-stage TNBC [[2]], responses are often short-lived, leading to rapid relapse [[2]].  Additionally,  the presence of tumor-infiltrating lymphocytes (TILs) correlates with a better response to neoadjuvant chemotherapy and improved survival in early-stage TNBC [[1]].  Recent progress integrates immune checkpoint inhibitors (ICIs) with chemotherapeutic agents, emphasizing escalating chemotherapy regimens for early TNBC [[3]].\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[1]]\n",
       "[[2]]\n",
       "[[3]]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.60)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.60)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 9) (similarity score: 0.65)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Based on the provided text, one TNBC subgroup showing recent advances with novel agents is the \"immune-desert\" phenotype (Cluster 1), characterized by poor immune cell permeation, high MYC amplification, and consequently, lower innate immune cell recruitment [[2]].  The text also mentions that integrating immune checkpoint inhibitors (ICIs) and novel agents has revolutionized treatment for early-stage TNBC [[1]], though it doesn't specify further subgroups within this category.  There's mention of clinical trials exploring immunotherapy for TNBC, both as monotherapy and in combination with other therapies [[3], [4], [5]], but no specific subgroup delineation within those trials.\n",
       "\n",
       "\n",
       "Sources:\n",
       "* [[1]] New biomarkers and frontiers in TNBC\n",
       "* [[2]] Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 234\n",
       "* [[3]] 3. The Landscape of Clinical Trials on TNBC Immunotherapy\n",
       "* [[4]] WON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES1250\n",
       "* [[5]] 1). As of March 2020, 399 ongoing studies for TNBC have been listed on ClinicalTrials.gov and select Phase III studies are listed in Table I.\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 9) (similarity score: 0.80)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.81)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.93)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 53) (similarity score: 0.98)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.98)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Based on the provided text, the standard of care for locally advanced or metastatic triple-negative breast cancer (TNBC) includes first-line treatment with atezolizumab plus ipatasertib plus paclitaxel or nab-paclitaxel (nab-P) [[1]].  There are also ongoing studies investigating other combinations, such as atezolizumab plus paclitaxel plus ipatasertib [[1]], and pembrolizumab plus carboplatin plus docetaxel [[2]].  For early-stage TNBC,  studies are exploring combinations of camrelizumab and chemotherapy versus placebo and chemotherapy [[2]].  Further information on neoadjuvant therapy includes the use of carboplatin/nab-paclitaxel +/- atezolizumab [[4]].\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[1]]  \n",
       "[[2]]\n",
       "[[3]]\n",
       "[[4]]\n",
       "[[5]]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 33) (similarity score: 0.95)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 27) (similarity score: 1.04)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 24) (similarity score: 1.06)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 51) (similarity score: 1.07)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 54) (similarity score: 1.08)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Breast cancer subtypes are classified according to their molecular profile, primarily based on the expression levels of estrogen receptor α (ERα), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/ERBB2) [[3]].  Triple-negative breast cancer (TNBC), a specific subtype, is defined by ≤1% cellular expression of ER and PR by immunohistochemistry (IHC), and HER2 expression of 0 to 1+ by IHC, or 2+ by IHC and fluorescence in situ hybridization (FISH) negative [[4]].  TNBC further comprises at least four distinct transcriptional subtypes: BL1, BL2, M, and LAR [[4]].  Traditional staging also considers tumor size, lymph node involvement, and metastasis [[3]].\n",
       "\n",
       "Sources:\n",
       "* [[3]]\n",
       "* [[4]]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[3]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.93)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.96)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "I don't have that information.  The provided text focuses on treatment trials and survival statistics for triple-negative breast cancer (TNBC) [[1, 2, 3, 4, 5]],  including its molecular subtypes [[3]] and response to various therapies, but doesn't describe how TNBC is characterized according to ASCO/CAP guidelines.\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[1]]  observation High-risk TNBC NA\n",
       "[[2]] SG PD-L1-negative mTNBC\n",
       "[[3]] TNBC is also subdivided into 6 different subgroups based on molecular heterogeneity\n",
       "[[4]] CT Operable-stage II-III TNBC NA\n",
       "[[5]] 54.9% − pCR rates: 45.3% vs. 30.3%\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 24) (similarity score: 0.93)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 32) (similarity score: 0.98)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 48) (similarity score: 1.02)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 27) (similarity score: 1.03)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 27) (similarity score: 1.06)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The four distinct transcriptional subtypes of TNBC are basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), and luminal androgen receptor (LAR). [[2]]  Note that other classifications exist, including six subtypes and classifications based on immune microenvironment. [[1], [4]]\n",
       "Sources\n",
       "[[1]]\n",
       "[[2]]\n",
       "[[3]]\n",
       "[[4]]\n",
       "[[5]]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.70)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.83)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.90)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.96)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 2) (similarity score: 1.01)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "TNBC represents approximately 15-20% of all newly diagnosed breast cancers. [[1]] [[5]]\n",
       "\n",
       "Sources:\n",
       "[[1]]\n",
       "[[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.40)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 2) (similarity score: 0.80)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The median overall survival (OS) for TNBC with current therapies is 10.2 months. [[1]]\n",
       "Sources:\n",
       "[[1]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 48) (similarity score: 0.49)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The provided text mentions several ongoing and completed trials investigating various treatment approaches for early-stage triple-negative breast cancer (TNBC), including combinations of chemotherapy with immunotherapy agents like pembrolizumab and durvalumab [[1], [4], [5]].  However, it does not explicitly state the current standard of care (SOC).  While studies show improved pathological complete remission (pCR) rates with immunotherapy combinations [[1], [5]],  the exact composition of the current SOC for newly diagnosed early TNBC is not specified.\n",
       "\n",
       "Sources:\n",
       "[[1]]:  Text excerpt describing clinical trials.\n",
       "[[4]]:  Text excerpt referencing a table of TNBC clinical trials.\n",
       "[[5]]:  Text excerpt discussing immunotherapy in early-stage TNBC.\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 27) (similarity score: 0.83)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 51) (similarity score: 0.88)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 29) (similarity score: 0.91)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Available therapies for patients with advanced TNBC include anti-metabolites capecitabine and gemcitabine, the non-taxane microtubule inhibitor eribulin, and DNA cross-linking platinums. [[1]]  There is also ongoing research into the combination of immune checkpoint inhibitors (ICIs) with small molecule inhibitors. [[4]]  Clinical trials are exploring immunotherapy, either as monotherapy or in combination with other therapies. [[3]]\n",
       "Sources:\n",
       "[[1]] WON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES1246\n",
       "[[3]] 3. The Landscape of Clinical Trials on TNBC Immunotherapy\n",
       "[[4]] Cancers 2023, 15, 321 16 of 28\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.62)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.75)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 35) (similarity score: 0.76)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Some studies suggest that TNBC has higher PD-L1 expression and tumor-infiltrating lymphocytes (TILs) compared to other breast cancer subtypes [[5]], making it a potentially more immunogenic subtype and more likely to benefit from immunotherapy.  However, clinical results show that only a small proportion of TNBC patients respond to immunotherapy [[2]].\n",
       "Sources:\n",
       "[[2]]:  Section on TNBC immunotherapy conclusions.\n",
       "[[5]]: Section on the rationale of immunotherapy and TIME in TNBC.\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[2]] ilovepdf_merged.pdf (Page 39) (similarity score: 0.50)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 21) (similarity score: 0.59)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "PD-L1 is overexpressed in TNBC compared to other breast cancer subtypes [[3]], and this overexpression can predict responsiveness to immunotherapy [[3]].  However, the predictive value of PD-L1 expression for the efficacy of PD-(L)1 inhibitors in TNBC is limited [[2]].  This is because PD-L1 expression is spatiotemporally variable, changing over time and across metastatic locations [[2]], and its predictive power is less strong in early-stage TNBC than in late-stage disease [[2]].  While some studies show a correlation between PD-L1 expression and response to PD-(L)1 inhibitors [[2]], the prognostic role of PD-L1 remains controversial [[3]].\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[2]]: Biomarkers for Predicting Immunological Response section\n",
       "[[3]]: Explor Target Antitumor Ther. 2024;5:232–50\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[2]] ilovepdf_merged.pdf (Page 37) (similarity score: 0.83)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 4) (similarity score: 0.91)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Atezolizumab (an anti-PD-L1 antibody) was approved by the FDA in combination with nab-paclitaxel as a first-line treatment for triple-negative breast cancer (TNBC). [[1], [5]]\n",
       "\n",
       "Sources\n",
       "[[1]] Cancers 2023, 15, 321 10 of 28\n",
       "[[5]]  Unnumbered text provided in the context.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 29) (similarity score: 0.61)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.73)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Atezolizumab was granted accelerated approval by the FDA in March 2019 for use in combination with nab-paclitaxel as a first-line treatment for late-stage triple-negative breast cancer (TNBC) patients. [[1]]\n",
       "Sources\n",
       "* [[1]]: Cancers 2023, 15, 321\n",
       "* [[2]]: 6/28/2024 NCT04148911\n",
       "* [[3]]:  Cancers 2023, 15, 321\n",
       "* [[4]]: Cancers 2023, 15, 321\n",
       "* [[5]]: ; White, S.; Marx, G.; Cheuk, R.; Grogan, M.; Farrell, M.; et al. A randomised phase II trial of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with atezolizumab in patients with advanced triple negative breast cancer (AZTEC trial). Cancer Res. 2022, 82, PD10–02. [CrossRef]\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 29) (similarity score: 0.65)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 53) (similarity score: 0.67)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 31) (similarity score: 0.73)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 25) (similarity score: 0.73)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 43) (similarity score: 0.76)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "41% of enrolled patients in the IMpassion130 trial showed PD-L1-positive expression. [[1]]\n",
       "\n",
       "Sources:\n",
       "[[1]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.49)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Pembrolizumab (an anti-PD-1 antibody) was approved in 2017 as a histology-agnostic immunotherapy for all microsatellite instability-high (MSI-H) and/or mismatch repair deficient (dMMR) tumors. [[1]]\n",
       "Sources\n",
       "[[1]]  In the pre‑specified second interim analysis (data cutoff January 2, 2019), the median OS was 25.0 vs. 18.0 months with chemotherapy. Overall, the combination was well-tolerated and immune -related adverse events (AEs) included rash, hypothyroidism, and pneumonitis (15). Another immunotherapy, pembrolizumab (anti -PD-1 antibody), was approved in 2017 as a histology agnostic immunotherapy in all microsatellite instability-high (MSI-H) and/or mismatch repair deficient (dMMR) tumors. This is the first FDA -approved cancer treatment based on a tumor biomarker without regard to the original location of the tumor.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.47)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "MSI-H is rare in breast cancer, occurring in less than 2% of cases. [[1]]\n",
       "\r\n",
       "Sources\r\n",
       "[[1]]  Unnumbered text within the provided context.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.77)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "BRCA1/2-deficient tumors, or those exhibiting \"BRCAness\" (a similar phenotype without BRCA1/2 mutations), are susceptible to PARP inhibitors [[1], [2]].  This susceptibility is due to the role of BRCA1/2 in DNA repair;  inhibition of PARP, another DNA repair pathway, leads to synthetic lethality in these deficient cells [[1], [2]].  Various PARP inhibitors have been studied in clinical trials for BRCA-mutated or BRCAness TNBC, showing effectiveness both alone and in combination with other therapies [[2], [5]].  The response rate to PARP inhibitors in combination with pembrolizumab is notably higher in patients with BRCA mutations [[5]].\n",
       "\n",
       "\n",
       "Sources:\n",
       "* [[1]]:  Text excerpt 1\n",
       "* [[2]]: Text excerpt 2\n",
       "* [[3]]: Text excerpt 3\n",
       "* [[4]]: Text excerpt 4\n",
       "* [[5]]: Text excerpt 5\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 3) (similarity score: 0.54)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 54) (similarity score: 0.56)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 43) (similarity score: 0.60)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 63) (similarity score: 0.69)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 55) (similarity score: 0.71)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The FDA approved olaparib and talazoparib in 2018 to treat advanced-stage HER2-negative breast cancer in individuals with BRCA1 or BRCA2 mutations. [[1]]\n",
       "Sources\n",
       "[[1]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.48)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Approximately 5% of breast cancer patients carry a germline BRCA mutation (gBRCAm). [[1]]\n",
       "\n",
       "Sources:\n",
       "[[1]]  Text provided.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.70)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "In the OlympiAD Phase III trial, olaparib was compared to a physician's choice of chemotherapy (capecitabine, vinorelbine, or eribulin). [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]]  Text provided.\n",
       "[[2]] Text provided.\n",
       "[[3]] Text provided.\n",
       "[[4]] Text provided.\n",
       "[[5]] Text provided.\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.94)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 49) (similarity score: 1.04)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 55) (similarity score: 1.05)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 61) (similarity score: 1.10)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 7) (similarity score: 1.17)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Olaparib showed a 42% increase in median PFS compared to the control group (7 vs. 4 months) in the OlympiAD trial. [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.96)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "In the EMBRACA Phase III trial, talazoparib was compared to gemcitabine or to a physician's choice of standard therapy. [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]]  Provided text.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.66)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "In the EMBRACA trial, talazoparib increased median progression-free survival (PFS) by 46% compared to the control group (8.6 months vs. 5.6 months). [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]]  Context information provided.\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.80)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The primary grade 3-4 adverse event (AE) associated with talazoparib was anemia. [[1]]\n",
       "\n",
       "Sources\n",
       "[[1]]  Uncited text from the provided context.\n",
       "[[2]] Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, et al : Talazoparib in patients with advanced breast cancer and a germ -line BRCA mutation. N Engl J Med 379: 753-763, 2018.\n",
       "[[3]] Uncited text from the provided context.\n",
       "[[4]] Uncited text from the provided context.\n",
       "[[5]] Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, et al: Neoadjuvant talazoparib for patients with oper -able breast cancer with a germline BRCA pathogenic variant. J Clin Oncol 38: 388-394, 2020.\n",
       "\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 1.01)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 61) (similarity score: 1.07)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 49) (similarity score: 1.24)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 32) (similarity score: 1.28)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 61) (similarity score: 1.31)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "Clinical studies exploring improved TNBC treatment have investigated immune checkpoint inhibitors (ICIs), specifically targeting PD-(L)1 [[2]],  in combination with nearly all available TNBC therapies [[2]].  These studies include monotherapy trials [[2]] and combinations with small molecule inhibitors [[3]].  Pembrolizumab, a PD-1 inhibitor, has been explored as single-agent therapy [[5]] and in first/second-line and beyond treatment settings [[5]].  Apatinib, used in combination with another drug, has also shown promise [[3]].  Durvalumab has been studied in early TNBC, though further research is needed to determine optimal duration and biomarkers [[4]].  The overall approach emphasizes escalating chemotherapeutic agents based on standard neoadjuvant regimens [[1]].\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[1]], [[2]], [[3]], [[4]], [[5]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 9) (similarity score: 0.56)\n",
       "- [[2]] ilovepdf_merged.pdf (Page 22) (similarity score: 0.65)\n",
       "- [[3]] ilovepdf_merged.pdf (Page 35) (similarity score: 0.67)\n",
       "- [[4]] ilovepdf_merged.pdf (Page 6) (similarity score: 0.68)\n",
       "- [[5]] ilovepdf_merged.pdf (Page 23) (similarity score: 0.68)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The median progression-free survival (PFS) with chemotherapy for TNBC ranges from 1.7 to 3.7 months [[1]],  while in clinical trials using single-agent taxane- or platinum-based chemotherapy, the median PFS is 4 to 6 months [[1]].\n",
       "\n",
       "\n",
       "Sources:\n",
       "[[1]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[1]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.55)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "The median overall survival (OS) from the onset of metastasis for triple-negative breast cancer (TNBC) is 10 to 13 months. [[2]]\n",
       "\n",
       "Sources:\n",
       "[[2]]\n",
       "\n",
       "\n",
       "## Sources\n",
       "- [[2]] ilovepdf_merged.pdf (Page 49) (similarity score: 0.84)\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Waiting 2.00 seconds before next question...\n",
      "Predicted answers saved to 'with_predictions.xlsx'\n"
     ]
    }
   ],
   "source": [
    "\n",
    "import pandas as pd\n",
    "import time\n",
    "import random\n",
    "\n",
    "\n",
    "# Extract questions\n",
    "questions = df['Question'].tolist()\n",
    "predicted_answers = []\n",
    "\n",
    "# Loop through each question\n",
    "for question in questions:\n",
    "    try:\n",
    "        # Use your FAISS-based retrieval + LLM answering function\n",
    "        predicted = ask_faiss(\n",
    "            question,\n",
    "            faiss_index,\n",
    "            texts,\n",
    "            metadatas,\n",
    "            embedding_model,\n",
    "            k=5\n",
    "        )\n",
    "        predicted_answers.append(predicted)\n",
    "    except Exception as e:\n",
    "        print(f\"Error generating answer for: {question} | Error: {e}\")\n",
    "        predicted_answers.append(\"Error generating answer\")\n",
    "\n",
    "    # Add delay between calls (2–4 seconds randomly)\n",
    "    delay = 2\n",
    "    print(f\"Waiting {delay:.2f} seconds before next question...\")\n",
    "    time.sleep(delay)\n",
    "\n",
    "# Add predictions to DataFrame\n",
    "df['Predicted_Answer'] = predicted_answers\n",
    "\n",
    "# Save to new Excel file\n",
    "df.to_excel(\"with_predictions.xlsx\", index=False)\n",
    "print(\"Predicted answers saved to 'with_predictions.xlsx'\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "0498de19-97b7-4610-8937-5a4c9a68b15e",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_new=pd.read_excel(\"with_predictions.xlsx\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "9900ff48-2c07-42fb-907d-8052ed12bb83",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Actual_Answer</th>\n",
       "      <th>Predicted_Answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>what defines triple negative breast cancer (tn...</td>\n",
       "      <td>lack of expression (&lt; 1%) of er, pgr, and her2.</td>\n",
       "      <td>Triple-negative breast cancer (TNBC) is define...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>what percentage of all breast cancers does tnb...</td>\n",
       "      <td>approximately 10-20%.</td>\n",
       "      <td>TNBC accounts for approximately 15-20% of all ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>what patient population is most commonly affec...</td>\n",
       "      <td>young, premenopausal women.</td>\n",
       "      <td>TNBC mainly affects young, premenopausal women...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>what kind of genetic alterations are associate...</td>\n",
       "      <td>brca 1/2 mutations.</td>\n",
       "      <td>Triple-negative breast cancer (TNBC) is associ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>how would you describe the biological behavior...</td>\n",
       "      <td>aggressive, higher grade, often lymph node inv...</td>\n",
       "      <td>Triple-negative breast cancer (TNBC) is a high...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>what was the effect of talazoparib on median p...</td>\n",
       "      <td>a 46% increase in median pfs.</td>\n",
       "      <td>In the EMBRACA trial, talazoparib increased me...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>what grade 3-4 aes were primarily associated w...</td>\n",
       "      <td>anemia.</td>\n",
       "      <td>The primary grade 3-4 adverse event (AE) assoc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>what agents have been explored in clinical stu...</td>\n",
       "      <td>immuno- and targeted therapies.</td>\n",
       "      <td>Clinical studies exploring improved TNBC treat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>what is the median progression-free survival (...</td>\n",
       "      <td>1.7 to 3.7 months.</td>\n",
       "      <td>The median progression-free survival (PFS) wit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>what is the median os from the onset of metast...</td>\n",
       "      <td>10 to 13 months.</td>\n",
       "      <td>The median overall survival (OS) from the onse...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>90 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                             Question  \\\n",
       "0   what defines triple negative breast cancer (tn...   \n",
       "1   what percentage of all breast cancers does tnb...   \n",
       "2   what patient population is most commonly affec...   \n",
       "3   what kind of genetic alterations are associate...   \n",
       "4   how would you describe the biological behavior...   \n",
       "..                                                ...   \n",
       "85  what was the effect of talazoparib on median p...   \n",
       "86  what grade 3-4 aes were primarily associated w...   \n",
       "87  what agents have been explored in clinical stu...   \n",
       "88  what is the median progression-free survival (...   \n",
       "89  what is the median os from the onset of metast...   \n",
       "\n",
       "                                        Actual_Answer  \\\n",
       "0     lack of expression (< 1%) of er, pgr, and her2.   \n",
       "1                               approximately 10-20%.   \n",
       "2                         young, premenopausal women.   \n",
       "3                                 brca 1/2 mutations.   \n",
       "4   aggressive, higher grade, often lymph node inv...   \n",
       "..                                                ...   \n",
       "85                      a 46% increase in median pfs.   \n",
       "86                                            anemia.   \n",
       "87                    immuno- and targeted therapies.   \n",
       "88                                 1.7 to 3.7 months.   \n",
       "89                                   10 to 13 months.   \n",
       "\n",
       "                                     Predicted_Answer  \n",
       "0   Triple-negative breast cancer (TNBC) is define...  \n",
       "1   TNBC accounts for approximately 15-20% of all ...  \n",
       "2   TNBC mainly affects young, premenopausal women...  \n",
       "3   Triple-negative breast cancer (TNBC) is associ...  \n",
       "4   Triple-negative breast cancer (TNBC) is a high...  \n",
       "..                                                ...  \n",
       "85  In the EMBRACA trial, talazoparib increased me...  \n",
       "86  The primary grade 3-4 adverse event (AE) assoc...  \n",
       "87  Clinical studies exploring improved TNBC treat...  \n",
       "88  The median progression-free survival (PFS) wit...  \n",
       "89  The median overall survival (OS) from the onse...  \n",
       "\n",
       "[90 rows x 3 columns]"
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_new"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "962edc4b-8098-4710-9e16-883214d663a1",
   "metadata": {},
   "source": [
    "# Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "id": "3bcb4076-b004-4528-a7b0-8918ca7e72de",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Evaluating 1/90\n",
      "Evaluating 2/90\n",
      "Evaluating 3/90\n",
      "Evaluating 4/90\n",
      "Evaluating 5/90\n",
      "Evaluating 6/90\n",
      "Evaluating 7/90\n",
      "Evaluating 8/90\n",
      "Evaluating 9/90\n",
      "Evaluating 10/90\n",
      "Evaluating 11/90\n",
      "Evaluating 12/90\n",
      "Evaluating 13/90\n",
      "Evaluating 14/90\n",
      "Evaluating 15/90\n",
      "Evaluating 16/90\n",
      "Evaluating 17/90\n",
      "Attempt 1/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 6\n",
      "}\n",
      "]\n",
      "Attempt 2/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 3\n",
      "}\n",
      "]\n",
      "Evaluating 18/90\n",
      "Evaluating 19/90\n",
      "Evaluating 20/90\n",
      "Evaluating 21/90\n",
      "Evaluating 22/90\n",
      "Evaluating 23/90\n",
      "Evaluating 24/90\n",
      "Evaluating 25/90\n",
      "Evaluating 26/90\n",
      "Evaluating 27/90\n",
      "Evaluating 28/90\n",
      "Evaluating 29/90\n",
      "Evaluating 30/90\n",
      "Evaluating 31/90\n",
      "Evaluating 32/90\n",
      "Evaluating 33/90\n",
      "Attempt 1/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 33\n",
      "}\n",
      "]\n",
      "Attempt 2/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 30\n",
      "}\n",
      "]\n",
      "Attempt 3/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 27\n",
      "}\n",
      "]\n",
      "Attempt 4/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 23\n",
      "}\n",
      "]\n",
      "Attempt 5/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 20\n",
      "}\n",
      "]\n",
      "Evaluating 34/90\n",
      "Attempt 1/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 15\n",
      "}\n",
      "]\n",
      "Attempt 2/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 12\n",
      "}\n",
      "]\n",
      "Attempt 3/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 9\n",
      "}\n",
      "]\n",
      "Attempt 4/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 5\n",
      "}\n",
      "]\n",
      "Attempt 5/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 2\n",
      "}\n",
      "]\n",
      "Evaluating 35/90\n",
      "Evaluating 36/90\n",
      "Evaluating 37/90\n",
      "Evaluating 38/90\n",
      "Evaluating 39/90\n",
      "Evaluating 40/90\n",
      "Evaluating 41/90\n",
      "Evaluating 42/90\n",
      "Evaluating 43/90\n",
      "Evaluating 44/90\n",
      "Evaluating 45/90\n",
      "Evaluating 46/90\n",
      "Evaluating 47/90\n",
      "Evaluating 48/90\n",
      "Evaluating 49/90\n",
      "Evaluating 50/90\n",
      "Evaluating 51/90\n",
      "Attempt 1/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 31\n",
      "}\n",
      "]\n",
      "Attempt 2/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 28\n",
      "}\n",
      "]\n",
      "Attempt 3/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 25\n",
      "}\n",
      "]\n",
      "Attempt 4/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 21\n",
      "}\n",
      "]\n",
      "Attempt 5/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 18\n",
      "}\n",
      "]\n",
      "Evaluating 52/90\n",
      "Evaluating 53/90\n",
      "Attempt 1/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 12\n",
      "}\n",
      "]\n",
      "Attempt 2/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 8\n",
      "}\n",
      "]\n",
      "Attempt 3/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 5\n",
      "}\n",
      "]\n",
      "Attempt 4/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 1\n",
      "}\n",
      "]\n",
      "Evaluating 54/90\n",
      "Evaluating 55/90\n",
      "Evaluating 56/90\n",
      "Evaluating 57/90\n",
      "Evaluating 58/90\n",
      "Evaluating 59/90\n",
      "Evaluating 60/90\n",
      "Evaluating 61/90\n",
      "Evaluating 62/90\n",
      "Evaluating 63/90\n",
      "Evaluating 64/90\n",
      "Evaluating 65/90\n",
      "Evaluating 66/90\n",
      "Evaluating 67/90\n",
      "Evaluating 68/90\n",
      "Evaluating 69/90\n",
      "Attempt 1/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 32\n",
      "}\n",
      "]\n",
      "Attempt 2/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 28\n",
      "}\n",
      "]\n",
      "Attempt 3/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 25\n",
      "}\n",
      "]\n",
      "Attempt 4/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 22\n",
      "}\n",
      "]\n",
      "Evaluating 70/90\n",
      "Attempt 1/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 17\n",
      "}\n",
      "]\n",
      "Attempt 2/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 13\n",
      "}\n",
      "]\n",
      "Attempt 3/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 10\n",
      "}\n",
      "]\n",
      "Attempt 4/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 6\n",
      "}\n",
      "]\n",
      "Attempt 5/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 3\n",
      "}\n",
      "]\n",
      "Evaluating 71/90\n",
      "Evaluating 72/90\n",
      "Evaluating 73/90\n",
      "Evaluating 74/90\n",
      "Evaluating 75/90\n",
      "Evaluating 76/90\n",
      "Evaluating 77/90\n",
      "Evaluating 78/90\n",
      "Evaluating 79/90\n",
      "Evaluating 80/90\n",
      "Evaluating 81/90\n",
      "Evaluating 82/90\n",
      "Evaluating 83/90\n",
      "Evaluating 84/90\n",
      "Evaluating 85/90\n",
      "Evaluating 86/90\n",
      "Evaluating 87/90\n",
      "Attempt 1/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 33\n",
      "}\n",
      "]\n",
      "Attempt 2/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 29\n",
      "}\n",
      "]\n",
      "Attempt 3/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 26\n",
      "}\n",
      "]\n",
      "Attempt 4/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 23\n",
      "}\n",
      "]\n",
      "Attempt 5/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 19\n",
      "}\n",
      "]\n",
      "Evaluating 88/90\n",
      "Attempt 1/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 15\n",
      "}\n",
      "]\n",
      "Attempt 2/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 11\n",
      "}\n",
      "]\n",
      "Attempt 3/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 8\n",
      "}\n",
      "]\n",
      "Attempt 4/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 5\n",
      "}\n",
      "]\n",
      "Attempt 5/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 1\n",
      "}\n",
      "]\n",
      "Evaluating 89/90\n",
      "Attempt 1/5 failed: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {\n",
      "}\n",
      ", links {\n",
      "  description: \"Learn more about Gemini API quotas\"\n",
      "  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n",
      "}\n",
      ", retry_delay {\n",
      "  seconds: 57\n",
      "}\n",
      "]\n",
      "Evaluating 90/90\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Some weights of RobertaModel were not initialized from the model checkpoint at roberta-large and are newly initialized: ['pooler.dense.bias', 'pooler.dense.weight']\n",
      "You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "calculating scores...\n",
      "computing bert embedding.\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "74f9f51933524a81890b7d36d6435621",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "  0%|          | 0/3 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "computing greedy matching.\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f2c7aaf9153a4ca2949f4e87896ae5c2",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "  0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "done in 302.01 seconds, 0.30 sentences/sec\n",
      "✅ Evaluation complete! Saved to qa_evaluation_with_gemini_and_bertscore.xlsx\n",
      "                                            Question  \\\n",
      "0  what defines triple negative breast cancer (tn...   \n",
      "1  what percentage of all breast cancers does tnb...   \n",
      "2  what patient population is most commonly affec...   \n",
      "3  what kind of genetic alterations are associate...   \n",
      "4  how would you describe the biological behavior...   \n",
      "\n",
      "                                       Actual_Answer  \\\n",
      "0    lack of expression (< 1%) of er, pgr, and her2.   \n",
      "1                              approximately 10-20%.   \n",
      "2                        young, premenopausal women.   \n",
      "3                                brca 1/2 mutations.   \n",
      "4  aggressive, higher grade, often lymph node inv...   \n",
      "\n",
      "                                    Predicted_Answer  Gemini_Correctness  \\\n",
      "0  triple-negative breast cancer (tnbc) is define...                  85   \n",
      "1  tnbc accounts for approximately 15-20% of all ...                  85   \n",
      "2  tnbc mainly affects young, premenopausal women...                  85   \n",
      "3  triple-negative breast cancer (tnbc) is associ...                  85   \n",
      "4  triple-negative breast cancer (tnbc) is a high...                  75   \n",
      "\n",
      "   BERT_Precision  BERT_Recall   BERT_F1  \n",
      "0        0.739961     0.846251  0.789545  \n",
      "1        0.775518     0.880787  0.824807  \n",
      "2        0.734041     0.906650  0.811266  \n",
      "3        0.738922     0.849000  0.790146  \n",
      "4        0.730522     0.833855  0.778776  \n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import time\n",
    "import numpy as np\n",
    "import google.generativeai as genai\n",
    "from bert_score import score\n",
    "\n",
    "# 1. Configure Gemini API\n",
    "genai.configure(api_key='AIzaSyDXG4o4UnII5VFD1u5TaWgleG2kCfJ0Ofw')  # Replace with your actual API key\n",
    "gemini_instance = genai.GenerativeModel('gemini-1.5-flash')  # or 'gemini-pro' if available\n",
    "\n",
    "# 2. Load your dataset\n",
    "df = pd.read_excel(\"with_predictions.xlsx\")  # Assumes predicted answers are added\n",
    "\n",
    "# 3. Normalize the text\n",
    "def normalize_text(text):\n",
    "    return ' '.join(str(text).strip().lower().split())\n",
    "\n",
    "df['Question'] = df['Question'].fillna('').apply(normalize_text)\n",
    "df['Actual_Answer'] = df['Actual_Answer'].fillna('').apply(normalize_text)\n",
    "df['Predicted_Answer'] = df['Predicted_Answer'].fillna('').apply(normalize_text)\n",
    "\n",
    "# 4. Gemini Evaluation Function\n",
    "def evaluate_with_gemini(question, predicted, actual):\n",
    "    prompt = f\"\"\"\n",
    "    You are an AI evaluator tasked with assessing the correctness of a predicted answer compared to the actual answer, given the question.\n",
    "    Score the predicted answer out of 90 based on semantic accuracy, factual correctness, and relevance to both the question and the actual answer.\n",
    "    Provide only a numeric score (0-90) as the response, nothing else.\n",
    "\n",
    "    Question: {question}\n",
    "    Actual Answer: {actual}\n",
    "    Predicted Answer: {predicted}\n",
    "    \"\"\"\n",
    "    max_attempts = 5\n",
    "    for attempt in range(max_attempts):\n",
    "        try:\n",
    "            response = gemini_instance.generate_content(prompt)\n",
    "            score = int(response.text.strip())\n",
    "            if 0 <= score <= 90:\n",
    "                return score\n",
    "        except Exception as e:\n",
    "            print(f\"Attempt {attempt+1}/{max_attempts} failed: {e}\")\n",
    "            time.sleep(3)  # Still retry after 3 seconds if Gemini fails\n",
    "    return 0\n",
    "\n",
    "# 5. Evaluate all entries with Gemini\n",
    "gemini_scores = []\n",
    "for idx, row in df.iterrows():\n",
    "    print(f\"Evaluating {idx+1}/{len(df)}\")\n",
    "    score_val = evaluate_with_gemini(row['Question'], row['Predicted_Answer'], row['Actual_Answer'])\n",
    "    gemini_scores.append(score_val)\n",
    "    time.sleep(1)  # Delay to prevent rate-limiting\n",
    "\n",
    "df['Gemini_Correctness'] = gemini_scores\n",
    "\n",
    "# 6. Compute BERTScore\n",
    "P, R, F1 = score(df['Predicted_Answer'].tolist(), df['Actual_Answer'].tolist(), lang=\"en\", model_type=\"roberta-large\", verbose=True)\n",
    "\n",
    "df['BERT_Precision'] = P.numpy()\n",
    "df['BERT_Recall'] = R.numpy()\n",
    "df['BERT_F1'] = F1.numpy()\n",
    "\n",
    "# 7. Save to Excel\n",
    "output_file = \"qa_evaluation_with_gemini_and_bertscore.xlsx\"\n",
    "df.to_excel(output_file, index=False)\n",
    "print(f\"✅ Evaluation complete! Saved to {output_file}\")\n",
    "\n",
    "# 8. Quick Preview\n",
    "print(df.head())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "073051fd-d3eb-451a-b50c-83da0a68d6f5",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0a2e5c83-8872-47a7-8d7a-8624e90ef214",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "a8ef66b4-9064-487e-ad65-5d4d38ab0c06",
   "metadata": {},
   "source": [
    "# Level 2: Recursive Character Text Splitting\n",
    "\n",
    "The problem with Level #1 is that we don't take into account the structure of our document at all. We simply split by a fix number of characters.\n",
    "\n",
    "The Recursive Character Text Splitter helps with this. With it, we'll specify a series of separatators which will be used to split our docs.\n",
    "\n",
    "You can see the default separators for LangChain here. Let's take a look at them one by one.\n",
    "\n",
    "\"\\n\\n\" - Double new line, or most commonly paragraph breaks\n",
    "\"\\n\" - New lines\n",
    "\" \" - Spaces\n",
    "\"\" - Characters\n",
    "I'm not sure why a period (\".\") isn't included on the list, perhaps it is not universal enough? If you know,"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "07f8d907-dfd1-4efb-9eae-965ea6fd5dbe",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "52ec56b7-545c-48e5-a8ca-8395b097f1d5",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "text_splitter = RecursiveCharacterTextSplitter(chunk_size = 65, chunk_overlap=0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "dc3c26a2-7824-4964-9357-f04428e3820d",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 232'),\n",
       " Document(metadata={}, page_content='© The Author(s) 2024. This is an Open Access article licensed'),\n",
       " Document(metadata={}, page_content='under a Creative Commons Attribution 4.0 International'),\n",
       " Document(metadata={}, page_content='License (https://creativecommons.org/licenses/by/4.0/), which'),\n",
       " Document(metadata={}, page_content='permits unrestricted use, sharing, adaptation, distribution'),\n",
       " Document(metadata={}, page_content='and reproduction in any medium or format, for any purpose, even'),\n",
       " Document(metadata={}, page_content='commercially, as long as you give appropriate credit to the'),\n",
       " Document(metadata={}, page_content='original author(s) and the source, provide a link to the'),\n",
       " Document(metadata={}, page_content='Creative Commons license, and indicate if changes were made.'),\n",
       " Document(metadata={}, page_content='Exploration of Targeted Anti-tumor Therapy\\nOpen Access\\nReview'),\n",
       " Document(metadata={}, page_content='Early-stage triple negative breast cancer: the therapeutic role'),\n",
       " Document(metadata={}, page_content='of'),\n",
       " Document(metadata={}, page_content='immunotherapy and the prognostic value of pathological complete'),\n",
       " Document(metadata={}, page_content='response'),\n",
       " Document(metadata={}, page_content='Pierluigi De Santis1, Martina Perrone1, Chiara Guarini1, Anna'),\n",
       " Document(metadata={}, page_content='Natalizia Santoro1, Carmelo Laface1,'),\n",
       " Document(metadata={}, page_content='Daniela Carrozzo1, Gaia Rachele Oliva2, Palma Fedele1*'),\n",
       " Document(metadata={}, page_content='1Oncology Unit, Francavilla Fontana Ceglie Messapica Hospital'),\n",
       " Document(metadata={}, page_content='District, 72021 Francavilla Fontana, Italy'),\n",
       " Document(metadata={}, page_content='2Department of Medicine and Translational Surgery, Università'),\n",
       " Document(metadata={}, page_content='Cattolica del Sacro Cuore, 00168 Roma, Italy'),\n",
       " Document(metadata={}, page_content='*Correspondence: Palma Fedele, Oncology Unit, Francavilla'),\n",
       " Document(metadata={}, page_content='Fontana Ceglie Messapica Hospital District, 72021 Francavilla'),\n",
       " Document(metadata={}, page_content='Fontana, Italy. minafedele@hotmail.com'),\n",
       " Document(metadata={}, page_content='Academic Editor: Laura Cerchia, Institute of Experimental'),\n",
       " Document(metadata={}, page_content='Endocrinology and Oncology “G. Salvatore”-National Research'),\n",
       " Document(metadata={}, page_content='Council (IEOS-CNR), Italy; Simona Camorani, Institute of'),\n",
       " Document(metadata={}, page_content='Experimental Endocrinology and Oncology “G. Salvatore”-National'),\n",
       " Document(metadata={}, page_content='Research Council (IEOS-CNR), Italy'),\n",
       " Document(metadata={}, page_content='Received: May 26, 2023  Accepted: December 26, 2023  Published:'),\n",
       " Document(metadata={}, page_content='February 28, 2024'),\n",
       " Document(metadata={}, page_content='Cite this article: De Santis P, Perrone M, Guarini C, Santoro'),\n",
       " Document(metadata={}, page_content='AN, Laface C, Carrozzo D, et al. Early-stage triple negative'),\n",
       " Document(metadata={}, page_content='breast'),\n",
       " Document(metadata={}, page_content='cancer: the therapeutic role of immunotherapy and the prognostic'),\n",
       " Document(metadata={}, page_content='value of pathological complete response. Explor Target'),\n",
       " Document(metadata={}, page_content='Antitumor Ther. 2024;5:232–50.'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Abstract'),\n",
       " Document(metadata={}, page_content='Triple negative breast cancer (TNBC) represents an aggressive'),\n",
       " Document(metadata={}, page_content='disease associated with a high risk of'),\n",
       " Document(metadata={}, page_content='recurrence after curative treatment and a poor prognosis in the'),\n",
       " Document(metadata={}, page_content='metastatic setting. Chemotherapy was for'),\n",
       " Document(metadata={}, page_content='years the only treatment available in the early and metastatic'),\n",
       " Document(metadata={}, page_content='setting, due to the lack of actionable targets.'),\n",
       " Document(metadata={}, page_content='Clinical practice has changed following the results obtained'),\n",
       " Document(metadata={}, page_content='with the addition of immunotherapy to'),\n",
       " Document(metadata={}, page_content='standard chemotherapy, the development of novel drugs [i.e.'),\n",
       " Document(metadata={}, page_content='antibody-drug conjugates (ADCs)], and the'),\n",
       " Document(metadata={}, page_content='use of targeted treatments for patients carrying germline'),\n",
       " Document(metadata={}, page_content='pathogenic breast cancer susceptibility genes'),\n",
       " Document(metadata={}, page_content='(BRCA) 1 or BRCA 2 variants. The treatment of early-stage'),\n",
       " Document(metadata={}, page_content='disease has had a shift in clinical practice since'),\n",
       " Document(metadata={}, page_content='July 2021, after the Food and Drug Administration (FDA) approval'),\n",
       " Document(metadata={}, page_content='of pembrolizumab in association with'),\n",
       " Document(metadata={}, page_content='chemotherapy as neoadjuvant treatment for TNBC and as a single'),\n",
       " Document(metadata={}, page_content='agent in the subsequent adjuvant setting.'),\n",
       " Document(metadata={}, page_content='This intensive treatment based on the combination of a'),\n",
       " Document(metadata={}, page_content='poly-chemotherapy and an immune checkpoint'),\n",
       " Document(metadata={}, page_content='inhibitor (ICI) led to the improvement of short- and long-term'),\n",
       " Document(metadata={}, page_content='outcomes, but it has highlighted some new'),\n",
       " Document(metadata={}, page_content='unmet clinical needs in the treatment of early-stage TNBC: the'),\n",
       " Document(metadata={}, page_content='selection of the most effective adjuvant'),\n",
       " Document(metadata={}, page_content='therapy and the integration of pembrolizumab with other'),\n",
       " Document(metadata={}, page_content='therapeutic strategies [capecitabine, poly(ADP-'),\n",
       " Document(metadata={}, page_content='ribose) polymerase (PARP) inhibitors] based on the achievement'),\n",
       " Document(metadata={}, page_content='of pathologic complete response (pCR);'),\n",
       " Document(metadata={}, page_content='the identification of predictive biomarkers to select patients'),\n",
       " Document(metadata={}, page_content='who could most benefit from the addition of'),\n",
       " Document(metadata={}, page_content='ICI, to minimize toxicities and to maximize outcomes; the'),\n",
       " Document(metadata={}, page_content='possibility of de-escalating chemotherapy in favor'),\n",
       " Document(metadata={}, page_content='of immune-combo or novel agents, such as ADCs; the role of'),\n",
       " Document(metadata={}, page_content='immunotherapy in estrogen receptor (ER)-low'),\n",
       " Document(metadata={}, page_content='patients. The advent of immunotherapy not only addresses current'),\n",
       " Document(metadata={}, page_content='challenges in TNBC treatment but also'),\n",
       " Document(metadata={}, page_content='holds the promise of a radical transformation in its therapeutic'),\n",
       " Document(metadata={}, page_content='paradigm, enhancing significantly clinical'),\n",
       " Document(metadata={}, page_content='outcomes and offering new perspectives for patients grappling'),\n",
       " Document(metadata={}, page_content='with this aggressive form of breast cancer.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 233\\nKeywords'),\n",
       " Document(metadata={}, page_content='Triple negative breast cancer, immunotherapy, pathological'),\n",
       " Document(metadata={}, page_content='complete response, neoadjuvant combination'),\n",
       " Document(metadata={}, page_content='treatment, adjuvant treatment\\nIntroduction'),\n",
       " Document(metadata={}, page_content='Triple negative Breast Cancer (TNBC) is a histological subtype'),\n",
       " Document(metadata={}, page_content='of breast cancer (BC) characterized by the'),\n",
       " Document(metadata={}, page_content='immunohistochemical lack of expression (< 1%) of estrogen'),\n",
       " Document(metadata={}, page_content='receptor (ER), progesterone receptor (PgR),'),\n",
       " Document(metadata={}, page_content='and human epidermal growth factor receptor 2 (HER2). It accounts'),\n",
       " Document(metadata={}, page_content='for approximately 10–20% of all BC,'),\n",
       " Document(metadata={}, page_content='affecting mainly young, premenopausal women, and individuals'),\n",
       " Document(metadata={}, page_content='with inherited gene alterations, such as BC'),\n",
       " Document(metadata={}, page_content='susceptibility genes 1/2 (BRCA 1/2) mutations [1–3]. It notably'),\n",
       " Document(metadata={}, page_content='presents an aggressive biological behavior'),\n",
       " Document(metadata={}, page_content='with a trend to have a higher grade and an often lymph node'),\n",
       " Document(metadata={}, page_content='involvement at diagnosis, an inclination to'),\n",
       " Document(metadata={}, page_content='metastasize after curative treatment, and a poorer prognosis in'),\n",
       " Document(metadata={}, page_content='metastatic setting when compared with'),\n",
       " Document(metadata={}, page_content='other BC subtypes [4, 5].'),\n",
       " Document(metadata={}, page_content='For decades, treatment for early TNBC has been based on surgery'),\n",
       " Document(metadata={}, page_content='and subsequent adjuvant'),\n",
       " Document(metadata={}, page_content='chemotherapy (CHT) for the reduction of disease recurrence [6].'),\n",
       " Document(metadata={}, page_content='Therefore, conventional cytotoxic CHT has'),\n",
       " Document(metadata={}, page_content='represented the backbone of systemic treatment in the early'),\n",
       " Document(metadata={}, page_content='TNBC, including neoadjuvant treatment, which'),\n",
       " Document(metadata={}, page_content='used to reduce tumor size in larger tumors increasing the'),\n",
       " Document(metadata={}, page_content='chances of a breast-conserving surgery [7, 8]. In'),\n",
       " Document(metadata={}, page_content='recent years the development of novel therapeutic approaches has'),\n",
       " Document(metadata={}, page_content='been difficult, due to the heterogeneity'),\n",
       " Document(metadata={}, page_content='of TNBC and lack of therapeutic targets [9, 10]. Nevertheless,'),\n",
       " Document(metadata={}, page_content='immunotherapy and poly(ADP-ribose)'),\n",
       " Document(metadata={}, page_content='polymerase (PARP) inhibitors have shown survival benefits in'),\n",
       " Document(metadata={}, page_content='recent studies.'),\n",
       " Document(metadata={}, page_content='Specifically, combinations of immune checkpoint inhibitors'),\n",
       " Document(metadata={}, page_content='(ICIs) with CHT or other alternative'),\n",
       " Document(metadata={}, page_content='therapeutic compounds could emerge as a successful therapeutic'),\n",
       " Document(metadata={}, page_content='approach in the management of TNBC'),\n",
       " Document(metadata={}, page_content='patients. Despite the progress in ICIs representing a notable'),\n",
       " Document(metadata={}, page_content='milestone in TNBC treatment, additional'),\n",
       " Document(metadata={}, page_content='investigations are necessary to tackle this issue'),\n",
       " Document(metadata={}, page_content='comprehensively. A profound comprehension of tumor'),\n",
       " Document(metadata={}, page_content='subtypes, alongside tumor microenvironment (TME) and in terms of'),\n",
       " Document(metadata={}, page_content='molecular, genetic, and immune'),\n",
       " Document(metadata={}, page_content='aspects, would amplify the potential for developing targeted'),\n",
       " Document(metadata={}, page_content='immunotherapy to achieve superior'),\n",
       " Document(metadata={}, page_content='therapeutic effectiveness, especially in TNBC [11].'),\n",
       " Document(metadata={}, page_content='Therefore, in this review, we aimed to investigate the role of'),\n",
       " Document(metadata={}, page_content='immunotherapy in early-stage TNBC, the'),\n",
       " Document(metadata={}, page_content='prognostic value of pathologic complete response (pCR) with its'),\n",
       " Document(metadata={}, page_content='therapeutic implications, and the future'),\n",
       " Document(metadata={}, page_content='perspectives regarding the systemic treatment of early TNBC,'),\n",
       " Document(metadata={}, page_content='including the discovery of new biomarkers.'),\n",
       " Document(metadata={}, page_content='The landscape of immunotherapy in TNBC'),\n",
       " Document(metadata={}, page_content='The immune system plays a crucial role in TNBC compared to the'),\n",
       " Document(metadata={}, page_content='other molecular subtypes of BC. Although'),\n",
       " Document(metadata={}, page_content='originally BC was considered non-immunogenic, TNBC has a high'),\n",
       " Document(metadata={}, page_content='immunogenic potential, making it a'),\n",
       " Document(metadata={}, page_content='promising candidate for immunotherapy, especially with ICIs [12,'),\n",
       " Document(metadata={}, page_content='13]. TNBC immunogenicity is related to'),\n",
       " Document(metadata={}, page_content='intrinsic tumor cell signatures and tumoral surrounding'),\n",
       " Document(metadata={}, page_content='microenvironment features.'),\n",
       " Document(metadata={}, page_content='Over the last decades thanks to emerging technologies such as'),\n",
       " Document(metadata={}, page_content='next-generation sequencing (NGS), the'),\n",
       " Document(metadata={}, page_content='knowledge of the molecular and genetic background of TNBC'),\n",
       " Document(metadata={}, page_content='improved, bringing to light its intertumoral'),\n",
       " Document(metadata={}, page_content='and intratumoral heterogeneity.'),\n",
       " Document(metadata={}, page_content='A first classification divided TNBC into six subtypes:'),\n",
       " Document(metadata={}, page_content='basal-like 1 (BL1), basal-like 2 (BL2),'),\n",
       " Document(metadata={}, page_content='mesenchymal (M), M stem-like (MSL), immunomodulatory (IM), and'),\n",
       " Document(metadata={}, page_content='luminal androgen receptor (LAR) [14].'),\n",
       " Document(metadata={}, page_content='Subsequently, analyzing RNA and DNA-based profiles of 198 TNBC'),\n",
       " Document(metadata={}, page_content='tumors, a four-type classification of'),\n",
       " Document(metadata={}, page_content='TNBC was shaped: basal-like immunosuppressed (BLIS), basal-like'),\n",
       " Document(metadata={}, page_content='immune-activated (BLIA), M and LAR'),\n",
       " Document(metadata={}, page_content='[15]. This classification was further revised with the'),\n",
       " Document(metadata={}, page_content='identification of four specific TNBC subtypes: BL1, BL2,'),\n",
       " Document(metadata={}, page_content='M, and LAR, omitting IM and MSL because of the dependence of'),\n",
       " Document(metadata={}, page_content='these two subtypes on the TME features'),\n",
       " Document(metadata={}, page_content='[14].'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 234'),\n",
       " Document(metadata={}, page_content='In addition, TNBC could be classified into three'),\n",
       " Document(metadata={}, page_content='microenvironment phenotypes or clusters:'),\n",
       " Document(metadata={}, page_content='Cluster 1: “immune-desert” with poor immune cell permeation, due'),\n",
       " Document(metadata={}, page_content='to a high presence of MYC'),\n",
       " Document(metadata={}, page_content='amplifications and, consequently, a lower recruitment of innate'),\n",
       " Document(metadata={}, page_content='immune cells.'),\n",
       " Document(metadata={}, page_content='(1).'),\n",
       " Document(metadata={}, page_content='Cluster 2: “innate immune-inactivated” characterized by a'),\n",
       " Document(metadata={}, page_content='hyper-activation of'),\n",
       " Document(metadata={}, page_content='phosphatidylinositide 3-kinase/protein kinase B (PI3K-AKT)'),\n",
       " Document(metadata={}, page_content='pathway in tumor cells, low tumor'),\n",
       " Document(metadata={}, page_content='antigen burden and infiltration of deactivated innate immune'),\n",
       " Document(metadata={}, page_content='cells, fibroblasts, and endothelial'),\n",
       " Document(metadata={}, page_content='cells. Clusters 1 and 2 are therefore referred to as “cold'),\n",
       " Document(metadata={}, page_content='tumors”.'),\n",
       " Document(metadata={}, page_content='(2).'),\n",
       " Document(metadata={}, page_content='Cluster 3: “immune-inflamed”, the so-called “hot tumor” that'),\n",
       " Document(metadata={}, page_content='represents about 30% of TNBCs and'),\n",
       " Document(metadata={}, page_content='is characterized by an abundant adaptive and innate immune cells'),\n",
       " Document(metadata={}, page_content='infiltration and with a high'),\n",
       " Document(metadata={}, page_content='expression of immune checkpoint molecules [16].\\n(3).'),\n",
       " Document(metadata={}, page_content='The potential “hot” conversion of “cold” tumors could improve'),\n",
       " Document(metadata={}, page_content='the efficacy of cancer immunotherapy.'),\n",
       " Document(metadata={}, page_content='For example, local IM therapies can express a synergistic effect'),\n",
       " Document(metadata={}, page_content='with immunotherapy by acting on'),\n",
       " Document(metadata={}, page_content='components of the TME and immune system function, such as'),\n",
       " Document(metadata={}, page_content='elevating the expression of tumor antigens'),\n",
       " Document(metadata={}, page_content='and increasing the recruitment of activated immune cells in the'),\n",
       " Document(metadata={}, page_content='TME [17].'),\n",
       " Document(metadata={}, page_content='TNBC cancer cell immunological features include genomic'),\n",
       " Document(metadata={}, page_content='instability and high tumor mutational'),\n",
       " Document(metadata={}, page_content='burden (TMB), resulting in more somatic mutations and'),\n",
       " Document(metadata={}, page_content='neoantigens [18].'),\n",
       " Document(metadata={}, page_content='Moreover, approximately 10–20% of TNBC harbor BRCA 1 or BRCA 2'),\n",
       " Document(metadata={}, page_content='germinal mutations, with a'),\n",
       " Document(metadata={}, page_content='consequent hereditary deficit in the DNA repair mechanism and'),\n",
       " Document(metadata={}, page_content='strong genomic instability. Several studies'),\n",
       " Document(metadata={}, page_content='have demonstrated that TNBC-carrying BRCA mutations are more'),\n",
       " Document(metadata={}, page_content='sensitive to DNA-damaging drugs such as'),\n",
       " Document(metadata={}, page_content='anthracyclines, but also platinum agents and PARP inhibitors'),\n",
       " Document(metadata={}, page_content='[19–21]. Sensitivity to these drugs was also'),\n",
       " Document(metadata={}, page_content='observed in tumors with alterations in other genes, sharing'),\n",
       " Document(metadata={}, page_content='BRCA-mutant phenotype in the absence of a'),\n",
       " Document(metadata={}, page_content='BRCA 1/2 mutation, namely “BRCAness” [22, 23].'),\n",
       " Document(metadata={}, page_content='Tumors with BRCA 1/2 mutations or BRCAness TNBC are more'),\n",
       " Document(metadata={}, page_content='immunogenic than TNBC without these'),\n",
       " Document(metadata={}, page_content='genetic alterations [24–26].'),\n",
       " Document(metadata={}, page_content='Compared to the other BC subtypes the immunogenic TME features'),\n",
       " Document(metadata={}, page_content='in TNBC consist of higher levels of'),\n",
       " Document(metadata={}, page_content='vascular endothelial growth factor (VEGF), that promote tumor'),\n",
       " Document(metadata={}, page_content='cell growth and migration such as mitogen-'),\n",
       " Document(metadata={}, page_content='activated protein kinases (MAPKs), tumor-associated macrophages'),\n",
       " Document(metadata={}, page_content='(TAMs), and tumor-infiltrating'),\n",
       " Document(metadata={}, page_content='lymphocytes (TILs), white blood cells that migrate towards the'),\n",
       " Document(metadata={}, page_content='tumor, leading to an important'),\n",
       " Document(metadata={}, page_content='immunogenic effect and consequently that are involved in killing'),\n",
       " Document(metadata={}, page_content='cancer cells [27–29].'),\n",
       " Document(metadata={}, page_content='TAMs regulate the interaction between the immune system and'),\n",
       " Document(metadata={}, page_content='cancer cells. CD163+ M2 macrophages,'),\n",
       " Document(metadata={}, page_content='which are associated with tumors characterized by higher'),\n",
       " Document(metadata={}, page_content='proliferation and poorer differentiation [30], are'),\n",
       " Document(metadata={}, page_content='more present in TNBC and basal-like BC [31]. A prosperous'),\n",
       " Document(metadata={}, page_content='infiltration of TILs is found in TNBC tumors and'),\n",
       " Document(metadata={}, page_content='the stroma surrounding them, with a recognized predictive and'),\n",
       " Document(metadata={}, page_content='prognostic role, specifically for CD4+ CD8+'),\n",
       " Document(metadata={}, page_content='T cells [32]. Several studies have reported better response to'),\n",
       " Document(metadata={}, page_content='neoadjuvant CHT (NACT) [33] and better'),\n",
       " Document(metadata={}, page_content='clinical outcomes in BC with high TIL infiltrate [34–39]. Based'),\n",
       " Document(metadata={}, page_content='on this evidence, the international TILs'),\n",
       " Document(metadata={}, page_content='working group started standardizing the evaluation of BC TILs to'),\n",
       " Document(metadata={}, page_content='use it in clinical practice identifying those'),\n",
       " Document(metadata={}, page_content='patients that may benefit from emerging immunotherapies with'),\n",
       " Document(metadata={}, page_content='ICIs or combination therapies [40].'),\n",
       " Document(metadata={}, page_content='All these TME elements contribute to TNBC immunogenicity which'),\n",
       " Document(metadata={}, page_content='also appears to be closely related to'),\n",
       " Document(metadata={}, page_content='the concept of TMB, depending on the ineffective DNA repair'),\n",
       " Document(metadata={}, page_content='system with the consequent generation of'),\n",
       " Document(metadata={}, page_content='high rates of neoantigens. The upregulated antigen presentation'),\n",
       " Document(metadata={}, page_content='system leads to an increasing number of'),\n",
       " Document(metadata={}, page_content='innate and adaptative immune cells and many cytokines'),\n",
       " Document(metadata={}, page_content='interplaying with cancer cells. However, the exact'),\n",
       " Document(metadata={}, page_content='relationship between TMB, neoantigens, and immune infiltration'),\n",
       " Document(metadata={}, page_content='is not yet completely understood, and'),\n",
       " Document(metadata={}, page_content='some studies have reported an inverse association between immune'),\n",
       " Document(metadata={}, page_content='cells in TME and the rate of somatic'),\n",
       " Document(metadata={}, page_content='copy number alterations [41, 42].'),\n",
       " Document(metadata={}, page_content='Moreover, although TMB is comparable across the three clusters'),\n",
       " Document(metadata={}, page_content='of TNBC, the “immune-inflated”'),\n",
       " Document(metadata={}, page_content='phenotype is characterized by a higher degree of immune cells in'),\n",
       " Document(metadata={}, page_content='the TME, but also a high expression of'),\n",
       " Document(metadata={}, page_content='immune checkpoints by cancer cells [16]. The rate of TILs,'),\n",
       " Document(metadata={}, page_content='indeed, has been positively related to'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 235'),\n",
       " Document(metadata={}, page_content='programmed death ligand 1 (PD-L1) expression [43]. PD-L1 is an'),\n",
       " Document(metadata={}, page_content='immune checkpoint that mediates local'),\n",
       " Document(metadata={}, page_content='immune escape in many tumors inducing saturation of activated T'),\n",
       " Document(metadata={}, page_content='cells. Even if PD-L1 prognostic role is yet'),\n",
       " Document(metadata={}, page_content='controversial [44], however it results more overexpressed in'),\n",
       " Document(metadata={}, page_content='TNBC compared with other BC and it can'),\n",
       " Document(metadata={}, page_content='predict responsiveness to immunotherapy [16].'),\n",
       " Document(metadata={}, page_content='Therefore, TNBC represents an aggressive BC subtype, associated'),\n",
       " Document(metadata={}, page_content='with high mutational load, high'),\n",
       " Document(metadata={}, page_content='tumor immunogenicity and TME diversity.'),\n",
       " Document(metadata={}, page_content='New paradigms in early TNBC: from CHT to immunotherapy'),\n",
       " Document(metadata={}, page_content='CHT in adjuvant treatment for TNBC'),\n",
       " Document(metadata={}, page_content='In early TNBC patients, CHT represents the mainstay of adjuvant'),\n",
       " Document(metadata={}, page_content='and neoadjuvant treatments. Adjuvant'),\n",
       " Document(metadata={}, page_content='CHT is recommended for tumor sizes greater than 1.0 cm and'),\n",
       " Document(metadata={}, page_content='patients with nodal involvement, regardless'),\n",
       " Document(metadata={}, page_content='of tumor size. Therefore, it can be considered for tumor sizes'),\n",
       " Document(metadata={}, page_content='between 0.6–1.0 cm [45]. A recent large meta-'),\n",
       " Document(metadata={}, page_content='analysis demonstrated that adjuvant CHT with'),\n",
       " Document(metadata={}, page_content='anthracyclines-containing regimens plus taxanes, compared'),\n",
       " Document(metadata={}, page_content='with no CHT, can reduce BC mortality rates by about 40% during'),\n",
       " Document(metadata={}, page_content='the first decade after diagnosis. Moreover,'),\n",
       " Document(metadata={}, page_content='regimens with higher cumulative and dose-dense schedules of'),\n",
       " Document(metadata={}, page_content='anthracycline (with granulocyte colony-'),\n",
       " Document(metadata={}, page_content='stimulating factor support) have shown better survival benefits'),\n",
       " Document(metadata={}, page_content='and more reductions in recurrence [46].'),\n",
       " Document(metadata={}, page_content='Three-weekly docetaxel and paclitaxel can be considered in'),\n",
       " Document(metadata={}, page_content='adjuvant setting, but weekly paclitaxel, in a'),\n",
       " Document(metadata={}, page_content='subgroup analysis, has shown improved outcomes and is preferred'),\n",
       " Document(metadata={}, page_content='for TNBC [47]. In TNBC in frail patients'),\n",
       " Document(metadata={}, page_content='with a known history of heart disease, to minimize the'),\n",
       " Document(metadata={}, page_content='cardiotoxicity of adjuvant treatments, docetaxel'),\n",
       " Document(metadata={}, page_content='combined with cyclophosphamide (TC) has proven to be a viable'),\n",
       " Document(metadata={}, page_content='alternative to doxorubicin and'),\n",
       " Document(metadata={}, page_content='cyclophosphamide (AC), demonstrating a favorable disease-free'),\n",
       " Document(metadata={}, page_content='survival (DFS) [48]. Therefore, there is a'),\n",
       " Document(metadata={}, page_content='broad spectrum of chemotherapeutic treatments for early TNBC'),\n",
       " Document(metadata={}, page_content='that should be customised according to the'),\n",
       " Document(metadata={}, page_content='patient and expected toxicities.'),\n",
       " Document(metadata={}, page_content='The role of platinum in adjuvant setting for TNBC'),\n",
       " Document(metadata={}, page_content='TNBC patients commonly harbor BRCA 1/2 or BRCAness mutations'),\n",
       " Document(metadata={}, page_content='with a homologous recombination'),\n",
       " Document(metadata={}, page_content='deficiency (HRD) that makes them particularly susceptible to'),\n",
       " Document(metadata={}, page_content='platinum agents due to their ability to hit'),\n",
       " Document(metadata={}, page_content='cancer cells that have deficient DNA repair mechanisms [49–51].'),\n",
       " Document(metadata={}, page_content='Several retrospective single-center studies'),\n",
       " Document(metadata={}, page_content='have explored the role of adjuvant platinum combined with'),\n",
       " Document(metadata={}, page_content='standard anthracycline and taxane-based'),\n",
       " Document(metadata={}, page_content='regimens, with controversial results not showing clear clinical'),\n",
       " Document(metadata={}, page_content='benefits [52, 53]. Nevertheless, a recent'),\n",
       " Document(metadata={}, page_content='phase III trials have demonstrated a longer 5-year DFS (86.5%'),\n",
       " Document(metadata={}, page_content='vs. 80.3%) with similar results in distant DFS'),\n",
       " Document(metadata={}, page_content='and relapse-free survival (RFS) of platinum-containing adjuvant'),\n",
       " Document(metadata={}, page_content='regimens (paclitaxel-carboplatin)'),\n",
       " Document(metadata={}, page_content='compared to a standard anthracyclines-containing regimen'),\n",
       " Document(metadata={}, page_content='followed by taxane, however with no benefit in'),\n",
       " Document(metadata={}, page_content='overall survival (OS) [54].'),\n",
       " Document(metadata={}, page_content='Another important factor is platinum resistance. Platinum'),\n",
       " Document(metadata={}, page_content='sensitivity may be affected by changes in the'),\n",
       " Document(metadata={}, page_content='hazard ratio (HR) pathway or, in the case of patients with BRCA'),\n",
       " Document(metadata={}, page_content='1/2 mutations, by the secondary'),\n",
       " Document(metadata={}, page_content='appearance of new BRCA 1 or 2 mutations that make cancer cells'),\n",
       " Document(metadata={}, page_content='less sensitive to platinum [55, 56].'),\n",
       " Document(metadata={}, page_content='Other mechanisms of resistance to platinum compounds are:'),\n",
       " Document(metadata={}, page_content='Modification of drug transport within the tumor cell, by'),\n",
       " Document(metadata={}, page_content='determining decreased influx or increased'),\n",
       " Document(metadata={}, page_content='efflux.\\n(1).\\nIncrease of detoxification systems.\\n(2).'),\n",
       " Document(metadata={}, page_content='Decrease of cell apoptosis [57].\\n(3).'),\n",
       " Document(metadata={}, page_content='Therefore, the benefit of adjuvant platinum-based regimens'),\n",
       " Document(metadata={}, page_content='remains controversial and needs'),\n",
       " Document(metadata={}, page_content='validation by prospective adjuvant ongoing trials.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 236\\nNeoadjuvant treatments for TNBC\\nNACT'),\n",
       " Document(metadata={}, page_content='Several treatment guidelines recommend NACT as the preferred'),\n",
       " Document(metadata={}, page_content='option for stage II or III TNBC and for'),\n",
       " Document(metadata={}, page_content='stage I with a tumor size greater than 1 cm. It can be'),\n",
       " Document(metadata={}, page_content='considered in stage I TNBC with a tumor size from'),\n",
       " Document(metadata={}, page_content='0.6 cm to 1 cm and/or in the case of tumors with nodal'),\n",
       " Document(metadata={}, page_content='micrometastases. [6, 45]. There is no significant'),\n",
       " Document(metadata={}, page_content='difference in survival benefits between patients receiving'),\n",
       " Document(metadata={}, page_content='neoadjuvant or adjuvant CHT after surgical'),\n",
       " Document(metadata={}, page_content='resection. However, neoadjuvant treatments can be useful for'),\n",
       " Document(metadata={}, page_content='inoperable tumors rendering them operable'),\n",
       " Document(metadata={}, page_content='and they can also downstage patients with operable BC promoting'),\n",
       " Document(metadata={}, page_content='breast-conservation [58, 59]. The use of'),\n",
       " Document(metadata={}, page_content='neoadjuvant treatments provides important prognostic information'),\n",
       " Document(metadata={}, page_content='based on response to therapy.'),\n",
       " Document(metadata={}, page_content='Achieving a pCR, defined as the lack of cancer cells in tissue'),\n",
       " Document(metadata={}, page_content='samples of breast and axillary lymph nodes,'),\n",
       " Document(metadata={}, page_content='after a neoadjuvant treatment, is associated with favorable'),\n",
       " Document(metadata={}, page_content='disease-free and OS in early TNBC, as'),\n",
       " Document(metadata={}, page_content='demonstrated in Collaborative Trials in Neoadjuvant Breast'),\n",
       " Document(metadata={}, page_content='Cancer (CTNeoBC) pooled analysis. In this'),\n",
       " Document(metadata={}, page_content='study, patients with early BC treated with NACT and followed by'),\n",
       " Document(metadata={}, page_content='surgery who obtained pCR (ypT0 ypN0,'),\n",
       " Document(metadata={}, page_content='ypT0/is ypN0) were associated with improved event-free survival'),\n",
       " Document(metadata={}, page_content='(EFS) and OS, especially in TNBC (HR ='),\n",
       " Document(metadata={}, page_content='0.24 and HR = 0.16, respectively) [33]. Like adjuvant treatment,'),\n",
       " Document(metadata={}, page_content='traditional NACT is based on anthracyclines'),\n",
       " Document(metadata={}, page_content='and taxanes, and a dose-dense regimen is preferred in'),\n",
       " Document(metadata={}, page_content='neoadjuvant settings based on proven improved DFS'),\n",
       " Document(metadata={}, page_content='and OS in a large meta-analysis [60].'),\n",
       " Document(metadata={}, page_content='In recent years, the use of platinum-based combination regimens'),\n",
       " Document(metadata={}, page_content='has been the focus of neoadjuvant'),\n",
       " Document(metadata={}, page_content='treatment to increase the rate of pCR in TNBC. Three recent'),\n",
       " Document(metadata={}, page_content='studies demonstrated that combining platinum'),\n",
       " Document(metadata={}, page_content='with taxane and anthracycline led to an improvement in the pCR'),\n",
       " Document(metadata={}, page_content='rate in TNBC, with a similar survival'),\n",
       " Document(metadata={}, page_content='benefit [61–63]. In Brightness Trial patients with II–III stage'),\n",
       " Document(metadata={}, page_content='TNBC were randomly assigned to receive'),\n",
       " Document(metadata={}, page_content='paclitaxel alone, paclitaxel and carboplatin and this'),\n",
       " Document(metadata={}, page_content='combination with a PARP inhibitor, veliparib followed'),\n",
       " Document(metadata={}, page_content='by AC. Although the addition of veliparib and carboplatin was'),\n",
       " Document(metadata={}, page_content='associated with an increase of patients who'),\n",
       " Document(metadata={}, page_content='achieved a pCR compared to paclitaxel alone (53% vs. 31%, P <'),\n",
       " Document(metadata={}, page_content='0.0001), but not to paclitaxel and'),\n",
       " Document(metadata={}, page_content='carboplatin, this benefit could be related to the addition of'),\n",
       " Document(metadata={}, page_content='the carboplatin [63]. The initial rationale for'),\n",
       " Document(metadata={}, page_content='using the combination of platinum in NACT was that sporadic TNBC'),\n",
       " Document(metadata={}, page_content='can show BRCAness with a major'),\n",
       " Document(metadata={}, page_content='response to platinum regimens [50, 51]. However, the greatest'),\n",
       " Document(metadata={}, page_content='benefit was seen in patients who were'),\n",
       " Document(metadata={}, page_content='germline BRCA wild type, and only a marginal benefit was'),\n",
       " Document(metadata={}, page_content='observed in the germline BRCA mutant'),\n",
       " Document(metadata={}, page_content='subgroup, as was shown in the recent GeparOLA trial. In this'),\n",
       " Document(metadata={}, page_content='trial, patients were randomized to'),\n",
       " Document(metadata={}, page_content='neoadjuvant therapy with paclitaxel and carboplatin vs.'),\n",
       " Document(metadata={}, page_content='neoadjuvant therapy with paclitaxel and olaparib'),\n",
       " Document(metadata={}, page_content='(PARP inhibitor). In both arms, the combination of epirubicin'),\n",
       " Document(metadata={}, page_content='and cyclophosphamide was administered'),\n",
       " Document(metadata={}, page_content='next. This study, although limited by a small number of patients'),\n",
       " Document(metadata={}, page_content='enrolled, showed an advantage for the'),\n",
       " Document(metadata={}, page_content='carboplatin arm in patients without BRCA mutation (germ or'),\n",
       " Document(metadata={}, page_content='somatic) and high HRD. The 4-year invasive'),\n",
       " Document(metadata={}, page_content='DFS (iDFS) rate with olaparib-paclitaxel was 81.2% vs. 93.4%'),\n",
       " Document(metadata={}, page_content='with carboplatin-paclitaxel (CP) [HR = 3.03;'),\n",
       " Document(metadata={}, page_content='95% confidence interval (CI) = 0.67–13.67; log-rank P = 0.1290].'),\n",
       " Document(metadata={}, page_content='The 4-year OS rate was 89.2% with the'),\n",
       " Document(metadata={}, page_content='olaparib combination vs. 96.6% with carboplatin (HR = 3.27; 95%'),\n",
       " Document(metadata={}, page_content='CI = 0.39–27.20; log-rank P = 0.2444).'),\n",
       " Document(metadata={}, page_content='The trend of the iDFS curves was similar in the two treatment'),\n",
       " Document(metadata={}, page_content='arms and independent of germline or somatic'),\n",
       " Document(metadata={}, page_content='BRCA mutation [64].'),\n",
       " Document(metadata={}, page_content='Platinum combinations are currently recommended for selected'),\n",
       " Document(metadata={}, page_content='patients with TNBC who require'),\n",
       " Document(metadata={}, page_content='adequate local control before surgical resection [45]. A more'),\n",
       " Document(metadata={}, page_content='recent phase III trial presented at the San'),\n",
       " Document(metadata={}, page_content='Antonio Breast Cancer Symposium evaluating the efficacy and'),\n",
       " Document(metadata={}, page_content='safety of adding carboplatin to standard'),\n",
       " Document(metadata={}, page_content='sequential taxane-anthracycline NACT in patients with TNBC who'),\n",
       " Document(metadata={}, page_content='had no evidence of metastatic disease,'),\n",
       " Document(metadata={}, page_content='has observed improvements in terms of DFS (5-year DFS were 70.6%'),\n",
       " Document(metadata={}, page_content='and 64.5% respectively with a HR ='),\n",
       " Document(metadata={}, page_content='0.79, 95% CI = 0.61–1.02, P = 0.073) and OS (5-year OS were'),\n",
       " Document(metadata={}, page_content='74.0% and 66.7% respectively with a HR ='),\n",
       " Document(metadata={}, page_content='0.75, 95% CI = 0.57–0.98, P = 0.034) with the addition of'),\n",
       " Document(metadata={}, page_content='carboplatin, but these benefits were limited to'),\n",
       " Document(metadata={}, page_content='patients who were 50 years of age or younger. Therefore, the pCR'),\n",
       " Document(metadata={}, page_content='in the intention-to-treat population was'),\n",
       " Document(metadata={}, page_content='54.5% in the carboplatin arm and 40.3% in the control arm (P <'),\n",
       " Document(metadata={}, page_content='0.001) [65].'),\n",
       " Document(metadata={}, page_content='The inclusion of platinum agents as NACT for TNBC remains'),\n",
       " Document(metadata={}, page_content='controversial. Long-term outcomes and'),\n",
       " Document(metadata={}, page_content='new prospective studies are needed to clarify the role of'),\n",
       " Document(metadata={}, page_content='platinum agents in this setting.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 237\\nNeoadjuvant immunotherapy'),\n",
       " Document(metadata={}, page_content='The success of ICIs in metastatic TNBC led to expand their role'),\n",
       " Document(metadata={}, page_content='in neoadjuvant settings. Pembrolizumab and'),\n",
       " Document(metadata={}, page_content='atezolizumab have shown progression-free survival (PFS) benefits'),\n",
       " Document(metadata={}, page_content='in phase III trials in advanced setting'),\n",
       " Document(metadata={}, page_content='[66, 67]. In contrast to atezolizumab that showed conflicting'),\n",
       " Document(metadata={}, page_content='results [68, 69], pembrolizumab consistently'),\n",
       " Document(metadata={}, page_content='showed OS benefits in advanced TNBC [66, 70]. In early-stage'),\n",
       " Document(metadata={}, page_content='TNBC two studies evaluated atezolizumab in'),\n",
       " Document(metadata={}, page_content='neoadjuvant setting. In the NeoTRIPaPDL1 trial, no improvement'),\n",
       " Document(metadata={}, page_content='in pCR was shown with the addition of'),\n",
       " Document(metadata={}, page_content='atezolizumab to a non-anthracycline-containing CHT regimen [71].'),\n",
       " Document(metadata={}, page_content='More recent Impassion031 phase III'),\n",
       " Document(metadata={}, page_content='study evaluating the association of atezolizumab to a standard'),\n",
       " Document(metadata={}, page_content='NACT (nab-palclitaxel weekly for 12 weeks'),\n",
       " Document(metadata={}, page_content='followed by 4 cycles of AC), has demonstrated a significant'),\n",
       " Document(metadata={}, page_content='improvement of pCR rates in intention to treat'),\n",
       " Document(metadata={}, page_content='(ITT) population (58% in atezolizumab arm vs. 41% in placebo'),\n",
       " Document(metadata={}, page_content='arm, P = 0.0044), regardless of PD-L1 status,'),\n",
       " Document(metadata={}, page_content='meeting the primary endpoint of the study [72]. Therefore, in'),\n",
       " Document(metadata={}, page_content='early BC the combination of pembrolizumab'),\n",
       " Document(metadata={}, page_content='with paclitaxel-carboplatin followed by anthracycline increased'),\n",
       " Document(metadata={}, page_content='pCR rate and EFS rate in the KEYNOTE-522'),\n",
       " Document(metadata={}, page_content='trial, representing a turning point for the role of'),\n",
       " Document(metadata={}, page_content='immunotherapy in neoadjuvant therapy of TNBC and'),\n",
       " Document(metadata={}, page_content='establishing pembrolizumab as a standard treatment during'),\n",
       " Document(metadata={}, page_content='neoadjuvant treatment for stage II and III'),\n",
       " Document(metadata={}, page_content='TNBC. The trial evaluated the combination of pembrolizumab (18'),\n",
       " Document(metadata={}, page_content='cycles, 200 mg every 3 weeks) combined'),\n",
       " Document(metadata={}, page_content='with four cycles of paclitaxel (weekly or 3-weekly) and'),\n",
       " Document(metadata={}, page_content='carboplatin (3-weekly), followed by 3-weekly AC for'),\n",
       " Document(metadata={}, page_content='4 cycles, compared to placebo with CHT. Pembrolizumab arm showed'),\n",
       " Document(metadata={}, page_content='a 13.6% improvement in pCR [64.8%'),\n",
       " Document(metadata={}, page_content='(95% CI = 59.9–69.5%) vs. 51.2% (95% CI = 44.1–58.3%)] and in'),\n",
       " Document(metadata={}, page_content='EFS rate [84.5% (95% CI = 81.7–86.9%)'),\n",
       " Document(metadata={}, page_content='vs. 76.8% (95% CI = 72.2–80.7%)], meeting the primary endpoint'),\n",
       " Document(metadata={}, page_content='of the study, regardless nodal'),\n",
       " Document(metadata={}, page_content='involvement and PD-L1 status. The average duration of follow-up'),\n",
       " Document(metadata={}, page_content='is still immature, but a trend of'),\n",
       " Document(metadata={}, page_content='superiority in terms of OS in the pembrolizumab arm was'),\n",
       " Document(metadata={}, page_content='nevertheless detected [73]. Limits of this study'),\n",
       " Document(metadata={}, page_content='are the lack of biomarkers that predict what patient may benefit'),\n",
       " Document(metadata={}, page_content='from the addition of pembrolizumab and'),\n",
       " Document(metadata={}, page_content='the non-utilization of dose-dense schedule of AC which showed'),\n",
       " Document(metadata={}, page_content='superior OS benefit in the neoadjuvant'),\n",
       " Document(metadata={}, page_content='setting in TNBC [74].'),\n",
       " Document(metadata={}, page_content='Moreover, the recent GeparNuevo trial showed that durvalumab'),\n",
       " Document(metadata={}, page_content='(1,500 mg every 4 weeks) added to'),\n",
       " Document(metadata={}, page_content='NACT consisting of nab-paclitaxel 125 mg/m2 weekly for 12 weeks,'),\n",
       " Document(metadata={}, page_content='followed by epirubicin/'),\n",
       " Document(metadata={}, page_content='cyclophosphamide every 2 weeks, in early TNBC significantly'),\n",
       " Document(metadata={}, page_content='improved iDFS (85.6% with durvalumab vs.'),\n",
       " Document(metadata={}, page_content='77.2% with placebo HR = 0.48, 95% CI = 0.24–0.97, stratified'),\n",
       " Document(metadata={}, page_content='log-rank P = 0.036) and OS (95.2% vs. 83.5%'),\n",
       " Document(metadata={}, page_content='with a HR = 0.24, 95% CI = 0.08–0.72, P = 0.006), despite a'),\n",
       " Document(metadata={}, page_content='modest pCR increase and no adjuvant'),\n",
       " Document(metadata={}, page_content='component of durvalumab [75]. Future studies should aim to'),\n",
       " Document(metadata={}, page_content='define the role of immunotherapy in the'),\n",
       " Document(metadata={}, page_content='treatment of early TNBC, to define the ideal duration of these'),\n",
       " Document(metadata={}, page_content='treatments, and should research new'),\n",
       " Document(metadata={}, page_content='biomarkers to personalize treatments.'),\n",
       " Document(metadata={}, page_content='Pathological complete response: prognostic role and therapeutic'),\n",
       " Document(metadata={}, page_content='implications'),\n",
       " Document(metadata={}, page_content='In clinical practice, the achievement of pCR after neoadjuvant'),\n",
       " Document(metadata={}, page_content='treatment is correlated to the improvement of'),\n",
       " Document(metadata={}, page_content='long-term benefits concerning EFS and OS. Its prognostic value'),\n",
       " Document(metadata={}, page_content='is greatest in aggressive tumor subtypes,'),\n",
       " Document(metadata={}, page_content='like in TNBC (EFS: HR = 0.24; OS: HR = 0.16) [33]. Patients who'),\n",
       " Document(metadata={}, page_content='have residual invasive BC after the receipt'),\n",
       " Document(metadata={}, page_content='of NACT have a high risk of relapse. Patients with TNBC who do'),\n",
       " Document(metadata={}, page_content='not experience pCR have an estimated 5-'),\n",
       " Document(metadata={}, page_content='year EFS of 57% and OS of 47% (compared with 90% EFS and 84% OS,'),\n",
       " Document(metadata={}, page_content='respectively, for patients with early-'),\n",
       " Document(metadata={}, page_content='stage TNBC who demonstrate pCR) [76, 77].'),\n",
       " Document(metadata={}, page_content='After pre-operative CHT and surgical treatment, patients can'),\n",
       " Document(metadata={}, page_content='receive postoperative radiation therapy'),\n",
       " Document(metadata={}, page_content='(RT). Patients with hormone receptor-positive BC [hormone'),\n",
       " Document(metadata={}, page_content='receptor-positive (HR+) BC] are candidates for'),\n",
       " Document(metadata={}, page_content='adjuvant endocrine treatment. However, until recently, no'),\n",
       " Document(metadata={}, page_content='adjuvant CHT was expected as standard in'),\n",
       " Document(metadata={}, page_content='patients with TNBC. Only follow-up was recommended in those who'),\n",
       " Document(metadata={}, page_content='have pCR or in those with residual'),\n",
       " Document(metadata={}, page_content='invasive BC after the receipt of neoadjuvant regimens [78]. To'),\n",
       " Document(metadata={}, page_content='address the unmet clinical need for optimal'),\n",
       " Document(metadata={}, page_content='adjuvant treatment in the subgroup of patients with TNBC at high'),\n",
       " Document(metadata={}, page_content='risk of recurrence (those who have not'),\n",
       " Document(metadata={}, page_content='achieved the pCR after NACT containing anthracycline, taxane, or'),\n",
       " Document(metadata={}, page_content='both), the Capecitabine for Residual'),\n",
       " Document(metadata={}, page_content='Cancer as Adjuvant Therapy (CREATE-X) was designed. The trial'),\n",
       " Document(metadata={}, page_content='did not include only patients with TNBC'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 238'),\n",
       " Document(metadata={}, page_content='but also patients with HR+ HER2 negative BC [79]. The results of'),\n",
       " Document(metadata={}, page_content='this phase III trial showed that the'),\n",
       " Document(metadata={}, page_content='addition of adjuvant capecitabine (1,250 mg per square meter of'),\n",
       " Document(metadata={}, page_content='body-surface area, twice per day, on days'),\n",
       " Document(metadata={}, page_content='1 to 14, every 3 weeks for six or eight cycles) was safe and'),\n",
       " Document(metadata={}, page_content='effective in prolonging DFS and OS among the'),\n",
       " Document(metadata={}, page_content='ITT population. The study showed a superior DFS in the'),\n",
       " Document(metadata={}, page_content='capecitabine group than in the control group'),\n",
       " Document(metadata={}, page_content='(74.1% vs. 67.6% at 5 years; HR = 0.70; P = 0.01). Therefore, OS'),\n",
       " Document(metadata={}, page_content='was longer in the experimental group:'),\n",
       " Document(metadata={}, page_content='89.2% vs. 83.6% of the patients were alive at 5 years (HR ='),\n",
       " Document(metadata={}, page_content='0.59; P = 0.01). Thirty percent of the patients'),\n",
       " Document(metadata={}, page_content='had triple negative (TN) disease, and they represent the'),\n",
       " Document(metadata={}, page_content='subgroup with poor prognosis (approximately half'),\n",
       " Document(metadata={}, page_content='the patients with TNBC who had a pCR did not have the recurrence'),\n",
       " Document(metadata={}, page_content='of the disease) [33]. The benefit of'),\n",
       " Document(metadata={}, page_content='capecitabine vs. control in DFS and OS was notable among this'),\n",
       " Document(metadata={}, page_content='subgroup of patients (HR = 0.58 and HR ='),\n",
       " Document(metadata={}, page_content='0.52, respectively) [79].'),\n",
       " Document(metadata={}, page_content='The reflection in the treatment algorithm due to these results'),\n",
       " Document(metadata={}, page_content='was significant.'),\n",
       " Document(metadata={}, page_content='Some limits of this study are the exclusion of patients who had'),\n",
       " Document(metadata={}, page_content='reached the pCR, for whom only follow-'),\n",
       " Document(metadata={}, page_content='up was indicated, and the lack of efficacy results selected for'),\n",
       " Document(metadata={}, page_content='residual cancer burden (RCB). The RCB'),\n",
       " Document(metadata={}, page_content='quantifies the extent of residual disease after neoadjuvant'),\n",
       " Document(metadata={}, page_content='treatment at the time of surgery. This score uses'),\n",
       " Document(metadata={}, page_content='the diameter of residual disease, percentage of vital tumor'),\n",
       " Document(metadata={}, page_content='cells, and diameter of the largest involved lymph'),\n",
       " Document(metadata={}, page_content='node to calculate the amount of residual disease. It has been'),\n",
       " Document(metadata={}, page_content='validated with distinct prognostic RCB classes'),\n",
       " Document(metadata={}, page_content='in all BC subtypes, with the most significant discriminatory'),\n",
       " Document(metadata={}, page_content='power in TN and Her-2 positive BC. It is'),\n",
       " Document(metadata={}, page_content='categorized as RCB-0 (equivalent to a pCR), RCB-1, RCB-2, and'),\n",
       " Document(metadata={}, page_content='RCB-3, reflecting increasingly larger residual'),\n",
       " Document(metadata={}, page_content='cancer and respective poor prognoses (in terms of EFS) [80].'),\n",
       " Document(metadata={}, page_content='Finally, the CREATE-X trial did not examine'),\n",
       " Document(metadata={}, page_content='capecitabine efficacy in patients with germline BRCA 1 or BRCA 2'),\n",
       " Document(metadata={}, page_content='pathogenic variants (less than 15% of'),\n",
       " Document(metadata={}, page_content='those enrolled) [79].'),\n",
       " Document(metadata={}, page_content='OlympiA is a phase III study designed to investigate how the'),\n",
       " Document(metadata={}, page_content='PARP inhibitor olaparib might improve'),\n",
       " Document(metadata={}, page_content='DFS and OS in patients with resected HR+ BC and TNBC with'),\n",
       " Document(metadata={}, page_content='germline BRCA 1 or BRCA 2 mutation. It'),\n",
       " Document(metadata={}, page_content='enrolled patients treated with CHT (containing anthracyclines,'),\n",
       " Document(metadata={}, page_content='taxanes or the combination of both) in'),\n",
       " Document(metadata={}, page_content='neoadjuvant or adjuvant setting and randomized them to receive'),\n",
       " Document(metadata={}, page_content='olaparib (orally administered at the dose'),\n",
       " Document(metadata={}, page_content='of 300 mg twice daily) vs. placebo for 1 year after surgical'),\n",
       " Document(metadata={}, page_content='resection (and radiotherapy when indicated).'),\n",
       " Document(metadata={}, page_content='Also in this trial, patients with TNBC who underwent NACT'),\n",
       " Document(metadata={}, page_content='followed by surgery were required to have'),\n",
       " Document(metadata={}, page_content='residual invasive BC in the breast and/or resected lymph nodes'),\n",
       " Document(metadata={}, page_content='(non-pCR) [81]. Postneoadjuvant'),\n",
       " Document(metadata={}, page_content='capecitabine was not foreseen in this trial. iDFS, the primary'),\n",
       " Document(metadata={}, page_content='endpoint of the study, was significantly longer'),\n",
       " Document(metadata={}, page_content='among patients assigned to receive olaparib than among those'),\n",
       " Document(metadata={}, page_content='assigned placebo (HR = 0.58; P < 0.001). The'),\n",
       " Document(metadata={}, page_content='percentage of patients alive and free of invasive disease at 3'),\n",
       " Document(metadata={}, page_content='years was 85.9% in the olaparib group and'),\n",
       " Document(metadata={}, page_content='77.1% in the placebo group. The benefit of adjuvant olaparib was'),\n",
       " Document(metadata={}, page_content='observed irrespective of the germline'),\n",
       " Document(metadata={}, page_content='BRCA mutation (BRCA 1 vs. BRCA 2), the hormone-receptor status,'),\n",
       " Document(metadata={}, page_content='or the timing of previous CHT'),\n",
       " Document(metadata={}, page_content='(neoadjuvant vs. adjuvant) [81] 4-year iDFS for the olaparib'),\n",
       " Document(metadata={}, page_content='group was 82.7% (vs. 75.4% in placebo group)'),\n",
       " Document(metadata={}, page_content='and 4-year distant DFS (DDFS) was 86.5% (vs. 79.1%). Adjuvant'),\n",
       " Document(metadata={}, page_content='olaparib improves OS, with an HR of 0.68'),\n",
       " Document(metadata={}, page_content='and a P value of 0.009 at 3.5 years of median follow-up, meeting'),\n",
       " Document(metadata={}, page_content='the significance threshold for OS at the'),\n",
       " Document(metadata={}, page_content='second planned interim analysis. The OS benefit at 4 years in'),\n",
       " Document(metadata={}, page_content='the olaparib arm compared with the placebo'),\n",
       " Document(metadata={}, page_content='arm was reported (89.8% vs. 86.4%, respectively) [82].'),\n",
       " Document(metadata={}, page_content='Both studies have defined the standard of adjuvant therapy'),\n",
       " Document(metadata={}, page_content='post-NACT for patients with BRCA wild'),\n",
       " Document(metadata={}, page_content='type (CREATE-X) and BRCA mutated (OlympiA) TNBC, that did not'),\n",
       " Document(metadata={}, page_content='reach the pCR.'),\n",
       " Document(metadata={}, page_content='The low percentage of BRCA mutated patients enrolled in the'),\n",
       " Document(metadata={}, page_content='CREATE-X, the absence of pre-planned'),\n",
       " Document(metadata={}, page_content='subgroup analyzes for this population do not allow for a'),\n",
       " Document(metadata={}, page_content='description of the efficacy of capecitabine in this'),\n",
       " Document(metadata={}, page_content='subgroup of patients.'),\n",
       " Document(metadata={}, page_content='Moreover, there are no prospective randomized trials between'),\n",
       " Document(metadata={}, page_content='capecitabine and olaparib to guide the'),\n",
       " Document(metadata={}, page_content='clinical decision in this population, nor combination or'),\n",
       " Document(metadata={}, page_content='sequence data between these two drugs.'),\n",
       " Document(metadata={}, page_content='It would also be important to consider the potentially severe'),\n",
       " Document(metadata={}, page_content='toxicity profile of such a combination,'),\n",
       " Document(metadata={}, page_content='given their overlapping side effects (in particular,'),\n",
       " Document(metadata={}, page_content='cytopenias).'),\n",
       " Document(metadata={}, page_content='The treatment paradigm of early TNBC has had a real evolution'),\n",
       " Document(metadata={}, page_content='since July 2021, with the introduction'),\n",
       " Document(metadata={}, page_content='of immunotherapy following the Food and Drug Administration'),\n",
       " Document(metadata={}, page_content='(FDA) approval of pembrolizumab for high-'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 239'),\n",
       " Document(metadata={}, page_content='risk TNBC (tumor size > 1 cm but ≤ 2 cm in diameter with nodal'),\n",
       " Document(metadata={}, page_content='involvement or tumor size > 2 cm in'),\n",
       " Document(metadata={}, page_content='diameter regardless of nodal involvement), regardless of tumor'),\n",
       " Document(metadata={}, page_content='PD-L1 expression, in combination with CHT'),\n",
       " Document(metadata={}, page_content='as neoadjuvant treatment, and then continued as a single agent'),\n",
       " Document(metadata={}, page_content='as adjuvant treatment after surgery for a'),\n",
       " Document(metadata={}, page_content='total duration of approximately 1 year [83].'),\n",
       " Document(metadata={}, page_content='Results from the KEYNOTE-522 study were the basis for this'),\n",
       " Document(metadata={}, page_content='approval, demonstrating a significantly'),\n",
       " Document(metadata={}, page_content='higher rate of pCR at the time of definitive surgery among'),\n",
       " Document(metadata={}, page_content='patients who received pembrolizumab plus NACT'),\n",
       " Document(metadata={}, page_content='than among those who received placebo plus NACT and an'),\n",
       " Document(metadata={}, page_content='improvement in long-term benefits [73, 84]. The'),\n",
       " Document(metadata={}, page_content='aim of the trial was not to identify the contributions of the'),\n",
       " Document(metadata={}, page_content='neoadjuvant and adjuvant treatment phases, so it'),\n",
       " Document(metadata={}, page_content='is difficult to define if these long-term results are related to'),\n",
       " Document(metadata={}, page_content='exposure to adjuvant pembrolizumab or a'),\n",
       " Document(metadata={}, page_content='lesser RCB at the end of the neoadjuvant phase in the'),\n",
       " Document(metadata={}, page_content='pembrolizumab–CHT group.'),\n",
       " Document(metadata={}, page_content='An exploratory analysis of the study then provided data to'),\n",
       " Document(metadata={}, page_content='further describe the prognosis related to the'),\n",
       " Document(metadata={}, page_content='RCB after neoadjuvant experimental treatment (Figure 1) [85].'),\n",
       " Document(metadata={}, page_content='Figure 1. The unmet need for the optimal adjuvant treatment'),\n",
       " Document(metadata={}, page_content='according to RCB [85]'),\n",
       " Document(metadata={}, page_content='The HR for recurrence event in subgroups RBO-0, RCB-1, RCB-2,'),\n",
       " Document(metadata={}, page_content='and RCB-3 are respectively 0.70'),\n",
       " Document(metadata={}, page_content='(rates: 5.2% vs. 7.3% in the pembrolizumab + CHT vs. placebo +'),\n",
       " Document(metadata={}, page_content='CHT), 0.92 (rates: 17.4% vs. 20%), 0.52'),\n",
       " Document(metadata={}, page_content='(rates: 25.5% vs. 44.3%), 1.24 (72.5% vs. 69.2%).'),\n",
       " Document(metadata={}, page_content='The rate of recurrence was numerically lower in all RCB groups'),\n",
       " Document(metadata={}, page_content='with pembrolizumab + CHT, except in'),\n",
       " Document(metadata={}, page_content='the small RCB-3 subset (that is represented by 5% and 7% of the'),\n",
       " Document(metadata={}, page_content='population in the study, respectively in'),\n",
       " Document(metadata={}, page_content='the experimental and control group). Pembrolizumab shifted RCB'),\n",
       " Document(metadata={}, page_content='to lower categories in most patients'),\n",
       " Document(metadata={}, page_content='(RCB-0: 63% vs. 56% of patients in the experimental vs. the'),\n",
       " Document(metadata={}, page_content='control arm; RCB-1: 9% vs. 11%; RCB 18% vs.'),\n",
       " Document(metadata={}, page_content='20%).'),\n",
       " Document(metadata={}, page_content='No patients in this trial received adjuvant capecitabine, and'),\n",
       " Document(metadata={}, page_content='there are no randomized efficacy and'),\n",
       " Document(metadata={}, page_content='safety data showing that multiagent therapy with pembrolizumab'),\n",
       " Document(metadata={}, page_content='and capecitabine is superior to single-'),\n",
       " Document(metadata={}, page_content='agent therapy in high-risk patients (stage II–III) who did not'),\n",
       " Document(metadata={}, page_content='reach pCR.'),\n",
       " Document(metadata={}, page_content='At the time, only results from phase II studies in metastatic'),\n",
       " Document(metadata={}, page_content='TNBC demonstrated no new safety signals'),\n",
       " Document(metadata={}, page_content='with this combination [86, 87].'),\n",
       " Document(metadata={}, page_content='Pembrolizumab has also not been studied in combination with'),\n",
       " Document(metadata={}, page_content='olaparib in the adjuvant setting, for the'),\n",
       " Document(metadata={}, page_content='treatment of patients with BRCA mutations. No efficacy data are'),\n",
       " Document(metadata={}, page_content='reported in the literature, even if some'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 240'),\n",
       " Document(metadata={}, page_content='safety data are reported in the metastatic setting, in some'),\n",
       " Document(metadata={}, page_content='early-phase studies that have evaluated the'),\n",
       " Document(metadata={}, page_content='combination of PARPis and ICIs, not reporting unexpected'),\n",
       " Document(metadata={}, page_content='toxicities [88, 89].'),\n",
       " Document(metadata={}, page_content='Prospective trials would be needed to define what is the optimal'),\n",
       " Document(metadata={}, page_content='adjuvant strategy according to RCB'),\n",
       " Document(metadata={}, page_content='(single-agent CHT or poly-CHT), how the clinician should decide'),\n",
       " Document(metadata={}, page_content='between olaparib, immunotherapy or'),\n",
       " Document(metadata={}, page_content='capecitabine in the treatment of the population with BRCA'),\n",
       " Document(metadata={}, page_content='mutations and whether these therapies can be'),\n",
       " Document(metadata={}, page_content='administered in combination or sequence, with data in terms of'),\n",
       " Document(metadata={}, page_content='efficacy and safety.'),\n",
       " Document(metadata={}, page_content='Additional treatment strategies with new drugs are being studied'),\n",
       " Document(metadata={}, page_content='as adjuvant treatment after NACT,'),\n",
       " Document(metadata={}, page_content='with antibody-drug conjugates (ADCs) such as datopotamab'),\n",
       " Document(metadata={}, page_content='deruxtecan (with or without durvalumab in'),\n",
       " Document(metadata={}, page_content='TROPICS-Breast 03, ClinicalTrials.gov identifier: NCT05629585),'),\n",
       " Document(metadata={}, page_content='and patritumab deruxtecan (HER3-DXd)'),\n",
       " Document(metadata={}, page_content='which showed promising clinical response and biological changes'),\n",
       " Document(metadata={}, page_content='in early TNBC [SOLTI TOT-HER3 window'),\n",
       " Document(metadata={}, page_content='of opportunity trial part B, presented at European Society for'),\n",
       " Document(metadata={}, page_content='Medical Oncology (ESMO) Breast 2023], or'),\n",
       " Document(metadata={}, page_content='with ICIs (A-BRAVE trial, NCT02926196 and SWOG S1418/BR006'),\n",
       " Document(metadata={}, page_content='trial, NCT02954874).'),\n",
       " Document(metadata={}, page_content='New biomarkers and frontiers in TNBC'),\n",
       " Document(metadata={}, page_content='Recent progress in integrating ICIs and novel agents has'),\n",
       " Document(metadata={}, page_content='revolutionized the therapeutic approach for early'),\n",
       " Document(metadata={}, page_content='TNBC. Treatment strategies now emphasize escalating'),\n",
       " Document(metadata={}, page_content='chemotherapeutic agents based on standard'),\n",
       " Document(metadata={}, page_content='neoadjuvant regimens. An example is a phase II trial'),\n",
       " Document(metadata={}, page_content='(ACTRN12617000651381) presented at the San'),\n",
       " Document(metadata={}, page_content='Antonio Breast Cancer Symposium 2022 evaluating in high-risk'),\n",
       " Document(metadata={}, page_content='TNBC, the addition of ipilimumab and'),\n",
       " Document(metadata={}, page_content='nivolumab to neoadjuvant paclitaxel following a suboptimal'),\n",
       " Document(metadata={}, page_content='response to anthracycline-based CHT (< 50%'),\n",
       " Document(metadata={}, page_content='tumor reduction) and resulting in promising objective response'),\n",
       " Document(metadata={}, page_content='rate (ORR) (43.7%) and pCR (18.8%) rates,'),\n",
       " Document(metadata={}, page_content='regardless of PD-L1 status.'),\n",
       " Document(metadata={}, page_content='However, it is also crucial to identify subgroups of patients'),\n",
       " Document(metadata={}, page_content='with favorable prognoses, where NACT'),\n",
       " Document(metadata={}, page_content='could potentially be de-escalated. Therefore, discovering novel'),\n",
       " Document(metadata={}, page_content='biomarkers to categorize patients with good'),\n",
       " Document(metadata={}, page_content='prognoses and safely de-escalate NACT is essential.'),\n",
       " Document(metadata={}, page_content='TILs show promise as a biomarker for selecting patients who may'),\n",
       " Document(metadata={}, page_content='have favorable outcomes with'),\n",
       " Document(metadata={}, page_content='treatment de-escalation. In recent trials, higher TILs levels'),\n",
       " Document(metadata={}, page_content='were associated with a higher pCR rate [71, 75,'),\n",
       " Document(metadata={}, page_content='90] and with a better response [75, 91]. Liquid biopsies, such'),\n",
       " Document(metadata={}, page_content='as circulating tumor DNA (ctDNA), could'),\n",
       " Document(metadata={}, page_content='serve as promising markers for identifying patients who might'),\n",
       " Document(metadata={}, page_content='benefit from de-escalating or escalating'),\n",
       " Document(metadata={}, page_content='neoadjuvant or adjuvant treatment. Rapid ctDNA clearance during'),\n",
       " Document(metadata={}, page_content='NACT in early TNBC is linked to a high'),\n",
       " Document(metadata={}, page_content='likelihood of achieving pCR [92]. Conversely, detecting ctDNA'),\n",
       " Document(metadata={}, page_content='after completing NACT and surgery is'),\n",
       " Document(metadata={}, page_content='associated with higher recurrence rates and poorer prognoses'),\n",
       " Document(metadata={}, page_content='[93]. The use of dynamic biomarkers, such'),\n",
       " Document(metadata={}, page_content='as ctDNA, to guide the choice of treatments in high-risk'),\n",
       " Document(metadata={}, page_content='patients appears increasingly to be an important'),\n",
       " Document(metadata={}, page_content='resource to be exploited in future studies.'),\n",
       " Document(metadata={}, page_content='Furthermore, ADCs are emerging. Particularly, sacituzumab'),\n",
       " Document(metadata={}, page_content='govitecan (SG) an ADC targeting Trop-2'),\n",
       " Document(metadata={}, page_content='was approved in metastatic TNBC patients who received ≥ 2 prior'),\n",
       " Document(metadata={}, page_content='systemic therapies in the light of the'),\n",
       " Document(metadata={}, page_content='results of the phase III ASCENT study. In this trial patients'),\n",
       " Document(metadata={}, page_content='were randomized (1:1) to receive sacituzumab'),\n",
       " Document(metadata={}, page_content='govitecan 10 mg/kg via intravenous infusion on day 1 and day 8'),\n",
       " Document(metadata={}, page_content='of a 21-day treatment cycle or a treatment'),\n",
       " Document(metadata={}, page_content='of physician’s choice (TPC) achieving the primary endpoint (PFS'),\n",
       " Document(metadata={}, page_content='4.8 vs. 1.7 months) and also demonstrating'),\n",
       " Document(metadata={}, page_content='an advantage in terms of OS (11.8 months vs. 6.9 months) [94].'),\n",
       " Document(metadata={}, page_content='Another single-arm phase II trial is'),\n",
       " Document(metadata={}, page_content='evaluating SG and atezolizumab in combination as adjuvant'),\n",
       " Document(metadata={}, page_content='treatment for patients with TNBC who have'),\n",
       " Document(metadata={}, page_content='residual invasive disease after neoadjuvant therapy and'),\n",
       " Document(metadata={}, page_content='detectable ctDNA (ClinicalTrials.gov identifier'),\n",
       " Document(metadata={}, page_content='NCT04434040).'),\n",
       " Document(metadata={}, page_content='Finally, it is essential to redefine, with new dedicated trials,'),\n",
       " Document(metadata={}, page_content='the role of ER-low (1–9%) BC which,'),\n",
       " Document(metadata={}, page_content='biologically and prognostically very similar to TNBC, could'),\n",
       " Document(metadata={}, page_content='potentially benefit from the addition of'),\n",
       " Document(metadata={}, page_content='immunotherapy to CHT and the role of HER-2 low [score 1+ or 2+'),\n",
       " Document(metadata={}, page_content='not amplified in fluorescence in situ'),\n",
       " Document(metadata={}, page_content='hybridization (FISH)] BC in the light of recent results of'),\n",
       " Document(metadata={}, page_content='efficacy of trastuzumab deruxtecan in advanced BC'),\n",
       " Document(metadata={}, page_content='HER-2 low. Therefore, future studies are likely to expand the'),\n",
       " Document(metadata={}, page_content='armamentarium at our disposal in this setting.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 241\\nNew frontiers in early TNBC are summarized in Figure 2.'),\n",
       " Document(metadata={}, page_content='Figure 2. New frontiers in early TNBC'),\n",
       " Document(metadata={}, page_content='Interpretation and clinical implications'),\n",
       " Document(metadata={}, page_content='TNBC has long been a challenging disease to treat due to its'),\n",
       " Document(metadata={}, page_content='aggressive behavior and the lack of target'),\n",
       " Document(metadata={}, page_content='therapies [95].'),\n",
       " Document(metadata={}, page_content='Thanks to recent developments on TNBC, a series of therapeutic'),\n",
       " Document(metadata={}, page_content='targets have been identified for the'),\n",
       " Document(metadata={}, page_content='treatment of metastatic and early setting diseases. Especially'),\n",
       " Document(metadata={}, page_content='for the radically operable disease, the chances'),\n",
       " Document(metadata={}, page_content='of cure are increased with treatments aimed at reducing the odds'),\n",
       " Document(metadata={}, page_content='of recurrence after tumor removal.'),\n",
       " Document(metadata={}, page_content='Anthracycline and taxane-based poly-CHT remains the standard of'),\n",
       " Document(metadata={}, page_content='treatment, most often administered'),\n",
       " Document(metadata={}, page_content='preoperatively to assess tumor sensitivity. It aims to increase'),\n",
       " Document(metadata={}, page_content='the rate of local control, making it useful to'),\n",
       " Document(metadata={}, page_content='guide breast-conserving surgery and to ensure survival benefits'),\n",
       " Document(metadata={}, page_content='by reaching the pCR.'),\n",
       " Document(metadata={}, page_content='The introduction of immunotherapy in association with poly-CHT'),\n",
       " Document(metadata={}, page_content='in the neoadjuvant setting has'),\n",
       " Document(metadata={}, page_content='increased the rate of pCR, guaranteeing better results in terms'),\n",
       " Document(metadata={}, page_content='of long-term benefits in the KEYNOTE-522,'),\n",
       " Document(metadata={}, page_content='the pivotal trial that led to the approval in clinical practice'),\n",
       " Document(metadata={}, page_content='of the use of the anti-PD1, pembrolizumab, in the'),\n",
       " Document(metadata={}, page_content='early setting disease (neoadjuvant and adjuvant setting). These'),\n",
       " Document(metadata={}, page_content='clinical findings were based on preclinical'),\n",
       " Document(metadata={}, page_content='investigations that overturned the previous belief that BC was'),\n",
       " Document(metadata={}, page_content='not an immunogenic disease [12].'),\n",
       " Document(metadata={}, page_content='The actual need is to define the optimal adjuvant strategy after'),\n",
       " Document(metadata={}, page_content='neoadjuvant chemo-immunotherapy,'),\n",
       " Document(metadata={}, page_content='which must be affected by the patient’s risk of recurrence based'),\n",
       " Document(metadata={}, page_content='on the histological prognostic and evidence'),\n",
       " Document(metadata={}, page_content='after radical surgery, the individual’s tolerance of'),\n",
       " Document(metadata={}, page_content='therapy-induced side effects (Figure 3).'),\n",
       " Document(metadata={}, page_content='In patients with low RCB and a low overall risk of recurrence,'),\n",
       " Document(metadata={}, page_content='pembrolizumab alone should be'),\n",
       " Document(metadata={}, page_content='continued. In patients with poor prognostic features of high'),\n",
       " Document(metadata={}, page_content='RCB, this strategy may not be the best choice.'),\n",
       " Document(metadata={}, page_content='Patients with high RCB, BRCA wild type, could benefit from'),\n",
       " Document(metadata={}, page_content='capecitabine alone, although it would be'),\n",
       " Document(metadata={}, page_content='reasonable to use a combination of capecitabine and'),\n",
       " Document(metadata={}, page_content='pembrolizumab. Patients with high RCB, germline'),\n",
       " Document(metadata={}, page_content='BRCA mutations, could benefit from olaparib (according to the'),\n",
       " Document(metadata={}, page_content='inclusion criteria of the OlympiA trial),'),\n",
       " Document(metadata={}, page_content='although it would be reasonable to use olaparib and'),\n",
       " Document(metadata={}, page_content='pembrolizumab in combination or sequentially.'),\n",
       " Document(metadata={}, page_content='However, none of these strategies, in monotherapy and/or in'),\n",
       " Document(metadata={}, page_content='combination, have evidence from specific'),\n",
       " Document(metadata={}, page_content='randomized trials after the neoadjuvant immunotherapy. There are'),\n",
       " Document(metadata={}, page_content='no data on efficacy and safety in this'),\n",
       " Document(metadata={}, page_content='setting. Currently, the best schedule is not known, and new data'),\n",
       " Document(metadata={}, page_content='are awaited on new adjuvant strategies.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 242'),\n",
       " Document(metadata={}, page_content='Figure 3. Current treatment algorithm for stage II–III TNBC'),\n",
       " Document(metadata={}, page_content='Extensive efforts will also be required to investigate and'),\n",
       " Document(metadata={}, page_content='expand access to immunotherapy to ER-low'),\n",
       " Document(metadata={}, page_content='populations (ER 1–9%), not included in KEYNOTE-522. It'),\n",
       " Document(metadata={}, page_content='represents a subgroup that does not formally'),\n",
       " Document(metadata={}, page_content='meet the definition of TNBC, but shares biology, with nearly 90%'),\n",
       " Document(metadata={}, page_content='of these tumors harboring a basal-like'),\n",
       " Document(metadata={}, page_content='intrinsic subtype, and prognosis with TNBC and could share the'),\n",
       " Document(metadata={}, page_content='same benefit from the addition of'),\n",
       " Document(metadata={}, page_content='immunotherapy [96, 97].'),\n",
       " Document(metadata={}, page_content='Furthermore, novel active agents are emerging for the treatment'),\n",
       " Document(metadata={}, page_content='of TNBC and could provide an'),\n",
       " Document(metadata={}, page_content='opportunity for a de-escalation of traditional CHT, the'),\n",
       " Document(metadata={}, page_content='anti-trophoblast cell-surface antigen 2 (Trop2)'),\n",
       " Document(metadata={}, page_content='sacituzumab govitecan that is currently being investigated in'),\n",
       " Document(metadata={}, page_content='the early setting, including in combination'),\n",
       " Document(metadata={}, page_content='with immunotherapy in the ASPRIA trial (ClinicalTrials.gov'),\n",
       " Document(metadata={}, page_content='identifier NCT04434040).'),\n",
       " Document(metadata={}, page_content='Conclusions'),\n",
       " Document(metadata={}, page_content='This review highlights the multitude of advances in the'),\n",
       " Document(metadata={}, page_content='treatment of early-stage TNBC and the important'),\n",
       " Document(metadata={}, page_content='issues raised.'),\n",
       " Document(metadata={}, page_content='The management of triple-negative breast cancer (TNBC) has seen'),\n",
       " Document(metadata={}, page_content='notable advancements with the'),\n",
       " Document(metadata={}, page_content='identification of therapeutic targets and successful integration'),\n",
       " Document(metadata={}, page_content='of immunotherapy in neoadjuvant'),\n",
       " Document(metadata={}, page_content='treatment. However, the current challenge lies in determining'),\n",
       " Document(metadata={}, page_content='the optimal adjuvant strategy post-chemo-'),\n",
       " Document(metadata={}, page_content='immunotherapy, tailoring decisions to individual patient'),\n",
       " Document(metadata={}, page_content='characteristics and prognostic factors. The'),\n",
       " Document(metadata={}, page_content='uncertainty surrounding the efficacy and safety of these'),\n",
       " Document(metadata={}, page_content='strategies necessitates further randomized studies,'),\n",
       " Document(metadata={}, page_content='while ongoing research explores novel approaches, such as the'),\n",
       " Document(metadata={}, page_content='potential use of innovative agents like'),\n",
       " Document(metadata={}, page_content='sacituzumab govitecan in the context of de-escalating'),\n",
       " Document(metadata={}, page_content='traditional CHT. The imperative to extend access to'),\n",
       " Document(metadata={}, page_content='immunotherapy to subgroups, such as those with low ER'),\n",
       " Document(metadata={}, page_content='expression, holds crucial promise, paving the way'),\n",
       " Document(metadata={}, page_content='for a more personalized and targeted future direction in TNBC'),\n",
       " Document(metadata={}, page_content='treatment.'),\n",
       " Document(metadata={}, page_content='In the next few years, it will be necessary to design new'),\n",
       " Document(metadata={}, page_content='prospective clinical trials and wait for the'),\n",
       " Document(metadata={}, page_content='results of those in progress, for a better knowledge of the'),\n",
       " Document(metadata={}, page_content='efficacy of combination therapies, therapeutic'),\n",
       " Document(metadata={}, page_content='sequences and new target drugs for the treatment of a disease'),\n",
       " Document(metadata={}, page_content='which up to a few years ago was considered'),\n",
       " Document(metadata={}, page_content='“untargetable”. This should be accompanied by a commitment to'),\n",
       " Document(metadata={}, page_content='biomarker discovery, which could help the'),\n",
       " Document(metadata={}, page_content='oncologist make the best decision for patient care.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 243\\nAbbreviations\\nAC: doxorubicin and cyclophosphamide'),\n",
       " Document(metadata={}, page_content='ADCs: antibody-drug conjugates\\nBC: breast cancer'),\n",
       " Document(metadata={}, page_content='BRCA: breast cancer susceptibility genes\\nCHT: chemotherapy'),\n",
       " Document(metadata={}, page_content='CI: confidence interval'),\n",
       " Document(metadata={}, page_content='CREATE-X: Capecitabine for Residual Cancer as Adjuvant Therapy'),\n",
       " Document(metadata={}, page_content='ctDNA: circulating tumor DNA\\nDFS: disease-free survival'),\n",
       " Document(metadata={}, page_content='EFS: event-free survival\\nER: estrogen receptor'),\n",
       " Document(metadata={}, page_content='FDA: Food and Drug Administration'),\n",
       " Document(metadata={}, page_content='HER2: human epidermal growth factor receptor 2\\nHR: hazard ratio'),\n",
       " Document(metadata={}, page_content='HR+: hormone receptor-positive\\nICI: immune checkpoint inhibitor'),\n",
       " Document(metadata={}, page_content='iDFS: invasive disease-free survival\\nIM: immunomodulatory'),\n",
       " Document(metadata={}, page_content='LAR: luminal androgen receptor\\nM: mesenchymal'),\n",
       " Document(metadata={}, page_content='NACT: neoadjuvant chemotherapy\\nOS: overall survival'),\n",
       " Document(metadata={}, page_content='PARP: Poly(ADP-ribose) polymerase'),\n",
       " Document(metadata={}, page_content='pCR: pathologic complete response'),\n",
       " Document(metadata={}, page_content='PD-L1: programmed death ligand 1\\nRCB: residual cancer burden'),\n",
       " Document(metadata={}, page_content='TILs: tumor-infiltrating lymphocytes'),\n",
       " Document(metadata={}, page_content='TMB: tumor mutational burden\\nTME: tumor microenvironment'),\n",
       " Document(metadata={}, page_content='TNBC: triple negative breast cancer\\nDeclarations'),\n",
       " Document(metadata={}, page_content='Author contributions'),\n",
       " Document(metadata={}, page_content='PDS: Conceptualization, Investigation, Writing—original draft,'),\n",
       " Document(metadata={}, page_content='Writing—review & editing, Validation,'),\n",
       " Document(metadata={}, page_content='Supervision. MP, CG, and GRO: Conceptualization, Investigation,'),\n",
       " Document(metadata={}, page_content='Writing—original draft, Writing—review &'),\n",
       " Document(metadata={}, page_content='editing. ANS, PF, and CL: Validation, Writing—review & editing,'),\n",
       " Document(metadata={}, page_content='Supervision. DC: Investigation. All authors'),\n",
       " Document(metadata={}, page_content='read and approved the submitted version.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 244\\nConflicts of interest'),\n",
       " Document(metadata={}, page_content='The authors declare that they have no conflicts of interest.'),\n",
       " Document(metadata={}, page_content='Ethical approval\\nNot applicable.\\nConsent to participate'),\n",
       " Document(metadata={}, page_content='Not applicable.\\nConsent to publication\\nNot applicable.'),\n",
       " Document(metadata={}, page_content='Availability of data and materials\\nNot applicable.\\nFunding'),\n",
       " Document(metadata={}, page_content='Not applicable.\\nCopyright\\n© The Author(s) 2024.\\nReferences'),\n",
       " Document(metadata={}, page_content='Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic'),\n",
       " Document(metadata={}, page_content='markers in triple-negative breast cancer.'),\n",
       " Document(metadata={}, page_content='Clin Breast Cancer. 2018;18:e841–50.\\n1.'),\n",
       " Document(metadata={}, page_content='Howard FM, Olopade OI. Epidemiology of triple-negative breast'),\n",
       " Document(metadata={}, page_content='cancer: a review. Cancer J. 2021;27:'),\n",
       " Document(metadata={}, page_content='8–16.\\n2.'),\n",
       " Document(metadata={}, page_content='Almansour NM. Triple-negative breast cancer: a brief review'),\n",
       " Document(metadata={}, page_content='about epidemiology, risk factors,'),\n",
       " Document(metadata={}, page_content='signaling pathways, treatment and role of artificial'),\n",
       " Document(metadata={}, page_content='intelligence. Front Mol Biosci. 2022;9:836417.'),\n",
       " Document(metadata={}, page_content='3.'),\n",
       " Document(metadata={}, page_content='Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ,'),\n",
       " Document(metadata={}, page_content='et al. The genomic and transcriptomic'),\n",
       " Document(metadata={}, page_content='architecture of 2,000 breast tumours reveals novel subgroups.'),\n",
       " Document(metadata={}, page_content='Nature. 2012;486:346–52.'),\n",
       " Document(metadata={}, page_content='4.'),\n",
       " Document(metadata={}, page_content='Azim HA, Ghosn M, Oualla K, Kassem L. Personalized treatment in'),\n",
       " Document(metadata={}, page_content='metastatic triple-negative breast'),\n",
       " Document(metadata={}, page_content='cancer: the outlook in 2020. Breast J. 2020;26:69–80.\\n5.'),\n",
       " Document(metadata={}, page_content='Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P,'),\n",
       " Document(metadata={}, page_content='Rubio IT, et al.; ESMO Guidelines'),\n",
       " Document(metadata={}, page_content='Committee. Early breast cancer: ESMO Clinical Practice'),\n",
       " Document(metadata={}, page_content='Guidelines for diagnosis, treatment and'),\n",
       " Document(metadata={}, page_content='follow-up†. Ann Oncol. 2019;30:1194–220. Erratum in: Ann Oncol.'),\n",
       " Document(metadata={}, page_content='2019;30:1674. Erratum in: Ann'),\n",
       " Document(metadata={}, page_content='Oncol. 2021;32:284. \\n6.'),\n",
       " Document(metadata={}, page_content='Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et'),\n",
       " Document(metadata={}, page_content='al.; National Surgical Adjuvant'),\n",
       " Document(metadata={}, page_content='Breast and Bowel Project Protocol B-27. The effect on tumor'),\n",
       " Document(metadata={}, page_content='response of adding sequential'),\n",
       " Document(metadata={}, page_content='preoperative docetaxel to preoperative doxorubicin and'),\n",
       " Document(metadata={}, page_content='cyclophosphamide: preliminary results from'),\n",
       " Document(metadata={}, page_content='National Surgical Adjuvant Breast and Bowel Project Protocol'),\n",
       " Document(metadata={}, page_content='B-27. J Clin Oncol. 2003;21:4165–74.'),\n",
       " Document(metadata={}, page_content='7.'),\n",
       " Document(metadata={}, page_content='Golshan M, Loibl S, Wong SM, Houber JB, O’Shaughnessy J, Rugo'),\n",
       " Document(metadata={}, page_content='HS, et al. Breast conservation after'),\n",
       " Document(metadata={}, page_content='neoadjuvant chemotherapy for triple-negative breast cancer:'),\n",
       " Document(metadata={}, page_content='surgical results from the BrighTNess'),\n",
       " Document(metadata={}, page_content='randomized clinical trial. JAMA Surg. 2020;155:e195410. Erratum'),\n",
       " Document(metadata={}, page_content='in: JAMA Surg. 2021;156:503.'),\n",
       " Document(metadata={}, page_content='8.'),\n",
       " Document(metadata={}, page_content='Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan'),\n",
       " Document(metadata={}, page_content='R, et al. Integrative molecular'),\n",
       " Document(metadata={}, page_content='profiling of triple negative breast cancers identifies amplicon'),\n",
       " Document(metadata={}, page_content='drivers and potential therapeutic'),\n",
       " Document(metadata={}, page_content='targets. Oncogene. 2010;29:2013–23.\\n9.'),\n",
       " Document(metadata={}, page_content='Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G.'),\n",
       " Document(metadata={}, page_content='Practical classification of triple-negative breast'),\n",
       " Document(metadata={}, page_content='cancer: intratumoral heterogeneity, mechanisms of drug'),\n",
       " Document(metadata={}, page_content='resistance, and novel therapies. NPJ Breast'),\n",
       " Document(metadata={}, page_content='Cancer. 2020;6:54.\\n10.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 |'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.37349/etat.2024.00215'),\n",
       " Document(metadata={}, page_content='Page 245'),\n",
       " Document(metadata={}, page_content='Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al.'),\n",
       " Document(metadata={}, page_content='Advancements in clinical aspects of targeted'),\n",
       " Document(metadata={}, page_content='therapy and immunotherapy in breast cancer. Mol Cancer.'),\n",
       " Document(metadata={}, page_content='2023;22:105.'),\n",
       " Document(metadata={}, page_content='11.'),\n",
       " Document(metadata={}, page_content='Liu Z, Li M, Jiang Z, Wang X. A comprehensive immunologic'),\n",
       " Document(metadata={}, page_content='portrait of triple-negative breast cancer.'),\n",
       " Document(metadata={}, page_content='Transl Oncol. 2018;11:311–29.\\n12.'),\n",
       " Document(metadata={}, page_content='Farshbafnadi M, Pastaki Khoshbin A, Rezaei N. Immune checkpoint'),\n",
       " Document(metadata={}, page_content='inhibitors for triple-negative'),\n",
       " Document(metadata={}, page_content='breast cancer: from immunological mechanisms to clinical'),\n",
       " Document(metadata={}, page_content='evidence. Int Immunopharmacol. 2021;98:'),\n",
       " Document(metadata={}, page_content='107876.\\n13.'),\n",
       " Document(metadata={}, page_content='Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y,'),\n",
       " Document(metadata={}, page_content='et al. Refinement of triple-negative'),\n",
       " Document(metadata={}, page_content='breast cancer molecular subtypes: implications for neoadjuvant'),\n",
       " Document(metadata={}, page_content='chemotherapy selection. PLoS One.'),\n",
       " Document(metadata={}, page_content='2016;11:e0157368.\\n14.'),\n",
       " Document(metadata={}, page_content='Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A,'),\n",
       " Document(metadata={}, page_content='Fuqua SAW, et al. Comprehensive'),\n",
       " Document(metadata={}, page_content='genomic analysis identifies novel subtypes and targets of'),\n",
       " Document(metadata={}, page_content='triple-negative breast cancer. Clin Cancer'),\n",
       " Document(metadata={}, page_content='Res. 2015;21:1688–98.\\n15.'),\n",
       " Document(metadata={}, page_content='Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue MZ, et al.; AME Breast'),\n",
       " Document(metadata={}, page_content='Cancer Collaborative Group. Multi-omics'),\n",
       " Document(metadata={}, page_content='profiling reveals distinct microenvironment characterization and'),\n",
       " Document(metadata={}, page_content='suggests immune escape'),\n",
       " Document(metadata={}, page_content='mechanisms of triple-negative breast cancer. Clin Cancer Res.'),\n",
       " Document(metadata={}, page_content='2019;25:5002–14.'),\n",
       " Document(metadata={}, page_content='16.'),\n",
       " Document(metadata={}, page_content='Pelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, Hutton C,'),\n",
       " Document(metadata={}, page_content='et al. Anti-inflammatory drugs'),\n",
       " Document(metadata={}, page_content='remodel the tumor immune environment to enhance immune'),\n",
       " Document(metadata={}, page_content='checkpoint blockade efficacy. Cancer'),\n",
       " Document(metadata={}, page_content='Discov. 2021;11:2602–19.\\n17.'),\n",
       " Document(metadata={}, page_content='Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y,'),\n",
       " Document(metadata={}, page_content='Harrington S, et al. PD-L1 expression in'),\n",
       " Document(metadata={}, page_content='triple-negative breast cancer. Cancer Immunol Res.'),\n",
       " Document(metadata={}, page_content='2014;2:361–70.'),\n",
       " Document(metadata={}, page_content='18.'),\n",
       " Document(metadata={}, page_content='Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, et al.'),\n",
       " Document(metadata={}, page_content='Prevalence of BRCA1 mutations and responses'),\n",
       " Document(metadata={}, page_content='to neoadjuvant chemotherapy among BRCA1 carriers and'),\n",
       " ...]"
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "text_splitter.create_documents([text])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "14732269-22da-4837-8188-c1d9b5010919",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 232\\n© The Author(s) 2024. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International \\nLicense (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution'),\n",
       " Document(metadata={}, page_content='and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the \\noriginal author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.\\nExploration of Targeted Anti-tumor Therapy\\nOpen Access\\nReview\\nEarly-stage triple negative breast cancer: the therapeutic role of \\nimmunotherapy and the prognostic value of pathological complete \\nresponse'),\n",
       " Document(metadata={}, page_content='response\\nPierluigi De Santis1, Martina Perrone1, Chiara Guarini1, Anna Natalizia Santoro1, Carmelo Laface1, \\nDaniela Carrozzo1, Gaia Rachele Oliva2, Palma Fedele1*\\n1Oncology Unit, Francavilla Fontana Ceglie Messapica Hospital District, 72021 Francavilla Fontana, Italy\\n2Department of Medicine and Translational Surgery, Università Cattolica del Sacro Cuore, 00168 Roma, Italy'),\n",
       " Document(metadata={}, page_content='*Correspondence: Palma Fedele, Oncology Unit, Francavilla Fontana Ceglie Messapica Hospital District, 72021 Francavilla \\nFontana, Italy. minafedele@hotmail.com\\nAcademic Editor: Laura Cerchia, Institute of Experimental Endocrinology and Oncology “G. Salvatore”-National Research \\nCouncil (IEOS-CNR), Italy; Simona Camorani, Institute of Experimental Endocrinology and Oncology “G. Salvatore”-National \\nResearch Council (IEOS-CNR), Italy'),\n",
       " Document(metadata={}, page_content='Research Council (IEOS-CNR), Italy\\nReceived: May 26, 2023  Accepted: December 26, 2023  Published: February 28, 2024\\nCite this article: De Santis P, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, et al. Early-stage triple negative breast \\ncancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response. Explor Target \\nAntitumor Ther. 2024;5:232–50. https://doi.org/10.37349/etat.2024.00215\\nAbstract'),\n",
       " Document(metadata={}, page_content='Abstract\\nTriple negative breast cancer (TNBC) represents an aggressive disease associated with a high risk of \\nrecurrence after curative treatment and a poor prognosis in the metastatic setting. Chemotherapy was for \\nyears the only treatment available in the early and metastatic setting, due to the lack of actionable targets. \\nClinical practice has changed following the results obtained with the addition of immunotherapy to'),\n",
       " Document(metadata={}, page_content='standard chemotherapy, the development of novel drugs [i.e. antibody-drug conjugates (ADCs)], and the \\nuse of targeted treatments for patients carrying germline pathogenic breast cancer susceptibility genes \\n(BRCA) 1 or BRCA 2 variants. The treatment of early-stage disease has had a shift in clinical practice since \\nJuly 2021, after the Food and Drug Administration (FDA) approval of pembrolizumab in association with'),\n",
       " Document(metadata={}, page_content='chemotherapy as neoadjuvant treatment for TNBC and as a single agent in the subsequent adjuvant setting. \\nThis intensive treatment based on the combination of a poly-chemotherapy and an immune checkpoint \\ninhibitor (ICI) led to the improvement of short- and long-term outcomes, but it has highlighted some new \\nunmet clinical needs in the treatment of early-stage TNBC: the selection of the most effective adjuvant'),\n",
       " Document(metadata={}, page_content='therapy and the integration of pembrolizumab with other therapeutic strategies [capecitabine, poly(ADP-\\nribose) polymerase (PARP) inhibitors] based on the achievement of pathologic complete response (pCR); \\nthe identification of predictive biomarkers to select patients who could most benefit from the addition of \\nICI, to minimize toxicities and to maximize outcomes; the possibility of de-escalating chemotherapy in favor'),\n",
       " Document(metadata={}, page_content='of immune-combo or novel agents, such as ADCs; the role of immunotherapy in estrogen receptor (ER)-low \\npatients. The advent of immunotherapy not only addresses current challenges in TNBC treatment but also \\nholds the promise of a radical transformation in its therapeutic paradigm, enhancing significantly clinical \\noutcomes and offering new perspectives for patients grappling with this aggressive form of breast cancer.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 233\\nKeywords\\nTriple negative breast cancer, immunotherapy, pathological complete response, neoadjuvant combination \\ntreatment, adjuvant treatment\\nIntroduction\\nTriple negative Breast Cancer (TNBC) is a histological subtype of breast cancer (BC) characterized by the'),\n",
       " Document(metadata={}, page_content='immunohistochemical lack of expression (< 1%) of estrogen receptor (ER), progesterone receptor (PgR), \\nand human epidermal growth factor receptor 2 (HER2). It accounts for approximately 10–20% of all BC, \\naffecting mainly young, premenopausal women, and individuals with inherited gene alterations, such as BC \\nsusceptibility genes 1/2 (BRCA 1/2) mutations [1–3]. It notably presents an aggressive biological behavior'),\n",
       " Document(metadata={}, page_content='with a trend to have a higher grade and an often lymph node involvement at diagnosis, an inclination to \\nmetastasize after curative treatment, and a poorer prognosis in metastatic setting when compared with \\nother BC subtypes [4, 5].\\nFor decades, treatment for early TNBC has been based on surgery and subsequent adjuvant \\nchemotherapy (CHT) for the reduction of disease recurrence [6]. Therefore, conventional cytotoxic CHT has'),\n",
       " Document(metadata={}, page_content='represented the backbone of systemic treatment in the early TNBC, including neoadjuvant treatment, which \\nused to reduce tumor size in larger tumors increasing the chances of a breast-conserving surgery [7, 8]. In \\nrecent years the development of novel therapeutic approaches has been difficult, due to the heterogeneity \\nof TNBC and lack of therapeutic targets [9, 10]. Nevertheless, immunotherapy and poly(ADP-ribose)'),\n",
       " Document(metadata={}, page_content='polymerase (PARP) inhibitors have shown survival benefits in recent studies.\\nSpecifically, combinations of immune checkpoint inhibitors (ICIs) with CHT or other alternative \\ntherapeutic compounds could emerge as a successful therapeutic approach in the management of TNBC \\npatients. Despite the progress in ICIs representing a notable milestone in TNBC treatment, additional'),\n",
       " Document(metadata={}, page_content='investigations are necessary to tackle this issue comprehensively. A profound comprehension of tumor \\nsubtypes, alongside tumor microenvironment (TME) and in terms of molecular, genetic, and immune \\naspects, would amplify the potential for developing targeted immunotherapy to achieve superior \\ntherapeutic effectiveness, especially in TNBC [11].\\nTherefore, in this review, we aimed to investigate the role of immunotherapy in early-stage TNBC, the'),\n",
       " Document(metadata={}, page_content='prognostic value of pathologic complete response (pCR) with its therapeutic implications, and the future \\nperspectives regarding the systemic treatment of early TNBC, including the discovery of new biomarkers.\\nThe landscape of immunotherapy in TNBC\\nThe immune system plays a crucial role in TNBC compared to the other molecular subtypes of BC. Although'),\n",
       " Document(metadata={}, page_content='originally BC was considered non-immunogenic, TNBC has a high immunogenic potential, making it a \\npromising candidate for immunotherapy, especially with ICIs [12, 13]. TNBC immunogenicity is related to \\nintrinsic tumor cell signatures and tumoral surrounding microenvironment features.\\nOver the last decades thanks to emerging technologies such as next-generation sequencing (NGS), the'),\n",
       " Document(metadata={}, page_content='knowledge of the molecular and genetic background of TNBC improved, bringing to light its intertumoral \\nand intratumoral heterogeneity.\\nA first classification divided TNBC into six subtypes: basal-like 1 (BL1), basal-like 2 (BL2), \\nmesenchymal (M), M stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR) [14].\\nSubsequently, analyzing RNA and DNA-based profiles of 198 TNBC tumors, a four-type classification of'),\n",
       " Document(metadata={}, page_content='TNBC was shaped: basal-like immunosuppressed (BLIS), basal-like immune-activated (BLIA), M and LAR \\n[15]. This classification was further revised with the identification of four specific TNBC subtypes: BL1, BL2, \\nM, and LAR, omitting IM and MSL because of the dependence of these two subtypes on the TME features \\n[14].\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 234'),\n",
       " Document(metadata={}, page_content='Page 234\\nIn addition, TNBC could be classified into three microenvironment phenotypes or clusters:\\nCluster 1: “immune-desert” with poor immune cell permeation, due to a high presence of MYC \\namplifications and, consequently, a lower recruitment of innate immune cells.\\n(1).\\nCluster 2: “innate immune-inactivated” characterized by a hyper-activation of \\nphosphatidylinositide 3-kinase/protein kinase B (PI3K-AKT) pathway in tumor cells, low tumor'),\n",
       " Document(metadata={}, page_content='antigen burden and infiltration of deactivated innate immune cells, fibroblasts, and endothelial \\ncells. Clusters 1 and 2 are therefore referred to as “cold tumors”.\\n(2).\\nCluster 3: “immune-inflamed”, the so-called “hot tumor” that represents about 30% of TNBCs and \\nis characterized by an abundant adaptive and innate immune cells infiltration and with a high \\nexpression of immune checkpoint molecules [16].\\n(3).'),\n",
       " Document(metadata={}, page_content='(3).\\nThe potential “hot” conversion of “cold” tumors could improve the efficacy of cancer immunotherapy. \\nFor example, local IM therapies can express a synergistic effect with immunotherapy by acting on \\ncomponents of the TME and immune system function, such as elevating the expression of tumor antigens \\nand increasing the recruitment of activated immune cells in the TME [17].'),\n",
       " Document(metadata={}, page_content='TNBC cancer cell immunological features include genomic instability and high tumor mutational \\nburden (TMB), resulting in more somatic mutations and neoantigens [18].\\nMoreover, approximately 10–20% of TNBC harbor BRCA 1 or BRCA 2 germinal mutations, with a \\nconsequent hereditary deficit in the DNA repair mechanism and strong genomic instability. Several studies'),\n",
       " Document(metadata={}, page_content='have demonstrated that TNBC-carrying BRCA mutations are more sensitive to DNA-damaging drugs such as \\nanthracyclines, but also platinum agents and PARP inhibitors [19–21]. Sensitivity to these drugs was also \\nobserved in tumors with alterations in other genes, sharing BRCA-mutant phenotype in the absence of a \\nBRCA 1/2 mutation, namely “BRCAness” [22, 23].'),\n",
       " Document(metadata={}, page_content='BRCA 1/2 mutation, namely “BRCAness” [22, 23].\\nTumors with BRCA 1/2 mutations or BRCAness TNBC are more immunogenic than TNBC without these \\ngenetic alterations [24–26].\\nCompared to the other BC subtypes the immunogenic TME features in TNBC consist of higher levels of \\nvascular endothelial growth factor (VEGF), that promote tumor cell growth and migration such as mitogen-'),\n",
       " Document(metadata={}, page_content='activated protein kinases (MAPKs), tumor-associated macrophages (TAMs), and tumor-infiltrating \\nlymphocytes (TILs), white blood cells that migrate towards the tumor, leading to an important \\nimmunogenic effect and consequently that are involved in killing cancer cells [27–29].\\nTAMs regulate the interaction between the immune system and cancer cells. CD163+ M2 macrophages,'),\n",
       " Document(metadata={}, page_content='which are associated with tumors characterized by higher proliferation and poorer differentiation [30], are \\nmore present in TNBC and basal-like BC [31]. A prosperous infiltration of TILs is found in TNBC tumors and \\nthe stroma surrounding them, with a recognized predictive and prognostic role, specifically for CD4+ CD8+ \\nT cells [32]. Several studies have reported better response to neoadjuvant CHT (NACT) [33] and better'),\n",
       " Document(metadata={}, page_content='clinical outcomes in BC with high TIL infiltrate [34–39]. Based on this evidence, the international TILs \\nworking group started standardizing the evaluation of BC TILs to use it in clinical practice identifying those \\npatients that may benefit from emerging immunotherapies with ICIs or combination therapies [40].\\nAll these TME elements contribute to TNBC immunogenicity which also appears to be closely related to'),\n",
       " Document(metadata={}, page_content='the concept of TMB, depending on the ineffective DNA repair system with the consequent generation of \\nhigh rates of neoantigens. The upregulated antigen presentation system leads to an increasing number of \\ninnate and adaptative immune cells and many cytokines interplaying with cancer cells. However, the exact \\nrelationship between TMB, neoantigens, and immune infiltration is not yet completely understood, and'),\n",
       " Document(metadata={}, page_content='some studies have reported an inverse association between immune cells in TME and the rate of somatic \\ncopy number alterations [41, 42].\\nMoreover, although TMB is comparable across the three clusters of TNBC, the “immune-inflated” \\nphenotype is characterized by a higher degree of immune cells in the TME, but also a high expression of \\nimmune checkpoints by cancer cells [16]. The rate of TILs, indeed, has been positively related to'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 235\\nprogrammed death ligand 1 (PD-L1) expression [43]. PD-L1 is an immune checkpoint that mediates local \\nimmune escape in many tumors inducing saturation of activated T cells. Even if PD-L1 prognostic role is yet \\ncontroversial [44], however it results more overexpressed in TNBC compared with other BC and it can'),\n",
       " Document(metadata={}, page_content='predict responsiveness to immunotherapy [16].\\nTherefore, TNBC represents an aggressive BC subtype, associated with high mutational load, high \\ntumor immunogenicity and TME diversity.\\nNew paradigms in early TNBC: from CHT to immunotherapy\\nCHT in adjuvant treatment for TNBC\\nIn early TNBC patients, CHT represents the mainstay of adjuvant and neoadjuvant treatments. Adjuvant'),\n",
       " Document(metadata={}, page_content='CHT is recommended for tumor sizes greater than 1.0 cm and patients with nodal involvement, regardless \\nof tumor size. Therefore, it can be considered for tumor sizes between 0.6–1.0 cm [45]. A recent large meta-\\nanalysis demonstrated that adjuvant CHT with anthracyclines-containing regimens plus taxanes, compared \\nwith no CHT, can reduce BC mortality rates by about 40% during the first decade after diagnosis. Moreover,'),\n",
       " Document(metadata={}, page_content='regimens with higher cumulative and dose-dense schedules of anthracycline (with granulocyte colony-\\nstimulating factor support) have shown better survival benefits and more reductions in recurrence [46]. \\nThree-weekly docetaxel and paclitaxel can be considered in adjuvant setting, but weekly paclitaxel, in a \\nsubgroup analysis, has shown improved outcomes and is preferred for TNBC [47]. In TNBC in frail patients'),\n",
       " Document(metadata={}, page_content='with a known history of heart disease, to minimize the cardiotoxicity of adjuvant treatments, docetaxel \\ncombined with cyclophosphamide (TC) has proven to be a viable alternative to doxorubicin and \\ncyclophosphamide (AC), demonstrating a favorable disease-free survival (DFS) [48]. Therefore, there is a \\nbroad spectrum of chemotherapeutic treatments for early TNBC that should be customised according to the \\npatient and expected toxicities.'),\n",
       " Document(metadata={}, page_content='patient and expected toxicities.\\nThe role of platinum in adjuvant setting for TNBC\\nTNBC patients commonly harbor BRCA 1/2 or BRCAness mutations with a homologous recombination \\ndeficiency (HRD) that makes them particularly susceptible to platinum agents due to their ability to hit \\ncancer cells that have deficient DNA repair mechanisms [49–51]. Several retrospective single-center studies'),\n",
       " Document(metadata={}, page_content='have explored the role of adjuvant platinum combined with standard anthracycline and taxane-based \\nregimens, with controversial results not showing clear clinical benefits [52, 53]. Nevertheless, a recent \\nphase III trials have demonstrated a longer 5-year DFS (86.5% vs. 80.3%) with similar results in distant DFS \\nand relapse-free survival (RFS) of platinum-containing adjuvant regimens (paclitaxel-carboplatin)'),\n",
       " Document(metadata={}, page_content='compared to a standard anthracyclines-containing regimen followed by taxane, however with no benefit in \\noverall survival (OS) [54].\\nAnother important factor is platinum resistance. Platinum sensitivity may be affected by changes in the \\nhazard ratio (HR) pathway or, in the case of patients with BRCA 1/2 mutations, by the secondary \\nappearance of new BRCA 1 or 2 mutations that make cancer cells less sensitive to platinum [55, 56].'),\n",
       " Document(metadata={}, page_content='Other mechanisms of resistance to platinum compounds are:\\nModification of drug transport within the tumor cell, by determining decreased influx or increased \\nefflux.\\n(1).\\nIncrease of detoxification systems.\\n(2).\\nDecrease of cell apoptosis [57].\\n(3).\\nTherefore, the benefit of adjuvant platinum-based regimens remains controversial and needs \\nvalidation by prospective adjuvant ongoing trials.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 236\\nNeoadjuvant treatments for TNBC\\nNACT\\nSeveral treatment guidelines recommend NACT as the preferred option for stage II or III TNBC and for \\nstage I with a tumor size greater than 1 cm. It can be considered in stage I TNBC with a tumor size from \\n0.6 cm to 1 cm and/or in the case of tumors with nodal micrometastases. [6, 45]. There is no significant'),\n",
       " Document(metadata={}, page_content='difference in survival benefits between patients receiving neoadjuvant or adjuvant CHT after surgical \\nresection. However, neoadjuvant treatments can be useful for inoperable tumors rendering them operable \\nand they can also downstage patients with operable BC promoting breast-conservation [58, 59]. The use of \\nneoadjuvant treatments provides important prognostic information based on response to therapy.'),\n",
       " Document(metadata={}, page_content='Achieving a pCR, defined as the lack of cancer cells in tissue samples of breast and axillary lymph nodes, \\nafter a neoadjuvant treatment, is associated with favorable disease-free and OS in early TNBC, as \\ndemonstrated in Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) pooled analysis. In this \\nstudy, patients with early BC treated with NACT and followed by surgery who obtained pCR (ypT0 ypN0,'),\n",
       " Document(metadata={}, page_content='ypT0/is ypN0) were associated with improved event-free survival (EFS) and OS, especially in TNBC (HR = \\n0.24 and HR = 0.16, respectively) [33]. Like adjuvant treatment, traditional NACT is based on anthracyclines \\nand taxanes, and a dose-dense regimen is preferred in neoadjuvant settings based on proven improved DFS \\nand OS in a large meta-analysis [60].'),\n",
       " Document(metadata={}, page_content='and OS in a large meta-analysis [60].\\nIn recent years, the use of platinum-based combination regimens has been the focus of neoadjuvant \\ntreatment to increase the rate of pCR in TNBC. Three recent studies demonstrated that combining platinum \\nwith taxane and anthracycline led to an improvement in the pCR rate in TNBC, with a similar survival \\nbenefit [61–63]. In Brightness Trial patients with II–III stage TNBC were randomly assigned to receive'),\n",
       " Document(metadata={}, page_content='paclitaxel alone, paclitaxel and carboplatin and this combination with a PARP inhibitor, veliparib followed \\nby AC. Although the addition of veliparib and carboplatin was associated with an increase of patients who \\nachieved a pCR compared to paclitaxel alone (53% vs. 31%, P < 0.0001), but not to paclitaxel and \\ncarboplatin, this benefit could be related to the addition of the carboplatin [63]. The initial rationale for'),\n",
       " Document(metadata={}, page_content='using the combination of platinum in NACT was that sporadic TNBC can show BRCAness with a major \\nresponse to platinum regimens [50, 51]. However, the greatest benefit was seen in patients who were \\ngermline BRCA wild type, and only a marginal benefit was observed in the germline BRCA mutant \\nsubgroup, as was shown in the recent GeparOLA trial. In this trial, patients were randomized to'),\n",
       " Document(metadata={}, page_content='neoadjuvant therapy with paclitaxel and carboplatin vs. neoadjuvant therapy with paclitaxel and olaparib \\n(PARP inhibitor). In both arms, the combination of epirubicin and cyclophosphamide was administered \\nnext. This study, although limited by a small number of patients enrolled, showed an advantage for the \\ncarboplatin arm in patients without BRCA mutation (germ or somatic) and high HRD. The 4-year invasive'),\n",
       " Document(metadata={}, page_content='DFS (iDFS) rate with olaparib-paclitaxel was 81.2% vs. 93.4% with carboplatin-paclitaxel (CP) [HR = 3.03; \\n95% confidence interval (CI) = 0.67–13.67; log-rank P = 0.1290]. The 4-year OS rate was 89.2% with the \\nolaparib combination vs. 96.6% with carboplatin (HR = 3.27; 95% CI = 0.39–27.20; log-rank P = 0.2444). \\nThe trend of the iDFS curves was similar in the two treatment arms and independent of germline or somatic \\nBRCA mutation [64].'),\n",
       " Document(metadata={}, page_content='BRCA mutation [64].\\nPlatinum combinations are currently recommended for selected patients with TNBC who require \\nadequate local control before surgical resection [45]. A more recent phase III trial presented at the San \\nAntonio Breast Cancer Symposium evaluating the efficacy and safety of adding carboplatin to standard \\nsequential taxane-anthracycline NACT in patients with TNBC who had no evidence of metastatic disease,'),\n",
       " Document(metadata={}, page_content='has observed improvements in terms of DFS (5-year DFS were 70.6% and 64.5% respectively with a HR = \\n0.79, 95% CI = 0.61–1.02, P = 0.073) and OS (5-year OS were 74.0% and 66.7% respectively with a HR = \\n0.75, 95% CI = 0.57–0.98, P = 0.034) with the addition of carboplatin, but these benefits were limited to \\npatients who were 50 years of age or younger. Therefore, the pCR in the intention-to-treat population was'),\n",
       " Document(metadata={}, page_content='54.5% in the carboplatin arm and 40.3% in the control arm (P < 0.001) [65].\\nThe inclusion of platinum agents as NACT for TNBC remains controversial. Long-term outcomes and \\nnew prospective studies are needed to clarify the role of platinum agents in this setting.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 237\\nNeoadjuvant immunotherapy'),\n",
       " Document(metadata={}, page_content='Page 237\\nNeoadjuvant immunotherapy\\nThe success of ICIs in metastatic TNBC led to expand their role in neoadjuvant settings. Pembrolizumab and \\natezolizumab have shown progression-free survival (PFS) benefits in phase III trials in advanced setting \\n[66, 67]. In contrast to atezolizumab that showed conflicting results [68, 69], pembrolizumab consistently'),\n",
       " Document(metadata={}, page_content='showed OS benefits in advanced TNBC [66, 70]. In early-stage TNBC two studies evaluated atezolizumab in \\nneoadjuvant setting. In the NeoTRIPaPDL1 trial, no improvement in pCR was shown with the addition of \\natezolizumab to a non-anthracycline-containing CHT regimen [71]. More recent Impassion031 phase III \\nstudy evaluating the association of atezolizumab to a standard NACT (nab-palclitaxel weekly for 12 weeks'),\n",
       " Document(metadata={}, page_content='followed by 4 cycles of AC), has demonstrated a significant improvement of pCR rates in intention to treat \\n(ITT) population (58% in atezolizumab arm vs. 41% in placebo arm, P = 0.0044), regardless of PD-L1 status, \\nmeeting the primary endpoint of the study [72]. Therefore, in early BC the combination of pembrolizumab \\nwith paclitaxel-carboplatin followed by anthracycline increased pCR rate and EFS rate in the KEYNOTE-522'),\n",
       " Document(metadata={}, page_content='trial, representing a turning point for the role of immunotherapy in neoadjuvant therapy of TNBC and \\nestablishing pembrolizumab as a standard treatment during neoadjuvant treatment for stage II and III \\nTNBC. The trial evaluated the combination of pembrolizumab (18 cycles, 200 mg every 3 weeks) combined \\nwith four cycles of paclitaxel (weekly or 3-weekly) and carboplatin (3-weekly), followed by 3-weekly AC for'),\n",
       " Document(metadata={}, page_content='4 cycles, compared to placebo with CHT. Pembrolizumab arm showed a 13.6% improvement in pCR [64.8% \\n(95% CI = 59.9–69.5%) vs. 51.2% (95% CI = 44.1–58.3%)] and in EFS rate [84.5% (95% CI = 81.7–86.9%) \\nvs. 76.8% (95% CI = 72.2–80.7%)], meeting the primary endpoint of the study, regardless nodal \\ninvolvement and PD-L1 status. The average duration of follow-up is still immature, but a trend of'),\n",
       " Document(metadata={}, page_content='superiority in terms of OS in the pembrolizumab arm was nevertheless detected [73]. Limits of this study \\nare the lack of biomarkers that predict what patient may benefit from the addition of pembrolizumab and \\nthe non-utilization of dose-dense schedule of AC which showed superior OS benefit in the neoadjuvant \\nsetting in TNBC [74].\\nMoreover, the recent GeparNuevo trial showed that durvalumab (1,500 mg every 4 weeks) added to'),\n",
       " Document(metadata={}, page_content='NACT consisting of nab-paclitaxel 125 mg/m2 weekly for 12 weeks, followed by epirubicin/\\ncyclophosphamide every 2 weeks, in early TNBC significantly improved iDFS (85.6% with durvalumab vs. \\n77.2% with placebo HR = 0.48, 95% CI = 0.24–0.97, stratified log-rank P = 0.036) and OS (95.2% vs. 83.5% \\nwith a HR = 0.24, 95% CI = 0.08–0.72, P = 0.006), despite a modest pCR increase and no adjuvant'),\n",
       " Document(metadata={}, page_content='component of durvalumab [75]. Future studies should aim to define the role of immunotherapy in the \\ntreatment of early TNBC, to define the ideal duration of these treatments, and should research new \\nbiomarkers to personalize treatments.\\nPathological complete response: prognostic role and therapeutic \\nimplications\\nIn clinical practice, the achievement of pCR after neoadjuvant treatment is correlated to the improvement of'),\n",
       " Document(metadata={}, page_content='long-term benefits concerning EFS and OS. Its prognostic value is greatest in aggressive tumor subtypes, \\nlike in TNBC (EFS: HR = 0.24; OS: HR = 0.16) [33]. Patients who have residual invasive BC after the receipt \\nof NACT have a high risk of relapse. Patients with TNBC who do not experience pCR have an estimated 5-\\nyear EFS of 57% and OS of 47% (compared with 90% EFS and 84% OS, respectively, for patients with early-'),\n",
       " Document(metadata={}, page_content='stage TNBC who demonstrate pCR) [76, 77].\\nAfter pre-operative CHT and surgical treatment, patients can receive postoperative radiation therapy \\n(RT). Patients with hormone receptor-positive BC [hormone receptor-positive (HR+) BC] are candidates for \\nadjuvant endocrine treatment. However, until recently, no adjuvant CHT was expected as standard in \\npatients with TNBC. Only follow-up was recommended in those who have pCR or in those with residual'),\n",
       " Document(metadata={}, page_content='invasive BC after the receipt of neoadjuvant regimens [78]. To address the unmet clinical need for optimal \\nadjuvant treatment in the subgroup of patients with TNBC at high risk of recurrence (those who have not \\nachieved the pCR after NACT containing anthracycline, taxane, or both), the Capecitabine for Residual \\nCancer as Adjuvant Therapy (CREATE-X) was designed. The trial did not include only patients with TNBC'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 238\\nbut also patients with HR+ HER2 negative BC [79]. The results of this phase III trial showed that the \\naddition of adjuvant capecitabine (1,250 mg per square meter of body-surface area, twice per day, on days \\n1 to 14, every 3 weeks for six or eight cycles) was safe and effective in prolonging DFS and OS among the'),\n",
       " Document(metadata={}, page_content='ITT population. The study showed a superior DFS in the capecitabine group than in the control group \\n(74.1% vs. 67.6% at 5 years; HR = 0.70; P = 0.01). Therefore, OS was longer in the experimental group: \\n89.2% vs. 83.6% of the patients were alive at 5 years (HR = 0.59; P = 0.01). Thirty percent of the patients \\nhad triple negative (TN) disease, and they represent the subgroup with poor prognosis (approximately half'),\n",
       " Document(metadata={}, page_content='the patients with TNBC who had a pCR did not have the recurrence of the disease) [33]. The benefit of \\ncapecitabine vs. control in DFS and OS was notable among this subgroup of patients (HR = 0.58 and HR = \\n0.52, respectively) [79].\\nThe reflection in the treatment algorithm due to these results was significant.\\nSome limits of this study are the exclusion of patients who had reached the pCR, for whom only follow-'),\n",
       " Document(metadata={}, page_content='up was indicated, and the lack of efficacy results selected for residual cancer burden (RCB). The RCB \\nquantifies the extent of residual disease after neoadjuvant treatment at the time of surgery. This score uses \\nthe diameter of residual disease, percentage of vital tumor cells, and diameter of the largest involved lymph \\nnode to calculate the amount of residual disease. It has been validated with distinct prognostic RCB classes'),\n",
       " Document(metadata={}, page_content='in all BC subtypes, with the most significant discriminatory power in TN and Her-2 positive BC. It is \\ncategorized as RCB-0 (equivalent to a pCR), RCB-1, RCB-2, and RCB-3, reflecting increasingly larger residual \\ncancer and respective poor prognoses (in terms of EFS) [80]. Finally, the CREATE-X trial did not examine \\ncapecitabine efficacy in patients with germline BRCA 1 or BRCA 2 pathogenic variants (less than 15% of \\nthose enrolled) [79].'),\n",
       " Document(metadata={}, page_content='those enrolled) [79].\\nOlympiA is a phase III study designed to investigate how the PARP inhibitor olaparib might improve \\nDFS and OS in patients with resected HR+ BC and TNBC with germline BRCA 1 or BRCA 2 mutation. It \\nenrolled patients treated with CHT (containing anthracyclines, taxanes or the combination of both) in \\nneoadjuvant or adjuvant setting and randomized them to receive olaparib (orally administered at the dose'),\n",
       " Document(metadata={}, page_content='of 300 mg twice daily) vs. placebo for 1 year after surgical resection (and radiotherapy when indicated). \\nAlso in this trial, patients with TNBC who underwent NACT followed by surgery were required to have \\nresidual invasive BC in the breast and/or resected lymph nodes (non-pCR) [81]. Postneoadjuvant \\ncapecitabine was not foreseen in this trial. iDFS, the primary endpoint of the study, was significantly longer'),\n",
       " Document(metadata={}, page_content='among patients assigned to receive olaparib than among those assigned placebo (HR = 0.58; P < 0.001). The \\npercentage of patients alive and free of invasive disease at 3 years was 85.9% in the olaparib group and \\n77.1% in the placebo group. The benefit of adjuvant olaparib was observed irrespective of the germline \\nBRCA mutation (BRCA 1 vs. BRCA 2), the hormone-receptor status, or the timing of previous CHT'),\n",
       " Document(metadata={}, page_content='(neoadjuvant vs. adjuvant) [81] 4-year iDFS for the olaparib group was 82.7% (vs. 75.4% in placebo group) \\nand 4-year distant DFS (DDFS) was 86.5% (vs. 79.1%). Adjuvant olaparib improves OS, with an HR of 0.68 \\nand a P value of 0.009 at 3.5 years of median follow-up, meeting the significance threshold for OS at the \\nsecond planned interim analysis. The OS benefit at 4 years in the olaparib arm compared with the placebo'),\n",
       " Document(metadata={}, page_content='arm was reported (89.8% vs. 86.4%, respectively) [82].\\nBoth studies have defined the standard of adjuvant therapy post-NACT for patients with BRCA wild \\ntype (CREATE-X) and BRCA mutated (OlympiA) TNBC, that did not reach the pCR.\\nThe low percentage of BRCA mutated patients enrolled in the CREATE-X, the absence of pre-planned \\nsubgroup analyzes for this population do not allow for a description of the efficacy of capecitabine in this'),\n",
       " Document(metadata={}, page_content='subgroup of patients.\\nMoreover, there are no prospective randomized trials between capecitabine and olaparib to guide the \\nclinical decision in this population, nor combination or sequence data between these two drugs.\\nIt would also be important to consider the potentially severe toxicity profile of such a combination, \\ngiven their overlapping side effects (in particular, cytopenias).'),\n",
       " Document(metadata={}, page_content='The treatment paradigm of early TNBC has had a real evolution since July 2021, with the introduction \\nof immunotherapy following the Food and Drug Administration (FDA) approval of pembrolizumab for high-\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 239\\nrisk TNBC (tumor size > 1 cm but ≤ 2 cm in diameter with nodal involvement or tumor size > 2 cm in'),\n",
       " Document(metadata={}, page_content='diameter regardless of nodal involvement), regardless of tumor PD-L1 expression, in combination with CHT \\nas neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery for a \\ntotal duration of approximately 1 year [83].\\nResults from the KEYNOTE-522 study were the basis for this approval, demonstrating a significantly'),\n",
       " Document(metadata={}, page_content='higher rate of pCR at the time of definitive surgery among patients who received pembrolizumab plus NACT \\nthan among those who received placebo plus NACT and an improvement in long-term benefits [73, 84]. The \\naim of the trial was not to identify the contributions of the neoadjuvant and adjuvant treatment phases, so it \\nis difficult to define if these long-term results are related to exposure to adjuvant pembrolizumab or a'),\n",
       " Document(metadata={}, page_content='lesser RCB at the end of the neoadjuvant phase in the pembrolizumab–CHT group.\\nAn exploratory analysis of the study then provided data to further describe the prognosis related to the \\nRCB after neoadjuvant experimental treatment (Figure 1) [85].\\nFigure 1. The unmet need for the optimal adjuvant treatment according to RCB [85]\\nThe HR for recurrence event in subgroups RBO-0, RCB-1, RCB-2, and RCB-3 are respectively 0.70'),\n",
       " Document(metadata={}, page_content='(rates: 5.2% vs. 7.3% in the pembrolizumab + CHT vs. placebo + CHT), 0.92 (rates: 17.4% vs. 20%), 0.52 \\n(rates: 25.5% vs. 44.3%), 1.24 (72.5% vs. 69.2%).\\nThe rate of recurrence was numerically lower in all RCB groups with pembrolizumab + CHT, except in \\nthe small RCB-3 subset (that is represented by 5% and 7% of the population in the study, respectively in'),\n",
       " Document(metadata={}, page_content='the experimental and control group). Pembrolizumab shifted RCB to lower categories in most patients \\n(RCB-0: 63% vs. 56% of patients in the experimental vs. the control arm; RCB-1: 9% vs. 11%; RCB 18% vs. \\n20%).\\nNo patients in this trial received adjuvant capecitabine, and there are no randomized efficacy and \\nsafety data showing that multiagent therapy with pembrolizumab and capecitabine is superior to single-'),\n",
       " Document(metadata={}, page_content='agent therapy in high-risk patients (stage II–III) who did not reach pCR.\\nAt the time, only results from phase II studies in metastatic TNBC demonstrated no new safety signals \\nwith this combination [86, 87].\\nPembrolizumab has also not been studied in combination with olaparib in the adjuvant setting, for the \\ntreatment of patients with BRCA mutations. No efficacy data are reported in the literature, even if some'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 240\\nsafety data are reported in the metastatic setting, in some early-phase studies that have evaluated the \\ncombination of PARPis and ICIs, not reporting unexpected toxicities [88, 89].\\nProspective trials would be needed to define what is the optimal adjuvant strategy according to RCB'),\n",
       " Document(metadata={}, page_content='(single-agent CHT or poly-CHT), how the clinician should decide between olaparib, immunotherapy or \\ncapecitabine in the treatment of the population with BRCA mutations and whether these therapies can be \\nadministered in combination or sequence, with data in terms of efficacy and safety.\\nAdditional treatment strategies with new drugs are being studied as adjuvant treatment after NACT,'),\n",
       " Document(metadata={}, page_content='with antibody-drug conjugates (ADCs) such as datopotamab deruxtecan (with or without durvalumab in \\nTROPICS-Breast 03, ClinicalTrials.gov identifier: NCT05629585), and patritumab deruxtecan (HER3-DXd) \\nwhich showed promising clinical response and biological changes in early TNBC [SOLTI TOT-HER3 window \\nof opportunity trial part B, presented at European Society for Medical Oncology (ESMO) Breast 2023], or'),\n",
       " Document(metadata={}, page_content='with ICIs (A-BRAVE trial, NCT02926196 and SWOG S1418/BR006 trial, NCT02954874).\\nNew biomarkers and frontiers in TNBC\\nRecent progress in integrating ICIs and novel agents has revolutionized the therapeutic approach for early \\nTNBC. Treatment strategies now emphasize escalating chemotherapeutic agents based on standard \\nneoadjuvant regimens. An example is a phase II trial (ACTRN12617000651381) presented at the San'),\n",
       " Document(metadata={}, page_content='Antonio Breast Cancer Symposium 2022 evaluating in high-risk TNBC, the addition of ipilimumab and \\nnivolumab to neoadjuvant paclitaxel following a suboptimal response to anthracycline-based CHT (< 50% \\ntumor reduction) and resulting in promising objective response rate (ORR) (43.7%) and pCR (18.8%) rates, \\nregardless of PD-L1 status.\\nHowever, it is also crucial to identify subgroups of patients with favorable prognoses, where NACT'),\n",
       " Document(metadata={}, page_content='could potentially be de-escalated. Therefore, discovering novel biomarkers to categorize patients with good \\nprognoses and safely de-escalate NACT is essential.\\nTILs show promise as a biomarker for selecting patients who may have favorable outcomes with \\ntreatment de-escalation. In recent trials, higher TILs levels were associated with a higher pCR rate [71, 75,'),\n",
       " Document(metadata={}, page_content='90] and with a better response [75, 91]. Liquid biopsies, such as circulating tumor DNA (ctDNA), could \\nserve as promising markers for identifying patients who might benefit from de-escalating or escalating \\nneoadjuvant or adjuvant treatment. Rapid ctDNA clearance during NACT in early TNBC is linked to a high \\nlikelihood of achieving pCR [92]. Conversely, detecting ctDNA after completing NACT and surgery is'),\n",
       " Document(metadata={}, page_content='associated with higher recurrence rates and poorer prognoses [93]. The use of dynamic biomarkers, such \\nas ctDNA, to guide the choice of treatments in high-risk patients appears increasingly to be an important \\nresource to be exploited in future studies.\\nFurthermore, ADCs are emerging. Particularly, sacituzumab govitecan (SG) an ADC targeting Trop-2'),\n",
       " Document(metadata={}, page_content='was approved in metastatic TNBC patients who received ≥ 2 prior systemic therapies in the light of the \\nresults of the phase III ASCENT study. In this trial patients were randomized (1:1) to receive sacituzumab \\ngovitecan 10 mg/kg via intravenous infusion on day 1 and day 8 of a 21-day treatment cycle or a treatment \\nof physician’s choice (TPC) achieving the primary endpoint (PFS 4.8 vs. 1.7 months) and also demonstrating'),\n",
       " Document(metadata={}, page_content='an advantage in terms of OS (11.8 months vs. 6.9 months) [94]. Another single-arm phase II trial is \\nevaluating SG and atezolizumab in combination as adjuvant treatment for patients with TNBC who have \\nresidual invasive disease after neoadjuvant therapy and detectable ctDNA (ClinicalTrials.gov identifier \\nNCT04434040).\\nFinally, it is essential to redefine, with new dedicated trials, the role of ER-low (1–9%) BC which,'),\n",
       " Document(metadata={}, page_content='biologically and prognostically very similar to TNBC, could potentially benefit from the addition of \\nimmunotherapy to CHT and the role of HER-2 low [score 1+ or 2+ not amplified in fluorescence in situ \\nhybridization (FISH)] BC in the light of recent results of efficacy of trastuzumab deruxtecan in advanced BC \\nHER-2 low. Therefore, future studies are likely to expand the armamentarium at our disposal in this setting.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 241\\nNew frontiers in early TNBC are summarized in Figure 2.\\nFigure 2. New frontiers in early TNBC\\nInterpretation and clinical implications\\nTNBC has long been a challenging disease to treat due to its aggressive behavior and the lack of target \\ntherapies [95].'),\n",
       " Document(metadata={}, page_content='therapies [95].\\nThanks to recent developments on TNBC, a series of therapeutic targets have been identified for the \\ntreatment of metastatic and early setting diseases. Especially for the radically operable disease, the chances \\nof cure are increased with treatments aimed at reducing the odds of recurrence after tumor removal.\\nAnthracycline and taxane-based poly-CHT remains the standard of treatment, most often administered'),\n",
       " Document(metadata={}, page_content='preoperatively to assess tumor sensitivity. It aims to increase the rate of local control, making it useful to \\nguide breast-conserving surgery and to ensure survival benefits by reaching the pCR.\\nThe introduction of immunotherapy in association with poly-CHT in the neoadjuvant setting has \\nincreased the rate of pCR, guaranteeing better results in terms of long-term benefits in the KEYNOTE-522,'),\n",
       " Document(metadata={}, page_content='the pivotal trial that led to the approval in clinical practice of the use of the anti-PD1, pembrolizumab, in the \\nearly setting disease (neoadjuvant and adjuvant setting). These clinical findings were based on preclinical \\ninvestigations that overturned the previous belief that BC was not an immunogenic disease [12].\\nThe actual need is to define the optimal adjuvant strategy after neoadjuvant chemo-immunotherapy,'),\n",
       " Document(metadata={}, page_content='which must be affected by the patient’s risk of recurrence based on the histological prognostic and evidence \\nafter radical surgery, the individual’s tolerance of therapy-induced side effects (Figure 3).\\nIn patients with low RCB and a low overall risk of recurrence, pembrolizumab alone should be \\ncontinued. In patients with poor prognostic features of high RCB, this strategy may not be the best choice.'),\n",
       " Document(metadata={}, page_content='Patients with high RCB, BRCA wild type, could benefit from capecitabine alone, although it would be \\nreasonable to use a combination of capecitabine and pembrolizumab. Patients with high RCB, germline \\nBRCA mutations, could benefit from olaparib (according to the inclusion criteria of the OlympiA trial), \\nalthough it would be reasonable to use olaparib and pembrolizumab in combination or sequentially.'),\n",
       " Document(metadata={}, page_content='However, none of these strategies, in monotherapy and/or in combination, have evidence from specific \\nrandomized trials after the neoadjuvant immunotherapy. There are no data on efficacy and safety in this \\nsetting. Currently, the best schedule is not known, and new data are awaited on new adjuvant strategies.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 242'),\n",
       " Document(metadata={}, page_content='Page 242\\nFigure 3. Current treatment algorithm for stage II–III TNBC\\nExtensive efforts will also be required to investigate and expand access to immunotherapy to ER-low \\npopulations (ER 1–9%), not included in KEYNOTE-522. It represents a subgroup that does not formally \\nmeet the definition of TNBC, but shares biology, with nearly 90% of these tumors harboring a basal-like'),\n",
       " Document(metadata={}, page_content='intrinsic subtype, and prognosis with TNBC and could share the same benefit from the addition of \\nimmunotherapy [96, 97].\\nFurthermore, novel active agents are emerging for the treatment of TNBC and could provide an \\nopportunity for a de-escalation of traditional CHT, the anti-trophoblast cell-surface antigen 2 (Trop2) \\nsacituzumab govitecan that is currently being investigated in the early setting, including in combination'),\n",
       " Document(metadata={}, page_content='with immunotherapy in the ASPRIA trial (ClinicalTrials.gov identifier NCT04434040).\\nConclusions\\nThis review highlights the multitude of advances in the treatment of early-stage TNBC and the important \\nissues raised.\\nThe management of triple-negative breast cancer (TNBC) has seen notable advancements with the \\nidentification of therapeutic targets and successful integration of immunotherapy in neoadjuvant'),\n",
       " Document(metadata={}, page_content='treatment. However, the current challenge lies in determining the optimal adjuvant strategy post-chemo-\\nimmunotherapy, tailoring decisions to individual patient characteristics and prognostic factors. The \\nuncertainty surrounding the efficacy and safety of these strategies necessitates further randomized studies, \\nwhile ongoing research explores novel approaches, such as the potential use of innovative agents like'),\n",
       " Document(metadata={}, page_content='sacituzumab govitecan in the context of de-escalating traditional CHT. The imperative to extend access to \\nimmunotherapy to subgroups, such as those with low ER expression, holds crucial promise, paving the way \\nfor a more personalized and targeted future direction in TNBC treatment.\\nIn the next few years, it will be necessary to design new prospective clinical trials and wait for the'),\n",
       " Document(metadata={}, page_content='results of those in progress, for a better knowledge of the efficacy of combination therapies, therapeutic \\nsequences and new target drugs for the treatment of a disease which up to a few years ago was considered \\n“untargetable”. This should be accompanied by a commitment to biomarker discovery, which could help the \\noncologist make the best decision for patient care.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 243\\nAbbreviations\\nAC: doxorubicin and cyclophosphamide\\nADCs: antibody-drug conjugates\\nBC: breast cancer\\nBRCA: breast cancer susceptibility genes\\nCHT: chemotherapy\\nCI: confidence interval\\nCREATE-X: Capecitabine for Residual Cancer as Adjuvant Therapy\\nctDNA: circulating tumor DNA\\nDFS: disease-free survival\\nEFS: event-free survival\\nER: estrogen receptor'),\n",
       " Document(metadata={}, page_content='EFS: event-free survival\\nER: estrogen receptor\\nFDA: Food and Drug Administration\\nHER2: human epidermal growth factor receptor 2\\nHR: hazard ratio\\nHR+: hormone receptor-positive\\nICI: immune checkpoint inhibitor\\niDFS: invasive disease-free survival\\nIM: immunomodulatory\\nLAR: luminal androgen receptor\\nM: mesenchymal\\nNACT: neoadjuvant chemotherapy\\nOS: overall survival\\nPARP: Poly(ADP-ribose) polymerase\\npCR: pathologic complete response'),\n",
       " Document(metadata={}, page_content='pCR: pathologic complete response\\nPD-L1: programmed death ligand 1\\nRCB: residual cancer burden\\nTILs: tumor-infiltrating lymphocytes\\nTMB: tumor mutational burden\\nTME: tumor microenvironment\\nTNBC: triple negative breast cancer\\nDeclarations\\nAuthor contributions\\nPDS: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Validation,'),\n",
       " Document(metadata={}, page_content='Supervision. MP, CG, and GRO: Conceptualization, Investigation, Writing—original draft, Writing—review & \\nediting. ANS, PF, and CL: Validation, Writing—review & editing, Supervision. DC: Investigation. All authors \\nread and approved the submitted version.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 244\\nConflicts of interest\\nThe authors declare that they have no conflicts of interest.'),\n",
       " Document(metadata={}, page_content='Ethical approval\\nNot applicable.\\nConsent to participate\\nNot applicable.\\nConsent to publication\\nNot applicable.\\nAvailability of data and materials\\nNot applicable.\\nFunding\\nNot applicable.\\nCopyright\\n© The Author(s) 2024.\\nReferences\\nSporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic markers in triple-negative breast cancer. \\nClin Breast Cancer. 2018;18:e841–50.\\n1.'),\n",
       " Document(metadata={}, page_content='Clin Breast Cancer. 2018;18:e841–50.\\n1.     \\nHoward FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J. 2021;27:\\n8–16.\\n2.     \\nAlmansour NM. Triple-negative breast cancer: a brief review about epidemiology, risk factors, \\nsignaling pathways, treatment and role of artificial intelligence. Front Mol Biosci. 2022;9:836417.\\n3.'),\n",
       " Document(metadata={}, page_content='3.     \\nCurtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic \\narchitecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.\\n4.     \\nAzim HA, Ghosn M, Oualla K, Kassem L. Personalized treatment in metastatic triple-negative breast \\ncancer: the outlook in 2020. Breast J. 2020;26:69–80.\\n5.'),\n",
       " Document(metadata={}, page_content='5.     \\nCardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al.; ESMO Guidelines \\nCommittee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and \\nfollow-up†. Ann Oncol. 2019;30:1194–220. Erratum in: Ann Oncol. 2019;30:1674. Erratum in: Ann \\nOncol. 2021;32:284. \\n6.     \\nBear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al.; National Surgical Adjuvant'),\n",
       " Document(metadata={}, page_content='Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential \\npreoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from \\nNational Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74.\\n7.     \\nGolshan M, Loibl S, Wong SM, Houber JB, O’Shaughnessy J, Rugo HS, et al. Breast conservation after'),\n",
       " Document(metadata={}, page_content='neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess \\nrandomized clinical trial. JAMA Surg. 2020;155:e195410. Erratum in: JAMA Surg. 2021;156:503. \\n8.     \\nTurner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular \\nprofiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic \\ntargets. Oncogene. 2010;29:2013–23.\\n9.'),\n",
       " Document(metadata={}, page_content='targets. Oncogene. 2010;29:2013–23.\\n9.     \\nMarra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast \\ncancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast \\nCancer. 2020;6:54.\\n10.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 245'),\n",
       " Document(metadata={}, page_content='Page 245\\nYe F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advancements in clinical aspects of targeted \\ntherapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105.\\n11.     \\nLiu Z, Li M, Jiang Z, Wang X. A comprehensive immunologic portrait of triple-negative breast cancer. \\nTransl Oncol. 2018;11:311–29.\\n12.     \\nFarshbafnadi M, Pastaki Khoshbin A, Rezaei N. Immune checkpoint inhibitors for triple-negative'),\n",
       " Document(metadata={}, page_content='breast cancer: from immunological mechanisms to clinical evidence. Int Immunopharmacol. 2021;98:\\n107876.\\n13.     \\nLehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative \\nbreast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. \\n2016;11:e0157368.\\n14.     \\nBurstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, et al. Comprehensive'),\n",
       " Document(metadata={}, page_content='genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer \\nRes. 2015;21:1688–98.\\n15.     \\nXiao Y, Ma D, Zhao S, Suo C, Shi J, Xue MZ, et al.; AME Breast Cancer Collaborative Group. Multi-omics \\nprofiling reveals distinct microenvironment characterization and suggests immune escape \\nmechanisms of triple-negative breast cancer. Clin Cancer Res. 2019;25:5002–14.\\n16.'),\n",
       " Document(metadata={}, page_content='16.     \\nPelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, Hutton C, et al. Anti-inflammatory drugs \\nremodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer \\nDiscov. 2021;11:2602–19.\\n17.     \\nMittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in \\ntriple-negative breast cancer. Cancer Immunol Res. 2014;2:361–70.\\n18.'),\n",
       " Document(metadata={}, page_content='18.     \\nWang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, et al. Prevalence of BRCA1 mutations and responses \\nto neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast \\ncancer. Ann Oncol. 2015;26:523–8.\\n19.     \\nHahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, et al. Germline mutation status, \\npathological complete response, and disease-free survival in triple-negative breast cancer: secondary'),\n",
       " Document(metadata={}, page_content='analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017;3:1378–85.\\n20.     \\nPohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, et al. Association of germline \\nvariant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of \\nthe GeparOcto randomized clinical trial. JAMA Oncol. 2020;6:744–8.\\n21.'),\n",
       " Document(metadata={}, page_content='21.     \\nVollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, et al. Genomic patterns \\nresembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-\\nbased chemotherapy. Breast Cancer Res. 2014;16:R47.\\n22.     \\nBelli C, Duso BA, Ferraro E, Curigliano G. Homologous recombination deficiency in triple negative \\nbreast cancer. Breast. 2019;45:15–21.\\n23.'),\n",
       " Document(metadata={}, page_content='breast cancer. Breast. 2019;45:15–21.\\n23.     \\nvan Verschuer VMT, Hooning MJ, van Baare-Georgieva RD, Hollestelle A, Timmermans AM, Koppert \\nLB, et al. Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast \\ncancer. Hum Pathol. 2015;46:182–90.\\n24.     \\nNolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, et al.; Kathleen Cuningham'),\n",
       " Document(metadata={}, page_content='Foundation Consortium for Research into Familial Breast Cancer (kConFab); Perou CM, Visvader JE, \\nGray DHD, Loi S, Lindeman GJ. Combined immune checkpoint blockade as a therapeutic strategy for \\nBRCA1-mutated breast cancer. Sci Transl Med. 2017;9:eaal4922.\\n25.     \\nParkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of STING-'),\n",
       " Document(metadata={}, page_content='dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer \\nInst. 2016;109:djw199.\\n26.     \\nCastaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, et al. Tumor infiltrating \\nlymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol. \\n2016;7:387–94.\\n27.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 246'),\n",
       " Document(metadata={}, page_content='Page 246\\nGarcía-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-infiltrating lymphocytes in triple negative \\nbreast cancer: the future of immune targeting. Clin Med Insights Oncol. 2016;10:31–9.\\n28.     \\nGomez-Macias GS, Molinar-Flores G, Lopez-Garcia CA, Santuario-Facio S, Decanini-Arcaute H, Valero-\\nElizondo J, et al. Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and'),\n",
       " Document(metadata={}, page_content='genetic characterization. Oncol Lett. 2020;20:140.\\n29.     \\nSousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, et al. Human breast cancer cells \\neducate macrophages toward the M2 activation status. Breast Cancer Res. 2015;17:101.\\n30.     \\nMedrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in \\ntumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306.\\n31.'),\n",
       " Document(metadata={}, page_content='31.     \\nSavas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host \\nimmunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228–41.\\n32.     \\nCortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete \\nresponse and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;\\n384:164–72.\\n33.'),\n",
       " Document(metadata={}, page_content='384:164–72.\\n33.     \\nDenkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-\\ninfiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of \\n3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.\\n34.     \\nAdams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-'),\n",
       " Document(metadata={}, page_content='infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant \\nbreast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–66.\\n35.     \\nLoi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of \\ntumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive'),\n",
       " Document(metadata={}, page_content='breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based \\nchemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–7.\\n36.     \\nLoi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are \\nprognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast \\ncancer: results from the FinHER trial. Ann Oncol. 2014;25:1544–50.\\n37.'),\n",
       " Document(metadata={}, page_content='37.     \\nHida AI, Watanabe T, Sagara Y, Kashiwaba M, Sagara Y, Aogi K, et al. Diffuse distribution of tumor-\\ninfiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-\\nnegative breast cancer. Breast Cancer Res Treat. 2019;178:283–94.\\n38.     \\nIbrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. The prognostic value of tumor-infiltrating'),\n",
       " Document(metadata={}, page_content='lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014;148:\\n467–76.\\n39.     \\nSalgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al.; International TILs Working \\nGroup 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: \\nrecommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71.\\n40.'),\n",
       " Document(metadata={}, page_content='40.     \\nKarn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, et al. Association between genomic metrics and \\nimmune infiltration in triple-negative breast cancer. JAMA Oncol. 2017;3:1707–11.\\n41.     \\nSafonov A, Jiang T, Bianchini G, Győrffy B, Karn T, Hatzis C, et al. Immune gene expression is associated \\nwith genomic aberrations in breast cancer. Cancer Res. 2017;77:3317–24.\\n42.'),\n",
       " Document(metadata={}, page_content='42.     \\nLotfinejad P, Asghari Jafarabadi M, Abdoli Shadbad M, Kazemi T, Pashazadeh F, Sandoghchian \\nShotorbani S, et al. Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and \\nprogrammed death ligand 1 (PD-L1) expression in triple-negative breast cancer (TNBC): a systematic \\nreview and meta-analysis study. Diagnostics (Basel). 2020;10:704.\\n43.'),\n",
       " Document(metadata={}, page_content='43.     \\nZhu X, Zhang Q, Wang D, Liu C, Han B, Yang JM. Expression of PD-L1 attenuates the positive impacts of \\nhigh-level tumor-infiltrating lymphocytes on prognosis of triple-negative breast cancer. Cancer Biol \\nTher. 2019;20:1105–12.\\n44.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 247\\nNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer. National'),\n",
       " Document(metadata={}, page_content='Comprehensive Cancer Network® (NCCN®); c2020 [cited 2023 May 21]. Available from: https://\\nwww2.tri-kobe.org/nccn/guideline/breast/english/breast.pdf\\n45.     \\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxane-\\ncontaining chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of \\n100\\u2008000 women from 86 randomised trials. Lancet. 2023;401:1277-1292.\\n46.'),\n",
       " Document(metadata={}, page_content='46.     \\nSparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, et al. Long-term follow-up of the E1199 \\nphase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol. 2015;\\n33:2353–60.\\n47.     \\nJones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing \\ndoxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for'),\n",
       " Document(metadata={}, page_content='operable breast cancer. J Clin Oncol. 2006;24:5381–7. Erratum in: J Clin Oncol. 2007;25:1819. \\n48.     \\nWheate NJ, Collins JG. Multi-nuclear platinum drugs: a new paradigm in chemotherapy. Curr Med \\nChem Anticancer Agents. 2005;5:267–79.\\n49.     \\nGarutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, et al. Platinum salts in patients \\nwith breast cancer: a focus on predictive factors. Int J Mol Sci. 2019;20:3390.\\n50.'),\n",
       " Document(metadata={}, page_content='50.     \\nChalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with \\n“BRCAness”: a review. Oncologist. 2013;18:909–16.\\n51.     \\nVetter M, Fokas S, Biskup E, Schmid T, Schwab F, Schoetzau A, et al. Efficacy of adjuvant chemotherapy \\nwith carboplatin for early triple negative breast cancer: a single center experience. Oncotarget. 2017;\\n8:75617–26.\\n52.'),\n",
       " Document(metadata={}, page_content='8:75617–26.\\n52.     \\nSu YW, Hung CY, Lam HB, Chang YC, Yang PS. A single institution experience of incorporation of \\ncisplatin into adjuvant chemotherapy for patients with triple-negative breast cancer of unknown \\nBRCA mutation status. Clin Med Insights Oncol. 2018;12:1179554918794672.\\n53.     \\nYu KD, Ye FG, He M, Fan L, Ma D, Mo M, et al. Effect of adjuvant paclitaxel and carboplatin on survival'),\n",
       " Document(metadata={}, page_content='in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6:\\n1390–6.\\n54.     \\nNorquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary Somatic Mutations \\nRestoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas. J Clin Oncol. \\n2011;29:3008–15.\\n55.     \\nGuillemette S, Serra RW, Peng M, Hayes JA, Konstantinopoulos PA, Green MR, et al. Resistance to'),\n",
       " Document(metadata={}, page_content='therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. Genes Dev. \\n2015;29:489–94.\\n56.     \\nZhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, et al. The drug-resistance mechanisms of five platinum-\\nbased antitumor agents. Front Pharmacol. 2020;11:343.\\n57.     \\nRastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative'),\n",
       " Document(metadata={}, page_content='chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-\\n27. J Clin Oncol. 2008;26:778–85. Erratum in: J Clin Oncol. 2008;26:2793. \\n58.     \\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant \\nversus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from \\nten randomised trials. Lancet Oncol. 2018;19:27–39.\\n59.'),\n",
       " Document(metadata={}, page_content='59.     \\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of \\nchemotherapy by more frequent administration or sequential scheduling: a patient-level meta-\\nanalysis of 37\\u2008298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393:\\n1440–52.\\n60.     \\nvon Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in'),\n",
       " Document(metadata={}, page_content='patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a \\nrandomised phase 2 trial. Lancet Oncol. 2014;15:747–56.\\n61.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 248\\nSikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of \\ncarboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense'),\n",
       " Document(metadata={}, page_content='doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-\\nnegative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13–21.\\n62.     \\nLoibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP \\ninhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in'),\n",
       " Document(metadata={}, page_content='triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:\\n497–509.\\n63.     \\nFasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, et al.; German Breast Group and \\nArbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in \\ncomparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and'),\n",
       " Document(metadata={}, page_content='homologous recombination deficiency (GeparOLA study). Ann Oncol. 2021;32:49–57.\\n64.     \\nGupta S, Nair NS, Hawaldar R, Vanmali V, Parmar V, Gulia S, et al. Abstract GS5-01: Addition of \\nplatinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-\\nnegative breast cancer: a phase III randomized controlled trial. Cancer Res. 2023;83:GS5-01.\\n65.'),\n",
       " Document(metadata={}, page_content='65.     \\nCortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al.; KEYNOTE-355 Investigators. \\nPembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated \\nlocally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a \\nrandomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–28.\\n66.'),\n",
       " Document(metadata={}, page_content='66.     \\nSchmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al.; IMpassion130 Trial \\nInvestigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J \\nMed. 2018;379:2108–21.\\n67.     \\nMiles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al.; IMpassion131 investigators. \\nPrimary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of'),\n",
       " Document(metadata={}, page_content='first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-\\nnegative breast cancer. Ann Oncol. 2021;32:994–1004.\\n68.     \\nEmens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-\\npaclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer:'),\n",
       " Document(metadata={}, page_content='IMpassion130 final overall survival analysis. Ann Oncol. 2021;32:983–93. Erratum in: Ann Oncol. \\n2021;32:1650. \\n69.     \\nCortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al.; KEYNOTE-355 Investigators. \\nPembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;\\n387:217–26.\\n70.     \\nGianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR)'),\n",
       " Document(metadata={}, page_content='to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally \\nadvanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33:534–43.\\n71.     \\nMittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in \\ncombination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo'),\n",
       " Document(metadata={}, page_content='and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a \\nrandomised, double-blind, phase 3 trial. Lancet. 2020;396:1090–100.\\n72.     \\nSchmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al.; KEYNOTE-522 Investigators. \\nEvent-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;\\n386:556–67.\\n73.'),\n",
       " Document(metadata={}, page_content='386:556–67.\\n73.     \\nDel Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, et al.; Gruppo Italiano \\nMammella Investigators. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-\\nstage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Lancet Oncol. \\n2022;23:1571–82.\\n74.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 249'),\n",
       " Document(metadata={}, page_content='Page 249\\nLoibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, et al.; GBG and AGO-B. Neoadjuvant \\ndurvalumab improves survival in early triple-negative breast cancer independent of pathological \\ncomplete response. Ann Oncol. 2022;33:1149–58.\\n75.     \\nKuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, et al. Prognostic significance of subtype and'),\n",
       " Document(metadata={}, page_content='pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies \\nof JBCRG. Breast Cancer. 2015;22:486–95.\\n76.     \\nSpring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic complete response after \\nneoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive \\nmeta-analysis. Clin Cancer Res. 2020;26:2838–48.\\n77.'),\n",
       " Document(metadata={}, page_content='77.     \\nCoates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart MJ, et al.; Panel Members. \\nTailoring therapies—improving the management of early breast cancer: St Gallen international expert \\nconsensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26:1533–46.\\n78.     \\nMasuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer'),\n",
       " Document(metadata={}, page_content='after Preoperative Chemotherapy. N Engl J Med. 2017;376:2147–59.\\n79.     \\nSymmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual \\nbreast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:\\n4414–22.\\n80.     \\nTutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al.; OlympiA Clinical Trial Steering'),\n",
       " Document(metadata={}, page_content='Committee and Investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast \\ncancer. N Engl J Med. 2021;384:2394–405.\\n81.     \\nGeyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al.; OlympiA Clinical Trial Steering \\nCommittee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in'),\n",
       " Document(metadata={}, page_content='patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. \\n2022;33:1250–68.\\n82.     \\nFDA D.I.S.C.D. burst edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage \\ntriple-negative breast cancer [Internet]. [cited 2023 May 21]. Available from: https://www.fda.gov/\\ndrugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-'),\n",
       " Document(metadata={}, page_content='pembrolizumab-high-risk-early-stage-triple-negative\\n83.     \\nSchmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al.; KEYNOTE-522 Investigators. \\nPembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21.\\n84.     \\nPusztai L, Denkert C, O’Shaughnessy J, Cortes J, Dent RA, McArthur HL, et al. Event-free survival by \\nresidual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo +'),\n",
       " Document(metadata={}, page_content='chemotherapy for early TNBC: exploratory analysis from KEYNOTE-522. J Clin Oncol. 2022;40:503.\\n85.     \\nShah AN, Flaum L, Helenowski I, Santa-Maria CA, Jain S, Rademaker A, et al. Phase II study of \\npembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2–negative \\nendocrine-refractory metastatic breast cancer. J Immunother Cancer. 2020;8:e000173.\\n86.'),\n",
       " Document(metadata={}, page_content='86.     \\nPage D, Pucilowska J, Bennetts L, Kim I, Sanchez K, Martel M, et al. Updated efficacy of first or second-\\nline pembrolizumab plus in metastatic triple negative breast cancer and correlations with baseline \\nlymphocyte and naïve CD4+ T-cell count. 2018 San Antonio Breast Cancer Symposium. San Antonio: \\nBooks, Presentations, Posters, Etc. 2018.\\n87.'),\n",
       " Document(metadata={}, page_content='87.     \\nVinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. Open-label clinical trial of \\nniraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative \\nbreast cancer. JAMA Oncol. 2019;5:1132–40.\\n88.     \\nDomchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. Olaparib and durvalumab in \\npatients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label,'),\n",
       " Document(metadata={}, page_content='multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155–64.\\n89.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 250\\nNederlof I, De Bortoli D, Bareche Y, Hooijer GKJ, Sotiriou C, Van De Vijver MJ, et al. Relationship \\nbetween tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+'),\n",
       " Document(metadata={}, page_content='chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase \\nIb KEYNOTE-173 trial. Ann Oncol. 2019;30:III2.\\n90.     \\nDoroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of \\nresponse to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345–62.\\n91.     \\nMagbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, et al. Circulating tumor DNA in'),\n",
       " Document(metadata={}, page_content='neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32:229–39.\\n92.     \\nRadovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, et al. Association of circulating \\ntumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in \\npatients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 \\nrandomized clinical trial. JAMA Oncol. 2020;6:1410–5.'),\n",
       " Document(metadata={}, page_content='93.     \\nBardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al.; ASCENT Clinical Trial \\nInvestigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;\\n384:1529–41.\\n94.     \\nLoibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750–69.\\n95.     \\nSchrodi S, Braun M, Andrulat A, Harbeck N, Mahner S, Kiechle M, et al. Outcome of breast cancer'),\n",
       " Document(metadata={}, page_content='patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann \\nOncol. 2021;32:1410–24.\\n96.     \\nVillegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, et al. Therapy response and prognosis \\nof patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 \\npatients from neoadjuvant clinical trials. Eur J Cancer. 2021;148:159–70.\\n97.'),\n",
       " Document(metadata={}, page_content='97.     \\nCitation: Li, L.; Zhang, F.; Liu, Z.;\\nFan, Z. Immunotherapy for\\nTriple-Negative Breast Cancer:\\nCombination Strategies to Improve\\nOutcome. Cancers 2023, 15, 321.\\nhttps://doi.org/10.3390/cancers\\n15010321\\nAcademic Editors: Claudia De\\nLorenzo and Laura Cerchia\\nReceived: 14 November 2022\\nRevised: 27 December 2022\\nAccepted: 29 December 2022\\nPublished: 3 January 2023\\nCopyright:\\n© 2023 by the authors.\\nLicensee MDPI, Basel, Switzerland.'),\n",
       " Document(metadata={}, page_content='Licensee MDPI, Basel, Switzerland.\\nThis article is an open access article\\ndistributed\\nunder\\nthe\\nterms\\nand\\nconditions of the Creative Commons\\nAttribution (CC BY) license (https://\\ncreativecommons.org/licenses/by/\\n4.0/).\\ncancers\\nReview\\nImmunotherapy for Triple-Negative Breast Cancer:\\nCombination Strategies to Improve Outcome\\nLiying Li, Fan Zhang, Zhenyu Liu and Zhimin Fan *'),\n",
       " Document(metadata={}, page_content='Liying Li, Fan Zhang, Zhenyu Liu and Zhimin Fan *\\nDepartment of Breast Surgery, General Surgery Centre, The First Hospital of Jilin University,\\nChangchun 130012, China\\n* Correspondence: fanzm@jlu.edu.cn\\nSimple Summary: For decades, countless efforts have been devoted to developing targeted drugs\\nto improve the prognosis of triple-negative breast cancer (TNBC). Among the novel therapies that'),\n",
       " Document(metadata={}, page_content='have been approved for the clinical management of TNBC, immunotherapy shows great potential.\\nAlthough exciting progress has been made in immunotherapy for TNBC, there are still gaps to\\nﬁll. This review will analyze current immunotherapy strategies in TNBC, summarize the current\\nlandscape of clinical trials, review the results achieved, and shed light on future developments.'),\n",
       " Document(metadata={}, page_content='Abstract: Due to the absence of hormone receptor (both estrogen receptors and progesterone receptors)\\nalong with human epidermal growth factor receptor 2 (HER-2) ampliﬁcation, the treatment of triple-\\nnegative breast cancer (TNBC) cannot beneﬁt from endocrine or anti-HER-2 therapy. For a long time,\\nchemotherapy was the only systemic treatment for TNBC. Due to the lack of effective treatment'),\n",
       " Document(metadata={}, page_content='options, the prognosis for TNBC is extremely poor. The successful application of immune checkpoint\\ninhibitors (ICIs) launched the era of immunotherapy in TNBC. However, the current ﬁndings show\\nmodest efﬁcacy of programmed cell death- (ligand) 1 (PD-(L)1) inhibitors monotherapy and only\\na small proportion of patients can beneﬁt from this approach. Based on the basic principles of'),\n",
       " Document(metadata={}, page_content='immunotherapy and the characteristics of the tumor immune microenvironment (TIME) in TNBC,\\nimmune combination therapy is expected to further enhance the efﬁcacy and expand the beneﬁciary\\npopulation of patients. Given the diversity of drugs that can be combined, it is important to select\\neffective biomarkers to identify the target population. Moreover, the side effects associated with the\\ncombination of multiple drugs should also be considered.'),\n",
       " Document(metadata={}, page_content='Keywords: triple-negative breast cancer; immunotherapy; immune checkpoint; tumor immune\\nmicroenvironment; clinical trials\\n1. Introduction\\nTriple-negative breast cancer (TNBC) accounts for approximately 15–20% of breast\\nmalignancies and is the only subtype of breast cancer that lacks targeted treatment [1].\\nCompared with other subtypes, TNBC is more aggressive, and most patients develop'),\n",
       " Document(metadata={}, page_content='recurrence and metastasis within 3 years, with poor prognosis [2]. Anthracycline- and\\ntaxane-based chemotherapy remains the mainstay of treatment for early-stage patients, but\\nresistance has emerged [3]; for patients with recurrence or metastasis, there are even fewer\\ntreatment options. There is an urgent need for novel and more effective treatments.\\nGenomic advances reveal a high degree of heterogeneity in TNBC and set the stage'),\n",
       " Document(metadata={}, page_content='for the development of targeted therapies [4–6]. In the past few years, poly ADP-ribose\\npolymerase inhibitors (PARPi), programmed cell death- (ligand) 1 (PD-(L)1) inhibitors,\\nand antibody–drug conjugates (ADCs) have been approved successively for the treat-\\nment of TNBC. Among these, PD-1 inhibitor pembrolizumab is approved for patients\\nwith advanced PD-L1-positive and early high-risk disease, displaying great therapeutic\\npotential.'),\n",
       " Document(metadata={}, page_content='potential.\\nCancers 2023, 15, 321. https://doi.org/10.3390/cancers15010321\\nhttps://www.mdpi.com/journal/cancers\\nCancers 2023, 15, 321\\n2 of 28\\nSome studies have found that TNBC has higher PD-L1 expression and tumor-inﬁltrating\\nlymphocytes (TILs) in comparison with other subtypes [7,8], making it the most likely\\nsubtype to beneﬁt from immunotherapy. However, PD-(L)1 inhibitors beneﬁt only a'),\n",
       " Document(metadata={}, page_content='small proportion of individuals, with a single-agent effectiveness of approximately 20%\\nin patients with PD-L1-positive metastatic TNBC (mTNBC) [9]. Numerous preclinical\\nand clinical studies have been conducted to investigate the reasons for this disappointing\\nresult, expand the beneﬁciary population, and improve the efﬁcacy of immune checkpoint\\ninhibitors (ICIs).'),\n",
       " Document(metadata={}, page_content='inhibitors (ICIs).\\nIn this review, we will analyze the reasons for the poor efﬁcacy of PD-(L)1 inhibitors\\nmonotherapy in terms of tumor immune escape mechanisms and tumor immune microen-\\nvironment (TIME) characteristics of TNBC. We summarize the current landscape of clinical\\ntrials in TNBC, highlight the major immune combination therapy strategies in clinical'),\n",
       " Document(metadata={}, page_content='practice and the progress achieved, and brieﬂy discuss the biomarkers for predicting im-\\nmunological response, as well as possible adverse events associated with immunotherapy.\\n2. Rationale of Immunotherapy and the TIME of TNBC\\nThe cross-talk between tumor cells and the TIME can be described as “cancer immu-\\nnoediting”, encompassing three stages: (1) elimination; (2) equilibrium, in which the host'),\n",
       " Document(metadata={}, page_content='immune system and tumor cells that survive enter a dynamic balance; and (3) escape [10]\\n(Figure 1).\\n \\nFigure 1. Schematic diagram of immune elimination and escape in TNBC. (A) Cascade events of\\ntumor cell elimination by the immune system. (B) Mechanisms of tumor cell immune escape. Abbre-\\nviations: TAA, tumor-associated antigen; TSA, tumor-speciﬁc antigen; DC, dendritic cell; M1/2, M1/2'),\n",
       " Document(metadata={}, page_content='macrophage; Th1/2, CD4+ helper T cell 1/2; TCR, T cell receptor; MHC, major histocompatibility\\ncomplex; NK, natural killer cell; ADCC, antibody-dependent cell-medicated cytotoxicity; SIPR-α,\\nsignal regulatory protein-α; CTLA-4, cytotoxic T-lymphocyte antigen-4; VEGF, vascular endothelial\\ngrowth factor; CXCL, chemokine (C-X-C motif) ligand; IL, interleukin; CSF, colony-stimulating factor;'),\n",
       " Document(metadata={}, page_content='TGF, transforming growth factor; Treg, regulatory T cell; MDSCs, myeloid-derived suppressor cells;\\nTAP, transporter associated with antigen processing; PD-L1, programmed death-ligand 1; LAG3,\\nlymphocyte-activation gene 3; TIM-3, T cell immunoglobulin-3; TIGIT, T cell immunoreceptor with\\nIg and ITIM domains.\\nNormally, a cascade of events needs to be initiated for the elimination of tumor cells.'),\n",
       " Document(metadata={}, page_content='First, tumor cells release speciﬁc antigens that are captured and processed by antigen-\\npresenting cells (APCs), which mainly include dendritic cells (DCs). Next, DCs migrate to\\nCancers 2023, 15, 321\\n3 of 28\\nlymphoid tissue to present antigenic signals to T cells. Later, T cells initiate, activate, and\\nthen transport and inﬁltrate tumor tissues. Finally, T cells speciﬁcally recognize and kill'),\n",
       " Document(metadata={}, page_content='tumor cells [11]. B cells and innate immune cells, such as natural killer (NK) cells, are also\\nessential for the elimination of tumor cells (Figure 1).\\nHowever, tumors can evade surveillance and attack from the immune system via\\ncomplex intrinsic signaling or external microenvironment mechanisms. In general, this can\\nbe summed up in these aspects. First, immunogenicity of tumors is decreased via down-'),\n",
       " Document(metadata={}, page_content='regulation of antigen expression, sequestering of antigens, or downregulation of major\\nhistocompatibility complex (MHC) molecules [12,13]. Second, there are functional and/or\\nquantitative defects in intrinsic and/or adaptive immune cells, including recruitment fail-\\nure, insufﬁcient maturation, failure to activate, and impaired chemotaxis and transport [14].\\nFurther, an immunosuppressive microenvironment is generated through an increase in the'),\n",
       " Document(metadata={}, page_content='proportion of immunosuppressive cells (regulatory T cells (Tregs), M2 macrophage cells,\\nand myeloid-derived suppressor cells (MDSCs)) and cytokines, as well as the accumulation\\nof immunosuppressive substances [15,16]. Moreover, there is an upregulation of immune\\ncheckpoints, a negative regulatory mechanism used by the body to prevent over-activation\\nof the immune system and to protect normal tissues from the autoimmune system [17,18]\\n(Figure 1).'),\n",
       " Document(metadata={}, page_content='(Figure 1).\\nBased on the above information, immunotherapy has emerged that involves the use\\nof various agents or means to enhance immune system function (in a tumor-localized\\nrather than whole-body manner) or to block immune escape pathways of tumor cells (by\\nnormalizing anti-tumor immunity), thereby recognizing and eliminating tumor cells. These\\nimmunotherapy approaches include: therapeutic cancer vaccines (TCVs), which are active'),\n",
       " Document(metadata={}, page_content='immunotherapies; targeted monoclonal antibodies (mAb) and their derivatives, such as\\nADCs, adoptive cell therapies (ACTs), and cytokines, which are passive therapies; as well\\nas the best-known ICIs [19].\\nTumors that lack immune cell inﬁltration and do not respond to ICIs are referred to as\\n“cold tumors”, while tumors with high levels of immune cell inﬁltration and upregulated'),\n",
       " Document(metadata={}, page_content='immune checkpoints that may respond to ICIs are referred as “hot tumors” [20]. Based\\non omics analysis, heterogeneity of the TIME in TNBC has been revealed. According\\nto the data from these studies, the percentage of TNBC cases that present with “hot\\ntumors” is approximately 25%, which may explain the poor clinical efﬁcacy of ICIs as single\\nagents [21–23]. Moreover, the suppressive TIME found in “hot tumors” and the decreased'),\n",
       " Document(metadata={}, page_content='MHC of tumor cells also make ICIs less effective [14].\\nWhen all of these ﬁndings are considered, it is clear that combining ICIs with other\\ntherapies that block immune escape pathways of tumor cells or convert “cold tumors” to\\n“hot tumors” is a potential strategy to improve the clinical response of ICIs.\\n3. The Landscape of Clinical Trials on TNBC Immunotherapy'),\n",
       " Document(metadata={}, page_content='As of 1 September 2022, we had screened a total of 234 clinical trials on clinicaltrials.gov\\n(accessed on 1 September 2022), that primarily explore immunotherapy for TNBC, either as\\na monotherapy or in combination with other therapies (Figure 2). Apart from that, more\\nthan 100 immunotherapy clinical trials are being conducted on advanced solid tumors,\\nincluding TNBC. Of note, these are just the tip of the iceberg as there are trials registered'),\n",
       " Document(metadata={}, page_content='on other websites. In addition to observing the surge in clinical trials of immunotherapy\\nfor TNBC in the past decade, we further analyzed the data and found that: (1) there are\\n197 trials involving ICIs that target PD-(L)1, accounting for 84% of all trials, of which\\nonly 13 trials involved monotherapy, while in the other trials, PD-(L)1 inhibitors were\\ncombined with almost all therapies that can be applied to TNBC; (2) there are considerable'),\n",
       " Document(metadata={}, page_content='numbers of clinical trials in both early and metastatic settings, which demonstrates the\\ngeneralizability of immunotherapy for TNBC; and (3) there is a gradual increase in the\\nnumber of window-of-opportunity (WOP) trials to test for optimal timing of interventions\\nand changes in biomarkers.\\nCancers 2023, 15, 321\\n4 of 28\\n \\n(a) \\n(b) \\nFigure 2. Clinical trials of immunotherapy for TNBC registered at clinicaltrials.gov: (a) Number of'),\n",
       " Document(metadata={}, page_content='clinical trials in each phase per year; (b) Number of clinical trials by disease stage per year.\\n4. Performance of PD-(L)1 Inhibitors Monotherapy\\nPD-(L)1 is the most powerful immune checkpoint found in TNBC. PD-1 can be ex-\\npressed on a variety of immune cells, the most important of which are activated T cells.\\nPD-1 has two ligands: PD-L1 and PD-L2 [24]. PD-L1 is abnormally overexpressed on the'),\n",
       " Document(metadata={}, page_content='surface of tumor cells and some APCs [25]. Through binding to PD-1, it leads to lymphocyte\\napoptosis, unresponsiveness, and abnormal secretion of cytokines, thus mediating immune\\nescape of tumor cells [25]. In contrast, PD-L2 has a dual role of suppressing and activating\\nT cells, and its role in tumors is gaining attention [26]. PD-(L)1 inhibitors are monoclonal'),\n",
       " Document(metadata={}, page_content='antibodies that block the PD-1/PD-L1 signaling pathway and restore the immune function\\nof T cells to kill tumor cells.\\n4.1. In Advanced TNBC\\nThe phase Ib study, KEYNOTE-012, ﬁrst demonstrated acceptable safety and durable\\nanti-tumor activity of single-agent pembrolizumab in previously treated patients with\\nadvanced PD-L1-positive TNBC. The objective response rate (ORR) in 32 TNBC patients'),\n",
       " Document(metadata={}, page_content='was 18.5% [27]. The phase II KEYNOTE-086 study then further conﬁrmed the safety and\\nanti-tumor activity of pembrolizumab as ﬁrst-line or second-line and beyond therapy\\nin patients with mTNBC, using more appropriate dosages and dosing intervals. This\\nstudy found that pembrolizumab monotherapy performed better in previously untreated\\nPD-L1-positive patients with an ORR of 21.4%, whereas the response was ﬂat in heavily'),\n",
       " Document(metadata={}, page_content='pre-treated mTNBC patients with an ORR of 5.3%. Although there was no signiﬁcant\\ndifference in ORR, progression-free survival (PFS), and overall survival (OS) between the\\nPD-L1-positive and PD-L1-negative subgroups in pre-treated mTNBC, a more durable\\nclinical response was observed in PD-L1-positive patients [28,29]. In the next large phase\\nIII randomized KEYNOTE-119 trial, as second- or third-line treatment for mTNBC, pem-'),\n",
       " Document(metadata={}, page_content='brolizumab failed to signiﬁcantly improve OS compared to chemotherapy in the total\\npopulation (9.9 vs. 10.8 months, HR = 0.97, 95% CI: 0.82 to 1.15) or in the PD-L1-positive\\npopulation (10.7 vs. 10.2 months, HR = 0.86, 95% CI: 0.69 to 1.06, p = 0.073). However, the\\nimproved effect of pembrolizumab was consistent with increased tumor PD-L1 expression\\nin the efﬁcacy endpoints of ORR, PFS, and OS [30] (Table 1).\\nCancers 2023, 15, 321\\n5 of 28'),\n",
       " Document(metadata={}, page_content='Cancers 2023, 15, 321\\n5 of 28\\nTable 1. Clinical trials of PD-(L)1 inhibitors monotherapy.\\nClinical Trial\\nPhase\\nStatus\\nArms (n)\\nPopulation (n)\\nPD-L1 Status\\nMajor Outcomes\\nTrials in advanced\\nTNBC\\nKEYNOTE-012\\n(NCT01848834)\\nIb\\nCompleted\\nPemb\\nPre-treated: PD-L1\\n(+) (32)\\n+(stroma/\\n≥1% TC a)\\nORR: 18.5%\\nmPFS: 1.9 months\\nmOS: 11.2 months\\nKEYNOTE-086\\n(NCT02447003)\\nII\\nCompleted\\nPemb\\nCohort A (170):\\npre-treated\\nOverall\\nORR: 5.3%\\nmPFS: 2.0 months'),\n",
       " Document(metadata={}, page_content='pre-treated\\nOverall\\nORR: 5.3%\\nmPFS: 2.0 months\\nmOS: 9.0 months\\n+(CPS b ≥1)\\nORR: 5.7%\\nmPFS: 2.0 months\\nmOS: 8.8 months\\n−\\nORR: 4.7%\\nmPFS: 1.9 months\\nmOS: 9.7 months\\nCohort B (84):\\npre-untreated,\\nPD-L1 (+)\\n+(CPS ≥1)\\nORR: 21.4%\\nmPFS: 2.1 months\\nmOS: 18.0 months\\nKEYNOTE-119\\n(NCT02555657)\\nIII\\nCompleted\\nPemb (312)\\nvs. CT c (310)\\nPre-treated: 1–2\\nprior therapy\\n(622)\\nOverall\\nORR: 9.6 vs. 10.6%\\nmPFS: 2.1 vs. 3.3 months\\nmOS: 9.9 vs. 10.8 months\\n+(CPS ≥1)'),\n",
       " Document(metadata={}, page_content='mOS: 9.9 vs. 10.8 months\\n+(CPS ≥1)\\nORR: 12.3 vs. 9.4%\\nmPFS: 2.1 vs. 3.1 months\\nmOS: 10.7 vs. 10.2 months\\n+(CPS ≥10)\\nORR: 17.7 vs. 9.2%\\nmPFS: 2.1 vs. 3.4 months\\nmOS: 12.7 vs. 11.6 months\\n+(CPS ≥20)\\nORR: 26.3 vs. 11.5%\\nmPFS: 3.4 vs. 2.4 months\\nmOS: 14.9 vs. 12.5 months\\nJAVELIN\\n(NCT01772004)\\nIb\\nCompleted\\nAvel\\nReceived a median\\nof 2 prior therapies\\n(58)\\nOverall\\nORR: 5.2%\\nmPFS: 5.9 months\\nmOS: 9.2 months\\n+(≥10% IC d)\\nORR: 22.2%\\n−\\nORR: 2.6%'),\n",
       " Document(metadata={}, page_content='+(≥10% IC d)\\nORR: 22.2%\\n−\\nORR: 2.6%\\nNCT01375842\\nIa\\nCompleted\\nAtez\\nmTNBC: 58% ≥2\\nprior therapies (116)\\nOverall\\nORR: 10%\\nmPFS: 1.4 months\\nmOS: 8.9 months\\n+(≥1% IC)\\nORR: 12%\\nmOS: 10.1 months\\n−\\nORR: 0%\\nmOS: 6.0 months\\nSAFIR02-BREAST\\nIMMUNO\\n(NCT02299999)\\nII\\nCompleted\\nDurv (47) vs. CT\\n(35)\\nMaintenance\\nsetting (82)\\nOverall\\nmOS: 21.2 vs. 14 months\\n+(≥1% IC)\\nmOS: 27.3 vs. 12.1 months\\n−\\nmOS: 19.5 vs. 14 months\\nTrials in early-stage\\nTNBC as adjuvant'),\n",
       " Document(metadata={}, page_content='Trials in early-stage\\nTNBC as adjuvant\\ntherapy\\nSWOG 1418\\n(NCT02954874)\\nIII\\nOngoing\\nPemb vs.\\nobservation\\nTNBC with ≥1 cm\\nRIC or LN (+) after\\nNACT\\nNA\\nA-Brave\\n(NCT02926196)\\nIII\\nOngoing\\nAvel vs.\\nobservation\\nHigh-risk TNBC\\nNA\\nAbbreviations: mTNBC, metastatic triple-negative breast cancer; Pemb, pembrolizumab; Avel, avelumab; Atez,\\natezolizumab; Durv, durvalumab; NACT, neoadjuvant chemotherapy; CT, chemotherapy; RIC, residual invasive'),\n",
       " Document(metadata={}, page_content='cancer; LN, lymph node; ORR, objective response rate; mOS, median overall survival; mPFS, median progression-\\nfree survival; +, PD-L1 positive; −, PD-L1 negative; TC, tumor cells; CPS, combined positive score; IC, immune\\ncells; NA, not available. a PD-L1 positivity was deﬁned as membranous staining in at least 1% of cells (neoplastic\\nand intercalated mononuclear inﬂammatory cells) within tumor nests. b Immunohistochemistry 22C3 assay, CPS'),\n",
       " Document(metadata={}, page_content='= PD-L1 stained cells (including tumor cells, lymphocytes, and macrophages) / the number of all viable tumor\\ncells × 100. c In KEYNOTE-119, the chemotherapy regimens included capecitabine, eribulin, gemcitabine, or\\nvinorelbine. d The percentage of PD-L1 stained tumor-associated immune cells in the tumor area; immune cells\\nincluding lymphocytes, macrophages, dendritic cells, plasma cells, and granulocytes.\\nCancers 2023, 15, 321\\n6 of 28'),\n",
       " Document(metadata={}, page_content='Cancers 2023, 15, 321\\n6 of 28\\nIn addition to the above, some trials also tested single-drug ICIs targeting PD-L1 in\\na metastatic setting. In the phase Ib JAVELIN trial, avelumab showed acceptable safety\\nand clinical activity in the mTNBC subgroup. The ORRs were 5.2% and 22.2% for the total\\nTNBC population and PD-L1-positive TNBC patients, respectively [31]. Moreover, a phase'),\n",
       " Document(metadata={}, page_content='Ia study (NCT01375842) veriﬁed that atezolizumab monotherapy was well tolerated in\\npatients with mTNBC and the ORR for the unselected TNBC population was 10%. The\\nPD-L1 expression status and prior treatment history continue to strongly inﬂuence the\\nefﬁcacy of atezolizumab [32]. In addition, durvalumab was tested in the SAFIR02-BREAST\\nIMMUNO trial as a maintenance therapy. Subgroup analysis showed that, compared'),\n",
       " Document(metadata={}, page_content='with maintenance chemotherapy, durvalumab improved OS in patients with mTNBC\\n(21.2 vs. 14 months, HR = 0.54, 95% CI: 0.30 to 0.97, p = 0.0377), especially in PD-L1-positive\\npatients (27.3 vs. 12.1 months, HR = 0.37, 95% CI: 0.12 to 1.13, p = 0.0678) [33] (Table 1).\\nThe preliminary results of these trials suggest that PD-(L)1 blockade alone has a\\nmodest clinical response across the entire mTNBC population. However, more durable'),\n",
       " Document(metadata={}, page_content='responses have been observed in speciﬁc patients, such as PD-L1-positive patients receiving\\nﬁrst-line treatment. These ﬁndings encourage further research on PD-(L)1 inhibitors.\\n4.2. In Early-Stage TNBC\\nThere are studies on PD-(L)1 inhibitors monotherapy currently underway in early-\\nstage TNBC patients. SWOG 1418 is an ongoing phase III trial investigating the efﬁcacy of'),\n",
       " Document(metadata={}, page_content='pembrolizumab on TNBC patients with ≥1 cm residual invasive cancer or positive lymph\\nnodes after neoadjuvant chemotherapy (NACT) [34]. One year of postoperative intravenous\\navelumab is currently being evaluated for its impact on survival in high-risk TNBC patients\\nin the A-Brave trial [35]. The results of these trials are eagerly anticipated and could provide'),\n",
       " Document(metadata={}, page_content='additional options for the intensive treatment of patients with early-stage, high-risk TNBC\\n(Table 1).\\n5. Research Progress of PD-(L)1 Inhibitors in Combination with Chemotherapy\\nPreclinical and clinical studies have shown that in addition to direct toxicity to tumor\\ncells, some chemotherapeutic agents kill tumor cells through a pathway of immunogenic\\ncell death (ICD), which stimulates the recruitment and maturation of APCs, enhances the'),\n",
       " Document(metadata={}, page_content='antigen presentation process, and promotes the activation of T cells [36]. Chemotherapeutic\\nagents also increase the immunogenicity of tumors by exposing MHC molecules and\\nantigens on the surface of tumor cells [37]. The transient immunosuppression induced by\\nchemotherapy causes a massive release of cytokines and chemokines, which increases the\\ninﬁltration and activation of immune cells [38]. Furthermore, chemotherapeutic agents'),\n",
       " Document(metadata={}, page_content='reduce immunosuppressive cells such as Tregs and MDSCs [39]. These chemotherapy drugs\\ninclude anthracyclines, cyclophosphamide, and others commonly used for TNBC. Thus,\\ncombining PD-(L)1 inhibitors with chemotherapy is a promising approach to enhance\\nthe efﬁcacy of immunotherapy and facilitate synergistic anti-tumor activity. Based on\\nthis concept, a number of trials combining chemotherapy and immunotherapy are being'),\n",
       " Document(metadata={}, page_content='conducted in the clinic and some breakthroughs have been made (Table 2).\\nTable 2. Clinical trials of PD-(L)1 inhibitors in combination with chemotherapy.\\nClinical Trial\\nPhase\\nStatus\\nArms (n)\\nPopulation (n)\\nPD-L1 Status\\nMajor Outcomes\\nTrials in\\nadvanced\\nTNBC\\nKEYNOTE-355\\n(NCT02819518)\\nIII\\nOngoing\\nPemb + CT a (566) vs.\\nplacebo + CT (281)\\nFirst-line\\ntreatment in mTNBC\\n(847)\\nITT\\npopulation\\nmPFS: 7.5 vs. 5.6 months\\nmOS: 17.2 vs. 15.5 months'),\n",
       " Document(metadata={}, page_content='mOS: 17.2 vs. 15.5 months\\n+(CPS b ≥1)\\nmPFS: 7.6 vs. 5.6 months\\nmOS: 17.6 vs. 16.0 months\\n+(CPS ≥10)\\nmPFS: 9.7 vs. 5.6 months\\nmOS: 23.0 vs. 16.1 months\\nCancers 2023, 15, 321\\n7 of 28\\nTable 2. Cont.\\nClinical Trial\\nPhase\\nStatus\\nArms (n)\\nPopulation (n)\\nPD-L1 Status\\nMajor Outcomes\\nKEYNOTE-150/\\nENHANCE 1\\n(NCT02513472)\\nIb/II\\nCompleted\\nPemb + eribulin mesylate\\n≤2 prior lines\\ntherapies in the\\nmetastatic setting\\n(167)\\nOverall\\nORR in total: 23.4%'),\n",
       " Document(metadata={}, page_content='(167)\\nOverall\\nORR in total: 23.4%\\nstratum 1: 25.8%\\nstratum 2: 21.8%\\nmPFS in total: 4.1 months\\nstratum 1: 4.2 months\\nstratum 2: 4.1 months\\nmOS in total: 16.1 months\\nstratum 1: 17.4 months\\nstratum 2: 15.5 months\\n+(CPS ≥1)\\nORR in stratum 1: 34.5%\\nORR in stratum 2: 24.4%\\nmPFS in stratum 1: 6.1 months\\nmPFS in stratum 2: 4.1 months\\nmOS in stratum 1: 21.0 months\\nmOS in stratum 2: 14.0 months\\n−\\nORR in stratum 1: 16.1%\\nORR in stratum 2: 18.2%'),\n",
       " Document(metadata={}, page_content='−\\nORR in stratum 1: 16.1%\\nORR in stratum 2: 18.2%\\nmPFS in stratum 1: 3.5 months\\nmPFS in stratum 2: 3.9 months\\nmOS in stratum 1: 15.2 months\\nmOS in stratum 2: 15.5 months\\nTORCHLIGHT\\n(NCT04085276)\\nIII\\nRecruiting\\nTori + nab-P vs. placebo +\\nnab-P\\n≤1 line of CT\\nin the metastatic\\nsetting\\nNA\\nNCT04537286\\nII\\nRecruiting\\nCari + nab-P + Cp\\nFirst-line\\ntreatment in mTNBC\\nNA\\nNCT02755272\\nII\\nRecruiting\\nPemb + Cb + gemcitabine\\nvs. Cb + gemcitabine\\n>2 prior lines'),\n",
       " Document(metadata={}, page_content='vs. Cb + gemcitabine\\n>2 prior lines\\ntherapies\\nin the metastatic\\nsetting\\nNA\\nTONIC\\n(NCT02499367)\\nII\\nOngoing\\nA/C/Cp/\\nRT/no induction + Nivo\\n(70)\\nmTNBC (70)\\nORR in total: 20%\\nCp induction ORR: 23%\\nA induction ORR: 35%\\nmPFS in total: 1.9 months\\nTONIC-2\\n(NCT04159818)\\nII\\nRecruiting\\nCp/ low dose A/no\\ninduction\\n+ Nivo\\nMetastatic or\\nincurable locally\\nadvanced TNBC\\nNA\\nNCT01633970\\nIb\\nCompleted\\nAtez + nab-P\\n(33)\\n≤2 lines prior CT in\\nthe metastatic setting'),\n",
       " Document(metadata={}, page_content='(33)\\n≤2 lines prior CT in\\nthe metastatic setting\\n(33)\\nORR: 39.4%\\nmPFS: 5.5 months\\nmOS: 14.7 months\\nIMpassion130\\n(NCT02425891)\\nIII\\nCompleted\\nAtez + nab-P (451) vs.\\nplacebo + nab-P (451)\\nFirst-line treatment in\\nmTNBC\\n(902)\\nITT\\npopulation\\nmPFS: 7.2 vs. 5.5 months\\nmOS: 21.0 vs. 18.7 months\\n+(≥1% IC c)\\nmPFS: 7.5 vs. 5.0 months\\nmOS: 25.4 vs. 17.9 months\\nIMpassion131\\n(NCT03125902)\\nIII\\nOngoing\\nAtez + P (431) vs. placebo +\\nP (220)\\nFirst-line treatment in'),\n",
       " Document(metadata={}, page_content='P (220)\\nFirst-line treatment in\\nmTNBC (651)\\nITT\\npopulation\\nmPFS: 5.7 vs. 5.6 months\\nmOS: 19.2 vs. 22.8 months\\n+(≥1% IC)\\nmPFS: 6.0 vs. 5.7 months\\nmOS: 22.1 vs. 28.3 months\\nIMpassion132\\n(NCT03371017)\\nIII\\nRecruiting\\nAtez + CT d vs. placebo +\\nCT\\nFirst-line treatment\\nfor locally\\nadvanced inoperable\\nor mTNBC\\nNA\\nALICE\\n(NCT03164993)\\nII\\nOngoing\\nAtez + PLD + C vs. placebo\\n+ PLD + C\\n≤1 line previous\\nCT in the\\nmetastatic setting\\nNA\\nGIM25-CAPT\\n(NCT05266937)'),\n",
       " Document(metadata={}, page_content='metastatic setting\\nNA\\nGIM25-CAPT\\n(NCT05266937)\\nII\\nRecruiting\\nAtez + nab-P + Cb\\nFirst-line therapy\\nin PD-L1-positive\\nmTNBC\\nNA\\nEL1SSAR\\n(NCT04148911)\\nIII\\nOngoing\\nAtez + nab-P\\nFirst-line therapy\\nin PD-L1-positive\\nmTNBC\\nNA\\nCancers 2023, 15, 321\\n8 of 28\\nTable 2. Cont.\\nClinical Trial\\nPhase\\nStatus\\nArms (n)\\nPopulation (n)\\nPD-L1 Status\\nMajor Outcomes\\nTrials in early-stage\\nTNBC as\\nneoadjuvant\\ntherapy\\nI-SPY2\\n(NCT01042379)\\nII\\nRecruiting\\nPemb + P→AC (29) vs.'),\n",
       " Document(metadata={}, page_content='(NCT01042379)\\nII\\nRecruiting\\nPemb + P→AC (29) vs.\\nP→AC\\n(85)\\nHER-2 negative, stage\\nII or\\nIII at high risk\\n(250, including 114\\nTNBC)\\npCR rates in TNBC:\\n60% vs. 22%\\nKEYNOTE-173\\n(NCT02622074)\\nIb\\nCompleted\\nPemb + (nab-P ± Cb→AC)\\n(60)\\nHigh-risk, early-stage\\nTNBC (60)\\nOverall pCR rate: 60%\\nKEYNOTE-522\\n(NCT03036488)\\nIII\\nOngoing\\nPemb + (PCb→AC/EC)\\n(784) vs. placebo +\\n(PCb→AC/EC) (390)\\n(→surgery→Pemb/placebo\\nfor up to 9 cycles)\\nStage II-III TNBC\\n(1174)'),\n",
       " Document(metadata={}, page_content='for up to 9 cycles)\\nStage II-III TNBC\\n(1174)\\nOverall\\npCR rates e:\\n64.8% vs. 51.2%\\n3-year EFS:\\n84.5% vs. 76.8%\\n+(CPS ≥1)\\npCR rates:\\n68.9% vs. 54.9%\\n−\\npCR rates:\\n45.3% vs. 30.3%\\nNeoPACT\\n(NCT03639948)\\nII\\nOngoing\\nPemb + Cb + docetaxel\\nEarly-stage TNBC\\nNA\\nNCT04613674\\nIII\\nRecruiting\\nCamr + CT vs. placebo + CT\\nEarly or Locally\\nAdvanced TNBC\\nNA\\nGeparNuevo\\n(NCT02685059)\\nII\\nCompleted\\nDurv×2w f→durv + (nab-P\\n→EC) (88) vs. placebo +\\n(nab-P →EC) (86)'),\n",
       " Document(metadata={}, page_content='→EC) (88) vs. placebo +\\n(nab-P →EC) (86)\\n(→surgery→physician’s\\nchoice)\\nPrimary, cT1b-cT4a-d\\ndisease, centrally\\nconﬁrmed TNBC\\n(174)\\nOverall pCR rates:\\n53.4% vs. 44.2%\\npCR rates in the window\\ncohort: 61.0% vs. 41.4%\\n3-year iDFS: 85.6% vs. 77.2%\\n3-year DDFS: 91.7% vs. 78.4%\\n3-year OS: 95.2% vs. 83.5%\\nNeoTRIPaPDL1\\n(NCT02620280)\\nIII\\nOngoing\\nAtez + nab-P + Cb (138) vs.\\nnab-P + Cb (142)\\n(→surgery→adjuvant\\nanthracycline regimen as'),\n",
       " Document(metadata={}, page_content='(→surgery→adjuvant\\nanthracycline regimen as\\nper investigator’s choice)\\nEarly high-risk and\\nlocally advanced\\nTNBC (280)\\nITT\\npopulation\\npCR rates: 48.6% vs. 44.4%\\n+(≥1% IC)\\npCR rates: 59.5% vs. 51.9%\\nIMpassion031\\n(NCT03197935)\\nIII\\nOngoing\\nAtez + (nab-P →AC) (165)\\nvs. placebo + (nab-P →AC)\\n(168)\\n(→surgery→\\nadjuvant Atez/placebo\\nfor up to 11 cycles)\\nStage II–III TNBC\\n(333)\\nOverall\\npCR rates: 58% vs. 41%\\n+(≥1% IC)\\npCR rates: 69% vs. 49%\\n−'),\n",
       " Document(metadata={}, page_content='+(≥1% IC)\\npCR rates: 69% vs. 49%\\n−\\npCR rates: 48% vs. 34%\\nNSABP B-59\\n(NCT03281954)\\nIII\\nOngoing\\nAtez + (PCb→AC) vs.\\nplacebo + (PCb →AC)\\n(→surgery→adjuvant\\nAtez/placebo\\nuntil 1 year after the ﬁrst\\ndose)\\nStage II–III TNBC\\nNA\\nNCT02530489\\nII\\nOngoing\\nAtez + nab-P\\n(→surgery→adjuvant Atez\\nfor 4 cycles)\\nTNBC that were\\nnon-responders to\\ninitial AC\\nchemotherapy\\nNA\\nTrials in early-stage\\nTNBC as adjuvant\\ntherapy\\nNCT03487666\\nII\\nOngoing'),\n",
       " Document(metadata={}, page_content='TNBC as adjuvant\\ntherapy\\nNCT03487666\\nII\\nOngoing\\nNivo vs. capecitabine vs.\\nNivo + capecitabine\\nTNBC with ≥1 cm\\nRIC or LN (+) after\\nNACT\\nNA\\nIMpassion030\\n(NCT03498716)\\nIII\\nRecruiting\\nAtez + A/P-based CT vs.\\nCT\\nOperable-stage II-III\\nTNBC\\nNA\\nCancers 2023, 15, 321\\n9 of 28\\nTable 2. Cont.\\nClinical Trial\\nPhase\\nStatus\\nArms (n)\\nPopulation (n)\\nPD-L1 Status\\nMajor Outcomes\\nNCT03756298\\nII\\nRecruiting\\nAtez + capecitabine vs.\\ncapecitabine\\nTNBC with RIC after\\nNACT'),\n",
       " Document(metadata={}, page_content='capecitabine\\nTNBC with RIC after\\nNACT\\nNA\\nAbbreviations: mTNBC, metastatic triple-negative breast cancer; Pemb, pembrolizumab; Atez, atezolizumab; Durv.\\ndurvalumab; Cari, carilizumab; Tori, toripalimab; Nivo, nivolumab; Camr, camrelizumab; CT. chemotherapy;\\nRT, radiotherapy; Nab-P, nab-paclitaxel; P, paclitaxel; E, epirubicin; A, doxorubicin; C, cyclophosphamide; Cb,'),\n",
       " Document(metadata={}, page_content='carboplatin; Cp, cisplatin; PLD, pegylated liposomal doxorubicin; mOS, median overall survival; mPFS, median\\nprogression-free survival; EFS, event-free survival; iDFS, invasive disease-free survival; DDFS, distant disease-\\nfree survival; ITT population, intention-to-treat population; ORR. objective response rate; pCR, pathological\\ncomplete remission; CPS, combined positive score; IC, immune cells; +, PD-L1 positive; −, PD-L1 negative;'),\n",
       " Document(metadata={}, page_content='RIC, residual invasive cancer; NA, not available. a In KEYNOTE-355, the chemotherapy regimens included\\nnab-paclitaxel; paclitaxel; or gem citabine plus carboplatin. b Immunohistochemistry 22C3 assay, CPS = PD-L1\\nstained cells (including tumor cells, lymphocytes, and macrophages) / the number of all viable tumor cells\\n× 100.\\nc The percentage of PD-L1 stained tumor-associated immune cells in the tumor area; immune cells'),\n",
       " Document(metadata={}, page_content='including lymphocytes, macrophages, dendritic cells, plasma cells, and granulocytes. d In the IMpassion132,\\nthe chemotherapy regimens include gemcitabine, capecitabine, and car boplatin. e In KEYNOTE-522, the ﬁrst\\ninterim pCR analysis was conducted on the ﬁrst 602 patients who underwent randomization (401 patients in\\npembrolizumab–chemotherapy group and 201 in placebo–chemotherapy group). f In the GeparNuevo study, 117'),\n",
       " Document(metadata={}, page_content='patients participated in the window phase.\\n5.1. In Advanced TNBC\\nAt present, a majority of clinical trials apply immunotherapy with chemotherapy\\nconcomitantly. The reason for this is that ICIs take time to work, while chemotherapy\\nagents kill tumor cells and modify the TIME during this waiting period.\\nKEYNOTE-355 is a phase III randomized controlled trial (RCT) assessing the efﬁ-'),\n",
       " Document(metadata={}, page_content='cacy and safety of pembrolizumab plus chemotherapy versus placebo plus chemother-\\napy as ﬁrst-line treatment for patients with advanced TNBC; chemotherapy regimens\\nwere based on the physician’s choice including nab-paclitaxel, paclitaxel, and gemc-\\nitabine/carboplatin. Initial results showed that the combination of pembrolizumab with\\nchemotherapy improved PFS in the intention-to-treat (ITT) population and in the com-'),\n",
       " Document(metadata={}, page_content='bined positive score (CPS) ≥1 subgroup (7.5 vs. 5.6 months, HR = 0.82, 95% CI: 0.69 to\\n0.97 and 7.6 vs. 5.6 months, HR = 0.74, 95% CI: 0.61 to 0.90, p = 0.0014, respectively); the\\nimprovement was particularly signiﬁcant in the CPS ≥10 subgroup (9.7 vs. 5.6 months,\\nHR = 0.65, 95% CI: 0.49 to 0.86, p = 0.0012) [40]. According to the latest release of follow-up\\ndata, OS was improved by almost 7 months in the CPS ≥10 subgroup after the addition'),\n",
       " Document(metadata={}, page_content='of pembrolizumab to chemotherapy (23.0 vs. 16.1 months, HR = 0.73, 95% CI: 0.55 to 0.95,\\np = 0.0185) and the adverse effects were manageable [41].\\nAnother single-arm phase Ib/II trial, KEYNOTE-150, used pembrolizumab in com-\\nbination with eribulin mesylate in patients with mTNBC who had received ≤2 lines of\\nprior therapy in the metastatic setting. Of the 167 patients enrolled, 40% had not received'),\n",
       " Document(metadata={}, page_content='previous systemic therapies and were classiﬁed in stratum 1. The results showed that the\\nsurvival beneﬁt was most signiﬁcant in PD-L1-positive patients who had not received prior\\nsystemic therapy, which was consistent with previous studies. This study offers a new\\nimmuno–chemotherapy combination for the treatment of patients with mTNBC, although\\nfurther conﬁrmation is needed [42].'),\n",
       " Document(metadata={}, page_content='further conﬁrmation is needed [42].\\nAfter a phase Ib trial (NCT01633970) demonstrated the safety and feasibility of ate-\\nzolizumab plus nab-paclitaxel in patients with locally recurrent or metastatic TNBC [43],\\nthe efﬁcacy of this immuno–chemotherapy combination for TNBC patients who did not\\nreceive systemic therapy in the metastatic setting was further validated by IMpassion130,'),\n",
       " Document(metadata={}, page_content='the ﬁrst phase III RCT of immunotherapy for TNBC [44]. Preliminary results showed that a\\nPFS beneﬁt was observed with the addition of atezolizumab in both the ITT population\\n(7.2 vs. 5.5 months, HR = 0.80, 95% CI: 0.69 to 0.92, p = 0.002) and the PD-L1-positive pop-\\nulation (7.5 vs. 5.0 months, HR = 0.62, 95% CI: 0.49 to 0.78, p < 0.001). The second set of\\ninterim results indicated that atezolizumab signiﬁcantly improved OS from 18.0 months'),\n",
       " Document(metadata={}, page_content='to 25.0 months in the PD-L1-positive subgroup (HR = 0.71, 95% CI: 0.54 to 0.94), but the\\ndifference was not signiﬁcant in the ITT population (21.0 vs. 18.7 months, HR = 0.86, 95%\\nCancers 2023, 15, 321\\n10 of 28\\nCI: 0.72 to 1.02, p = 0.078) [45]. As a result, in March 2019, atezolizumab was granted accel-\\nerated approval by the Food and Drug Administration (FDA) to be used in combination'),\n",
       " Document(metadata={}, page_content='with nab-paclitaxel as a ﬁrst-line treatment for late-stage TNBC patients. Additionally, the\\n7.5-month survival beneﬁt shown in the ﬁnal OS data further demonstrated the durable\\nefﬁcacy of this treatment combination for PD-L1-positive patients (25.4 vs. 17.9 months,\\nHR = 0.67, 95% CI: 0.53 to 0.86) [46].\\nHowever, these ﬁndings were contradicted when atezolizumab was combined with'),\n",
       " Document(metadata={}, page_content='paclitaxel and compared to placebo plus paclitaxel in the phase III clinical study IMpas-\\nsion131, which also investigated this as ﬁrst-line treatment for patients with advanced or\\nmetastatic TNBC. The study found no obvious differences in PFS between the two arms,\\nregardless of PD-L1 expression status (5.7 vs. 5.6 months, HR = 0.86, 95% CI: 0.70 to 1.05 for'),\n",
       " Document(metadata={}, page_content='the ITT population and 6.0 vs. 5.7 months, HR = 0.82, 95% CI: 0.60 to 1.12, p = 0.20 for the\\nPD-L1-positive patients). With respect to OS, the atezolizumab arm appeared to be worse\\nbut not detrimental in the PD-L1-positive population (22.1 vs. 28.3 months, HR = 1.11, 95%\\nCI: 0.76 to 1.64) and in the ITT population (19.2 vs. 22.8 months, HR = 1.12, 95% CI: 0.88 to'),\n",
       " Document(metadata={}, page_content='1.43). Different chemotherapeutic agents, steroid pre-treatment with paclitaxel, and subtle\\ndifferences between study populations may explain the difference in results between IM-\\npassion130 and IMpassion131 [47]. In addition, levels of TILs, breast cancer susceptibility\\ngene (BRCA) mutational load, and the proportion of patients with residual disease after'),\n",
       " Document(metadata={}, page_content='NACT (which were unreported in the trial) may also have contributed to the unclear results\\nfrom IMpassion131 [48]. As the reason for this discrepancy remains undeﬁned, Roche has\\nvoluntarily withdrawn the indication for atezolizumab for the treatment of PD-L1 positive\\nadvanced TNBC. Recently, a small sample-based single-cell sequencing study suggested\\nthat paclitaxel may affect the efﬁcacy of atezolizumab by reducing key anti-tumor immune'),\n",
       " Document(metadata={}, page_content='cells in the TIME but enhancing immunosuppressive macrophages, yet this ﬁnding needs\\nto be further explored [49].\\nDespite some setbacks in the exploration of combination treatments with taxanes,\\natezolizumab is still being tested in different trials to investigate the safety and efﬁcacy of\\ncombination treatment with other chemotherapy agents in TNBC (Table 2).\\nBeyond concurrent chemotherapy, the induction use of small doses of chemothera-'),\n",
       " Document(metadata={}, page_content='peutic agents prior to immunotherapy is another strategy of the immuno–chemotherapy\\ncombination that is in the experimental phase. In the ﬁve cohorts of the phase II TONIC\\ntrial, patients with mTNBC received no induction or 2 weeks induction with low-dose\\ncyclophosphamide, cisplatin, doxorubicin, and hypofractionated irradiation, respectively,\\nall followed by the PD-1 blocking drug nivolumab. The total ORR was 20%, with a median'),\n",
       " Document(metadata={}, page_content='PFS (mPFS) of 1.9 months; a higher ORR occurred in the doxorubicin and carboplatin\\ncohorts at 35% and 23%, respectively. Analysis of patient samples suggested that short-\\nterm doxorubicin or cisplatin induction can convert the tumor microenvironment towards\\ninﬂammation and improve the response of nivolumab in TNBC. However, due to the limi-\\ntations of the trial itself, this conclusion needs further conﬁrmation [50]. The subsequent'),\n",
       " Document(metadata={}, page_content='trial, TONIC-2, is currently recruiting (Table 2).\\n5.2. In Early-Stage TNBC\\nStudies based on transcriptomics and immunohistochemical techniques have revealed\\nthat mTNBC has signiﬁcantly reduced expression of immune activation genes as well\\nas immunotherapeutic targets, such as PD-L1, and a lower number of TILs compared to\\nprimary TNBC [51,52]. Thus, the TIME in the early-stage disease setting is more suitable'),\n",
       " Document(metadata={}, page_content='for ICIs to function and to potentially achieve a true cure.\\nSeveral trials have indicated that the combination of pembrolizumab with chemother-\\napy can improve pathological complete remission (pCR) rates in early-stage TNBC. One of\\nthe cohorts in the I-SPY2 trial ﬁrst determined the feasibility of 4 cycles of pembrolizumab\\nin combination with paclitaxel- and anthracycline-based chemotherapy regimen in women'),\n",
       " Document(metadata={}, page_content='with early-stage, high-risk HER-2-negative breast cancer. Compared to standard NACT regi-\\nmens, the addition of pembrolizumab increased the pCR rate for patients with TNBC by 38%\\nCancers 2023, 15, 321\\n11 of 28\\n(60% vs. 22% for pembrolizumab vs. control) [53]. Another phase Ib KEYNOTE-173 trial\\nwith a relatively small sample volume evaluated the safety and efﬁcacy of pembrolizumab'),\n",
       " Document(metadata={}, page_content='in combination with chemotherapy regimens, including different doses of nab-paclitaxel\\nwith or without carboplatin followed by doxorubicin and cyclophosphamide; the overall\\npCR rate was consistent with I-PSY2 at 60% [54].\\nIn the phase III trial KEYNOTE-522, 1174 patients with previously untreated early-\\nstage TNBC were randomized in a 2:1 ratio to either the pembrolizumab–chemotherapy arm'),\n",
       " Document(metadata={}, page_content='or the placebo–chemotherapy arm (chemotherapy backbone of 4 cycles of paclitaxel plus\\ncarboplatin, followed by 4 cycles of anthracycline plus cyclophosphamide every 3 weeks),\\nwith up to 9 cycles of adjuvant pembrolizumab or placebo after surgery. Preliminary results\\nbased on the ﬁrst 602 patients showed that the addition of pembrolizumab increased the\\npCR rate by 13.6% compared to the placebo–chemotherapy arm (64.8% vs. 51.2%, 95%'),\n",
       " Document(metadata={}, page_content='CI: 5.4% to 21.8%, p < 0.001). This beneﬁt was observed in most subgroups, including\\nPD-L1-negative patients [55]. Based on this undifferentiated beneﬁt, in July 2021, the\\nFDA approved pembrolizumab in combination with chemotherapy as a neoadjuvant\\ntreatment for early-stage, high-risk TNBC and for continued use as a single agent in the\\nadjuvant phase. Furthermore, recently updated follow-up data after 39.1 months showed'),\n",
       " Document(metadata={}, page_content='that pembrolizumab treatment for almost 1 year reduced the risk of disease progression\\nby 37% (3-year event-free survival (EFS) of 84.5% vs. 76.8%, HR = 0.63, 95% CI: 0.48 to\\n0.82, p < 0.001). This EFS beneﬁt was independent of PD-L1 expression status, which is\\nconsistent with previous results and further demonstrates the long-term effectiveness of\\nthe perioperative addition of pembrolizumab. At the time of this analysis, data on OS were'),\n",
       " Document(metadata={}, page_content='immature and further follow-up data are expected [56].\\nIn addition, the phase II NeoPACT trial is also ongoing, combining pembrolizumab\\nwith carboplatin and docetaxel as neoadjuvant therapy. The results of this study will\\ndemonstrate whether similar pCR rates and survival beneﬁts can be achieved by removing\\nanthracyclines from neoadjuvant chemotherapy regimens in early TNBC.'),\n",
       " Document(metadata={}, page_content='However, the situation becomes more complicated upon review of the results of\\nclinical trials with PD-L1 inhibitors.\\nThe phase II GeparNuevo study compared the efﬁcacy of receiving durvalumab or\\nplacebo every 4 weeks in addition to chemotherapy of nab-paclitaxel sequentially with\\nepirubicin and cyclophosphamide. A total of 174 patients with early TNBC were enrolled.'),\n",
       " Document(metadata={}, page_content='It was noteworthy that 117 patients in this study received an additional, 2-week earlier\\nwindow treatment of durvalumab or placebo before the start of nab-paclitaxel, and 87% of\\n158 detected patients were PD-L1 positive. The intensive postoperative treatment regimen\\nfor patients enrolled in this trial was based on the physician’s choice. In the window cohort,'),\n",
       " Document(metadata={}, page_content='the pCR rates were statistically increased by the addition of durvalumab (61.0% vs. 41.4%,\\nOR = 2.22, 95% CI: 1.06 to 4.64, p = 0.035), but not in the whole study population (53.4% vs.\\n44.2%, OR = 1.45, 95% CI: 0.80 to 2.63, p = 0.224). However, it remains uncertain whether this\\ndifference was due to one dose of durvalumab window treatment [57]. Surprisingly, after'),\n",
       " Document(metadata={}, page_content='a median follow-up of 43.7 months, signiﬁcant improvements in 3-year invasive disease-\\nfree survival (iDFS), distant disease-free survival (DDFS), and OS were observed in the\\ndurvalumab group, even without the adjuvant durvalumab treatment, which contradicts\\nthe pCR results obtained initially (iDFS was 85.6% vs. 77.2%, HR = 0.48, 95% CI: 0.24 to\\n0.97, p = 0.036; DDFS was 91.7% vs. 78.4%, HR = 0.31, 95% CI: 0.13 to 0.74, p = 0.005; OS was'),\n",
       " Document(metadata={}, page_content='95.2% vs. 83.5%, HR = 0.24, 95% CI: 0.08 to 0.72, p = 0.006) [58]. More studies are needed to\\nelucidate this result and to explore the timing and sequence of ICIs when combined with\\nchemotherapy to treat early-stage TNBC.\\nThe efﬁcacy of 8 cycles of nab-paclitaxel and carboplatin with or without atezolizumab\\nin early-stage, high-risk TNBC was investigated in the NeoTRIPaPDL1 trial, with 4 cycles'),\n",
       " Document(metadata={}, page_content='of anthracycline regimen chemotherapy administered as adjuvant treatment. The pub-\\nlished results thus far have shown that the addition of atezolizumab to the neoadjuvant\\nsetting did not signiﬁcantly increase the pCR rate in the ITT population (48.6% vs. 44.4%,\\nOR = 1.18, 95% CI: 0.74 to 1.89, p = 0.48) or in the PD-L1-positive subgroup (59.5% vs.\\nCancers 2023, 15, 321\\n12 of 28'),\n",
       " Document(metadata={}, page_content='Cancers 2023, 15, 321\\n12 of 28\\n51.9%). Nevertheless, the primary endpoint of the study, the EFS data, still requires further\\nfollow-up [59].\\nOn the contrary, in the Impassion031 trial, a signiﬁcant increase in pCR rates was ob-\\nserved when atezolizumab was combined with a standard nab-paclitaxel- and doxorubicin-\\nbased chemotherapy regimen and applied in the adjuvant phase as a single agent (58% vs.'),\n",
       " Document(metadata={}, page_content='41%, rate difference 17%, 95% CI: 6% to 27%, p = 0.0044). The mature long-term survival\\nfollow-up data are not available at present. Similar to the KEYNOTE-522 results, the beneﬁt\\nof pCR was not signiﬁcantly related to PD-L1 expression status. Of note, platinum agents\\nwere removed from the NACT regimen in this trial [55,60].\\nFurthermore, it is noteworthy that anthracyclines were given preoperatively in both'),\n",
       " Document(metadata={}, page_content='the KEYNOTE-522 and Impassion031 trials, whereas anthracyclines were applied postop-\\neratively in the NeoTRIPaPDL1 trial. This may be one reason why the difference in pCR\\nrates between the two arms in the NeoTRIPaPDL1 trial was not signiﬁcant.\\nThe safety and efﬁcacy of other combinations of PD-(L)1 inhibitors with chemotherapy\\ndrugs are also being tested in clinical trials. Last but not least, trials using ICIs plus'),\n",
       " Document(metadata={}, page_content='chemotherapy in the adjuvant phase of early-stage TNBC are underway and the results are\\nawaited with great interest (Table 2).\\n6. Research Progress of PD-(L)1 Inhibitors in Combination with Radiotherapy\\nSimilar to chemotherapy, radiotherapy (RT) has a dual role of mediating DNA damage-\\ninduced tumor cell death and immunomodulation, which can make the TIME more inﬂam-'),\n",
       " Document(metadata={}, page_content='matory and facilitate the role of ICIs [61]. Whereas RT acts locally, the systemic side effects\\nare less severe and well tolerated.\\nA small single-arm phase II trial (NCT02730130) enrolled 17 unselected patients with\\nmTNBC with a median of 3 lines on prior systemic therapy. They received RT with\\n3000 centigrays (cGy) in ﬁve fractions over 5–7 days and pembrolizumab within 1 to 3 days'),\n",
       " Document(metadata={}, page_content='after the ﬁrst fraction. The median follow-up was 34.5 weeks, with an ORR of 17.6%,\\nmPFS of 2.6 months, and median OS (mOS) of 8.25 months. Although the 3 patients who\\nexperienced complete remission were all PD-L1 positive, the analysis showed that PD-L1\\nstatus was not associated with therapeutic effects [62].\\nAnother phase II AZTEC trial enrolled 50 patients who had received less than 2 lines'),\n",
       " Document(metadata={}, page_content='of prior systemic therapy to receive RT combined with atezolizumab. Participants were\\nrandomly assigned to 20 Gy stereotactic ablative body RT (SABR) in one fraction or 24 Gy\\nSABR in three fractions to irradiate 1–4 lesions with at least one metastasis left unirradiated.\\nAtezolizumab was initiated within 5 days after the last part of RT. The median follow-up\\nwas 17 months, with mPFS of 3.1 months. No difference was observed in mPFS between the'),\n",
       " Document(metadata={}, page_content='two groups. PD-L1 expression status and TIL levels (5%) had little effect on the efﬁcacy [63].\\nIn these studies, the combination of pembrolizumab and RT showed modest but\\nencouraging clinical activity in unselected patients and was well tolerated, offering a new\\ntreatment idea for pre-treated patients with advanced TNBC. Additional trials are still\\nbeing explored (Table 3).'),\n",
       " Document(metadata={}, page_content='being explored (Table 3).\\n7. Research Progress of PD-(L)1 Inhibitors in Combination with Targeted Therapy\\n7.1. Combination with PARPi\\nPARPi are drugs that block the repair of single-strand DNA damage. These drugs\\nkill tumor cells through synthetic lethal effects that are formed by the accumulation of\\nhomologous recombination (HR) repair defects for DNA double-strand breaks due to'),\n",
       " Document(metadata={}, page_content='mutations in BRCA1/2. In addition to direct killing of tumor cells, previous in vitro studies\\nhave shown that PARPi can stimulate intrinsic immunity and upregulate interferon (IFN)\\nrelease by activating the cyclic GMP–AMP synthase-stimulator of interferon genes (cGAS-\\nSTING) signaling pathway, further upregulating tumor PD-L1 expression and inﬁltration\\nof CD8+ T cells [64–66]. In short, PARPi have the potential to turn cold tumors into hot'),\n",
       " Document(metadata={}, page_content='tumors and set the stage for the application of PD-(L)1 blockers.\\nCancers 2023, 15, 321\\n13 of 28\\nKEYNOTE-162 is a single-arm phase I/II trial evaluating the efﬁcacy and safety of\\npembrolizumab in combination with niraparib in 55 patients with advanced TNBC. The\\ntotal ORR was 21%, with ORR of 47% vs. 11% and 32% vs. 8% for the two subgroups,\\nrespectively, when considering tumor BRCA mutations as well as PD-L1 status [67]. Re-'),\n",
       " Document(metadata={}, page_content='markably, the mPFS in patients with BRCA mutations was 8.3 months, which was nearly\\n3 months longer than the mPFS of 5.6 months for olaparib reported in the OlympiAD trial\\nor 5.8 months for talazoparib reported in the TALA trial [68,69].\\nA cohort in the I-SPY2 trial studied the efﬁcacy of adding durvalumab and olaparib\\nto standard NACT regimens of paclitaxel compared to paclitaxel alone. In the TNBC'),\n",
       " Document(metadata={}, page_content='subgroup analysis, although the addition of durvalumab and olaparib increased the pCR\\nrate in the experimental arm by 20% (47% vs. 27%), by comparison with related trials, the\\ninvestigators concluded that the contribution from olaparib to the increased pCR rate in\\nthe I-SPY2 experimental arm was relatively modest [70]. However, survival data from this\\nexperiment have not been published and a more reasonable random grouping should also'),\n",
       " Document(metadata={}, page_content='be considered.\\nPD-(L)1 blockers combined with PARPi have shown initial efﬁcacy in both advanced\\nand early-stage TNBC patients, with more trials ongoing (Table 3).\\nTable 3. Clinical trials of PD-(L)1 inhibitors in combination with radiotherapy, targeted therapy, and\\nother immunotherapies.\\nClinical Trial\\nPhase\\nStatus\\nArms\\nPopulation\\nNCT02730130\\nII\\nOngoing\\nPemb + RT\\nmTNBC: a median of 3 lines\\nprior systemic therapy\\nAZTEC\\n(NCT03464942)\\nII\\nOngoing'),\n",
       " Document(metadata={}, page_content='AZTEC\\n(NCT03464942)\\nII\\nOngoing\\nAtez + RT\\nAdvanced TNBC:\\n<2 lines of prior\\nsystemic therapy\\nNCT03483012\\nII\\nOngoing\\nAtez + RT\\nmTNBC with brain metastases\\nKEYNOTE-162\\n(NCT02657889)\\nI/II\\nCompleted\\nPemb + niraparib\\nAdvanced TNBC: a median of 1 prior\\nline of therapy (range, 0–3)\\nin the metastatic setting\\nI-SPY2\\n(NCT01042379)\\nII\\nRecruiting\\nDurv + olaparib + paclitaxel\\nvs. paclitaxel\\nStage II-III TNBC: preoperative treatment\\nDORA\\n(NCT03167619)\\nII'),\n",
       " Document(metadata={}, page_content='DORA\\n(NCT03167619)\\nII\\nOngoing\\nDurv + olaparib\\nPlatinum-treated mTNBC\\nKEYLYNK-009\\n(NCT04191135)\\nII/III\\nOngoing\\nPemb + olaparib vs. Pemb + Cb\\n+ gemcitabine\\nLocally recurrent inoperable\\nor metastatic TNBC: after induction\\nwith ﬁrst-line CT + Pemb\\nNCT03594396\\nI/II\\nOngoing\\nOlaparib + Durv\\nStage II/III TNBC or low ER\\nbreast cancer:\\npreoperative treatment\\nNCT03310957\\nIb/II\\nRecruiting\\nPemb + ladiratuzumab vedotin\\nUnresectable locally advanced'),\n",
       " Document(metadata={}, page_content='Unresectable locally advanced\\nor metastatic TNBC:\\nﬁrst-line treatment\\nASCENT-04\\n(NCT05382286)\\nIII\\nRecruiting\\nPemb + SG vs. pemb + TPC\\nPreviously untreated, locally advanced\\ninoperable, or metastatic\\nPD-L1-positive TNBC\\nNCT04468061\\nII\\nRecruiting\\nPemb + SG vs. SG\\nPD-L1-negative mTNBC\\nASPRIA\\n(NCT04434040)\\nII\\nRecruiting\\nAtez + SG\\nEarly-stage TNBC with RIC after NACT\\nNCT03394287\\nII\\nCompleted\\nCamr + apatinib\\nAdvanced TNBC: <3 lines\\nof systemic therapy'),\n",
       " Document(metadata={}, page_content='Advanced TNBC: <3 lines\\nof systemic therapy\\nCancers 2023, 15, 321\\n14 of 28\\nTable 3. Cont.\\nClinical Trial\\nPhase\\nStatus\\nArms\\nPopulation\\nNCT05447702\\nII\\nNot yet\\nrecruiting\\nCamr + apatinib + CT\\nNeoadjuvant therapy for stage II-III TNBC\\nNCT04303741\\nII\\nOngoing\\nCamr + apatinib + eribulin\\nUnresectable recurrent or mTNBC;\\npre-treated with anthracycline\\nand taxane\\nNCT04427293\\nI\\nRecruiting\\nPemb + Lenvatinib\\nEarly-stage TNBC: preoperative treatment'),\n",
       " Document(metadata={}, page_content='Early-stage TNBC: preoperative treatment\\nNCT04335006\\nIII\\nRecruiting\\nCare + nab-P + apatinib vs. Care\\n+ nab-P vs. nab-P\\nLocally advanced or metastatic TNBC:\\nﬁrst-line treatment\\nNCT03800836\\nIb\\nCompleted\\nAtez + ipatasertib + P/nab-P\\nmTNBC: ﬁrst-line treatment\\nBARBICAN\\n(NCT05498896)\\nII\\nOngoing\\nAtez + PAC + ipatasertib\\nvs. Atez + PAC\\nEarly-stage TNBC:\\npreoperative treatment\\nNCT04177108\\nIII\\nOngoing\\nAtez/placebo +\\nipatasertib/placebo + P'),\n",
       " Document(metadata={}, page_content='Ongoing\\nAtez/placebo +\\nipatasertib/placebo + P\\nLocally advanced unresectable or metastatic\\nTNBC\\nCOLET\\n(NCT02322814)\\nII\\nCompleted\\nAtez + cobimetinib + P (cohorts\\nII)/Atez + cobimetinib + nab-P\\n(cohort III)\\nFirst-line treatment for mTNBC\\nNCT02536794\\nII\\nCompleted\\nDurv + tremelimumab\\nPre-treated mTNBC\\nNCT03872791\\nIb/II\\nOngoing\\nKN046 vs. KN046 + nab-P\\nmTNBC\\nSYNERGY\\n(NCT03616886)\\nIb/II\\nOngoing\\nDurv + oleclumab +PCb vs.\\nDurv + PCb'),\n",
       " Document(metadata={}, page_content='Ongoing\\nDurv + oleclumab +PCb vs.\\nDurv + PCb\\nFirst-line treatment for mTNBC\\nNCT04584112\\nIb\\nOngoing\\nAtez + tiragolumab + CT\\nFirst-line treatment for PD-L1 (+) mTNBC\\nNCT05227664\\nII\\nRecruiting\\nAK117 + P/nab-P vs. AK112 +\\nP/nab-P vs. AK117+AK112 +\\nP/nab-P\\nFirst-line treatment for mTNBC\\nNCT03362060\\nI\\nOngoing\\nPemb + PVX-410 vaccine\\nPre-treated HLA-A2 (+) mTNBC\\nNCT02826434\\nI\\nOngoing\\nDurv + PVX-410\\nHLA-A2 (+) stage II or III TNBC\\nNCT03606967\\nII'),\n",
       " Document(metadata={}, page_content='HLA-A2 (+) stage II or III TNBC\\nNCT03606967\\nII\\nRecruiting\\nCT →Durv + tremelimumab +\\nVaccine vs. CT →Durv +\\ntremelimumab\\nFirst-line treatment for\\nPD-L1-negative mTNBC\\nNCT03199040\\nI\\nOngoing\\nDurv + DNA vaccine vs. DNA\\nvaccine\\nEarly-stage TNBC\\nNSABP FB-14\\n(NCT04024800)\\nII\\nOngoing\\nAE37 peptide vaccine + Pemb\\nAdvanced TNBC: ≤1 line\\nof systemic therapy\\nNCT03387085\\nIb/II\\nOngoing\\nCombination of multiple\\ntreatments\\nmTNBC: ≥2 lines of prior therapy'),\n",
       " Document(metadata={}, page_content='treatments\\nmTNBC: ≥2 lines of prior therapy\\nNCT04445844\\nII\\nRecruiting\\nRetifanlimab + pelareorep\\nmTNBC: received 1–2 prior lines\\nof systemic therapy\\nNCT03004183\\nII\\nOngoing\\nADV/HSV-tk + RT + Pemb +\\nPre-treated mTNBC\\nNCT03256344\\nI\\nCompleted\\nAtez + talimogene laherparepvec\\nmTNBC with liver metastases\\nNCT05081492\\nI\\nRecruiting\\nCF33-hNIS-antiPDL1\\nmTNBC: ≥2 prior lines of therapy\\nfor metastatic disease\\nNCT04185311\\nI\\nOngoing\\nTalimogene laherparepvec +'),\n",
       " Document(metadata={}, page_content='NCT04185311\\nI\\nOngoing\\nTalimogene laherparepvec +\\nnivolumab + ipilimumab\\nLocalized, palpable HER-2 negative\\nbreast cancer\\nAbbreviations: mTNBC, metastatic triple-negative breast cancer; Pemb, pembrolizumab; Camr, camrelizumab;\\nAtez. atezolizumab; Durv. durvalumab; Nivo, nivolumab; Care, carelizumab; CT, chemotherapy; RT, radiotherapy;\\nNab-P, nab-paclitaxel; P, paclitaxel; E, epirubicin; A, doxorubicin; C, cyclophosphamide; Cb, carboplatin; mOS,'),\n",
       " Document(metadata={}, page_content='median overall survival; mPFS, median progression-free survival; ORR, objective response rate; pCR, pathological\\ncomplete remission; DOR, median duration of response; SG, sacituzumab govitecan; TPC, treatment of physician’s\\nchoice; HLA, human leukocyte antigen; RIC, residual invasive cancer; NACT, neoadjuvant chemotherapy.\\nCancers 2023, 15, 321\\n15 of 28\\n7.2. Combination with ADCs'),\n",
       " Document(metadata={}, page_content='15 of 28\\n7.2. Combination with ADCs\\nADCs consist of three components: mAb, linker, and cytotoxic payload. In addi-\\ntion to targeting antigen-expressing tumor cells for payload delivery, the mAb mediates\\nantibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated\\nphagocytosis (ADCP), and/or complement-dependent cytotoxicity (CDC), as well as the'),\n",
       " Document(metadata={}, page_content='unique bystander killing effect of ADCs to clear tumor cells [71,72]. The cytotoxic pay-\\nload, apart from directly killing tumor cells, also has immunomodulatory effects, as with\\nthe chemotherapeutic agents discussed above [73,74]. Furthermore, payload microtubule\\ninhibitors and topoisomerase inhibitors can directly activate DCs and promote their matu-\\nration [75,76]. Therefore, ADCs may create a more conducive TIME for the enhancement of'),\n",
       " Document(metadata={}, page_content='PD-(L)1 inhibitors and work synergistically with PD-(L)1 inhibitors to ﬁght against tumors.\\nSacituzumab govitecan, an ADC that targets the tumor cell surface antigen trop2 and\\nhas the irinotecan metabolite SN-38 as its payload, has been approved by the FDA for\\npatients with advanced TNBC who have received 2 or more lines treatments. Clinical trials\\nare currently underway to evaluate the potential of sacituzumab govitecan in combination'),\n",
       " Document(metadata={}, page_content='with pembrolizumab as ﬁrst-line treatment for mTNBC.\\nLadiratuzumab vedotin is an ADC that targets the zinc transporter protein LIV-1\\nwith the microtubule inhibitor monomethyl auristatin E (MMAE) as a payload. A phase\\nIb/II trial (NCT03310957) evaluated the safety and efﬁcacy of its combination with pem-\\nbrolizumab as ﬁrst-line treatment for advanced TNBC. The initial 51 patients included'),\n",
       " Document(metadata={}, page_content='showed moderate tolerability and a manageable safety proﬁle. Among the 26 patients\\nevaluable for efﬁcacy, the ORR was 54% [77]. This trial is currently underway and initial\\nresults are encouraging.\\nSeveral additional trials are testing the safety and efﬁcacy of PD-(L)1 inhibitors in\\ncombination with ADCs in both early-stage and advanced TNBC (Table 3).\\n7.3. Combination with Small Molecule Inhibitors'),\n",
       " Document(metadata={}, page_content='7.3. Combination with Small Molecule Inhibitors\\nThe serine/threonine kinase AKT is a key component of the phosphatidylinositol-\\n3-kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways.\\nActivation of this pathway and its downstream pathways is associated with the growth,\\ninvasion, and drug resistance of a variety of tumors and is cross-linked with multiple'),\n",
       " Document(metadata={}, page_content='signaling pathways, such as the mitogen-activated protein kinase (MAPK) pathway [78].\\nIt has been shown that activation of these two pathways is associated with an increase\\nin immunosuppressive cells and cytokines as well as a decrease in IFNγ, interleukin-2\\n(IL-2), and tumor necrosis factor α (TNFα) [79–81]. Therefore, a simultaneous blockade\\nof these pathways as well as PD-(L)1 would confer a better therapeutic effect. Results of'),\n",
       " Document(metadata={}, page_content='a phase Ib trial (NCT03800836) combining the AKT inhibitors ipatasertib, atezolizumab,\\nand paclitaxel or nab-paclitaxel as a ﬁrst-line treatment for mTNBC showed an ORR of\\n54% and mPFS of 7.2 months in 114 patients. Subgroup analysis according to PD-L1 status,\\nPIK3CA/AKT1/phosphatase and tensin homolog (PTEN) alteration status, or taxane back-\\nbone showed no consistent trend across endpoints. Treatment was generally tolerable [82].'),\n",
       " Document(metadata={}, page_content='Cobimetinib is a MAPK/extracellular signal-regulated kinase (MEK) inhibitor. In the phase\\nII COLET trial, a combination regimen of cobimetinib with atezolizumab and paclitaxel\\nor nab-paclitaxel as ﬁrst-line treatment failed to signiﬁcantly improve ORRs in mTNBC\\n(34.4% for the paclitaxel cohort and 29.0% for the nab-paclitaxel cohort) [83]. These ﬁndings\\nsuggest that more effort is still needed in the understanding of classical pathways and in'),\n",
       " Document(metadata={}, page_content='clinical translation.\\nAbnormal morphological and functional vascularity within solid tumors results in\\nhypoxia of tumor tissue and increased immunosuppressive TIME, as well as reduced and\\nsuppressed immune cell inﬁltration and activity [84,85]. Preclinical studies have shown\\nthat anti-vascular therapy increases immune cell inﬁltration and PD-L1 expression in tumor'),\n",
       " Document(metadata={}, page_content='tissues [86]. Thus, anti-tumor vascular therapy is a potential method to convert cold tumors\\ninto hot tumors. A phase II clinical trial (NCT03394287) combined camrelizumab with the\\nvascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor apatinib\\nCancers 2023, 15, 321\\n16 of 28\\nin patients with advanced TNBC with fewer than 3 lines of systemic therapy. Of the'),\n",
       " Document(metadata={}, page_content='40 patients included, 10 were treated intermittently with apatinib and 30 were treated\\ncontinuously. The ORR in the continuous dosing cohort was 43.3%, while no objective\\nresponse was observed in the intermittent dosing cohort. This trial demonstrated that the\\ncombination of the two drugs is safe and it shows a superior clinical response to single\\ndrug application [87].'),\n",
       " Document(metadata={}, page_content='drug application [87].\\nMore trials on the combination of ICIs with small molecule inhibitors are underway\\n(Table 3).\\n8. Exploration of PD-(L)1 Inhibitors in Combination with Other Immunotherapies\\n8.1. Combination with Other ICIs\\nIn addition to PD-(L)1, immune checkpoints such as cytotoxic T-lymphocyte antigen-4\\n(CTLA-4), lymphocyte-activation gene 3 (LAG-3), and T cell immunoreceptor with Ig'),\n",
       " Document(metadata={}, page_content='and ITIM domains (TIGIT) are also signiﬁcantly upregulated in TNBC; their expression\\nlevels are further boosted by PD-(L)1 blockade, which may mediate acquired resistance\\nto PD-(L)1 blockade [88,89]. Therefore, to further reverse the tumor immunosuppressive\\nmicroenvironment and overcome PD-(L)1 inhibitor resistance, dual ICIs therapies have\\nbeen developed.\\nCTLA-4 is a co-suppressor molecule expressed by T cells. As a homologous receptor'),\n",
       " Document(metadata={}, page_content='of CD28, CTLA-4 can replace CD28 and bind to the B7 ligand on the surface of APCs,\\npreventing the activation and proliferation of T cells [90]. Anti-CTLA-4 antibodies en-\\nhance tumor cell killing by blocking the CTLA-4-B7 checkpoint pathway or by selectively\\ndepleting Treg cells, although this requires further validation [91]. In a small single-arm\\nstudy (NCT02536794), durvalumab in combination with tremelimumab demonstrated'),\n",
       " Document(metadata={}, page_content='preliminary efﬁcacy and a tolerable safety proﬁle in 7 patients with mTNBC, with an ORR\\nof 43% [92]. In particular, a combination regimen of KN046, a bispeciﬁc antibody that\\ntargets both PD-L1 and CTLA-4, with nab-paclitaxel for advanced TNBC showed initially\\npromising results in a phase Ib/II trial (NCT03872791), which may herald the coming of\\nthe era of bispeciﬁc antibodies [93].'),\n",
       " Document(metadata={}, page_content='the era of bispeciﬁc antibodies [93].\\nNevertheless, the idea of combining ICIs for the treatment of TNBC met a waterloo in\\nthe SYNERGY trial. CD73, a metabolic immune checkpoint, is an ecto-5′-nucleotidase that\\nis expressed on a wide range of cells and works synergistically with CD39 to convert ATP\\ninto adenosine. Adenosine is a potent immunosuppressive molecule that suppresses the'),\n",
       " Document(metadata={}, page_content='function of a wide range of immune cells, especially T cells [94]. CD73 is highly expressed\\nin TNBC and is associated with poor prognosis [95]. The preliminary results at week 24\\nwere presented at the European Society for Medical Oncology (ESMO) 2022 and showed\\nthat the addition of the CD73 inhibitor oleclumab to chemotherapy and durvalumab did\\nnot improve clinical beneﬁts as a ﬁrst-line treatment for advanced TNBC (the clinical beneﬁt'),\n",
       " Document(metadata={}, page_content='rates were 42.9% vs. 43.3%, respectively) [96].\\nThe mixed results suggest that the functions and interactions of various immune\\ncheckpoints still need to be more thoroughly explored. Clinical trials on the effects of\\nPD-(L)1 inhibitors in combination with other ICIs, such as novel phagocytosis checkpoints,\\nare in full swing (Table 3).\\n8.2. TCVs and PD-(L)1 Inhibitors'),\n",
       " Document(metadata={}, page_content='8.2. TCVs and PD-(L)1 Inhibitors\\nThe practice of utilizing vaccines against breast tumors predates even ICI uses. How-\\never, due to limited efﬁcacy, this approach is not widely applied clinically. Personalized\\nTCVs based on neoantigens may beneﬁt speciﬁc patients via injection of tumor neoanti-\\ngens that were extracted from tumor tissues or human body ﬂuids along with adjuvants.'),\n",
       " Document(metadata={}, page_content='Such therapy ampliﬁes the process of antigen capture and presentation, increases the\\nnumber of tumor-speciﬁc effector T cells, and establishes long-term memory to inhibit\\ntumor recurrence [97,98]. The major types currently in trials include: autologous cells,\\nwhole/genetically modiﬁed tumor cells, or DCs; cancer antigens, DNA/RNA/peptide\\nvaccines; and tumor cell products, such as exosomes [99].\\nCancers 2023, 15, 321\\n17 of 28'),\n",
       " Document(metadata={}, page_content='Cancers 2023, 15, 321\\n17 of 28\\nTCVs and PD-(L)1 inhibitors act in different steps of tumor elimination, and thus\\ncombination treatment will synergistically activate the entire immune system. Several\\nclinical trials are currently testing the safety and efﬁcacy of TCVs in combination with\\nPD-(L)1 inhibitors for the treatment of TNBC, in both early and advanced stages (Table 3).'),\n",
       " Document(metadata={}, page_content='Notably, a preclinical study showed that the sequence of PD-(L)1 inhibitors and vaccine\\ncombinations is critical to treatment efﬁcacy [100], which deserves special attention when\\nconducting clinical trials.\\n8.3. Oncolytic Virus (OVs) and PD-(L)1 Inhibitors\\nOVs immunotherapy utilizes natural or modiﬁed viruses to selectively infect tumor\\ncells and replicate in large numbers, thereby lysing tumor cells without harming normal'),\n",
       " Document(metadata={}, page_content='cells [101]. In addition to direct killing of tumor cells, OVs also enhance host anti-tumor\\nimmunity by mediating ICD, promoting the release of TAAs, increasing the recruitment and\\nmaturation of immune cells, and regulating the suppressive TIME, all together rapidly and\\neffectively transforming cold tumors into inﬂammatory tumors [102]. The efﬁcacy of OVs\\nalone or in combination with therapies such as ICIs has been demonstrated in preclinical'),\n",
       " Document(metadata={}, page_content='tumor models of TNBC [103]. While oncorine (H101) and talimogene laherparepvec (T-\\nVEC) have been approved by the Chinese Food and Drug Administration and the FDA\\nfor the treatment of head and neck cancer and melanoma, respectively, clinical studies\\nof OVs in TNBC are still in their infancy with few results published. A phase I trial\\n(NCT03256344) evaluated the safety of intrahepatic injection of T-VEC in combination'),\n",
       " Document(metadata={}, page_content='with intravenous atezolizumab in patients with mTNBC or colorectal cancer, and no dose-\\nlimiting toxicity (DLT) was seen in the four TNBC patients who could be evaluated [104]. In\\naddition, scientists have developed chimeric oncolytic poxvirus that can express anti-PD-L1\\nantibodies and are currently in a phase I trial. Several trials combining PD-(L)1 blockade\\nand OVs are underway (Table 3).\\n8.4. ACT and PD-(L)1 Inhibitors'),\n",
       " Document(metadata={}, page_content='8.4. ACT and PD-(L)1 Inhibitors\\nACT refers to a therapy in which immune-active cells are isolated from tumor patients,\\nexpanded, modiﬁed, and characterized in vitro, and then infused back for the purpose of\\ndirectly killing tumor cells or stimulating an immune response to kill tumor cells. Adoptive\\nTILs and genetically modiﬁed T cells expressing modiﬁed T cell receptors (TCR-T) or'),\n",
       " Document(metadata={}, page_content='chimeric antigen receptors (CAR-T) are currently the most studied, while therapies such\\nas adoptive NK cells and cytokine-induced killer cells (CIK) are also gaining attention.\\nHowever, in the ﬁeld of TNBC, this treatment is still in early phase trials. ACT can directly\\nincrease populations of immune killer cells in cold tumors, but its efﬁcacy may be greatly\\nreduced due to the presence of immune checkpoints. Therefore, combining ACT with'),\n",
       " Document(metadata={}, page_content='PD-(L)1 inhibitors is a promising approach to enhance anti-tumor efﬁcacy. A phase Ib/II\\ntrial (NCT03387085) ﬁrst demonstrated a safe and tolerable combination treatment of low-\\ndose chemoradiation, TCV, NK cells therapy, and a PD-L1 inhibitor as third- or greater-line\\ntherapy for mTNBC. The ORR was 56% and the disease control rate was 78% in the initial\\nenrollment of 9 patients [105] (Table 3). These preliminary encouraging results provide'),\n",
       " Document(metadata={}, page_content='ideas for additional combination therapies. More outcomes are to be expected.\\n9. Potential Therapeutic Targets for Reversing Cold Tumors\\nAlthough considerable clinical trials have been conducted on TNBC patients with some\\nachievements, the mechanisms of tumor immunity are still being explored. Meanwhile,\\nsome potential therapeutic targets that can convert cold tumors have been identiﬁed.'),\n",
       " Document(metadata={}, page_content='According to a fundamental study, the mRNA N6-methyladenosine (m6A)-binding\\nprotein YTHDF1 can recognize and bind transcripts encoding lysosomal proteases, which\\nin turn increases the translation of lysosomal histone proteases in DCs, resulting in the\\nimpaired presentation of tumor neoantigens and T cell initiation. In addition, the anti-\\ntumor effect of PD-L1 blockade was enhanced in the YTHDF1-/- tumor-bearing mouse'),\n",
       " Document(metadata={}, page_content='models [106]. These suggest that the combination of ICIs and YTHDF1 depletion may be\\nCancers 2023, 15, 321\\n18 of 28\\na potential new therapeutic strategy. Research on innate immunity activation by STING\\nagonists are also proceeding in full swing.\\nTumor stromal ﬁbrosis is one mechanism by which T cell inﬁltration is restricted in\\ncold tumors. A recent study showed that discoidin domain receptor 1 (DDR1), a collagen'),\n",
       " Document(metadata={}, page_content='receptor with tyrosine kinase activity, can enhance the collagen ﬁbril alignment and impede\\nimmune inﬁltration through the binding of its extracellular domain (ECD) to collagen.\\nConversely, ECD-neutralizing antibodies could disrupt this alignment, attenuate immune\\nrejection, and inhibit tumor growth [107]. This study suggests that disruption of tumor\\nstromal ﬁbrosis is one way to convert cold tumors and holds promise to improve anti-tumor'),\n",
       " Document(metadata={}, page_content='efﬁcacy in combination with ICIs in the future.\\nThere are also a growing number of studies focusing on the impact of the host nervous\\nsystem and commensal microbes on anti-tumor immunity. The effects of sympathetic-β-\\nadrenergic signaling on MDSCs’ survival, expression of immunosuppressive molecules\\nsuch as arginase-I and PD-L1, and proliferation and function of effector T cells in tumor'),\n",
       " Document(metadata={}, page_content='tissues have been revealed in mouse tumor models. A reduction of this signaling con-\\ntributed to the conversion of tumors to an immunoreactive tumor microenvironment, and\\nthis conversion signiﬁcantly improved the efﬁcacy of PD-1 ICI [108,109]. A multi-omics\\nanalysis of a TNBC cohort showed that genera under Clostridiales and the related metabo-\\nlite trimethylamine N-oxide (TMAO) were positively associated with the TIME activation'),\n",
       " Document(metadata={}, page_content='and immunotherapy efﬁcacy [110]. Although showing promising prospects for converting\\ncold tumors and improving the efﬁcacy of immunotherapy, these aspects of TNBC have\\nnot been studied sufﬁciently as of now, and more research is required.\\n10. Biomarkers for Predicting Immunological Response\\n10.1. PD-L1 Expression and TILs\\nThe predictive value of PD-L1 expression for the efﬁcacy of PD-(L)1 inhibitors in TNBC'),\n",
       " Document(metadata={}, page_content='has been demonstrated in several trials [27,40,44]. However, there are still limitations re-\\nlated to choosing PD-L1 as a predictive marker. First, PD-L1 expression is spatiotemporally\\nvariable. It not only evolves over time with disease progression but also varies by metastatic\\nlocation, with the highest prevalence of positivity in lymph nodes and the lowest in the'),\n",
       " Document(metadata={}, page_content='liver [111]. Moreover, PD-L1 status was found to be less predictive of efﬁcacy in early-stage\\nTNBC compared to late-stage disease, as discussed previously [55,60]. Second, there are a\\nvariety of immunohistochemistry assays for PD-L1 expression status detection, but a lack\\nof standard test methods. The ﬁve mainstream assays commonly used from two companies\\nare the 22C3, 28-8, and 73-10 assays on the DAKO AutoStainer Link 48 platform and the'),\n",
       " Document(metadata={}, page_content='SP142 and SP263 assays on the Ventana Benchmark Ultra platform. These assays use differ-\\nent primary antibodies to assess PD-L1 expression in tumor cells and/or tumor-inﬁltrating\\nimmune cells with different scoring criteria and deﬁnitions of PD-L1 positivity [112,113].\\nThe 22C3 assay uses a combined positive score (CPS) based on both tumor cells and im-\\nmune cells (lymphocytes and macrophages) staining to determine PD-L1-positive tumors'),\n",
       " Document(metadata={}, page_content='in mTNBC patients for pembrolizumab, with a cutoff value of 10 in KEYNOTE-355. In\\ncontrast, the SP142 assay uses the percentage of stained tumor-inﬁltrating immune cells\\n(IC) to the tumor area to determine PD-L1-positive tumors for atezolizumab, with a cutoff\\nvalue of 1% in IMpassion130. Occasionally, in some trials, the percentage of tumor cells\\n(TC) stained is also used to assess PD-L1 expression [27,57]. It is worth noting that the three'),\n",
       " Document(metadata={}, page_content='scoring systems differ signiﬁcantly in terms of algorithms and the types of cells evaluated.\\nA comparative study analyzed the concordance between different PD-L1 assays and the\\nrelationship with patient clinical outcomes. The results showed poor equivalence between\\nthe different assays and they were not analytically interchangeable. SP142 assay (≥1%\\nIC) detected the least prevalence of PD-L1 positivity at 46.4% (74.9% for SP263 (≥1% IC)'),\n",
       " Document(metadata={}, page_content='and 80.9% for 22C3 (CPS ≥1)), with almost all of these patients captured by the other\\ntwo assays, and these patients had better clinical outcome improvement with the applica-\\ntion of atezolizumab [114]. In addition, tissue ﬁxation methods and subjective factors of\\npathologists may also affect PD-L1 results [115,116]. Finally, with the advent of some new\\nCancers 2023, 15, 321\\n19 of 28'),\n",
       " Document(metadata={}, page_content='Cancers 2023, 15, 321\\n19 of 28\\ntreatment combinations, some patients who are negative for PD-L1 can also proﬁt from ICIs,\\nsince some drugs upregulate PD-L1 expression during treatment, which is unpredictable\\nbefore therapy. Conclusively, the predictive value of PD-L1 expression for the efﬁcacy of\\nPD-(L)1 blockade is undeniable, but is not a determinant. Therefore, caution should be\\nexercised when making treatment decisions based on PD-L1 status.'),\n",
       " Document(metadata={}, page_content='TILs are a cell population consisting of T cells, B cells, and NK cells, including both\\ntumor-killing and immunosuppressive cells [117]. As with PD-L1 expression, TILs are\\nalso spatiotemporally variable [51,111]. In KEYNOTE-086, higher levels of TILs were\\nassociated with better ORR [118]. In a biomarker analysis of KEYNOTE-119, high TIL levels\\nwere related to better clinical outcomes with pembrolizumab, but not with chemotherapy.'),\n",
       " Document(metadata={}, page_content='Patients with TNBC and TILs ≥5% survived longer with pembrolizumab than with\\nchemotherapy, but this difference was not signiﬁcant [119]. In contrast, IMpassion130\\nshowed that stromal TIL (sTIL) levels were synergistic with PD-L1 expression; when\\nassessed independent of PD-L1, TILs failed to provide prognostic value [111]. A simple\\nmethod of section staining is recommended to quantify the extent of TIL inﬁltration [120].'),\n",
       " Document(metadata={}, page_content='TILs appear to be a promising biomarker for predicting the efﬁcacy of ICIs at a lower\\ncost, but more evidence is needed. Furthermore, in addition to the numerical level, the\\ncomposition ratio of cellular components, activation status, and spatial location distribution\\nof TILs are additional important factors that deserve further investigation when exploring\\nthe predictive effect of TILs on the efﬁcacy of immunotherapy.'),\n",
       " Document(metadata={}, page_content='10.2. TMB and Microsatellite Instability (MSI)/Mismatch Repair Deﬁciency (dMMR)\\nTumor mutational burden (TMB) is a measurement of the number of nonsynonymous\\nsomatic mutations in the genome of tumor cells [121]. When TMB > 10 mutations/Mb,\\nneoantigen production becomes common to tumor cells and can be recognized by TILs [121].\\nHigh TMB has been associated with efﬁcacy beneﬁts for ICIs in various tumors [122,123].'),\n",
       " Document(metadata={}, page_content='Despite being the highest TMB subtype of breast cancer, TNBC still has a low mutational\\nload compared to other tumors such as melanoma. One study showed that the median TMB\\nin breast cancer was 2.63 mut/Mb and only 5% of patients had high TMB (>10 mut/Mb),\\nwith metastatic tumors having higher TMB. Of these, the median mutational burden in\\nTNBC was 1.8 mut/Mb [124]. Data from 149 TNBC patients in the GeparNuevo trial'),\n",
       " Document(metadata={}, page_content='showed a median TMB of 1.52 mut/Mb, and continuous TMB independently predicted\\npCR [125]. Data from 253 patients in the KEYNOTE-119 trial showed a positive correlation\\nbetween TMB and clinical response to pembrolizumab, but not to chemotherapy [126].\\nHowever, in another study, high TMB failed to predict response to ICIs. In the TNBC\\nsubgroup, 10 patients with high TMB (>10 mut/Mb) had an ORR of 0, compared to 20.5%'),\n",
       " Document(metadata={}, page_content='in patients with low TMB. The reason for the immaturity of TMB as a predictor for the\\nefﬁcacy of ICIs is mainly due to the fact that antigens generated by tumor mutations may\\nnot be immunogenic [127].\\nIn fact, MSI/dMMR is one possible cause of high TMB [128]. Although MSI-high/dMMR\\nhas been shown to be associated with immunotherapy efﬁcacy in a variety of tumors and'),\n",
       " Document(metadata={}, page_content='has been approved by the FDA as a biomarker for the application of PD-1 blockers in\\nsolid tumors [129–131], its frequency is extremely low in TNBC, even in the high-level TIL\\nsubtype [132,133]. Based on the available evidence, MSI-high/dMMR is not a practical\\nbiomarker for screening TNBC patients who are or are not suitable for immunotherapy.\\nThe aforementioned biomarkers predict PD-(L)1 blockade responses either from the'),\n",
       " Document(metadata={}, page_content='perspective of the TIME or the tumor itself, but none of them are perfect. For now, the\\ncombination of several biomarkers to screen suitable patients may be more reliable. The\\nmost critical point in selecting immunotherapy-sensitive individuals and giving the most\\nappropriate therapy is to identify the immune deﬁciency at the tumor site; this is quite dif-\\nﬁcult, especially in patients with metastases, as many mechanisms of immune escape may'),\n",
       " Document(metadata={}, page_content='exist. However, with further understanding of tumor immune mechanisms, individualized\\nand precise immunotherapy becomes increasingly possible, especially with the inﬂux of\\nnovel genomics, single-cell sequencing, and artiﬁcial intelligence technologies.\\nCancers 2023, 15, 321\\n20 of 28\\n11. Pseudoprogression and Immune-Related Adverse Events\\nThe unique biological mechanisms of immunotherapy-ﬁghting tumors enable a long-'),\n",
       " Document(metadata={}, page_content='term or even complete response. However, they also require a long response time, which\\nmay lead to the emergence of immune-related patterns of pseudoprogression, hyperpro-\\ngression, or a mixed response [134–137]. Pseudoprogression refers to an initial increase in\\ntumor size followed by a decrease of tumor burden, and is associated with immune cell\\ninﬁltration, edema, or necrosis due to immunotherapy [138]. Pseudoprogression after im-'),\n",
       " Document(metadata={}, page_content='munotherapy for TNBC has been reported [139], but incidence rates based on large samples\\nare lacking. Previous data suggest that the incidence of pseudoprogression in solid tumors\\nis less than 10%, which implies that some patients who present with progression after\\ntreatment are likely to have true progression [140]. Although the immune-related response\\ncriteria (irRC), immune-related RECIST (irRECIST), and immune RECIST (iRECIST) have'),\n",
       " Document(metadata={}, page_content='been published to assist clinicians in evaluating response to immunotherapy, these are not\\nyet widely used in clinical practice [141–143]. Therefore, in patients presenting with tumor\\nprogression after initial immune-based therapy, clinicians must assess patients’ clinical\\nconditions and toxicity responses thoroughly before carefully deciding on subsequent\\ntreatments. This is especially important when immunotherapy is used in combination with'),\n",
       " Document(metadata={}, page_content='other therapies that have tumor-killing effects.\\nAlong with durable anti-tumor activity comes immune-related adverse events (irAEs)\\nthat are distinct from the toxicity of conventional chemotherapy. These irAEs vary according\\nto the type of immunotherapy, but there are some common features among ICIs [144].\\nFirst, irAEs are mostly organ-speciﬁc, occurring mainly in immune-related organs, with'),\n",
       " Document(metadata={}, page_content='rare cases reported involving multiple organ events at the same time [144,145]. Second,\\nwhile some irAEs occur rapidly, others are regularly delayed, even after treatment [144].\\nFinally, there is no clear relationship between irAEs and ICI dose [144,146]. These features\\nremind us that irAEs require long-term management that cannot be limited to the period of'),\n",
       " Document(metadata={}, page_content='dosing. Furthermore, the appearance of some toxicities often requires interruptions or even\\npermanent discontinuation of dosing. The most common irAEs in breast cancer patients are\\nrashes, followed by thyroid dysfunction (hypothyroidism > hyperthyroidism), and infusion\\nreactions [147]. Although these irAEs are not usually fatal, they often require high-dose\\ncorticosteroid treatment, which may lead to a reduced efﬁcacy of immunotherapy along'),\n",
       " Document(metadata={}, page_content='with additional side effects. On the other hand, patients with permanent endocrine organ\\ndamage (such as the thyroid) are required to take therapeutic drugs for the rest of their\\nlife and their quality of life is therefore compromised. Notably, the current addition of\\nPD-(L)1 inhibitors to conventional therapies in TNBC patients has already increased the\\nincidence of associated irAEs, although severe incident rates are less than 10% [147–149].'),\n",
       " Document(metadata={}, page_content='Lessons from other tumor types show us that some novel immunotherapies, as well as\\ncombination treatments with immunotherapies, can lead to a higher incidence of irAEs\\nand even severe cytokine release syndromes [150–152]. Therefore, the introduction of\\nnovel immunotherapies and new combination regimens is something that should be given\\nextra attention. Early identiﬁcation and management of irAEs is extremely important.'),\n",
       " Document(metadata={}, page_content='Of particular consideration is the impact of immunotherapy on fertility, as a signiﬁcant\\nproportion of patients with TNBC are younger than 40 years of age.\\n12. Conclusions\\nTNBC is the subtype of breast cancer with the worst prognosis. To date, although\\nseveral targeted drugs have been approved for the treatment of TNBC, the urgent need\\nfor improved survival has not been met. The practice of immunotherapy in TNBC is just'),\n",
       " Document(metadata={}, page_content='beginning to take off. An advantage of the later start in this ﬁeld is that experience can be\\nlearned from other tumor types, both successful and failed. Although some progress has\\nbeen made with respect to ICIs for TNBC, many challenges remain. Clinical results show\\nthat only a small proportion of patients with TNBC actually beneﬁt from immunotherapy.\\nThus, identifying the target population and expanding the efﬁcacy is a top priority. Overall,'),\n",
       " Document(metadata={}, page_content='combination treatment is the way forward, but the combination treatment mode, sequence,\\nCancers 2023, 15, 321\\n21 of 28\\ndosage, and duration require further exploration and careful attention should be focused\\non balancing economics and toxicity. As a growing number of preclinical and clinical\\nstudies are conducted in this ﬁeld, we expect to reach the ultimate goal: to select the most'),\n",
       " Document(metadata={}, page_content='suitable patients for immunotherapy, to give the most appropriate immunotherapy or\\nimmune-combination therapy, to accurately assess the efﬁcacy of the treatment, and to\\nachieve optimal therapeutic results with minimal toxic damage.\\nAuthor Contributions: Conceptualization, L.L. and Z.F.; methodology, L.L.; software, L.L.; validation,\\nL.L., F.Z., and Z.L.; resources, L.L.; data curation, L.L. and F.Z.; writing—original draft preparation,'),\n",
       " Document(metadata={}, page_content='L.L.; writing—review and editing, L.L., F.Z., and Z.L.; visualization, L.L.; supervision, Z.F. All authors\\nhave read and agreed to the published version of the manuscript.\\nFunding: This research received no external funding.\\nConﬂicts of Interest: The authors declare no conﬂict of interest.\\nReferences\\n1.\\nLin, N.U.; Vanderplas, A.; Hughes, M.E.; Theriault, R.L.; Edge, S.B.; Wong, Y.N.; Blayney, D.W.; Niland, J.C.; Winer, E.P.; Weeks,'),\n",
       " Document(metadata={}, page_content='J.C. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the\\nNational Comprehensive Cancer Network. Cancer 2012, 118, 5463–5472. [CrossRef] [PubMed]\\n2.\\nDent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A.'),\n",
       " Document(metadata={}, page_content='Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13, 4429–4434. [CrossRef]\\n3.\\nNedeljkovic, M.; Damjanovic, A. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to\\nthe Challenge. Cells 2019, 8, 957. [CrossRef]\\n4.\\nLehmann, B.D.; Jovanovic, B.; Chen, X.; Estrada, M.V.; Johnson, K.N.; Shyr, Y.; Moses, H.L.; Sanders, M.E.; Pietenpol, J.A.'),\n",
       " Document(metadata={}, page_content='Reﬁnement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS\\nOne 2016, 11, e0157368. [CrossRef]\\n5.\\nBurstein, M.D.; Tsimelzon, A.; Poage, G.M.; Covington, K.R.; Contreras, A.; Fuqua, S.A.; Savage, M.I.; Osborne, C.K.; Hilsenbeck,\\nS.G.; Chang, J.C.; et al. Comprehensive genomic analysis identiﬁes novel subtypes and targets of triple-negative breast cancer.'),\n",
       " Document(metadata={}, page_content='Clin. Cancer Res. 2015, 21, 1688–1698. [CrossRef]\\n6.\\nJiang, Y.Z.; Ma, D.; Suo, C.; Shi, J.; Xue, M.; Hu, X.; Xiao, Y.; Yu, K.D.; Liu, Y.R.; Yu, Y.; et al. Genomic and Transcriptomic\\nLandscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell 2019, 35, 428–440.e5. [CrossRef]\\n[PubMed]\\n7.'),\n",
       " Document(metadata={}, page_content='[PubMed]\\n7.\\nDe Melo Gagliato, D.; Cortes, J.; Curigliano, G.; Loi, S.; Denkert, C.; Perez-Garcia, J.; Holgado, E. Tumor-inﬁltrating lymphocytes\\nin Breast Cancer and implications for clinical practice. Biochim. Biophys. Acta. Rev. Cancer 2017, 1868, 527–537. [CrossRef]\\n[PubMed]\\n8.\\nMittendorf, E.A.; Philips, A.V.; Meric-Bernstam, F.; Qiao, N.; Wu, Y.; Harrington, S.; Su, X.; Wang, Y.; Gonzalez-Angulo, A.M.;'),\n",
       " Document(metadata={}, page_content='Akcakanat, A.; et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2014, 2, 361–370. [CrossRef]\\n[PubMed]\\n9.\\nKwa, M.J.; Adams, S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. Cancer 2018, 124,\\n2086–2103. [CrossRef]\\n10.\\nDunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape.'),\n",
       " Document(metadata={}, page_content='Nat. Immunol. 2002, 3, 991–998. [CrossRef] [PubMed]\\n11.\\nChen, D.S.; Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013, 39, 1–10. [CrossRef]\\n12.\\nCampoli, M.; Ferrone, S. HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic signiﬁcance. Oncogene\\n2008, 27, 5869–5885. [CrossRef]\\n13.'),\n",
       " Document(metadata={}, page_content='2008, 27, 5869–5885. [CrossRef]\\n13.\\nSchreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion.\\nScience 2011, 331, 1565–1570. [CrossRef] [PubMed]\\n14.\\nKim, J.M.; Chen, D.S. Immune escape to PD-L1/PD-1 blockade: Seven steps to success (or failure). Ann. Oncol. 2016, 27,\\n1492–1504. [CrossRef] [PubMed]\\n15.'),\n",
       " Document(metadata={}, page_content='1492–1504. [CrossRef] [PubMed]\\n15.\\nDou, A.; Fang, J. Heterogeneous Myeloid Cells in Tumors. Cancers 2021, 13, 3772. [CrossRef] [PubMed]\\n16.\\nSpranger, S. Mechanisms of tumor escape in the context of the T-cell-inﬂamed and the non-T-cell-inﬂamed tumor microenviron-\\nment. Int. Immunol. 2016, 28, 383–391. [CrossRef]\\n17.\\nDyck, L.; Mills, K.H.G. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur. J. Immunol. 2017, 47,'),\n",
       " Document(metadata={}, page_content='765–779. [CrossRef] [PubMed]\\n18.\\nFeng, M.; Jiang, W.; Kim, B.Y.S.; Zhang, C.C.; Fu, Y.X.; Weissman, I.L. Phagocytosis checkpoints as new targets for cancer\\nimmunotherapy. Nat. Rev. Cancer. 2019, 19, 568–586. [CrossRef]\\n19.\\nSanmamed, M.F.; Chen, L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 2018, 175,\\n313–326. [CrossRef]\\nCancers 2023, 15, 321\\n22 of 28\\n20.'),\n",
       " Document(metadata={}, page_content='Cancers 2023, 15, 321\\n22 of 28\\n20.\\nChen, D.S.; Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 2017, 541, 321–330. [CrossRef]\\n21.\\nXiao, Y.; Ma, D.; Zhao, S.; Suo, C.; Shi, J.; Xue, M.Z.; Ruan, M.; Wang, H.; Zhao, J.; Li, Q.; et al. Multi-Omics Proﬁling Reveals\\nDistinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clin.'),\n",
       " Document(metadata={}, page_content='Cancer Res. 2019, 25, 5002–5014. [CrossRef] [PubMed]\\n22.\\nGruosso, T.; Gigoux, M.; Manem, V.S.K.; Bertos, N.; Zuo, D.; Perlitch, I.; Saleh, S.M.I.; Zhao, H.; Souleimanova, M.; Johnson,\\nR.M.; et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J. Clin. Investig. 2019, 129,\\n1785–1800. [CrossRef] [PubMed]\\n23.'),\n",
       " Document(metadata={}, page_content='1785–1800. [CrossRef] [PubMed]\\n23.\\nBareche, Y.; Buisseret, L.; Gruosso, T.; Girard, E.; Venet, D.; Dupont, F.; Desmedt, C.; Larsimont, D.; Park, M.; Rothe, F.; et al.\\nUnraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.\\nJ. Natl. Cancer Inst. 2020, 112, 708–719. [CrossRef] [PubMed]\\n24.'),\n",
       " Document(metadata={}, page_content='24.\\nKeir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26,\\n677–704. [CrossRef] [PubMed]\\n25.\\nBalar, A.V.; Weber, J.S. PD-1 and PD-L1 antibodies in cancer: Current status and future directions. Cancer Immunol. Immunother.\\n2017, 66, 551–564. [CrossRef]\\n26.'),\n",
       " Document(metadata={}, page_content='2017, 66, 551–564. [CrossRef]\\n26.\\nSolinas, C.; Aiello, M.; Rozali, E.; Lambertini, M.; Willard-Gallo, K.; Migliori, E. Programmed cell death-ligand 2: A neglected but\\nimportant target in the immune response to cancer? Transl. Oncol. 2020, 13, 100811. [CrossRef]\\n27.\\nNanda, R.; Chow, L.Q.; Dees, E.C.; Berger, R.; Gupta, S.; Geva, R.; Pusztai, L.; Pathiraja, K.; Aktan, G.; Cheng, J.D.; et al.'),\n",
       " Document(metadata={}, page_content='Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J. Clin. Oncol. 2016, 34,\\n2460–2467. [CrossRef]\\n28.\\nAdams, S.; Loi, S.; Toppmeyer, D.; Cescon, D.W.; De Laurentiis, M.; Nanda, R.; Winer, E.P.; Mukai, H.; Tamura, K.; Armstrong, A.;\\net al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B'),\n",
       " Document(metadata={}, page_content='of the phase II KEYNOTE-086 study. Ann. Oncol. 2019, 30, 405–411. [CrossRef]\\n29.\\nAdams, S.; Schmid, P.; Rugo, H.S.; Winer, E.P.; Loirat, D.; Awada, A.; Cescon, D.W.; Iwata, H.; Campone, M.; Nanda, R.;\\net al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II\\nKEYNOTE-086 study. Ann. Oncol. 2019, 30, 397–404. [CrossRef]\\n30.'),\n",
       " Document(metadata={}, page_content='30.\\nWiner, E.P.; Lipatov, O.; Im, S.A.; Goncalves, A.; Munoz-Couselo, E.; Lee, K.S.; Schmid, P.; Tamura, K.; Testa, L.; Witzel, I.;\\net al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A\\nrandomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22, 499–511. [CrossRef]\\n31.'),\n",
       " Document(metadata={}, page_content='31.\\nDirix, L.Y.; Takacs, I.; Jerusalem, G.; Nikolinakos, P.; Arkenau, H.T.; Forero-Torres, A.; Boccia, R.; Lippman, M.E.; Somer, R.;\\nSmakal, M.; et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b\\nJAVELIN Solid Tumor study. Breast. Cancer Res. Tr. 2018, 167, 671–686. [CrossRef] [PubMed]\\n32.'),\n",
       " Document(metadata={}, page_content='32.\\nEmens, L.A.; Cruz, C.; Eder, J.P.; Braiteh, F.; Chung, C.; Tolaney, S.M.; Kuter, I.; Nanda, R.; Cassier, P.A.; Delord, J.P.; et al.\\nLong-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative\\nBreast Cancer A Phase 1 Study. Jama. Oncol. 2019, 5, 74–82. [CrossRef] [PubMed]\\n33.'),\n",
       " Document(metadata={}, page_content='33.\\nBachelot, T.; Filleron, T.; Bieche, I.; Arnedos, M.; Campone, M.; Dalenc, F.; Coussy, F.; Sablin, M.P.; Debled, M.; Lefeuvre-\\nPlesse, C.; et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: The randomized phase II\\nSAFIR02-BREAST IMMUNO trial. Nat. Med. 2021, 27, 250–255. [CrossRef] [PubMed]\\n34.'),\n",
       " Document(metadata={}, page_content='34.\\nPusztai, L.; Barlow, W.E.; Ganz, P.A.; Henry, N.L.; White, J.; Jagsi, R.; Mammen, J.M.V.; Lew, D.; Mejia, J.; Karantza, V.; et al.\\nSWOG S1418/NRG-BR006: A randomized, phase III trial to evaluate the efﬁcacy and safety of MK-3475 as adjuvant therapy for\\ntriple receptor-negative breast cancer with ≥1 cm residual invasive cancer or positive lymph nodes (> pN1mic) after neoadjuvant'),\n",
       " Document(metadata={}, page_content='chemotherapy. Cancer Res. 2018, 78 (Suppl. 4), OT1-02-04. [CrossRef]\\n35.\\nConte, P.F.; Dieci, M.V.; Bisagni, G.; De Laurentiis, M.; Tondini, C.A.; Schmid, P.; De Salvo, G.L.; Moratello, G.; Guarneri, V. Phase\\nIII randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer\\npatients: The A-BRAVE trial. J. Clin. Oncol. 2020, 38, TPS598. [CrossRef]\\n36.'),\n",
       " Document(metadata={}, page_content='36.\\nGalluzzi, L.; Buque, A.; Kepp, O.; Zitvogel, L.; Kroemer, G. Immunological Effects of Conventional Chemotherapy and Targeted\\nAnticancer Agents. Cancer Cell 2015, 28, 690–714. [CrossRef]\\n37.\\nZitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat. Rev.\\nImmunol. 2006, 6, 715–727. [CrossRef]\\n38.'),\n",
       " Document(metadata={}, page_content='Immunol. 2006, 6, 715–727. [CrossRef]\\n38.\\nWu, J.; Waxman, D.J. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.\\nCancer Lett. 2018, 419, 210–221. [CrossRef]\\n39.\\nAhlmann, M.; Hempel, G. The effect of cyclophosphamide on the immune system: Implications for clinical cancer therapy. Cancer\\nChemoth. Pharm. 2016, 78, 661–671. [CrossRef]\\n40.'),\n",
       " Document(metadata={}, page_content='Chemoth. Pharm. 2016, 78, 661–671. [CrossRef]\\n40.\\nCortes, J.; Cescon, D.W.; Rugo, H.S.; Nowecki, Z.; Im, S.A.; Yusof, M.M.; Gallardo, C.; Lipatov, O.; Barrios, C.H.; Holgado, E.; et al.\\nPembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or\\nmetastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial.'),\n",
       " Document(metadata={}, page_content='Lancet 2020, 396, 1817–1828. [CrossRef]\\n41.\\nCortes, J.; Rugo, H.S.; Cescon, D.W.; Im, S.A.; Yusof, M.M.; Gallardo, C.; Lipatov, O.; Barrios, C.H.; Perez-Garcia, J.; Iwata, H.; et al.\\nPembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N. Engl. J. Med. 2022, 387, 217–226. [CrossRef]\\n[PubMed]\\nCancers 2023, 15, 321\\n23 of 28\\n42.'),\n",
       " Document(metadata={}, page_content='[PubMed]\\nCancers 2023, 15, 321\\n23 of 28\\n42.\\nTolaney, S.M.; Kalinsky, K.; Kaklamani, V.G.; D’Adamo, D.R.; Aktan, G.; Tsai, M.L.; O’Regan, R.M.; Kaufman, P.A.; Wilks, S.T.;\\nAndreopoulou, E.; et al. Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1):\\nA Phase Ib/II Study. Clin. Cancer Res. 2021, 27, 3061–3068. [CrossRef]\\n43.'),\n",
       " Document(metadata={}, page_content='43.\\nAdams, S.; Diamond, J.R.; Hamilton, E.; Pohlmann, P.R.; Tolaney, S.M.; Chang, C.W.; Zhang, W.; Iizuka, K.; Foster, P.G.; Molinero,\\nL.; et al. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival\\nFollow-up: A Phase 1b Clinical Trial. Jama. Oncol. 2019, 5, 334–342. [CrossRef] [PubMed]\\n44.'),\n",
       " Document(metadata={}, page_content='44.\\nSchmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Dieras, V.; Hegg, R.; Im, S.A.; Shaw Wright, G.; et al.\\nAtezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N. Engl. J. Med. 2018, 379, 2108–2121. [CrossRef]\\n[PubMed]\\n45.\\nSchmid, P.; Rugo, H.S.; Adams, S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Dieras, V.; Henschel, V.; Molinero, L.; Chui, S.Y.; et al.'),\n",
       " Document(metadata={}, page_content='Atezolizumab plus nab-paclitaxel as ﬁrst-line treatment for unresectable, locally advanced or metastatic triple-negative breast\\ncancer (IMpassion130): Updated efﬁcacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.\\n2020, 21, 44–59. [CrossRef]\\n46.\\nEmens, L.A.; Adams, S.; Barrios, C.H.; Dieras, V.; Iwata, H.; Loi, S.; Rugo, H.S.; Schneeweiss, A.; Winer, E.P.; Patel, S.; et al. First-'),\n",
       " Document(metadata={}, page_content='line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130\\nﬁnal overall survival analysis. Ann. Oncol. 2021, 32, 983–993. [CrossRef]\\n47.\\nMiles, D.; Gligorov, J.; Andre, F.; Cameron, D.; Schneeweiss, A.; Barrios, C.; Xu, B.; Wardley, A.; Kaen, D.; Andrade, L.; et al.'),\n",
       " Document(metadata={}, page_content='Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of ﬁrst-line paclitaxel with or\\nwithout atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann. Oncol. 2021, 32, 994–1004.\\n[CrossRef]\\n48.\\nFranzoi, M.A.; de Azambuja, E. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials-how to'),\n",
       " Document(metadata={}, page_content='explain different results? ESMO Open 2020, 5, e001112. [CrossRef]\\n49.\\nZhang, Y.Y.; Chen, H.Y.; Mo, H.N.; Hu, X.D.; Gao, R.R.; Zhao, Y.H.; Liu, B.L.; Niu, L.J.; Sun, X.Y.; Yu, X.; et al. Single-cell analyses\\nreveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 2021, 39,\\n1578–1593.e8. [CrossRef]\\n50.'),\n",
       " Document(metadata={}, page_content='1578–1593.e8. [CrossRef]\\n50.\\nVoorwerk, L.; Slagter, M.; Horlings, H.M.; Sikorska, K.; van de Vijver, K.K.; de Maaker, M.; Nederlof, I.; Kluin, R.J.C.; Warren, S.;\\nOng, S.; et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade:\\nThe TONIC trial. Nat. Med. 2019, 25, 920–928. [CrossRef]\\n51.'),\n",
       " Document(metadata={}, page_content='51.\\nHutchinson, K.E.; Yost, S.E.; Chang, C.W.; Johnson, R.M.; Carr, A.R.; McAdam, P.R.; Halligan, D.L.; Chang, C.C.; Schmolze, D.;\\nLiang, J.; et al. Comprehensive Proﬁling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals\\nImmune Phenotype Shifts. Clin. Cancer Res. 2020, 26, 657–668. [CrossRef]\\n52.'),\n",
       " Document(metadata={}, page_content='52.\\nSzekely, B.; Bossuyt, V.; Li, X.; Wali, V.B.; Patwardhan, G.A.; Frederick, C.; Silber, A.; Park, T.; Harigopal, M.; Pelekanou, V.; et al.\\nImmunological differences between primary and metastatic breast cancer. Ann. Oncol. 2018, 29, 2232–2239. [CrossRef] [PubMed]\\n53.\\nNanda, R.; Liu, M.C.; Yau, C.; Shatsky, R.; Pusztai, L.; Wallace, A.; Chien, A.J.; Forero-Torres, A.; Ellis, E.; Han, H.; et al. Effect of'),\n",
       " Document(metadata={}, page_content='Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer:\\nAn Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020, 6, 676–684. [CrossRef] [PubMed]\\n54.\\nSchmid, P.; Salgado, R.; Park, Y.H.; Munoz-Couselo, E.; Kim, S.B.; Sohn, J.; Im, S.A.; Foukakis, T.; Kuemmel, S.; Dent, R.; et al.'),\n",
       " Document(metadata={}, page_content='Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from\\nthe phase 1b open-label, multicohort KEYNOTE-173 study. Ann. Oncol. 2020, 31, 569–581. [CrossRef] [PubMed]\\n55.\\nSchmid, P.; Cortes, J.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y.H.; Hui, R.; Harbeck, N.; et al.'),\n",
       " Document(metadata={}, page_content='Pembrolizumab for Early Triple-Negative Breast Cancer. N. Engl. J. Med. 2020, 382, 810–821. [CrossRef]\\n56.\\nSchmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y.H.; Hui, R.; et al. Event-free\\nSurvival with Pembrolizumab in Early Triple-Negative Breast Cancer. N. Engl. J. Med. 2022, 386, 556–567. [CrossRef]\\n57.'),\n",
       " Document(metadata={}, page_content='57.\\nLoibl, S.; Untch, M.; Burchardi, N.; Huober, J.; Sinn, B.V.; Blohmer, J.U.; Grischke, E.M.; Furlanetto, J.; Tesch, H.; Hanusch, C.; et al.\\nA randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in\\nearly triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol. 2019, 30, 1279–1288.\\n[CrossRef]\\n58.'),\n",
       " Document(metadata={}, page_content='[CrossRef]\\n58.\\nLoibl, S.; Schneeweiss, A.; Huober, J.; Braun, M.; Rey, J.; Blohmer, J.U.; Furlanetto, J.; Zahm, D.M.; Hanusch, C.; Thomalla, J.;\\net al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete\\nresponse. Ann. Oncol. 2022, 33, 1149–1158. [CrossRef]\\n59.'),\n",
       " Document(metadata={}, page_content='59.\\nGianni, L.; Huang, C.S.; Egle, D.; Bermejo, B.; Zamagni, C.; Thill, M.; Anton, A.; Zambelli, S.; Bianchini, G.; Russo, S.; et al.\\nPathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk\\nand locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann. Oncol. 2022, 33, 534–543. [CrossRef]\\n60.'),\n",
       " Document(metadata={}, page_content='60.\\nMittendorf, E.A.; Zhang, H.; Barrios, C.H.; Saji, S.; Jung, K.H.; Hegg, R.; Koehler, A.; Sohn, J.; Iwata, H.; Telli, M.L.; et al.\\nNeoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo\\nand chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase\\n3 trial. Lancet 2020, 396, 1090–1100. [CrossRef]\\n61.'),\n",
       " Document(metadata={}, page_content='61.\\nMcLaughlin, M.; Patin, E.C.; Pedersen, M.; Wilkins, A.; Dillon, M.T.; Melcher, A.A.; Harrington, K.J. Inﬂammatory microenviron-\\nment remodelling by tumour cells after radiotherapy. Nat. Rev. Cancer 2020, 20, 203–217. [CrossRef]\\nCancers 2023, 15, 321\\n24 of 28\\n62.\\nHo, A.Y.; Barker, C.A.; Arnold, B.B.; Powell, S.N.; Hu, Z.I.; Gucalp, A.; Lebron-Zapata, L.; Wen, H.Y.; Kallman, C.; D’Agnolo,'),\n",
       " Document(metadata={}, page_content='A.; et al. A phase 2 clinical trialassessing theefﬁcacy and safety of pembrolizumab and radiotherapy in patients with metastatic\\ntriple-negative breast cancer. Cancer 2020, 126, 850–860. [CrossRef] [PubMed]\\n63.\\nDavid, S.; Savas, P.; Siva, S.; White, M.; Neeson, M.W.; White, S.; Marx, G.; Cheuk, R.; Grogan, M.; Farrell, M.; et al. A randomised'),\n",
       " Document(metadata={}, page_content='phase II trial of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with atezolizumab in patients\\nwith advanced triple negative breast cancer (AZTEC trial). Cancer Res. 2022, 82, PD10–02. [CrossRef]\\n64.\\nPantelidou, C.; Sonzogni, O.; De Oliveria Taveira, M.; Mehta, A.K.; Kothari, A.; Wang, D.; Visal, T.; Li, M.K.; Pinto, J.; Castrillon,'),\n",
       " Document(metadata={}, page_content='J.A.; et al. PARP Inhibitor Efﬁcacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in\\nBRCA-Deﬁcient Models of Triple-Negative Breast Cancer. Cancer Discov. 2019, 9, 722–737. [CrossRef] [PubMed]\\n65.\\nSen, T.; Rodriguez, B.L.; Chen, L.; Corte, C.M.D.; Morikawa, N.; Fujimoto, J.; Cristea, S.; Nguyen, T.; Diao, L.; Li, L.; et al. Targeting'),\n",
       " Document(metadata={}, page_content='DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.\\nCancer Discov. 2019, 9, 646–661. [CrossRef] [PubMed]\\n66.\\nReislander, T.; Lombardi, E.P.; Groelly, F.J.; Miar, A.; Porru, M.; Di Vito, S.; Wright, B.; Lockstone, H.; Biroccio, A.; Harris, A.; et al.\\nBRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat. Commun. 2019, 10,'),\n",
       " Document(metadata={}, page_content='3143. [CrossRef]\\n67.\\nVinayak, S.; Tolaney, S.M.; Schwartzberg, L.; Mita, M.; McCann, G.; Tan, A.R.; Wahner-Hendrickson, A.E.; Forero, A.; Anders, C.;\\nWulf, G.M.; et al. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic\\nTriple-Negative Breast Cancer. JAMA Oncol. 2019, 5, 1132–1140. [CrossRef]\\n68.'),\n",
       " Document(metadata={}, page_content='68.\\nSenkus-Konefka, E.; Domchek, S.M.; Im, S.A.; Xu, B.; Armstrong, A.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Conte, P.; et al.\\nSubgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients\\nwith HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Eur. J. Cancer 2018, 92, S19–S20.\\n[CrossRef]\\n69.'),\n",
       " Document(metadata={}, page_content='[CrossRef]\\n69.\\nEiermann, W.; Rugo, H.S.; Diab, S.; Ettl, J.; Hurvitz, S.A.; Goncalves, A. Analysis of germline BRCA1/2 mutated (gBRCA(mut))\\nhormone receptor-positive (HR plus ) and triple negative breast cancer (TNBC) treated with talazoparib (TALA). J. Clin. Oncol.\\n2018, 36, 1070. [CrossRef]\\n70.\\nPusztai, L.; Yau, C.; Wolf, D.M.; Han, H.S.; Du, L.; Wallace, A.M.; String-Reasor, E.; Boughey, J.C.; Chien, A.J.; Elias, A.D.; et al.'),\n",
       " Document(metadata={}, page_content='Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively\\nrandomized I-SPY2 trial. Cancer Cell. 2021, 39, 989–998 e985. [CrossRef]\\n71.\\nYu, J.F.; Song, Y.P.; Tian, W.Z. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J. Hematol. Oncol.\\n2020, 13, 45. [CrossRef]\\n72.'),\n",
       " Document(metadata={}, page_content='2020, 13, 45. [CrossRef]\\n72.\\nLi, F.; Ulrich, M.; Jonas, M.; Stone, I.J.; Linares, G.; Zhang, X.Q.; Westendorf, L.; Benjamin, D.R.; Law, C.L. Tumor-Associated\\nMacrophages Can Contribute to Antitumor Activity through Fc gamma R-Mediated Processing of Antibody-Drug Conjugates.\\nMol. Cancer Ther. 2017, 16, 1347–1354. [CrossRef]\\n73.'),\n",
       " Document(metadata={}, page_content='73.\\nCao, A.T.; Higgins, S.; Stevens, N.; Gardai, S.J.; Sussman, D. Additional mechanisms of action of ladiratuzumab vedotin contribute\\nto increased immune cell activation within the tumor. Cancer Res. 2018, 78, 2742. [CrossRef]\\n74.\\nBauzon, M.; Drake, P.M.; Barﬁeld, R.M.; Cornali, B.M.; Rupniewski, I.; Rabuka, D. Maytansine-bearing antibody-drug conjugates'),\n",
       " Document(metadata={}, page_content='induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. Oncoimmunology 2019, 8, e1565859.\\n[CrossRef]\\n75.\\nMuller, P.; Martin, K.; Theurich, S.; Schreiner, J.; Savic, S.; Terszowski, G.; Lardinois, D.; Heinzelmann-Schwarz, V.A.; Schlaak, M.;\\nKvasnicka, H.M.; et al. Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by'),\n",
       " Document(metadata={}, page_content='Stimulation of Dendritic Cells. Cancer Immunol. Res. 2014, 2, 741–755. [CrossRef] [PubMed]\\n76.\\nMcKenzie, J.A.; Mbofung, R.M.; Malu, S.; Zhang, M.; Ashkin, E.; Devi, S.; Williams, L.; Tieu, T.; Peng, W.Y.; Pradeep, S.; et al.\\nThe Effect of Topoisomerase I Inhibitors on the Efﬁcacy of T-Cell-Based Cancer Immunotherapy. Jnci.-J. Natl. Cancer I 2018, 110,\\n777–786. [CrossRef] [PubMed]\\n77.'),\n",
       " Document(metadata={}, page_content='777–786. [CrossRef] [PubMed]\\n77.\\nHan, H.; Diab, S.; Alemany, C.; Basho, R.; Brown-Glaberman, U.; Meisel, J.; Pluard, T.; Cortes, J.; Dillon, P.; Ettl, J.; et al. Open\\nlabel phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for ﬁrst-line treatment of patients with\\nunresectable locally-advanced or metastatic triple-negative breast cancer. Cancer Res. 2020, 80, PD1-06. [CrossRef]\\n78.'),\n",
       " Document(metadata={}, page_content='78.\\nBergholz, J.S.; Zhao, J.J. How Compensatory Mechanisms and Adaptive Rewiring Have Shaped Our Understanding of Therapeutic\\nResistance in Cancer. Cancer Res. 2021, 81, 6074–6077. [CrossRef] [PubMed]\\n79.\\nZhang, Z.; Richmond, A.; Yan, C. Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition\\nAugment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2022, 23,\\n7353. [CrossRef]'),\n",
       " Document(metadata={}, page_content='7353. [CrossRef]\\n80.\\nZhang, Z.; Richmond, A. The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune\\nCheckpoint Inhibitors. Front Mol. Biosci. 2021, 8, 648663. [CrossRef]\\n81.\\nHo, P.C.; Meeth, K.M.; Tsui, Y.C.; Srivastava, B.; Bosenberg, M.W.; Kaech, S.M. Immune-based antitumor effects of BRAF inhibitors\\nrely on signaling by CD40L and IFNgamma. Cancer Res. 2014, 74, 3205–3217. [CrossRef] [PubMed]\\n82.'),\n",
       " Document(metadata={}, page_content='82.\\nSchmid, P.; Savas, P.; Espinosa, E.; Boni, V.; Italiano, A.; White, S.; Cheng, K.; Lam, L.; Robert, L.; Laliman, V.; et al. Phase\\n1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as ﬁrst-line therapy for locally\\nadvanced/metastatic triple-negative breast cancer (TNBC). Cancer Res. 2021, 81, PS12-28. [CrossRef]\\nCancers 2023, 15, 321\\n25 of 28\\n83.'),\n",
       " Document(metadata={}, page_content='Cancers 2023, 15, 321\\n25 of 28\\n83.\\nBrufsky, A.; Kim, S.B.; Zvirbule, Z.; Eniu, A.; Mebis, J.; Sohn, J.H.; Wongchenko, M.; Chohan, S.; Amin, R.; Yan, Y.; et al. A phase II\\nrandomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as ﬁrst-line treatment for patients with locally\\nadvanced or metastatic triple-negative breast cancer (COLET): Primary analysis. Ann. Oncol. 2021, 32, 652–660. [CrossRef]\\n84.'),\n",
       " Document(metadata={}, page_content='84.\\nLanitis, E.; Irving, M.; Coukos, G. Targeting the tumor vasculature to enhance T cell activity. Curr. Opin. Immunol. 2015, 33, 55–63.\\n[CrossRef]\\n85.\\nCorzo, C.A.; Condamine, T.; Lu, L.; Cotter, M.J.; Youn, J.I.; Cheng, P.; Cho, H.I.; Celis, E.; Quiceno, D.G.; Padhya, T.; et al. HIF-1α\\nregulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010, 207,\\n2439–2453. [CrossRef] [PubMed]'),\n",
       " Document(metadata={}, page_content='2439–2453. [CrossRef] [PubMed]\\n86.\\nLi, Q.; Wang, Y.; Jia, W.; Deng, H.; Li, G.; Deng, W.; Chen, J.; Kim, B.Y.S.; Jiang, W.; Liu, Q.; et al. Low-Dose Anti-Angiogenic\\nTherapy Sensitizes Breast Cancer to PD-1 Blockade. Clin. Cancer Res. 2020, 26, 1712–1724. [CrossRef] [PubMed]\\n87.\\nLiu, J.Q.; Liu, Q.; Li, Y.; Li, Q.; Su, F.X.; Yao, H.R.; Su, S.C.; Wang, Q.R.; Jin, L.; Wang, Y.; et al. Efﬁcacy and safety of camrelizumab'),\n",
       " Document(metadata={}, page_content='combined with apatinib in advanced triple-negative breast cancer: An open-label phase II trial. J. Immunother. Cancer 2020, 8,\\ne000696. [CrossRef] [PubMed]\\n88.\\nLiu, Z.; Li, M.; Jiang, Z.; Wang, X. A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer. Transl. Oncol. 2018,\\n11, 311–329. [CrossRef] [PubMed]\\n89.'),\n",
       " Document(metadata={}, page_content='11, 311–329. [CrossRef] [PubMed]\\n89.\\nSaleh, R.; Toor, S.M.; Khalaf, S.; Elkord, E. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1,\\nCTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells. Vaccines 2019, 7, 149. [CrossRef] [PubMed]\\n90.\\nRowshanravan, B.; Halliday, N.; Sansom, D.M. CTLA-4: A moving target in immunotherapy. Blood 2018, 131, 58–67. [CrossRef]\\n91.'),\n",
       " Document(metadata={}, page_content='91.\\nTang, F.; Du, X.; Liu, M.; Zheng, P.; Liu, Y. Anti-CTLA-4 antibodies in cancer immunotherapy: Selective depletion of intratumoral\\nregulatory T cells or checkpoint blockade? Cell Biosci. 2018, 8, 30. [CrossRef]\\n92.\\nSanta-Maria, C.A.; Kato, T.; Park, J.H.; Flaum, L.E.; Jain, S.; Tellez, C.; Stein, R.M.; Shah, A.N.; Gross, L.; Uthe, R.; et al. Durvalumab'),\n",
       " Document(metadata={}, page_content='and tremelimumab in metastatic breast cancer (MBC): Immunotherapy and immunopharmacogenomic dynamics. J. Clin. Oncol.\\n2017, 35, 3052. [CrossRef]\\n93.\\nXu, B.H.; Li, Q.; Zhang, Q.Y.; Zhang, Y.; Ouyang, Q.C.; Zhang, Y.; Liu, Q.; Sun, T.; Xu, J.; Yang, J.; et al. Preliminary safety\\ntolerability & efﬁcacy results of KN046 (an anti-PD-L1/CTLA-4 bispeciﬁc antibody) in combination with Nab-paclitaxel in'),\n",
       " Document(metadata={}, page_content='patients with metastatic triple-negative breast cancer (mTNBC). Cancer Res. 2021, 81, 1660.\\n94.\\nGhalamfarsa, G.; Kazemi, M.H.; Mohseni, S.R.; Masjedi, A.; Hojjat-Farsangi, M.; Azizi, G.; Youseﬁ, M.; Jadidi-Niaragh, F. CD73 as\\na potential opportunity for cancer immunotherapy. Expert. Opin. Ther. Tar. 2019, 23, 127–142. [CrossRef] [PubMed]\\n95.'),\n",
       " Document(metadata={}, page_content='95.\\nLoi, S.; Pommey, S.; Haibe-Kains, B.; Beavis, P.A.; Darcy, P.K.; Smyth, M.J.; Stagg, J. CD73 promotes anthracycline resistance and\\npoor prognosis in triple negative breast cancer. Proc. Natl. Acad. Sci. USA 2013, 110, 11091–11096. [CrossRef]\\n96.\\nBuisseret, L.; Loirat, D.; Aftimos, P.G.; Punie, K.; Maurer, C.; Debien, V.; Goncalves, A.; Ghiringhelli, F.; Taylor, D.; Clatot, F.;'),\n",
       " Document(metadata={}, page_content='et al. Primary endpoint results of SYNERGY, a randomized phase II trial, ﬁrst-line chemo-immunotherapy trial of durvalumab,\\npaclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-\\nnegative breast cancer (TNBC). Ann. Oncol. 2022, 33 (Suppl.7), S808–S869. [CrossRef]\\n97.'),\n",
       " Document(metadata={}, page_content='97.\\nShemesh, C.S.; Hsu, J.C.; Hosseini, I.; Shen, B.Q.; Rotte, A.; Twomey, P.; Girish, S.; Wu, B. Personalized Cancer Vaccines: Clinical\\nLandscape, Challenges, and Opportunities. Mol. Ther. 2021, 29, 555–570. [CrossRef]\\n98.\\nSchumacher, T.N.; Scheper, W.; Kvistborg, P. Cancer Neoantigens. Annu. Rev. Immunol. 2019, 37, 173–200. [CrossRef]\\n99.'),\n",
       " Document(metadata={}, page_content='99.\\nFritah, H.; Rovelli, R.; Chiang, C.L.; Kandalaft, L.E. The current clinical landscape of personalized cancer vaccines. Cancer Treat.\\nRev. 2022, 106, 102383. [CrossRef] [PubMed]\\n100. Verma, V.; Shrimali, R.K.; Ahmad, S.; Dai, W.; Wang, H.; Lu, S.; Nandre, R.; Gaur, P.; Lopez, J.; Sade-Feldman, M.; et al. PD-1\\nblockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat. Immunol. 2019, 20,'),\n",
       " Document(metadata={}, page_content='1231–1243. [CrossRef]\\n101. Hemminki, O.; dos Santos, J.M.; Hemminki, A. Oncolytic viruses for cancer immunotherapy. J. Hematol. Oncol. 2020, 13, 84.\\n[CrossRef] [PubMed]\\n102. Ylosmaki, E.; Cerullo, V. Design and application of oncolytic viruses for cancer immunotherapy. Curr. Opin. Biotech. 2020, 65,\\n25–36. [CrossRef]'),\n",
       " Document(metadata={}, page_content='25–36. [CrossRef]\\n103. Jin, S.; Wang, Q.; Wu, H.; Pang, D.; Xu, S. Oncolytic viruses for triple negative breast cancer and beyond. Biomark Res. 2021, 9, 71.\\n[CrossRef] [PubMed]\\n104. Hecht, J.R.; Chan, A.; Baurain, J.F.; Martin, M.; Longo-Munoz, F.; Kalinsky, K.; Raman, S.; Liu, C.X.; Cha, E.; Chan, E. Preliminary\\nsafety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer.'),\n",
       " Document(metadata={}, page_content='Cancer Res. 2020, 80, P3-09. [CrossRef]\\n105. Kistler, M.; Nangia, C.; To, C.; Sender, L.; Lee, J.; Jones, F.; Jafari, O.; Seery, T.; Rabizadeh, S.; Niazi, K.; et al. Safety and efﬁcacy\\nfrom ﬁrst-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-afﬁnity CD16 NK cell line (haNK)\\nin patients with 2nd-line or greater metastatic triple-negative breast cancer (TNBC). Cancer Res. 2020, 80, P5-04-02. [CrossRef]'),\n",
       " Document(metadata={}, page_content='106. Han, D.; Liu, J.; Chen, C.; Dong, L.; Liu, Y.; Chang, R.; Huang, X.; Liu, Y.; Wang, J.; Dougherty, U.; et al. Anti-tumour immunity\\ncontrolled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature 2019, 566, 270–274. [CrossRef]\\n107. Sun, X.; Wu, B.; Chiang, H.C.; Deng, H.; Zhang, X.; Xiong, W.; Liu, J.; Rozeboom, A.M.; Harris, B.T.; Blommaert, E.; et al. Tumour'),\n",
       " Document(metadata={}, page_content='DDR1 promotes collagen ﬁbre alignment to instigate immune exclusion. Nature 2021, 599, 673–678. [CrossRef]\\nCancers 2023, 15, 321\\n26 of 28\\n108. Mohammadpour, H.; MacDonald, C.R.; Qiao, G.; Chen, M.; Dong, B.; Hylander, B.L.; McCarthy, P.L.; Abrams, S.I.; Repasky, E.A.\\nβ2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. J.\\nClin. Investig. 2019, 129, 5537–5552. [CrossRef]'),\n",
       " Document(metadata={}, page_content='Clin. Investig. 2019, 129, 5537–5552. [CrossRef]\\n109. Bucsek, M.J.; Qiao, G.; MacDonald, C.R.; Giridharan, T.; Evans, L.; Niedzwecki, B.; Liu, H.; Kokolus, K.M.; Eng, J.W.; Messmer,\\nM.N.; et al. β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8(+) T\\nCells and Undermines Checkpoint Inhibitor Therapy. Cancer Res. 2017, 77, 5639–5651. [CrossRef] [PubMed]'),\n",
       " Document(metadata={}, page_content='110. Wang, H.; Rong, X.; Zhao, G.; Zhou, Y.; Xiao, Y.; Ma, D.; Jin, X.; Wu, Y.; Yan, Y.; Yang, H.; et al. The microbial metabolite\\ntrimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metab. 2022, 34, 581–594 e588.\\n[CrossRef]\\n111. Emens, L.A.; Molinero, L.; Loi, S.; Rugo, H.S.; Schneeweiss, A.; Dieras, V.; Iwata, H.; Barrios, C.H.; Nechaeva, M.; Nguyen-Duc, A.;'),\n",
       " Document(metadata={}, page_content='et al. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130\\nStudy. J. Natl. Cancer Inst. 2021, 113, 1005–1016. [CrossRef]\\n112. Badve, S.S.; Penault-Llorca, F.; Reis-Filho, J.S.; Deurloo, R.; Siziopikou, K.P.; D’Arrigo, C.; Viale, G. Determining PD-L1 Status\\nin Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. J. Natl. Cancer Inst. 2022, 114, 664–675.'),\n",
       " Document(metadata={}, page_content='[CrossRef]\\n113. Chebib, I.; Mino-Kenudson, M. PD-L1 immunohistochemistry: Clones, cutoffs, and controversies. APMIS 2022, 130, 295–313.\\n[CrossRef]\\n114. Rugo, H.S.; Loi, S.; Adams, S.; Schmid, P.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Dieras, V.; Winer, E.P.; Kockx, M.M.; et al.\\nPD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast'),\n",
       " Document(metadata={}, page_content='Cancer. J. Natl. Cancer Inst. 2021, 113, 1733–1743. [CrossRef] [PubMed]\\n115. Ghebeh, H.; Mansour, F.A.; Colak, D.; Alfuraydi, A.A.; Al-Thubiti, A.A.; Monies, D.; Al-Alwan, M.; Al-Tweigeri, T.; Tulbah, A.\\nHigher PD-L1 Immunohistochemical Detection Signal in Frozen Compared to Matched Parafﬁn-Embedded Formalin-Fixed\\nTissues. Antibodies 2021, 10, 24. [CrossRef] [PubMed]'),\n",
       " Document(metadata={}, page_content='116. Reisenbichler, E.S.; Han, G.; Bellizzi, A.; Bossuyt, V.; Brock, J.; Cole, K.; Fadare, O.; Hameed, O.; Hanley, K.; Harrison, B.T.; et al.\\nProspective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast\\ncancer. Mod. Pathol. 2020, 33, 1746–1752. [CrossRef] [PubMed]'),\n",
       " Document(metadata={}, page_content='117. Paijens, S.T.; Vledder, A.; de Bruyn, M.; Nijman, H.W. Tumor-inﬁltrating lymphocytes in the immunotherapy era. Cell Mol.\\nImmunol. 2021, 18, 842–859. [CrossRef]\\n118. Loi, S.; Adams, S.; Schmid, P.; Cortes, J.; Cescon, D.W.; Winer, E.P.; Toppmeyer, D.L.; Rugo, H.S.; De Laurentiis, M.; Nanda, R.;\\net al. Relationship between tumor inﬁltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic'),\n",
       " Document(metadata={}, page_content='triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. Ann. Oncol. 2017, 28, v608. [CrossRef]\\n119. Loi, S.; Winer, E.; Lipatov, O.; Im, S.A.; Goncalves, A.; Cortes, J.; Lee, K.S.; Schmid, P.; Testa, L.; Witzel, I.; et al. Relationship\\nbetween tumor-inﬁltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy'),\n",
       " Document(metadata={}, page_content='for previously treated metastatic triple-negative breast cancer (mTNBC). Cancer Res. 2020, 80, PD5-03. [CrossRef]\\n120. Loi, S.; Michiels, S.; Adams, S.; Loibl, S.; Budczies, J.; Denkert, C.; Salgado, R. The journey of tumor-inﬁltrating lymphocytes as a\\nbiomarker in breast cancer: Clinical utility in an era of checkpoint inhibition. Ann. Oncol. 2021, 32, 1236–1244. [CrossRef]'),\n",
       " Document(metadata={}, page_content='121. Schumacher, T.N.; Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 2015, 348, 69–74. [CrossRef]\\n122. Ott, P.A.; Bang, Y.J.; Piha-Paul, S.A.; Razak, A.R.A.; Bennouna, J.; Soria, J.C.; Rugo, H.S.; Cohen, R.B.; O’Neil, B.H.; Mehnert, J.M.;\\net al. T-Cell-Inﬂamed Gene-Expression Proﬁle, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict'),\n",
       " Document(metadata={}, page_content='Efﬁcacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J. Clin. Oncol. 2019, 37, 318–327. [CrossRef]\\n[PubMed]\\n123. Samstein, R.M.; Lee, C.H.; Shoushtari, A.N.; Hellmann, M.D.; Shen, R.; Janjigian, Y.Y.; Barron, D.A.; Zehir, A.; Jordan, E.J.; Omuro,\\nA.; et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 2019, 51,\\n202–206. [CrossRef] [PubMed]'),\n",
       " Document(metadata={}, page_content='202–206. [CrossRef] [PubMed]\\n124. Barroso-Sousa, R.; Jain, E.; Cohen, O.; Kim, D.; Buendia-Buendia, J.; Winer, E.; Lin, N.; Tolaney, S.M.; Wagle, N. Prevalence and\\nmutational determinants of high tumor mutation burden in breast cancer. Ann. Oncol. 2020, 31, 387–394. [CrossRef]\\n125. Karn, T.; Denkert, C.; Weber, K.E.; Holtrich, U.; Hanusch, C.; Sinn, B.V.; Higgs, B.W.; Jank, P.; Sinn, H.P.; Huober, J.; et al. Tumor'),\n",
       " Document(metadata={}, page_content='mutational burden and immune inﬁltration as independent predictors of response to neoadjuvant immune checkpoint inhibition\\nin early TNBC in GeparNuevo. Ann. Oncol. 2020, 31, 1216–1222. [CrossRef] [PubMed]\\n126. Winer, E.P.; Lipatov, O.; Im, S.A.; Goncalves, A.; Munoz-Couselo, E.; Lee, K.S.; Schmid, P.; Testa, L.; Witzel, I.; Ohtani, S.; et al.'),\n",
       " Document(metadata={}, page_content='Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy\\n(chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. J. Clin. Oncol. 2020, 38, 1013.\\n[CrossRef]\\n127. Jardim, D.L.; Goodman, A.; de Melo Gagliato, D.; Kurzrock, R. The Challenges of Tumor Mutational Burden as an Immunotherapy\\nBiomarker. Cancer Cell 2021, 39, 154–173. [CrossRef]'),\n",
       " Document(metadata={}, page_content='128. Chalmers, Z.R.; Connelly, C.F.; Fabrizio, D.; Gay, L.; Ali, S.M.; Ennis, R.; Schrock, A.; Campbell, B.; Shlien, A.; Chmielecki, J.;\\net al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017, 9, 34.\\n[CrossRef]\\nCancers 2023, 15, 321\\n27 of 28\\n129. Zhao, P.; Li, L.; Jiang, X.; Li, Q. Mismatch repair deﬁciency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1'),\n",
       " Document(metadata={}, page_content='immunotherapy efﬁcacy. J. Hematol. Oncol. 2019, 12, 54. [CrossRef]\\n130. Prasad, V.; Kaestner, V.; Mailankody, S. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of\\nPembrolizumab for Mismatch Repair-Deﬁcient Solid Cancers. JAMA Oncol. 2018, 4, 157–158. [CrossRef]\\n131. Marcus, L.; Lemery, S.J.; Keegan, P.; Pazdur, R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite'),\n",
       " Document(metadata={}, page_content='Instability-High Solid Tumors. Clin. Cancer Res. 2019, 25, 3753–3758. [CrossRef]\\n132. Ren, X.Y.; Song, Y.; Wang, J.; Chen, L.Y.; Pang, J.Y.; Zhou, L.R.; Shen, S.J.; Cao, X.; Wang, Y.X.; Shao, M.M.; et al. Mismatch Repair\\nDeﬁciency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. Front Oncol.\\n2021, 11, 570623. [CrossRef]'),\n",
       " Document(metadata={}, page_content='2021, 11, 570623. [CrossRef]\\n133. Horimoto, Y.; Hlaing, M.T.; Saeki, H.; Kitano, S.; Nakai, K.; Sasaki, R.; Kurisaki-Arakawa, A.; Arakawa, A.; Otsuji, N.; Matsuoka,\\nS.; et al. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer. Cancer Sci.\\n2020, 111, 2647–2654. [CrossRef] [PubMed]'),\n",
       " Document(metadata={}, page_content='2020, 111, 2647–2654. [CrossRef] [PubMed]\\n134. Schadendorf, D.; Hodi, F.S.; Robert, C.; Weber, J.S.; Margolin, K.; Hamid, O.; Patt, D.; Chen, T.T.; Berman, D.M.; Wolchok, J.D.\\nPooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic\\nMelanoma. J. Clin. Oncol. 2015, 33, 1889–1894. [CrossRef] [PubMed]'),\n",
       " Document(metadata={}, page_content='135. Wolchok, J.D.; Hamid, O.; Ribas, A.; Robert, C.; Kefford, R.; Hwu, W.J.; Weber, J.S.; Joshua, A.M.; Gangadhar, T.C.; Dronca,\\nR.S.; et al. Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in\\nKEYNOTE-001. J. Clin. Oncol. 2015, 33, 3000. [CrossRef]\\n136. Champiat, S.; Dercle, L.; Ammari, S.; Massard, C.; Hollebecque, A.; Postel-Vinay, S.; Chaput, N.; Eggermont, A.; Marabelle, A.;'),\n",
       " Document(metadata={}, page_content='Soria, J.C.; et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.\\nClinical. Cancer Res. 2017, 23, 1920–1928. [CrossRef]\\n137. Tazdait, M.; Mezquita, L.; Lahmar, J.; Ferrara, R.; Bidault, F.; Ammari, S.; Balleyguier, C.; Planchard, D.; Gazzah, A.; Soria, J.C.;\\net al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST'),\n",
       " Document(metadata={}, page_content='and iRECIST criteria. Eur. J. Cancer 2018, 88, 38–47. [CrossRef]\\n138. Chiou, V.L.; Burotto, M. Pseudoprogression and Immune-Related Response in Solid Tumors. J. Clin. Oncol. 2015, 33, 3541–3543.\\n[CrossRef]\\n139. Schmid, P.; Cruz, C.; Braiteh, F.S.; Eder, J.P.; Tolaney, S.; Kuter, I.; Nanda, R.; Chung, C.; Cassier, P.; Delord, J.P.; et al. Atezolizumab'),\n",
       " Document(metadata={}, page_content='in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Cancer Res. 2017, 77, 2986. [CrossRef]\\n140. Borcoman, E.; Kanjanapan, Y.; Champiat, S.; Kato, S.; Servois, V.; Kurzrock, R.; Goel, S.; Bedard, P.; Le Tourneau, C. Novel patterns\\nof response under immunotherapy. Ann. Oncol. 2019, 30, 385–396. [CrossRef]'),\n",
       " Document(metadata={}, page_content='141. Wolchok, J.D.; Hoos, A.; O’Day, S.; Weber, J.S.; Hamid, O.; Lebbe, C.; Maio, M.; Binder, M.; Bohnsack, O.; Nichol, G.; et al.\\nGuidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res.\\n2009, 15, 7412–7420. [CrossRef] [PubMed]\\n142. Seymour, L.; Bogaerts, J.; Perrone, A.; Ford, R.; Schwartz, L.H.; Mandrekar, S.; Lin, N.U.; Litiere, S.; Dancey, J.; Chen, A.;'),\n",
       " Document(metadata={}, page_content='et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017, 18, E143–E152.\\n[CrossRef] [PubMed]\\n143. Nishino, M.; Giobbie-Hurder, A.; Gargano, M.; Suda, M.; Ramaiya, N.H.; Hodi, F.S. Developing a Common Language for Tumor\\nResponse to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements. Clin. Cancer Res. 2013,\\n19, 3936–3943. [CrossRef]'),\n",
       " Document(metadata={}, page_content='19, 3936–3943. [CrossRef]\\n144. Majd, N.; de Groot, J. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblas-\\ntoma. Expert Opin Pharm. 2019, 20, 1609–1624. [CrossRef]\\n145. Yang, Y.; Wu, Q.; Chen, L.; Qian, K.; Xu, X. Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the'),\n",
       " Document(metadata={}, page_content='treatment of triple-negative breast cancer: A case report. Ann. Transl. Med. 2022, 10, 424. [CrossRef]\\n146. Wang, P.F.; Chen, Y.; Song, S.Y.; Wang, T.J.; Ji, W.J.; Li, S.W.; Liu, N.; Yan, C.X. Immune-Related Adverse Events Associated with\\nAnti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharm. 2017, 8, 730. [CrossRef]'),\n",
       " Document(metadata={}, page_content='147. Balibegloo, M.; Nejadghaderi, S.A.; Sadeghalvad, M.; Soleymanitabar, A.; Nezamabadi, S.S.; Saghazadeh, A.; Rezaei, N. Adverse\\nevents associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis. Int.\\nImmunopharmacol. 2021, 96, 107796. [CrossRef] [PubMed]'),\n",
       " Document(metadata={}, page_content='148. Xin, Y.; Shen, G.; Zheng, Y.; Guan, Y.; Huo, X.; Li, J.; Ren, D.; Zhao, F.; Liu, Z.; Li, Z.; et al. Immune checkpoint inhibitors plus\\nneoadjuvant chemotherapy in early triple-negative breast cancer: A systematic review and meta-analysis. BMC Cancer 2021, 21,\\n1261. [CrossRef] [PubMed]\\n149. Villacampa, G.; Tolosa, P.; Salvador, F.; Sanchez-Bayona, R.; Villanueva, L.; Dienstmann, R.; Ciruelos, E.; Pascual, T. Addition of'),\n",
       " Document(metadata={}, page_content='immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in ﬁrst-line metastatic triple-negative breast cancer:\\nA systematic review and meta-analysis. Cancer Treat. Rev. 2022, 104, 102352. [CrossRef] [PubMed]\\n150. Wolchok, J.D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Wagstaff, J.; Schadendorf, D.;'),\n",
       " Document(metadata={}, page_content='Ferrucci, P.F.; et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2017,\\n377, 1345–1356. [CrossRef]\\nCancers 2023, 15, 321\\n28 of 28\\n151. Ceschi, A.; Noseda, R.; Palin, K.; Verhamme, K. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of\\nWHO Global Pharmacovigilance Database. Front Pharmacol. 2020, 11, 557. [CrossRef] [PubMed]'),\n",
       " Document(metadata={}, page_content='152. Ciner, A.T.; Hochster, H.S.; August, D.A.; Carpizo, D.R.; Spencer, K.R. Delayed cytokine release syndrome after neoadjuvant\\nnivolumab: A case report and literature review. Immunotherapy 2021, 13, 1071–1078. [CrossRef] [PubMed]\\nDisclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual'),\n",
       " Document(metadata={}, page_content='author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to\\npeople or property resulting from any ideas, methods, instructions or products referred to in the content.\\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\nAbstract. Triple‑negative breast cancer (TNBC) accounts for \\n10‑15% of all breast cancer cases. TNBCs lack estrogen and'),\n",
       " Document(metadata={}, page_content='progesterone receptors and express low levels of HER2, and \\ntherefore do not respond to hormonal or anti‑HER2 therapies. \\nTNBC is a particularly aggressive form of breast cancer that \\ngenerally displays poorer prognosis compared to other breast \\ncancer subtypes. TNBC is chemotherapy sensitive, and this \\ntreatment remains the standard of care despite its limited benefit. \\nRecent advances with novel agents have been made for specific'),\n",
       " Document(metadata={}, page_content='subgroups with PD‑L1+ tumors or germline Brca‑mutated \\ntumors. However, only a fraction of these patients responds to \\nimmune checkpoint or PARP inhibitors and even those who \\ndo respond often develop resistance and relapse. Various new \\nagents and combination strategies have been explored to further \\nunderstand molecular and immunological aspects of TNBC. \\nIn this review, we discuss clinical trials in the management of'),\n",
       " Document(metadata={}, page_content='TNBC as well as perspectives for potential future treatments.\\nContents\\n1.\\t Introduction\\n2.\\t Current treatment paradigm\\n3.\\t Investigational drugs\\n4.\\t New potential therapeutic strategies\\n5.\\t Conclusion\\n1. Introduction\\nBreast cancer is characterized by heterogeneity at the \\nmolecular and clinical levels. Several biomarkers including \\nestrogen receptor α (ERα), progesterone receptor (PR), and \\nhuman epidermal growth factor receptor‑2 (ERBB2/HER2)'),\n",
       " Document(metadata={}, page_content='have been established, and the main breast cancer subtypes are \\nclassified according to their molecular profile\\xa0(1,2). Traditional \\nstaging of breast cancer is based on tumor size, lymph node \\ninvolvement, and presence of metastasis, and recently biologic \\nmarkers have been incorporated in the 8th edition of the \\nAmerican Joint Committee on Cancer (AJCC), improving the \\nprognostic discrimination over anatomic staging alone\\xa0(3).'),\n",
       " Document(metadata={}, page_content='Triple‑negative breast cancer (TNBC) is characterized as \\nhaving ≤1% cellular expression of ER and PR as determined \\nby immunohistochemistry (IHC), and having HER2 expres\\xad\\nsion of 0 to 1+ by IHC, or 2+ by IHC and fluorescence in\\xa0situ \\nhybridization (FISH) negative (i.e. not an amplified gene \\ncopy number), according to American Society of Clinical \\nOncology/College of American Pathologists (ASCO/CAP)'),\n",
       " Document(metadata={}, page_content='guidelines\\xa0(4,5). TNBCs are comprised of at least four distinct \\ntranscriptional subtypes: Two basal subtypes, BL1 and BL2; a \\nmesenchymal subtype M, which is devoid of immune cells; and \\na luminal androgen receptor (AR) subtype LAR\\xa0(1,2). TNBC is \\nalso subdivided into 6 different subgroups based on molecular \\nheterogeneity: Basal‑like; mesenchymal‑like; mesenchymal \\nstem‑like; luminal AR expression; immunomodulatory; and'),\n",
       " Document(metadata={}, page_content='unstable type\\xa0(6). TNBC represents approximately 15‑20% of \\nall newly diagnosed breast cancers and is generally a more \\naggressive disease with a poorer prognosis and higher grade \\nthan other types of breast cancer, accounting for 5% of all \\ncancer‑related deaths annually. The median overall survival \\n(OS) for the disease is 10.2\\xa0months with current therapies, with \\na 5‑year survival rate of ~65% for regional tumors and 11% for'),\n",
       " Document(metadata={}, page_content='those that have spread to distant organs\\xa0(7,8).\\nIn this review, we discuss current TNBC treatments and \\nkey examples of improved clinical benefit, as well as new \\ntherapeutic strategies with which to treat the disease.\\n2. Current treatment paradigm\\nTNBC is chemotherapy sensitive, and this treatment remains \\nthe standard of care (SOC). Common chemotherapies \\ninclude anthracycline (e.g., DNA intercalating agent and'),\n",
       " Document(metadata={}, page_content='topoisomerase II blocker doxorubicin), alkylating agents (e.g., \\ncyclophosamide), an anti‑microtubule agent taxane, and an \\nanti‑metabolite fluorouracil (5‑FU). The current SOC for newly \\nTriple‑negative breast cancer therapy: Current \\nand future perspectives (Review)\\nKWANG‑AI WON1,2  and  CHARLES SPRUCK3\\n1ConsultantCA, Moraga, CA 94556; 2Pin Pharmaceuticals, Inc., South San Francisco, CA 94080;'),\n",
       " Document(metadata={}, page_content='3Tumor Initiation and Maintenance Program, NCI‑Designated Cancer Center,\\nSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA\\nReceived July 14, 2020;  Accepted September 9, 2020\\nDOI: 10.3892/ijo.2020.5135\\nCorrespondence to: Dr Kwang‑Ai Won, ConsultantCA, 1988 Ascot \\nDrive, Unit A, Moraga, CA 94556, USA\\nE‑mail: wonk12pharm@yahoo.com\\nKey words: triple‑negative breast cancer, clinical studies, \\nimmunotherapy, \\nDNA‑damage'),\n",
       " Document(metadata={}, page_content='immunotherapy, \\nDNA‑damage \\nresponse, \\ntargeted \\ntherapy, \\ntherapeutic strategy\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1246\\ndiagnosed early TNBC consists of neoadjuvant chemotherapy, \\nfollowed by surgery. For patients with relapsed/refractory \\nTNBC, there is no standard chemotherapy regimen. Responses \\nto treatment are usually short in duration and followed by'),\n",
       " Document(metadata={}, page_content='rapid relapse, and visceral and brain metastases are common. \\nAvailable therapies for patients with advanced TNBC include \\nanti‑metabolites capecitabine and gemcitabine, non‑taxane \\nmicrotubule inhibitor eribulin, and DNA cross‑linker \\nplatinums. The median progression‑free survival (PFS) with \\nchemotherapy ranges from 1.7 to 3.7\\xa0months; the median OS \\nfrom the onset of metastasis is 10 to 13\\xa0months. In clinical'),\n",
       " Document(metadata={}, page_content='trials, patients with advanced TNBC treated with single‑agent \\ntaxane‑ or platinum‑based chemotherapy had a median PFS \\nof 4 to 6\\xa0months and a median OS of 11 to 17\\xa0months\\xa0(9‑11).\\nNew treatment options for patients with advanced TNBC \\nhave recently emerged, especially in cases where surgery is \\nnot an option.\\nTNBC is more immunogenic than other breast cancer \\nsubtypes with tumor‑infiltrating lymphocytes (TILs) in its'),\n",
       " Document(metadata={}, page_content='microenvironment. However, TNBC also displays a high level \\nof programmed cell death‑ligand 1 (PD‑L1) expression\\xa0(12,13). \\nThus, immunotherapies targeting the programmed cell \\ndeath‑1 (PD‑1) receptor/PD‑L1 pathway that maintains immu\\xad\\nnosuppression in the tumor environment in TNBC have been \\nexplored and atezolizumab (anti‑PD‑L1 antibody) in combi\\xad\\nnation with nanoparticle albumin‑bound (nab)‑paclitaxel'),\n",
       " Document(metadata={}, page_content='was approved as a first‑line therapy by the US Food and \\nDrug Administration (FDA) based on the IMpassion130 \\ntrial (NCT02425891) in 2019. This immuno‑chemotherapy \\nbecame SOC for patients with PD‑L1+, unresectable, locally \\nadvanced or metastatic TNBC. Note that the survival benefit \\nwas exclusively in PD‑L1+ TNBC patients. The threshold is \\n1% PD‑L1 expression on infiltrating immune cells by an'),\n",
       " Document(metadata={}, page_content='approved companion diagnostic SP142 IHC assay and 41% \\nof enrolled patients showed PD‑L1‑positive expression in \\nthe IMpassion130 trial. This is in contrast to studies in other \\ntypes of cancer which showed benefit for checkpoint inhibitor \\ntherapy even in patients with negative PD‑L1 expression. In \\nthe first interim analysis of IMpassion130, the median PFS \\nwas 7.5 vs. 5.0\\xa0months with chemotherapy and the median OS'),\n",
       " Document(metadata={}, page_content='was 25.0 vs. 15.5\\xa0months with chemotherapy among patients \\nwith PD‑L1+ tumors\\xa0(14). In the pre‑specified second interim \\nanalysis (data cutoff January 2, 2019), the median OS was 25.0 \\nvs. 18.0\\xa0months with chemotherapy. Overall, the combination \\nwas well‑tolerated and immune‑related adverse events (AEs) \\nincluded rash, hypothyroidism, and pneumonitis\\xa0(15). Another \\nimmunotherapy, pembrolizumab (anti‑PD‑1 antibody), was'),\n",
       " Document(metadata={}, page_content='approved in 2017 as a histology agnostic immunotherapy in all \\nmicrosatellite instability‑high (MSI‑H) and/or mismatch repair \\ndeficient (dMMR) tumors. This is the first FDA‑approved \\ncancer treatment based on a tumor biomarker without regard \\nto the original location of the tumor. However, MSI‑H is rare \\nin breast cancer (<2%)\\xa0(16‑18).\\nBRCA1 and BRCA2‑deficient tumors exhibit impaired'),\n",
       " Document(metadata={}, page_content='homologous recombination repair (HRR) and synthetic lethality \\nwith poly(ADP‑ribose) polymerase (PARP) inhibitors\\xa0(19,20). \\nThe FDA approved olaparib and talazoparib in 2018 to treat \\nadvanced‑stage HER2‑negative breast cancer in individuals \\nwith a Brca1 or Brca2 mutation. The FDA also approved the \\ncompanion diagnostic test to identify germline Brca‑mutated \\n(gBRCAm) breast cancer patients. Approximately 5% of patients'),\n",
       " Document(metadata={}, page_content=\"with breast cancer carry a gBRCAm. Olaparib approval was \\nbased on data from the OlympiAD Phase\\xa0III (NCT02000622) \\ntrial comparing olaparib to physician's choice of chemotherapy \\n(capecitabine, vinorelbine or eribulin). Olaparib was associated \\nwith a 42% increase in median PFS as compared to the control \\ngroup (7 vs. 4\\xa0months) in gBRCAm HER2‑negative meta\\xad\\nstatic breast cancer patients with previous chemotherapy\\xa0(21).\"),\n",
       " Document(metadata={}, page_content='There was no statistically significant improvement in OS with \\nolaparib compared to the control group (19.3 vs. 17.1\\xa0months), \\nbut there was potential OS benefit among patients with no prior \\nchemotherapy for metastatic breast cancer (HR 0.51, 95%\\xa0CI \\n0.29‑0.90)\\xa0(22). Olaparib was generally well‑tolerated, with no \\nevidence of cumulative toxicity including the risk of developing \\nanemia during extended exposure. Talazoparib approval was'),\n",
       " Document(metadata={}, page_content='based on data from the EMBRACA Phase\\xa0III (NCT01945775) \\ntrial comparing talazoparib to gemcitabine or to the same \\nphysician choice of standard therapy as the OlympiAD trial. \\nTalazoparib increased median PFS by 46% (8.6 vs. 5.6\\xa0months) \\nin gBRCAm HER2‑negative locally advanced or metastatic \\nbreast cancer patients with previous chemotherapy including an \\nanthracycline and/or taxane. Talazoparib presented with hema\\xad'),\n",
       " Document(metadata={}, page_content='tologic grade 3‑4 AEs (primarily anemia), which occurred in 55 \\nvs. 38% of the patients with standard therapy, and an improved \\nside‑effect profile in patient‑reported outcomes\\xa0(23).\\n3. Investigational drugs\\nTo improve therapeutic benefit in TNBC treatment, \\nvarious agents have been explored in clinical studies. They \\ninclude immuno‑ and targeted‑therapies in the networks of \\ntumor‑stroma, DNA damage response (DDR), cell surface or'),\n",
       " Document(metadata={}, page_content='intracellular receptors, and signaling pathways as well as cell \\nsurface markers for selective drug delivery, and antibody‑drug \\nconjugates (ADCs) (Fig.\\xa01). As of March 2020, 399 ongoing \\nstudies for TNBC have been listed on ClinicalTrials.gov and \\nselect Phase\\xa0III studies are listed in Table\\xa0I.\\nImmunotherapy: Immune checkpoint. TILs are frequent \\nin TNBC, correlate with increased pathologic complete'),\n",
       " Document(metadata={}, page_content='response (pCR) to neoadjuvant chemotherapy, and are predic\\xad\\ntive of disease‑free survival (DFS) and OS in early‑stage \\nTNBC\\xa0(24‑26). Expression of immune regulatory checkpoints \\nis an adaptive method of tumor resistance to infiltrating lympho\\xad\\ncytes within the tumor microenvironment. Multiple strategies \\nhave been used to enhance the response to PD‑1/PD‑L1 \\nblockade in pre‑clinical and early clinical studies, including'),\n",
       " Document(metadata={}, page_content='several intratumoral immune modulators and targeted \\nagents\\xa0(27). The activity of immunotherapy, such as immune \\ncheckpoint inhibitors, can be enhanced by chemotherapeutic \\nagents through the stimulation/release of antigens, thus leading \\nto promotion of immunogenic cell death. Currently, clinical \\ntrials investigating the use of immune checkpoint inhibitors \\nare ongoing either as a single agent or in various combinations'),\n",
       " Document(metadata={}, page_content='with other agents beyond the metastatic setting and even in the \\nfirst‑line setting\\xa0(28).\\nNeoadjuvant treatment. Studies determining benefit from \\nneoadjuvant checkpoint inhibitor therapy have yielded mixed \\noutcomes. Neoadjuvant chemotherapy with pembrolizumab \\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1247\\nhave demonstrated manageable safety and promising anti\\xad\\ntumor activity for patients with early‑stage TNBC in the'),\n",
       " Document(metadata={}, page_content='KEYNOTE‑173 Phase 1b (NCT02622074)\\xa0(29) and I‑SPY2 \\nPhase\\xa0II (NCT01042379) trials\\xa0(30). The KEYNOTE‑522 \\nPhase\\xa0III trial (NCT03036488) further explored neoadjuvant \\nchemotherapy with or without pembrolizumab followed by \\nsurgery and pembrolizumab or placebo adjuvantly. The neoad\\xad\\njuvant combination showed a significantly higher pCR rate \\nthan the placebo‑chemotherapy group (65 vs. 51%). Note that'),\n",
       " Document(metadata={}, page_content='a similar pCR benefit (~15%) in both the PD‑L‑positive and \\n‑negative subgroups was observed, suggesting that neoadju\\xad\\nvant pembrolizumab may benefit patients regardless of PD‑L1 \\nlevels. This is different from the advanced setting where only \\nthe PD‑L1‑positive patients benefit from atezolizumab. The \\ntoxicity profiles were as expected for each treatment, with \\nsimilar rates (78 vs. 73%) of grade ≥3 treatment‑related AEs \\n(TRAEs)\\xa0(31).'),\n",
       " Document(metadata={}, page_content='(TRAEs)\\xa0(31).\\nNeoTRIPaPDL1 Phase\\xa0 III (NCT02620280) trial also \\nexplored neoadjuvant chemotherapy with or without atezoli\\xad\\nzumab followed by surgery and four cycles of an anthracycline \\nregimen. However, in this trial for patients with early‑stage \\nhigh‑risk or locally advanced unilateral breast cancer there \\nwas no improvement in pCR with the combination therapy \\n(44 vs. 41% with the control arm)\\xa0(32). Note that the neoad\\xad'),\n",
       " Document(metadata={}, page_content='juvant chemo‑regimen was different from KEYNOTE‑522 \\nwhich included another round of chemotherapy following \\ncarboplatin and nab‑paclitaxel. The difference in the targets, \\nPD‑1 for pembrolizumab vs. PD‑L1 for atezolizumab, may \\nalso have contributed to the different outcomes. Another \\nPhase\\xa0III (NCT03197935) trial, IMpassion031 study also \\nexplored atezolizumab in combination with chemotherapy'),\n",
       " Document(metadata={}, page_content='(nab‑paclitaxel followed by doxorubicin and cyclophospha\\xad\\nmide) in comparison to placebo plus chemotherapy in the \\nneoadjuvant setting. Treatment with atezolizumab continued \\nadjuvantly for those in the combination arm of the study\\xa0(33). \\nThe primary endpoint was pCR.\\nIn the advanced setting. As a first‑line treatment option for \\npatients with locally recurrent, inoperable or metastatic TNBC,'),\n",
       " Document(metadata={}, page_content=\"pembrolizumab was evaluated in combination with investiga\\xad\\ntor's choice of chemotherapy (i.e. nab‑paclitaxel, paclitaxel or \\ngemcitabine/carboplatin), compared to placebo plus chemo\\xad\\ntherapy (KEYNOTE‑355 Phase\\xa0 III trial, NCT02819518). \\nA significant PFS benefit with the pembrolizumab‑chemo \\ncombination in patients whose tumors expressed PD‑L1 \\n(CPS ≥10) was reported (9.7 vs. 5.6\\xa0months for chemotherapy\"),\n",
       " Document(metadata={}, page_content='alone)\\xa0(34). The study is currently in progress to evaluate OS, \\nthe other primary endpoint of the trial.\\nIn contrast to other studies of immunotherapy combined \\nwith SOC chemotherapy, the Tonic trial (NCT02499367) \\nin metastatic TNBC was based on an adaptive trial design \\nthat explores a sequential treatment with anti‑PD‑1 antibody \\nnivolumab after 2\\xa0weeks of chemotherapy or radiotherapy. The'),\n",
       " Document(metadata={}, page_content='hypothesis is that short‑term treatment induces a more favor\\xad\\nable tumor microenvironment that would enhance sensitivity \\nto immune checkpoint blockade in TNBC. The highest overall \\nFigure 1. Immuno‑ and targeted‑therapies in key TNBC clinical studies. Various agents in the networks of TNBCs and immune cells have been explored,'),\n",
       " Document(metadata={}, page_content='as well as tumor‑stroma interactions in the tumor microenvironment (TME). Targets and agents relevant to immune checkpoint, cell surface or intracel\\xad\\nlular receptors, signaling pathways, DNA damage response, and cell cycle checkpoint are shown. Various chemotherapy agents are listed in the box. AS, \\nAdagloxad simolenin); LV, Ladiratuzumab vedotin; SG, Sacituzumab govitecan‑hziy; T‑DXd, tastuzumab deruxtecan; TNBC, triple‑negative breast cancer;'),\n",
       " Document(metadata={}, page_content='A2aR, adenosine 2A receptor; A2bR, 2B receptor; PD‑1, programmed cell death‑1; PD‑L1, programmed cell death‑ligand 1; VEGF‑A, vascular endothelial \\ngrowth factor A; RTKs, receptor tyrosine kinases; PARP, poly(ADP‑ribose) polymerase; CDK, cyclin‑dependent kinase; CD, cluster of differentiation; ATR,'),\n",
       " Document(metadata={}, page_content='ataxia telangiectasia and Rad3‑related kinase; CHK1, checkpoint kinase 1; DNA‑PK, DNA‑dependent protein kinase; AR, androgen receptor; PI3K, phospha\\xad\\ntidylinositol 3‑kinase. \\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1248\\nTable I. Current phase III studies concerning TNBC.\\n\\t\\n\\t\\n\\t\\n\\t\\n\\t\\nStudy start; Primary\\n\\t\\n\\t\\n\\t\\n\\t\\nNo. of\\t\\ncompletion(month/\\t\\nClinicalTrials.gov\\nTherapeutic approach\\t\\nTreatment\\t\\nTNBC patient population'),\n",
       " Document(metadata={}, page_content='Treatment\\t\\nTNBC patient population\\t\\nRecruitment status\\t\\npatients\\t\\nday/year)\\t\\nIdentifier\\nNeoadjuvant therapy: \\t\\n(Carbo/nab‑pac) +/‑ atezolizumab.\\t\\nEarly high‑risk and\\t\\nActive, not recruiting\\t\\n278\\t\\n4/1/2016; May 2022\\t\\nNCT02620280\\nImmuno + chemotherapy \\t\\nThen, four cycles of AC, EC or\\t\\nlocally advanced\\n(NeoTRIPaPDL1)\\t\\nFEC as adjuvant chemotherapy\\nImmuno + chemotherapy\\t\\n(Pac/carbo, followed by AC or EC) \\t\\nLocally advanced\\t\\nActive, not recruiting'),\n",
       " Document(metadata={}, page_content='Locally advanced\\t\\nActive, not recruiting\\t\\n1,174\\t\\n3/7/2017; 9/30/2025\\t\\nNCT03036488\\nas neoadjuvant therapy \\t\\n+/‑ pembrolizumab as neoadjuvant\\nand immunotherapy as \\t\\ntherapy prior to surgery. Then, \\nadjuvant therapy \\t\\npembrolizumab vs. placebo as\\n(KEYNOTE‑522)\\t\\nadjuvant therapy post‑surgery\\nNeoadjuvant therapy: \\t\\n(Nab‑pac +/‑ atezolizumab), \\t\\nEligible for surgery with\\t\\nActive, not recruiting\\t\\n324\\t\\n7/24/2017; 9/30/2020\\t\\nNCT03197935'),\n",
       " Document(metadata={}, page_content='324\\t\\n7/24/2017; 9/30/2020\\t\\nNCT03197935\\nImmuno + chemotherapy \\t\\nfollowed by AC\\t\\ninitial clinically assessed\\n(IMpassion031)\\t\\n\\t\\nprimary invasive (early\\n\\t\\n\\t\\nstage)\\nNeoadjuvant therapy: \\t\\n(Carbo/pac, then AC or EC) +/‑ \\t\\nNo metastatic disease\\t\\nRecruiting\\t\\n1,520\\t\\n12/19/2017; 12/31/2023\\t\\nNCT03281954\\nImmuno + chemotherapy\\t\\natezolizumab, followed after\\n\\t\\nsurgery by atezolizumab or placebo\\t\\nImmuno + chemotherapy\\t\\n(Nab‑pac/carbo, followed by AC'),\n",
       " Document(metadata={}, page_content='(Nab‑pac/carbo, followed by AC\\t\\nPreviously untreated and\\t\\nNot yet recruiting\\t\\n522\\t\\n4/17/2020; 9/7/2022\\t\\nNCT04301739\\nas neoadjuvant therapy \\t\\nor EC) +/‑ HLX10 (anti‑PD‑1) as\\t\\npotentially resectable\\nand immunotherapy as \\t\\nneoadjuvant therapy prior to\\t\\npatients without distant\\nadjuvant therapy\\t\\nsurgery. Then, HLX10 vs. placebo\\t\\nmetastasis\\n\\t\\nas adjuvant therapy post‑surgery\\nImmunotherapy: Immune\\t\\nAdagloxad simolenin\\t\\nEarly stage at high risk for'),\n",
       " Document(metadata={}, page_content='Early stage at high risk for\\t\\nRecruiting\\t\\n668\\t\\n12/5/2018; 11/30/2025\\t\\nNCT03562637\\nstimulant following\\t\\n(OBI 822)/OBI‑821 vs. placebo\\t\\nrecurrence; defined as\\nneoadjuvant or adjuvant\\t\\n\\t\\nresidual invasive disease\\nchemotherapy\\t\\n\\t\\nfollowing neoadjuvant\\n\\t\\n\\t\\nchemotherapy or ≥4 positive\\n\\t\\n\\t\\naxillary nodes. The Globo\\t\\n\\t\\n\\t\\nH IHC assay for identifying\\n\\t\\n\\t\\neligible patient\\nPARP inhibitor + \\t\\n[(Veliparib/pac/carbo) vs. \\t\\nEarly stage\\t\\nActive, not recruiting'),\n",
       " Document(metadata={}, page_content='Early stage\\t\\nActive, not recruiting\\t\\n634\\t\\n4/2/2014; 3/18/2016;\\t\\nNCT02032277\\nchemotherapy as\\t\\n(pac/carbo) vs. pac], \\t\\n\\t\\n\\t\\n\\t\\n(10/18/2020a)\\nneoadjuvant therapy \\t\\nfollowed by AC\\n(BrighTNess)\\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1249\\nTable I. Continued.\\n\\t\\n\\t\\n\\t\\n\\t\\n\\t\\nStudy start; Primary\\n\\t\\n\\t\\n\\t\\n\\t\\nNo. of\\t\\ncompletion(month/\\t\\nClinicalTrials.gov\\nTherapeutic approach\\t\\nTreatment\\t\\nTNBC patient population\\t\\nRecruitment status\\t\\npatients'),\n",
       " Document(metadata={}, page_content='Recruitment status\\t\\npatients\\t\\nday/year)\\t\\nIdentifier\\nPARP inhibitor + \\t\\n(Pac/carbo) +/‑ olaparib\\t\\nTNBC and/or gBRCAm\\t\\nRecruiting\\t\\n527\\t\\n5/1/2016; January 2022\\t\\nNCT03150576\\nchemotherapy as\\t\\n\\t\\npositive breast cancer\\nneoadjuvant therapy\\n(PARTNER, Phase II/III)\\nAdjuvant therapy: \\t\\nAvelumab (anti‑PD‑L1) vs. \\t\\nHigh‑risk; completed\\t\\nRecruiting\\t\\n335\\t\\nJune 2016; June 2021\\t\\nNCT02926196\\nImmunotherapy\\t\\nobservation\\t\\ntreatment with curative\\n(A‑Brave)'),\n",
       " Document(metadata={}, page_content='observation\\t\\ntreatment with curative\\n(A‑Brave)\\t\\n\\t\\nintent including surgery of\\n\\t\\n\\t\\nthe primary tumor, neo‑ or\\n\\t\\n\\t\\nadjuvant chemotherapy, and\\t\\n\\t\\n\\t\\n(if indicated) radiotherapy\\nAdjuvant therapy: \\t\\nPembrolizumab adjuvant therapy\\t\\nTNBC or low ER‑positive\\t\\nRecruiting\\t\\n1,000\\t\\n11/15/2016; 5/31/2026\\t\\nNCT02954874\\nImmunotherapy\\t\\nvs. no therapy\\t\\nand/or HER2 borderline\\n\\t\\n\\t\\nbreast cancer who have\\n\\t\\n\\t\\n≥1 cm residual invasive\\t\\n\\t\\n\\t\\nbreast cancer and/or positive'),\n",
       " Document(metadata={}, page_content='breast cancer and/or positive\\n\\t\\n\\t\\nlymph nodes after\\n\\t\\n\\t\\nneoadjuvant chemotherapy\\nAdjuvant therapy: \\t\\nPac +/‑ atezolizumab, followed by\\t\\nStage II‑III operable\\t\\nRecruiting\\t\\n2,300\\t\\n8/2/2018; 1/15/2022\\t\\nNCT03498716\\nImmuno + chemotherapy\\t\\ndose‑dense AC or EC alone\\n(IMpassion030)\\nImmuno + chemotherapy\\t\\nNab‑pac +/‑ atezolizumab\\t\\nPreviously untreated locally\\t\\nActive, not recruiting\\t\\n900\\t\\n6/23/2015; 4/14/2020\\t\\nNCT02425891\\n(IMpassion130)'),\n",
       " Document(metadata={}, page_content='NCT02425891\\n(IMpassion130)\\t\\n\\t\\nadvanced or metastatic\\nSingle agent\\t\\nPembrolizumab vs. chemotherapy\\t\\nMetastatic (second/third\\t\\nActive, not recruiting\\t\\n622\\t\\n10/13/2015; 4/11/2019\\t\\nNCT02555657\\nimmunotherapy\\t\\n(cape, eribulin, gem, or vinorelbine)\\t\\nlines)\\n(KEYNOTE‑119)\\nImmuno + chemotherapy\\t\\n(Nab‑pac or pac or gem/carbo) +/‑ \\t\\nPreviously untreated locally\\t\\nActive, not recruiting\\t\\n882\\t\\n7/27/2016; 12/30/2019\\t\\nNCT02819518\\n(KEYNOTE‑355)\\t\\npembrolizumab'),\n",
       " Document(metadata={}, page_content='NCT02819518\\n(KEYNOTE‑355)\\t\\npembrolizumab\\t\\nrecurrent inoperable or\\n\\t\\n\\t\\nmetastatic\\t\\nImmuno + chemotherapy\\t\\nPac +/‑ atezolizumab\\t\\nPreviously untreated, \\t\\nRecruiting\\t\\n600\\t\\n8/25/2017; 11/15/2019\\t\\nNCT03125902\\n(IMpassion131)\\t\\n\\t\\ninoperable locally advanced\\n\\t\\n\\t\\nor metastatic\\t\\nImmuno + chemotherapy\\t\\n(Gem/cape/carbo) +/‑ atezolizumab\\t\\nEarly relapsing recurrent\\t\\nRecruiting\\t\\n540\\t\\n1/11/2018; 1/1/2023\\t\\nNCT03371017\\n(IMpassion132)\\t\\n\\t\\n(inoperable locally advanced'),\n",
       " Document(metadata={}, page_content='(IMpassion132)\\t\\n\\t\\n(inoperable locally advanced\\n\\t\\n\\t\\nor metastatic)\\t\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1250\\nTable I. Continued.\\n\\t\\n\\t\\n\\t\\n\\t\\n\\t\\nStudy start; Primary\\n\\t\\n\\t\\n\\t\\n\\t\\nNo. of\\t\\ncompletion(month/\\t\\nClinicalTrials.gov\\nTherapeutic approach\\t\\nTreatment\\t\\nTNBC patient population\\t\\nRecruitment status\\t\\npatients\\t\\nday/year)\\t\\nIdentifier\\nImmuno + \\t\\nNab‑pac +/‑ toripalimab\\t\\nFirst/second‑line treatment\\t\\nRecruiting\\t\\n600'),\n",
       " Document(metadata={}, page_content='First/second‑line treatment\\t\\nRecruiting\\t\\n600\\t\\n12/21/2018; 2/28/2022\\t\\nNCT04085276\\nchemotherapy\\t\\n(anti‑PD‑1)\\t\\nof metastatic or recurrent\\t\\n(TORCHLIGHT)\\nImmuno + chemotherapy\\xa0 \\t Single arm: (Nab‑pac or pac) + \\t\\nPD‑L1‑positive\\t\\nRecruiting\\t\\n280\\t\\n12/17/2019; 6/28/2024\\t\\nNCT04148911\\n(EL1SSAR)\\t\\natezolizumab\\t\\nunresectable locally\\n\\t\\n\\t\\nadvanced or metastatic; not\\n\\t\\n\\t\\nreceived prior systemic\\n\\t\\n\\t\\ncytotoxic therapy\\nPARP inhibitor +'),\n",
       " Document(metadata={}, page_content='cytotoxic therapy\\nPARP inhibitor + \\xa0\\t\\nOlaparib + pembrolizumab vs. \\t\\nLocally recurrent inoperable\\t\\nRecruiting\\t\\n932\\t\\n12/19/2019; 1/26/2026\\t\\nNCT04191135\\nimmunotherapy as the\\t\\n(carbo/gem) + pembrolizumab after\\t or metastatic\\npost‑induction therapy\\t\\ninduction with first‑line\\n(KEYLYNK‑009, Phase\\t\\n(carbo/gem) + pembrolizumab\\nII/III)\\nAKT inhibitor + \\t\\nCohort 1 (PD‑L1 non‑positive): \\xa0\\t\\nLocally advanced\\t\\nRecruiting\\t\\n1,155\\t\\n11/25/2019; 10/10/2025'),\n",
       " Document(metadata={}, page_content='Recruiting\\t\\n1,155\\t\\n11/25/2019; 10/10/2025\\t\\nNCT04177108\\nimmuno + chemotherapy\\t\\npaclitaxel (P)/ipatasertib\\t\\nunresectable or metastatic\\n\\t\\n(I)/atezolizumab (A) vs. P/I vs. P; \\n\\t\\nCohort 2 (PD‑L1 positive): P/I/A\\n\\t\\nvs. P/A\\nAKT inhibitor + \\t\\nPac +/‑ ipatasertib\\t\\nPIK3CA/AKT1/PTEN‑\\t\\nRecruiting\\t\\n450\\t\\n1/6/2018; 12/22/2021\\t\\nNCT03337724\\nchemotherapy\\xa0 \\t\\n\\t\\naltered, locally advanced or\\n(IPATunity130)\\t\\n\\t\\nmetastatic TNBC and locally\\n\\t\\n\\t\\nadvanced or metastatic'),\n",
       " Document(metadata={}, page_content='advanced or metastatic\\n\\t\\n\\t\\nHR+/HER2‑breast\\n\\t\\n\\t\\nadenocarcinoma, not\\n\\t\\n\\t\\nsuitable for endocrine \\n\\t\\n\\t\\ntherapy\\nAKT inhibitor + \\t\\nPac +/‑ capivasertib\\t\\nLocally advanced\\t\\nRecruiting\\t\\n800\\t\\n6/25/2019; 9/1/2021\\t\\nNCT03997123\\nchemotherapy as first\\t\\n\\t\\n(inoperable) or metastatic\\t\\nline therapy \\n(CapItello290)\\nPI3K inhibitor + \\t\\nNab‑pac +/‑ alpelisib\\t\\nAdvanced; a PIK3CA\\t\\nNot yet recruiting\\t\\n566\\t\\n4/22/2020; 3/19/2024\\t\\nNCT04251533\\nchemotherapy'),\n",
       " Document(metadata={}, page_content='4/22/2020; 3/19/2024\\t\\nNCT04251533\\nchemotherapy\\t\\n\\t\\nmutation (Study Part A) or\\n(EPIK‑B3)\\t\\n\\t\\nPTEN loss without PIK3CA\\n\\t\\n\\t\\nmutation (Study Parts B1 and B2)\\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1251\\nresponse rate (ORR) was observed with doxorubicin induc\\xad\\ntion (35%) followed by nivolumab/doxorubicin. Doxorubicin \\ninduction also upregulated immune‑related genes as well \\nas inflammation, JAK‑STAT, and TNF‑α signaling‑related'),\n",
       " Document(metadata={}, page_content='genes, suggesting a more favorable tumor microenvironment \\ninduced by these chemotherapies\\xa0(35). The InCITe Phase\\xa0II \\ntrial (NCT03971409) also includes a two‑week induction of \\nbinimetinib (MEK inhibitor), utomilumab (4‑1BB agonist), or \\nPF‑04518600 (anti‑OX40 antibody) which may help activate \\nthe immune system. The trial explores how well anti‑PD‑L1 \\nantibody avelumab might work with one of those agents after'),\n",
       " Document(metadata={}, page_content='induction in stage\\xa0IV or unresectable and recurrent TNBC.\\nImmunotherapy: Adenosine pathway. Adenosine is catabo\\xad\\nlized from ATP and often overproduced and released by \\ntumor cells. It is also converted from extracellular nucleotides \\nby the plasma membrane protein, cluster of differentiation 73 \\n(CD73), which is upregulated in many cancer types\\xa0(36,37). \\nThe excess adenosine in the tumor microenvironment'),\n",
       " Document(metadata={}, page_content='activates the adenosine 2A receptor (A2aR) and 2B receptor \\n(A2bR)\\xa0(38,39) which are highly expressed on the cell surfaces \\nof lymphocytes and myeloid cells, respectively, leading to \\nimmunosuppressive effects (Fig.\\xa02). Targeting these receptors \\nand enzymes could lead to reactivation of antitumor immunity \\nby abrogating the inhibitory effect on the immune system \\nand enhancing the cytotoxic T lymphocyte (CTL)‑mediated \\nimmune response\\xa0(40,41).'),\n",
       " Document(metadata={}, page_content='immune response\\xa0(40,41). \\nCombinations of adenosine pathway inhibitors and \\nimmune checkpoint inhibitors have been explored in clinical \\ntrials. NZV930 (SRF373) is an anti‑CD73 monoclonal \\nantibody that binds to CD73 on tumor cells, leading to \\ninternalization of CD73, thereby preventing CD73‑mediated \\nconversion of extracellular AMP to adenosine. A Phase\\xa0I/Ib \\nstudy (NCT03549000) is underway to evaluate NZV930 alone'),\n",
       " Document(metadata={}, page_content='and in combination with PD‑1 inhibitor PDR001 and/or A2aR \\nantagonist NIR178 in patients with advanced malignancies \\nincluding TNBC. NIR178 is an antagonist of A2aR, blocking \\nadenosine/A2aR‑mediated inhibition of T lymphocytes. A \\nPhase\\xa0II study (NCT03207867) is underway for NIR178 in \\ncombination with PD‑1 inhibitor spartalizumab in multiple \\nsolid tumors and diffuse large B‑cell lymphoma (DLBCL)'),\n",
       " Document(metadata={}, page_content='to assess if the addition of the adenosine antagonist improves \\nthe efficacy of PD‑1 inhibition. A dual adenosine A2aR/A2bR \\nreceptor antagonist, AB928, is currently being evaluated in a \\nPhase\\xa0I study (NCT03629756) in combination with the PD‑1 \\ninhibitor AB122 in patients with advanced malignancies. Early \\nresults show a favorable safety profile of AB928 combination \\ntherapy and predictable PK/PD correlation\\xa0(42).'),\n",
       " Document(metadata={}, page_content='therapy and predictable PK/PD correlation\\xa0(42). \\nDNA‑damage response: PARP. Approximately 60‑70% of \\nbreast cancer patients with an inherited Brca1/2 mutation \\nare TNBC subtype and 10‑30% of TNBC patients harbor \\na Brca pathogenic variant\\xa0(43,44). A condition defined as \\n‘BRCAness’\\xa0(45), which includes mutations in HRR genes \\nthrough genetic or epigenetic inactivation, leads to suscep\\xad\\ntibility to both platinum and PARP inhibitors. Various'),\n",
       " Document(metadata={}, page_content='PARP inhibitors (e.g. veliparib, niraparib, and rucaparib as \\nwell as olaparib and talazoparib) have been assessed in the \\nneoadjuvant and adjuvant settings and in combination with \\nother agents.\\nTable I. Continued.\\n\\t\\n\\t\\n\\t\\n\\t\\n\\t\\nStudy start; Primary\\n\\t\\n\\t\\n\\t\\n\\t\\nNo. of\\t\\ncompletion(month/\\t\\nClinicalTrials.gov\\nTherapeutic approach\\t\\nTreatment\\t\\nTNBC patient population\\t\\nRecruitment status\\t\\npatients\\t\\nday/year)\\t\\nIdentifier\\nAR antagonist as first'),\n",
       " Document(metadata={}, page_content='day/year)\\t\\nIdentifier\\nAR antagonist as first\\t\\nBicalutamide vs. (docetaxel/cape\\t\\nAR‑positive metastatic\\t\\nRecruiting\\t\\n262\\t\\n12/1/2016; \\t\\nNCT03055312\\nline therapy\\t\\nor gem/docetaxel or gem/carbo)\\t\\n\\t\\n\\t\\n\\t\\nDecember 2020\\n(SYSUCC‑007)\\nAmino acid metabolism\\t\\n(Gem/carbo) +/‑ eryaspase\\xa0\\t\\nLocally recurrent or metastatic; \\t\\nRecruiting\\t\\n64\\t\\n6/13/2019; \\t\\nNCT03674242\\ntarget + chemotherapy as\\t\\n(L‑asparaginase encapsulated\\t\\nnot received prior systemic'),\n",
       " Document(metadata={}, page_content='not received prior systemic\\t\\n\\t\\n\\t\\nDecember 2020\\nfirst line therapy\\t\\ninside a donor‑derived red blood\\t\\ntherapy\\n(TRYbeCA‑2, \\t\\ncell)\\nPhase II/III)\\nAntibody‑drug conjugate\\t\\nSacituzumab Govitecan vs. \\t\\nRefractory/relapsed metastatic\\t\\nActive, not recruiting\\t\\n529\\t\\n11/3/2017; April 2020\\t\\nNCT02574455\\n(ASCENT)\\t\\n(eribulin, cape, gem, vinorelbine)'),\n",
       " Document(metadata={}, page_content='(ASCENT)\\t\\n(eribulin, cape, gem, vinorelbine)\\nTNBC, triple‑negative breast cancer; AR, androgen receptor; A, doxorubicin; C, cyclophosphamide; Cape, capecitabine; Carbo, carboplatin; E, epirubicin; F, fluorouracil; Gem, gemcitabine; Nab‑pac, \\nNab‑paclitaxel); Pac, paclitaxel; gBRCAm, germline BRCA‑mutated. aEstimated Study Completion Date.\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1252'),\n",
       " Document(metadata={}, page_content='1252\\nNeoadjuvant and adjuvant settings. A PARP inhibitor appears \\nto have efficacy for neoadjuvant treatment of patients with \\ngBRCAm TNBC. Talazoparib achieved encouraging pCR \\nin patients with gBRCAm breast cancer, including TNBC, \\nand HR+ breast cancer, as a neoadjuvant single‑agent without \\nthe addition of chemotherapy\\xa0(46). Currently a larger, multi\\xad\\ncenter, neoadjuvant Phase\\xa0II trial (NCT03499353) is ongoing.'),\n",
       " Document(metadata={}, page_content='However, the addition of a PARP inhibitor to standard neoad\\xad\\njuvant chemotherapy was found to be not beneficial. In the \\nBrighTNess Phase\\xa0III trial (NCT02032277) the addition of \\nPARP inhibitor veliparib to carboplatin and paclitaxel followed \\nby doxorubicin and cyclophosphamide did not improve pCR \\nwhereas the addition of veliparib and carboplatin to paclitaxel \\ndid. Therefore, the addition of carboplatin but not veliparib to'),\n",
       " Document(metadata={}, page_content='paclitaxel was proposed as a potential component of neoad\\xad\\njuvant chemotherapy for patients with high‑risk TNBC\\xa0(47). \\nPARP inhibitors have also been studied as an adju\\xad\\nvant single‑agent therapy. The OlympiA Phase\\xa0 III trial \\n(NCT02032823) was designed to assess olaparib in patients \\nwith gBRCAm and high‑risk HER2‑negative breast cancer \\nwho completed definitive local treatment and neoadjuvant or'),\n",
       " Document(metadata={}, page_content='adjuvant chemotherapy. The primary outcome measure will be \\ninvasive DFS with a time frame of up to 10\\xa0years.\\nIn combination with immunotherapy. A crosstalk exists \\nbetween PARP inhibition and the PD‑L1/PD‑1 immune \\ncheckpoint axis. PARP inhibitors upregulate PD‑L1 expres\\xad\\nsion on tumor cells by inhibiting glycogen synthase kinase 3 \\nbeta (GSK3β) and activating the cGAS‑STING pathway\\xa0(48).'),\n",
       " Document(metadata={}, page_content='Thus, primary/acquired resistance to PARP inhibitors seems \\nto be associated with the development of immune evasion \\nmechanisms. Multiple clinical studies are underway to assess \\nsynergy between therapeutic strategies of PARP inhibition and \\nimmune checkpoint blockers.\\nIn platinum‑resistant, advanced, or metastatic \\nTNBC, niraparib combined with pembrolizumab \\n(TOPACIO/KEYNOTE‑162 Phase\\xa0II trial, NCT02657889)'),\n",
       " Document(metadata={}, page_content='showed higher response rates in patients with tumor Brca muta\\xad\\ntions (tBRCAm): ORR of 28% in all (biomarker‑unselected) \\npatients vs. 60% for tBRCAm patients. The combination \\ntherapy was safe with a tolerable safety profile\\xa0(49). \\nIn MEDIOLA Phase\\xa0I/II trial (NCT02734004) the combi\\xad\\nnation of olaparib and durvalumab showed ORR of 63% in a \\ncohort of patients with gBRCAm metastatic breast cancer\\xa0(50).'),\n",
       " Document(metadata={}, page_content='In the I‑SPY 2 Phase\\xa0II study (NCT01042379), adding the same \\ncombination to neoadjuvant paclitaxel led to improved pCR \\nrates in patients with high‑risk, HER2‑negative stage\\xa0II/III \\nbreast cancer compared with single‑agent paclitaxel. In those \\nwith TNBC, the pCR rate was 47 vs. 27% with paclitaxel alone. \\nAEs were consistent with the known safety profiles of each \\nagent alone\\xa0(51). In metastatic TNBC, the efficacy of induction'),\n",
       " Document(metadata={}, page_content='treatment of olaparib followed by the combination treatment of \\nolaparib and durvalumab is being assessed in a Phase\\xa0II study \\n(NCT03801369)\\xa0(52). Patients with ≤2 prior chemotherapy \\nregimens for metastatic breast cancer are eligible, but patients \\nwith gBRCAm TNBC are excluded. The primary end point is \\nORR. \\nThe DORA Phase\\xa0 II trial (NCT03167619) is evalu\\xad\\nating olaparib as a maintenance therapy with or without'),\n",
       " Document(metadata={}, page_content='durvalumab in patients with advanced TNBC who achieve at \\nleast stable disease after 3\\xa0cycles of platinum‑based chemo\\xad\\ntherapy. Another study of a PARP inhibitor as a maintenance \\ntherapy, KEYLYNK‑009 Phase\\xa0II/III trial (NCT04191135), \\nis underway in metastatic TNBC to assess the efficacy of \\nolaparib plus pembrolizumab vs. chemotherapy plus pembro\\xad\\nlizumab after induction with first‑line chemotherapy plus \\npembrolizumab\\xa0(53).'),\n",
       " Document(metadata={}, page_content='pembrolizumab\\xa0(53).\\nIn combination with DDR‑HRR pathway inhibitors. \\nResistance to PARP inhibitors can occur in certain cancer \\ncontexts by various mechanisms, including increased HRR \\ncapacity and decreased cell cycle progression and DNA \\nreplication stress. RAD51 overexpression has been observed \\nin a wide range of human cancers, particularly TNBCs and \\nserous ovarian cancers\\xa0(54,55). Upregulation of RAD51 in'),\n",
       " Document(metadata={}, page_content='BRCA1‑defective cells is also associated with resistance to \\nPARP inhibitor\\xa0(56,57). Inhibitors of key mediators of DNA \\nrepair and replication, such as ataxia telangiectasia mutated \\nkinase (ATM), ataxia telangiectasia and Rad3‑related kinase \\n(ATR), checkpoint kinase 1 (CHK1) and checkpoint kinase \\n2 (CHK2), DNA‑dependent protein kinase (DNA‑PK), and \\nWEE1 kinase (Fig.\\xa03) have been assessed to determine if they'),\n",
       " Document(metadata={}, page_content='can sensitize tumor cells to treatment with PARP inhibitors, \\nas these inhibitors were found to prevent the accumulation of \\nRAD51 in TNBC\\xa0(58).\\nThe VIOLETTE Phase\\xa0 II study (NCT03330847) was \\nset up to assess the combinatory inhibition of PARP and a \\ncomponent of the ATR‑CHK1‑WEE1 axis. Olaparib with \\nDDR kinase ATR inhibitor AZD6738 was compared to \\nolaparib monotherapy in the second‑ or third‑line setting of'),\n",
       " Document(metadata={}, page_content='metastatic TNBC. Patients were stratified by Brca and HRR \\ngene mutation status and the primary endpoint was PFS\\xa0(59). \\nThe study also included a combination arm of olaparib with \\nthe first‑in‑class WEE1 inhibitor adavosertib. WEE1 inhibitor \\nwas found to potentiate the activity of DNA‑damaging agents \\nin preclinical TNBC models\\xa0(60,61) and its potential clinical \\nFigure 2. ATP‑adenosine pathway. Adenosine is generated from ATP by'),\n",
       " Document(metadata={}, page_content='CD39 and CD73. It binds to A2 receptors on immune cells and blocks T cell \\npriming, expansion, and activation, natural killer (NK) cell degranulation, \\ndendritic cell (DC) maturation and activation, and tumor‑associated macro\\xad\\nphage (TAM) M1 polarization, thus leading to immunosuppression. ATP, \\nadenosine triphosphate; AMP, adenosine monophosphate; CD, cluster of \\ndifferentiation.\\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1253'),\n",
       " Document(metadata={}, page_content='1253\\nvalue was observed in a Phase\\xa0I study in patients with Brca \\nmutations\\xa0(62). However, the combination treatment arm of \\nolaparib and adavosertib was discontinued in the VIOLETTE \\nstudy and patients were offered the opportunity to continue \\ntreatment on olaparib monotherapy. The CHK1 inhibitor \\nprexasertib in combination with olaparib was also explored in \\nearly clinical trials\\xa0(63), but development of prexasertib was'),\n",
       " Document(metadata={}, page_content='discontinued by the sponsor in 2019. \\nIntracellular signaling pathway targets\\nPI3K/AKT pathway. A wide range of malignancies including \\nTNBC show dysregulated phosphatase and tensin homolog \\n(PTEN)/phosphoinositide 3‑kinases (PI3K)/protein kinase B \\n(AKT)/mammalian target of rapamycin (mTOR) signaling \\ndue to mutations in multiple signaling components. Loss \\nof PTEN, a negative regulator of AKT, was found to be'),\n",
       " Document(metadata={}, page_content='correlated with decreased T‑cell infiltration at tumor \\nsites in patients, and inhibition of the PI3K‑AKT pathway \\nre‑sensitized to T‑cell‑mediated immunotherapy\\xa0(64). As the \\nPI3K/AKT pathway has emerged as a potential mechanism \\nof resistance to immunotherapy and chemotherapy, multiple \\nclinical trials have assessed inhibitors of the various pathway \\ncomponents.\\nAlpelisib is an oral PI3K inhibitor that selectively inhibits'),\n",
       " Document(metadata={}, page_content='p110α. It showed efficacy in targeting Pik3ca‑mutated breast \\ncancer\\xa0(65) and was FDA approved in 2019 in combination \\nwith fulvestrant for postmenopausal women and men, with \\nHR+, HER2‑negative, Pik3ca‑mutated, advanced or metastatic \\nbreast cancer following progression on or after an endo\\xad\\ncrine‑based regimen. For patients with advanced TNBC, the \\nEPIK‑B3 Phase\\xa0III trial (NCT04251533) is planned with study'),\n",
       " Document(metadata={}, page_content='start date of April 2020 to assess alpelisib in combination with \\nnab‑paclitaxel. Patients have Pik3ca mutations or PTEN loss \\nwith ≤1 prior line of therapy for metastatic disease.\\nIPI‑549 is a selective PI3K‑gamma inhibitor targeting \\nimmune‑suppressive tumor‑associated myeloid cells. The \\nMARIO‑3 Phase\\xa0II study (NCT03961698) was designed to \\nexplore the addition of IPI‑549 to the FDA approved regimen'),\n",
       " Document(metadata={}, page_content='atezolizumab/nab‑paclitaxel in front‑line TNBC. Cohort A \\nwill be composed of patients with locally advanced, metastatic \\nTNBC, which will include two sub‑cohorts based on PD‑L1 \\nIHC status. The primary objective is CR rate.\\nIpatasertib and capivasertib are pan‑AKT inhibitors that \\nbind to all three isoforms of AKT. Both are now in Phase\\xa0III \\ntrials evaluating the efficacy of combination with paclitaxel'),\n",
       " Document(metadata={}, page_content='as first‑line therapy for locally advanced or metastatic TNBC. \\nIn the LOTUS Phase\\xa0II trial, adding ipatasertib to first‑line \\npaclitaxel improved PFS, particularly in patients with \\nPTEN/PI3K/AKT‑altered tumors (HR, 0.44)\\xa0(66). In this \\nsubgroup of patients, median OS was 23.1 vs. 16.2\\xa0months with \\nplacebo (HR, 0.65)\\xa0(67). To confirm the findings from LOTUS, \\nthe IPATunity130 Phase\\xa0III trial (NCT03337724) is evaluating'),\n",
       " Document(metadata={}, page_content='ipatasertib + paclitaxel for PTEN/PI3K/AKT‑altered advanced \\nTNBC or HR+, HER2‑negative breast cancers. The primary \\nendpoint is PFS\\xa0(68). An independent trial also supported the \\npotential benefit for addition of AKT inhibitor to chemotherapy. \\nIn the PAKT Phase\\xa0II study (NCT02423603), addition of the \\noral AKT inhibitor capivasertib to first‑line paclitaxel resulted \\nin significantly longer PFS and OS in patients with advanced'),\n",
       " Document(metadata={}, page_content='TNBC, especially in patients with PTEN/PI3K/AKT‑altered \\ntumors. The median PFS duration was 5.9 vs. 4.2\\xa0months with \\nplacebo, meeting the predefined significance level, and better \\nbenefit in patients with PTEN/PI3K/AKT‑altered tumors with \\nmedian PFS of 9.3\\xa0months (HR, 0.30). The median OS was \\nprolonged by 6.5\\xa0months with capivasertib\\xa0(69). The most \\ncommon AEs of grade ≥3 were diarrhea, infection, rash, and'),\n",
       " Document(metadata={}, page_content='fatigue, similar to those observed with ipatasertib in the LOTUS \\ntrial. The CAPItello‑290 Phase\\xa0III trial (NCT03997123) is \\nunderway and the primary endpoints are PFS and OS\\xa0(70).\\nEfficacy of immunotherapy was also found to be \\nenhanced by AKT inhibitors as a first‑line therapy for locally \\nadvanced/metastatic TNBC. Phase\\xa0Ib study (NCT03800836) \\nwas designed to evaluate the triplet combination of ipatasertib'),\n",
       " Document(metadata={}, page_content='(I), atezolizumab (A), and paclitaxel or nab‑paclitaxel (P). \\nPreliminary efficacy and safety data up to January 5, 2019 \\nshowed that the triplet regimen had promising antitumor \\nFigure 3. DNA damage response pathways. Double‑strand breaks (DSB) or single‑strand breaks (SSB) activate DNA damage response (DDR) pathways,'),\n",
       " Document(metadata={}, page_content='leading to cell cycle arrest and DNA repair or cell death depending on cell context. PARP1 senses DNA breaks and is involved in SSB repair. Oncogenic \\npathways including RAS, PI3K, AR, and MYC signaling can affect HR repair activity and contribute to resistance to PARP inhibitor treatment. MRN, \\nMRE11-RAD50-NBS1 complex; ATRIP, ATP interacting protein; HR, homologous recombination; NHEJ, non\\xadhomologous end joining; H2AX, histone'),\n",
       " Document(metadata={}, page_content='H2AX; XRCC4, X‑ray repair cross‑complementing protein 4; ATR, ataxia telangiectasia and Rad3‑related protein; CHK1/2, checkpoint kinase 1/2; CDK1/2, \\ncyclin‑dependent kinase 1/2; DNA‑PK, DNA‑dependent protein kinase; AR, androgen receptor; PI3K, phosphatidylinositol 3‑kinase.\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1254\\nactivity (73% confirmed ORR), irrespective of biomarker'),\n",
       " Document(metadata={}, page_content='PD‑L1 status or PTEN/PI3K/AKT alteration status, and \\nmanageable toxicity\\xa0(71). In Phase\\xa0III trial (NCT04177108), \\npatients were enrolled in two cohorts according to PD‑L1 \\nstatus: Cohort 1 for PD‑L1‑negative tumors and cohort 2 for \\nPD‑L1‑positive tumors. Three arms, P + I + A vs. P + I vs. P, \\nwill be evaluated in cohort 1 and 2 arms, P + I + A vs. P + A, \\nwill be evaluated in cohort 2.\\nCDK4/6/Rb/E2F pathway. The G1‑S phase checkpoint of the'),\n",
       " Document(metadata={}, page_content='cell cycle is regulated by CDK4/6 activity which is controlled \\nby their binding partners D‑type cyclins and p16 INK4 inhib\\xad\\nitor. The active CDK4/6‑cyclin D complex phosphorylates the \\nretinoblastoma (Rb) protein, thereby activating E2F function \\nand transition from G1 to S phase of the cell cycle\\xa0(72). The \\nFDA approved CDK4/6 inhibitors palbociclib, ribociclib, and \\nabemaciclib based on improvements in PFS for the treatment'),\n",
       " Document(metadata={}, page_content='of ER+, HER2‑negative advanced or metastatic breast cancer \\nin combination with an endocrine therapy. TNBCs with a Rb+, \\np16 INK4‑negative profile might represent the subpopulation \\nof TNBC suitable for treatment with CDK4/6 inhibitors.\\nPreclinical combination studies of CDK4/6 inhibitors with \\nchemotherapy suggest that the timing and sequence of drug \\nexposure/drug delivery schedule might play a critical role in'),\n",
       " Document(metadata={}, page_content='drug activity, and the evaluation of different schedules of treat\\xad\\nment may represent a new approach\\xa0(73,74). The hypothesis was \\nthat reversible G1 arrest of palbociclib could synchronize tumor \\ncells in the cell cycle and following their re‑entry later would \\nensure a higher fraction in mitosis (M) phase when exposed \\nto paclitaxel. In the first combination trial for palbociclib and \\npaclitaxel (NCT01320592) an alternative dosing schedule was'),\n",
       " Document(metadata={}, page_content='feasible and safe, without evidence of additive toxicity in Rb+ \\nbreast cancer regardless of subtype\\xa0(75). Phase\\xa0I follow‑up \\ntrial (NCT02599363) of ribocilcib and weekly paclitaxel is in \\nprogress in patients with Rb+ advanced breast cancer. In this \\nstudy, pharmacodynamic, histologic, and imaging biomarkers \\nwill be utilized to confirm synchronization and schedule and \\nidentify a patient population that benefits from this treatment \\napproach.'),\n",
       " Document(metadata={}, page_content='approach.\\nThe standard chemotherapy regimen causes treat\\xad\\nment‑limiting cumulative myelosuppression that may \\ncompromise antitumor efficacy in TNBC. CDK4/6 inhibitors \\ninduce transient G1 arrest in immune cells and hematopoietic \\nstem and progenitor cells, potentially helping to preserve \\nT‑cell function and bone marrow. To test this hypothesis, an \\ninvestigational CDK4/6 inhibitor trilaciclib in combination'),\n",
       " Document(metadata={}, page_content='with gemcitabine and carboplatin was explored to evaluate \\nbenefit for patients with ≤2 prior chemotherapy regimens in \\nmetastatic TNBC. Phase\\xa0II trial (NCT02978716) was negative \\nfor a safety‑related primary endpoint (i.e. no difference in the \\nfrequency or duration of severe grade 4 neutropenia). However, \\nthe median OS was improved by more than 60%, which was \\nlikely due to increased chemotherapy duration and exposure.'),\n",
       " Document(metadata={}, page_content='Trilaciclib‑treated patients also had a higher number of acti\\xad\\nvated CD8+ T cells over the first 5\\xa0cycles of chemotherapy, \\nwhich potentially enhanced antitumor immunity\\xa0(76).\\nMYC and CDK. Transcription factor c‑MYC triggers selective \\ngene expression to promote cell growth and proliferation. It is \\namplified in several different cancer types including TNBC, \\nfunctioning as a proto‑oncogene\\xa0(77). c‑MYC compensates for'),\n",
       " Document(metadata={}, page_content='BRCA loss by upregulating HRR through increased RAD51 \\nexpression\\xa0(55,78). TNBC patients with high c‑MYC and \\nRAD51 expression exhibit poor prognosis and less favorable \\nresponse to chemotherapy and PARP inhibitors\\xa0(55,57,79). \\nc‑MYC blockade in TNBC was found to be synthetic lethal \\nwith PARP inhibitors, independent of BRCA status\\xa0(80). \\nc‑MYC pathway activation in TNBC is also synthetic'),\n",
       " Document(metadata={}, page_content='lethal with CDK inhibition\\xa0(81). Dinaciclib is a pan‑CDK \\n(CDK1/2/5/9) inhibitor and the combination with PARP1 \\ninhibitor veliparib is currently being pursued in patients with \\nadvanced solid tumors for which no curative therapy exists \\n(Phase\\xa0I trial, NCT01434316). Dinaciclib induced immuno\\xad\\ngenic cell death (ICD) but also increased expression of PD1 \\non tumor‑infiltrating T cells and expression of PD‑L1 on'),\n",
       " Document(metadata={}, page_content='tumor cells, thus limiting its antitumor effect in preclinical \\nstudies. However, dinaciclib inhibits tumor growth in combi\\xad\\nnation with anti‑PD‑1\\xa0(82). Phase\\xa0Ib trial (NCT01676753) \\nwas designed to evaluate the efficacy of combined dinaciclib \\nand pembrolizumab in patients with metastatic or locally \\nadvanced and unresectable TNBC. Its clinical benefit rate was \\n47% in preliminary efficacy analysis and high c‑MYC expres\\xad'),\n",
       " Document(metadata={}, page_content='sion correlated significantly with clinical response, warranting \\nfurther validation of c‑MYC as a predicative biomarker of \\nresponse to CDK/checkpoint inhibitors\\xa0(83). \\nAR antagonists. The androgen receptor (AR) is an intracellular \\nsteroid receptor that dimerizes and translocates to the nucleus \\nafter binding androgen ligands. In the nucleus, AR binds to \\nandrogen response elements to promote target gene transcrip\\xad'),\n",
       " Document(metadata={}, page_content='tion in a tissue‑specific manner. AR can also be activated \\nin a ligand‑independent manner through crosstalk with key \\nsignaling pathways, including PI3K/AKT and ERK\\xa0(84). AR \\nis involved in cell cycle regulation and the epithelial‑to‑mesen\\xad\\nchymal transition (EMT)\\xa0(85,86). AR has emerged as a new \\nbiomarker and a potential therapeutic target in TNBC. AR is \\nexpressed in ≥40% of TNBCs and its expression level varies'),\n",
       " Document(metadata={}, page_content='considerably among TNBC molecular subtypes. It has been \\nassociated with favorable prognosis, with better DFS and \\nhigher OS in the LAR subtype\\xa0(87,88). However, patients \\nwith AR+ TNBCs have a decreased chance of achieving pCR \\nto neoadjuvant chemotherapy and the LAR subtype has been \\nlinked to poorer response to chemotherapy compared to other \\nTNBC patients\\xa0(89‑91). Multiple selective AR inhibitors have'),\n",
       " Document(metadata={}, page_content='been approved by the FDA for the treatment of prostate cancer \\nand are currently part of standard care\\xa0(92). The role of the AR \\nin signaling pathways in TNBC is still not clear and clinical \\nstudies are underway to provide more insight into the role of \\nthe AR as well as to assess whether AR targeting is a valuable \\ntherapeutic strategy in TNBC.\\nThe first proof‑of‑concept trial of AR‑targeted treatment'),\n",
       " Document(metadata={}, page_content='established activity of the first‑generation AR antagonist \\nbicalutamide in patients with advanced AR+ TNBC. The \\nTBCRC 011 Phase\\xa0II trial (NCT00468715) showed a modest \\nclinical benefit rate (CBR) of 19% at 6\\xa0months and a median \\nPFS duration of 12\\xa0weeks\\xa0(93).\\nAR+ TNBC expresses a luminal profile with intact Rb \\nprotein, the target of CDK4/6 activity. Thus, CDK4/6 inhibi\\xad\\ntors may increase the efficacy of AR antagonists in metastatic'),\n",
       " Document(metadata={}, page_content='AR+ TNBC. The single group Phase\\xa0I/II trial (NCT02605486) \\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1255\\nwas carried out to explore this hypothesis. The combination \\nof palbociclib and bicalutamide was well‑tolerated with no \\nunexpected toxicity\\xa0(94). It also met its prespecified efficacy \\nendpoint as measured by PFS with 11\\xa0patients (31 evaluable \\npatients) at 6\\xa0months\\xa0(95).\\nAs one of the second‑generation anti‑androgen thera\\xad'),\n",
       " Document(metadata={}, page_content='pies, abiraterone is a steroidal CYP17 inhibitor with potent \\nhydroxylase activity, targeting androgen biosynthesis. The \\nFrench Breast Cancer Intergroup (UCBG) 12‑1 Phase\\xa0II trial \\n(NCT01842321) was designed to evaluate abiraterone acetate \\n(AA) with its requisite concomitant medication prednisone \\nin AR+ advanced or metastatic TNBC. Androgen deprivation \\nby AA resulted in 20% of the 6‑month CBR. This treatment'),\n",
       " Document(metadata={}, page_content='appeared to be beneficial for some patients with molecular \\napocrine tumors, a subtype that expresses AR but not ERα\\xa0(96). \\nConsidering that prednisone stimulates the glucocorticoid \\nreceptor (GR), which is expressed in approximately 25% of \\nTNBCs, GR activity might limit the efficacy of AA.\\nSeviteronel is an investigational lyase‑selective \\nnon‑steroidal CYP17 inhibitor that targets androgen and'),\n",
       " Document(metadata={}, page_content='estrogen production. The CLARITY‑01 Phase\\xa0 I/II trial \\n(NCT02580448) was set up to evaluate seviteronel in locally \\nadvanced or metastatic TNBC or ER+ breast cancer. It revealed \\nthat seviteronel was generally well‑tolerated and provided \\nclinical benefit. A total of 26 and 11% of patients reached at \\nleast a CBR at 4 and 6\\xa0months, respectively. Levels of circu\\xad\\nlating tumor cells (CTCs) also decreased\\xa0(97,98).'),\n",
       " Document(metadata={}, page_content='lating tumor cells (CTCs) also decreased\\xa0(97,98).\\nA second‑generation AR antagonist enzalutamide not only \\ncompetitively binds to the AR ligand‑binding domain, but also \\ninhibits nuclear translocation of AR, DNA binding, and coacti\\xad\\nvator recruitment. Phase\\xa0II single arm study (NCT01889238) \\nassessed the efficacy of enzalutamide in patients with locally \\nadvanced or metastatic, AR+ TNBC. The primary endpoint'),\n",
       " Document(metadata={}, page_content='was CBR at 16\\xa0weeks, which was 25% in the intention‑to‑treat \\n(ITT) population and 33% in the evaluable subgroup whose \\ntumors expressed ≥10% nuclear AR. The only treatment‑related \\ngrade 3 or greater AE occurring in ≥2% of patients was \\nfatigue (3.4%)\\xa0(99). The randomized ENDEAR Phase\\xa0III study \\n(NCT02929576) comparing enzalutamide and paclitaxel to \\nplacebo and paclitaxel in advanced TNBC was in place\\xa0(100)'),\n",
       " Document(metadata={}, page_content='but withdrawn in 2018, citing that further understanding about \\nthe role of androgen signaling in TNBC was required. The \\nTBCRC 032 Phase\\xa0Ib/II trial (NCT02457910) investigated the \\nsafety and efficacy of enzalutamide alone or in combination with \\nPI3K inhibitor taselisib in patients with metastatic AR+ TNBC. \\nPrimary endpoint of CBR at 16\\xa0weeks was 36% and median PFS \\nwas 3.4\\xa0months. The trial was not completed due to termination of'),\n",
       " Document(metadata={}, page_content='the development of taselisib. Although this study was exploratory \\ndue to sample size limitation, it revealed subtype‑specific treat\\xad\\nment response (favorable trend for luminal over non‑luminal) and \\nidentified novel Fgfr2 gene fusions that likely activate the PI3K \\npathway and AR splice variants that may contribute to enzalu\\xad\\ntamide resistance. Therefore, an AR IHC score of ≥10% alone'),\n",
       " Document(metadata={}, page_content='may not identify patients with AR‑dependent tumors, and LAR \\nsubtype and AR splice variants may help identify patients likely \\nto benefit from AR antagonists\\xa0(101).\\nCell surface targets\\nTumor‑associated carbohydrate antigens. The Globo H \\nantigen is a hexasaccharyl sphingolipid expressed on the \\nsurface of various cancer types and has been explored as a \\npotential target for vaccine therapy. Adagloxad simolenin (AS)'),\n",
       " Document(metadata={}, page_content='is an immune stimulant comprising the Globo H hexasac\\xad\\ncharide epitope linked to the carrier protein keyhole limpet \\nhemocyanin (KLH). KLH facilitates a more vigorous immune \\nresponse given the weak antigen, Globo H. As a first‑in‑class \\nactive immunotherapy in development for metastatic breast \\ncancer, AS with the saponin‑based adjuvant OBI‑821 induced \\nantibodies reactive with Globo H+ tumor cells that mediate'),\n",
       " Document(metadata={}, page_content='antibody‑dependent cell‑mediated cytotoxicity (ADCC) and \\ncomplement‑dependent cytotoxicity (CDC)\\xa0(102). Phase\\xa0II \\ntrial (NCT01516307) assessed low‑dose cyclophosphamide \\nwith or without active immunotherapy (AS + adjuvant) in \\npost‑treated metastatic breast cancer subjects with stable \\ndisease or response to treatment. Although it did not meet its \\nprimary efficacy endpoint of PFS, patients who developed an'),\n",
       " Document(metadata={}, page_content='immune response to the vaccine showed significantly improved \\nPFS and OS\\xa0(103). Based on these subgroup data, Phase\\xa0III \\nstudy (NCT03562637) of AS with adjuvant vs. placebo treat\\xad\\nment is in progress for high‑risk early‑stage TNBC patients \\nfollowing neoadjuvant or adjuvant chemotherapy. Patients will \\nbe screened for Globo H expression (IHC H‑score ≥15) and \\nthe primary objective is improvement of invasive disease‑free'),\n",
       " Document(metadata={}, page_content='survival (IDFS) in the time frame of 5\\xa0years.\\nAntibody‑drug conjugates (ADCs). An ADC is designed to \\nbe stable in plasma, target a tumor cell surface antigen with \\na high affinity and specificity, and is internalized, cleaved, \\nand releases a payload drug which drives antitumor activity \\nthrough direct cytotoxic cell killing and induces ICD.\\nSacituzumab govitecan‑hziy (SG) targets a glycoprotein,'),\n",
       " Document(metadata={}, page_content='the human trophoblast cell‑surface antigen 2 (TROP‑2), that \\nis expressed in more than 90% of TNBCs. Its payload is the \\nactive metabolite of irinotecan (SN‑38), which is conjugated \\nto the anti‑TROP‑2 antibody by a cleavable linker. Phase\\xa0I/II \\nsingle group study (NCT01631552) included 108\\xa0patients with \\nTNBC and 80% of patients had visceral metastases. The \\nmedian number of prior regimens was 3 (range, 2‑10), which'),\n",
       " Document(metadata={}, page_content='included chemotherapies and checkpoint inhibitors. Although \\nit did not include biomarker selection of patients, 57\\xa0patients \\nhad moderate (2+) to strong (3+) and 5\\xa0patients had weak \\nor absent TROP‑2 expression by IHC according to available \\ndata. The ORR was 33% and the median duration of response \\n(DOR) was 7.7\\xa0months. The median PFS was 5.5\\xa0months and \\nthe median OS was 13.0\\xa0months. Myelotoxic effects were the'),\n",
       " Document(metadata={}, page_content=\"main adverse reactions and grade 3 or 4 AEs included anemia \\nand neutropenia\\xa0(104). The confirmatory ASCENT Phase\\xa0III \\nstudy (NCT02574455) of SG in comparison with treatment \\nof physician's choice for patients with metastatic TNBC \\nwas stopped due to compelling evidence of efficacy across \\nmultiple endpoints and SG was granted accelerated approval \\nby the FDA based on the results of the IMMU‑132‑01 Phase\\xa0II\"),\n",
       " Document(metadata={}, page_content='clinical trial for the treatment of adult patients with metastatic \\nTNBC who have received ≥2 prior therapies for metastatic \\ndisease. It is the first ADC approved by the FDA specifically \\nfor relapsed or refractory metastatic TNBC as well as the first \\nFDA‑approved anti‑TROP‑2 ADC. \\nLadiratuzumab vedotin (LV) targets LIV‑1, which is \\nexpressed in >90% of breast tumors with limited expression'),\n",
       " Document(metadata={}, page_content='in normal tissues. LIV‑1 is a transmembrane protein with \\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1256\\nzinc transporter and metalloproteinase activity. The payload \\nof LV is the microtubule disrupting agent monomethyl \\nauristatin E (MMAE). Phase\\xa0I study (NCT01969643) in \\npatients with heavily pretreated metastatic TNBC showed \\n25% ORR and medium PFS of 11\\xa0weeks. Treatment was'),\n",
       " Document(metadata={}, page_content='generally well‑tolerated and related AEs were neutropenia, \\nanemia, and neuropathy\\xa0(105). LV was further explored \\nin combination studies and in earlier lines of treatment. \\nThe SGNLVA‑002 Phase\\xa0Ib/II trial (NCT03310957) was \\ndesigned to assess whether combining LV and pembroli\\xad\\nzumab results in synergistic activity through LV‑induced \\nICD that creates a microenvironment favorable for'),\n",
       " Document(metadata={}, page_content='enhanced anti‑PD‑L1 activity. It was for first‑line treatment \\nof patients with unresectable locally advanced or metastatic \\nTNBC. Initial dose‑finding studies revealed ORR of 35% \\nwith responses independent of PD‑L1 status and manage\\xad\\nable toxicity\\xa0(106).\\nADC has also been explored for HER2‑low or nega\\xad\\ntive breast cancer. The rationale is based on the bystander \\neffect, that is, the cleaved drug from an ADC may leak from'),\n",
       " Document(metadata={}, page_content='the targeted tumor cell and affect cells in close proximity \\nregardless of their target antigen expression status. Thus, an \\nADC having a high drug‑to‑antibody ratio and high‑potency \\npayload would increase the killing of tumor cells even with \\nlow HER2 expression. Trastuzumab deruxtecan (T‑DXd) \\nis the first HER2‑targeted agent to demonstrate promising \\nclinical antitumor activity with a manageable safety profile'),\n",
       " Document(metadata={}, page_content='in patients considered to be HER2‑negative. T‑DXd delivers \\na potent topoisomerase I inhibitor payload (an exatecan \\nderivative) which is linked to a humanized anti‑HER2 anti\\xad\\nbody. In Phase\\xa0Ib (NCT02564900) trial of T‑DXd for heavily \\npretreated patients with advanced HER2‑low breast cancer, \\nORR was 37% with the median DOR being 10.4\\xa0months. \\nMost toxicities were gastrointestinal or hematologic‑related,'),\n",
       " Document(metadata={}, page_content=\"and interstitial lung disease (ILD) was an important \\nidentified risk\\xa0(107). The DESTINY‑Breast04 Phase\\xa0III \\n(NCT03734029) was initiated to compare the efficacy and \\nsafety of T‑DXd to physician's choice (capecitabine, eribulin, \\ngemcitabine, paclitaxel, or nab‑paclitaxel) in patients \\nwith HER2‑low, unresectable, and/or metastatic breast \\ncancer\\xa0(108).\\n4. New potential therapeutic strategies\"),\n",
       " Document(metadata={}, page_content='4. New potential therapeutic strategies\\nConversion of TNBC: Access to endocrine therapy. Gene \\nexpression analysis and functional studies have revealed a high \\ndegree of plasticity and heterogeneity in luminal and basal‑like \\ntumors. Expression of ERα, FOXA1 or GATA3 can result \\nin transition from basal‑like breast cancer to luminal type \\nwhereas epigenetic reprogramming can result in a reverse tran\\xad'),\n",
       " Document(metadata={}, page_content='sition\\xa0(109‑111). The CDK2‑EZH2 axis in tumors with TNBC \\nphenotype (i.e. basal‑like breast cancer) has been explored for \\nconversion to the ERα+ subtype. Epigenetic enzyme EZH2, a \\nhistone‑lysine N‑methyltransferase that promotes histone H3 \\nlysine 27 mono‑, di‑ and tri‑methylation (H3K27me1/2/3), \\ndrives transcriptional repression\\xa0(112,113). EZH2 can be \\nphosphorylated at T416 (pT416‑EZH2) by cyclin E/CDK2 and'),\n",
       " Document(metadata={}, page_content='>80% of TNBC patient specimens exhibit high pT416‑EZH2 \\nlevels, which correlate with poorer survival\\xa0(114). In preclinical \\nstudies, transgenic expression of a phospho‑mimicking mutant \\nEZH2(T416D) in the mammary glands of mice reprogramed \\nthe committed luminal breast cancer cells into the basal‑like \\nTNBC phenotype. In this setting inhibition of the CDK2‑EZH2 \\naxis by EZH2 inhibitors reactivated ERα expression and thus'),\n",
       " Document(metadata={}, page_content='combination with tamoxifen suppressed tumor growth and \\nimproved the survival of mice bearing tumors with the TNBC \\nphenotype\\xa0(115). Therefore, inhibitors of CDK2 or EZH2 \\ncombined with hormonal therapy may be a novel therapeutic \\nstrategy in TNBC with especially high pT416‑EZH2 levels. \\nAnother mechanism‑based therapy exploits the lack of \\nER expression due to hypermethylation of the ERα promoter.'),\n",
       " Document(metadata={}, page_content='A combination epigenetic therapy of a DNA methyltrans\\xad\\nferase (DNMT) inhibitor and a histone deacetylase (HDAC) \\ninhibitor led to re‑expression of genes including ERα and \\nrestored tamoxifen sensitivity in ER‑negative breast cancer \\nmodels\\xa0(116,117). However, Phase\\xa0II study (NCT01349959) \\nin patients with advanced hormone‑resistant breast cancer \\nor TNBC revealed that combination of DNMT inhibitor'),\n",
       " Document(metadata={}, page_content='5‑azacitidine and HDAC inhibitor entinostat did not induce \\nERα expression and primary endpoint ORR was not met\\xa0(118). \\nERα re‑expression induced by DNMT/HDAC inhibition might \\nbe attenuated by an active CDK2‑EZH2 axis, which affected \\noutcomes in this study.\\nThe conversion of basal‑like breast cancer into ERα+ is \\nalso under microenvironmental control. A paracrine signaling \\nnetwork involving platelet‑derived growth factor (PDGF)‑CC'),\n",
       " Document(metadata={}, page_content='and PDGF receptor‑α accelerated tumor growth through \\nrecruitment and activation of different subsets of cancer‑asso\\xad\\nciated fibroblasts\\xa0(119). In mouse models, impairing PDGF \\nsignaling was found to convert basal‑like breast cancers into \\nERα+, and thus enhanced sensitivity to tamoxifen in previously \\nresistant tumors\\xa0(120). Therefore, PDGF inhibitors combined \\nwith endocrine therapy may be a novel therapeutic strategy in \\nTNBC treatment.'),\n",
       " Document(metadata={}, page_content='TNBC treatment.\\nAdaptive clinical studies: Molecular markers. Under the \\nmaster protocol framework, basket trials, where a targeted \\ntherapy is evaluated for multiple diseases that share common \\nmolecular alterations, and umbrella trials, where multiple \\ntargeted therapies are evaluated for a single disease that is \\nstratified into multiple subgroups based on different molecular \\nfactors, have been developed\\xa0(121). Recently there have been'),\n",
       " Document(metadata={}, page_content='more adaptive, signal‑finding clinical trial designs coupled \\nwith correlative studies to investigate mechanisms of action. \\nThey also facilitate identifying active drug combinations as \\nwell as novel tumor indications. Patients are enrolled based on \\nmolecular markers from genetic profiling performed on their \\ntumors. Some examples are listed below.\\nIn the OLAPCO Phase\\xa0II trial (NCT02576444), PARP'),\n",
       " Document(metadata={}, page_content='In the OLAPCO Phase\\xa0II trial (NCT02576444), PARP \\ninhibitor olaparib was assessed in combination with various \\nagents according to identified tumor mutations. It included \\nAKT inhibitor capivasertib for tumors with mutations in \\nthe PI3K‑AKT pathway, WEE1 inhibitor adavosertib for \\ntumors with tp53 or/and Kras mutations, and ATR inhibitor \\nceralasertib for tumors with mutations in HRR genes. Primary'),\n",
       " Document(metadata={}, page_content='outcome measure was ORR, and the trial also identified \\ngenetic determinants of response and resistance. Another \\nPhase\\xa0II trial (NCT03718091) evaluated ATR inhibitor M6620 \\nin selected solid tumors. Patients were enrolled in different \\ncohorts based on tumor mutation status, including truncating \\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1257\\nAtm mutations, germline Brca mutations, somatic Brca muta\\xad'),\n",
       " Document(metadata={}, page_content='tions or other HRR gene mutations, c‑MYC amplification, \\nFbxw7 mutations, cyclin E amplification, and Arid1a muta\\xad\\ntions. Primary outcome measures included disease control rate \\n(DCR) and changes in pCHK1 and γH2AX levels. The I‑SPY \\n2 Phase\\xa0II trial (NCT01042379) was a neoadjuvant breast \\ncancer trial using response‑adaptive randomization. It had \\nmultiple concurrent experimental arms with shared controls.'),\n",
       " Document(metadata={}, page_content='Each biomarker signature was established at trial entry. A new \\nregimen of combination with standard chemotherapy will be \\nmoved up to Phase\\xa0III trial if it shows a high probability of \\nimproved pCR over standard chemotherapy.\\n5. Conclusion\\nDeveloping novel treatments in both early and advanced \\nTNBC settings remains a significant unmet need. Recent \\nadvances with novel agents have been made for specific'),\n",
       " Document(metadata={}, page_content='subgroups with PD‑L1+ tumors or gBRCAm tumors. However, \\nonly a fraction of those patients respond to immune check\\xad\\npoint or PARP inhibitors, and even those who do respond \\noften develop resistance and relapse. In diverse tumor \\nmicroenvironments, a given therapeutic agent shows vari\\xad\\nable responses, thus compromising the survival endpoints \\nespecially in an unselected TNBC population. Therefore,'),\n",
       " Document(metadata={}, page_content='developing novel predictive biomarkers are crucial for \\nselecting patients that will benefit the most from a given \\ntherapy. Single cell technologies will provide additional \\ninsight on tumor‑stroma interactions and facilitate compel\\xad\\nling rationale for new treatments based on novel biomarkers. \\nA non‑invasive testing of plasma circulating tumor DNA \\n(ctDNA) and CTCs can potentially provide real‑time disease'),\n",
       " Document(metadata={}, page_content='monitoring and even early therapy modification. However, \\ntheir prognostic value needs further evaluation. With recent \\nadvances in multiomic analyses of cancers, there appears to \\nbe genomic and molecular similarities between TNBC and \\nhigh‑grade serous ovarian carcinoma (HGSOC), suggesting \\nthat similar biological mechanisms drive some aspects of \\nboth cancer types. Therefore, treatment strategies for HGSOC'),\n",
       " Document(metadata={}, page_content='can be explored in TNBC as well. The recent increase in the \\nnumber of clinical trials investigating various new agents \\nand combination strategies reflects further efforts to under\\xad\\nstand molecular and immunological aspects of TNBC. This \\nmay lead to more meaningful clinical benefits, including \\nevent‑free and overall survival. \\nAcknowledgements \\nThe authors would like to thank Professor Ian Collins of the'),\n",
       " Document(metadata={}, page_content=\"Institute of Cancer Research, UK for valuable discussions on \\nthe DNA damage response pathways and checkpoint kinases.\\nFunding \\nNo funding was declared.\\nAvailability of data and materials \\nAll information provided in this review is documented with \\nrelevant and current references.\\nAuthors' contributions\\nKAW was responsible for conceptualization, design, interpre\\xad\\ntation and visualization. KAW and CS were responsible for\"),\n",
       " Document(metadata={}, page_content='writing, reviewing and editing. Both authors approved the final \\nmanuscript. \\nEthics approval and consent to participate \\nNot applicable. \\nPatient consent for publication \\nNot applicable. \\nCompeting interests \\nNo competing interests are declared. \\nReferences\\n\\u2002 1.\\tLehmann\\xa0BD, Bauer\\xa0JA, Chen\\xa0X, Sanders\\xa0ME, Chakravarthy\\xa0AB, \\nShyr\\xa0Y and Pietenpol\\xa0JA: Identification of human triple‑negative'),\n",
       " Document(metadata={}, page_content='breast cancer subtypes and preclinical models for selection of \\ntargeted therapies. J\\xa0Clin Invest\\xa0121: 2750‑2767, 2011.\\n\\u2002 2.\\tLehmann\\xa0BD, Jovanović\\xa0B, Chen\\xa0X, Estrada\\xa0MV, Johnson\\xa0KN, \\nShyr\\xa0Y, Moses\\xa0HL, Sanders\\xa0ME and Pietenpol\\xa0JA: Refinement of \\ntriple‑negative breast cancer molecular subtypes: Implications for \\nneoadjuvant chemotherapy selection. PLoS One\\xa011: e0157368, 2016.\\n\\u2002 3.\\tGiuliano\\xa0AE, Connolly\\xa0JL, Edge\\xa0SB, Mittendorf\\xa0EA, Rugo\\xa0HS,'),\n",
       " Document(metadata={}, page_content='Solin\\xa0 LJ, Weaver\\xa0 DL, Winchester\\xa0 DJ and Hortobagyi\\xa0 GN: \\nBreast cancer‑major changes in the American Joint Committee \\non cancer eighth edition cancer staging manual. CA Cancer \\nJ\\xa0Clin\\xa067: 290‑303, 2017.\\n\\u2002 4.\\tWolff\\xa0AC, Hammond\\xa0MEH, Allison\\xa0KH, Harvey\\xa0BE, Mangu\\xa0PB, \\nBartlett\\xa0JMS, Bilous\\xa0M, Ellis\\xa0IO, Fitzgibbons\\xa0P, Hanna\\xa0W,\\xa0et\\xa0al: \\nHuman epidermal growth factor receptor 2 testing in breast'),\n",
       " Document(metadata={}, page_content='cancer: American Society of Clinical Oncology/College of \\nAmerican pathologists clinical practice guideline focused \\nupdate. J\\xa0Clin Oncol\\xa036: 2105‑2122, 2018.\\n\\u2002 5.\\tAllison\\xa0 KH, Hammond\\xa0 MEH, Dowsett\\xa0 M, McKernin\\xa0 SE, \\nCarey\\xa0 LA, Fitzgibbons\\xa0 PL, Hayes\\xa0 DF, Lakhani\\xa0 SR, \\nChavez‑MacGregor\\xa0M, Perlmutter\\xa0J,\\xa0et\\xa0al: Estrogen and proges\\xad\\nterone receptor testing in breast cancer: ASCO/CAP guideline \\nupdate. J\\xa0Clin Oncol\\xa038: 1346‑1366, 2020.'),\n",
       " Document(metadata={}, page_content='update. J\\xa0Clin Oncol\\xa038: 1346‑1366, 2020.\\n\\u2002 6.\\tYam\\xa0C, Mani\\xa0SA and Moulder\\xa0SL: Targeting the molecular \\nsubtypes of triple negative breast cancer: Understanding the \\ndiversity to progress the field. Oncologist\\xa022: 1086‑1093, 2017.\\n\\u2002 7.\\t Bonotto\\xa0M, Gerratana\\xa0L, Poletto\\xa0E, Driol\\xa0P, Giangreco\\xa0M, \\nRusso\\xa0S, Minisini\\xa0AM, Andreetta\\xa0C, Mansutti\\xa0M, Pisa\\xa0FE,\\xa0et\\xa0al: \\nMeasures of outcome in metastatic breast cancer: Insights from a'),\n",
       " Document(metadata={}, page_content=\"real‑world scenario. Oncologist\\xa019: 608‑615, 2014.\\n\\u2002 8.\\tKohler\\xa0BA, Sherman\\xa0RL, Howlader\\xa0N, Jemal\\xa0A, Ryerson\\xa0AB, \\nHenry\\xa0KA, Boscoe\\xa0FP, Cronin\\xa0KA, Lake\\xa0A, Noone\\xa0AM,\\xa0et\\xa0al: \\nAnnual report to the nation on the status of cancer, 1975‑2011, \\nfeaturing incidence of breast cancer subtypes by race/ethnicity, \\npoverty, and state. J\\xa0Natl Cancer Inst\\xa0107: djv048, 2015.\\n\\u2002 9.\\tO'Shaughnessy\\xa0J, Schwartzberg\\xa0L, Danso\\xa0MA, Miller\\xa0 KD,\"),\n",
       " Document(metadata={}, page_content='Rugo\\xa0 HS, Neubauer\\xa0 M, Robert\\xa0 N, Hellerstedt\\xa0 B, Saleh\\xa0 M, \\nRichards\\xa0P,\\xa0et\\xa0al: Phase\\xa0III study of iniparib plus gemcitabine \\nand carboplatin versus gemcitabine and carboplatin in patients \\nwith metastatic triple‑negative breast cancer. J\\xa0Clin Oncol\\xa032: \\n3840‑3847, 2014.\\n10.\\tCaswell‑Jin\\xa0 JL, Plevritis\\xa0 SK, Tian\\xa0 L, Cadham\\xa0 CJ, Xu\\xa0 C, \\nStout\\xa0NK, Sledge\\xa0GW, Mandelblatt\\xa0JS and Kurian\\xa0AW: Change'),\n",
       " Document(metadata={}, page_content='in survival in metastatic breast cancer with treatment advances: \\nMeta‑analysis and systematic review. JNCI Cancer Spectr\\xa02: \\npky062, 2018.\\n11.\\t Plevritis\\xa0 SK, Munoz\\xa0 D, Kurian\\xa0 AW, Stout\\xa0 NK, Alagoz\\xa0 O, \\nNear\\xa0AM, Lee\\xa0SJ, van\\xa0den\\xa0Broek\\xa0JJ, Huang\\xa0X, Schechter\\xa0CB,\\xa0et\\xa0al: \\nAssociation of screening and treatment with breast cancer \\nmortality by molecular subtype in US women, 2000‑2012. \\nJAMA\\xa0319: 154‑164, 2018.'),\n",
       " Document(metadata={}, page_content='JAMA\\xa0319: 154‑164, 2018.\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1258\\n12.\\tStanton\\xa0SE, Adams\\xa0S and Disis\\xa0ML: Variation in the incidence \\nand magnitude of tumor‑infiltrating lymphocytes in breast cancer \\nsubtypes: A systematic review. JAMA Oncol\\xa02: 1354‑1360, 2016. \\n13.\\tSafonov\\xa0A, Jiang\\xa0T, Bianchini\\xa0G, Győrffy\\xa0B, Karn\\xa0T, Hatzis\\xa0C and \\nPusztai\\xa0L: Immune gene expression is associated with genomic'),\n",
       " Document(metadata={}, page_content='aberrations in breast cancer. Cancer Res\\xa077: 3317‑3324, 2017.\\n14.\\t Schmid\\xa0P, Adams\\xa0S, Rugo\\xa0HS, Schneeweiss\\xa0A, Barrios\\xa0CH, \\nIwata\\xa0H, Diéras\\xa0V, Hegg\\xa0R, Im\\xa0SA, Shaw\\xa0Wright\\xa0G,\\xa0et\\xa0al: \\nAtezolizumab and Nab‑Paclitaxel in advanced triple‑negative \\nbreast cancer. N Engl J\\xa0Med\\xa0379: 2108‑2121, 2018. \\n15.\\tSchmid\\xa0P, Rugo\\xa0HS, Adams\\xa0S, Schneeweiss\\xa0A, Barrios\\xa0CH, \\nIwata\\xa0H, Diéras\\xa0V, Henschel\\xa0V, Molinero\\xa0L, Chui\\xa0SY,\\xa0et\\xa0al:'),\n",
       " Document(metadata={}, page_content='Atezolizumab plus nab‑paclitaxel as first‑line treatment for \\nunresectable, locally advanced or metastatic triple‑negative \\nbreast cancer (IMpassion130): Updated efficacy results from a \\nrandomised, double‑blind, placebo‑controlled, phase 3 trial. \\nLancet Oncol\\xa021: 44‑59, 2020. \\n16.\\tDudley\\xa0JC, Lin\\xa0MT, Le\\xa0DT and Eshleman\\xa0JR: Microsatellite \\ninstability as a biomarker for PD‑1 blockade. Clin Cancer Res\\xa022: \\n813‑820, 2016.'),\n",
       " Document(metadata={}, page_content='813‑820, 2016.\\n17.\\t Bonneville\\xa0 R, Krook\\xa0 MA, Kautto\\xa0 EA, Miya\\xa0 J, Wing\\xa0 MR, \\nChen\\xa0HZ, Reeser\\xa0JW, Yu\\xa0L and Roychowdhury\\xa0S: Landscape \\nof microsatellite instability across 39 cancer types. JCO Precis \\nOncol\\xa02017: PO.17.00073, 2017.\\n18.\\tKurata\\xa0K, Kubo\\xa0M, Mori\\xa0H, Kawaji\\xa0H, Motoyama\\xa0Y, Kuroki\\xa0L, \\nYamada\\xa0M, Kaneshiro\\xa0K, Kai\\xa0M and Nakamura\\xa0M: Microsatellite \\ninstability in triple negative breast cancers. In: Proceedings of'),\n",
       " Document(metadata={}, page_content='the 2018 San Antonio Breast Cancer Symposium. Cancer Res\\xa079 \\n(Suppl\\xa04): Abstract nr P1-06-11. 2019.\\n19.\\t Bryant\\xa0HE, Schultz\\xa0N, Thomas\\xa0HD, Parker\\xa0KM, Flower\\xa0D, \\nLopez\\xa0 E, Kyle\\xa0 S, Meuth\\xa0 M, Curtin\\xa0 NJ and Helleday\\xa0 T: \\nSpecific killing of BRCA2‑deficient tumours with inhibitors of \\npoly(ADP‑ribose) polymerase. Nature\\xa0434: 913‑917, 2005.\\n20.\\tFarmer\\xa0 H, McCabe\\xa0 N, Lord\\xa0 CJ, Tutt\\xa0 AN, Johnson\\xa0 DA,'),\n",
       " Document(metadata={}, page_content='Richardson\\xa0 TB, Santarosa\\xa0 M, Dillon\\xa0 KJ, Hickson\\xa0 I, \\nKnights\\xa0C,\\xa0et\\xa0al: Targeting the DNA repair defect in BRCA \\nmutant cells as a therapeutic strategy. Nature\\xa0434: 917‑921, 2005.\\n21.\\t Robson\\xa0M, Im\\xa0SA, Senkus\\xa0E, Xu\\xa0B, Domchek\\xa0SM, Masuda\\xa0N, \\nDelaloge\\xa0S, Li\\xa0W, Tung\\xa0N, Armstrong\\xa0A,\\xa0et\\xa0al: Olaparib for meta\\xad\\nstatic breast cancer in patients with a germline BRCA mutation. \\nN Engl J\\xa0Med\\xa0377: 523‑533, 2017.'),\n",
       " Document(metadata={}, page_content=\"N Engl J\\xa0Med\\xa0377: 523‑533, 2017. \\n22.\\tRobson\\xa0ME, Tung\\xa0N, Conte\\xa0P, Im\\xa0SA, Senkus\\xa0E, Xu\\xa0B, Masuda\\xa0N, \\nDelaloge\\xa0S, Li\\xa0W, Armstrong\\xa0A,\\xa0et\\xa0al: OlympiAD final overall \\nsurvival and tolerability results: Olaparib versus chemotherapy \\ntreatment of physician's choice in patients with a germline BRCA \\nmutation and HER2‑negative metastatic breast cancer. Ann \\nOncol\\xa030: 558‑566, 2019. \\n23.\\tLitton\\xa0JK, Rugo\\xa0HS, Ettl\\xa0J, Hurvitz\\xa0SA, Gonçalves\\xa0A, Lee\\xa0KH,\"),\n",
       " Document(metadata={}, page_content='Fehrenbacher\\xa0L, Yerushalmi\\xa0R, Mina\\xa0LA, Martin\\xa0M,\\xa0et\\xa0al: \\nTalazoparib in patients with advanced breast cancer and a germ\\xad\\nline BRCA mutation. N Engl J\\xa0Med\\xa0379: 753‑763, 2018. \\n24.\\tDenkert\\xa0C, von\\xa0Minckwitz\\xa0G, Darb‑Esfahani\\xa0S, Lederer\\xa0B, \\nHeppner\\xa0BI, Weber\\xa0KE, Budczies\\xa0J, Huober\\xa0J, Klauschen\\xa0F, \\nFurlanetto\\xa0J,\\xa0et\\xa0al: Tumour‑infiltrating lymphocytes and prog\\xad\\nnosis in different subtypes of breast cancer: A pooled analysis of'),\n",
       " Document(metadata={}, page_content='3771\\xa0patients treated with neoadjuvant therapy. Lancet Oncol\\xa019: \\n40‑50, 2018. \\n25.\\tHida\\xa0AI, Watanabe\\xa0T, Sagara\\xa0Y, Kashiwaba\\xa0M, Sagara\\xa0Y, Aogi\\xa0K, \\nOhi\\xa0Y and Tanimoto\\xa0A: Diffuse distribution of tumor‑infiltrating \\nlymphocytes is a marker for better prognosis and chemo\\xad\\ntherapeutic effect in triple‑negative breast cancer. Breast Cancer \\nRes\\xa0Treat 178: 283‑294, 2019. \\n26.\\tLoi\\xa0 S, Drubay\\xa0 D, Adams\\xa0 S, Pruneri\\xa0 G, Francis\\xa0 PA,'),\n",
       " Document(metadata={}, page_content='Lacroix‑Triki\\xa0M, Joensuu\\xa0H, Dieci\\xa0MV, Badve\\xa0S, Demaria\\xa0S,\\xa0et\\xa0al: \\nTumor‑infiltrating lymphocytes and prognosis: A pooled \\nindividual patient analysis of early‑stage triple‑negative breast \\ncancers. J\\xa0Clin Oncol\\xa037: 559‑569, 2019. \\n27.\\t Galon\\xa0J and Bruni\\xa0D: Approaches to treat immune hot, altered \\nand cold tumours with combination immunotherapies. Nat Rev \\nDrug Discov\\xa018: 197‑218, 2019.'),\n",
       " Document(metadata={}, page_content='Drug Discov\\xa018: 197‑218, 2019. \\n28.\\tAdams\\xa0S, Gatti‑Mays\\xa0ME, Kalinsky\\xa0K, Korde\\xa0LA, Sharon\\xa0E, \\nAmiri‑Kordestani\\xa0 L, Bear\\xa0 H, McArthur\\xa0 HL, Frank\\xa0 E, \\nPerlmutter\\xa0J,\\xa0et\\xa0al: Current landscape of immunotherapy in breast \\ncancer: A review. JAMA Oncol: Apr 11, 2019 (Epub ahead of print).\\n29.\\tSchmid\\xa0P, Salgado\\xa0R, Park\\xa0YH, Muñoz‑Couselo\\xa0E, Kim\\xa0SB, \\nSohn\\xa0 J, Im\\xa0 S‑A, Foukakis\\xa0 T, Kuemmel\\xa0 S, Dent\\xa0 R,\\xa0 et\\xa0 al:'),\n",
       " Document(metadata={}, page_content='Pembrolizumab plus chemotherapy as neoadjuvant treatment of \\nhigh‑risk, early‑stage triple‑negative breast cancer: Results from \\nthe phase 1b open‑label, multicohort KEYNOTE‑173 study. Ann \\nOncol\\xa031: 569‑581, 2020. \\n30.\\tNanda\\xa0R, Liu\\xa0MC, Yau\\xa0C, Shatsky\\xa0R, Pusztai\\xa0L, Wallace\\xa0A, \\nChien\\xa0AJ, Forero‑Torres\\xa0A, Ellis\\xa0E, Han\\xa0H,\\xa0et\\xa0al: Effect of \\npembrolizumab plus neoadjuvant chemotherapy on Pathologic'),\n",
       " Document(metadata={}, page_content='complete response in women with early‑stage breast cancer: An \\nanalysis of the ongoing phase 2 adaptively randomized I‑SPY2 \\ntrial. JAMA Oncol\\xa06: 1‑9, 2020.\\n31.\\t Schmid\\xa0P, Cortes\\xa0J, Pusztai\\xa0L, McArthur\\xa0H, Kümmel\\xa0S, Bergh\\xa0J, \\nDenkert\\xa0C, Park\\xa0YH, Hui\\xa0R, Harbeck\\xa0N,\\xa0et\\xa0al: Pembrolizumab for \\nearly triple‑negative breast cancer. N Engl J\\xa0Med\\xa0382: 810‑821, \\n2020. \\n32.\\tGianni\\xa0L, Huang\\xa0CS, Egle\\xa0D, Bermejo\\xa0B, Zamagni\\xa0C, Thill\\xa0M,'),\n",
       " Document(metadata={}, page_content='Anton\\xa0A, Zambelli\\xa0S, Bianchini\\xa0G, Russo\\xa0S and Ciruelos\\xa0E: \\nPathologic complete response (pCR) to neoadjvaunt treat\\xad\\nment with or without atezolizumab in triple negative, early \\nhigh‑risk and locally advanced breast cancer. NeoTRIPaPDL1 \\nMichelangelo randomized study. In: Proceedings of the 2019 San \\nAntonio Breast Cancer Symposium. Cancer Res 80 (Suppl\\xa04): \\nAbstract nr GS3-04, 2020.'),\n",
       " Document(metadata={}, page_content='Abstract nr GS3-04, 2020. \\n33.\\tMittendorf\\xa0E, Barrios\\xa0CH, Harbeck\\xa0N, Miles\\xa0D, Saji\\xa0S, Zhang\\xa0H, \\nDuc\\xa0AN, Rafii\\xa0S and Lai\\xa0C: IMpassion031: A phase\\xa0III study \\ncomparing neoadjuvant atezolizumab vs placebo in combination \\nwith nab‑paclitaxel‑based chemotherapy in early triple‑negative \\nbreast cancer (TNBC). In: Proceedings of the 2017 San Antonio \\nBreast Cancer Symposium. Cancer Res\\xa078 (Suppl\\xa04): Abstract nr \\nOT2-07-03, 2018.'),\n",
       " Document(metadata={}, page_content='OT2-07-03, 2018.\\n34.\\tCortes\\xa0J, Cescon\\xa0DW, Rugo\\xa0HS, Nowecki\\xa0Z, Im\\xa0SA, Yusof\\xa0MM, \\nGallardo\\xa0 C, Lipatov\\xa0 O, Barrios\\xa0 CH, Holgado\\xa0 E,\\xa0 et\\xa0 al: \\nKEYNOTE‑355: Randomized, double‑blind, phase\\xa0III study of \\npembrolizumab + chemotherapy versus placebo + chemotherapy \\nfor previously untreated locally recurrent inoperable or meta\\xad\\nstatic triple‑negative breast cancer. J\\xa0Clin Oncol\\xa038: (Suppl\\xa015): \\nS1000‑S1000, 2020.'),\n",
       " Document(metadata={}, page_content='S1000‑S1000, 2020.\\n35.\\tVoorwerk\\xa0 L, Slagter\\xa0 M, Horlings\\xa0 HM, Sikorska\\xa0 K, \\nvan\\xa0de\\xa0Vijver\\xa0KK, de\\xa0Maaker\\xa0M, Nederlof\\xa0I, Kluin\\xa0RJC, \\nWarren\\xa0S, Ong\\xa0S,\\xa0et\\xa0al: Immune induction strategies in meta\\xad\\nstatic triple‑negative breast cancer to enhance the sensitivity \\nto PD‑1 blockade: The TONIC trial. Nat Med\\xa025: 920‑928, \\n2019. \\n36.\\tAllard\\xa0B, Longhi\\xa0MS, Robson\\xa0SC and Stagg\\xa0J: The ectonucleo\\xad\\ntidases CD39 and CD73: Novel checkpoint inhibitor targets.'),\n",
       " Document(metadata={}, page_content='Immunol Rev\\xa0276: 121‑144, 2017. \\n37.\\t Ghalamfarsa\\xa0G, Kazemi\\xa0MH, Raoofi\\xa0Mohseni\\xa0S, Masjedi\\xa0A, \\nHojjat‑Farsangi\\xa0M, Azizi\\xa0G, Yousefi\\xa0M and Jadidi‑Niaragh\\xa0F: \\nCD73 as a potential opportunity for cancer immunotherapy. \\nExpert Opin Ther Targets\\xa023: 127‑142, 2019.\\n38.\\tDuhant\\xa0X, Schandené\\xa0L, Bruyns\\xa0C, Gonzalez\\xa0NS, Goldman\\xa0M, \\nBoeynaems\\xa0JM and Communi\\xa0D: Extracellular adenine nucleo\\xad\\ntides inhibit the activation of human CD4+ T lymphocytes.'),\n",
       " Document(metadata={}, page_content='J\\xa0Immunol\\xa0169: 15‑21, 2002. \\n39.\\t Allard\\xa0B, Beavis\\xa0PA, Darcy\\xa0PK and Stagg\\xa0J: Immunosuppressive \\nactivities of adenosine in cancer. Curr Opin Pharmacol\\xa029: 7‑16, \\n2016. \\n40.\\tOhta\\xa0A: A metabolic immune checkpoint: Adenosine in tumor \\nmicroenvironment. Front Immunol\\xa07: 109, 2016. \\n41.\\t Buisseret\\xa0L, Pommey\\xa0S, Allard\\xa0B, Garaud\\xa0S, Bergeron\\xa0 M, \\nCousineau\\xa0I, Ameye\\xa0L, Bareche\\xa0Y, Paesmans\\xa0M, Crown\\xa0JPA,\\xa0et\\xa0al:'),\n",
       " Document(metadata={}, page_content='Clinical significance of CD73 in triple‑negative breast cancer: \\nMultiplex analysis of a phase\\xa0III clinical trial. Ann Oncol\\xa029: \\n1056‑1062, 2018. \\n42.\\tPowderly\\xa0J, Spira\\xa0A, Gutierrez\\xa0R, DiRenzo\\xa0D, Udyavar\\xa0A, \\nKarakunnel\\xa0JJ, Rieger\\xa0A, Colabella\\xa0J, Lai\\xa0DW and de\\xa0Souza\\xa0P: \\nPhase\\xa01 evaluation of AB928, a novel dual adenosine receptor \\nantagonist, combined with chemotherapy or AB122 (anti‑PD‑1)'),\n",
       " Document(metadata={}, page_content='in patients with advanced malignancies. Ann Oncol\\xa030 (Suppl\\xa05): \\nv475‑v532, 2019.\\n43.\\tHartman\\xa0 AR, Kaldate\\xa0 RR, Sailer\\xa0 LM, Painter\\xa0 L, \\nGrier\\xa0CE, Endsley\\xa0RR, Griffin\\xa0M, Hamilton\\xa0SA, Frye\\xa0CA, \\nSilberman\\xa0 MA,\\xa0 et\\xa0 al: Prevalence of BRCA mutations in \\nan unselected population of triple‑negative breast cancer. \\nCancer\\xa0118: 2787‑2795, 2012. \\n44.\\tOkuma\\xa0 HS and Yonemori\\xa0 K: BRCA gene mutations and'),\n",
       " Document(metadata={}, page_content='poly(ADP‑Ribose) polymerase inhibitors in triple‑negative \\nbreast cancer. Adv Exp Med Biol\\xa01026: 271‑286, 2017. \\n45.\\tLord\\xa0 CJ and Ashworth\\xa0 A: BRCAness revisited. Nat Rev \\nCancer\\xa016: 110‑120, 2016.\\n46.\\tLitton\\xa0JK, Scoggins\\xa0ME, Hess\\xa0KR, Adrada\\xa0BE, Murthy\\xa0RK, \\nDamodaran\\xa0S, DeSnyder\\xa0SM, Brewster\\xa0AM, Barcenas\\xa0CH, \\nValero\\xa0V,\\xa0et\\xa0al: Neoadjuvant talazoparib for patients with oper\\xad\\nable breast cancer with a germline BRCA pathogenic variant.'),\n",
       " Document(metadata={}, page_content=\"J\\xa0Clin Oncol\\xa038: 388‑394, 2020. \\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1259\\n47.\\t Loibl\\xa0S, O'Shaughnessy\\xa0J, Untch\\xa0M, Sikov\\xa0WM, Rugo\\xa0HS, \\nMcKee\\xa0 MD, Huober\\xa0 J, Golshan\\xa0 M, von\\xa0 Minckwitz\\xa0 G, \\nMaag\\xa0D,\\xa0et\\xa0al: Addition of the PARP inhibitor veliparib plus \\ncarboplatin or carboplatin alone to standard neoadjuvant \\nchemotherapy in triple‑negative breast cancer (BrighTNess): A\"),\n",
       " Document(metadata={}, page_content='randomised, phase\\xa03 trial. Lancet Oncol\\xa019: 497‑509, 2018. \\n48.\\tJiao\\xa0S, Xia\\xa0W, Yamaguchi\\xa0H, Wei\\xa0Y, Chen\\xa0MK, Hsu\\xa0JM, Hsu\\xa0JL, \\nYu\\xa0WH, Du\\xa0Y, Lee\\xa0HH,\\xa0et\\xa0al: PARP inhibitor upregulates PD‑L1 \\nexpression and enhances cancer‑associated immunosuppression. \\nClin Cancer Res\\xa023: 3711‑3720, 2017. \\n49.\\tVinayak\\xa0S, Tolaney\\xa0SM, Schwartzberg\\xa0L, Mita\\xa0M, McCann\\xa0G, \\nTan\\xa0 AR, Wahner‑Hendrickson\\xa0 AE, Forero\\xa0 A, Anders\\xa0 C,'),\n",
       " Document(metadata={}, page_content='Wulf\\xa0 GM,\\xa0 et\\xa0 al: Open‑label clinical trial of niraparib \\ncombined with pembrolizumab for treatment of advanced \\nor metastatic triple‑negative breast cancer. JAMA Oncol\\xa05: \\n1132‑1140, 2019. \\n50.\\tDomchek\\xa0S, Postel‑Vinay\\xa0S, Im\\xa0S, Park\\xa0YH, Delord\\xa0J, Italiano\\xa0A, \\nAlexandre\\xa0J, You\\xa0B, Bastian\\xa0S, Krebs\\xa0MG,\\xa0et\\xa0al: Phase II study \\nof olaparib (o) and durvalumab (d) (MEDIOLA): Updated results \\nin patients (pts) with germline BRCA‑mutated (gBRCAm) meta\\xad'),\n",
       " Document(metadata={}, page_content='static breast cancer (mbc). Ann Oncol\\xa030 (Suppl\\xa05): v475‑v532, \\n2019.\\n51.\\t Pusztai\\xa0L, Han\\xa0HS, Yau\\xa0C, Wolf\\xa0D, Wallace\\xa0AM, Shatsky\\xa0R, \\nHelsten\\xa0T, Boughey JC, Haddad T, Stringer‑Reasor E,\\xa0et\\xa0al: \\nDurvalumab in combination with olaparib and paclitaxel in \\nhigh‑risk HER2 negative stage\\xa0II/III breast cancer: Results from \\nthe I‑SPY 2 trial. In: Proceedings of the Annual Meeting of the \\nAmerican Association for Cancer Research 2020. Cancer Res\\xa080'),\n",
       " Document(metadata={}, page_content='(Suppl\\xa016): Abstract nr CT011, 2020.\\n52.\\tMitri\\xa0 ZI, Vuky\\xa0 J, Kemmer\\xa0 KA, Savin\\xa0 MA, Parmar\\xa0 S, \\nKolodzie\\xa0 AK, Johnson\\xa0 B, Williams‑Belizaire\\xa0 R, Gray\\xa0 JW \\nand Mills\\xa0GB: A phase\\xa0II trial of olaparib and durvalumab in \\nmetastatic BRCA wild type triple‑negative breast cancer. J\\xa0Clin \\nOncol\\xa037: TPS1111, 2019. \\n53.\\t Rugo\\xa0HS, Llombart‑Cussac\\xa0A, Andre\\xa0F, Robson\\xa0ME, Saji\\xa0S, \\nHarbeck\\xa0N, Schmid\\xa0P, Cescon\\xa0DW, Ahn\\xa0JS, Nanda\\xa0R,\\xa0et\\xa0al:'),\n",
       " Document(metadata={}, page_content='KEYLYNK‑009: A phase II/III, open‑label, randomized study \\nof pembrolizumab (pembro) plus olaparib vs pembro plus \\nchemotherapy after induction with first‑line pembro plus chemo\\xad\\ntherapy in patients with locally recurrent inoperable or metastatic \\ntriple‑negative breast cancer (TNBC). J\\xa0Clin Oncol\\xa038: TPS596, \\n2020.\\n54.\\tMaacke\\xa0 H, Opitz\\xa0 S, Jost\\xa0 K, Hamdorf\\xa0 W, Henning\\xa0 W, \\nKrüger\\xa0S, Feller\\xa0AC, Lopens\\xa0A, Diedrich\\xa0K, Schwinger\\xa0E and'),\n",
       " Document(metadata={}, page_content='Stürzbecher\\xa0HW: Over‑expression of wild‑type Rad51 correlates \\nwith histological grading of invasive ductal breast cancer. Int \\nJ\\xa0Cancer\\xa088: 907‑913, 2000.\\n55.\\t Martin\\xa0RW, Orelli\\xa0BJ, Yamazoe\\xa0M, Minn\\xa0AJ, Takeda\\xa0S and \\nBishop\\xa0DK: RAD51 up‑regulation bypasses BRCA1 function \\nand is a common feature of BRCA1‑deficient breast tumors. \\nCancer Res\\xa067: 9658‑9665, 2007.\\n56.\\tWiegmans\\xa0AP, Yap\\xa0PY, Ward\\xa0A, Lim\\xa0YC and Khanna\\xa0KK:'),\n",
       " Document(metadata={}, page_content='Differences in expression of key DNA damage repair genes after \\nepigenetic‑induced BRCAness dictate synthetic lethality with \\nPARP1 inhibition. Mol Cancer Ther\\xa014: 2321‑2331, 2015.\\n57.\\t Liu\\xa0Y, Burness\\xa0ML, Martin‑Trevino\\xa0R, Guy\\xa0J, Bai\\xa0S, Harouaka\\xa0R, \\nBrooks\\xa0MD, Shang\\xa0L, Fox\\xa0A, Luther\\xa0TK,\\xa0et\\xa0al: RAD51 mediates \\nresistance of cancer stem cells to PARP inhibition in triple‑nega\\xad\\ntive breast cancer. Clin Cancer Res\\xa023: 514‑522, 2017.'),\n",
       " Document(metadata={}, page_content='58.\\tMarzio\\xa0A, Puccini\\xa0J, Kwon\\xa0Y, Maverakis\\xa0NK, Arbini\\xa0A, Sung\\xa0P, \\nBar‑Sagi\\xa0 D and Pagano\\xa0 M: The F‑Box domain‑dependent \\nactivity of EMI1 regulates PARPi sensitivity in triple‑negative \\nbreast cancers. Mol Cell\\xa073: 224‑237.e6, 2019. \\n59.\\t Tutt\\xa0A, Stephens\\xa0C, Frewer\\xa0P, Pierce\\xa0A, Rhee\\xa0J, So\\xa0K, Ottesen\\xa0L, \\nDean\\xa0E and Hollingsworth\\xa0SJ: VIOLETTE: A randomized phase \\nII study to assess DNA damage response inhibitors in combina\\xad'),\n",
       " Document(metadata={}, page_content='tion with olaparib (Ola) vs. Ola monotherapy in patients (pts) with \\nmetastatic, triple‑negative breast cancer (TNBC) stratified by \\nalterations in homologous recombination repair (HRR)‑related \\ngenes. J\\xa0Clin Oncol\\xa036 (Suppl\\xa015): TPS1112, 2018. \\n60.\\tHirai\\xa0H, Arai\\xa0T, Okada\\xa0M, Nishibata\\xa0T, Kobayashi\\xa0M, Sakai\\xa0N, \\nImagaki\\xa0K, Ohtani\\xa0J, Sakai\\xa0T, Yoshizumi\\xa0T,\\xa0et\\xa0al: MK‑1775, a \\nsmall molecule Wee1 inhibitor, enhances anti‑tumor efficacy of'),\n",
       " Document(metadata={}, page_content='various DNA‑damaging agents, including 5‑fluorouracil. Cancer \\nBiol Ther\\xa09: 514‑522, 2010.\\n61.\\t Pitts\\xa0 TM, Simmons\\xa0 DM, Bagby\\xa0 SM, Hartman\\xa0 SJ, \\nYacob\\xa0BW, Gittleman\\xa0B, Tentler\\xa0JJ, Cittelly\\xa0D, Ormond\\xa0DR, \\nMessersmith\\xa0WA,\\xa0et\\xa0al: Wee1 inhibition enhances the anti‑tumor \\neffects of capecitabine in preclinical models of triple‑negative \\nbreast cancer. Cancers (Basel)\\xa012: 719, 2020.'),\n",
       " Document(metadata={}, page_content='breast cancer. Cancers (Basel)\\xa012: 719, 2020. \\n62.\\t Do\\xa0K, Wilsker\\xa0D, Ji\\xa0J, Zlott\\xa0J, Freshwater\\xa0T, Kinders\\xa0RJ, Collins\\xa0J, \\nChen\\xa0AP, Doroshow\\xa0JH and Kummar\\xa0S: Phase I study of single‑agent \\nAZD1775 (MK‑1775), a Wee1 kinase inhibitor, in patients with \\nrefractory solid tumors. J\\xa0Clin Oncol\\xa033: 3409‑3415, 2015.\\n63.\\tDo\\xa0 KT, Hill\\xa0 SJ, Kochupurakkal\\xa0 B, Supko\\xa0 JG, Gannon\\xa0 C, \\nAnderson\\xa0 A, Muzikansky\\xa0 A, Wolanski\\xa0 A, Hedglin\\xa0 J,'),\n",
       " Document(metadata={}, page_content='Parmar\\xa0K,\\xa0et\\xa0al: Abstract CT232: Phase I combination study \\nof the CHK1 inhibitor prexasertib (LY2606368) and olaparib \\nin patients with high‑grade serous ovarian cancer and other \\nadvanced solid tumors. In: Proceedings of the American \\nAssociation for Cancer Research Annual Meeting 2019. Cancer \\nRes\\xa079 (Suppl\\xa013): Abstract nr CT232, 2019. \\n64.\\tPeng\\xa0W, Chen\\xa0JQ, Liu\\xa0C, Malu\\xa0S, Creasy\\xa0C, Tetzlaff\\xa0MT, Xu\\xa0C,'),\n",
       " Document(metadata={}, page_content='McKenzie\\xa0JA, Zhang\\xa0C, Liang\\xa0X,\\xa0et\\xa0al: Loss of PTEN promotes \\nresistance to T cell‑mediated immunotherapy. Cancer Discov\\xa06: \\n202‑216, 2016.\\n65.\\tAndré\\xa0 F, Ciruelos\\xa0 E, Rubovszky\\xa0 G, Campone\\xa0 M, Loibl\\xa0 S, \\nRugo\\xa0HS, Iwata\\xa0H, Conte\\xa0P, Mayer\\xa0IA, Kaufman\\xa0B,\\xa0et\\xa0al: Alpelisib \\nfor PIK3CA‑mutated, hormone receptor‑positive advanced breast \\ncancer. N Engl J\\xa0Med\\xa0380: 1929‑1940, 2019. \\n66.\\tKim\\xa0SB, Dent\\xa0R, Im\\xa0SA, Espié\\xa0M, Blau\\xa0S, Tan\\xa0AR, Isakoff\\xa0SJ,'),\n",
       " Document(metadata={}, page_content='Oliveira\\xa0M, Saura\\xa0C, Wongchenko\\xa0MJ,\\xa0et\\xa0al: Ipatasertib plus \\npaclitaxel versus placebo plus paclitaxel as first‑line therapy for \\nmetastatic triple‑negative breast cancer (LOTUS): A multicentre, \\nrandomised, double‑blind, placebo‑controlled, phase 2 trial. \\nLancet Oncol\\xa018: 1360‑1372, 2017.\\n67.\\t Dent\\xa0R, Im\\xa0SA, Espie\\xa0M, Blau\\xa0S, Tan\\xa0AR, Isakoff\\xa0SJ, Oliveira\\xa0M, \\nSaura\\xa0C, Wongchenko\\xa0M, Kapp\\xa0AV,\\xa0et\\xa0al: Overall survival (OS)'),\n",
       " Document(metadata={}, page_content=\"update of the double‑blind placebo (PBO)‑controlled random\\xad\\nized phase 2 LOTUS trial of first‑line ipatasertib (IPAT) + \\npaclitaxel (PAC) for locally advanced/metastatic triple‑negative \\nbreast cancer (mTNBC). J\\xa0Clin Oncol\\xa036: 1008, 2018.\\n68.\\tDent\\xa0 R, Kim\\xa0 SB, Oliveira\\xa0 M, Isakoff\\xa0 SJ, Barrios\\xa0 CH, \\nO'Shaughnessy\\xa0 J, Lu\\xa0 X, Wongchenko\\xa0 M, Bradley\\xa0 D, \\nMani\\xa0 A,\\xa0 et\\xa0 al: IPATunity130: A pivotal randomized phase\"),\n",
       " Document(metadata={}, page_content='III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for \\nPIK3CA/AKT1/PTEN‑altered advanced triple‑negative (TN) or \\nhormone receptor‑positive HER2‑negative (HR+/HER2‑) breast \\ncancer (BC). J\\xa0Clin Oncol\\xa036 (Suppl 15): TPS1117, 2018.\\n69.\\tSchmid\\xa0 P, Abraham\\xa0 J, Chan\\xa0 S, Wheatley\\xa0 D, Brunt\\xa0 AM, \\nNemsadze\\xa0G, Baird\\xa0RD, Park\\xa0YH, Hall\\xa0PS, Perren\\xa0T,\\xa0et\\xa0al: \\nCapivasertib plus paclitaxel versus placebo plus paclitaxel as'),\n",
       " Document(metadata={}, page_content='first‑line therapy for metastatic triple‑negative breast cancer: The \\nPAKT trial. J\\xa0Clin Oncol\\xa038: 423‑433, 2020. \\n70.\\tSchmid\\xa0P, Cortes\\xa0J, Robson\\xa0M, Iwata\\xa0H, Hegg\\xa0R, Verma\\xa0S, \\nNechaeva\\xa0M, Xu\\xa0B, Haddad\\xa0V, Imedio\\xa0RE,\\xa0et\\xa0al: Abstract \\nOT2‑08‑02: Capivasertib and paclitaxel in first‑line treatment of \\npatients with metastatic triple‑negative breast cancer: A phase III \\ntrial (CAPItello‑290). In: Proceedings of the 2019 San Antonio'),\n",
       " Document(metadata={}, page_content='Breast Cancer Symposium. Cancer Res\\xa080 (Suppl\\xa04): Abstract \\nnr\\xa0OT2-08-02, 2020. \\n71.\\tSchmid\\xa0P, Loirat\\xa0D, Savas\\xa0P, Espinosa\\xa0E, Boni\\xa0V, Italiano\\xa0A, \\nWhite\\xa0S, Singel\\xa0MS, Withana\\xa0N, Mani\\xa0A,\\xa0et\\xa0al: Phase Ib study \\nevaluating a triplet combination of ipatasertib (IPAT), atezoli\\xad\\nzumab (atezo), and paclitaxel (PAC) or nab‑PAC as first‑line \\n(1L) therapy for locally advanced/metastatic triple‑negative'),\n",
       " Document(metadata={}, page_content='breast cancer (TNBC). In: Proceedings of the American \\nAssociation for Cancer Research Annual Meeting 2019. \\nCancer Res\\xa079 (Suppl\\xa013): Abstract nr CT049, 2019. \\n72.\\tHanahan\\xa0D and Weinberg\\xa0RA: Hallmarks of cancer: The next \\ngeneration. Cell\\xa0144: 646‑674, 2011.\\n73.\\tDean\\xa0JL, McClendon\\xa0AK and Knudsen\\xa0ES: Modification of the \\nDNA damage response by therapeutic CDK4/6 inhibition. J\\xa0Biol \\nChem\\xa0287: 29075‑29087, 2012.'),\n",
       " Document(metadata={}, page_content='Chem\\xa0287: 29075‑29087, 2012.\\n74.\\t Cretella\\xa0D, Fumarola\\xa0C, Bonelli\\xa0M, Alfieri\\xa0R, La\\xa0Monica\\xa0S, \\nDigiacomo\\xa0G, Cavazzoni\\xa0A, Galetti\\xa0M, Generali\\xa0D and Petronini\\xa0PG: \\nPre‑treatment with the CDK4/6 inhibitor palbociclib improves the \\nefficacy of paclitaxel in TNBC cells. Sci Rep\\xa09: 13014, 2019. \\n75.\\t Clark\\xa0AS, McAndrew\\xa0NP, Troxel\\xa0A, Feldman\\xa0M, Lal\\xa0P, Rosen\\xa0M, \\nBurrell\\xa0 J, Redlinger\\xa0 C, Gallagher\\xa0 M, Bradbury\\xa0 AR,\\xa0 et\\xa0 al:'),\n",
       " Document(metadata={}, page_content='Combination paclitaxel and palbociclib: Results of a phase I trial \\nin advanced breast cancer. Clin Cancer Res\\xa025: 2072‑2079, 2019. \\n76.\\tTan\\xa0AR, Wright\\xa0GS, Thummala\\xa0AR, Danso\\xa0MA, Popovic\\xa0L, \\nPluard\\xa0TJ, Han\\xa0HS, Vojnović\\xa0Ž, Vasev\\xa0N, Ma\\xa0L,\\xa0et\\xa0al: Trilaciclib \\nplus chemotherapy versus chemotherapy alone in patients \\nwith metastatic triple‑negative breast cancer: A multicentre, \\nrandomised, open‑label, phase 2 trial. Lancet Oncol\\xa0 20:'),\n",
       " Document(metadata={}, page_content='1587‑1601, 2019. \\n77.\\t Stine\\xa0ZE, Walton\\xa0ZE, Altman\\xa0BJ, Hsieh\\xa0AL and Dang\\xa0CV: MYC, \\nmetabolism, and cancer. Cancer Discov\\xa05: 1024‑1039, 2015.\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1260\\n78.\\tAmbrosio\\xa0S, Amente\\xa0S, Napolitano\\xa0G, Di\\xa0Palo\\xa0G, Lania\\xa0L \\nand Majello\\xa0B: MYC impairs resolution of site‑specific DNA \\ndouble‑strand breaks repair. Mutat Res\\xa0774: 6‑13, 2015. \\n79.\\t Wiegmans\\xa0 AP, Al‑Ejeh\\xa0 F, Chee\\xa0 N, Yap\\xa0 PY, Gorski\\xa0 JJ,'),\n",
       " Document(metadata={}, page_content='Da\\xa0Silva\\xa0L, Bolderson\\xa0E, Chenevix‑Trench\\xa0G, Anderson\\xa0R, \\nSimpson\\xa0PT,\\xa0et\\xa0al: Rad51 supports triple negative breast cancer \\nmetastasis. Oncotarget\\xa05: 3261‑3272, 2014.\\n80.\\tCarey\\xa0JPW, Karakas\\xa0C, Bui\\xa0T, Chen\\xa0X, Vijayaraghavan\\xa0S, Zhao\\xa0Y, \\nWang\\xa0J, Mikule\\xa0K, Litton\\xa0JK, Hunt\\xa0KK and Keyomarsi\\xa0K: \\nSynthetic lethality of PARP inhibitors in combination with MYC \\nblockade is independent of BRCA status in triple negative breast'),\n",
       " Document(metadata={}, page_content='cancer. Cancer Res\\xa078: 742‑757, 2018. \\n81.\\t Horiuchi\\xa0D, Kusdra\\xa0L, Huskey\\xa0NE, Chandriani\\xa0S, Lenburg\\xa0ME, \\nGonzalez‑Angulo\\xa0AM, Creasman\\xa0KJ, Bazarov\\xa0AV, Smyth\\xa0JW, \\nDavis\\xa0SE,\\xa0et\\xa0al: MYC pathway activation in triple‑negative breast \\ncancer is synthetic lethal with CDK inhibition. J\\xa0Exp Med\\xa0209: \\n679‑696, 2012.\\n82.\\tHossain\\xa0DMS, Javaid\\xa0S, Cai\\xa0M, Zhang\\xa0C, Sawant\\xa0A, Hinton\\xa0M, \\nSathe\\xa0 M, Grein\\xa0 J, Blumenschein\\xa0 W, Pinheiro\\xa0 EM and'),\n",
       " Document(metadata={}, page_content='Chackerian\\xa0 A: Dinaciclib induces immunogenic cell death \\nand enhances anti‑PD1‑mediated tumor suppression. J\\xa0Clin \\nInvest\\xa0128: 644‑654, 2018. \\n83.\\tChien\\xa0AJ, Gliwa\\xa0AS, Rahmaputri\\xa0S, Dittrich\\xa0HF, Majure\\xa0MC, \\nRugo\\xa0HS, Melisko\\xa0ME, Munster\\xa0PN, Park\\xa0JW, Moasser\\xa0MM,\\xa0et\\xa0al: \\nA phase Ib trial of the cyclin‑dependent kinase inhibitor dinaci\\xad\\nclib (dina) in combination with pembrolizumab (P) in patients'),\n",
       " Document(metadata={}, page_content='with advanced triple‑negative breast cancer (TNBC) and \\nresponse correlation with MYC‑overexpression. J\\xa0Clin Oncol\\xa038: \\n1076, 2020\\n84.\\tKono\\xa0M, Fujii\\xa0T, Lim\\xa0B, Karuturi\\xa0MS, Tripathy\\xa0D and Ueno\\xa0NT: \\nAndrogen receptor function and androgen receptor‑targeted thera\\xad\\npies in breast cancer: A Review. JAMA Oncol\\xa03: 1266‑1273, 2017. \\n85.\\tGerratana\\xa0L, Basile\\xa0D, Buono\\xa0G, De\\xa0Placido\\xa0S, Giuliano\\xa0M, \\nMinichillo\\xa0 S, Coinu\\xa0 A, Martorana\\xa0 F, De\\xa0 Santo\\xa0 I,'),\n",
       " Document(metadata={}, page_content='Del\\xa0Mastro\\xa0L,\\xa0et\\xa0al: Androgen receptor in triple negative breast \\ncancer: A potential target for the targetless subtype. Cancer Treat \\nRev\\xa068: 102‑110, 2018. \\n86.\\tAnestis\\xa0 A, Zoi\\xa0 I, Papavassiliou\\xa0 AG and Karamouzis\\xa0 MV: \\nAndrogen receptor in breast cancer‑clinical and preclinical \\nresearch insights. Molecules\\xa025: 358, 2020 \\n87.\\t Masuda\\xa0H, Baggerly\\xa0KA, Wang\\xa0Y, Zhang\\xa0Y, Gonzalez‑Angulo\\xa0AM,'),\n",
       " Document(metadata={}, page_content='Meric‑Bernstam\\xa0 F, Valero\\xa0 V, Lehmann\\xa0 BD, Pietenpol\\xa0 JA, \\nHortobagyi\\xa0GN,\\xa0et\\xa0al: Differential response to neoadjuvant \\nchemotherapy among 7 triple‑negative breast cancer molecular \\nsubtypes. Clin Cancer Res\\xa019: 5533‑5540, 2013.\\n88.\\tThike\\xa0 AA, Yong‑Zheng Chong\\xa0 L, Cheok\\xa0 PY, Li\\xa0 HH, \\nWai‑Cheong\\xa0Yip\\xa0G, Huat\\xa0Bay\\xa0B, Tse\\xa0GM, Iqbal\\xa0J and Tan\\xa0PH: \\nLoss of androgen receptor expression predicts early recurrence'),\n",
       " Document(metadata={}, page_content=\"in triple‑negative and basal‑like breast cancer. Mod Pathol\\xa027: \\n352‑360, 2014.\\n89.\\tEchavarria\\xa0I, Lopez‑Tarruella\\xa0S, Picornell\\xa0A, García‑Saenz\\xa0JA, \\nJerez\\xa0Y, Hoadley\\xa0K, Gómez\\xa0HL, Moreno\\xa0F, Monte‑Millan\\xa0MD, \\nMárquez‑Rodas\\xa0I,\\xa0et\\xa0al: Pathological response in a triple‑negative \\nbreast cancer cohort treated with neoadjuvant carboplatin and \\ndocetaxel according to Lehmann's refined classification. Clin \\nCancer Res\\xa024: 1845‑1852, 2018.\"),\n",
       " Document(metadata={}, page_content='Cancer Res\\xa024: 1845‑1852, 2018.\\n90.\\tSantonja\\xa0A, Sánchez‑Muñoz\\xa0A, Lluch\\xa0A, Chica‑Parrado\\xa0MR, \\nAlbanell\\xa0 J, Chacón\\xa0 JI, Antolín\\xa0 S, Jerez\\xa0 JM, de\\xa0 la\\xa0 Haba\\xa0 J, \\nde\\xa0Luque\\xa0V,\\xa0et\\xa0al: Triple negative breast cancer subtypes and \\npathologic complete response rate to neoadjuvant chemotherapy. \\nOncotarget\\xa09: 26406‑26416, 2018.\\n91.\\t Venema\\xa0 CM, Bense\\xa0 RD, Steenbruggen\\xa0 TG, Nienhuis\\xa0 HH, \\nQiu\\xa0SQ, van\\xa0Kruchten\\xa0M, Brown\\xa0M, Tamimi\\xa0RM, Hospers\\xa0GAP,'),\n",
       " Document(metadata={}, page_content='Schröder\\xa0CP,\\xa0et\\xa0al: Consideration of breast cancer subtype in \\ntargeting the androgen receptor. Pharmacol Ther\\xa0200: 135‑147, 2019. \\n92.\\tRice\\xa0MA, Malhotra\\xa0SV and Stoyanova\\xa0T: Second‑generation \\nantiandrogens: From discovery to standard of care in castration \\nresistant prostate cancer. Front Oncol\\xa09: 801, 2019. \\n93.\\tGucalp\\xa0A, Tolaney\\xa0S, Isakoff\\xa0SJ, Ingle\\xa0JN, Liu\\xa0MC, Carey\\xa0LA, \\nBlackwell\\xa0K, Rugo\\xa0H, Nabell\\xa0L, Forero\\xa0A,\\xa0et\\xa0al: Phase II trial'),\n",
       " Document(metadata={}, page_content='of bicalutamide in patients with androgen receptor‑positive, \\nestrogen receptor‑negative metastatic breast cancer. Clin Cancer \\nRes\\xa019: 5505‑5512, 2013.\\n94.\\tGucalp\\xa0A, Edelweiss\\xa0M, Patil\\xa0S, Gounder\\xa0MM, Feigin\\xa0KN, \\nCorben\\xa0 A, Arumov\\xa0 A and Traina\\xa0 TA: Abstract P3‑11‑04: \\nPhase\\xa0I/II trial of palbociclib in combination with bicalutamide \\nfor the treatment of androgen receptor (AR)+ metastatic breast'),\n",
       " Document(metadata={}, page_content=\"cancer (MBC). In: Proceedings of the 2017 San Antonio Breast \\nCancer Symposium. Cancer Res 2018;78 (Suppl\\xa04): Abstract \\nnr\\xa0P3-11-04, 2018. \\n\\u2002 95.\\tGucalp\\xa0A, Boyle\\xa0LA, Alano\\xa0T, Arumov\\xa0A, Gounder\\xa0MM, \\nPatil\\xa0S, Feigin\\xa0K, Edelweiss\\xa0M, D'Andrea\\xa0G, Bromberg\\xa0J,\\xa0et\\xa0al: \\nPhase II trial of bicalutamide in combination with palbociclib \\nfor the treatment of androgen receptor (+) metastatic breast \\ncancer. J\\xa0Clin Oncol\\xa038, 2020.\"),\n",
       " Document(metadata={}, page_content=\"cancer. J\\xa0Clin Oncol\\xa038, 2020.\\n\\u2002 96.\\tBonnefoi\\xa0H, Grellety\\xa0T, Tredan\\xa0O, Saghatchian\\xa0M, Dalenc\\xa0F, \\nMailliez\\xa0 A, L'Haridon\\xa0 T, Cottu\\xa0 P, Abadie‑Lacourtoisie\\xa0 S, \\nYou\\xa0B,\\xa0et\\xa0al: A phase II trial of abiraterone acetate plus predni\\xad\\nsone in patients with triple‑negative androgen receptor positive \\nlocally advanced or metastatic breast cancer (UCBG 12‑1). Ann \\nOncol\\xa027: 812‑818, 2016. \\n\\u2002 97.\\tGucalp\\xa0A, Danso\\xa0MA, Elias\\xa0AD, Bardia\\xa0A, Ali\\xa0HY, Potter\\xa0D,\"),\n",
       " Document(metadata={}, page_content='Gabrail\\xa0NY, Haley\\xa0BB, Khong\\xa0HT, Riley\\xa0EC,\\xa0et\\xa0al: Phase \\n(Ph) 2 stage 1 clinical activity of seviteronel, a selective \\nCYP17‑lyase and androgen receptor (AR) inhibitor, in women \\nwith advanced AR+ triple‑negative breast cancer (TNBC) or \\nestrogen receptor (ER)+ BC: CLARITY‑01. J\\xa0Clin Oncol\\xa035: \\n1102, 2017.\\n\\u2002 98.\\tBardia\\xa0A, Gucalp\\xa0A, DaCosta\\xa0N, Gabrail\\xa0N, Danso\\xa0M, Ali\\xa0H, \\nBlackwell\\xa0 KL, Carey\\xa0 LA, Eisner\\xa0 JR, Baskin‑Bey\\xa0 ES and'),\n",
       " Document(metadata={}, page_content=\"Traina\\xa0TA: Phase 1 study of seviteronel, a selective CYP17 \\nlyase and androgen receptor inhibitor, in women with estrogen \\nreceptor‑positive or triple‑negative breast cancer. Breast Cancer \\nRes Treat.\\xa0171: 111‑120, 2018. \\n\\u2002 99.\\tTraina\\xa0TA, Miller\\xa0K, Yardley\\xa0DA, Eakle\\xa0J, Schwartzberg\\xa0LS, \\nO'Shaughnessy\\xa0 J, Gradishar\\xa0 W, Schmid\\xa0 P, Winer\\xa0 E, \\nKelly\\xa0C,\\xa0et\\xa0al: Enzalutamide for the treatment of androgen\"),\n",
       " Document(metadata={}, page_content='receptor‑expressing triple‑negative breast cancer. J\\xa0 Clin \\nOncol\\xa036: 884‑890, 2018. \\n100.\\tDent\\xa0R, Schmid\\xa0P, Cortes\\xa0J, Kim\\xa0SB, Andre\\xa0F, Abramson\\xa0V, \\nCardoso\\xa0F, Colleoni\\xa0M, Morris\\xa0P, Steinberg\\xa0J,\\xa0et\\xa0al: Abstract \\nOT3‑02‑02: ENDEAR: A randomized international phase \\n3 study comparing the efficacy and safety of enzalutamide \\nin combination with paclitaxel chemotherapy or as mono\\xad\\ntherapy vs placebo with paclitaxel in patients with advanced'),\n",
       " Document(metadata={}, page_content='diagnostic‑positive triple‑negative breast cancer. Cancer Res\\xa077: \\nAbstract OT3‑02‑02, 2017. \\n101.\\tLehmann\\xa0 BD, Abramson\\xa0 VG, Sanders\\xa0 ME, Mayer\\xa0 EL, \\nHaddad\\xa0TC, Nanda\\xa0R, Van\\xa0Poznak\\xa0C, Storniolo\\xa0AM, Nangia\\xa0JR, \\nGonzalez‑Ericsson\\xa0PI,\\xa0et\\xa0al: TBCRC 032 IB/II multicenter \\nstudy: Molecular insights to AR antagonist and PI3K inhibitor \\nefficacy in patients with AR+ metastatic triple‑negative breast \\ncancer. Clin Cancer Res\\xa026: 2111‑2123, 2020.'),\n",
       " Document(metadata={}, page_content='cancer. Clin Cancer Res\\xa026: 2111‑2123, 2020.\\n102.\\tGilewski\\xa0T, Ragupathi\\xa0G, Bhuta\\xa0S, Williams\\xa0LJ, Musselli\\xa0C, \\nZhang\\xa0 XF, Bornmann\\xa0 WG, Spassova\\xa0 M, Bencsath\\xa0 KP, \\nPanageas\\xa0KS,\\xa0et\\xa0al: Immunization of metastatic breast cancer \\npatients with a fully synthetic globo H conjugate: A phase I trial. \\nProc Natl Acad Sci USA\\xa098: 3270‑3275, 2001.\\n103.\\tHuang\\xa0 CS, Yu\\xa0 AL, Tseng\\xa0 LM, Chow\\xa0 LWC, Hou\\xa0 MF,'),\n",
       " Document(metadata={}, page_content=\"Hurvitz\\xa0SA, Schwab\\xa0RB, Wong\\xa0CH, Murray\\xa0JL, Chang\\xa0SC,\\xa0et\\xa0al: \\nRandomized phase II/III trial of active immunotherapy with \\nOPT‑822/OPT‑821 in patients with metastatic breast cancer. \\nJ\\xa0Clin Oncol\\xa034 (Suppl\\xa015): S1003, 2016. \\n104.\\tBardia\\xa0 A, Mayer\\xa0 IA, Vahdat\\xa0 LT, Tolaney\\xa0 SM, Isakoff\\xa0 SJ, \\nDiamond\\xa0 JR, O'Shaughnessy\\xa0 J, Moroose\\xa0 RL, Santin\\xa0 AD, \\nAbramson\\xa0VG,\\xa0et\\xa0al: Sacituzumab govitecan‑hziy in refrac\\xad\"),\n",
       " Document(metadata={}, page_content='tory metastatic triple‑negative breast cancer. N Eng J\\xa0Med\\xa0380: \\n741‑751, 2019. \\n105.\\tModi\\xa0S, Pusztai\\xa0L, Forero\\xa0A, Mita\\xa0M, Miller\\xa0KD, Weise\\xa0A, \\nBurris\\xa0H\\xa0III, Kalinsky\\xa0K, Tsai\\xa0M, Liu\\xa0MC,\\xa0et\\xa0al: Abstract PD3‑14: \\nPhase 1 study of the antibody‑drug conjugate SGN‑LIV1A in \\npatients with heavily pretreated triple‑negative metastatic breast \\ncancer. Cancer Res\\xa078, 2018. \\n106.\\tHan\\xa0 HS, Alemany\\xa0 CA, Brown‑Glaberman\\xa0 UA, Pluard\\xa0 TJ,'),\n",
       " Document(metadata={}, page_content='Sinha\\xa0 R, Sterrenberg\\xa0 D, Albain\\xa0 KS, Basho\\xa0 RK, Biggs\\xa0 D, \\nBoni\\xa0V,\\xa0et\\xa0al: SGNLVA‑002: Single‑arm, open label phase \\nIb/II study of ladiratuzumab vedotin (LV) in combination with \\npembrolizumab for first‑line treatment of patients with unresect\\xad\\nable locally advanced or metastatic triple‑negative breast cancer. \\nJ\\xa0Clin Oncol\\xa037 (Suppl\\xa015): TPS1110, 2019. \\n107.\\tModi\\xa0S, Park\\xa0H, Murthy\\xa0RK, Iwata\\xa0H, Tamura\\xa0K, Tsurutani\\xa0J,'),\n",
       " Document(metadata={}, page_content=\"Moreno‑Aspitia\\xa0A, Doi\\xa0T, Sagara\\xa0Y, Redfern\\xa0C,\\xa0et\\xa0al: Antitumor \\nactivity and safety of trastuzumab Deruxtecan in patients with \\nHER2‑low‑expressing advanced breast cancer: Results from a \\nphase Ib study. J\\xa0Clin Oncol\\xa038: 1887‑1896, 2020.\\n108.\\tModi\\xa0S, Ohtani\\xa0S, Lee\\xa0CC, Wang\\xa0K, Saxena\\xa0K and Cameron\\xa0DA: \\nA phase III, multicenter, randomized, open label trial of [fam‑] \\ntrastuzumab deruxtecan (DS‑8201a) versus investigator's\"),\n",
       " Document(metadata={}, page_content='choice in HER2‑low breast cancer. J\\xa0Clin Oncol\\xa037: (Suppl\\xa015): \\nTPS1102, 2019.\\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1261\\n109.\\t Molyneux\\xa0G, Geyer\\xa0FC, Magnay\\xa0FA, McCarthy\\xa0A, Kendrick\\xa0H, \\nNatrajan\\xa0R, Mackay\\xa0A, Grigoriadis\\xa0A, Tutt\\xa0A, Ashworth\\xa0A,\\xa0et\\xa0al: BRCA1 \\nbasal‑like breast cancers originate from luminal epithelial progenitors \\nand not from basal stem cells. Cell Stem Cell\\xa07: 403‑417, 2010.'),\n",
       " Document(metadata={}, page_content='110.\\tBernardo\\xa0GM, Bebek\\xa0G, Ginther\\xa0CL, Sizemore\\xa0ST, Lozada\\xa0KL, \\nMiedler\\xa0JD, Anderson\\xa0LA, Godwin\\xa0AK, Abdul‑Karim\\xa0FW, \\nSlamon\\xa0DJ and Keri\\xa0RA: FOXA1 represses the molecular pheno\\xad\\ntype of basal breast cancer cells. Oncogene 32: 554‑563, 2013.\\n111.\\tSu\\xa0Y, Subedee\\xa0A, Bloushtain‑Qimron\\xa0N, Savova\\xa0V, Krzystanek\\xa0M, \\nLi\\xa0L, Marusyk\\xa0A, Tabassum\\xa0DP, Zak\\xa0A, Flacker\\xa0MJ,\\xa0et\\xa0al: \\nSomatic cell fusions reveal extensive heterogeneity in basal‑like'),\n",
       " Document(metadata={}, page_content='breast cancer. Cell Rep\\xa011: 1549‑1563, 2015.\\n112.\\tCao\\xa0R, Wang\\xa0L, Wang\\xa0H, Xia\\xa0L, Erdjument‑Bromage\\xa0H, Tempst\\xa0P, \\nJones\\xa0RS and Zhang\\xa0Y: Role of histone H3 lysine 27 methylation \\nin Polycomb‑group silencing. Science\\xa0298: 1039‑1043, 2002.\\n113.\\tYamagishi\\xa0M and Uchimaru\\xa0K: Targeting EZH2 in Cancer \\nTherapy. Curr Opin Oncol\\xa029: 375‑381, 2017.\\n114.\\tYang\\xa0CC, LaBaff\\xa0A, Wei\\xa0Y, Nie\\xa0L, Xia\\xa0W, Huo\\xa0L, Yamaguchi\\xa0H,'),\n",
       " Document(metadata={}, page_content='Hsu\\xa0YH, Hsu\\xa0JL, Liu\\xa0D,\\xa0et\\xa0al: Phosphorylation of EZH2 at T416 \\nby CDK2 contributes to the malignancy of triple negative breast \\ncancers. Am J\\xa0Transl Res\\xa07: 1009‑1020, 2015.\\n115.\\tNie\\xa0L, Wei\\xa0Y, Zhang\\xa0F, Hsu\\xa0YH, Chan\\xa0LC, Xia\\xa0W, Ke\\xa0B, Zhu\\xa0C, \\nDeng\\xa0R, Tang\\xa0J,\\xa0 et\\xa0al: CDK2‑mediated site‑specific phos\\xad\\nphorylation of EZH2 drives and maintains triple‑negative breast \\ncancer. Nat Commun\\xa010: 5114, 2019.'),\n",
       " Document(metadata={}, page_content='cancer. Nat Commun\\xa010: 5114, 2019. \\n116.\\tYang\\xa0X, Phillips\\xa0DL, Ferguson\\xa0AT, Nelson\\xa0WG, Herman\\xa0JG \\nand Davidson\\xa0NE: Synergistic activation of functional estrogen \\nreceptor (ER)‑alpha by DNA methyltransferase and histone \\ndeacetylase inhibition in human ER‑alpha‑negative breast \\ncancer cells. Cancer Res\\xa061: 7025‑7029, 2001.\\n117.\\tSharma\\xa0D, Saxena\\xa0NK, Davidson\\xa0NE and Vertino\\xa0PM: Restoration'),\n",
       " Document(metadata={}, page_content='of tamoxifen sensitivity in estrogen receptor‑negative breast \\ncancer cells: Tamoxifen‑bound reactivated ER recruits distinctive \\ncorepressor complexes. Cancer Res\\xa066: 6370‑6378, 2006.\\n118.\\tConnolly\\xa0RM, Li\\xa0H, Jankowitz\\xa0RC, Zhang\\xa0Z, Rudek\\xa0MA, Jeter\\xa0SC, \\nSlater\\xa0SA, Powers\\xa0P, Wolff\\xa0AC, Fetting\\xa0JH,\\xa0et\\xa0al: Combination \\nepigenetic therapy in advanced breast cancer with 5‑azacitidine \\nand entinostat: A phase II National Cancer Institute/Stand up to'),\n",
       " Document(metadata={}, page_content='cancer study. Clin Cancer Res\\xa023: 2691‑2701, 2017. \\n119.\\tAnderberg\\xa0C, Li\\xa0H, Fredriksson\\xa0L, Andrae\\xa0J, Betsholtz\\xa0C, Li\\xa0X, \\nEriksson\\xa0U and Pietras\\xa0K: Paracrine signaling by platelet‑derived \\ngrowth factor‑CC promotes tumor growth by recruitment of \\ncancer‑associated fibroblasts. Cancer Res\\xa069: 369‑378, 2009. \\n120.\\tRoswall\\xa0P, Bocci\\xa0M, Bartoschek\\xa0M, Li\\xa0H, Kristiansen\\xa0G, Jansson\\xa0S,'),\n",
       " Document(metadata={}, page_content='Lehn\\xa0S, Sjölund\\xa0J, Reid\\xa0S, Larsson\\xa0C,\\xa0et\\xa0al: Microenvironmental control \\nof breast cancer subtype elicited through paracrine platelet‑derived \\ngrowth factor‑CC signaling. Nat Med\\xa024: 463‑473, 2018. \\n121.\\tPark\\xa0JJH, Hsu\\xa0G, Siden\\xa0EG, Thorlund\\xa0K and Mills\\xa0EJ: An \\noverview of precision oncology basket and umbrella trials for \\nclinicians. CA Cancer J\\xa0Clin\\xa070: 125‑137, 2020.\\nThis work is licensed under a Creative Commons'),\n",
       " Document(metadata={}, page_content='This work is licensed under a Creative Commons \\nAttribution-NonCommercial-NoDerivatives 4.0 \\nInternational (CC BY-NC-ND 4.0) License.')]"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "text_splitter = RecursiveCharacterTextSplitter(chunk_size = 450, chunk_overlap=50,separators=[\n",
    "        \"\\n\\n\",\n",
    "        \"\\n\",\n",
    "        \" \",\n",
    "        \".\",\n",
    "        \",\",\n",
    "        \"\\u200b\",  # Zero-width space\n",
    "        \"\\uff0c\",  # Fullwidth comma\n",
    "        \"\\u3001\",  # Ideographic comma\n",
    "        \"\\uff0e\",  # Fullwidth full stop\n",
    "        \"\\u3002\",  # Ideographic full stop\n",
    "        \"\"\n",
    "    ]\n",
    "                                              )\n",
    "text_splitter.create_documents([text])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4cb3b6a6-80a5-4d12-baec-35af1c4f3759",
   "metadata": {},
   "source": [
    "# Level 3: Document Specific Splitting\n",
    "\n",
    "Stepping up our levels ladder, let's start to handle document types other than normal prose in a .txt. What if you have pictures? or a PDF? or code snippets?\n",
    "\n",
    "Our first two levels wouldn't work great for this so we'll need to find a different tactic.\n",
    "\n",
    "This level is all about making your chunking strategy fit your different data formats. Let's run through a bunch of examples of this in action\n",
    "\n",
    "The Markdown, Python, and JS splitters will basically be similar to Recursive Character, but with different separators."
   ]
  },
  {
   "cell_type": "raw",
   "id": "63b26ddc-64b8-4f7a-b579-e1dff1c3e8dc",
   "metadata": {},
   "source": [
    "Separators:\n",
    "\n",
    "\\n#{1,6} - Split by new lines followed by a header (H1 through H6)\n",
    "```\\n - Code blocks\n",
    "\\n\\\\*\\\\*\\\\*+\\n - Horizontal Lines\n",
    "\\n---+\\n - Horizontal Lines\n",
    "\\n___+\\n - Horizontal Lines\n",
    "\\n\\n Double new lines\n",
    "\\n - New line\n",
    "\" \" - Spaces\n",
    "\"\" - Character"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "5b481d90-9dac-4f0e-a4c2-aaa66e628c2a",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "from langchain.text_splitter import MarkdownTextSplitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "9d6271e5-8b16-4efe-91e9-5e25bd9c4177",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "splitter = MarkdownTextSplitter(chunk_size = 200, chunk_overlap=20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "d1dbfa10-09ce-4487-9ec2-9787bcb00f35",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 232'),\n",
       " Document(metadata={}, page_content='**© The Author(s) 2024.** This is an Open Access article licensed under a Creative Commons Attribution 4.0 International'),\n",
       " Document(metadata={}, page_content='License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution'),\n",
       " Document(metadata={}, page_content='and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the'),\n",
       " Document(metadata={}, page_content='original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.'),\n",
       " Document(metadata={}, page_content='#### Exploration of Targeted Anti-tumor Therapy\\n\\nOpen Access Review\\n\\n### Early-stage triple negative breast cancer: the therapeutic role of'),\n",
       " Document(metadata={}, page_content='### immunotherapy and the prognostic value of pathological complete\\n\\n### response'),\n",
       " Document(metadata={}, page_content='### response\\n\\nPierluigi De Santis^1 , Martina Perrone^1 , Chiara Guarini^1 , Anna Natalizia Santoro^1 , Carmelo Laface^1 ,\\nDaniela Carrozzo^1 , Gaia Rachele Oliva^2 , Palma Fedele^1 *'),\n",
       " Document(metadata={}, page_content='(^1) Oncology Unit, Francavilla Fontana Ceglie Messapica Hospital District, 72021 Francavilla Fontana, Italy'),\n",
       " Document(metadata={}, page_content='(^2) Department of Medicine and Translational Surgery, Università Cattolica del Sacro Cuore, 00168 Roma, Italy'),\n",
       " Document(metadata={}, page_content='***Correspondence:** Palma Fedele, Oncology Unit, Francavilla Fontana Ceglie Messapica Hospital District, 72021 Francavilla\\nFontana, Italy. minafedele@hotmail.com'),\n",
       " Document(metadata={}, page_content='**Academic Editor:** Laura Cerchia, Institute of Experimental Endocrinology and Oncology “G. Salvatore”-National Research'),\n",
       " Document(metadata={}, page_content='Council (IEOS-CNR), Italy; Simona Camorani, Institute of Experimental Endocrinology and Oncology “G. Salvatore”-National\\nResearch Council (IEOS-CNR), Italy'),\n",
       " Document(metadata={}, page_content='**Received:** May 26, 2023 **Accepted:** December 26, 2023 **Published:** February 28, 2024'),\n",
       " Document(metadata={}, page_content='**Cite this article:** De Santis P, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, et al. Early-stage triple negative breast'),\n",
       " Document(metadata={}, page_content='cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response. Explor Target\\nAntitumor Ther. 2024;5:232–50. https://doi.org/10.37349/etat.2024.'),\n",
       " Document(metadata={}, page_content='#### Abstract'),\n",
       " Document(metadata={}, page_content='Triple negative breast cancer (TNBC) represents an aggressive disease associated with a high risk of'),\n",
       " Document(metadata={}, page_content='recurrence after curative treatment and a poor prognosis in the metastatic setting. Chemotherapy was for'),\n",
       " Document(metadata={}, page_content='years the only treatment available in the early and metastatic setting, due to the lack of actionable targets.'),\n",
       " Document(metadata={}, page_content='Clinical practice has changed following the results obtained with the addition of immunotherapy to'),\n",
       " Document(metadata={}, page_content='standard chemotherapy, the development of novel drugs [i.e. antibody-drug conjugates (ADCs)], and the'),\n",
       " Document(metadata={}, page_content='use of targeted treatments for patients carrying germline pathogenic breast cancer susceptibility genes'),\n",
       " Document(metadata={}, page_content='( _BRCA_ ) _1_ or _BRCA 2_ variants. The treatment of early-stage disease has had a shift in clinical practice since'),\n",
       " Document(metadata={}, page_content='July 2021, after the Food and Drug Administration (FDA) approval of pembrolizumab in association with'),\n",
       " Document(metadata={}, page_content='chemotherapy as neoadjuvant treatment for TNBC and as a single agent in the subsequent adjuvant setting.'),\n",
       " Document(metadata={}, page_content='This intensive treatment based on the combination of a poly-chemotherapy and an immune checkpoint'),\n",
       " Document(metadata={}, page_content='inhibitor (ICI) led to the improvement of short- and long-term outcomes, but it has highlighted some new'),\n",
       " Document(metadata={}, page_content='unmet clinical needs in the treatment of early-stage TNBC: the selection of the most effective adjuvant'),\n",
       " Document(metadata={}, page_content='therapy and the integration of pembrolizumab with other therapeutic strategies [capecitabine, poly(ADP-'),\n",
       " Document(metadata={}, page_content='ribose) polymerase (PARP) inhibitors] based on the achievement of pathologic complete response (pCR);'),\n",
       " Document(metadata={}, page_content='the identification of predictive biomarkers to select patients who could most benefit from the addition of'),\n",
       " Document(metadata={}, page_content='ICI, to minimize toxicities and to maximize outcomes; the possibility of de-escalating chemotherapy in favor'),\n",
       " Document(metadata={}, page_content='of immune-combo or novel agents, such as ADCs; the role of immunotherapy in estrogen receptor (ER)-low'),\n",
       " Document(metadata={}, page_content='patients. The advent of immunotherapy not only addresses current challenges in TNBC treatment but also'),\n",
       " Document(metadata={}, page_content='holds the promise of a radical transformation in its therapeutic paradigm, enhancing significantly clinical'),\n",
       " Document(metadata={}, page_content='outcomes and offering new perspectives for patients grappling with this aggressive form of breast cancer.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 233\\n\\n#### Keywords'),\n",
       " Document(metadata={}, page_content='#### Keywords\\n\\nTriple negative breast cancer, immunotherapy, pathological complete response, neoadjuvant combination\\ntreatment, adjuvant treatment\\n\\n#### Introduction'),\n",
       " Document(metadata={}, page_content='Triple negative Breast Cancer (TNBC) is a histological subtype of breast cancer (BC) characterized by the'),\n",
       " Document(metadata={}, page_content='immunohistochemical lack of expression (< 1%) of estrogen receptor (ER), progesterone receptor (PgR),'),\n",
       " Document(metadata={}, page_content='and human epidermal growth factor receptor 2 (HER2). It accounts for approximately 10–20% of all BC,'),\n",
       " Document(metadata={}, page_content='affecting mainly young, premenopausal women, and individuals with inherited gene alterations, such as BC'),\n",
       " Document(metadata={}, page_content='susceptibility genes 1/2 ( _BRCA 1/2_ ) mutations [ 1 – 3 ]. It notably presents an aggressive biological behavior'),\n",
       " Document(metadata={}, page_content='with a trend to have a higher grade and an often lymph node involvement at diagnosis, an inclination to'),\n",
       " Document(metadata={}, page_content='metastasize after curative treatment, and a poorer prognosis in metastatic setting when compared with\\nother BC subtypes [ 4 , 5 ].'),\n",
       " Document(metadata={}, page_content='For decades, treatment for early TNBC has been based on surgery and subsequent adjuvant\\nchemotherapy (CHT) for the reduction of disease recurrence [ 6 ]. Therefore, conventional cytotoxic CHT has'),\n",
       " Document(metadata={}, page_content='represented the backbone of systemic treatment in the early TNBC, including neoadjuvant treatment, which'),\n",
       " Document(metadata={}, page_content='used to reduce tumor size in larger tumors increasing the chances of a breast-conserving surgery [ 7 , 8 ]. In'),\n",
       " Document(metadata={}, page_content='recent years the development of novel therapeutic approaches has been difficult, due to the heterogeneity'),\n",
       " Document(metadata={}, page_content='of TNBC and lack of therapeutic targets [ 9 , 10 ]. Nevertheless, immunotherapy and poly(ADP-ribose)\\npolymerase (PARP) inhibitors have shown survival benefits in recent studies.'),\n",
       " Document(metadata={}, page_content='Specifically, combinations of immune checkpoint inhibitors (ICIs) with CHT or other alternative\\ntherapeutic compounds could emerge as a successful therapeutic approach in the management of TNBC'),\n",
       " Document(metadata={}, page_content='patients. Despite the progress in ICIs representing a notable milestone in TNBC treatment, additional'),\n",
       " Document(metadata={}, page_content='investigations are necessary to tackle this issue comprehensively. A profound comprehension of tumor\\nsubtypes, alongside tumor microenvironment (TME) and in terms of molecular, genetic, and immune'),\n",
       " Document(metadata={}, page_content='aspects, would amplify the potential for developing targeted immunotherapy to achieve superior\\ntherapeutic effectiveness, especially in TNBC [ 11 ].'),\n",
       " Document(metadata={}, page_content='Therefore, in this review, we aimed to investigate the role of immunotherapy in early-stage TNBC, the'),\n",
       " Document(metadata={}, page_content='prognostic value of pathologic complete response (pCR) with its therapeutic implications, and the future'),\n",
       " Document(metadata={}, page_content='perspectives regarding the systemic treatment of early TNBC, including the discovery of new biomarkers.'),\n",
       " Document(metadata={}, page_content='#### The landscape of immunotherapy in TNBC'),\n",
       " Document(metadata={}, page_content='The immune system plays a crucial role in TNBC compared to the other molecular subtypes of BC. Although'),\n",
       " Document(metadata={}, page_content='originally BC was considered non-immunogenic, TNBC has a high immunogenic potential, making it a'),\n",
       " Document(metadata={}, page_content='promising candidate for immunotherapy, especially with ICIs [ 12 , 13 ]. TNBC immunogenicity is related to\\nintrinsic tumor cell signatures and tumoral surrounding microenvironment features.'),\n",
       " Document(metadata={}, page_content='Over the last decades thanks to emerging technologies such as next-generation sequencing (NGS), the'),\n",
       " Document(metadata={}, page_content='knowledge of the molecular and genetic background of TNBC improved, bringing to light its intertumoral\\nand intratumoral heterogeneity.'),\n",
       " Document(metadata={}, page_content='A first classification divided TNBC into six subtypes: basal-like 1 (BL1), basal-like 2 (BL2),\\nmesenchymal (M), M stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR) [ 14 ].'),\n",
       " Document(metadata={}, page_content='Subsequently, analyzing RNA and DNA-based profiles of 198 TNBC tumors, a four-type classification of'),\n",
       " Document(metadata={}, page_content='TNBC was shaped: basal-like immunosuppressed (BLIS), basal-like immune-activated (BLIA), M and LAR'),\n",
       " Document(metadata={}, page_content='[ 15 ]. This classification was further revised with the identification of four specific TNBC subtypes: BL1, BL2,'),\n",
       " Document(metadata={}, page_content='M, and LAR, omitting IM and MSL because of the dependence of these two subtypes on the TME features\\n[ 14 ].'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 234'),\n",
       " Document(metadata={}, page_content='```\\nIn addition, TNBC could be classified into three microenvironment phenotypes or clusters:\\nCluster 1: “immune-desert” with poor immune cell permeation, due to a high presence of MYC'),\n",
       " Document(metadata={}, page_content='amplifications and, consequently, a lower recruitment of innate immune cells.'),\n",
       " Document(metadata={}, page_content='```\\n##### (1).'),\n",
       " Document(metadata={}, page_content='```\\nCluster 2: “innate immune-inactivated” characterized by a hyper-activation of\\nphosphatidylinositide 3-kinase/protein kinase B (PI3K-AKT) pathway in tumor cells, low tumor'),\n",
       " Document(metadata={}, page_content='antigen burden and infiltration of deactivated innate immune cells, fibroblasts, and endothelial\\ncells. Clusters 1 and 2 are therefore referred to as “cold tumors”.'),\n",
       " Document(metadata={}, page_content='```\\n##### (2).'),\n",
       " Document(metadata={}, page_content='```\\nCluster 3: “immune-inflamed”, the so-called “hot tumor” that represents about 30% of TNBCs and\\nis characterized by an abundant adaptive and innate immune cells infiltration and with a high'),\n",
       " Document(metadata={}, page_content='expression of immune checkpoint molecules [ 16 ].'),\n",
       " Document(metadata={}, page_content='```\\n##### (3).'),\n",
       " Document(metadata={}, page_content='The potential “hot” conversion of “cold” tumors could improve the efficacy of cancer immunotherapy.\\nFor example, local IM therapies can express a synergistic effect with immunotherapy by acting on'),\n",
       " Document(metadata={}, page_content='components of the TME and immune system function, such as elevating the expression of tumor antigens\\nand increasing the recruitment of activated immune cells in the TME [ 17 ].'),\n",
       " Document(metadata={}, page_content='TNBC cancer cell immunological features include genomic instability and high tumor mutational\\nburden (TMB), resulting in more somatic mutations and neoantigens [ 18 ].'),\n",
       " Document(metadata={}, page_content='Moreover, approximately 10–20% of TNBC harbor _BRCA 1_ or _BRCA 2_ germinal mutations, with a'),\n",
       " Document(metadata={}, page_content='consequent hereditary deficit in the DNA repair mechanism and strong genomic instability. Several studies'),\n",
       " Document(metadata={}, page_content='have demonstrated that TNBC-carrying BRCA mutations are more sensitive to DNA-damaging drugs such as'),\n",
       " Document(metadata={}, page_content='anthracyclines, but also platinum agents and PARP inhibitors [ 19 – 21 ]. Sensitivity to these drugs was also'),\n",
       " Document(metadata={}, page_content='observed in tumors with alterations in other genes, sharing BRCA-mutant phenotype in the absence of a\\n_BRCA 1/2_ mutation, namely “BRCAness” [ 22 , 23 ].'),\n",
       " Document(metadata={}, page_content='Tumors with _BRCA 1/2_ mutations or BRCAness TNBC are more immunogenic than TNBC without these\\ngenetic alterations [ 24 – 26 ].'),\n",
       " Document(metadata={}, page_content='Compared to the other BC subtypes the immunogenic TME features in TNBC consist of higher levels of'),\n",
       " Document(metadata={}, page_content='vascular endothelial growth factor (VEGF), that promote tumor cell growth and migration such as mitogen-\\nactivated protein kinases (MAPKs), tumor-associated macrophages (TAMs), and tumor-infiltrating'),\n",
       " Document(metadata={}, page_content='lymphocytes (TILs), white blood cells that migrate towards the tumor, leading to an important\\nimmunogenic effect and consequently that are involved in killing cancer cells [ 27 – 29 ].'),\n",
       " Document(metadata={}, page_content='TAMs regulate the interaction between the immune system and cancer cells. CD163+ M2 macrophages,'),\n",
       " Document(metadata={}, page_content='which are associated with tumors characterized by higher proliferation and poorer differentiation [ 30 ], are'),\n",
       " Document(metadata={}, page_content='more present in TNBC and basal-like BC [ 31 ]. A prosperous infiltration of TILs is found in TNBC tumors and'),\n",
       " Document(metadata={}, page_content='the stroma surrounding them, with a recognized predictive and prognostic role, specifically for CD4+ CD8+'),\n",
       " Document(metadata={}, page_content='T cells [ 32 ]. Several studies have reported better response to neoadjuvant CHT (NACT) [ 33 ] and better'),\n",
       " Document(metadata={}, page_content='clinical outcomes in BC with high TIL infiltrate [ 34 – 39 ]. Based on this evidence, the international TILs'),\n",
       " Document(metadata={}, page_content='working group started standardizing the evaluation of BC TILs to use it in clinical practice identifying those'),\n",
       " Document(metadata={}, page_content='patients that may benefit from emerging immunotherapies with ICIs or combination therapies [ 40 ].'),\n",
       " Document(metadata={}, page_content='All these TME elements contribute to TNBC immunogenicity which also appears to be closely related to'),\n",
       " Document(metadata={}, page_content='the concept of TMB, depending on the ineffective DNA repair system with the consequent generation of'),\n",
       " Document(metadata={}, page_content='high rates of neoantigens. The upregulated antigen presentation system leads to an increasing number of'),\n",
       " Document(metadata={}, page_content='innate and adaptative immune cells and many cytokines interplaying with cancer cells. However, the exact'),\n",
       " Document(metadata={}, page_content='relationship between TMB, neoantigens, and immune infiltration is not yet completely understood, and'),\n",
       " Document(metadata={}, page_content='some studies have reported an inverse association between immune cells in TME and the rate of somatic\\ncopy number alterations [ 41 , 42 ].'),\n",
       " Document(metadata={}, page_content='Moreover, although TMB is comparable across the three clusters of TNBC, the “immune-inflated”\\nphenotype is characterized by a higher degree of immune cells in the TME, but also a high expression of'),\n",
       " Document(metadata={}, page_content='immune checkpoints by cancer cells [ 16 ]. The rate of TILs, indeed, has been positively related to'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 235'),\n",
       " Document(metadata={}, page_content='programmed death ligand 1 (PD-L1) expression [ 43 ]. PD-L1 is an immune checkpoint that mediates local'),\n",
       " Document(metadata={}, page_content='immune escape in many tumors inducing saturation of activated T cells. Even if PD-L1 prognostic role is yet'),\n",
       " Document(metadata={}, page_content='controversial [ 44 ], however it results more overexpressed in TNBC compared with other BC and it can\\npredict responsiveness to immunotherapy [ 16 ].'),\n",
       " Document(metadata={}, page_content='Therefore, TNBC represents an aggressive BC subtype, associated with high mutational load, high\\ntumor immunogenicity and TME diversity.\\n\\n#### New paradigms in early TNBC: from CHT to immunotherapy'),\n",
       " Document(metadata={}, page_content='**CHT in adjuvant treatment for TNBC**'),\n",
       " Document(metadata={}, page_content='In early TNBC patients, CHT represents the mainstay of adjuvant and neoadjuvant treatments. Adjuvant'),\n",
       " Document(metadata={}, page_content='CHT is recommended for tumor sizes greater than 1.0 cm and patients with nodal involvement, regardless'),\n",
       " Document(metadata={}, page_content='of tumor size. Therefore, it can be considered for tumor sizes between 0.6–1.0 cm [ 45 ]. A recent large meta-'),\n",
       " Document(metadata={}, page_content='analysis demonstrated that adjuvant CHT with anthracyclines-containing regimens plus taxanes, compared'),\n",
       " Document(metadata={}, page_content='with no CHT, can reduce BC mortality rates by about 40% during the first decade after diagnosis. Moreover,'),\n",
       " Document(metadata={}, page_content='regimens with higher cumulative and dose-dense schedules of anthracycline (with granulocyte colony-'),\n",
       " Document(metadata={}, page_content='stimulating factor support) have shown better survival benefits and more reductions in recurrence [ 46 ].'),\n",
       " Document(metadata={}, page_content='Three-weekly docetaxel and paclitaxel can be considered in adjuvant setting, but weekly paclitaxel, in a'),\n",
       " Document(metadata={}, page_content='subgroup analysis, has shown improved outcomes and is preferred for TNBC [ 47 ]. In TNBC in frail patients'),\n",
       " Document(metadata={}, page_content='with a known history of heart disease, to minimize the cardiotoxicity of adjuvant treatments, docetaxel\\ncombined with cyclophosphamide (TC) has proven to be a viable alternative to doxorubicin and'),\n",
       " Document(metadata={}, page_content='cyclophosphamide (AC), demonstrating a favorable disease-free survival (DFS) [ 48 ]. Therefore, there is a'),\n",
       " Document(metadata={}, page_content='broad spectrum of chemotherapeutic treatments for early TNBC that should be customised according to the\\npatient and expected toxicities.'),\n",
       " Document(metadata={}, page_content='**The role of platinum in adjuvant setting for TNBC**'),\n",
       " Document(metadata={}, page_content='TNBC patients commonly harbor _BRCA 1/2_ or BRCAness mutations with a homologous recombination'),\n",
       " Document(metadata={}, page_content='deficiency (HRD) that makes them particularly susceptible to platinum agents due to their ability to hit'),\n",
       " Document(metadata={}, page_content='cancer cells that have deficient DNA repair mechanisms [ 49 – 51 ]. Several retrospective single-center studies'),\n",
       " Document(metadata={}, page_content='have explored the role of adjuvant platinum combined with standard anthracycline and taxane-based'),\n",
       " Document(metadata={}, page_content='regimens, with controversial results not showing clear clinical benefits [ 52 , 53 ]. Nevertheless, a recent'),\n",
       " Document(metadata={}, page_content='phase III trials have demonstrated a longer 5-year DFS (86.5% _vs._ 80.3%) with similar results in distant DFS'),\n",
       " Document(metadata={}, page_content='and relapse-free survival (RFS) of platinum-containing adjuvant regimens (paclitaxel-carboplatin)'),\n",
       " Document(metadata={}, page_content='compared to a standard anthracyclines-containing regimen followed by taxane, however with no benefit in\\noverall survival (OS) [ 54 ].'),\n",
       " Document(metadata={}, page_content='Another important factor is platinum resistance. Platinum sensitivity may be affected by changes in the'),\n",
       " Document(metadata={}, page_content='hazard ratio (HR) pathway or, in the case of patients with _BRCA 1/2_ mutations, by the secondary'),\n",
       " Document(metadata={}, page_content='appearance of new _BRCA 1 or 2_ mutations that make cancer cells less sensitive to platinum [ 55 , 56 ].'),\n",
       " Document(metadata={}, page_content='```\\nOther mechanisms of resistance to platinum compounds are:\\nModification of drug transport within the tumor cell, by determining decreased influx or increased\\nefflux.'),\n",
       " Document(metadata={}, page_content='```\\n##### (1).'),\n",
       " Document(metadata={}, page_content='(2).Increase of detoxification systems.\\n(3).Decrease of cell apoptosis [ 57 ].\\nTherefore, the benefit of adjuvant platinum-based regimens remains controversial and needs'),\n",
       " Document(metadata={}, page_content='validation by prospective adjuvant ongoing trials.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 236\\n\\n**Neoadjuvant treatments for TNBC**\\n\\nNACT'),\n",
       " Document(metadata={}, page_content='Several treatment guidelines recommend NACT as the preferred option for stage II or III TNBC and for'),\n",
       " Document(metadata={}, page_content='stage I with a tumor size greater than 1 cm. It can be considered in stage I TNBC with a tumor size from'),\n",
       " Document(metadata={}, page_content='0.6 cm to 1 cm and/or in the case of tumors with nodal micrometastases. [ 6 , 45 ]. There is no significant'),\n",
       " Document(metadata={}, page_content='difference in survival benefits between patients receiving neoadjuvant or adjuvant CHT after surgical'),\n",
       " Document(metadata={}, page_content='resection. However, neoadjuvant treatments can be useful for inoperable tumors rendering them operable'),\n",
       " Document(metadata={}, page_content='and they can also downstage patients with operable BC promoting breast-conservation [ 58 , 59 ]. The use of'),\n",
       " Document(metadata={}, page_content='neoadjuvant treatments provides important prognostic information based on response to therapy.'),\n",
       " Document(metadata={}, page_content='Achieving a pCR, defined as the lack of cancer cells in tissue samples of breast and axillary lymph nodes,'),\n",
       " Document(metadata={}, page_content='after a neoadjuvant treatment, is associated with favorable disease-free and OS in early TNBC, as\\ndemonstrated in Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) pooled analysis. In this'),\n",
       " Document(metadata={}, page_content='study, patients with early BC treated with NACT and followed by surgery who obtained pCR (ypT0 ypN0,'),\n",
       " Document(metadata={}, page_content='ypT0/is ypN0) were associated with improved event-free survival (EFS) and OS, especially in TNBC (HR ='),\n",
       " Document(metadata={}, page_content='0.24 and HR = 0.16, respectively) [ 33 ]. Like adjuvant treatment, traditional NACT is based on anthracyclines'),\n",
       " Document(metadata={}, page_content='and taxanes, and a dose-dense regimen is preferred in neoadjuvant settings based on proven improved DFS\\nand OS in a large meta-analysis [ 60 ].'),\n",
       " Document(metadata={}, page_content='In recent years, the use of platinum-based combination regimens has been the focus of neoadjuvant'),\n",
       " Document(metadata={}, page_content='treatment to increase the rate of pCR in TNBC. Three recent studies demonstrated that combining platinum'),\n",
       " Document(metadata={}, page_content='with taxane and anthracycline led to an improvement in the pCR rate in TNBC, with a similar survival'),\n",
       " Document(metadata={}, page_content='benefit [ 61 – 63 ]. In Brightness Trial patients with II–III stage TNBC were randomly assigned to receive'),\n",
       " Document(metadata={}, page_content='paclitaxel alone, paclitaxel and carboplatin and this combination with a PARP inhibitor, veliparib followed'),\n",
       " Document(metadata={}, page_content='by AC. Although the addition of veliparib and carboplatin was associated with an increase of patients who'),\n",
       " Document(metadata={}, page_content='achieved a pCR compared to paclitaxel alone (53% _vs._ 31%, _P_ < 0.0001), but not to paclitaxel and'),\n",
       " Document(metadata={}, page_content='carboplatin, this benefit could be related to the addition of the carboplatin [ 63 ]. The initial rationale for'),\n",
       " Document(metadata={}, page_content='using the combination of platinum in NACT was that sporadic TNBC can show BRCAness with a major\\nresponse to platinum regimens [ 50 , 51 ]. However, the greatest benefit was seen in patients who were'),\n",
       " Document(metadata={}, page_content='germline BRCA wild type, and only a marginal benefit was observed in the germline BRCA mutant\\nsubgroup, as was shown in the recent GeparOLA trial. In this trial, patients were randomized to'),\n",
       " Document(metadata={}, page_content='neoadjuvant therapy with paclitaxel and carboplatin _vs._ neoadjuvant therapy with paclitaxel and olaparib'),\n",
       " Document(metadata={}, page_content='(PARP inhibitor). In both arms, the combination of epirubicin and cyclophosphamide was administered'),\n",
       " Document(metadata={}, page_content='next. This study, although limited by a small number of patients enrolled, showed an advantage for the'),\n",
       " Document(metadata={}, page_content='carboplatin arm in patients without BRCA mutation (germ or somatic) and high HRD. The 4-year invasive'),\n",
       " Document(metadata={}, page_content='DFS (iDFS) rate with olaparib-paclitaxel was 81.2% _vs._ 93.4% with carboplatin-paclitaxel (CP) [HR = 3.03;'),\n",
       " Document(metadata={}, page_content='95% confidence interval (CI) = 0.67–13.67; log-rank _P_ = 0.1290]. The 4-year OS rate was 89.2% with the'),\n",
       " Document(metadata={}, page_content='olaparib combination _vs._ 96.6% with carboplatin (HR = 3.27; 95% CI = 0.39–27.20; log-rank _P_ = 0.2444).'),\n",
       " Document(metadata={}, page_content='The trend of the iDFS curves was similar in the two treatment arms and independent of germline or somatic\\nBRCA mutation [ 64 ].'),\n",
       " Document(metadata={}, page_content='Platinum combinations are currently recommended for selected patients with TNBC who require'),\n",
       " Document(metadata={}, page_content='adequate local control before surgical resection [ 45 ]. A more recent phase III trial presented at the San'),\n",
       " Document(metadata={}, page_content='Antonio Breast Cancer Symposium evaluating the efficacy and safety of adding carboplatin to standard'),\n",
       " Document(metadata={}, page_content='sequential taxane-anthracycline NACT in patients with TNBC who had no evidence of metastatic disease,'),\n",
       " Document(metadata={}, page_content='has observed improvements in terms of DFS (5-year DFS were 70.6% and 64.5% respectively with a HR ='),\n",
       " Document(metadata={}, page_content='0.79, 95% CI = 0.61–1.02, _P_ = 0.073) and OS (5-year OS were 74.0% and 66.7% respectively with a HR ='),\n",
       " Document(metadata={}, page_content='0.75, 95% CI = 0.57–0.98, _P_ = 0.034) with the addition of carboplatin, but these benefits were limited to'),\n",
       " Document(metadata={}, page_content='patients who were 50 years of age or younger. Therefore, the pCR in the intention-to-treat population was\\n54.5% in the carboplatin arm and 40.3% in the control arm ( _P_ < 0.001) [ 65 ].'),\n",
       " Document(metadata={}, page_content='The inclusion of platinum agents as NACT for TNBC remains controversial. Long-term outcomes and\\nnew prospective studies are needed to clarify the role of platinum agents in this setting.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 237\\n\\nNeoadjuvant immunotherapy'),\n",
       " Document(metadata={}, page_content='The success of ICIs in metastatic TNBC led to expand their role in neoadjuvant settings. Pembrolizumab and'),\n",
       " Document(metadata={}, page_content='atezolizumab have shown progression-free survival (PFS) benefits in phase III trials in advanced setting'),\n",
       " Document(metadata={}, page_content='[ 66 , 67 ]. In contrast to atezolizumab that showed conflicting results [ 68 , 69 ], pembrolizumab consistently'),\n",
       " Document(metadata={}, page_content='showed OS benefits in advanced TNBC [ 66 , 70 ]. In early-stage TNBC two studies evaluated atezolizumab in'),\n",
       " Document(metadata={}, page_content='neoadjuvant setting. In the NeoTRIPaPDL1 trial, no improvement in pCR was shown with the addition of'),\n",
       " Document(metadata={}, page_content='atezolizumab to a non-anthracycline-containing CHT regimen [ 71 ]. More recent Impassion031 phase III'),\n",
       " Document(metadata={}, page_content='study evaluating the association of atezolizumab to a standard NACT (nab-palclitaxel weekly for 12 weeks'),\n",
       " Document(metadata={}, page_content='followed by 4 cycles of AC), has demonstrated a significant improvement of pCR rates in intention to treat'),\n",
       " Document(metadata={}, page_content='(ITT) population (58% in atezolizumab arm _vs._ 41% in placebo arm, _P_ = 0.0044), regardless of PD-L1 status,'),\n",
       " Document(metadata={}, page_content='meeting the primary endpoint of the study [ 72 ]. Therefore, in early BC the combination of pembrolizumab'),\n",
       " Document(metadata={}, page_content='with paclitaxel-carboplatin followed by anthracycline increased pCR rate and EFS rate in the KEYNOTE-'),\n",
       " Document(metadata={}, page_content='trial, representing a turning point for the role of immunotherapy in neoadjuvant therapy of TNBC and'),\n",
       " Document(metadata={}, page_content='establishing pembrolizumab as a standard treatment during neoadjuvant treatment for stage II and III'),\n",
       " Document(metadata={}, page_content='TNBC. The trial evaluated the combination of pembrolizumab (18 cycles, 200 mg every 3 weeks) combined'),\n",
       " Document(metadata={}, page_content='with four cycles of paclitaxel (weekly or 3-weekly) and carboplatin (3-weekly), followed by 3-weekly AC for'),\n",
       " Document(metadata={}, page_content='4 cycles, compared to placebo with CHT. Pembrolizumab arm showed a 13.6% improvement in pCR [64.8%'),\n",
       " Document(metadata={}, page_content='(95% CI = 59.9–69.5%) _vs._ 51.2% (95% CI = 44.1–58.3%)] and in EFS rate [84.5% (95% CI = 81.7–86.9%)\\n_vs._ 76.8% (95% CI = 72.2–80.7%)], meeting the primary endpoint of the study, regardless nodal'),\n",
       " Document(metadata={}, page_content='involvement and PD-L1 status. The average duration of follow-up is still immature, but a trend of'),\n",
       " Document(metadata={}, page_content='superiority in terms of OS in the pembrolizumab arm was nevertheless detected [ 73 ]. Limits of this study'),\n",
       " Document(metadata={}, page_content='are the lack of biomarkers that predict what patient may benefit from the addition of pembrolizumab and'),\n",
       " Document(metadata={}, page_content='the non-utilization of dose-dense schedule of AC which showed superior OS benefit in the neoadjuvant\\nsetting in TNBC [ 74 ].'),\n",
       " Document(metadata={}, page_content='Moreover, the recent GeparNuevo trial showed that durvalumab (1,500 mg every 4 weeks) added to\\nNACT consisting of nab-paclitaxel 125 mg/m^2 weekly for 12 weeks, followed by epirubicin/'),\n",
       " Document(metadata={}, page_content='cyclophosphamide every 2 weeks, in early TNBC significantly improved iDFS (85.6% with durvalumab _vs._'),\n",
       " Document(metadata={}, page_content='77.2% with placebo HR = 0.48, 95% CI = 0.24–0.97, stratified log-rank _P_ = 0.036) and OS (95.2% _vs._ 83.5%'),\n",
       " Document(metadata={}, page_content='with a HR = 0.24, 95% CI = 0.08–0.72, _P_ = 0.006), despite a modest pCR increase and no adjuvant\\ncomponent of durvalumab [ 75 ]. Future studies should aim to define the role of immunotherapy in the'),\n",
       " Document(metadata={}, page_content='treatment of early TNBC, to define the ideal duration of these treatments, and should research new\\nbiomarkers to personalize treatments.'),\n",
       " Document(metadata={}, page_content='#### Pathological complete response: prognostic role and therapeutic\\n\\n#### implications'),\n",
       " Document(metadata={}, page_content='In clinical practice, the achievement of pCR after neoadjuvant treatment is correlated to the improvement of'),\n",
       " Document(metadata={}, page_content='long-term benefits concerning EFS and OS. Its prognostic value is greatest in aggressive tumor subtypes,'),\n",
       " Document(metadata={}, page_content='like in TNBC (EFS: HR = 0.24; OS: HR = 0.16) [ 33 ]. Patients who have residual invasive BC after the receipt'),\n",
       " Document(metadata={}, page_content='of NACT have a high risk of relapse. Patients with TNBC who do not experience pCR have an estimated 5-'),\n",
       " Document(metadata={}, page_content='year EFS of 57% and OS of 47% (compared with 90% EFS and 84% OS, respectively, for patients with early-\\nstage TNBC who demonstrate pCR) [ 76 , 77 ].'),\n",
       " Document(metadata={}, page_content='After pre-operative CHT and surgical treatment, patients can receive postoperative radiation therapy'),\n",
       " Document(metadata={}, page_content='(RT). Patients with hormone receptor-positive BC [hormone receptor-positive (HR+) BC] are candidates for'),\n",
       " Document(metadata={}, page_content='adjuvant endocrine treatment. However, until recently, no adjuvant CHT was expected as standard in\\npatients with TNBC. Only follow-up was recommended in those who have pCR or in those with residual'),\n",
       " Document(metadata={}, page_content='invasive BC after the receipt of neoadjuvant regimens [ 78 ]. To address the unmet clinical need for optimal'),\n",
       " Document(metadata={}, page_content='adjuvant treatment in the subgroup of patients with TNBC at high risk of recurrence (those who have not'),\n",
       " Document(metadata={}, page_content='achieved the pCR after NACT containing anthracycline, taxane, or both), the Capecitabine for Residual'),\n",
       " Document(metadata={}, page_content='Cancer as Adjuvant Therapy (CREATE-X) was designed. The trial did not include only patients with TNBC'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 238'),\n",
       " Document(metadata={}, page_content='but also patients with HR+ HER2 negative BC [ 79 ]. The results of this phase III trial showed that the'),\n",
       " Document(metadata={}, page_content='addition of adjuvant capecitabine (1,250 mg per square meter of body-surface area, twice per day, on days'),\n",
       " Document(metadata={}, page_content='1 to 14, every 3 weeks for six or eight cycles) was safe and effective in prolonging DFS and OS among the'),\n",
       " Document(metadata={}, page_content='ITT population. The study showed a superior DFS in the capecitabine group than in the control group'),\n",
       " Document(metadata={}, page_content='(74.1% _vs._ 67.6% at 5 years; HR = 0.70; _P_ = 0.01). Therefore, OS was longer in the experimental group:'),\n",
       " Document(metadata={}, page_content='89.2% _vs._ 83.6% of the patients were alive at 5 years (HR = 0.59; _P_ = 0.01). Thirty percent of the patients'),\n",
       " Document(metadata={}, page_content='had triple negative (TN) disease, and they represent the subgroup with poor prognosis (approximately half'),\n",
       " Document(metadata={}, page_content='the patients with TNBC who had a pCR did not have the recurrence of the disease) [ 33 ]. The benefit of'),\n",
       " Document(metadata={}, page_content='capecitabine _vs._ control in DFS and OS was notable among this subgroup of patients (HR = 0.58 and HR =\\n0.52, respectively) [ 79 ].'),\n",
       " Document(metadata={}, page_content='The reflection in the treatment algorithm due to these results was significant.\\nSome limits of this study are the exclusion of patients who had reached the pCR, for whom only follow-'),\n",
       " Document(metadata={}, page_content='up was indicated, and the lack of efficacy results selected for residual cancer burden (RCB). The RCB'),\n",
       " Document(metadata={}, page_content='quantifies the extent of residual disease after neoadjuvant treatment at the time of surgery. This score uses'),\n",
       " Document(metadata={}, page_content='the diameter of residual disease, percentage of vital tumor cells, and diameter of the largest involved lymph'),\n",
       " Document(metadata={}, page_content='node to calculate the amount of residual disease. It has been validated with distinct prognostic RCB classes'),\n",
       " Document(metadata={}, page_content='in all BC subtypes, with the most significant discriminatory power in TN and Her-2 positive BC. It is'),\n",
       " Document(metadata={}, page_content='categorized as RCB-0 (equivalent to a pCR), RCB-1, RCB-2, and RCB-3, reflecting increasingly larger residual'),\n",
       " Document(metadata={}, page_content='cancer and respective poor prognoses (in terms of EFS) [ 80 ]. Finally, the CREATE-X trial did not examine'),\n",
       " Document(metadata={}, page_content='capecitabine efficacy in patients with germline _BRCA 1_ or _BRCA 2_ pathogenic variants (less than 15% of\\nthose enrolled) [ 79 ].'),\n",
       " Document(metadata={}, page_content='OlympiA is a phase III study designed to investigate how the PARP inhibitor olaparib might improve'),\n",
       " Document(metadata={}, page_content='DFS and OS in patients with resected HR+ BC and TNBC with germline _BRCA 1_ or _BRCA 2_ mutation. It'),\n",
       " Document(metadata={}, page_content='enrolled patients treated with CHT (containing anthracyclines, taxanes or the combination of both) in'),\n",
       " Document(metadata={}, page_content='neoadjuvant or adjuvant setting and randomized them to receive olaparib (orally administered at the dose'),\n",
       " Document(metadata={}, page_content='of 300 mg twice daily) _vs._ placebo for 1 year after surgical resection (and radiotherapy when indicated).'),\n",
       " Document(metadata={}, page_content='Also in this trial, patients with TNBC who underwent NACT followed by surgery were required to have\\nresidual invasive BC in the breast and/or resected lymph nodes (non-pCR) [ 81 ]. Postneoadjuvant'),\n",
       " Document(metadata={}, page_content='capecitabine was not foreseen in this trial. iDFS, the primary endpoint of the study, was significantly longer'),\n",
       " Document(metadata={}, page_content='among patients assigned to receive olaparib than among those assigned placebo (HR = 0.58; _P_ < 0.001). The'),\n",
       " Document(metadata={}, page_content='percentage of patients alive and free of invasive disease at 3 years was 85.9% in the olaparib group and'),\n",
       " Document(metadata={}, page_content='77.1% in the placebo group. The benefit of adjuvant olaparib was observed irrespective of the germline'),\n",
       " Document(metadata={}, page_content='_BRCA_ mutation (BRCA 1 _vs._ BRCA 2), the hormone-receptor status, or the timing of previous CHT'),\n",
       " Document(metadata={}, page_content='(neoadjuvant _vs._ adjuvant) [ 81 ] 4-year iDFS for the olaparib group was 82.7% ( _vs._ 75.4% in placebo group)'),\n",
       " Document(metadata={}, page_content='and 4-year distant DFS (DDFS) was 86.5% ( _vs._ 79.1%). Adjuvant olaparib improves OS, with an HR of 0.'),\n",
       " Document(metadata={}, page_content='and a _P_ value of 0.009 at 3.5 years of median follow-up, meeting the significance threshold for OS at the'),\n",
       " Document(metadata={}, page_content='second planned interim analysis. The OS benefit at 4 years in the olaparib arm compared with the placebo\\narm was reported (89.8% _vs._ 86.4%, respectively) [ 82 ].'),\n",
       " Document(metadata={}, page_content='Both studies have defined the standard of adjuvant therapy post-NACT for patients with _BRCA_ wild\\ntype (CREATE-X) and _BRCA_ mutated (OlympiA) TNBC, that did not reach the pCR.'),\n",
       " Document(metadata={}, page_content='The low percentage of _BRCA_ mutated patients enrolled in the CREATE-X, the absence of pre-planned'),\n",
       " Document(metadata={}, page_content='subgroup analyzes for this population do not allow for a description of the efficacy of capecitabine in this\\nsubgroup of patients.'),\n",
       " Document(metadata={}, page_content='Moreover, there are no prospective randomized trials between capecitabine and olaparib to guide the\\nclinical decision in this population, nor combination or sequence data between these two drugs.'),\n",
       " Document(metadata={}, page_content='It would also be important to consider the potentially severe toxicity profile of such a combination,\\ngiven their overlapping side effects (in particular, cytopenias).'),\n",
       " Document(metadata={}, page_content='The treatment paradigm of early TNBC has had a real evolution since July 2021, with the introduction'),\n",
       " Document(metadata={}, page_content='of immunotherapy following the Food and Drug Administration (FDA) approval of pembrolizumab for high-'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 239'),\n",
       " Document(metadata={}, page_content='risk TNBC (tumor size > 1 cm but ≤ 2 cm in diameter with nodal involvement or tumor size > 2 cm in'),\n",
       " Document(metadata={}, page_content='diameter regardless of nodal involvement), regardless of tumor PD-L1 expression, in combination with CHT'),\n",
       " Document(metadata={}, page_content='as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery for a\\ntotal duration of approximately 1 year [ 83 ].'),\n",
       " Document(metadata={}, page_content='Results from the KEYNOTE-522 study were the basis for this approval, demonstrating a significantly'),\n",
       " Document(metadata={}, page_content='higher rate of pCR at the time of definitive surgery among patients who received pembrolizumab plus NACT'),\n",
       " Document(metadata={}, page_content='than among those who received placebo plus NACT and an improvement in long-term benefits [ 73 , 84 ]. The'),\n",
       " Document(metadata={}, page_content='aim of the trial was not to identify the contributions of the neoadjuvant and adjuvant treatment phases, so it'),\n",
       " Document(metadata={}, page_content='is difficult to define if these long-term results are related to exposure to adjuvant pembrolizumab or a\\nlesser RCB at the end of the neoadjuvant phase in the pembrolizumab–CHT group.'),\n",
       " Document(metadata={}, page_content='An exploratory analysis of the study then provided data to further describe the prognosis related to the\\nRCB after neoadjuvant experimental treatment (Figure 1) [ 85 ].'),\n",
       " Document(metadata={}, page_content='**Figure 1.** The unmet need for the optimal adjuvant treatment according to RCB [ 85 ]'),\n",
       " Document(metadata={}, page_content='The HR for recurrence event in subgroups RBO-0, RCB-1, RCB-2, and RCB-3 are respectively 0.\\n(rates: 5.2% _vs._ 7.3% in the pembrolizumab + CHT _vs._ placebo + CHT), 0.92 (rates: 17.4% _vs._ 20%), 0.'),\n",
       " Document(metadata={}, page_content='(rates: 25.5% _vs._ 44.3%), 1.24 (72.5% _vs._ 69.2%).'),\n",
       " Document(metadata={}, page_content='The rate of recurrence was numerically lower in all RCB groups with pembrolizumab + CHT, except in'),\n",
       " Document(metadata={}, page_content='the small RCB-3 subset (that is represented by 5% and 7% of the population in the study, respectively in'),\n",
       " Document(metadata={}, page_content='the experimental and control group). Pembrolizumab shifted RCB to lower categories in most patients'),\n",
       " Document(metadata={}, page_content='(RCB-0: 63% _vs._ 56% of patients in the experimental _vs._ the control arm; RCB-1: 9% _vs._ 11%; RCB 18% _vs._\\n20%).'),\n",
       " Document(metadata={}, page_content='No patients in this trial received adjuvant capecitabine, and there are no randomized efficacy and'),\n",
       " Document(metadata={}, page_content='safety data showing that multiagent therapy with pembrolizumab and capecitabine is superior to single-\\nagent therapy in high-risk patients (stage II–III) who did not reach pCR.'),\n",
       " Document(metadata={}, page_content='At the time, only results from phase II studies in metastatic TNBC demonstrated no new safety signals\\nwith this combination [ 86 , 87 ].'),\n",
       " Document(metadata={}, page_content='Pembrolizumab has also not been studied in combination with olaparib in the adjuvant setting, for the'),\n",
       " Document(metadata={}, page_content='treatment of patients with _BRCA_ mutations. No efficacy data are reported in the literature, even if some'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 240'),\n",
       " Document(metadata={}, page_content='safety data are reported in the metastatic setting, in some early-phase studies that have evaluated the\\ncombination of PARPis and ICIs, not reporting unexpected toxicities [ 88 , 89 ].'),\n",
       " Document(metadata={}, page_content='Prospective trials would be needed to define what is the optimal adjuvant strategy according to RCB\\n(single-agent CHT or poly-CHT), how the clinician should decide between olaparib, immunotherapy or'),\n",
       " Document(metadata={}, page_content='capecitabine in the treatment of the population with _BRCA_ mutations and whether these therapies can be\\nadministered in combination or sequence, with data in terms of efficacy and safety.'),\n",
       " Document(metadata={}, page_content='Additional treatment strategies with new drugs are being studied as adjuvant treatment after NACT,\\nwith antibody-drug conjugates (ADCs) such as datopotamab deruxtecan (with or without durvalumab in'),\n",
       " Document(metadata={}, page_content='TROPICS-Breast 03, ClinicalTrials.gov identifier: NCT05629585), and patritumab deruxtecan (HER3-DXd)'),\n",
       " Document(metadata={}, page_content='which showed promising clinical response and biological changes in early TNBC [SOLTI TOT-HER3 window'),\n",
       " Document(metadata={}, page_content='of opportunity trial part B, presented at European Society for Medical Oncology (ESMO) Breast 2023], or\\nwith ICIs (A-BRAVE trial, NCT02926196 and SWOG S1418/BR006 trial, NCT02954874).'),\n",
       " Document(metadata={}, page_content='#### New biomarkers and frontiers in TNBC'),\n",
       " Document(metadata={}, page_content='Recent progress in integrating ICIs and novel agents has revolutionized the therapeutic approach for early'),\n",
       " Document(metadata={}, page_content='TNBC. Treatment strategies now emphasize escalating chemotherapeutic agents based on standard\\nneoadjuvant regimens. An example is a phase II trial (ACTRN12617000651381) presented at the San'),\n",
       " Document(metadata={}, page_content='Antonio Breast Cancer Symposium 2022 evaluating in high-risk TNBC, the addition of ipilimumab and\\nnivolumab to neoadjuvant paclitaxel following a suboptimal response to anthracycline-based CHT (< 50%'),\n",
       " Document(metadata={}, page_content='tumor reduction) and resulting in promising objective response rate (ORR) (43.7%) and pCR (18.8%) rates,\\nregardless of PD-L1 status.'),\n",
       " Document(metadata={}, page_content='However, it is also crucial to identify subgroups of patients with favorable prognoses, where NACT'),\n",
       " Document(metadata={}, page_content='could potentially be de-escalated. Therefore, discovering novel biomarkers to categorize patients with good\\nprognoses and safely de-escalate NACT is essential.'),\n",
       " Document(metadata={}, page_content='TILs show promise as a biomarker for selecting patients who may have favorable outcomes with'),\n",
       " Document(metadata={}, page_content='treatment de-escalation. In recent trials, higher TILs levels were associated with a higher pCR rate [ 71 , 75 ,'),\n",
       " Document(metadata={}, page_content='90 ] and with a better response [ 75 , 91 ]. Liquid biopsies, such as circulating tumor DNA (ctDNA), could'),\n",
       " Document(metadata={}, page_content='serve as promising markers for identifying patients who might benefit from de-escalating or escalating'),\n",
       " Document(metadata={}, page_content='neoadjuvant or adjuvant treatment. Rapid ctDNA clearance during NACT in early TNBC is linked to a high'),\n",
       " Document(metadata={}, page_content='likelihood of achieving pCR [ 92 ]. Conversely, detecting ctDNA after completing NACT and surgery is'),\n",
       " Document(metadata={}, page_content='associated with higher recurrence rates and poorer prognoses [ 93 ]. The use of dynamic biomarkers, such'),\n",
       " Document(metadata={}, page_content='as ctDNA, to guide the choice of treatments in high-risk patients appears increasingly to be an important\\nresource to be exploited in future studies.'),\n",
       " Document(metadata={}, page_content='Furthermore, ADCs are emerging. Particularly, sacituzumab govitecan (SG) an ADC targeting Trop-\\nwas approved in metastatic TNBC patients who received ≥ 2 prior systemic therapies in the light of the'),\n",
       " Document(metadata={}, page_content='results of the phase III ASCENT study. In this trial patients were randomized (1:1) to receive sacituzumab'),\n",
       " Document(metadata={}, page_content='govitecan 10 mg/kg via intravenous infusion on day 1 and day 8 of a 21-day treatment cycle or a treatment'),\n",
       " Document(metadata={}, page_content='of physician’s choice (TPC) achieving the primary endpoint (PFS 4.8 _vs._ 1.7 months) and also demonstrating'),\n",
       " Document(metadata={}, page_content='an advantage in terms of OS (11.8 months _vs._ 6.9 months) [ 94 ]. Another single-arm phase II trial is'),\n",
       " Document(metadata={}, page_content='evaluating SG and atezolizumab in combination as adjuvant treatment for patients with TNBC who have'),\n",
       " Document(metadata={}, page_content='residual invasive disease after neoadjuvant therapy and detectable ctDNA (ClinicalTrials.gov identifier\\nNCT04434040).'),\n",
       " Document(metadata={}, page_content='Finally, it is essential to redefine, with new dedicated trials, the role of ER-low (1–9%) BC which,'),\n",
       " Document(metadata={}, page_content='biologically and prognostically very similar to TNBC, could potentially benefit from the addition of'),\n",
       " Document(metadata={}, page_content='immunotherapy to CHT and the role of HER-2 low [score 1+ or 2+ not amplified in fluorescence _in situ_'),\n",
       " Document(metadata={}, page_content='hybridization (FISH)] BC in the light of recent results of efficacy of trastuzumab deruxtecan in advanced BC'),\n",
       " Document(metadata={}, page_content='HER-2 low. Therefore, future studies are likely to expand the armamentarium at our disposal in this setting.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 241'),\n",
       " Document(metadata={}, page_content='```\\nNew frontiers in early TNBC are summarized in Figure 2.'),\n",
       " Document(metadata={}, page_content='```\\n**Figure 2.** New frontiers in early TNBC\\n\\n#### Interpretation and clinical implications'),\n",
       " Document(metadata={}, page_content='TNBC has long been a challenging disease to treat due to its aggressive behavior and the lack of target\\ntherapies [ 95 ].'),\n",
       " Document(metadata={}, page_content='Thanks to recent developments on TNBC, a series of therapeutic targets have been identified for the'),\n",
       " Document(metadata={}, page_content='treatment of metastatic and early setting diseases. Especially for the radically operable disease, the chances'),\n",
       " Document(metadata={}, page_content='of cure are increased with treatments aimed at reducing the odds of recurrence after tumor removal.'),\n",
       " Document(metadata={}, page_content='Anthracycline and taxane-based poly-CHT remains the standard of treatment, most often administered'),\n",
       " Document(metadata={}, page_content='preoperatively to assess tumor sensitivity. It aims to increase the rate of local control, making it useful to\\nguide breast-conserving surgery and to ensure survival benefits by reaching the pCR.'),\n",
       " Document(metadata={}, page_content='The introduction of immunotherapy in association with poly-CHT in the neoadjuvant setting has'),\n",
       " Document(metadata={}, page_content='increased the rate of pCR, guaranteeing better results in terms of long-term benefits in the KEYNOTE-522,'),\n",
       " Document(metadata={}, page_content='the pivotal trial that led to the approval in clinical practice of the use of the anti-PD1, pembrolizumab, in the'),\n",
       " Document(metadata={}, page_content='early setting disease (neoadjuvant and adjuvant setting). These clinical findings were based on preclinical'),\n",
       " Document(metadata={}, page_content='investigations that overturned the previous belief that BC was not an immunogenic disease [ 12 ].'),\n",
       " Document(metadata={}, page_content='The actual need is to define the optimal adjuvant strategy after neoadjuvant chemo-immunotherapy,'),\n",
       " Document(metadata={}, page_content='which must be affected by the patient’s risk of recurrence based on the histological prognostic and evidence'),\n",
       " Document(metadata={}, page_content='after radical surgery, the individual’s tolerance of therapy-induced side effects (Figure 3).'),\n",
       " Document(metadata={}, page_content='In patients with low RCB and a low overall risk of recurrence, pembrolizumab alone should be'),\n",
       " Document(metadata={}, page_content='continued. In patients with poor prognostic features of high RCB, this strategy may not be the best choice.'),\n",
       " Document(metadata={}, page_content='Patients with high RCB, BRCA wild type, could benefit from capecitabine alone, although it would be\\nreasonable to use a combination of capecitabine and pembrolizumab. Patients with high RCB, germline'),\n",
       " Document(metadata={}, page_content='_BRCA_ mutations, could benefit from olaparib (according to the inclusion criteria of the OlympiA trial),'),\n",
       " Document(metadata={}, page_content='although it would be reasonable to use olaparib and pembrolizumab in combination or sequentially.'),\n",
       " Document(metadata={}, page_content='However, none of these strategies, in monotherapy and/or in combination, have evidence from specific'),\n",
       " Document(metadata={}, page_content='randomized trials after the neoadjuvant immunotherapy. There are no data on efficacy and safety in this'),\n",
       " Document(metadata={}, page_content='setting. Currently, the best schedule is not known, and new data are awaited on new adjuvant strategies.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 242\\n\\n**Figure 3.** Current treatment algorithm for stage II–III TNBC'),\n",
       " Document(metadata={}, page_content='Extensive efforts will also be required to investigate and expand access to immunotherapy to ER-low'),\n",
       " Document(metadata={}, page_content='populations (ER 1–9%), not included in KEYNOTE-522. It represents a subgroup that does not formally'),\n",
       " Document(metadata={}, page_content='meet the definition of TNBC, but shares biology, with nearly 90% of these tumors harboring a basal-like'),\n",
       " Document(metadata={}, page_content='intrinsic subtype, and prognosis with TNBC and could share the same benefit from the addition of\\nimmunotherapy [ 96 , 97 ].'),\n",
       " Document(metadata={}, page_content='Furthermore, novel active agents are emerging for the treatment of TNBC and could provide an\\nopportunity for a de-escalation of traditional CHT, the anti-trophoblast cell-surface antigen 2 (Trop2)'),\n",
       " Document(metadata={}, page_content='sacituzumab govitecan that is currently being investigated in the early setting, including in combination\\nwith immunotherapy in the ASPRIA trial (ClinicalTrials.gov identifier NCT04434040).'),\n",
       " Document(metadata={}, page_content='#### Conclusions\\n\\nThis review highlights the multitude of advances in the treatment of early-stage TNBC and the important\\nissues raised.'),\n",
       " Document(metadata={}, page_content='The management of triple-negative breast cancer (TNBC) has seen notable advancements with the\\nidentification of therapeutic targets and successful integration of immunotherapy in neoadjuvant'),\n",
       " Document(metadata={}, page_content='treatment. However, the current challenge lies in determining the optimal adjuvant strategy post-chemo-'),\n",
       " Document(metadata={}, page_content='immunotherapy, tailoring decisions to individual patient characteristics and prognostic factors. The'),\n",
       " Document(metadata={}, page_content='uncertainty surrounding the efficacy and safety of these strategies necessitates further randomized studies,'),\n",
       " Document(metadata={}, page_content='while ongoing research explores novel approaches, such as the potential use of innovative agents like'),\n",
       " Document(metadata={}, page_content='sacituzumab govitecan in the context of de-escalating traditional CHT. The imperative to extend access to'),\n",
       " Document(metadata={}, page_content='immunotherapy to subgroups, such as those with low ER expression, holds crucial promise, paving the way\\nfor a more personalized and targeted future direction in TNBC treatment.'),\n",
       " Document(metadata={}, page_content='In the next few years, it will be necessary to design new prospective clinical trials and wait for the'),\n",
       " Document(metadata={}, page_content='results of those in progress, for a better knowledge of the efficacy of combination therapies, therapeutic'),\n",
       " Document(metadata={}, page_content='sequences and new target drugs for the treatment of a disease which up to a few years ago was considered'),\n",
       " Document(metadata={}, page_content='“untargetable”. This should be accompanied by a commitment to biomarker discovery, which could help the\\noncologist make the best decision for patient care.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 243\\n\\n#### Abbreviations\\n\\nAC: doxorubicin and cyclophosphamide\\n\\nADCs: antibody-drug conjugates'),\n",
       " Document(metadata={}, page_content='BC: breast cancer\\n\\nBRCA: breast cancer susceptibility genes\\n\\nCHT: chemotherapy\\n\\nCI: confidence interval\\n\\nCREATE-X: Capecitabine for Residual Cancer as Adjuvant Therapy\\n\\nctDNA: circulating tumor DNA'),\n",
       " Document(metadata={}, page_content='DFS: disease-free survival\\n\\nEFS: event-free survival\\n\\nER: estrogen receptor\\n\\nFDA: Food and Drug Administration\\n\\nHER2: human epidermal growth factor receptor 2\\n\\nHR: hazard ratio'),\n",
       " Document(metadata={}, page_content='HR: hazard ratio\\n\\nHR+: hormone receptor-positive\\n\\nICI: immune checkpoint inhibitor\\n\\niDFS: invasive disease-free survival\\n\\nIM: immunomodulatory\\n\\nLAR: luminal androgen receptor\\n\\nM: mesenchymal'),\n",
       " Document(metadata={}, page_content='M: mesenchymal\\n\\nNACT: neoadjuvant chemotherapy\\n\\nOS: overall survival\\n\\nPARP: Poly(ADP-ribose) polymerase\\n\\npCR: pathologic complete response\\n\\nPD-L1: programmed death ligand 1'),\n",
       " Document(metadata={}, page_content='RCB: residual cancer burden\\n\\nTILs: tumor-infiltrating lymphocytes\\n\\nTMB: tumor mutational burden\\n\\nTME: tumor microenvironment\\n\\nTNBC: triple negative breast cancer\\n\\n#### Declarations'),\n",
       " Document(metadata={}, page_content='#### Declarations\\n\\n**Author contributions**'),\n",
       " Document(metadata={}, page_content='PDS: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Validation,'),\n",
       " Document(metadata={}, page_content='Supervision. MP, CG, and GRO: Conceptualization, Investigation, Writing—original draft, Writing—review &'),\n",
       " Document(metadata={}, page_content='editing. ANS, PF, and CL: Validation, Writing—review & editing, Supervision. DC: Investigation. All authors\\nread and approved the submitted version.'),\n",
       " Document(metadata={}, page_content='Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 244\\n\\n**Conflicts of interest**\\n\\nThe authors declare that they have no conflicts of interest.'),\n",
       " Document(metadata={}, page_content='**Ethical approval**\\n\\nNot applicable.\\n\\n**Consent to participate**\\n\\nNot applicable.\\n\\n**Consent to publication**\\n\\nNot applicable.\\n\\n**Availability of data and materials**\\n\\nNot applicable.\\n\\n**Funding**'),\n",
       " Document(metadata={}, page_content='**Funding**\\n\\nNot applicable.\\n\\n**Copyright**\\n\\n© The Author(s) 2024.\\n\\n#### References'),\n",
       " Document(metadata={}, page_content='```\\nSporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic markers in triple-negative breast cancer.\\nClin Breast Cancer. 2018;18:e841–50.\\n```\\n##### 1.'),\n",
       " Document(metadata={}, page_content='```\\n##### 1.\\n\\n```\\nHoward FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J. 2021;27:\\n8–16.\\n```\\n##### 2.'),\n",
       " Document(metadata={}, page_content='```\\nAlmansour NM. Triple-negative breast cancer: a brief review about epidemiology, risk factors,\\nsignaling pathways, treatment and role of artificial intelligence. Front Mol Biosci. 2022;9:836417.'),\n",
       " Document(metadata={}, page_content='```\\n##### 3.'),\n",
       " Document(metadata={}, page_content='```\\nCurtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic\\narchitecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.'),\n",
       " Document(metadata={}, page_content='```\\n##### 4.\\n\\n```\\nAzim HA, Ghosn M, Oualla K, Kassem L. Personalized treatment in metastatic triple-negative breast\\ncancer: the outlook in 2020. Breast J. 2020;26:69–80.\\n```\\n##### 5.'),\n",
       " Document(metadata={}, page_content='```\\nCardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al.; ESMO Guidelines\\nCommittee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and'),\n",
       " Document(metadata={}, page_content='follow-up†. Ann Oncol. 2019;30:1194–220. Erratum in: Ann Oncol. 2019;30:1674. Erratum in: Ann\\nOncol. 2021;32:284.'),\n",
       " Document(metadata={}, page_content='```\\n##### 6.'),\n",
       " Document(metadata={}, page_content='```\\nBear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al.; National Surgical Adjuvant\\nBreast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential'),\n",
       " Document(metadata={}, page_content='preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from\\nNational Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74.'),\n",
       " Document(metadata={}, page_content='```\\n##### 7.'),\n",
       " Document(metadata={}, page_content='```\\nGolshan M, Loibl S, Wong SM, Houber JB, O’Shaughnessy J, Rugo HS, et al. Breast conservation after\\nneoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess'),\n",
       " Document(metadata={}, page_content='randomized clinical trial. JAMA Surg. 2020;155:e195410. Erratum in: JAMA Surg. 2021;156:503.'),\n",
       " Document(metadata={}, page_content='```\\n##### 8.'),\n",
       " Document(metadata={}, page_content='```\\nTurner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular\\nprofiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic'),\n",
       " Document(metadata={}, page_content='targets. Oncogene. 2010;29:2013–23.'),\n",
       " Document(metadata={}, page_content='```\\n##### 9.'),\n",
       " Document(metadata={}, page_content='```\\nMarra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast'),\n",
       " Document(metadata={}, page_content='cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast\\nCancer. 2020;6:54.'),\n",
       " Document(metadata={}, page_content='```\\n##### 10.\\n\\n\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 245'),\n",
       " Document(metadata={}, page_content='```\\nYe F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advancements in clinical aspects of targeted\\ntherapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105.\\n```\\n##### 11.'),\n",
       " Document(metadata={}, page_content='```\\n##### 11.\\n\\n```\\nLiu Z, Li M, Jiang Z, Wang X. A comprehensive immunologic portrait of triple-negative breast cancer.\\nTransl Oncol. 2018;11:311–29.\\n```\\n##### 12.'),\n",
       " Document(metadata={}, page_content='```\\nFarshbafnadi M, Pastaki Khoshbin A, Rezaei N. Immune checkpoint inhibitors for triple-negative\\nbreast cancer: from immunological mechanisms to clinical evidence. Int Immunopharmacol. 2021;98:'),\n",
       " Document(metadata={}, page_content='107876.'),\n",
       " Document(metadata={}, page_content='```\\n##### 13.'),\n",
       " Document(metadata={}, page_content='```\\nLehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative'),\n",
       " Document(metadata={}, page_content='breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One.\\n2016;11:e0157368.'),\n",
       " Document(metadata={}, page_content='```\\n##### 14.'),\n",
       " Document(metadata={}, page_content='```\\nBurstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, et al. Comprehensive\\ngenomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer'),\n",
       " Document(metadata={}, page_content='Res. 2015;21:1688–98.'),\n",
       " Document(metadata={}, page_content='```\\n##### 15.'),\n",
       " Document(metadata={}, page_content='```\\nXiao Y, Ma D, Zhao S, Suo C, Shi J, Xue MZ, et al.; AME Breast Cancer Collaborative Group. Multi-omics\\nprofiling reveals distinct microenvironment characterization and suggests immune escape'),\n",
       " Document(metadata={}, page_content='mechanisms of triple-negative breast cancer. Clin Cancer Res. 2019;25:5002–14.'),\n",
       " Document(metadata={}, page_content='```\\n##### 16.'),\n",
       " Document(metadata={}, page_content='```\\nPelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, Hutton C, et al. Anti-inflammatory drugs\\nremodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer'),\n",
       " Document(metadata={}, page_content='Discov. 2021;11:2602–19.'),\n",
       " Document(metadata={}, page_content='```\\n##### 17.\\n\\n```\\nMittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in\\ntriple-negative breast cancer. Cancer Immunol Res. 2014;2:361–70.\\n```\\n##### 18.'),\n",
       " Document(metadata={}, page_content='```\\nWang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, et al. Prevalence of BRCA1 mutations and responses\\nto neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast'),\n",
       " Document(metadata={}, page_content='cancer. Ann Oncol. 2015;26:523–8.'),\n",
       " Document(metadata={}, page_content='```\\n##### 19.'),\n",
       " Document(metadata={}, page_content='```\\nHahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, et al. Germline mutation status,'),\n",
       " Document(metadata={}, page_content='pathological complete response, and disease-free survival in triple-negative breast cancer: secondary\\nanalysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017;3:1378–85.'),\n",
       " Document(metadata={}, page_content='```\\n##### 20.'),\n",
       " Document(metadata={}, page_content='```\\nPohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, et al. Association of germline'),\n",
       " Document(metadata={}, page_content='variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of\\nthe GeparOcto randomized clinical trial. JAMA Oncol. 2020;6:744–8.'),\n",
       " Document(metadata={}, page_content='```\\n##### 21.'),\n",
       " Document(metadata={}, page_content='```\\nVollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, et al. Genomic patterns\\nresembling BRCA1 - and BRCA2 -mutated breast cancers predict benefit of intensified carboplatin-'),\n",
       " Document(metadata={}, page_content='based chemotherapy. Breast Cancer Res. 2014;16:R47.'),\n",
       " Document(metadata={}, page_content='```\\n##### 22.\\n\\n```\\nBelli C, Duso BA, Ferraro E, Curigliano G. Homologous recombination deficiency in triple negative\\nbreast cancer. Breast. 2019;45:15–21.\\n```\\n##### 23.'),\n",
       " Document(metadata={}, page_content='```\\nvan Verschuer VMT, Hooning MJ, van Baare-Georgieva RD, Hollestelle A, Timmermans AM, Koppert\\nLB, et al. Tumor-associated inflammation as a potential prognostic tool in BRCA1/2 -associated breast'),\n",
       " Document(metadata={}, page_content='cancer. Hum Pathol. 2015;46:182–90.'),\n",
       " Document(metadata={}, page_content='```\\n##### 24.'),\n",
       " Document(metadata={}, page_content='```\\nNolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, et al.; Kathleen Cuningham\\nFoundation Consortium for Research into Familial Breast Cancer (kConFab); Perou CM, Visvader JE,'),\n",
       " Document(metadata={}, page_content='Gray DHD, Loi S, Lindeman GJ. Combined immune checkpoint blockade as a therapeutic strategy for\\nBRCA1 -mutated breast cancer. Sci Transl Med. 2017;9:eaal4922.'),\n",
       " Document(metadata={}, page_content='```\\n##### 25.'),\n",
       " Document(metadata={}, page_content='```\\nParkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of STING-\\ndependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer'),\n",
       " Document(metadata={}, page_content='Inst. 2016;109:djw199.'),\n",
       " Document(metadata={}, page_content='```\\n##### 26.'),\n",
       " Document(metadata={}, page_content='```\\nCastaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, et al. Tumor infiltrating'),\n",
       " Document(metadata={}, page_content='lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol.\\n2016;7:387–94.'),\n",
       " Document(metadata={}, page_content='```\\n##### 27.\\n\\n\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 246'),\n",
       " Document(metadata={}, page_content='```\\nGarcía-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-infiltrating lymphocytes in triple negative\\nbreast cancer: the future of immune targeting. Clin Med Insights Oncol. 2016;10:31–9.'),\n",
       " Document(metadata={}, page_content='```\\n##### 28.'),\n",
       " Document(metadata={}, page_content='```\\nGomez-Macias GS, Molinar-Flores G, Lopez-Garcia CA, Santuario-Facio S, Decanini-Arcaute H, Valero-'),\n",
       " Document(metadata={}, page_content='Elizondo J, et al. Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and\\ngenetic characterization. Oncol Lett. 2020;20:140.'),\n",
       " Document(metadata={}, page_content='```\\n##### 29.'),\n",
       " Document(metadata={}, page_content='```\\nSousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, et al. Human breast cancer cells\\neducate macrophages toward the M2 activation status. Breast Cancer Res. 2015;17:101.'),\n",
       " Document(metadata={}, page_content='```\\n##### 30.'),\n",
       " Document(metadata={}, page_content='```\\nMedrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in\\ntumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306.'),\n",
       " Document(metadata={}, page_content='```\\n##### 31.'),\n",
       " Document(metadata={}, page_content='```\\nSavas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host\\nimmunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228–41.'),\n",
       " Document(metadata={}, page_content='```\\n##### 32.'),\n",
       " Document(metadata={}, page_content='```\\nCortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete\\nresponse and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;'),\n",
       " Document(metadata={}, page_content='384:164–72.'),\n",
       " Document(metadata={}, page_content='```\\n##### 33.'),\n",
       " Document(metadata={}, page_content='```\\nDenkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-\\ninfiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of'),\n",
       " Document(metadata={}, page_content='3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.'),\n",
       " Document(metadata={}, page_content='```\\n##### 34.'),\n",
       " Document(metadata={}, page_content='```\\nAdams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-\\ninfiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant'),\n",
       " Document(metadata={}, page_content='breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–66.'),\n",
       " Document(metadata={}, page_content='```\\n##### 35.'),\n",
       " Document(metadata={}, page_content='```\\nLoi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of'),\n",
       " Document(metadata={}, page_content='tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive\\nbreast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based'),\n",
       " Document(metadata={}, page_content='chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–7.'),\n",
       " Document(metadata={}, page_content='```\\n##### 36.'),\n",
       " Document(metadata={}, page_content='```\\nLoi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are'),\n",
       " Document(metadata={}, page_content='prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast\\ncancer: results from the FinHER trial. Ann Oncol. 2014;25:1544–50.'),\n",
       " Document(metadata={}, page_content='```\\n##### 37.'),\n",
       " Document(metadata={}, page_content='```\\nHida AI, Watanabe T, Sagara Y, Kashiwaba M, Sagara Y, Aogi K, et al. Diffuse distribution of tumor-\\ninfiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-'),\n",
       " Document(metadata={}, page_content='negative breast cancer. Breast Cancer Res Treat. 2019;178:283–94.'),\n",
       " Document(metadata={}, page_content='```\\n##### 38.'),\n",
       " Document(metadata={}, page_content='```\\nIbrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. The prognostic value of tumor-infiltrating\\nlymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014;148:'),\n",
       " Document(metadata={}, page_content='467–76.'),\n",
       " Document(metadata={}, page_content='```\\n##### 39.'),\n",
       " Document(metadata={}, page_content='```\\nSalgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al.; International TILs Working\\nGroup 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer:'),\n",
       " Document(metadata={}, page_content='recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71.'),\n",
       " Document(metadata={}, page_content='```\\n##### 40.'),\n",
       " Document(metadata={}, page_content='```\\nKarn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, et al. Association between genomic metrics and\\nimmune infiltration in triple-negative breast cancer. JAMA Oncol. 2017;3:1707–11.'),\n",
       " Document(metadata={}, page_content='```\\n##### 41.\\n\\n```\\nSafonov A, Jiang T, Bianchini G, Győrffy B, Karn T, Hatzis C, et al. Immune gene expression is associated\\nwith genomic aberrations in breast cancer. Cancer Res. 2017;77:3317–24.'),\n",
       " Document(metadata={}, page_content='```\\n##### 42.'),\n",
       " Document(metadata={}, page_content='```\\nLotfinejad P, Asghari Jafarabadi M, Abdoli Shadbad M, Kazemi T, Pashazadeh F, Sandoghchian\\nShotorbani S, et al. Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and'),\n",
       " Document(metadata={}, page_content='programmed death ligand 1 (PD-L1) expression in triple-negative breast cancer (TNBC): a systematic\\nreview and meta-analysis study. Diagnostics (Basel). 2020;10:704.'),\n",
       " Document(metadata={}, page_content='```\\n##### 43.'),\n",
       " Document(metadata={}, page_content='```\\nZhu X, Zhang Q, Wang D, Liu C, Han B, Yang JM. Expression of PD-L1 attenuates the positive impacts of'),\n",
       " Document(metadata={}, page_content='high-level tumor-infiltrating lymphocytes on prognosis of triple-negative breast cancer. Cancer Biol\\nTher. 2019;20:1105–12.'),\n",
       " Document(metadata={}, page_content='```\\n##### 44.\\n\\n\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 247'),\n",
       " Document(metadata={}, page_content='```\\nNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer. National\\nComprehensive Cancer Network® (NCCN®); c2020 [cited 2023 May 21]. Available from: https://'),\n",
       " Document(metadata={}, page_content='www2.tri-kobe.org/nccn/guideline/breast/english/breast.pdf'),\n",
       " Document(metadata={}, page_content='```\\n##### 45.'),\n",
       " Document(metadata={}, page_content='```\\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxane-\\ncontaining chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of'),\n",
       " Document(metadata={}, page_content='100 000 women from 86 randomised trials. Lancet. 2023;401:1277-1292.'),\n",
       " Document(metadata={}, page_content='```\\n##### 46.'),\n",
       " Document(metadata={}, page_content='```\\nSparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, et al. Long-term follow-up of the E'),\n",
       " Document(metadata={}, page_content='phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol. 2015;\\n33:2353–60.'),\n",
       " Document(metadata={}, page_content='```\\n##### 47.'),\n",
       " Document(metadata={}, page_content='```\\nJones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing\\ndoxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for'),\n",
       " Document(metadata={}, page_content='operable breast cancer. J Clin Oncol. 2006;24:5381–7. Erratum in: J Clin Oncol. 2007;25:1819.'),\n",
       " Document(metadata={}, page_content='```\\n##### 48.\\n\\n```\\nWheate NJ, Collins JG. Multi-nuclear platinum drugs: a new paradigm in chemotherapy. Curr Med\\nChem Anticancer Agents. 2005;5:267–79.\\n```\\n##### 49.'),\n",
       " Document(metadata={}, page_content='```\\nGarutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, et al. Platinum salts in patients\\nwith breast cancer: a focus on predictive factors. Int J Mol Sci. 2019;20:3390.'),\n",
       " Document(metadata={}, page_content='```\\n##### 50.\\n\\n```\\nChalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with\\n“ BRCA ness”: a review. Oncologist. 2013;18:909–16.\\n```\\n##### 51.'),\n",
       " Document(metadata={}, page_content='```\\nVetter M, Fokas S, Biskup E, Schmid T, Schwab F, Schoetzau A, et al. Efficacy of adjuvant chemotherapy'),\n",
       " Document(metadata={}, page_content='with carboplatin for early triple negative breast cancer: a single center experience. Oncotarget. 2017;\\n8:75617–26.'),\n",
       " Document(metadata={}, page_content='```\\n##### 52.'),\n",
       " Document(metadata={}, page_content='```\\nSu YW, Hung CY, Lam HB, Chang YC, Yang PS. A single institution experience of incorporation of\\ncisplatin into adjuvant chemotherapy for patients with triple-negative breast cancer of unknown'),\n",
       " Document(metadata={}, page_content='BRCA mutation status. Clin Med Insights Oncol. 2018;12:1179554918794672.'),\n",
       " Document(metadata={}, page_content='```\\n##### 53.'),\n",
       " Document(metadata={}, page_content='```\\nYu KD, Ye FG, He M, Fan L, Ma D, Mo M, et al. Effect of adjuvant paclitaxel and carboplatin on survival'),\n",
       " Document(metadata={}, page_content='in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6:\\n1390–6.'),\n",
       " Document(metadata={}, page_content='```\\n##### 54.'),\n",
       " Document(metadata={}, page_content='```\\nNorquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary Somatic Mutations\\nRestoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas. J Clin Oncol.'),\n",
       " Document(metadata={}, page_content='2011;29:3008–15.'),\n",
       " Document(metadata={}, page_content='```\\n##### 55.'),\n",
       " Document(metadata={}, page_content='```\\nGuillemette S, Serra RW, Peng M, Hayes JA, Konstantinopoulos PA, Green MR, et al. Resistance to\\ntherapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. Genes Dev.'),\n",
       " Document(metadata={}, page_content='2015;29:489–94.'),\n",
       " Document(metadata={}, page_content='```\\n##### 56.\\n\\n```\\nZhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, et al. The drug-resistance mechanisms of five platinum-\\nbased antitumor agents. Front Pharmacol. 2020;11:343.\\n```\\n##### 57.'),\n",
       " Document(metadata={}, page_content='```\\nRastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative\\nchemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-'),\n",
       " Document(metadata={}, page_content='```\\n27. J Clin Oncol. 2008;26:778–85. Erratum in: J Clin Oncol. 2008;26:2793.\\n\\n##### 58.'),\n",
       " Document(metadata={}, page_content='```\\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant\\nversus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from'),\n",
       " Document(metadata={}, page_content='ten randomised trials. Lancet Oncol. 2018;19:27–39.'),\n",
       " Document(metadata={}, page_content='```\\n##### 59.'),\n",
       " Document(metadata={}, page_content='```\\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of\\nchemotherapy by more frequent administration or sequential scheduling: a patient-level meta-'),\n",
       " Document(metadata={}, page_content='analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393:\\n1440–52.'),\n",
       " Document(metadata={}, page_content='```\\n##### 60.'),\n",
       " Document(metadata={}, page_content='```\\nvon Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in\\npatients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a'),\n",
       " Document(metadata={}, page_content='randomised phase 2 trial. Lancet Oncol. 2014;15:747–56.'),\n",
       " Document(metadata={}, page_content='```\\n##### 61.\\n\\n\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 248'),\n",
       " Document(metadata={}, page_content='```\\nSikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of\\ncarboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense'),\n",
       " Document(metadata={}, page_content='doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-\\nnegative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13–21.'),\n",
       " Document(metadata={}, page_content='```\\n##### 62.'),\n",
       " Document(metadata={}, page_content='```\\nLoibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP\\ninhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in'),\n",
       " Document(metadata={}, page_content='triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:\\n497–509.'),\n",
       " Document(metadata={}, page_content='```\\n##### 63.'),\n",
       " Document(metadata={}, page_content='```\\nFasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, et al.; German Breast Group and\\nArbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in'),\n",
       " Document(metadata={}, page_content='comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and\\nhomologous recombination deficiency (GeparOLA study). Ann Oncol. 2021;32:49–57.'),\n",
       " Document(metadata={}, page_content='```\\n##### 64.'),\n",
       " Document(metadata={}, page_content='```\\nGupta S, Nair NS, Hawaldar R, Vanmali V, Parmar V, Gulia S, et al. Abstract GS5-01: Addition of\\nplatinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-'),\n",
       " Document(metadata={}, page_content='negative breast cancer: a phase III randomized controlled trial. Cancer Res. 2023;83:GS5-01.'),\n",
       " Document(metadata={}, page_content='```\\n##### 65.'),\n",
       " Document(metadata={}, page_content='```\\nCortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al.; KEYNOTE-355 Investigators.\\nPembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated'),\n",
       " Document(metadata={}, page_content='locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a\\nrandomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–28.'),\n",
       " Document(metadata={}, page_content='```\\n##### 66.'),\n",
       " Document(metadata={}, page_content='```\\nSchmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al.; IMpassion130 Trial\\nInvestigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J'),\n",
       " Document(metadata={}, page_content='Med. 2018;379:2108–21.'),\n",
       " Document(metadata={}, page_content='```\\n##### 67.'),\n",
       " Document(metadata={}, page_content='```\\nMiles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al.; IMpassion131 investigators.'),\n",
       " Document(metadata={}, page_content='Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of'),\n",
       " Document(metadata={}, page_content='first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-\\nnegative breast cancer. Ann Oncol. 2021;32:994–1004.'),\n",
       " Document(metadata={}, page_content='```\\n##### 68.'),\n",
       " Document(metadata={}, page_content='```\\nEmens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-\\npaclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer:'),\n",
       " Document(metadata={}, page_content='IMpassion130 final overall survival analysis. Ann Oncol. 2021;32:983–93. Erratum in: Ann Oncol.\\n2021;32:1650.'),\n",
       " Document(metadata={}, page_content='```\\n##### 69.'),\n",
       " Document(metadata={}, page_content='```\\nCortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al.; KEYNOTE-355 Investigators.\\nPembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;'),\n",
       " Document(metadata={}, page_content='387:217–26.'),\n",
       " Document(metadata={}, page_content='```\\n##### 70.'),\n",
       " Document(metadata={}, page_content='```\\nGianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR)'),\n",
       " Document(metadata={}, page_content='to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally\\nadvanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33:534–43.'),\n",
       " Document(metadata={}, page_content='```\\n##### 71.'),\n",
       " Document(metadata={}, page_content='```\\nMittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in\\ncombination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo'),\n",
       " Document(metadata={}, page_content='and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a\\nrandomised, double-blind, phase 3 trial. Lancet. 2020;396:1090–100.'),\n",
       " Document(metadata={}, page_content='```\\n##### 72.'),\n",
       " Document(metadata={}, page_content='```\\nSchmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al.; KEYNOTE-522 Investigators.\\nEvent-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;'),\n",
       " Document(metadata={}, page_content='386:556–67.'),\n",
       " Document(metadata={}, page_content='```\\n##### 73.'),\n",
       " Document(metadata={}, page_content='```\\nDel Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, et al.; Gruppo Italiano'),\n",
       " Document(metadata={}, page_content='Mammella Investigators. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-\\nstage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Lancet Oncol.'),\n",
       " Document(metadata={}, page_content='2022;23:1571–82.'),\n",
       " Document(metadata={}, page_content='```\\n##### 74.\\n\\n\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 249'),\n",
       " Document(metadata={}, page_content='```\\nLoibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, et al.; GBG and AGO-B. Neoadjuvant\\ndurvalumab improves survival in early triple-negative breast cancer independent of pathological'),\n",
       " Document(metadata={}, page_content='complete response. Ann Oncol. 2022;33:1149–58.'),\n",
       " Document(metadata={}, page_content='```\\n##### 75.'),\n",
       " Document(metadata={}, page_content='```\\nKuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, et al. Prognostic significance of subtype and'),\n",
       " Document(metadata={}, page_content='pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies\\nof JBCRG. Breast Cancer. 2015;22:486–95.'),\n",
       " Document(metadata={}, page_content='```\\n##### 76.'),\n",
       " Document(metadata={}, page_content='```\\nSpring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic complete response after\\nneoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive'),\n",
       " Document(metadata={}, page_content='meta-analysis. Clin Cancer Res. 2020;26:2838–48.'),\n",
       " Document(metadata={}, page_content='```\\n##### 77.'),\n",
       " Document(metadata={}, page_content='```\\nCoates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart MJ, et al.; Panel Members.'),\n",
       " Document(metadata={}, page_content='Tailoring therapies—improving the management of early breast cancer: St Gallen international expert\\nconsensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26:1533–46.'),\n",
       " Document(metadata={}, page_content='```\\n##### 78.\\n\\n```\\nMasuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer\\nafter Preoperative Chemotherapy. N Engl J Med. 2017;376:2147–59.\\n```\\n##### 79.'),\n",
       " Document(metadata={}, page_content='```\\nSymmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual\\nbreast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:'),\n",
       " Document(metadata={}, page_content='4414–22.'),\n",
       " Document(metadata={}, page_content='```\\n##### 80.'),\n",
       " Document(metadata={}, page_content='```\\nTutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al.; OlympiA Clinical Trial Steering'),\n",
       " Document(metadata={}, page_content='Committee and Investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2- mutated breast\\ncancer. N Engl J Med. 2021;384:2394–405.'),\n",
       " Document(metadata={}, page_content='```\\n##### 81.'),\n",
       " Document(metadata={}, page_content='```\\nGeyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al.; OlympiA Clinical Trial Steering'),\n",
       " Document(metadata={}, page_content='Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in'),\n",
       " Document(metadata={}, page_content='patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol.\\n2022;33:1250–68.'),\n",
       " Document(metadata={}, page_content='```\\n##### 82.'),\n",
       " Document(metadata={}, page_content='```\\nFDA D.I.S.C.D. burst edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage\\ntriple-negative breast cancer [Internet]. [cited 2023 May 21]. Available from: https://www.fda.gov/'),\n",
       " Document(metadata={}, page_content='drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-\\npembrolizumab-high-risk-early-stage-triple-negative'),\n",
       " Document(metadata={}, page_content='```\\n##### 83.'),\n",
       " Document(metadata={}, page_content='```\\nSchmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al.; KEYNOTE-522 Investigators.\\nPembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21.'),\n",
       " Document(metadata={}, page_content='```\\n##### 84.'),\n",
       " Document(metadata={}, page_content='```\\nPusztai L, Denkert C, O’Shaughnessy J, Cortes J, Dent RA, McArthur HL, et al. Event-free survival by\\nresidual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo +'),\n",
       " Document(metadata={}, page_content='chemotherapy for early TNBC: exploratory analysis from KEYNOTE-522. J Clin Oncol. 2022;40:503.'),\n",
       " Document(metadata={}, page_content='```\\n##### 85.'),\n",
       " Document(metadata={}, page_content='```\\nShah AN, Flaum L, Helenowski I, Santa-Maria CA, Jain S, Rademaker A, et al. Phase II study of\\npembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2–negative'),\n",
       " Document(metadata={}, page_content='endocrine-refractory metastatic breast cancer. J Immunother Cancer. 2020;8:e000173.'),\n",
       " Document(metadata={}, page_content='```\\n##### 86.'),\n",
       " Document(metadata={}, page_content='```\\nPage D, Pucilowska J, Bennetts L, Kim I, Sanchez K, Martel M, et al. Updated efficacy of first or second-'),\n",
       " Document(metadata={}, page_content='line pembrolizumab plus in metastatic triple negative breast cancer and correlations with baseline\\nlymphocyte and naïve CD4+ T-cell count. 2018 San Antonio Breast Cancer Symposium. San Antonio:'),\n",
       " Document(metadata={}, page_content='Books, Presentations, Posters, Etc. 2018.'),\n",
       " Document(metadata={}, page_content='```\\n##### 87.'),\n",
       " Document(metadata={}, page_content='```\\nVinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. Open-label clinical trial of\\nniraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative'),\n",
       " Document(metadata={}, page_content='breast cancer. JAMA Oncol. 2019;5:1132–40.'),\n",
       " Document(metadata={}, page_content='```\\n##### 88.'),\n",
       " Document(metadata={}, page_content='```\\nDomchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. Olaparib and durvalumab in\\npatients with germline BRCA -mutated metastatic breast cancer (MEDIOLA): an open-label,'),\n",
       " Document(metadata={}, page_content='multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155–64.'),\n",
       " Document(metadata={}, page_content='```\\n##### 89.\\n\\n\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215 Page 250'),\n",
       " Document(metadata={}, page_content='```\\nNederlof I, De Bortoli D, Bareche Y, Hooijer GKJ, Sotiriou C, Van De Vijver MJ, et al. Relationship\\nbetween tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+'),\n",
       " Document(metadata={}, page_content='chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase\\nIb KEYNOTE-173 trial. Ann Oncol. 2019;30:III2.'),\n",
       " Document(metadata={}, page_content='```\\n##### 90.\\n\\n```\\nDoroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of\\nresponse to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345–62.'),\n",
       " Document(metadata={}, page_content='```\\n##### 91.'),\n",
       " Document(metadata={}, page_content='```\\nMagbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, et al. Circulating tumor DNA in\\nneoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32:229–39.'),\n",
       " Document(metadata={}, page_content='```\\n##### 92.'),\n",
       " Document(metadata={}, page_content='```\\nRadovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, et al. Association of circulating\\ntumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in'),\n",
       " Document(metadata={}, page_content='patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-\\nrandomized clinical trial. JAMA Oncol. 2020;6:1410–5.'),\n",
       " Document(metadata={}, page_content='```\\n##### 93.'),\n",
       " Document(metadata={}, page_content='```\\nBardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al.; ASCENT Clinical Trial\\nInvestigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;'),\n",
       " Document(metadata={}, page_content='384:1529–41.'),\n",
       " Document(metadata={}, page_content='```\\n##### 94.'),\n",
       " Document(metadata={}, page_content='95. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750–69.'),\n",
       " Document(metadata={}, page_content='Schrodi S, Braun M, Andrulat A, Harbeck N, Mahner S, Kiechle M, et al. Outcome of breast cancer'),\n",
       " Document(metadata={}, page_content='patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann\\n    Oncol. 2021;32:1410–24.'),\n",
       " Document(metadata={}, page_content='##### 96.'),\n",
       " Document(metadata={}, page_content='```\\nVillegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, et al. Therapy response and prognosis'),\n",
       " Document(metadata={}, page_content='of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765\\npatients from neoadjuvant clinical trials. Eur J Cancer. 2021;148:159–70.'),\n",
       " Document(metadata={}, page_content='```\\n##### 97.'),\n",
       " Document(metadata={}, page_content='**Citation:** Li, L.; Zhang, F.; Liu, Z.;\\nFan, Z. Immunotherapy for\\nTriple-Negative Breast Cancer:\\nCombination Strategies to Improve\\nOutcome.Cancers **2023** , 15 , 321.'),\n",
       " Document(metadata={}, page_content='https://doi.org/10.3390/cancers\\n15010321'),\n",
       " Document(metadata={}, page_content='Academic Editors: Claudia De\\nLorenzo and Laura Cerchia\\nReceived: 14 November 2022\\nRevised: 27 December 2022\\nAccepted: 29 December 2022\\nPublished: 3 January 2023'),\n",
       " Document(metadata={}, page_content='**Copyright:** © 2023 by the authors.\\nLicensee MDPI, Basel, Switzerland.\\nThis article is an open access article\\ndistributed under the terms and\\nconditions of the Creative Commons'),\n",
       " Document(metadata={}, page_content='Attribution (CC BY) license (https://\\ncreativecommons.org/licenses/by/\\n4.0/).'),\n",
       " Document(metadata={}, page_content='# cancers\\n\\nReview\\n\\n## Immunotherapy for Triple-Negative Breast Cancer:\\n\\n## Combination Strategies to Improve Outcome'),\n",
       " Document(metadata={}, page_content='```\\nLiying Li, Fan Zhang, Zhenyu Liu and Zhimin Fan *\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nDepartment of Breast Surgery, General Surgery Centre, The First Hospital of Jilin University,\\nChangchun 130012, China\\n* Correspondence: fanzm@jlu.edu.cn\\n```'),\n",
       " Document(metadata={}, page_content='```\\nSimple Summary: For decades, countless efforts have been devoted to developing targeted drugs\\nto improve the prognosis of triple-negative breast cancer (TNBC). Among the novel therapies that'),\n",
       " Document(metadata={}, page_content='have been approved for the clinical management of TNBC, immunotherapy shows great potential.\\nAlthough exciting progress has been made in immunotherapy for TNBC, there are still gaps to'),\n",
       " Document(metadata={}, page_content='fill. This review will analyze current immunotherapy strategies in TNBC, summarize the current\\nlandscape of clinical trials, review the results achieved, and shed light on future developments.'),\n",
       " Document(metadata={}, page_content='```'),\n",
       " Document(metadata={}, page_content='```\\nAbstract: Due to the absence of hormone receptor (both estrogen receptors and progesterone receptors)'),\n",
       " Document(metadata={}, page_content='along with human epidermal growth factor receptor 2 (HER-2) amplification, the treatment of triple-\\nnegative breast cancer (TNBC) cannot benefit from endocrine or anti-HER-2 therapy. For a long time,'),\n",
       " Document(metadata={}, page_content='chemotherapy was the only systemic treatment for TNBC. Due to the lack of effective treatment\\noptions, the prognosis for TNBC is extremely poor. The successful application of immune checkpoint'),\n",
       " Document(metadata={}, page_content='inhibitors (ICIs) launched the era of immunotherapy in TNBC. However, the current findings show\\nmodest efficacy of programmed cell death- (ligand) 1 (PD-(L)1) inhibitors monotherapy and only'),\n",
       " Document(metadata={}, page_content='a small proportion of patients can benefit from this approach. Based on the basic principles of\\nimmunotherapy and the characteristics of the tumor immune microenvironment (TIME) in TNBC,'),\n",
       " Document(metadata={}, page_content='immune combination therapy is expected to further enhance the efficacy and expand the beneficiary\\npopulation of patients. Given the diversity of drugs that can be combined, it is important to select'),\n",
       " Document(metadata={}, page_content='effective biomarkers to identify the target population. Moreover, the side effects associated with the\\ncombination of multiple drugs should also be considered.'),\n",
       " Document(metadata={}, page_content='```\\n```\\nKeywords: triple-negative breast cancer; immunotherapy; immune checkpoint; tumor immune\\nmicroenvironment; clinical trials'),\n",
       " Document(metadata={}, page_content='```\\n**1. Introduction**\\n    Triple-negative breast cancer (TNBC) accounts for approximately 15–20% of breast\\nmalignancies and is the only subtype of breast cancer that lacks targeted treatment [ 1 ].'),\n",
       " Document(metadata={}, page_content='Compared with other subtypes, TNBC is more aggressive, and most patients develop\\nrecurrence and metastasis within 3 years, with poor prognosis [ 2 ]. Anthracycline- and'),\n",
       " Document(metadata={}, page_content='taxane-based chemotherapy remains the mainstay of treatment for early-stage patients, but\\nresistance has emerged [ 3 ]; for patients with recurrence or metastasis, there are even fewer'),\n",
       " Document(metadata={}, page_content='treatment options. There is an urgent need for novel and more effective treatments.\\n    Genomic advances reveal a high degree of heterogeneity in TNBC and set the stage'),\n",
       " Document(metadata={}, page_content='for the development of targeted therapies [ 4 – 6 ]. In the past few years, poly ADP-ribose\\npolymerase inhibitors (PARPi), programmed cell death- (ligand) 1 (PD-(L)1) inhibitors,'),\n",
       " Document(metadata={}, page_content='and antibody–drug conjugates (ADCs) have been approved successively for the treat-\\nment of TNBC. Among these, PD-1 inhibitor pembrolizumab is approved for patients'),\n",
       " Document(metadata={}, page_content='with advanced PD-L1-positive and early high-risk disease, displaying great therapeutic\\npotential.'),\n",
       " Document(metadata={}, page_content='Cancers **2023** , 15 , 321. https://doi.org/10.3390/cancers15010321 https://www.mdpi.com/journal/cancers\\n\\n\\nCancers **2023** , 15 , 321 2 of 28'),\n",
       " Document(metadata={}, page_content='```\\nSome studies have found that TNBC has higher PD-L1 expression and tumor-infiltrating\\nlymphocytes (TILs) in comparison with other subtypes [ 7 , 8 ], making it the most likely'),\n",
       " Document(metadata={}, page_content='subtype to benefit from immunotherapy. However, PD-(L)1 inhibitors benefit only a\\nsmall proportion of individuals, with a single-agent effectiveness of approximately 20%'),\n",
       " Document(metadata={}, page_content='in patients with PD-L1-positive metastatic TNBC (mTNBC) [ 9 ]. Numerous preclinical\\nand clinical studies have been conducted to investigate the reasons for this disappointing'),\n",
       " Document(metadata={}, page_content='result, expand the beneficiary population, and improve the efficacy of immune checkpoint\\ninhibitors (ICIs).\\nIn this review, we will analyze the reasons for the poor efficacy of PD-(L)1 inhibitors'),\n",
       " Document(metadata={}, page_content='monotherapy in terms of tumor immune escape mechanisms and tumor immune microen-\\nvironment (TIME) characteristics of TNBC. We summarize the current landscape of clinical'),\n",
       " Document(metadata={}, page_content='trials in TNBC, highlight the major immune combination therapy strategies in clinical\\npractice and the progress achieved, and briefly discuss the biomarkers for predicting im-'),\n",
       " Document(metadata={}, page_content='munological response, as well as possible adverse events associated with immunotherapy.'),\n",
       " Document(metadata={}, page_content='```\\n**2. Rationale of Immunotherapy and the TIME of TNBC**\\n    The cross-talk between tumor cells and the TIME can be described as “cancer immu-'),\n",
       " Document(metadata={}, page_content='noediting”, encompassing three stages: (1) elimination; (2) equilibrium, in which the host\\nimmune system and tumor cells that survive enter a dynamic balance; and (3) escape [10]\\n(Figure 1).'),\n",
       " Document(metadata={}, page_content='```\\nCancers 2023 , 15 , x 2 of 29\\n```'),\n",
       " Document(metadata={}, page_content='```\\nSome studies have found that TNBC has higher PD-L1 expression and tumor-infil-\\ntrating lymphocytes (TILs) in comparison with other subtypes [7,8], making it the most'),\n",
       " Document(metadata={}, page_content='likely subtype to benefit from immunotherapy. However, PD-(L)1 inhibitors benefit only\\na small proportion of individuals, with a single-agent effectiveness of approximately 20%'),\n",
       " Document(metadata={}, page_content='in patients with PD-L1-positive metastatic TNBC (mTNBC) [9]. Numerous preclinical and\\nclinical studies have been conducted to investigate the reasons for this disappointing re-'),\n",
       " Document(metadata={}, page_content='sult, expand the beneficiary population, and improve the efficacy of immune checkpoint\\ninhibitors (ICIs).\\nIn this review, we will analyze the reasons for the poor efficacy of PD-(L)1 inhibitors'),\n",
       " Document(metadata={}, page_content='monotherapy in terms of tumor immune escape mechanisms and tumor immune micro-\\nenvironment (TIME) characteristics of TNBC. We summarize the current landscape of'),\n",
       " Document(metadata={}, page_content='clinical trials in TNBC, highlight the major immune combination therapy strategies in clin-\\nical practice and the progress achieved, and briefly discuss the biomarkers for predicting'),\n",
       " Document(metadata={}, page_content='immunological response, as well as possible adverse events associated with immunother-\\napy.'),\n",
       " Document(metadata={}, page_content='```\\n**2. Rationale of Immunotherapy and the TIME of TNBC**\\n    The cross-talk between tumor cells and the TIME can be described as “cancer immu-'),\n",
       " Document(metadata={}, page_content='noediting”, encompassing three stages: (1) elimination; (2) equilibrium, in which the host\\nimmune system and tumor cells that survive enter a dynamic balance; and (3) escape [10]\\n(Figure 1).'),\n",
       " Document(metadata={}, page_content='```\\nFigure 1. Schematic diagram of immune elimination and escape in TNBC. ( A ) Cascade events of\\ntumor cell elimination by the immune system. ( B ) Mechanisms of tumor cell immune escape. Ab-'),\n",
       " Document(metadata={}, page_content='breviations: TAA, tumor-associated antigen; TSA, tumor-specific antigen; DC, dendritic cell; M1/2,\\nM1/2 macrophage; Th1/2, CD4+ helper T cell 1/2; TCR, T cell receptor; MHC, major histocompati-'),\n",
       " Document(metadata={}, page_content='bility complex; NK, natural killer cell; ADCC, antibody-dependent cell-medicated cytotoxicity;\\nSIPR-α, signal regulatory protein-α; CTLA-4, cytotoxic T-lymphocyte antigen-4; VEGF, vascular en-'),\n",
       " Document(metadata={}, page_content='dothelial growth factor; CXCL, chemokine (C-X-C motif) ligand; IL, interleukin; CSF, colony-stim-\\nulating factor; TGF, transforming growth factor; Treg, regulatory T cell; MDSCs, myeloid-derived'),\n",
       " Document(metadata={}, page_content='suppressor cells; TAP, transporter associated with antigen processing; PD-L1, programmed death-\\nligand 1; LAG3, lymphocyte-activation gene 3; TIM-3, T cell immunoglobulin-3; TIGIT, T cell im-'),\n",
       " Document(metadata={}, page_content='munoreceptor with Ig and ITIM domains.'),\n",
       " Document(metadata={}, page_content='```'),\n",
       " Document(metadata={}, page_content='```\\nNormally, a cascade of events needs to be initiated for the elimination of tumor cells.\\nFirst, tumor cells release specific antigens that are captured and processed by antigen-'),\n",
       " Document(metadata={}, page_content='presenting cells (APCs), which mainly include dendritic cells (DCs). Next, DCs migrate to'),\n",
       " Document(metadata={}, page_content='```'),\n",
       " Document(metadata={}, page_content='```\\nFigure 1. Schematic diagram of immune elimination and escape in TNBC. ( A ) Cascade events of\\ntumor cell elimination by the immune system. ( B ) Mechanisms of tumor cell immune escape. Abbre-'),\n",
       " Document(metadata={}, page_content='viations: TAA, tumor-associated antigen; TSA, tumor-specific antigen; DC, dendritic cell; M1/2, M1/2\\nmacrophage; Th1/2, CD4+ helper T cell 1/2; TCR, T cell receptor; MHC, major histocompatibility'),\n",
       " Document(metadata={}, page_content='complex; NK, natural killer cell; ADCC, antibody-dependent cell-medicated cytotoxicity; SIPR-α,\\nsignal regulatory protein-α; CTLA-4, cytotoxic T-lymphocyte antigen-4; VEGF, vascular endothelial'),\n",
       " Document(metadata={}, page_content='growth factor; CXCL, chemokine (C-X-C motif) ligand; IL, interleukin; CSF, colony-stimulating factor;'),\n",
       " Document(metadata={}, page_content='TGF, transforming growth factor; Treg, regulatory T cell; MDSCs, myeloid-derived suppressor cells;\\nTAP, transporter associated with antigen processing; PD-L1, programmed death-ligand 1; LAG3,'),\n",
       " Document(metadata={}, page_content='lymphocyte-activation gene 3; TIM-3, T cell immunoglobulin-3; TIGIT, T cell immunoreceptor with\\nIg and ITIM domains.'),\n",
       " Document(metadata={}, page_content='```'),\n",
       " Document(metadata={}, page_content='```\\nNormally, a cascade of events needs to be initiated for the elimination of tumor cells.\\nFirst, tumor cells release specific antigens that are captured and processed by antigen-'),\n",
       " Document(metadata={}, page_content='presenting cells (APCs), which mainly include dendritic cells (DCs). Next, DCs migrate to'),\n",
       " Document(metadata={}, page_content='```\\n\\nCancers **2023** , 15 , 321 3 of 28'),\n",
       " Document(metadata={}, page_content='```\\nlymphoid tissue to present antigenic signals to T cells. Later, T cells initiate, activate, and\\nthen transport and infiltrate tumor tissues. Finally, T cells specifically recognize and kill'),\n",
       " Document(metadata={}, page_content='tumor cells [ 11 ]. B cells and innate immune cells, such as natural killer (NK) cells, are also\\nessential for the elimination of tumor cells (Figure 1).'),\n",
       " Document(metadata={}, page_content='However, tumors can evade surveillance and attack from the immune system via\\ncomplex intrinsic signaling or external microenvironment mechanisms. In general, this can'),\n",
       " Document(metadata={}, page_content='be summed up in these aspects. First, immunogenicity of tumors is decreased via down-\\nregulation of antigen expression, sequestering of antigens, or downregulation of major'),\n",
       " Document(metadata={}, page_content='histocompatibility complex (MHC) molecules [ 12 , 13 ]. Second, there are functional and/or\\nquantitative defects in intrinsic and/or adaptive immune cells, including recruitment fail-'),\n",
       " Document(metadata={}, page_content='ure, insufficient maturation, failure to activate, and impaired chemotaxis and transport [ 14 ].\\nFurther, an immunosuppressive microenvironment is generated through an increase in the'),\n",
       " Document(metadata={}, page_content='proportion of immunosuppressive cells (regulatory T cells (Tregs), M2 macrophage cells,\\nand myeloid-derived suppressor cells (MDSCs)) and cytokines, as well as the accumulation'),\n",
       " Document(metadata={}, page_content='of immunosuppressive substances [ 15 , 16 ]. Moreover, there is an upregulation of immune\\ncheckpoints, a negative regulatory mechanism used by the body to prevent over-activation'),\n",
       " Document(metadata={}, page_content='of the immune system and to protect normal tissues from the autoimmune system [ 17 , 18 ]\\n(Figure 1).\\nBased on the above information, immunotherapy has emerged that involves the use'),\n",
       " Document(metadata={}, page_content='of various agents or means to enhance immune system function (in a tumor-localized\\nrather than whole-body manner) or to block immune escape pathways of tumor cells (by'),\n",
       " Document(metadata={}, page_content='normalizing anti-tumor immunity), thereby recognizing and eliminating tumor cells. These\\nimmunotherapy approaches include: therapeutic cancer vaccines (TCVs), which are active'),\n",
       " Document(metadata={}, page_content='immunotherapies; targeted monoclonal antibodies (mAb) and their derivatives, such as\\nADCs, adoptive cell therapies (ACTs), and cytokines, which are passive therapies; as well'),\n",
       " Document(metadata={}, page_content='as the best-known ICIs [19].\\nTumors that lack immune cell infiltration and do not respond to ICIs are referred to as'),\n",
       " Document(metadata={}, page_content='“cold tumors”, while tumors with high levels of immune cell infiltration and upregulated\\nimmune checkpoints that may respond to ICIs are referred as “hot tumors” [ 20 ]. Based'),\n",
       " Document(metadata={}, page_content='on omics analysis, heterogeneity of the TIME in TNBC has been revealed. According\\nto the data from these studies, the percentage of TNBC cases that present with “hot'),\n",
       " Document(metadata={}, page_content='tumors” is approximately 25%, which may explain the poor clinical efficacy of ICIs as single\\nagents [21–23]. Moreover, the suppressive TIME found in “hot tumors” and the decreased'),\n",
       " Document(metadata={}, page_content='MHC of tumor cells also make ICIs less effective [14].\\nWhen all of these findings are considered, it is clear that combining ICIs with other'),\n",
       " Document(metadata={}, page_content='therapies that block immune escape pathways of tumor cells or convert “cold tumors” to\\n“hot tumors” is a potential strategy to improve the clinical response of ICIs.'),\n",
       " Document(metadata={}, page_content='```\\n**3. The Landscape of Clinical Trials on TNBC Immunotherapy**\\n    As of 1 September 2022, we had screened a total of 234 clinical trials onclinicaltrials.gov'),\n",
       " Document(metadata={}, page_content='(accessed on 1 September 2022), that primarily explore immunotherapy for TNBC, either as\\na monotherapy or in combination with other therapies (Figure 2). Apart from that, more'),\n",
       " Document(metadata={}, page_content='than 100 immunotherapy clinical trials are being conducted on advanced solid tumors,\\nincluding TNBC. Of note, these are just the tip of the iceberg as there are trials registered'),\n",
       " Document(metadata={}, page_content='on other websites. In addition to observing the surge in clinical trials of immunotherapy\\nfor TNBC in the past decade, we further analyzed the data and found that: (1) there are'),\n",
       " Document(metadata={}, page_content='197 trials involving ICIs that target PD-(L)1, accounting for 84% of all trials, of which\\nonly 13 trials involved monotherapy, while in the other trials, PD-(L)1 inhibitors were'),\n",
       " Document(metadata={}, page_content='combined with almost all therapies that can be applied to TNBC; (2) there are considerable\\nnumbers of clinical trials in both early and metastatic settings, which demonstrates the'),\n",
       " Document(metadata={}, page_content='generalizability of immunotherapy for TNBC; and (3) there is a gradual increase in the\\nnumber of window-of-opportunity (WOP) trials to test for optimal timing of interventions'),\n",
       " Document(metadata={}, page_content='and changes in biomarkers.'),\n",
       " Document(metadata={}, page_content='Cancers _Cancers_ **20232023** ,, 15^15 , 321, x^4 4 of 28^ of^29'),\n",
       " Document(metadata={}, page_content='(^)\\n( **a** ) ( **b** )\\n**Figure 2.** Clinical trials of immunotherapy for TNBC registered at clinicaltrials.gov: ( **a** ) Number of'),\n",
       " Document(metadata={}, page_content='clinical trials in each phase per year; ( **b** ) Number of clinical trials by disease stage per year.'),\n",
       " Document(metadata={}, page_content='**4. Performance of PD-(L)1 Inhibitors Monotherapy**\\n    PD-(L)1 is the most powerful immune checkpoint found in TNBC. PD-1 can be ex-'),\n",
       " Document(metadata={}, page_content='pressed on a variety of immune cells, the most important of which are activated T cells.\\nPD-1 has two ligands: PD-L1 and PD-L2 [24]. PD-L1 is abnormally overexpressed on the'),\n",
       " Document(metadata={}, page_content='surface of tumor cells and some APCs [25]. Through binding to PD-1, it leads to lympho-\\ncyte apoptosis, unresponsiveness, and abnormal secretion of cytokines, thus mediating'),\n",
       " Document(metadata={}, page_content='immune escape of tumor cells [25]. In contrast, PD-L2 has a dual role of suppressing and\\nactivating T cells, and its role in tumors is gaining attention [26]. PD-(L)1 inhibitors are'),\n",
       " Document(metadata={}, page_content='monoclonal antibodies that block the PD-1/PD-L1 signaling pathway and restore the im-\\nmune function of T cells to kill tumor cells.'),\n",
       " Document(metadata={}, page_content='```\\n4.1. In Advanced TNBC\\nThe phase Ib study, KEYNOTE-012, first demonstrated acceptable safety and durable\\nanti-tumor activity of single-agent pembrolizumab in previously treated patients with ad-'),\n",
       " Document(metadata={}, page_content='vanced PD-L1-positive TNBC. The objective response rate (ORR) in 32 TNBC patients was\\n18.5% [27]. The phase II KEYNOTE- 086 study then further confirmed the safety and anti-'),\n",
       " Document(metadata={}, page_content='tumor activity of pembrolizumab as first-line or second-line and beyond therapy in pa-\\ntients with mTNBC, using more appropriate dosages and dosing intervals. This study'),\n",
       " Document(metadata={}, page_content='found that pembrolizumab monotherapy performed better in previously untreated PD-\\nL1-positive patients with an ORR of 21.4%, whereas the response was flat in heavily pre-'),\n",
       " Document(metadata={}, page_content='treated mTNBC patients with an ORR of 5.3%. Although there was no significant differ-\\nence in ORR, progression-free survival (PFS), and overall survival (OS) between the PD-'),\n",
       " Document(metadata={}, page_content='L1-positive and PD-L1-negative subgroups in pre-treated mTNBC, a more durable clinical\\nresponse was observed in PD-L1-positive patients [28,29]. In the next large phase III ran-'),\n",
       " Document(metadata={}, page_content='domized KEYNOTE-119 trial, as second- or third-line treatment for mTNBC, pembroli-\\nzumab failed to significantly improve OS compared to chemotherapy in the total popula-'),\n",
       " Document(metadata={}, page_content='tion (9.9 vs. 10.8 months, HR = 0.97, 95% CI: 0.82 to 1.15) or in the PD-L1-positive popula-\\ntion (10.7 vs. 10.2 months, HR = 0.86, 95% CI: 0.69 to 1.06, p = 0.073). However, the im-'),\n",
       " Document(metadata={}, page_content='proved effect of pembrolizumab was consistent with increased tumor PD-L1 expression\\nin the efficacy endpoints of ORR, PFS, and OS [30] (Table 1).'),\n",
       " Document(metadata={}, page_content='```\\n```\\nTable 1. Clinical trials of PD-(L)1 inhibitors monotherapy.\\n```\\n```\\nClinical Trial Phase Status Arms ( n ) Population ( n ) PD-L1 Status Major Outcomes\\n```\\n```\\nTrials in ad-\\nvanced TNBC\\n```'),\n",
       " Document(metadata={}, page_content='```\\nFigure 2. Clinical trials of immunotherapy for TNBC registered at clinicaltrials.gov: ( a ) Number of'),\n",
       " Document(metadata={}, page_content='clinical trials in each phase per year; ( b ) Number of clinical trials by disease stage per year.'),\n",
       " Document(metadata={}, page_content='```\\n**4. Performance of PD-(L)1 Inhibitors Monotherapy**\\n    PD-(L)1 is the most powerful immune checkpoint found in TNBC. PD-1 can be ex-'),\n",
       " Document(metadata={}, page_content='pressed on a variety of immune cells, the most important of which are activated T cells.\\nPD-1 has two ligands: PD-L1 and PD-L2 [ 24 ]. PD-L1 is abnormally overexpressed on the'),\n",
       " Document(metadata={}, page_content='surface of tumor cells and some APCs [ 25 ]. Through binding to PD-1, it leads to lymphocyte\\napoptosis, unresponsiveness, and abnormal secretion of cytokines, thus mediating immune'),\n",
       " Document(metadata={}, page_content='escape of tumor cells [ 25 ]. In contrast, PD-L2 has a dual role of suppressing and activating\\nT cells, and its role in tumors is gaining attention [ 26 ]. PD-(L)1 inhibitors are monoclonal'),\n",
       " Document(metadata={}, page_content='antibodies that block the PD-1/PD-L1 signaling pathway and restore the immune function\\nof T cells to kill tumor cells.'),\n",
       " Document(metadata={}, page_content='```\\n4.1. In Advanced TNBC\\nThe phase Ib study, KEYNOTE-012, first demonstrated acceptable safety and durable\\nanti-tumor activity of single-agent pembrolizumab in previously treated patients with'),\n",
       " Document(metadata={}, page_content='advanced PD-L1-positive TNBC. The objective response rate (ORR) in 32 TNBC patients\\nwas 18.5% [ 27 ]. The phase II KEYNOTE-086 study then further confirmed the safety and'),\n",
       " Document(metadata={}, page_content='anti-tumor activity of pembrolizumab as first-line or second-line and beyond therapy\\nin patients with mTNBC, using more appropriate dosages and dosing intervals. This'),\n",
       " Document(metadata={}, page_content='study found that pembrolizumab monotherapy performed better in previously untreated\\nPD-L1-positive patients with an ORR of 21.4%, whereas the response was flat in heavily'),\n",
       " Document(metadata={}, page_content='pre-treated mTNBC patients with an ORR of 5.3%. Although there was no significant\\ndifference in ORR, progression-free survival (PFS), and overall survival (OS) between the'),\n",
       " Document(metadata={}, page_content='PD-L1-positive and PD-L1-negative subgroups in pre-treated mTNBC, a more durable\\nclinical response was observed in PD-L1-positive patients [ 28 , 29 ]. In the next large phase'),\n",
       " Document(metadata={}, page_content='III randomized KEYNOTE-119 trial, as second- or third-line treatment for mTNBC, pem-\\nbrolizumab failed to significantly improve OS compared to chemotherapy in the total'),\n",
       " Document(metadata={}, page_content='population (9.9 vs. 10.8 months, HR = 0.97, 95% CI: 0.82 to 1.15) or in the PD-L1-positive\\npopulation (10.7 vs. 10.2 months, HR = 0.86, 95% CI: 0.69 to 1.06,p= 0.073). However, the'),\n",
       " Document(metadata={}, page_content='improved effect of pembrolizumab was consistent with increased tumor PD-L1 expression\\nin the efficacy endpoints of ORR, PFS, and OS [30] (Table 1).'),\n",
       " Document(metadata={}, page_content='```\\n\\nCancers **2023** , 15 , 321 5 of 28\\n\\n```\\nTable 1. Clinical trials of PD-(L)1 inhibitors monotherapy.\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nClinical Trial Phase Status Arms (n) Population (n) PD-L1 Status Major Outcomes\\nTrials in advanced\\nTNBC\\nKEYNOTE-012\\n(NCT01848834) Ib Completed Pemb\\n```\\n```\\nPre-treated: PD-L1\\n(+) (32)\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\n+(stroma/\\n≥1% TCa)\\n```\\n```\\nORR: 18.5%\\nmPFS: 1.9 months\\nmOS: 11.2 months\\n```\\n```\\nKEYNOTE-086\\n(NCT02447003) II Completed Pemb\\n```\\n```\\nCohort A (170):\\npre-treated\\n```\\n```\\nOverall\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nOverall\\n```\\n```\\nORR: 5.3%\\nmPFS: 2.0 months\\nmOS: 9.0 months\\n+(CPSb≥1)\\n```\\n```\\nORR: 5.7%\\nmPFS: 2.0 months\\nmOS: 8.8 months\\n−\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nORR: 4.7%\\nmPFS: 1.9 months\\nmOS: 9.7 months\\nCohort B (84):\\npre-untreated,\\nPD-L1 (+)\\n```\\n```\\n+(CPS≥1)\\n```\\n```\\nORR: 21.4%\\nmPFS: 2.1 months\\nmOS: 18.0 months\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nKEYNOTE-119\\n(NCT02555657) III Completed\\n```\\n```\\nPemb (312)\\nvs. CTc(310)\\n```\\n```\\nPre-treated: 1–2\\nprior therapy\\n(622)\\n```\\n```\\nOverall\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nOverall\\n```\\n```\\nORR: 9.6 vs. 10.6%\\nmPFS: 2.1 vs. 3.3 months\\nmOS: 9.9 vs. 10.8 months\\n+(CPS≥1)\\n```\\n```\\nORR: 12.3 vs. 9.4%\\nmPFS: 2.1 vs. 3.1 months\\nmOS: 10.7 vs. 10.2 months\\n+(CPS≥10)\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nORR: 17.7 vs. 9.2%\\nmPFS: 2.1 vs. 3.4 months\\nmOS: 12.7 vs. 11.6 months\\n+(CPS≥20)\\n```\\n```\\nORR: 26.3 vs. 11.5%\\nmPFS: 3.4 vs. 2.4 months\\nmOS: 14.9 vs. 12.5 months\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nJAVELIN\\n(NCT01772004) Ib Completed Avel\\n```\\n```\\nReceived a median\\nof 2 prior therapies\\n(58)\\n```\\n```\\nOverall\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nOverall\\n```\\n```\\nORR: 5.2%\\nmPFS: 5.9 months\\nmOS: 9.2 months\\n+(≥10% ICd) ORR: 22.2%\\n− ORR: 2.6%\\n```\\n```\\nNCT01375842 Ia Completed Atez prior therapies (116)mTNBC: 58%≥^2\\n```\\n```\\nOverall\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nOverall\\n```\\n```\\nORR: 10%\\nmPFS: 1.4 months\\nmOS: 8.9 months\\n+(≥1% IC) mOS: 10.1 monthsORR: 12%\\n− mOS: 6.0 monthsORR: 0%\\nSAFIR02-BREAST\\nIMMUNO\\n(NCT02299999)\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nII Completed Durv (47) vs. CT(35) Maintenancesetting (82)\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nOverall mOS: 21.2 vs. 14 months\\n+(≥1% IC) mOS: 27.3 vs. 12.1 months\\n− mOS: 19.5 vs. 14 months\\nTrials in early-stage\\nTNBC as adjuvant\\ntherapy\\nSWOG 1418\\n(NCT02954874) III Ongoing\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nPemb vs.\\nobservation\\n```\\n```\\nTNBC with≥1 cm\\nRIC or LN (+) after\\nNACT\\n```\\n```\\nNA\\n```\\n```\\nA-Brave\\n(NCT02926196) III Ongoing\\n```'),\n",
       " Document(metadata={}, page_content='```\\nAvel vs.\\nobservation High-risk TNBC NA\\nAbbreviations: mTNBC, metastatic triple-negative breast cancer; Pemb, pembrolizumab; Avel, avelumab; Atez,'),\n",
       " Document(metadata={}, page_content='atezolizumab; Durv, durvalumab; NACT, neoadjuvant chemotherapy; CT, chemotherapy; RIC, residual invasive'),\n",
       " Document(metadata={}, page_content='cancer; LN, lymph node; ORR, objective response rate; mOS, median overall survival; mPFS, median progression-'),\n",
       " Document(metadata={}, page_content='free survival; +, PD-L1 positive;−, PD-L1 negative; TC, tumor cells; CPS, combined positive score; IC, immune'),\n",
       " Document(metadata={}, page_content='cells; NA, not available.aPD-L1 positivity was defined as membranous staining in at least 1% of cells (neoplastic'),\n",
       " Document(metadata={}, page_content='and intercalated mononuclear inflammatory cells) within tumor nests.bImmunohistochemistry 22C3 assay, CPS'),\n",
       " Document(metadata={}, page_content='= PD-L1 stained cells (including tumor cells, lymphocytes, and macrophages) / the number of all viable tumor'),\n",
       " Document(metadata={}, page_content='cells×100.cIn KEYNOTE-119, the chemotherapy regimens included capecitabine, eribulin, gemcitabine, or'),\n",
       " Document(metadata={}, page_content='vinorelbine.dThe percentage of PD-L1 stained tumor-associated immune cells in the tumor area; immune cells\\nincluding lymphocytes, macrophages, dendritic cells, plasma cells, and granulocytes.'),\n",
       " Document(metadata={}, page_content='```\\n\\nCancers **2023** , 15 , 321 6 of 28'),\n",
       " Document(metadata={}, page_content='```\\nIn addition to the above, some trials also tested single-drug ICIs targeting PD-L1 in\\na metastatic setting. In the phase Ib JAVELIN trial, avelumab showed acceptable safety'),\n",
       " Document(metadata={}, page_content='and clinical activity in the mTNBC subgroup. The ORRs were 5.2% and 22.2% for the total\\nTNBC population and PD-L1-positive TNBC patients, respectively [ 31 ]. Moreover, a phase'),\n",
       " Document(metadata={}, page_content='Ia study (NCT01375842) verified that atezolizumab monotherapy was well tolerated in\\npatients with mTNBC and the ORR for the unselected TNBC population was 10%. The'),\n",
       " Document(metadata={}, page_content='PD-L1 expression status and prior treatment history continue to strongly influence the\\nefficacy of atezolizumab [ 32 ]. In addition, durvalumab was tested in the SAFIR02-BREAST'),\n",
       " Document(metadata={}, page_content='IMMUNO trial as a maintenance therapy. Subgroup analysis showed that, compared\\nwith maintenance chemotherapy, durvalumab improved OS in patients with mTNBC'),\n",
       " Document(metadata={}, page_content='(21.2 vs. 14 months, HR = 0.54, 95% CI: 0.30 to 0.97,p= 0.0377), especially in PD-L1-positive\\npatients (27.3 vs. 12.1 months, HR = 0.37, 95% CI: 0.12 to 1.13,p= 0.0678) [33] (Table 1).'),\n",
       " Document(metadata={}, page_content='The preliminary results of these trials suggest that PD-(L)1 blockade alone has a\\nmodest clinical response across the entire mTNBC population. However, more durable'),\n",
       " Document(metadata={}, page_content='responses have been observed in specific patients, such as PD-L1-positive patients receiving\\nfirst-line treatment. These findings encourage further research on PD-(L)1 inhibitors.'),\n",
       " Document(metadata={}, page_content='```'),\n",
       " Document(metadata={}, page_content='```\\n4.2. In Early-Stage TNBC\\nThere are studies on PD-(L)1 inhibitors monotherapy currently underway in early-\\nstage TNBC patients. SWOG 1418 is an ongoing phase III trial investigating the efficacy of'),\n",
       " Document(metadata={}, page_content='pembrolizumab on TNBC patients with≥1 cm residual invasive cancer or positive lymph\\nnodes after neoadjuvant chemotherapy (NACT) [ 34 ]. One year of postoperative intravenous'),\n",
       " Document(metadata={}, page_content='avelumab is currently being evaluated for its impact on survival in high-risk TNBC patients\\nin the A-Brave trial [ 35 ]. The results of these trials are eagerly anticipated and could provide'),\n",
       " Document(metadata={}, page_content='additional options for the intensive treatment of patients with early-stage, high-risk TNBC\\n(Table 1).'),\n",
       " Document(metadata={}, page_content='```\\n**5. Research Progress of PD-(L)1 Inhibitors in Combination with Chemotherapy**\\n    Preclinical and clinical studies have shown that in addition to direct toxicity to tumor'),\n",
       " Document(metadata={}, page_content='cells, some chemotherapeutic agents kill tumor cells through a pathway of immunogenic\\ncell death (ICD), which stimulates the recruitment and maturation of APCs, enhances the'),\n",
       " Document(metadata={}, page_content='antigen presentation process, and promotes the activation of T cells [ 36 ]. Chemotherapeutic\\nagents also increase the immunogenicity of tumors by exposing MHC molecules and'),\n",
       " Document(metadata={}, page_content='antigens on the surface of tumor cells [ 37 ]. The transient immunosuppression induced by\\nchemotherapy causes a massive release of cytokines and chemokines, which increases the'),\n",
       " Document(metadata={}, page_content='infiltration and activation of immune cells [ 38 ]. Furthermore, chemotherapeutic agents\\nreduce immunosuppressive cells such as Tregs and MDSCs [ 39 ]. These chemotherapy drugs'),\n",
       " Document(metadata={}, page_content='include anthracyclines, cyclophosphamide, and others commonly used for TNBC. Thus,\\ncombining PD-(L)1 inhibitors with chemotherapy is a promising approach to enhance'),\n",
       " Document(metadata={}, page_content='the efficacy of immunotherapy and facilitate synergistic anti-tumor activity. Based on\\nthis concept, a number of trials combining chemotherapy and immunotherapy are being'),\n",
       " Document(metadata={}, page_content='conducted in the clinic and some breakthroughs have been made (Table 2).'),\n",
       " Document(metadata={}, page_content='```\\nTable 2. Clinical trials of PD-(L)1 inhibitors in combination with chemotherapy.\\n```\\n```\\nClinical Trial Phase Status Arms (n) Population (n) PD-L1 Status Major Outcomes\\nTrials in\\nadvanced\\nTNBC'),\n",
       " Document(metadata={}, page_content='```\\n```\\nKEYNOTE-355\\n(NCT02819518) III Ongoing\\n```\\n```\\nPemb + CTa(566) vs.\\nplacebo + CT (281)\\n```\\n```\\nFirst-line\\ntreatment in mTNBC\\n(847)\\n```\\n```\\nITT\\npopulation\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nmPFS: 7.5 vs. 5.6 months\\nmOS: 17.2 vs. 15.5 months\\n+(CPSb≥1) mOS: 17.6 vs. 16.0 monthsmPFS: 7.6 vs. 5.6 months\\n+(CPS≥10) mOS: 23.0 vs. 16.1 monthsmPFS: 9.7 vs. 5.6 months'),\n",
       " Document(metadata={}, page_content='```\\n\\nCancers **2023** , 15 , 321 7 of 28\\n\\n```\\nTable 2. Cont.\\n```\\n```\\nClinical Trial Phase Status Arms (n) Population (n) PD-L1 Status Major Outcomes\\n```\\n```\\nKEYNOTE-150/\\nENHANCE 1\\n(NCT02513472)\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nIb/II Completed Pemb + eribulin mesylate\\n```\\n```\\n≤2 prior lines\\ntherapies in the\\nmetastatic setting\\n(167)\\n```\\n```\\nOverall\\n```'),\n",
       " Document(metadata={}, page_content='```\\nORR in total: 23.4%\\nstratum 1: 25.8%\\nstratum 2: 21.8%\\nmPFS in total: 4.1 months\\nstratum 1: 4.2 months\\nstratum 2: 4.1 months\\nmOS in total: 16.1 months\\nstratum 1: 17.4 months\\nstratum 2: 15.5 months'),\n",
       " Document(metadata={}, page_content='```\\n```\\n+(CPS≥1)\\n```\\n```\\nORR in stratum 1: 34.5%\\nORR in stratum 2: 24.4%\\nmPFS in stratum 1: 6.1 months\\nmPFS in stratum 2: 4.1 months\\nmOS in stratum 1: 21.0 months\\nmOS in stratum 2: 14.0 months\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\n−\\n```'),\n",
       " Document(metadata={}, page_content='```\\nORR in stratum 1: 16.1%\\nORR in stratum 2: 18.2%\\nmPFS in stratum 1: 3.5 months\\nmPFS in stratum 2: 3.9 months\\nmOS in stratum 1: 15.2 months\\nmOS in stratum 2: 15.5 months\\nTORCHLIGHT'),\n",
       " Document(metadata={}, page_content='TORCHLIGHT\\n(NCT04085276) III Recruiting'),\n",
       " Document(metadata={}, page_content='```\\n```\\nTori + nab-P vs. placebo +\\nnab-P\\n```\\n```\\n≤1 line of CT\\nin the metastatic\\nsetting\\n```\\n```\\nNA\\n```\\n```\\nNCT04537286 II Recruiting Cari + nab-P + Cp treatment in mTNBCFirst-line NA\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nNCT02755272 II Recruiting Pemb + Cb + gemcitabinevs. Cb + gemcitabine\\n```\\n```\\n>2 prior lines\\ntherapies\\nin the metastatic\\nsetting\\n```\\n```\\nNA\\n```\\n```\\nTONIC\\n(NCT02499367) II Ongoing\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nA/C/Cp/\\nRT/no induction + Nivo\\n(70)\\n```\\n```\\nmTNBC (70)\\n```\\n```\\nORR in total: 20%\\nCp induction ORR: 23%\\nA induction ORR: 35%\\nmPFS in total: 1.9 months\\nTONIC-2\\n(NCT04159818) II Recruiting\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nCp/ low dose A/no\\ninduction\\n+ Nivo\\n```\\n```\\nMetastatic or\\nincurable locally\\nadvanced TNBC\\n```\\n```\\nNA\\n```\\n```\\nNCT01633970 Ib Completed Atez + nab-P(33)\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\n≤2 lines prior CT in\\nthe metastatic setting\\n(33)\\n```\\n```\\nORR: 39.4%\\nmPFS: 5.5 months\\nmOS: 14.7 months\\n```\\n```\\nIMpassion130\\n(NCT02425891) III Completed\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nAtez + nab-P (451) vs.\\nplacebo + nab-P (451)\\n```\\n```\\nFirst-line treatment in\\nmTNBC\\n(902)\\n```\\n```\\nITT\\npopulation\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nmPFS: 7.2 vs. 5.5 months\\nmOS: 21.0 vs. 18.7 months\\n+(≥1% ICc) mOS: 25.4 vs. 17.9 monthsmPFS: 7.5 vs. 5.0 months\\n```\\n```\\nIMpassion131\\n(NCT03125902) III Ongoing\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nAtez + P (431) vs. placebo +\\nP (220)\\n```\\n```\\nFirst-line treatment in\\nmTNBC (651)\\n```\\n```\\nITT\\npopulation\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nmPFS: 5.7 vs. 5.6 months\\nmOS: 19.2 vs. 22.8 months\\n+(≥1% IC) mOS: 22.1 vs. 28.3 monthsmPFS: 6.0 vs. 5.7 months\\n```\\n```\\nIMpassion132\\n(NCT03371017) III Recruiting\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nAtez + CTdvs. placebo +\\nCT\\n```\\n```\\nFirst-line treatment\\nfor locally\\nadvanced inoperable\\nor mTNBC\\n```\\n```\\nNA\\n```\\n```\\nALICE\\n(NCT03164993) II Ongoing\\n```\\n```\\nAtez + PLD + C vs. placebo\\n+ PLD + C'),\n",
       " Document(metadata={}, page_content='```\\n```\\n≤1 line previous\\nCT in the\\nmetastatic setting\\n```\\n```\\nNA\\n```\\n```\\nGIM25-CAPT\\n(NCT05266937) II Recruiting Atez + nab-P + Cb\\n```\\n```\\nFirst-line therapy\\nin PD-L1-positive\\nmTNBC\\n```\\n```\\nNA\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nNA\\n```\\n```\\nEL1SSAR\\n(NCT04148911) III Ongoing Atez + nab-P\\n```\\n```\\nFirst-line therapy\\nin PD-L1-positive\\nmTNBC\\n```\\n```\\nNA\\n```\\n\\nCancers **2023** , 15 , 321 8 of 28\\n\\n```\\nTable 2. Cont.\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nClinical Trial Phase Status Arms (n) Population (n) PD-L1 Status Major Outcomes\\nTrials in early-stage\\nTNBC as\\nneoadjuvant\\ntherapy\\n```\\n```\\nI-SPY2\\n(NCT01042379) II Recruiting\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nPemb + P→AC (29) vs.\\nP→AC\\n(85)\\n```\\n```\\nHER-2 negative, stage\\nII or\\nIII at high risk\\n(250, including 114\\nTNBC)\\n```\\n```\\npCR rates in TNBC:\\n60% vs. 22%\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nKEYNOTE-173\\n(NCT02622074) Ib Completed\\n```\\n```\\nPemb + (nab-P±Cb→AC)\\n(60)\\n```\\n```\\nHigh-risk, early-stage\\nTNBC (60) Overall pCR rate: 60%\\n```\\n```\\nKEYNOTE-522\\n(NCT03036488) III Ongoing\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nPemb + (PCb→AC/EC)\\n(784) vs. placebo +\\n(PCb→AC/EC) (390)\\n(→surgery→Pemb/placebo\\nfor up to 9 cycles)\\n```\\n```\\nStage II-III TNBC\\n(1174)\\n```\\n```\\nOverall\\n```'),\n",
       " Document(metadata={}, page_content='```\\npCR ratese:\\n64.8% vs. 51.2%\\n3-year EFS:\\n84.5% vs. 76.8%\\n+(CPS≥1) 68.9% vs. 54.9%pCR rates:\\n− 45.3% vs. 30.3%pCR rates:\\nNeoPACT\\n(NCT03639948) II Ongoing Pemb + Cb + docetaxel Early-stage TNBC NA'),\n",
       " Document(metadata={}, page_content='NCT04613674 III Recruiting Camr + CT vs. placebo + CT Advanced TNBCEarly or Locally NA'),\n",
       " Document(metadata={}, page_content='```\\n```\\nGeparNuevo\\n(NCT02685059) II Completed\\n```\\n```\\nDurv×2wf→durv + (nab-P\\n→EC) (88) vs. placebo +\\n(nab-P→EC) (86)\\n(→surgery→physician’s\\nchoice)\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nPrimary, cT1b-cT4a-d\\ndisease, centrally\\nconfirmed TNBC\\n(174)\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nOverall pCR rates:\\n53.4% vs. 44.2%\\npCR rates in the window\\ncohort: 61.0% vs. 41.4%\\n3-year iDFS: 85.6% vs. 77.2%\\n3-year DDFS: 91.7% vs. 78.4%\\n3-year OS: 95.2% vs. 83.5%\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nNeoTRIPaPDL1\\n(NCT02620280) III Ongoing\\n```\\n```\\nAtez + nab-P + Cb (138) vs.\\nnab-P + Cb (142)\\n(→surgery→adjuvant\\nanthracycline regimen as\\nper investigator’s choice)\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nEarly high-risk and\\nlocally advanced\\nTNBC (280)\\n```\\n```\\nITT\\npopulation pCR rates: 48.6% vs. 44.4%\\n+(≥1% IC) pCR rates: 59.5% vs. 51.9%\\n```\\n```\\nIMpassion031\\n(NCT03197935) III Ongoing\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nAtez + (nab-P→AC) (165)\\nvs. placebo + (nab-P→AC)\\n(168)\\n(→surgery→\\nadjuvant Atez/placebo\\nfor up to 11 cycles)\\n```\\n```\\nStage II–III TNBC\\n(333)\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nOverall pCR rates: 58% vs. 41%\\n+(≥1% IC) pCR rates: 69% vs. 49%\\n− pCR rates: 48% vs. 34%\\n```\\n```\\nNSABP B-59\\n(NCT03281954) III Ongoing\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nAtez + (PCb→AC) vs.\\nplacebo + (PCb→AC)\\n(→surgery→adjuvant\\nAtez/placebo\\nuntil 1 year after the first\\ndose)\\n```\\n```\\nStage II–III TNBC NA\\n```\\n```\\nNCT02530489 II Ongoing\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nAtez + nab-P\\n(→surgery→adjuvant Atez\\nfor 4 cycles)\\n```\\n```\\nTNBC that were\\nnon-responders to\\ninitial AC\\nchemotherapy\\n```\\n```\\nNA\\n```\\n```\\nTrials in early-stage\\nTNBC as adjuvant\\ntherapy\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nNCT03487666 II Ongoing Nivo vs. capecitabine vs.Nivo + capecitabine\\n```\\n```\\nTNBC with≥1 cm\\nRIC or LN (+) after\\nNACT\\n```\\n```\\nNA\\n```\\n```\\nIMpassion030\\n(NCT03498716) III Recruiting\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nAtez + A/P-based CT vs.\\nCT\\n```\\n```\\nOperable-stage II-III\\nTNBC NA\\n```\\n\\nCancers **2023** , 15 , 321 9 of 28\\n\\n```\\nTable 2. Cont.\\n```'),\n",
       " Document(metadata={}, page_content='```\\nClinical Trial Phase Status Arms (n) Population (n) PD-L1 Status Major Outcomes\\nNCT03756298 II Recruiting Atez + capecitabine vs.capecitabine TNBC with RIC afterNACT NA'),\n",
       " Document(metadata={}, page_content='Abbreviations: mTNBC, metastatic triple-negative breast cancer; Pemb, pembrolizumab; Atez, atezolizumab; Durv.'),\n",
       " Document(metadata={}, page_content='durvalumab; Cari, carilizumab; Tori, toripalimab; Nivo, nivolumab; Camr, camrelizumab; CT. chemotherapy;'),\n",
       " Document(metadata={}, page_content='RT, radiotherapy; Nab-P, nab-paclitaxel; P, paclitaxel; E, epirubicin; A, doxorubicin; C, cyclophosphamide; Cb,'),\n",
       " Document(metadata={}, page_content='carboplatin; Cp, cisplatin; PLD, pegylated liposomal doxorubicin; mOS, median overall survival; mPFS, median'),\n",
       " Document(metadata={}, page_content='progression-free survival; EFS, event-free survival; iDFS, invasive disease-free survival; DDFS, distant disease-'),\n",
       " Document(metadata={}, page_content='free survival; ITT population, intention-to-treat population; ORR. objective response rate; pCR, pathological'),\n",
       " Document(metadata={}, page_content='complete remission; CPS, combined positive score; IC, immune cells; +, PD-L1 positive;−, PD-L1 negative;'),\n",
       " Document(metadata={}, page_content='RIC, residual invasive cancer; NA, not available.aIn KEYNOTE-355, the chemotherapy regimens included'),\n",
       " Document(metadata={}, page_content='nab-paclitaxel; paclitaxel; or gem citabine plus carboplatin.bImmunohistochemistry 22C3 assay, CPS = PD-L1'),\n",
       " Document(metadata={}, page_content='stained cells (including tumor cells, lymphocytes, and macrophages) / the number of all viable tumor cells'),\n",
       " Document(metadata={}, page_content='×100.cThe percentage of PD-L1 stained tumor-associated immune cells in the tumor area; immune cells'),\n",
       " Document(metadata={}, page_content='including lymphocytes, macrophages, dendritic cells, plasma cells, and granulocytes.dIn the IMpassion132,'),\n",
       " Document(metadata={}, page_content='the chemotherapy regimens include gemcitabine, capecitabine, and car boplatin.eIn KEYNOTE-522, the first'),\n",
       " Document(metadata={}, page_content='interim pCR analysis was conducted on the first 602 patients who underwent randomization (401 patients in'),\n",
       " Document(metadata={}, page_content='pembrolizumab–chemotherapy group and 201 in placebo–chemotherapy group).fIn the GeparNuevo study, 117\\npatients participated in the window phase.'),\n",
       " Document(metadata={}, page_content='```'),\n",
       " Document(metadata={}, page_content='```\\n5.1. In Advanced TNBC\\nAt present, a majority of clinical trials apply immunotherapy with chemotherapy\\nconcomitantly. The reason for this is that ICIs take time to work, while chemotherapy'),\n",
       " Document(metadata={}, page_content='agents kill tumor cells and modify the TIME during this waiting period.\\nKEYNOTE-355 is a phase III randomized controlled trial (RCT) assessing the effi-'),\n",
       " Document(metadata={}, page_content='cacy and safety of pembrolizumab plus chemotherapy versus placebo plus chemother-\\napy as first-line treatment for patients with advanced TNBC; chemotherapy regimens'),\n",
       " Document(metadata={}, page_content='were based on the physician’s choice including nab-paclitaxel, paclitaxel, and gemc-\\nitabine/carboplatin. Initial results showed that the combination of pembrolizumab with'),\n",
       " Document(metadata={}, page_content='chemotherapy improved PFS in the intention-to-treat (ITT) population and in the com-\\nbined positive score(CPS)≥1 subgroup(7.5 vs. 5.6 months, HR = 0.82, 95% CI: 0.69 to'),\n",
       " Document(metadata={}, page_content='0.97 and7.6 vs. 5.6 months,HR = 0.74, 95% CI: 0.61 to 0.90,p= 0.0014, respectively); the\\nimprovement was particularly significant in the CPS≥10 subgroup (9.7 vs. 5.6 months,'),\n",
       " Document(metadata={}, page_content='HR = 0.65, 95% CI: 0.49 to 0.86,p= 0.0012) [ 40 ]. According to the latest release of follow-up\\ndata, OS was improved by almost 7 months in the CPS≥10 subgroup after the addition'),\n",
       " Document(metadata={}, page_content='of pembrolizumab to chemotherapy (23.0 vs. 16.1 months, HR = 0.73, 95% CI: 0.55 to 0.95,\\np= 0.0185) and the adverse effects were manageable [41].'),\n",
       " Document(metadata={}, page_content='Another single-arm phase Ib/II trial, KEYNOTE-150, used pembrolizumab in com-\\nbination with eribulin mesylate in patients with mTNBC who had received≤2 lines of'),\n",
       " Document(metadata={}, page_content='prior therapy in the metastatic setting. Of the 167 patients enrolled, 40% had not received\\nprevious systemic therapies and were classified in stratum 1. The results showed that the'),\n",
       " Document(metadata={}, page_content='survival benefit was most significant in PD-L1-positive patients who had not received prior\\nsystemic therapy, which was consistent with previous studies. This study offers a new'),\n",
       " Document(metadata={}, page_content='immuno–chemotherapy combination for the treatment of patients with mTNBC, although\\nfurther confirmation is needed [42].'),\n",
       " Document(metadata={}, page_content='After a phase Ib trial (NCT01633970) demonstrated the safety and feasibility of ate-\\nzolizumab plus nab-paclitaxel in patients with locally recurrent or metastatic TNBC [ 43 ],'),\n",
       " Document(metadata={}, page_content='the efficacy of this immuno–chemotherapy combination for TNBC patients who did not\\nreceive systemic therapy in the metastatic setting was further validated by IMpassion130,'),\n",
       " Document(metadata={}, page_content='the first phase III RCT of immunotherapy for TNBC [ 44 ]. Preliminary results showed that a\\nPFS benefit was observed with the addition of atezolizumab in both the ITT population'),\n",
       " Document(metadata={}, page_content='(7.2 vs. 5.5 months, HR = 0.80, 95% CI: 0.69 to 0.92,p= 0.002) and the PD-L1-positive pop-\\nulation (7.5 vs. 5.0 months, HR = 0.62, 95% CI: 0.49 to 0.78,p <0.001). The second set of'),\n",
       " Document(metadata={}, page_content='interim results indicated that atezolizumab significantly improved OS from 18.0 months\\nto25.0 monthsin the PD-L1-positive subgroup (HR = 0.71, 95% CI: 0.54 to 0.94), but the'),\n",
       " Document(metadata={}, page_content='difference was not significant in the ITT population (21.0 vs. 18.7 months, HR = 0.86, 95%'),\n",
       " Document(metadata={}, page_content='```\\n\\nCancers **2023** , 15 , 321 10 of 28'),\n",
       " Document(metadata={}, page_content='```\\nCI: 0.72 to 1.02,p= 0.078) [ 45 ]. As a result, in March 2019, atezolizumab was granted accel-\\nerated approval by the Food and Drug Administration (FDA) to be used in combination'),\n",
       " Document(metadata={}, page_content='with nab-paclitaxel as a first-line treatment for late-stage TNBC patients. Additionally, the\\n7.5-month survival benefit shown in the final OS data further demonstrated the durable'),\n",
       " Document(metadata={}, page_content='efficacy of this treatment combination for PD-L1-positive patients (25.4 vs. 17.9 months,\\nHR = 0.67, 95% CI: 0.53 to 0.86) [46].'),\n",
       " Document(metadata={}, page_content='However, these findings were contradicted when atezolizumab was combined with\\npaclitaxel and compared to placebo plus paclitaxel in the phase III clinical study IMpas-'),\n",
       " Document(metadata={}, page_content='sion131, which also investigated this as first-line treatment for patients with advanced or\\nmetastatic TNBC. The study found no obvious differences in PFS between the two arms,'),\n",
       " Document(metadata={}, page_content='regardless of PD-L1 expression status (5.7 vs. 5.6 months, HR = 0.86, 95% CI: 0.70 to 1.05 for\\nthe ITT population and 6.0 vs. 5.7 months, HR = 0.82, 95% CI: 0.60 to 1.12,p= 0.20 for the'),\n",
       " Document(metadata={}, page_content='PD-L1-positive patients). With respect to OS, the atezolizumab arm appeared to be worse\\nbut not detrimental in the PD-L1-positive population (22.1 vs. 28.3 months,HR = 1.11, 95%'),\n",
       " Document(metadata={}, page_content='CI: 0.76 to 1.64) and in the ITT population (19.2 vs. 22.8 months, HR = 1.12, 95% CI: 0.88 to\\n1.43). Different chemotherapeutic agents, steroid pre-treatment with paclitaxel, and subtle'),\n",
       " Document(metadata={}, page_content='differences between study populations may explain the difference in results between IM-\\npassion130 and IMpassion131 [ 47 ]. In addition, levels of TILs, breast cancer susceptibility'),\n",
       " Document(metadata={}, page_content='gene (BRCA) mutational load, and the proportion of patients with residual disease after\\nNACT (which were unreported in the trial) may also have contributed to the unclear results'),\n",
       " Document(metadata={}, page_content='from IMpassion131 [ 48 ]. As the reason for this discrepancy remains undefined, Roche has\\nvoluntarily withdrawn the indication for atezolizumab for the treatment of PD-L1 positive'),\n",
       " Document(metadata={}, page_content='advanced TNBC. Recently, a small sample-based single-cell sequencing study suggested\\nthat paclitaxel may affect the efficacy of atezolizumab by reducing key anti-tumor immune'),\n",
       " Document(metadata={}, page_content='cells in the TIME but enhancing immunosuppressive macrophages, yet this finding needs\\nto be further explored [49].\\nDespite some setbacks in the exploration of combination treatments with taxanes,'),\n",
       " Document(metadata={}, page_content='atezolizumab is still being tested in different trials to investigate the safety and efficacy of\\ncombination treatment with other chemotherapy agents in TNBC (Table 2).'),\n",
       " Document(metadata={}, page_content='Beyond concurrent chemotherapy, the induction use of small doses of chemothera-\\npeutic agents prior to immunotherapy is another strategy of the immuno–chemotherapy'),\n",
       " Document(metadata={}, page_content='combination that is in the experimental phase. In the five cohorts of the phase II TONIC\\ntrial, patients with mTNBC received no induction or 2 weeks induction with low-dose'),\n",
       " Document(metadata={}, page_content='cyclophosphamide, cisplatin, doxorubicin, and hypofractionated irradiation, respectively,\\nall followed by the PD-1 blocking drug nivolumab. The total ORR was 20%, with a median'),\n",
       " Document(metadata={}, page_content='PFS (mPFS) of 1.9 months; a higher ORR occurred in the doxorubicin and carboplatin\\ncohorts at 35% and 23%, respectively. Analysis of patient samples suggested that short-'),\n",
       " Document(metadata={}, page_content='term doxorubicin or cisplatin induction can convert the tumor microenvironment towards\\ninflammation and improve the response of nivolumab in TNBC. However, due to the limi-'),\n",
       " Document(metadata={}, page_content='tations of the trial itself, this conclusion needs further confirmation [ 50 ]. The subsequent\\ntrial, TONIC-2, is currently recruiting (Table 2).'),\n",
       " Document(metadata={}, page_content='```'),\n",
       " Document(metadata={}, page_content='```\\n5.2. In Early-Stage TNBC\\nStudies based on transcriptomics and immunohistochemical techniques have revealed\\nthat mTNBC has significantly reduced expression of immune activation genes as well'),\n",
       " Document(metadata={}, page_content='as immunotherapeutic targets, such as PD-L1, and a lower number of TILs compared to\\nprimary TNBC [ 51 , 52 ]. Thus, the TIME in the early-stage disease setting is more suitable'),\n",
       " Document(metadata={}, page_content='for ICIs to function and to potentially achieve a true cure.\\nSeveral trials have indicated that the combination of pembrolizumab with chemother-'),\n",
       " Document(metadata={}, page_content='apy can improve pathological complete remission (pCR) rates in early-stage TNBC. One of\\nthe cohorts in the I-SPY2 trial first determined the feasibility of 4 cycles of pembrolizumab'),\n",
       " Document(metadata={}, page_content='in combination with paclitaxel- and anthracycline-based chemotherapy regimen in women\\nwith early-stage, high-risk HER-2-negative breast cancer. Compared to standard NACT regi-'),\n",
       " Document(metadata={}, page_content='mens, the addition of pembrolizumab increased the pCR rate for patients with TNBC by 38%'),\n",
       " Document(metadata={}, page_content='```\\n\\nCancers **2023** , 15 , 321 11 of 28'),\n",
       " Document(metadata={}, page_content='```\\n(60% vs. 22% for pembrolizumab vs. control) [ 53 ]. Another phase Ib KEYNOTE-173 trial\\nwith a relatively small sample volume evaluated the safety and efficacy of pembrolizumab'),\n",
       " Document(metadata={}, page_content='in combination with chemotherapy regimens, including different doses of nab-paclitaxel\\nwith or without carboplatin followed by doxorubicin and cyclophosphamide; the overall'),\n",
       " Document(metadata={}, page_content='pCR rate was consistent with I-PSY2 at 60% [54].\\nIn the phase III trial KEYNOTE-522, 1174 patients with previously untreated early-'),\n",
       " Document(metadata={}, page_content='stage TNBC were randomized in a 2:1 ratio to either the pembrolizumab–chemotherapy arm\\nor the placebo–chemotherapy arm (chemotherapy backbone of 4 cycles of paclitaxel plus'),\n",
       " Document(metadata={}, page_content='carboplatin, followed by 4 cycles of anthracycline plus cyclophosphamide every 3 weeks),\\nwith up to 9 cycles of adjuvant pembrolizumab or placebo after surgery. Preliminary results'),\n",
       " Document(metadata={}, page_content='based on the first 602 patients showed that the addition of pembrolizumab increased the\\npCR rate by 13.6% compared to the placebo–chemotherapy arm (64.8% vs. 51.2%, 95%'),\n",
       " Document(metadata={}, page_content='CI: 5.4% to 21.8%,p< 0.001). This benefit was observed in most subgroups, including\\nPD-L1-negative patients [ 55 ]. Based on this undifferentiated benefit, in July 2021, the'),\n",
       " Document(metadata={}, page_content='FDA approved pembrolizumab in combination with chemotherapy as a neoadjuvant\\ntreatment for early-stage, high-risk TNBC and for continued use as a single agent in the'),\n",
       " Document(metadata={}, page_content='adjuvant phase. Furthermore, recently updated follow-up data after 39.1 months showed\\nthat pembrolizumab treatment for almost 1 year reduced the risk of disease progression'),\n",
       " Document(metadata={}, page_content='by 37% (3-year event-free survival (EFS) of 84.5% vs. 76.8%, HR = 0.63, 95% CI: 0.48 to\\n0.82,p< 0.001). This EFS benefit was independent of PD-L1 expression status, which is'),\n",
       " Document(metadata={}, page_content='consistent with previous results and further demonstrates the long-term effectiveness of\\nthe perioperative addition of pembrolizumab. At the time of this analysis, data on OS were'),\n",
       " Document(metadata={}, page_content='immature and further follow-up data are expected [56].\\nIn addition, the phase II NeoPACT trial is also ongoing, combining pembrolizumab'),\n",
       " Document(metadata={}, page_content='with carboplatin and docetaxel as neoadjuvant therapy. The results of this study will\\ndemonstrate whether similar pCR rates and survival benefits can be achieved by removing'),\n",
       " Document(metadata={}, page_content='anthracyclines from neoadjuvant chemotherapy regimens in early TNBC.\\nHowever, the situation becomes more complicated upon review of the results of\\nclinical trials with PD-L1 inhibitors.'),\n",
       " Document(metadata={}, page_content='The phase II GeparNuevo study compared the efficacy of receiving durvalumab or\\nplacebo every 4 weeks in addition to chemotherapy of nab-paclitaxel sequentially with'),\n",
       " Document(metadata={}, page_content='epirubicin and cyclophosphamide. A total of 174 patients with early TNBC were enrolled.\\nIt was noteworthy that 117 patients in this study received an additional, 2-week earlier'),\n",
       " Document(metadata={}, page_content='window treatment of durvalumab or placebo before the start of nab-paclitaxel, and 87% of\\n158 detected patients were PD-L1 positive. The intensive postoperative treatment regimen'),\n",
       " Document(metadata={}, page_content='for patients enrolled in this trial was based on the physician’s choice. In the window cohort,\\nthe pCR rates were statistically increased by the addition of durvalumab (61.0% vs. 41.4%,'),\n",
       " Document(metadata={}, page_content='OR = 2.22, 95% CI: 1.06 to 4.64,p= 0.035), but not in the whole study population (53.4% vs.\\n44.2%, OR = 1.45, 95% CI: 0.80 to 2.63,p= 0.224). However, it remains uncertain whether this'),\n",
       " Document(metadata={}, page_content='difference was due to one dose of durvalumab window treatment [ 57 ]. Surprisingly, after\\na median follow-up of 43.7 months, significant improvements in 3-year invasive disease-'),\n",
       " Document(metadata={}, page_content='free survival (iDFS), distant disease-free survival (DDFS), and OS were observed in the\\ndurvalumab group, even without the adjuvant durvalumab treatment, which contradicts'),\n",
       " Document(metadata={}, page_content='the pCR results obtained initially (iDFS was 85.6% vs. 77.2%, HR = 0.48, 95% CI: 0.24 to\\n0.97,p= 0.036; DDFS was 91.7% vs. 78.4%, HR = 0.31, 95% CI: 0.13 to 0.74,p= 0.005; OS was'),\n",
       " Document(metadata={}, page_content='95.2% vs. 83.5%, HR = 0.24, 95% CI: 0.08 to 0.72,p= 0.006) [ 58 ]. More studies are needed to\\nelucidate this result and to explore the timing and sequence of ICIs when combined with'),\n",
       " Document(metadata={}, page_content='chemotherapy to treat early-stage TNBC.\\nThe efficacy of 8 cycles of nab-paclitaxel and carboplatin with or without atezolizumab'),\n",
       " Document(metadata={}, page_content='in early-stage, high-risk TNBC was investigated in the NeoTRIPaPDL1 trial, with 4 cycles\\nof anthracycline regimen chemotherapy administered as adjuvant treatment. The pub-'),\n",
       " Document(metadata={}, page_content='lished results thus far have shown that the addition of atezolizumab to the neoadjuvant\\nsetting did not significantly increase the pCR rate in the ITT population (48.6% vs. 44.4%,'),\n",
       " Document(metadata={}, page_content='OR = 1.18, 95% CI: 0.74 to 1.89,p= 0.48) or in the PD-L1-positive subgroup (59.5% vs.'),\n",
       " Document(metadata={}, page_content='```\\n\\nCancers **2023** , 15 , 321 12 of 28'),\n",
       " Document(metadata={}, page_content='```\\n51.9%). Nevertheless, the primary endpoint of the study, the EFS data, still requires further\\nfollow-up [59].'),\n",
       " Document(metadata={}, page_content='follow-up [59].\\nOn the contrary, in the Impassion031 trial, a significant increase in pCR rates was ob-\\nserved when atezolizumab was combined with a standard nab-paclitaxel- and doxorubicin-'),\n",
       " Document(metadata={}, page_content='based chemotherapy regimen and applied in the adjuvant phase as a single agent (58% vs.\\n41%, rate difference 17%, 95% CI: 6% to 27%,p= 0.0044). The mature long-term survival'),\n",
       " Document(metadata={}, page_content='follow-up data are not available at present. Similar to the KEYNOTE-522 results, the benefit\\nof pCR was not significantly related to PD-L1 expression status. Of note, platinum agents'),\n",
       " Document(metadata={}, page_content='were removed from the NACT regimen in this trial [55,60].\\nFurthermore, it is noteworthy that anthracyclines were given preoperatively in both'),\n",
       " Document(metadata={}, page_content='the KEYNOTE-522 and Impassion031 trials, whereas anthracyclines were applied postop-\\neratively in the NeoTRIPaPDL1 trial. This may be one reason why the difference in pCR'),\n",
       " Document(metadata={}, page_content='rates between the two arms in the NeoTRIPaPDL1 trial was not significant.\\nThe safety and efficacy of other combinations of PD-(L)1 inhibitors with chemotherapy'),\n",
       " Document(metadata={}, page_content='drugs are also being tested in clinical trials. Last but not least, trials using ICIs plus\\nchemotherapy in the adjuvant phase of early-stage TNBC are underway and the results are'),\n",
       " Document(metadata={}, page_content='awaited with great interest (Table 2).'),\n",
       " Document(metadata={}, page_content='```\\n**6. Research Progress of PD-(L)1 Inhibitors in Combination with Radiotherapy**\\n    Similar to chemotherapy, radiotherapy (RT) has a dual role of mediating DNA damage-'),\n",
       " Document(metadata={}, page_content='induced tumor cell death and immunomodulation, which can make the TIME more inflam-\\nmatory and facilitate the role of ICIs [ 61 ]. Whereas RT acts locally, the systemic side effects'),\n",
       " Document(metadata={}, page_content='are less severe and well tolerated.\\n    A small single-arm phase II trial (NCT02730130) enrolled 17 unselected patients with'),\n",
       " Document(metadata={}, page_content='mTNBC with a median of 3 lines on prior systemic therapy. They received RT with\\n3000 centigrays(cGy) in five fractions over 5–7 days and pembrolizumab within 1 to3 days'),\n",
       " Document(metadata={}, page_content='after the first fraction. The median follow-up was 34.5 weeks, with an ORR of 17.6%,\\nmPFS of 2.6 months, and median OS (mOS) of 8.25 months. Although the 3 patients who'),\n",
       " Document(metadata={}, page_content='experienced complete remission were all PD-L1 positive, the analysis showed that PD-L1\\nstatus was not associated with therapeutic effects [62].'),\n",
       " Document(metadata={}, page_content='Another phase II AZTEC trial enrolled 50 patients who had received less than 2 lines\\nof prior systemic therapy to receive RT combined with atezolizumab. Participants were'),\n",
       " Document(metadata={}, page_content='randomly assigned to 20 Gy stereotactic ablative body RT (SABR) in one fraction or 24 Gy\\nSABR in three fractions to irradiate 1–4 lesions with at least one metastasis left unirradiated.'),\n",
       " Document(metadata={}, page_content='Atezolizumab was initiated within 5 days after the last part of RT. The median follow-up\\nwas 17 months, with mPFS of 3.1 months. No difference was observed in mPFS between the'),\n",
       " Document(metadata={}, page_content='two groups. PD-L1 expression status and TIL levels (5%) had little effect on the efficacy [ 63 ].\\n    In these studies, the combination of pembrolizumab and RT showed modest but'),\n",
       " Document(metadata={}, page_content='encouraging clinical activity in unselected patients and was well tolerated, offering a new\\ntreatment idea for pre-treated patients with advanced TNBC. Additional trials are still'),\n",
       " Document(metadata={}, page_content='being explored (Table 3).\\n**7. Research Progress of PD-(L)1 Inhibitors in Combination with Targeted Therapy**\\n7.1. Combination with PARPi'),\n",
       " Document(metadata={}, page_content='PARPi are drugs that block the repair of single-strand DNA damage. These drugs\\nkill tumor cells through synthetic lethal effects that are formed by the accumulation of'),\n",
       " Document(metadata={}, page_content='homologous recombination (HR) repair defects for DNA double-strand breaks due to\\nmutations in BRCA1/2. In addition to direct killing of tumor cells, previousin vitrostudies'),\n",
       " Document(metadata={}, page_content='have shown that PARPi can stimulate intrinsic immunity and upregulate interferon (IFN)\\nrelease by activating the cyclic GMP–AMP synthase-stimulator of interferon genes (cGAS-'),\n",
       " Document(metadata={}, page_content='STING) signaling pathway, further upregulating tumor PD-L1 expression and infiltration\\nof CD8+ T cells [ 64 – 66 ]. In short, PARPi have the potential to turn cold tumors into hot'),\n",
       " Document(metadata={}, page_content='tumors and set the stage for the application of PD-(L)1 blockers.'),\n",
       " Document(metadata={}, page_content='Cancers **2023** , 15 , 321 13 of 28'),\n",
       " Document(metadata={}, page_content='```\\nKEYNOTE-162 is a single-arm phase I/II trial evaluating the efficacy and safety of\\npembrolizumab in combination with niraparib in 55 patients with advanced TNBC. The'),\n",
       " Document(metadata={}, page_content='total ORR was 21%, with ORR of 47% vs. 11% and 32% vs. 8% for the two subgroups,\\nrespectively, when considering tumor BRCA mutations as well as PD-L1 status [ 67 ]. Re-'),\n",
       " Document(metadata={}, page_content='markably, the mPFS in patients with BRCA mutations was 8.3 months, which was nearly\\n3 monthslonger than the mPFS of 5.6 months for olaparib reported in the OlympiAD trial'),\n",
       " Document(metadata={}, page_content='or 5.8 months for talazoparib reported in the TALA trial [68,69].\\nA cohort in the I-SPY2 trial studied the efficacy of adding durvalumab and olaparib'),\n",
       " Document(metadata={}, page_content='to standard NACT regimens of paclitaxel compared to paclitaxel alone. In the TNBC\\nsubgroup analysis, although the addition of durvalumab and olaparib increased the pCR'),\n",
       " Document(metadata={}, page_content='rate in the experimental arm by 20% (47% vs. 27%), by comparison with related trials, the\\ninvestigators concluded that the contribution from olaparib to the increased pCR rate in'),\n",
       " Document(metadata={}, page_content='the I-SPY2 experimental arm was relatively modest [ 70 ]. However, survival data from this\\nexperiment have not been published and a more reasonable random grouping should also\\nbe considered.'),\n",
       " Document(metadata={}, page_content='be considered.\\nPD-(L)1 blockers combined with PARPi have shown initial efficacy in both advanced\\nand early-stage TNBC patients, with more trials ongoing (Table 3).'),\n",
       " Document(metadata={}, page_content='```\\n```\\nTable 3. Clinical trials of PD-(L)1 inhibitors in combination with radiotherapy, targeted therapy, and\\nother immunotherapies.\\n```\\n```\\nClinical Trial Phase Status Arms Population\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nNCT02730130 II Ongoing Pemb + RT mTNBC: a median of 3 linesprior systemic therapy\\n```\\n```\\nAZTEC\\n(NCT03464942) II Ongoing Atez + RT\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nAdvanced TNBC:\\n<2 lines of prior\\nsystemic therapy\\nNCT03483012 II Ongoing Atez + RT mTNBC with brain metastases\\nKEYNOTE-162\\n(NCT02657889) I/II Completed Pemb + niraparib\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nAdvanced TNBC: a median of 1 prior\\nline of therapy (range, 0–3)\\nin the metastatic setting\\nI-SPY2\\n(NCT01042379) II Recruiting\\n```'),\n",
       " Document(metadata={}, page_content='```\\nDurv + olaparib + paclitaxel\\nvs. paclitaxel Stage II-III TNBC: preoperative treatment\\nDORA\\n(NCT03167619) II Ongoing Durv + olaparib Platinum-treated mTNBC\\nKEYLYNK-009\\n(NCT04191135) II/III Ongoing'),\n",
       " Document(metadata={}, page_content='```\\n```\\nPemb + olaparib vs. Pemb + Cb\\n+ gemcitabine\\n```\\n```\\nLocally recurrent inoperable\\nor metastatic TNBC: after induction\\nwith first-line CT + Pemb\\n```\\n```\\nNCT03594396 I/II Ongoing Olaparib + Durv'),\n",
       " Document(metadata={}, page_content='```\\n```\\nStage II/III TNBC or low ER\\nbreast cancer:\\npreoperative treatment\\n```\\n```\\nNCT03310957 Ib/II Recruiting Pemb + ladiratuzumab vedotin\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nUnresectable locally advanced\\nor metastatic TNBC:\\nfirst-line treatment\\nASCENT-04\\n(NCT05382286) III Recruiting Pemb + SG vs. pemb + TPC\\n```'),\n",
       " Document(metadata={}, page_content='```\\nPreviously untreated, locally advanced\\ninoperable, or metastatic\\nPD-L1-positive TNBC\\nNCT04468061 II Recruiting Pemb + SG vs. SG PD-L1-negative mTNBC\\nASPRIA'),\n",
       " Document(metadata={}, page_content='ASPRIA\\n(NCT04434040) II Recruiting Atez + SG Early-stage TNBC with RIC after NACT\\nNCT03394287 II Completed Camr + apatinib Advanced TNBC: <3 linesof systemic therapy'),\n",
       " Document(metadata={}, page_content='```\\n\\nCancers **2023** , 15 , 321 14 of 28\\n\\n```\\nTable 3. Cont.\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nClinical Trial Phase Status Arms Population\\nNCT05447702 II recruitingNot yet Camr + apatinib + CT Neoadjuvant therapy for stage II-III TNBC\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nNCT04303741 II Ongoing Camr + apatinib + eribulin\\n```'),\n",
       " Document(metadata={}, page_content='```\\nUnresectable recurrent or mTNBC;\\npre-treated with anthracycline\\nand taxane\\nNCT04427293 I Recruiting Pemb + Lenvatinib Early-stage TNBC: preoperative treatment'),\n",
       " Document(metadata={}, page_content='NCT04335006 III Recruiting Care + nab-P + apatinib vs. Care+ nab-P vs. nab-P Locally advanced or metastatic TNBC:first-line treatment'),\n",
       " Document(metadata={}, page_content='```\\n```\\nNCT03800836 Ib Completed Atez + ipatasertib + P/nab-P mTNBC: first-line treatment\\nBARBICAN\\n(NCT05498896) II Ongoing\\n```\\n```\\nAtez + PAC + ipatasertib\\nvs. Atez + PAC\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nEarly-stage TNBC:\\npreoperative treatment\\n```\\n```\\nNCT04177108 III Ongoing ipatasertib/placebo + PAtez/placebo + Locally advanced unresectable or metastaticTNBC\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nCOLET\\n(NCT02322814) II Completed\\n```\\n```\\nAtez + cobimetinib + P (cohorts\\nII)/Atez + cobimetinib + nab-P\\n(cohort III)\\n```\\n```\\nFirst-line treatment for mTNBC\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nNCT02536794 II Completed Durv + tremelimumab Pre-treated mTNBC\\nNCT03872791 Ib/II Ongoing KN046 vs. KN046 + nab-P mTNBC\\nSYNERGY\\n(NCT03616886) Ib/II Ongoing\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nDurv + oleclumab +PCb vs.\\nDurv + PCb First-line treatment for mTNBC\\nNCT04584112 Ib Ongoing Atez + tiragolumab + CT First-line treatment for PD-L1 (+) mTNBC\\n```\\n```\\nNCT05227664 II Recruiting'),\n",
       " Document(metadata={}, page_content='```\\n```\\nAK117 + P/nab-P vs. AK112 +\\nP/nab-P vs. AK117+AK112 +\\nP/nab-P\\n```\\n```\\nFirst-line treatment for mTNBC\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nNCT03362060 I Ongoing Pemb + PVX-410 vaccine Pre-treated HLA-A2 (+) mTNBC\\nNCT02826434 I Ongoing Durv + PVX-410 HLA-A2 (+) stage II or III TNBC\\n```\\n```\\nNCT03606967 II Recruiting\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nCT→Durv + tremelimumab +\\nVaccine vs. CT→Durv +\\ntremelimumab\\n```\\n```\\nFirst-line treatment for\\nPD-L1-negative mTNBC\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nNCT03199040 I Ongoing Durv + DNA vaccine vs. DNAvaccine Early-stage TNBC\\nNSABP FB-14\\n(NCT04024800) II Ongoing AE37 peptide vaccine + Pemb\\n```'),\n",
       " Document(metadata={}, page_content='```\\n```\\nAdvanced TNBC:≤1 line\\nof systemic therapy\\nNCT03387085 Ib/II Ongoing Combination of multipletreatments mTNBC:≥2 lines of prior therapy\\n```'),\n",
       " Document(metadata={}, page_content='```\\nNCT04445844 II Recruiting Retifanlimab + pelareorep mTNBC: received 1–2 prior linesof systemic therapy\\nNCT03004183 II Ongoing ADV/HSV-tk + RT + Pemb + Pre-treated mTNBC'),\n",
       " Document(metadata={}, page_content='NCT03256344 I Completed Atez + talimogene laherparepvec mTNBC with liver metastases\\nNCT05081492 I Recruiting CF33-hNIS-antiPDL1 mTNBC:for metastatic disease≥2 prior lines of therapy'),\n",
       " Document(metadata={}, page_content='```'),\n",
       " Document(metadata={}, page_content='```\\nNCT04185311 I Ongoing Talimogene laherparepvec +nivolumab + ipilimumab Localized, palpable HER-2 negativebreast cancer'),\n",
       " Document(metadata={}, page_content='Abbreviations: mTNBC, metastatic triple-negative breast cancer; Pemb, pembrolizumab; Camr, camrelizumab;'),\n",
       " Document(metadata={}, page_content='Atez. atezolizumab; Durv. durvalumab; Nivo, nivolumab; Care, carelizumab; CT, chemotherapy; RT, radiotherapy;'),\n",
       " Document(metadata={}, page_content='Nab-P, nab-paclitaxel; P, paclitaxel; E, epirubicin; A, doxorubicin; C, cyclophosphamide; Cb, carboplatin; mOS,'),\n",
       " Document(metadata={}, page_content='median overall survival; mPFS, median progression-free survival; ORR, objective response rate; pCR, pathological'),\n",
       " Document(metadata={}, page_content='complete remission; DOR, median duration of response; SG, sacituzumab govitecan; TPC, treatment of physician’s'),\n",
       " Document(metadata={}, page_content='choice; HLA, human leukocyte antigen; RIC, residual invasive cancer; NACT, neoadjuvant chemotherapy.'),\n",
       " ...]"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "splitter.create_documents([markdown_text])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "id": "5e5a9d8b-8d9e-4dd3-b293-43c15a34a042",
   "metadata": {},
   "outputs": [
    {
     "ename": "ImportError",
     "evalue": "cannot import name 'open_filename' from 'pdfminer.utils' (C:\\Users\\YELISETTY RAHUL\\Music\\aiml\\env\\Lib\\site-packages\\pdfminer\\utils.py)",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mImportError\u001b[0m                               Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[93], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01munstructured\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mpartition\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mpdf\u001b[39;00m \u001b[38;5;28;01mimport\u001b[39;00m partition_pdf\n",
      "File \u001b[1;32m~\\Music\\aiml\\env\\Lib\\site-packages\\unstructured\\partition\\pdf.py:15\u001b[0m\n\u001b[0;32m     13\u001b[0m \u001b[38;5;28;01mimport\u001b[39;00m \u001b[38;5;21;01mwrapt\u001b[39;00m\n\u001b[0;32m     14\u001b[0m \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01mpdfminer\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mlayout\u001b[39;00m \u001b[38;5;28;01mimport\u001b[39;00m LTContainer, LTImage, LTItem, LTTextBox\n\u001b[1;32m---> 15\u001b[0m \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01mpdfminer\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mutils\u001b[39;00m \u001b[38;5;28;01mimport\u001b[39;00m open_filename\n\u001b[0;32m     16\u001b[0m \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01mpi_heif\u001b[39;00m \u001b[38;5;28;01mimport\u001b[39;00m register_heif_opener\n\u001b[0;32m     17\u001b[0m \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01mPIL\u001b[39;00m \u001b[38;5;28;01mimport\u001b[39;00m Image \u001b[38;5;28;01mas\u001b[39;00m PILImage\n",
      "\u001b[1;31mImportError\u001b[0m: cannot import name 'open_filename' from 'pdfminer.utils' (C:\\Users\\YELISETTY RAHUL\\Music\\aiml\\env\\Lib\\site-packages\\pdfminer\\utils.py)"
     ]
    }
   ],
   "source": [
    "\n",
    "from unstructured.partition.pdf import partition_pdf\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "id": "94bad867-3fd6-4772-85e0-2ee29903ec69",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pdfminer"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "929addb4-c25b-4b8e-9416-f7cc110d1556",
   "metadata": {},
   "source": [
    "# Semantic chunker\n",
    "\n",
    "mbeddings represent the semantic meaning of a string. They don't do much on their own, but when compared to embeddings of other texts you can start to infer the relationship between chunks. I want to lean into this property and explore using embeddings to find clusters of semantically similar texts.\n",
    "\n",
    "The hypothesis is that semantically similar chunks should be held together.\n",
    "\n",
    "I tried a few methods:\n",
    "\n",
    "Heirarchical clustering with positional reward - I wanted to see how heirarchical clustering of sentence embeddings would do. But because I chose to split on sentences, there was an issue with small short sentences after a long one. You know? (like this last sentenence). They could change the meaning of a chunk, so I added a positional reward and clusters were more likely to form if they were sentences next to each other. This ended up being ok, but tuning the parameters was slow and unoptimal.\n",
    "Find break points between sequential sentences - Next up I tried a walk method. I started at the first sentence, got the embedding, then compared it to sentence #2, then compared #2 and #3 and so on. I was looking for \"break points\" where embedding distance was large. If it was above a threshold, then I considered it the start of a new semantic section. I originally tried taking embeddings of every sentence, but this turned out to be too noisy. So I ended up taking groups of 3 sentences (a window), then got an embedding, then dropped the first sentence, and added the next one. This worked out a bit better."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "id": "a445aeaf-128d-4876-8645-9750cd63329d",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 232\\n© The Author(s) 2024. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International \\nLicense (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution \\nand reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the \\noriginal author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.\\nExploration of Targeted Anti-tumor Therapy\\nOpen Access\\nReview\\nEarly-stage triple negative breast cancer: the therapeutic role of \\nimmunotherapy and the prognostic value of pathological complete \\nresponse\\nPierluigi De Santis1, Martina Perrone1, Chiara Guarini1, Anna Natalizia Santoro1, Carmelo Laface1, \\nDaniela Carrozzo1, Gaia Rachele Oliva2, Palma Fedele1*\\n1Oncology Unit, Francavilla Fontana Ceglie Messapica Hospital District, 72021 Francavilla Fontana, Italy\\n2Department of Medicine and Translational Surgery, Università Cattolica del Sacro Cuore, 00168 Roma, Italy\\n*Correspondence: Palma Fedele, Oncology Unit, Francavilla Fontana Ceglie Messapica Hospital District, 72021 Francavilla \\nFontana, Italy. minafedele@hotmail.com\\nAcademic Editor: Laura Cerchia, Institute of Experimental Endocrinology and Oncology “G. Salvatore”-National Research \\nCouncil (IEOS-CNR), Italy; Simona Camorani, Institute of Experimental Endocrinology and Oncology “G. Salvatore”-National \\nResearch Council (IEOS-CNR), Italy\\nReceived: May 26, 2023  Accepted: December 26, 2023  Published: February 28, 2024\\nCite this article: De Santis P, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, et al. Early-stage triple negative breast \\ncancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response. Explor Target \\nAntitumor Ther. 2024;5:232–50. https://doi.org/10.37349/etat.2024.00215\\nAbstract\\nTriple negative breast cancer (TNBC) represents an aggressive disease associated with a high risk of \\nrecurrence after curative treatment and a poor prognosis in the metastatic setting. Chemotherapy was for \\nyears the only treatment available in the early and metastatic setting, due to the lack of actionable targets. \\nClinical practice has changed following the results obtained with the addition of immunotherapy to \\nstandard chemotherapy, the development of novel drugs [i.e. antibody-drug conjugates (ADCs)], and the \\nuse of targeted treatments for patients carrying germline pathogenic breast cancer susceptibility genes \\n(BRCA) 1 or BRCA 2 variants. The treatment of early-stage disease has had a shift in clinical practice since \\nJuly 2021, after the Food and Drug Administration (FDA) approval of pembrolizumab in association with \\nchemotherapy as neoadjuvant treatment for TNBC and as a single agent in the subsequent adjuvant setting. \\nThis intensive treatment based on the combination of a poly-chemotherapy and an immune checkpoint \\ninhibitor (ICI) led to the improvement of short- and long-term outcomes, but it has highlighted some new \\nunmet clinical needs in the treatment of early-stage TNBC: the selection of the most effective adjuvant \\ntherapy and the integration of pembrolizumab with other therapeutic strategies [capecitabine, poly(ADP-\\nribose) polymerase (PARP) inhibitors] based on the achievement of pathologic complete response (pCR); \\nthe identification of predictive biomarkers to select patients who could most benefit from the addition of \\nICI, to minimize toxicities and to maximize outcomes; the possibility of de-escalating chemotherapy in favor \\nof immune-combo or novel agents, such as ADCs; the role of immunotherapy in estrogen receptor (ER)-low \\npatients. The advent of immunotherapy not only addresses current challenges in TNBC treatment but also \\nholds the promise of a radical transformation in its therapeutic paradigm, enhancing significantly clinical \\noutcomes and offering new perspectives for patients grappling with this aggressive form of breast cancer.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 233\\nKeywords\\nTriple negative breast cancer, immunotherapy, pathological complete response, neoadjuvant combination \\ntreatment, adjuvant treatment\\nIntroduction\\nTriple negative Breast Cancer (TNBC) is a histological subtype of breast cancer (BC) characterized by the \\nimmunohistochemical lack of expression (< 1%) of estrogen receptor (ER), progesterone receptor (PgR), \\nand human epidermal growth factor receptor 2 (HER2). It accounts for approximately 10–20% of all BC, \\naffecting mainly young, premenopausal women, and individuals with inherited gene alterations, such as BC \\nsusceptibility genes 1/2 (BRCA 1/2) mutations [1–3]. It notably presents an aggressive biological behavior \\nwith a trend to have a higher grade and an often lymph node involvement at diagnosis, an inclination to \\nmetastasize after curative treatment, and a poorer prognosis in metastatic setting when compared with \\nother BC subtypes [4, 5].\\nFor decades, treatment for early TNBC has been based on surgery and subsequent adjuvant \\nchemotherapy (CHT) for the reduction of disease recurrence [6]. Therefore, conventional cytotoxic CHT has \\nrepresented the backbone of systemic treatment in the early TNBC, including neoadjuvant treatment, which \\nused to reduce tumor size in larger tumors increasing the chances of a breast-conserving surgery [7, 8]. In \\nrecent years the development of novel therapeutic approaches has been difficult, due to the heterogeneity \\nof TNBC and lack of therapeutic targets [9, 10]. Nevertheless, immunotherapy and poly(ADP-ribose) \\npolymerase (PARP) inhibitors have shown survival benefits in recent studies.\\nSpecifically, combinations of immune checkpoint inhibitors (ICIs) with CHT or other alternative \\ntherapeutic compounds could emerge as a successful therapeutic approach in the management of TNBC \\npatients. Despite the progress in ICIs representing a notable milestone in TNBC treatment, additional \\ninvestigations are necessary to tackle this issue comprehensively. A profound comprehension of tumor \\nsubtypes, alongside tumor microenvironment (TME) and in terms of molecular, genetic, and immune \\naspects, would amplify the potential for developing targeted immunotherapy to achieve superior \\ntherapeutic effectiveness, especially in TNBC [11].\\nTherefore, in this review, we aimed to investigate the role of immunotherapy in early-stage TNBC, the \\nprognostic value of pathologic complete response (pCR) with its therapeutic implications, and the future \\nperspectives regarding the systemic treatment of early TNBC, including the discovery of new biomarkers.\\nThe landscape of immunotherapy in TNBC\\nThe immune system plays a crucial role in TNBC compared to the other molecular subtypes of BC. Although \\noriginally BC was considered non-immunogenic, TNBC has a high immunogenic potential, making it a \\npromising candidate for immunotherapy, especially with ICIs [12, 13]. TNBC immunogenicity is related to \\nintrinsic tumor cell signatures and tumoral surrounding microenvironment features.\\nOver the last decades thanks to emerging technologies such as next-generation sequencing (NGS), the \\nknowledge of the molecular and genetic background of TNBC improved, bringing to light its intertumoral \\nand intratumoral heterogeneity.\\nA first classification divided TNBC into six subtypes: basal-like 1 (BL1), basal-like 2 (BL2), \\nmesenchymal (M), M stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR) [14].\\nSubsequently, analyzing RNA and DNA-based profiles of 198 TNBC tumors, a four-type classification of \\nTNBC was shaped: basal-like immunosuppressed (BLIS), basal-like immune-activated (BLIA), M and LAR \\n[15]. This classification was further revised with the identification of four specific TNBC subtypes: BL1, BL2, \\nM, and LAR, omitting IM and MSL because of the dependence of these two subtypes on the TME features \\n[14].\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 234\\nIn addition, TNBC could be classified into three microenvironment phenotypes or clusters:\\nCluster 1: “immune-desert” with poor immune cell permeation, due to a high presence of MYC \\namplifications and, consequently, a lower recruitment of innate immune cells.\\n(1).\\nCluster 2: “innate immune-inactivated” characterized by a hyper-activation of \\nphosphatidylinositide 3-kinase/protein kinase B (PI3K-AKT) pathway in tumor cells, low tumor \\nantigen burden and infiltration of deactivated innate immune cells, fibroblasts, and endothelial \\ncells. Clusters 1 and 2 are therefore referred to as “cold tumors”.\\n(2).\\nCluster 3: “immune-inflamed”, the so-called “hot tumor” that represents about 30% of TNBCs and \\nis characterized by an abundant adaptive and innate immune cells infiltration and with a high \\nexpression of immune checkpoint molecules [16].\\n(3).\\nThe potential “hot” conversion of “cold” tumors could improve the efficacy of cancer immunotherapy. \\nFor example, local IM therapies can express a synergistic effect with immunotherapy by acting on \\ncomponents of the TME and immune system function, such as elevating the expression of tumor antigens \\nand increasing the recruitment of activated immune cells in the TME [17].\\nTNBC cancer cell immunological features include genomic instability and high tumor mutational \\nburden (TMB), resulting in more somatic mutations and neoantigens [18].\\nMoreover, approximately 10–20% of TNBC harbor BRCA 1 or BRCA 2 germinal mutations, with a \\nconsequent hereditary deficit in the DNA repair mechanism and strong genomic instability. Several studies \\nhave demonstrated that TNBC-carrying BRCA mutations are more sensitive to DNA-damaging drugs such as \\nanthracyclines, but also platinum agents and PARP inhibitors [19–21]. Sensitivity to these drugs was also \\nobserved in tumors with alterations in other genes, sharing BRCA-mutant phenotype in the absence of a \\nBRCA 1/2 mutation, namely “BRCAness” [22, 23].\\nTumors with BRCA 1/2 mutations or BRCAness TNBC are more immunogenic than TNBC without these \\ngenetic alterations [24–26].\\nCompared to the other BC subtypes the immunogenic TME features in TNBC consist of higher levels of \\nvascular endothelial growth factor (VEGF), that promote tumor cell growth and migration such as mitogen-\\nactivated protein kinases (MAPKs), tumor-associated macrophages (TAMs), and tumor-infiltrating \\nlymphocytes (TILs), white blood cells that migrate towards the tumor, leading to an important \\nimmunogenic effect and consequently that are involved in killing cancer cells [27–29].\\nTAMs regulate the interaction between the immune system and cancer cells. CD163+ M2 macrophages, \\nwhich are associated with tumors characterized by higher proliferation and poorer differentiation [30], are \\nmore present in TNBC and basal-like BC [31]. A prosperous infiltration of TILs is found in TNBC tumors and \\nthe stroma surrounding them, with a recognized predictive and prognostic role, specifically for CD4+ CD8+ \\nT cells [32]. Several studies have reported better response to neoadjuvant CHT (NACT) [33] and better \\nclinical outcomes in BC with high TIL infiltrate [34–39]. Based on this evidence, the international TILs \\nworking group started standardizing the evaluation of BC TILs to use it in clinical practice identifying those \\npatients that may benefit from emerging immunotherapies with ICIs or combination therapies [40].\\nAll these TME elements contribute to TNBC immunogenicity which also appears to be closely related to \\nthe concept of TMB, depending on the ineffective DNA repair system with the consequent generation of \\nhigh rates of neoantigens. The upregulated antigen presentation system leads to an increasing number of \\ninnate and adaptative immune cells and many cytokines interplaying with cancer cells. However, the exact \\nrelationship between TMB, neoantigens, and immune infiltration is not yet completely understood, and \\nsome studies have reported an inverse association between immune cells in TME and the rate of somatic \\ncopy number alterations [41, 42].\\nMoreover, although TMB is comparable across the three clusters of TNBC, the “immune-inflated” \\nphenotype is characterized by a higher degree of immune cells in the TME, but also a high expression of \\nimmune checkpoints by cancer cells [16]. The rate of TILs, indeed, has been positively related to \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 235\\nprogrammed death ligand 1 (PD-L1) expression [43]. PD-L1 is an immune checkpoint that mediates local \\nimmune escape in many tumors inducing saturation of activated T cells. Even if PD-L1 prognostic role is yet \\ncontroversial [44], however it results more overexpressed in TNBC compared with other BC and it can \\npredict responsiveness to immunotherapy [16].\\nTherefore, TNBC represents an aggressive BC subtype, associated with high mutational load, high \\ntumor immunogenicity and TME diversity.\\nNew paradigms in early TNBC: from CHT to immunotherapy\\nCHT in adjuvant treatment for TNBC\\nIn early TNBC patients, CHT represents the mainstay of adjuvant and neoadjuvant treatments. Adjuvant \\nCHT is recommended for tumor sizes greater than 1.0 cm and patients with nodal involvement, regardless \\nof tumor size. Therefore, it can be considered for tumor sizes between 0.6–1.0 cm [45]. A recent large meta-\\nanalysis demonstrated that adjuvant CHT with anthracyclines-containing regimens plus taxanes, compared \\nwith no CHT, can reduce BC mortality rates by about 40% during the first decade after diagnosis. Moreover, \\nregimens with higher cumulative and dose-dense schedules of anthracycline (with granulocyte colony-\\nstimulating factor support) have shown better survival benefits and more reductions in recurrence [46]. \\nThree-weekly docetaxel and paclitaxel can be considered in adjuvant setting, but weekly paclitaxel, in a \\nsubgroup analysis, has shown improved outcomes and is preferred for TNBC [47]. In TNBC in frail patients \\nwith a known history of heart disease, to minimize the cardiotoxicity of adjuvant treatments, docetaxel \\ncombined with cyclophosphamide (TC) has proven to be a viable alternative to doxorubicin and \\ncyclophosphamide (AC), demonstrating a favorable disease-free survival (DFS) [48]. Therefore, there is a \\nbroad spectrum of chemotherapeutic treatments for early TNBC that should be customised according to the \\npatient and expected toxicities.\\nThe role of platinum in adjuvant setting for TNBC\\nTNBC patients commonly harbor BRCA 1/2 or BRCAness mutations with a homologous recombination \\ndeficiency (HRD) that makes them particularly susceptible to platinum agents due to their ability to hit \\ncancer cells that have deficient DNA repair mechanisms [49–51]. Several retrospective single-center studies \\nhave explored the role of adjuvant platinum combined with standard anthracycline and taxane-based \\nregimens, with controversial results not showing clear clinical benefits [52, 53]. Nevertheless, a recent \\nphase III trials have demonstrated a longer 5-year DFS (86.5% vs. 80.3%) with similar results in distant DFS \\nand relapse-free survival (RFS) of platinum-containing adjuvant regimens (paclitaxel-carboplatin) \\ncompared to a standard anthracyclines-containing regimen followed by taxane, however with no benefit in \\noverall survival (OS) [54].\\nAnother important factor is platinum resistance. Platinum sensitivity may be affected by changes in the \\nhazard ratio (HR) pathway or, in the case of patients with BRCA 1/2 mutations, by the secondary \\nappearance of new BRCA 1 or 2 mutations that make cancer cells less sensitive to platinum [55, 56].\\nOther mechanisms of resistance to platinum compounds are:\\nModification of drug transport within the tumor cell, by determining decreased influx or increased \\nefflux.\\n(1).\\nIncrease of detoxification systems.\\n(2).\\nDecrease of cell apoptosis [57].\\n(3).\\nTherefore, the benefit of adjuvant platinum-based regimens remains controversial and needs \\nvalidation by prospective adjuvant ongoing trials.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 236\\nNeoadjuvant treatments for TNBC\\nNACT\\nSeveral treatment guidelines recommend NACT as the preferred option for stage II or III TNBC and for \\nstage I with a tumor size greater than 1 cm. It can be considered in stage I TNBC with a tumor size from \\n0.6 cm to 1 cm and/or in the case of tumors with nodal micrometastases. [6, 45]. There is no significant \\ndifference in survival benefits between patients receiving neoadjuvant or adjuvant CHT after surgical \\nresection. However, neoadjuvant treatments can be useful for inoperable tumors rendering them operable \\nand they can also downstage patients with operable BC promoting breast-conservation [58, 59]. The use of \\nneoadjuvant treatments provides important prognostic information based on response to therapy. \\nAchieving a pCR, defined as the lack of cancer cells in tissue samples of breast and axillary lymph nodes, \\nafter a neoadjuvant treatment, is associated with favorable disease-free and OS in early TNBC, as \\ndemonstrated in Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) pooled analysis. In this \\nstudy, patients with early BC treated with NACT and followed by surgery who obtained pCR (ypT0 ypN0, \\nypT0/is ypN0) were associated with improved event-free survival (EFS) and OS, especially in TNBC (HR = \\n0.24 and HR = 0.16, respectively) [33]. Like adjuvant treatment, traditional NACT is based on anthracyclines \\nand taxanes, and a dose-dense regimen is preferred in neoadjuvant settings based on proven improved DFS \\nand OS in a large meta-analysis [60].\\nIn recent years, the use of platinum-based combination regimens has been the focus of neoadjuvant \\ntreatment to increase the rate of pCR in TNBC. Three recent studies demonstrated that combining platinum \\nwith taxane and anthracycline led to an improvement in the pCR rate in TNBC, with a similar survival \\nbenefit [61–63]. In Brightness Trial patients with II–III stage TNBC were randomly assigned to receive \\npaclitaxel alone, paclitaxel and carboplatin and this combination with a PARP inhibitor, veliparib followed \\nby AC. Although the addition of veliparib and carboplatin was associated with an increase of patients who \\nachieved a pCR compared to paclitaxel alone (53% vs. 31%, P < 0.0001), but not to paclitaxel and \\ncarboplatin, this benefit could be related to the addition of the carboplatin [63]. The initial rationale for \\nusing the combination of platinum in NACT was that sporadic TNBC can show BRCAness with a major \\nresponse to platinum regimens [50, 51]. However, the greatest benefit was seen in patients who were \\ngermline BRCA wild type, and only a marginal benefit was observed in the germline BRCA mutant \\nsubgroup, as was shown in the recent GeparOLA trial. In this trial, patients were randomized to \\nneoadjuvant therapy with paclitaxel and carboplatin vs. neoadjuvant therapy with paclitaxel and olaparib \\n(PARP inhibitor). In both arms, the combination of epirubicin and cyclophosphamide was administered \\nnext. This study, although limited by a small number of patients enrolled, showed an advantage for the \\ncarboplatin arm in patients without BRCA mutation (germ or somatic) and high HRD. The 4-year invasive \\nDFS (iDFS) rate with olaparib-paclitaxel was 81.2% vs. 93.4% with carboplatin-paclitaxel (CP) [HR = 3.03; \\n95% confidence interval (CI) = 0.67–13.67; log-rank P = 0.1290]. The 4-year OS rate was 89.2% with the \\nolaparib combination vs. 96.6% with carboplatin (HR = 3.27; 95% CI = 0.39–27.20; log-rank P = 0.2444). \\nThe trend of the iDFS curves was similar in the two treatment arms and independent of germline or somatic \\nBRCA mutation [64].\\nPlatinum combinations are currently recommended for selected patients with TNBC who require \\nadequate local control before surgical resection [45]. A more recent phase III trial presented at the San \\nAntonio Breast Cancer Symposium evaluating the efficacy and safety of adding carboplatin to standard \\nsequential taxane-anthracycline NACT in patients with TNBC who had no evidence of metastatic disease, \\nhas observed improvements in terms of DFS (5-year DFS were 70.6% and 64.5% respectively with a HR = \\n0.79, 95% CI = 0.61–1.02, P = 0.073) and OS (5-year OS were 74.0% and 66.7% respectively with a HR = \\n0.75, 95% CI = 0.57–0.98, P = 0.034) with the addition of carboplatin, but these benefits were limited to \\npatients who were 50 years of age or younger. Therefore, the pCR in the intention-to-treat population was \\n54.5% in the carboplatin arm and 40.3% in the control arm (P < 0.001) [65].\\nThe inclusion of platinum agents as NACT for TNBC remains controversial. Long-term outcomes and \\nnew prospective studies are needed to clarify the role of platinum agents in this setting.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 237\\nNeoadjuvant immunotherapy\\nThe success of ICIs in metastatic TNBC led to expand their role in neoadjuvant settings. Pembrolizumab and \\natezolizumab have shown progression-free survival (PFS) benefits in phase III trials in advanced setting \\n[66, 67]. In contrast to atezolizumab that showed conflicting results [68, 69], pembrolizumab consistently \\nshowed OS benefits in advanced TNBC [66, 70]. In early-stage TNBC two studies evaluated atezolizumab in \\nneoadjuvant setting. In the NeoTRIPaPDL1 trial, no improvement in pCR was shown with the addition of \\natezolizumab to a non-anthracycline-containing CHT regimen [71]. More recent Impassion031 phase III \\nstudy evaluating the association of atezolizumab to a standard NACT (nab-palclitaxel weekly for 12 weeks \\nfollowed by 4 cycles of AC), has demonstrated a significant improvement of pCR rates in intention to treat \\n(ITT) population (58% in atezolizumab arm vs. 41% in placebo arm, P = 0.0044), regardless of PD-L1 status, \\nmeeting the primary endpoint of the study [72]. Therefore, in early BC the combination of pembrolizumab \\nwith paclitaxel-carboplatin followed by anthracycline increased pCR rate and EFS rate in the KEYNOTE-522 \\ntrial, representing a turning point for the role of immunotherapy in neoadjuvant therapy of TNBC and \\nestablishing pembrolizumab as a standard treatment during neoadjuvant treatment for stage II and III \\nTNBC. The trial evaluated the combination of pembrolizumab (18 cycles, 200 mg every 3 weeks) combined \\nwith four cycles of paclitaxel (weekly or 3-weekly) and carboplatin (3-weekly), followed by 3-weekly AC for \\n4 cycles, compared to placebo with CHT. Pembrolizumab arm showed a 13.6% improvement in pCR [64.8% \\n(95% CI = 59.9–69.5%) vs. 51.2% (95% CI = 44.1–58.3%)] and in EFS rate [84.5% (95% CI = 81.7–86.9%) \\nvs. 76.8% (95% CI = 72.2–80.7%)], meeting the primary endpoint of the study, regardless nodal \\ninvolvement and PD-L1 status. The average duration of follow-up is still immature, but a trend of \\nsuperiority in terms of OS in the pembrolizumab arm was nevertheless detected [73]. Limits of this study \\nare the lack of biomarkers that predict what patient may benefit from the addition of pembrolizumab and \\nthe non-utilization of dose-dense schedule of AC which showed superior OS benefit in the neoadjuvant \\nsetting in TNBC [74].\\nMoreover, the recent GeparNuevo trial showed that durvalumab (1,500 mg every 4 weeks) added to \\nNACT consisting of nab-paclitaxel 125 mg/m2 weekly for 12 weeks, followed by epirubicin/\\ncyclophosphamide every 2 weeks, in early TNBC significantly improved iDFS (85.6% with durvalumab vs. \\n77.2% with placebo HR = 0.48, 95% CI = 0.24–0.97, stratified log-rank P = 0.036) and OS (95.2% vs. 83.5% \\nwith a HR = 0.24, 95% CI = 0.08–0.72, P = 0.006), despite a modest pCR increase and no adjuvant \\ncomponent of durvalumab [75]. Future studies should aim to define the role of immunotherapy in the \\ntreatment of early TNBC, to define the ideal duration of these treatments, and should research new \\nbiomarkers to personalize treatments.\\nPathological complete response: prognostic role and therapeutic \\nimplications\\nIn clinical practice, the achievement of pCR after neoadjuvant treatment is correlated to the improvement of \\nlong-term benefits concerning EFS and OS. Its prognostic value is greatest in aggressive tumor subtypes, \\nlike in TNBC (EFS: HR = 0.24; OS: HR = 0.16) [33]. Patients who have residual invasive BC after the receipt \\nof NACT have a high risk of relapse. Patients with TNBC who do not experience pCR have an estimated 5-\\nyear EFS of 57% and OS of 47% (compared with 90% EFS and 84% OS, respectively, for patients with early-\\nstage TNBC who demonstrate pCR) [76, 77].\\nAfter pre-operative CHT and surgical treatment, patients can receive postoperative radiation therapy \\n(RT). Patients with hormone receptor-positive BC [hormone receptor-positive (HR+) BC] are candidates for \\nadjuvant endocrine treatment. However, until recently, no adjuvant CHT was expected as standard in \\npatients with TNBC. Only follow-up was recommended in those who have pCR or in those with residual \\ninvasive BC after the receipt of neoadjuvant regimens [78]. To address the unmet clinical need for optimal \\nadjuvant treatment in the subgroup of patients with TNBC at high risk of recurrence (those who have not \\nachieved the pCR after NACT containing anthracycline, taxane, or both), the Capecitabine for Residual \\nCancer as Adjuvant Therapy (CREATE-X) was designed. The trial did not include only patients with TNBC \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 238\\nbut also patients with HR+ HER2 negative BC [79]. The results of this phase III trial showed that the \\naddition of adjuvant capecitabine (1,250 mg per square meter of body-surface area, twice per day, on days \\n1 to 14, every 3 weeks for six or eight cycles) was safe and effective in prolonging DFS and OS among the \\nITT population. The study showed a superior DFS in the capecitabine group than in the control group \\n(74.1% vs. 67.6% at 5 years; HR = 0.70; P = 0.01). Therefore, OS was longer in the experimental group: \\n89.2% vs. 83.6% of the patients were alive at 5 years (HR = 0.59; P = 0.01). Thirty percent of the patients \\nhad triple negative (TN) disease, and they represent the subgroup with poor prognosis (approximately half \\nthe patients with TNBC who had a pCR did not have the recurrence of the disease) [33]. The benefit of \\ncapecitabine vs. control in DFS and OS was notable among this subgroup of patients (HR = 0.58 and HR = \\n0.52, respectively) [79].\\nThe reflection in the treatment algorithm due to these results was significant.\\nSome limits of this study are the exclusion of patients who had reached the pCR, for whom only follow-\\nup was indicated, and the lack of efficacy results selected for residual cancer burden (RCB). The RCB \\nquantifies the extent of residual disease after neoadjuvant treatment at the time of surgery. This score uses \\nthe diameter of residual disease, percentage of vital tumor cells, and diameter of the largest involved lymph \\nnode to calculate the amount of residual disease. It has been validated with distinct prognostic RCB classes \\nin all BC subtypes, with the most significant discriminatory power in TN and Her-2 positive BC. It is \\ncategorized as RCB-0 (equivalent to a pCR), RCB-1, RCB-2, and RCB-3, reflecting increasingly larger residual \\ncancer and respective poor prognoses (in terms of EFS) [80]. Finally, the CREATE-X trial did not examine \\ncapecitabine efficacy in patients with germline BRCA 1 or BRCA 2 pathogenic variants (less than 15% of \\nthose enrolled) [79].\\nOlympiA is a phase III study designed to investigate how the PARP inhibitor olaparib might improve \\nDFS and OS in patients with resected HR+ BC and TNBC with germline BRCA 1 or BRCA 2 mutation. It \\nenrolled patients treated with CHT (containing anthracyclines, taxanes or the combination of both) in \\nneoadjuvant or adjuvant setting and randomized them to receive olaparib (orally administered at the dose \\nof 300 mg twice daily) vs. placebo for 1 year after surgical resection (and radiotherapy when indicated). \\nAlso in this trial, patients with TNBC who underwent NACT followed by surgery were required to have \\nresidual invasive BC in the breast and/or resected lymph nodes (non-pCR) [81]. Postneoadjuvant \\ncapecitabine was not foreseen in this trial. iDFS, the primary endpoint of the study, was significantly longer \\namong patients assigned to receive olaparib than among those assigned placebo (HR = 0.58; P < 0.001). The \\npercentage of patients alive and free of invasive disease at 3 years was 85.9% in the olaparib group and \\n77.1% in the placebo group. The benefit of adjuvant olaparib was observed irrespective of the germline \\nBRCA mutation (BRCA 1 vs. BRCA 2), the hormone-receptor status, or the timing of previous CHT \\n(neoadjuvant vs. adjuvant) [81] 4-year iDFS for the olaparib group was 82.7% (vs. 75.4% in placebo group) \\nand 4-year distant DFS (DDFS) was 86.5% (vs. 79.1%). Adjuvant olaparib improves OS, with an HR of 0.68 \\nand a P value of 0.009 at 3.5 years of median follow-up, meeting the significance threshold for OS at the \\nsecond planned interim analysis. The OS benefit at 4 years in the olaparib arm compared with the placebo \\narm was reported (89.8% vs. 86.4%, respectively) [82].\\nBoth studies have defined the standard of adjuvant therapy post-NACT for patients with BRCA wild \\ntype (CREATE-X) and BRCA mutated (OlympiA) TNBC, that did not reach the pCR.\\nThe low percentage of BRCA mutated patients enrolled in the CREATE-X, the absence of pre-planned \\nsubgroup analyzes for this population do not allow for a description of the efficacy of capecitabine in this \\nsubgroup of patients.\\nMoreover, there are no prospective randomized trials between capecitabine and olaparib to guide the \\nclinical decision in this population, nor combination or sequence data between these two drugs.\\nIt would also be important to consider the potentially severe toxicity profile of such a combination, \\ngiven their overlapping side effects (in particular, cytopenias).\\nThe treatment paradigm of early TNBC has had a real evolution since July 2021, with the introduction \\nof immunotherapy following the Food and Drug Administration (FDA) approval of pembrolizumab for high-\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 239\\nrisk TNBC (tumor size > 1 cm but ≤ 2 cm in diameter with nodal involvement or tumor size > 2 cm in \\ndiameter regardless of nodal involvement), regardless of tumor PD-L1 expression, in combination with CHT \\nas neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery for a \\ntotal duration of approximately 1 year [83].\\nResults from the KEYNOTE-522 study were the basis for this approval, demonstrating a significantly \\nhigher rate of pCR at the time of definitive surgery among patients who received pembrolizumab plus NACT \\nthan among those who received placebo plus NACT and an improvement in long-term benefits [73, 84]. The \\naim of the trial was not to identify the contributions of the neoadjuvant and adjuvant treatment phases, so it \\nis difficult to define if these long-term results are related to exposure to adjuvant pembrolizumab or a \\nlesser RCB at the end of the neoadjuvant phase in the pembrolizumab–CHT group.\\nAn exploratory analysis of the study then provided data to further describe the prognosis related to the \\nRCB after neoadjuvant experimental treatment (Figure 1) [85].\\nFigure 1. The unmet need for the optimal adjuvant treatment according to RCB [85]\\nThe HR for recurrence event in subgroups RBO-0, RCB-1, RCB-2, and RCB-3 are respectively 0.70 \\n(rates: 5.2% vs. 7.3% in the pembrolizumab + CHT vs. placebo + CHT), 0.92 (rates: 17.4% vs. 20%), 0.52 \\n(rates: 25.5% vs. 44.3%), 1.24 (72.5% vs. 69.2%).\\nThe rate of recurrence was numerically lower in all RCB groups with pembrolizumab + CHT, except in \\nthe small RCB-3 subset (that is represented by 5% and 7% of the population in the study, respectively in \\nthe experimental and control group). Pembrolizumab shifted RCB to lower categories in most patients \\n(RCB-0: 63% vs. 56% of patients in the experimental vs. the control arm; RCB-1: 9% vs. 11%; RCB 18% vs. \\n20%).\\nNo patients in this trial received adjuvant capecitabine, and there are no randomized efficacy and \\nsafety data showing that multiagent therapy with pembrolizumab and capecitabine is superior to single-\\nagent therapy in high-risk patients (stage II–III) who did not reach pCR.\\nAt the time, only results from phase II studies in metastatic TNBC demonstrated no new safety signals \\nwith this combination [86, 87].\\nPembrolizumab has also not been studied in combination with olaparib in the adjuvant setting, for the \\ntreatment of patients with BRCA mutations. No efficacy data are reported in the literature, even if some \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 240\\nsafety data are reported in the metastatic setting, in some early-phase studies that have evaluated the \\ncombination of PARPis and ICIs, not reporting unexpected toxicities [88, 89].\\nProspective trials would be needed to define what is the optimal adjuvant strategy according to RCB \\n(single-agent CHT or poly-CHT), how the clinician should decide between olaparib, immunotherapy or \\ncapecitabine in the treatment of the population with BRCA mutations and whether these therapies can be \\nadministered in combination or sequence, with data in terms of efficacy and safety.\\nAdditional treatment strategies with new drugs are being studied as adjuvant treatment after NACT, \\nwith antibody-drug conjugates (ADCs) such as datopotamab deruxtecan (with or without durvalumab in \\nTROPICS-Breast 03, ClinicalTrials.gov identifier: NCT05629585), and patritumab deruxtecan (HER3-DXd) \\nwhich showed promising clinical response and biological changes in early TNBC [SOLTI TOT-HER3 window \\nof opportunity trial part B, presented at European Society for Medical Oncology (ESMO) Breast 2023], or \\nwith ICIs (A-BRAVE trial, NCT02926196 and SWOG S1418/BR006 trial, NCT02954874).\\nNew biomarkers and frontiers in TNBC\\nRecent progress in integrating ICIs and novel agents has revolutionized the therapeutic approach for early \\nTNBC. Treatment strategies now emphasize escalating chemotherapeutic agents based on standard \\nneoadjuvant regimens. An example is a phase II trial (ACTRN12617000651381) presented at the San \\nAntonio Breast Cancer Symposium 2022 evaluating in high-risk TNBC, the addition of ipilimumab and \\nnivolumab to neoadjuvant paclitaxel following a suboptimal response to anthracycline-based CHT (< 50% \\ntumor reduction) and resulting in promising objective response rate (ORR) (43.7%) and pCR (18.8%) rates, \\nregardless of PD-L1 status.\\nHowever, it is also crucial to identify subgroups of patients with favorable prognoses, where NACT \\ncould potentially be de-escalated. Therefore, discovering novel biomarkers to categorize patients with good \\nprognoses and safely de-escalate NACT is essential.\\nTILs show promise as a biomarker for selecting patients who may have favorable outcomes with \\ntreatment de-escalation. In recent trials, higher TILs levels were associated with a higher pCR rate [71, 75, \\n90] and with a better response [75, 91]. Liquid biopsies, such as circulating tumor DNA (ctDNA), could \\nserve as promising markers for identifying patients who might benefit from de-escalating or escalating \\nneoadjuvant or adjuvant treatment. Rapid ctDNA clearance during NACT in early TNBC is linked to a high \\nlikelihood of achieving pCR [92]. Conversely, detecting ctDNA after completing NACT and surgery is \\nassociated with higher recurrence rates and poorer prognoses [93]. The use of dynamic biomarkers, such \\nas ctDNA, to guide the choice of treatments in high-risk patients appears increasingly to be an important \\nresource to be exploited in future studies.\\nFurthermore, ADCs are emerging. Particularly, sacituzumab govitecan (SG) an ADC targeting Trop-2 \\nwas approved in metastatic TNBC patients who received ≥ 2 prior systemic therapies in the light of the \\nresults of the phase III ASCENT study. In this trial patients were randomized (1:1) to receive sacituzumab \\ngovitecan 10 mg/kg via intravenous infusion on day 1 and day 8 of a 21-day treatment cycle or a treatment \\nof physician’s choice (TPC) achieving the primary endpoint (PFS 4.8 vs. 1.7 months) and also demonstrating \\nan advantage in terms of OS (11.8 months vs. 6.9 months) [94]. Another single-arm phase II trial is \\nevaluating SG and atezolizumab in combination as adjuvant treatment for patients with TNBC who have \\nresidual invasive disease after neoadjuvant therapy and detectable ctDNA (ClinicalTrials.gov identifier \\nNCT04434040).\\nFinally, it is essential to redefine, with new dedicated trials, the role of ER-low (1–9%) BC which, \\nbiologically and prognostically very similar to TNBC, could potentially benefit from the addition of \\nimmunotherapy to CHT and the role of HER-2 low [score 1+ or 2+ not amplified in fluorescence in situ \\nhybridization (FISH)] BC in the light of recent results of efficacy of trastuzumab deruxtecan in advanced BC \\nHER-2 low. Therefore, future studies are likely to expand the armamentarium at our disposal in this setting.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 241\\nNew frontiers in early TNBC are summarized in Figure 2.\\nFigure 2. New frontiers in early TNBC\\nInterpretation and clinical implications\\nTNBC has long been a challenging disease to treat due to its aggressive behavior and the lack of target \\ntherapies [95].\\nThanks to recent developments on TNBC, a series of therapeutic targets have been identified for the \\ntreatment of metastatic and early setting diseases. Especially for the radically operable disease, the chances \\nof cure are increased with treatments aimed at reducing the odds of recurrence after tumor removal.\\nAnthracycline and taxane-based poly-CHT remains the standard of treatment, most often administered \\npreoperatively to assess tumor sensitivity. It aims to increase the rate of local control, making it useful to \\nguide breast-conserving surgery and to ensure survival benefits by reaching the pCR.\\nThe introduction of immunotherapy in association with poly-CHT in the neoadjuvant setting has \\nincreased the rate of pCR, guaranteeing better results in terms of long-term benefits in the KEYNOTE-522, \\nthe pivotal trial that led to the approval in clinical practice of the use of the anti-PD1, pembrolizumab, in the \\nearly setting disease (neoadjuvant and adjuvant setting). These clinical findings were based on preclinical \\ninvestigations that overturned the previous belief that BC was not an immunogenic disease [12].\\nThe actual need is to define the optimal adjuvant strategy after neoadjuvant chemo-immunotherapy, \\nwhich must be affected by the patient’s risk of recurrence based on the histological prognostic and evidence \\nafter radical surgery, the individual’s tolerance of therapy-induced side effects (Figure 3).\\nIn patients with low RCB and a low overall risk of recurrence, pembrolizumab alone should be \\ncontinued. In patients with poor prognostic features of high RCB, this strategy may not be the best choice. \\nPatients with high RCB, BRCA wild type, could benefit from capecitabine alone, although it would be \\nreasonable to use a combination of capecitabine and pembrolizumab. Patients with high RCB, germline \\nBRCA mutations, could benefit from olaparib (according to the inclusion criteria of the OlympiA trial), \\nalthough it would be reasonable to use olaparib and pembrolizumab in combination or sequentially.\\nHowever, none of these strategies, in monotherapy and/or in combination, have evidence from specific \\nrandomized trials after the neoadjuvant immunotherapy. There are no data on efficacy and safety in this \\nsetting. Currently, the best schedule is not known, and new data are awaited on new adjuvant strategies.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 242\\nFigure 3. Current treatment algorithm for stage II–III TNBC\\nExtensive efforts will also be required to investigate and expand access to immunotherapy to ER-low \\npopulations (ER 1–9%), not included in KEYNOTE-522. It represents a subgroup that does not formally \\nmeet the definition of TNBC, but shares biology, with nearly 90% of these tumors harboring a basal-like \\nintrinsic subtype, and prognosis with TNBC and could share the same benefit from the addition of \\nimmunotherapy [96, 97].\\nFurthermore, novel active agents are emerging for the treatment of TNBC and could provide an \\nopportunity for a de-escalation of traditional CHT, the anti-trophoblast cell-surface antigen 2 (Trop2) \\nsacituzumab govitecan that is currently being investigated in the early setting, including in combination \\nwith immunotherapy in the ASPRIA trial (ClinicalTrials.gov identifier NCT04434040).\\nConclusions\\nThis review highlights the multitude of advances in the treatment of early-stage TNBC and the important \\nissues raised.\\nThe management of triple-negative breast cancer (TNBC) has seen notable advancements with the \\nidentification of therapeutic targets and successful integration of immunotherapy in neoadjuvant \\ntreatment. However, the current challenge lies in determining the optimal adjuvant strategy post-chemo-\\nimmunotherapy, tailoring decisions to individual patient characteristics and prognostic factors. The \\nuncertainty surrounding the efficacy and safety of these strategies necessitates further randomized studies, \\nwhile ongoing research explores novel approaches, such as the potential use of innovative agents like \\nsacituzumab govitecan in the context of de-escalating traditional CHT. The imperative to extend access to \\nimmunotherapy to subgroups, such as those with low ER expression, holds crucial promise, paving the way \\nfor a more personalized and targeted future direction in TNBC treatment.\\nIn the next few years, it will be necessary to design new prospective clinical trials and wait for the \\nresults of those in progress, for a better knowledge of the efficacy of combination therapies, therapeutic \\nsequences and new target drugs for the treatment of a disease which up to a few years ago was considered \\n“untargetable”. This should be accompanied by a commitment to biomarker discovery, which could help the \\noncologist make the best decision for patient care.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 243\\nAbbreviations\\nAC: doxorubicin and cyclophosphamide\\nADCs: antibody-drug conjugates\\nBC: breast cancer\\nBRCA: breast cancer susceptibility genes\\nCHT: chemotherapy\\nCI: confidence interval\\nCREATE-X: Capecitabine for Residual Cancer as Adjuvant Therapy\\nctDNA: circulating tumor DNA\\nDFS: disease-free survival\\nEFS: event-free survival\\nER: estrogen receptor\\nFDA: Food and Drug Administration\\nHER2: human epidermal growth factor receptor 2\\nHR: hazard ratio\\nHR+: hormone receptor-positive\\nICI: immune checkpoint inhibitor\\niDFS: invasive disease-free survival\\nIM: immunomodulatory\\nLAR: luminal androgen receptor\\nM: mesenchymal\\nNACT: neoadjuvant chemotherapy\\nOS: overall survival\\nPARP: Poly(ADP-ribose) polymerase\\npCR: pathologic complete response\\nPD-L1: programmed death ligand 1\\nRCB: residual cancer burden\\nTILs: tumor-infiltrating lymphocytes\\nTMB: tumor mutational burden\\nTME: tumor microenvironment\\nTNBC: triple negative breast cancer\\nDeclarations\\nAuthor contributions\\nPDS: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Validation, \\nSupervision. MP, CG, and GRO: Conceptualization, Investigation, Writing—original draft, Writing—review & \\nediting. ANS, PF, and CL: Validation, Writing—review & editing, Supervision. DC: Investigation. All authors \\nread and approved the submitted version.\\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 244\\nConflicts of interest\\nThe authors declare that they have no conflicts of interest.\\nEthical approval\\nNot applicable.\\nConsent to participate\\nNot applicable.\\nConsent to publication\\nNot applicable.\\nAvailability of data and materials\\nNot applicable.\\nFunding\\nNot applicable.\\nCopyright\\n© The Author(s) 2024.\\nReferences\\nSporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic markers in triple-negative breast cancer. \\nClin Breast Cancer. 2018;18:e841–50.\\n1.     \\nHoward FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J. 2021;27:\\n8–16.\\n2.     \\nAlmansour NM. Triple-negative breast cancer: a brief review about epidemiology, risk factors, \\nsignaling pathways, treatment and role of artificial intelligence. Front Mol Biosci. 2022;9:836417.\\n3.     \\nCurtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic \\narchitecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.\\n4.     \\nAzim HA, Ghosn M, Oualla K, Kassem L. Personalized treatment in metastatic triple-negative breast \\ncancer: the outlook in 2020. Breast J. 2020;26:69–80.\\n5.     \\nCardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al.; ESMO Guidelines \\nCommittee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and \\nfollow-up†. Ann Oncol. 2019;30:1194–220. Erratum in: Ann Oncol. 2019;30:1674. Erratum in: Ann \\nOncol. 2021;32:284. \\n6.     \\nBear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al.; National Surgical Adjuvant \\nBreast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential \\npreoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from \\nNational Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74.\\n7.     \\nGolshan M, Loibl S, Wong SM, Houber JB, O’Shaughnessy J, Rugo HS, et al. Breast conservation after \\nneoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess \\nrandomized clinical trial. JAMA Surg. 2020;155:e195410. Erratum in: JAMA Surg. 2021;156:503. \\n8.     \\nTurner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular \\nprofiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic \\ntargets. Oncogene. 2010;29:2013–23.\\n9.     \\nMarra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast \\ncancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast \\nCancer. 2020;6:54.\\n10.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 245\\nYe F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advancements in clinical aspects of targeted \\ntherapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105.\\n11.     \\nLiu Z, Li M, Jiang Z, Wang X. A comprehensive immunologic portrait of triple-negative breast cancer. \\nTransl Oncol. 2018;11:311–29.\\n12.     \\nFarshbafnadi M, Pastaki Khoshbin A, Rezaei N. Immune checkpoint inhibitors for triple-negative \\nbreast cancer: from immunological mechanisms to clinical evidence. Int Immunopharmacol. 2021;98:\\n107876.\\n13.     \\nLehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative \\nbreast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. \\n2016;11:e0157368.\\n14.     \\nBurstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, et al. Comprehensive \\ngenomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer \\nRes. 2015;21:1688–98.\\n15.     \\nXiao Y, Ma D, Zhao S, Suo C, Shi J, Xue MZ, et al.; AME Breast Cancer Collaborative Group. Multi-omics \\nprofiling reveals distinct microenvironment characterization and suggests immune escape \\nmechanisms of triple-negative breast cancer. Clin Cancer Res. 2019;25:5002–14.\\n16.     \\nPelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, Hutton C, et al. Anti-inflammatory drugs \\nremodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer \\nDiscov. 2021;11:2602–19.\\n17.     \\nMittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in \\ntriple-negative breast cancer. Cancer Immunol Res. 2014;2:361–70.\\n18.     \\nWang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, et al. Prevalence of BRCA1 mutations and responses \\nto neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast \\ncancer. Ann Oncol. 2015;26:523–8.\\n19.     \\nHahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, et al. Germline mutation status, \\npathological complete response, and disease-free survival in triple-negative breast cancer: secondary \\nanalysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017;3:1378–85.\\n20.     \\nPohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, et al. Association of germline \\nvariant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of \\nthe GeparOcto randomized clinical trial. JAMA Oncol. 2020;6:744–8.\\n21.     \\nVollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, et al. Genomic patterns \\nresembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-\\nbased chemotherapy. Breast Cancer Res. 2014;16:R47.\\n22.     \\nBelli C, Duso BA, Ferraro E, Curigliano G. Homologous recombination deficiency in triple negative \\nbreast cancer. Breast. 2019;45:15–21.\\n23.     \\nvan Verschuer VMT, Hooning MJ, van Baare-Georgieva RD, Hollestelle A, Timmermans AM, Koppert \\nLB, et al. Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast \\ncancer. Hum Pathol. 2015;46:182–90.\\n24.     \\nNolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, et al.; Kathleen Cuningham \\nFoundation Consortium for Research into Familial Breast Cancer (kConFab); Perou CM, Visvader JE, \\nGray DHD, Loi S, Lindeman GJ. Combined immune checkpoint blockade as a therapeutic strategy for \\nBRCA1-mutated breast cancer. Sci Transl Med. 2017;9:eaal4922.\\n25.     \\nParkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of STING-\\ndependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer \\nInst. 2016;109:djw199.\\n26.     \\nCastaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, et al. Tumor infiltrating \\nlymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol. \\n2016;7:387–94.\\n27.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 246\\nGarcía-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-infiltrating lymphocytes in triple negative \\nbreast cancer: the future of immune targeting. Clin Med Insights Oncol. 2016;10:31–9.\\n28.     \\nGomez-Macias GS, Molinar-Flores G, Lopez-Garcia CA, Santuario-Facio S, Decanini-Arcaute H, Valero-\\nElizondo J, et al. Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and \\ngenetic characterization. Oncol Lett. 2020;20:140.\\n29.     \\nSousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, et al. Human breast cancer cells \\neducate macrophages toward the M2 activation status. Breast Cancer Res. 2015;17:101.\\n30.     \\nMedrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in \\ntumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306.\\n31.     \\nSavas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host \\nimmunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228–41.\\n32.     \\nCortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete \\nresponse and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;\\n384:164–72.\\n33.     \\nDenkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-\\ninfiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of \\n3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.\\n34.     \\nAdams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-\\ninfiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant \\nbreast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–66.\\n35.     \\nLoi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of \\ntumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive \\nbreast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based \\nchemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–7.\\n36.     \\nLoi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are \\nprognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast \\ncancer: results from the FinHER trial. Ann Oncol. 2014;25:1544–50.\\n37.     \\nHida AI, Watanabe T, Sagara Y, Kashiwaba M, Sagara Y, Aogi K, et al. Diffuse distribution of tumor-\\ninfiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-\\nnegative breast cancer. Breast Cancer Res Treat. 2019;178:283–94.\\n38.     \\nIbrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. The prognostic value of tumor-infiltrating \\nlymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014;148:\\n467–76.\\n39.     \\nSalgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al.; International TILs Working \\nGroup 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: \\nrecommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71.\\n40.     \\nKarn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, et al. Association between genomic metrics and \\nimmune infiltration in triple-negative breast cancer. JAMA Oncol. 2017;3:1707–11.\\n41.     \\nSafonov A, Jiang T, Bianchini G, Győrffy B, Karn T, Hatzis C, et al. Immune gene expression is associated \\nwith genomic aberrations in breast cancer. Cancer Res. 2017;77:3317–24.\\n42.     \\nLotfinejad P, Asghari Jafarabadi M, Abdoli Shadbad M, Kazemi T, Pashazadeh F, Sandoghchian \\nShotorbani S, et al. Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and \\nprogrammed death ligand 1 (PD-L1) expression in triple-negative breast cancer (TNBC): a systematic \\nreview and meta-analysis study. Diagnostics (Basel). 2020;10:704.\\n43.     \\nZhu X, Zhang Q, Wang D, Liu C, Han B, Yang JM. Expression of PD-L1 attenuates the positive impacts of \\nhigh-level tumor-infiltrating lymphocytes on prognosis of triple-negative breast cancer. Cancer Biol \\nTher. 2019;20:1105–12.\\n44.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 247\\nNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer. National \\nComprehensive Cancer Network® (NCCN®); c2020 [cited 2023 May 21]. Available from: https://\\nwww2.tri-kobe.org/nccn/guideline/breast/english/breast.pdf\\n45.     \\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxane-\\ncontaining chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of \\n100\\u2008000 women from 86 randomised trials. Lancet. 2023;401:1277-1292.\\n46.     \\nSparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, et al. Long-term follow-up of the E1199 \\nphase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol. 2015;\\n33:2353–60.\\n47.     \\nJones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing \\ndoxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for \\noperable breast cancer. J Clin Oncol. 2006;24:5381–7. Erratum in: J Clin Oncol. 2007;25:1819. \\n48.     \\nWheate NJ, Collins JG. Multi-nuclear platinum drugs: a new paradigm in chemotherapy. Curr Med \\nChem Anticancer Agents. 2005;5:267–79.\\n49.     \\nGarutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, et al. Platinum salts in patients \\nwith breast cancer: a focus on predictive factors. Int J Mol Sci. 2019;20:3390.\\n50.     \\nChalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with \\n“BRCAness”: a review. Oncologist. 2013;18:909–16.\\n51.     \\nVetter M, Fokas S, Biskup E, Schmid T, Schwab F, Schoetzau A, et al. Efficacy of adjuvant chemotherapy \\nwith carboplatin for early triple negative breast cancer: a single center experience. Oncotarget. 2017;\\n8:75617–26.\\n52.     \\nSu YW, Hung CY, Lam HB, Chang YC, Yang PS. A single institution experience of incorporation of \\ncisplatin into adjuvant chemotherapy for patients with triple-negative breast cancer of unknown \\nBRCA mutation status. Clin Med Insights Oncol. 2018;12:1179554918794672.\\n53.     \\nYu KD, Ye FG, He M, Fan L, Ma D, Mo M, et al. Effect of adjuvant paclitaxel and carboplatin on survival \\nin women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6:\\n1390–6.\\n54.     \\nNorquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary Somatic Mutations \\nRestoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas. J Clin Oncol. \\n2011;29:3008–15.\\n55.     \\nGuillemette S, Serra RW, Peng M, Hayes JA, Konstantinopoulos PA, Green MR, et al. Resistance to \\ntherapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. Genes Dev. \\n2015;29:489–94.\\n56.     \\nZhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, et al. The drug-resistance mechanisms of five platinum-\\nbased antitumor agents. Front Pharmacol. 2020;11:343.\\n57.     \\nRastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative \\nchemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-\\n27. J Clin Oncol. 2008;26:778–85. Erratum in: J Clin Oncol. 2008;26:2793. \\n58.     \\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant \\nversus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from \\nten randomised trials. Lancet Oncol. 2018;19:27–39.\\n59.     \\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of \\nchemotherapy by more frequent administration or sequential scheduling: a patient-level meta-\\nanalysis of 37\\u2008298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393:\\n1440–52.\\n60.     \\nvon Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in \\npatients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a \\nrandomised phase 2 trial. Lancet Oncol. 2014;15:747–56.\\n61.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 248\\nSikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of \\ncarboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense \\ndoxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-\\nnegative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13–21.\\n62.     \\nLoibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP \\ninhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in \\ntriple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:\\n497–509.\\n63.     \\nFasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, et al.; German Breast Group and \\nArbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in \\ncomparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and \\nhomologous recombination deficiency (GeparOLA study). Ann Oncol. 2021;32:49–57.\\n64.     \\nGupta S, Nair NS, Hawaldar R, Vanmali V, Parmar V, Gulia S, et al. Abstract GS5-01: Addition of \\nplatinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-\\nnegative breast cancer: a phase III randomized controlled trial. Cancer Res. 2023;83:GS5-01.\\n65.     \\nCortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al.; KEYNOTE-355 Investigators. \\nPembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated \\nlocally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a \\nrandomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–28.\\n66.     \\nSchmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al.; IMpassion130 Trial \\nInvestigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J \\nMed. 2018;379:2108–21.\\n67.     \\nMiles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al.; IMpassion131 investigators. \\nPrimary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of \\nfirst-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-\\nnegative breast cancer. Ann Oncol. 2021;32:994–1004.\\n68.     \\nEmens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-\\npaclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: \\nIMpassion130 final overall survival analysis. Ann Oncol. 2021;32:983–93. Erratum in: Ann Oncol. \\n2021;32:1650. \\n69.     \\nCortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al.; KEYNOTE-355 Investigators. \\nPembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;\\n387:217–26.\\n70.     \\nGianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) \\nto neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally \\nadvanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33:534–43.\\n71.     \\nMittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in \\ncombination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo \\nand chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a \\nrandomised, double-blind, phase 3 trial. Lancet. 2020;396:1090–100.\\n72.     \\nSchmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al.; KEYNOTE-522 Investigators. \\nEvent-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;\\n386:556–67.\\n73.     \\nDel Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, et al.; Gruppo Italiano \\nMammella Investigators. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-\\nstage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Lancet Oncol. \\n2022;23:1571–82.\\n74.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 249\\nLoibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, et al.; GBG and AGO-B. Neoadjuvant \\ndurvalumab improves survival in early triple-negative breast cancer independent of pathological \\ncomplete response. Ann Oncol. 2022;33:1149–58.\\n75.     \\nKuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, et al. Prognostic significance of subtype and \\npathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies \\nof JBCRG. Breast Cancer. 2015;22:486–95.\\n76.     \\nSpring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic complete response after \\nneoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive \\nmeta-analysis. Clin Cancer Res. 2020;26:2838–48.\\n77.     \\nCoates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart MJ, et al.; Panel Members. \\nTailoring therapies—improving the management of early breast cancer: St Gallen international expert \\nconsensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26:1533–46.\\n78.     \\nMasuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer \\nafter Preoperative Chemotherapy. N Engl J Med. 2017;376:2147–59.\\n79.     \\nSymmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual \\nbreast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:\\n4414–22.\\n80.     \\nTutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al.; OlympiA Clinical Trial Steering \\nCommittee and Investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast \\ncancer. N Engl J Med. 2021;384:2394–405.\\n81.     \\nGeyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al.; OlympiA Clinical Trial Steering \\nCommittee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in \\npatients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. \\n2022;33:1250–68.\\n82.     \\nFDA D.I.S.C.D. burst edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage \\ntriple-negative breast cancer [Internet]. [cited 2023 May 21]. Available from: https://www.fda.gov/\\ndrugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-\\npembrolizumab-high-risk-early-stage-triple-negative\\n83.     \\nSchmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al.; KEYNOTE-522 Investigators. \\nPembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21.\\n84.     \\nPusztai L, Denkert C, O’Shaughnessy J, Cortes J, Dent RA, McArthur HL, et al. Event-free survival by \\nresidual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + \\nchemotherapy for early TNBC: exploratory analysis from KEYNOTE-522. J Clin Oncol. 2022;40:503.\\n85.     \\nShah AN, Flaum L, Helenowski I, Santa-Maria CA, Jain S, Rademaker A, et al. Phase II study of \\npembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2–negative \\nendocrine-refractory metastatic breast cancer. J Immunother Cancer. 2020;8:e000173.\\n86.     \\nPage D, Pucilowska J, Bennetts L, Kim I, Sanchez K, Martel M, et al. Updated efficacy of first or second-\\nline pembrolizumab plus in metastatic triple negative breast cancer and correlations with baseline \\nlymphocyte and naïve CD4+ T-cell count. 2018 San Antonio Breast Cancer Symposium. San Antonio: \\nBooks, Presentations, Posters, Etc. 2018.\\n87.     \\nVinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. Open-label clinical trial of \\nniraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative \\nbreast cancer. JAMA Oncol. 2019;5:1132–40.\\n88.     \\nDomchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. Olaparib and durvalumab in \\npatients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, \\nmulticentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155–64.\\n89.     \\nExplor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 250\\nNederlof I, De Bortoli D, Bareche Y, Hooijer GKJ, Sotiriou C, Van De Vijver MJ, et al. Relationship \\nbetween tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+\\nchemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase \\nIb KEYNOTE-173 trial. Ann Oncol. 2019;30:III2.\\n90.     \\nDoroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of \\nresponse to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345–62.\\n91.     \\nMagbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, et al. Circulating tumor DNA in \\nneoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32:229–39.\\n92.     \\nRadovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, et al. Association of circulating \\ntumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in \\npatients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 \\nrandomized clinical trial. JAMA Oncol. 2020;6:1410–5.\\n93.     \\nBardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al.; ASCENT Clinical Trial \\nInvestigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;\\n384:1529–41.\\n94.     \\nLoibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750–69.\\n95.     \\nSchrodi S, Braun M, Andrulat A, Harbeck N, Mahner S, Kiechle M, et al. Outcome of breast cancer \\npatients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann \\nOncol. 2021;32:1410–24.\\n96.     \\nVillegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, et al. Therapy response and prognosis \\nof patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 \\npatients from neoadjuvant clinical trials. Eur J Cancer. 2021;148:159–70.\\n97.     \\nCitation: Li, L.; Zhang, F.; Liu, Z.;\\nFan, Z. Immunotherapy for\\nTriple-Negative Breast Cancer:\\nCombination Strategies to Improve\\nOutcome. Cancers 2023, 15, 321.\\nhttps://doi.org/10.3390/cancers\\n15010321\\nAcademic Editors: Claudia De\\nLorenzo and Laura Cerchia\\nReceived: 14 November 2022\\nRevised: 27 December 2022\\nAccepted: 29 December 2022\\nPublished: 3 January 2023\\nCopyright:\\n© 2023 by the authors.\\nLicensee MDPI, Basel, Switzerland.\\nThis article is an open access article\\ndistributed\\nunder\\nthe\\nterms\\nand\\nconditions of the Creative Commons\\nAttribution (CC BY) license (https://\\ncreativecommons.org/licenses/by/\\n4.0/).\\ncancers\\nReview\\nImmunotherapy for Triple-Negative Breast Cancer:\\nCombination Strategies to Improve Outcome\\nLiying Li, Fan Zhang, Zhenyu Liu and Zhimin Fan *\\nDepartment of Breast Surgery, General Surgery Centre, The First Hospital of Jilin University,\\nChangchun 130012, China\\n* Correspondence: fanzm@jlu.edu.cn\\nSimple Summary: For decades, countless efforts have been devoted to developing targeted drugs\\nto improve the prognosis of triple-negative breast cancer (TNBC). Among the novel therapies that\\nhave been approved for the clinical management of TNBC, immunotherapy shows great potential.\\nAlthough exciting progress has been made in immunotherapy for TNBC, there are still gaps to\\nﬁll. This review will analyze current immunotherapy strategies in TNBC, summarize the current\\nlandscape of clinical trials, review the results achieved, and shed light on future developments.\\nAbstract: Due to the absence of hormone receptor (both estrogen receptors and progesterone receptors)\\nalong with human epidermal growth factor receptor 2 (HER-2) ampliﬁcation, the treatment of triple-\\nnegative breast cancer (TNBC) cannot beneﬁt from endocrine or anti-HER-2 therapy. For a long time,\\nchemotherapy was the only systemic treatment for TNBC. Due to the lack of effective treatment\\noptions, the prognosis for TNBC is extremely poor. The successful application of immune checkpoint\\ninhibitors (ICIs) launched the era of immunotherapy in TNBC. However, the current ﬁndings show\\nmodest efﬁcacy of programmed cell death- (ligand) 1 (PD-(L)1) inhibitors monotherapy and only\\na small proportion of patients can beneﬁt from this approach. Based on the basic principles of\\nimmunotherapy and the characteristics of the tumor immune microenvironment (TIME) in TNBC,\\nimmune combination therapy is expected to further enhance the efﬁcacy and expand the beneﬁciary\\npopulation of patients. Given the diversity of drugs that can be combined, it is important to select\\neffective biomarkers to identify the target population. Moreover, the side effects associated with the\\ncombination of multiple drugs should also be considered.\\nKeywords: triple-negative breast cancer; immunotherapy; immune checkpoint; tumor immune\\nmicroenvironment; clinical trials\\n1. Introduction\\nTriple-negative breast cancer (TNBC) accounts for approximately 15–20% of breast\\nmalignancies and is the only subtype of breast cancer that lacks targeted treatment [1].\\nCompared with other subtypes, TNBC is more aggressive, and most patients develop\\nrecurrence and metastasis within 3 years, with poor prognosis [2]. Anthracycline- and\\ntaxane-based chemotherapy remains the mainstay of treatment for early-stage patients, but\\nresistance has emerged [3]; for patients with recurrence or metastasis, there are even fewer\\ntreatment options. There is an urgent need for novel and more effective treatments.\\nGenomic advances reveal a high degree of heterogeneity in TNBC and set the stage\\nfor the development of targeted therapies [4–6]. In the past few years, poly ADP-ribose\\npolymerase inhibitors (PARPi), programmed cell death- (ligand) 1 (PD-(L)1) inhibitors,\\nand antibody–drug conjugates (ADCs) have been approved successively for the treat-\\nment of TNBC. Among these, PD-1 inhibitor pembrolizumab is approved for patients\\nwith advanced PD-L1-positive and early high-risk disease, displaying great therapeutic\\npotential.\\nCancers 2023, 15, 321. https://doi.org/10.3390/cancers15010321\\nhttps://www.mdpi.com/journal/cancers\\nCancers 2023, 15, 321\\n2 of 28\\nSome studies have found that TNBC has higher PD-L1 expression and tumor-inﬁltrating\\nlymphocytes (TILs) in comparison with other subtypes [7,8], making it the most likely\\nsubtype to beneﬁt from immunotherapy. However, PD-(L)1 inhibitors beneﬁt only a\\nsmall proportion of individuals, with a single-agent effectiveness of approximately 20%\\nin patients with PD-L1-positive metastatic TNBC (mTNBC) [9]. Numerous preclinical\\nand clinical studies have been conducted to investigate the reasons for this disappointing\\nresult, expand the beneﬁciary population, and improve the efﬁcacy of immune checkpoint\\ninhibitors (ICIs).\\nIn this review, we will analyze the reasons for the poor efﬁcacy of PD-(L)1 inhibitors\\nmonotherapy in terms of tumor immune escape mechanisms and tumor immune microen-\\nvironment (TIME) characteristics of TNBC. We summarize the current landscape of clinical\\ntrials in TNBC, highlight the major immune combination therapy strategies in clinical\\npractice and the progress achieved, and brieﬂy discuss the biomarkers for predicting im-\\nmunological response, as well as possible adverse events associated with immunotherapy.\\n2. Rationale of Immunotherapy and the TIME of TNBC\\nThe cross-talk between tumor cells and the TIME can be described as “cancer immu-\\nnoediting”, encompassing three stages: (1) elimination; (2) equilibrium, in which the host\\nimmune system and tumor cells that survive enter a dynamic balance; and (3) escape [10]\\n(Figure 1).\\n \\nFigure 1. Schematic diagram of immune elimination and escape in TNBC. (A) Cascade events of\\ntumor cell elimination by the immune system. (B) Mechanisms of tumor cell immune escape. Abbre-\\nviations: TAA, tumor-associated antigen; TSA, tumor-speciﬁc antigen; DC, dendritic cell; M1/2, M1/2\\nmacrophage; Th1/2, CD4+ helper T cell 1/2; TCR, T cell receptor; MHC, major histocompatibility\\ncomplex; NK, natural killer cell; ADCC, antibody-dependent cell-medicated cytotoxicity; SIPR-α,\\nsignal regulatory protein-α; CTLA-4, cytotoxic T-lymphocyte antigen-4; VEGF, vascular endothelial\\ngrowth factor; CXCL, chemokine (C-X-C motif) ligand; IL, interleukin; CSF, colony-stimulating factor;\\nTGF, transforming growth factor; Treg, regulatory T cell; MDSCs, myeloid-derived suppressor cells;\\nTAP, transporter associated with antigen processing; PD-L1, programmed death-ligand 1; LAG3,\\nlymphocyte-activation gene 3; TIM-3, T cell immunoglobulin-3; TIGIT, T cell immunoreceptor with\\nIg and ITIM domains.\\nNormally, a cascade of events needs to be initiated for the elimination of tumor cells.\\nFirst, tumor cells release speciﬁc antigens that are captured and processed by antigen-\\npresenting cells (APCs), which mainly include dendritic cells (DCs). Next, DCs migrate to\\nCancers 2023, 15, 321\\n3 of 28\\nlymphoid tissue to present antigenic signals to T cells. Later, T cells initiate, activate, and\\nthen transport and inﬁltrate tumor tissues. Finally, T cells speciﬁcally recognize and kill\\ntumor cells [11]. B cells and innate immune cells, such as natural killer (NK) cells, are also\\nessential for the elimination of tumor cells (Figure 1).\\nHowever, tumors can evade surveillance and attack from the immune system via\\ncomplex intrinsic signaling or external microenvironment mechanisms. In general, this can\\nbe summed up in these aspects. First, immunogenicity of tumors is decreased via down-\\nregulation of antigen expression, sequestering of antigens, or downregulation of major\\nhistocompatibility complex (MHC) molecules [12,13]. Second, there are functional and/or\\nquantitative defects in intrinsic and/or adaptive immune cells, including recruitment fail-\\nure, insufﬁcient maturation, failure to activate, and impaired chemotaxis and transport [14].\\nFurther, an immunosuppressive microenvironment is generated through an increase in the\\nproportion of immunosuppressive cells (regulatory T cells (Tregs), M2 macrophage cells,\\nand myeloid-derived suppressor cells (MDSCs)) and cytokines, as well as the accumulation\\nof immunosuppressive substances [15,16]. Moreover, there is an upregulation of immune\\ncheckpoints, a negative regulatory mechanism used by the body to prevent over-activation\\nof the immune system and to protect normal tissues from the autoimmune system [17,18]\\n(Figure 1).\\nBased on the above information, immunotherapy has emerged that involves the use\\nof various agents or means to enhance immune system function (in a tumor-localized\\nrather than whole-body manner) or to block immune escape pathways of tumor cells (by\\nnormalizing anti-tumor immunity), thereby recognizing and eliminating tumor cells. These\\nimmunotherapy approaches include: therapeutic cancer vaccines (TCVs), which are active\\nimmunotherapies; targeted monoclonal antibodies (mAb) and their derivatives, such as\\nADCs, adoptive cell therapies (ACTs), and cytokines, which are passive therapies; as well\\nas the best-known ICIs [19].\\nTumors that lack immune cell inﬁltration and do not respond to ICIs are referred to as\\n“cold tumors”, while tumors with high levels of immune cell inﬁltration and upregulated\\nimmune checkpoints that may respond to ICIs are referred as “hot tumors” [20]. Based\\non omics analysis, heterogeneity of the TIME in TNBC has been revealed. According\\nto the data from these studies, the percentage of TNBC cases that present with “hot\\ntumors” is approximately 25%, which may explain the poor clinical efﬁcacy of ICIs as single\\nagents [21–23]. Moreover, the suppressive TIME found in “hot tumors” and the decreased\\nMHC of tumor cells also make ICIs less effective [14].\\nWhen all of these ﬁndings are considered, it is clear that combining ICIs with other\\ntherapies that block immune escape pathways of tumor cells or convert “cold tumors” to\\n“hot tumors” is a potential strategy to improve the clinical response of ICIs.\\n3. The Landscape of Clinical Trials on TNBC Immunotherapy\\nAs of 1 September 2022, we had screened a total of 234 clinical trials on clinicaltrials.gov\\n(accessed on 1 September 2022), that primarily explore immunotherapy for TNBC, either as\\na monotherapy or in combination with other therapies (Figure 2). Apart from that, more\\nthan 100 immunotherapy clinical trials are being conducted on advanced solid tumors,\\nincluding TNBC. Of note, these are just the tip of the iceberg as there are trials registered\\non other websites. In addition to observing the surge in clinical trials of immunotherapy\\nfor TNBC in the past decade, we further analyzed the data and found that: (1) there are\\n197 trials involving ICIs that target PD-(L)1, accounting for 84% of all trials, of which\\nonly 13 trials involved monotherapy, while in the other trials, PD-(L)1 inhibitors were\\ncombined with almost all therapies that can be applied to TNBC; (2) there are considerable\\nnumbers of clinical trials in both early and metastatic settings, which demonstrates the\\ngeneralizability of immunotherapy for TNBC; and (3) there is a gradual increase in the\\nnumber of window-of-opportunity (WOP) trials to test for optimal timing of interventions\\nand changes in biomarkers.\\nCancers 2023, 15, 321\\n4 of 28\\n \\n(a) \\n(b) \\nFigure 2. Clinical trials of immunotherapy for TNBC registered at clinicaltrials.gov: (a) Number of\\nclinical trials in each phase per year; (b) Number of clinical trials by disease stage per year.\\n4. Performance of PD-(L)1 Inhibitors Monotherapy\\nPD-(L)1 is the most powerful immune checkpoint found in TNBC. PD-1 can be ex-\\npressed on a variety of immune cells, the most important of which are activated T cells.\\nPD-1 has two ligands: PD-L1 and PD-L2 [24]. PD-L1 is abnormally overexpressed on the\\nsurface of tumor cells and some APCs [25]. Through binding to PD-1, it leads to lymphocyte\\napoptosis, unresponsiveness, and abnormal secretion of cytokines, thus mediating immune\\nescape of tumor cells [25]. In contrast, PD-L2 has a dual role of suppressing and activating\\nT cells, and its role in tumors is gaining attention [26]. PD-(L)1 inhibitors are monoclonal\\nantibodies that block the PD-1/PD-L1 signaling pathway and restore the immune function\\nof T cells to kill tumor cells.\\n4.1. In Advanced TNBC\\nThe phase Ib study, KEYNOTE-012, ﬁrst demonstrated acceptable safety and durable\\nanti-tumor activity of single-agent pembrolizumab in previously treated patients with\\nadvanced PD-L1-positive TNBC. The objective response rate (ORR) in 32 TNBC patients\\nwas 18.5% [27]. The phase II KEYNOTE-086 study then further conﬁrmed the safety and\\nanti-tumor activity of pembrolizumab as ﬁrst-line or second-line and beyond therapy\\nin patients with mTNBC, using more appropriate dosages and dosing intervals. This\\nstudy found that pembrolizumab monotherapy performed better in previously untreated\\nPD-L1-positive patients with an ORR of 21.4%, whereas the response was ﬂat in heavily\\npre-treated mTNBC patients with an ORR of 5.3%. Although there was no signiﬁcant\\ndifference in ORR, progression-free survival (PFS), and overall survival (OS) between the\\nPD-L1-positive and PD-L1-negative subgroups in pre-treated mTNBC, a more durable\\nclinical response was observed in PD-L1-positive patients [28,29]. In the next large phase\\nIII randomized KEYNOTE-119 trial, as second- or third-line treatment for mTNBC, pem-\\nbrolizumab failed to signiﬁcantly improve OS compared to chemotherapy in the total\\npopulation (9.9 vs. 10.8 months, HR = 0.97, 95% CI: 0.82 to 1.15) or in the PD-L1-positive\\npopulation (10.7 vs. 10.2 months, HR = 0.86, 95% CI: 0.69 to 1.06, p = 0.073). However, the\\nimproved effect of pembrolizumab was consistent with increased tumor PD-L1 expression\\nin the efﬁcacy endpoints of ORR, PFS, and OS [30] (Table 1).\\nCancers 2023, 15, 321\\n5 of 28\\nTable 1. Clinical trials of PD-(L)1 inhibitors monotherapy.\\nClinical Trial\\nPhase\\nStatus\\nArms (n)\\nPopulation (n)\\nPD-L1 Status\\nMajor Outcomes\\nTrials in advanced\\nTNBC\\nKEYNOTE-012\\n(NCT01848834)\\nIb\\nCompleted\\nPemb\\nPre-treated: PD-L1\\n(+) (32)\\n+(stroma/\\n≥1% TC a)\\nORR: 18.5%\\nmPFS: 1.9 months\\nmOS: 11.2 months\\nKEYNOTE-086\\n(NCT02447003)\\nII\\nCompleted\\nPemb\\nCohort A (170):\\npre-treated\\nOverall\\nORR: 5.3%\\nmPFS: 2.0 months\\nmOS: 9.0 months\\n+(CPS b ≥1)\\nORR: 5.7%\\nmPFS: 2.0 months\\nmOS: 8.8 months\\n−\\nORR: 4.7%\\nmPFS: 1.9 months\\nmOS: 9.7 months\\nCohort B (84):\\npre-untreated,\\nPD-L1 (+)\\n+(CPS ≥1)\\nORR: 21.4%\\nmPFS: 2.1 months\\nmOS: 18.0 months\\nKEYNOTE-119\\n(NCT02555657)\\nIII\\nCompleted\\nPemb (312)\\nvs. CT c (310)\\nPre-treated: 1–2\\nprior therapy\\n(622)\\nOverall\\nORR: 9.6 vs. 10.6%\\nmPFS: 2.1 vs. 3.3 months\\nmOS: 9.9 vs. 10.8 months\\n+(CPS ≥1)\\nORR: 12.3 vs. 9.4%\\nmPFS: 2.1 vs. 3.1 months\\nmOS: 10.7 vs. 10.2 months\\n+(CPS ≥10)\\nORR: 17.7 vs. 9.2%\\nmPFS: 2.1 vs. 3.4 months\\nmOS: 12.7 vs. 11.6 months\\n+(CPS ≥20)\\nORR: 26.3 vs. 11.5%\\nmPFS: 3.4 vs. 2.4 months\\nmOS: 14.9 vs. 12.5 months\\nJAVELIN\\n(NCT01772004)\\nIb\\nCompleted\\nAvel\\nReceived a median\\nof 2 prior therapies\\n(58)\\nOverall\\nORR: 5.2%\\nmPFS: 5.9 months\\nmOS: 9.2 months\\n+(≥10% IC d)\\nORR: 22.2%\\n−\\nORR: 2.6%\\nNCT01375842\\nIa\\nCompleted\\nAtez\\nmTNBC: 58% ≥2\\nprior therapies (116)\\nOverall\\nORR: 10%\\nmPFS: 1.4 months\\nmOS: 8.9 months\\n+(≥1% IC)\\nORR: 12%\\nmOS: 10.1 months\\n−\\nORR: 0%\\nmOS: 6.0 months\\nSAFIR02-BREAST\\nIMMUNO\\n(NCT02299999)\\nII\\nCompleted\\nDurv (47) vs. CT\\n(35)\\nMaintenance\\nsetting (82)\\nOverall\\nmOS: 21.2 vs. 14 months\\n+(≥1% IC)\\nmOS: 27.3 vs. 12.1 months\\n−\\nmOS: 19.5 vs. 14 months\\nTrials in early-stage\\nTNBC as adjuvant\\ntherapy\\nSWOG 1418\\n(NCT02954874)\\nIII\\nOngoing\\nPemb vs.\\nobservation\\nTNBC with ≥1 cm\\nRIC or LN (+) after\\nNACT\\nNA\\nA-Brave\\n(NCT02926196)\\nIII\\nOngoing\\nAvel vs.\\nobservation\\nHigh-risk TNBC\\nNA\\nAbbreviations: mTNBC, metastatic triple-negative breast cancer; Pemb, pembrolizumab; Avel, avelumab; Atez,\\natezolizumab; Durv, durvalumab; NACT, neoadjuvant chemotherapy; CT, chemotherapy; RIC, residual invasive\\ncancer; LN, lymph node; ORR, objective response rate; mOS, median overall survival; mPFS, median progression-\\nfree survival; +, PD-L1 positive; −, PD-L1 negative; TC, tumor cells; CPS, combined positive score; IC, immune\\ncells; NA, not available. a PD-L1 positivity was deﬁned as membranous staining in at least 1% of cells (neoplastic\\nand intercalated mononuclear inﬂammatory cells) within tumor nests. b Immunohistochemistry 22C3 assay, CPS\\n= PD-L1 stained cells (including tumor cells, lymphocytes, and macrophages) / the number of all viable tumor\\ncells × 100. c In KEYNOTE-119, the chemotherapy regimens included capecitabine, eribulin, gemcitabine, or\\nvinorelbine. d The percentage of PD-L1 stained tumor-associated immune cells in the tumor area; immune cells\\nincluding lymphocytes, macrophages, dendritic cells, plasma cells, and granulocytes.\\nCancers 2023, 15, 321\\n6 of 28\\nIn addition to the above, some trials also tested single-drug ICIs targeting PD-L1 in\\na metastatic setting. In the phase Ib JAVELIN trial, avelumab showed acceptable safety\\nand clinical activity in the mTNBC subgroup. The ORRs were 5.2% and 22.2% for the total\\nTNBC population and PD-L1-positive TNBC patients, respectively [31]. Moreover, a phase\\nIa study (NCT01375842) veriﬁed that atezolizumab monotherapy was well tolerated in\\npatients with mTNBC and the ORR for the unselected TNBC population was 10%. The\\nPD-L1 expression status and prior treatment history continue to strongly inﬂuence the\\nefﬁcacy of atezolizumab [32]. In addition, durvalumab was tested in the SAFIR02-BREAST\\nIMMUNO trial as a maintenance therapy. Subgroup analysis showed that, compared\\nwith maintenance chemotherapy, durvalumab improved OS in patients with mTNBC\\n(21.2 vs. 14 months, HR = 0.54, 95% CI: 0.30 to 0.97, p = 0.0377), especially in PD-L1-positive\\npatients (27.3 vs. 12.1 months, HR = 0.37, 95% CI: 0.12 to 1.13, p = 0.0678) [33] (Table 1).\\nThe preliminary results of these trials suggest that PD-(L)1 blockade alone has a\\nmodest clinical response across the entire mTNBC population. However, more durable\\nresponses have been observed in speciﬁc patients, such as PD-L1-positive patients receiving\\nﬁrst-line treatment. These ﬁndings encourage further research on PD-(L)1 inhibitors.\\n4.2. In Early-Stage TNBC\\nThere are studies on PD-(L)1 inhibitors monotherapy currently underway in early-\\nstage TNBC patients. SWOG 1418 is an ongoing phase III trial investigating the efﬁcacy of\\npembrolizumab on TNBC patients with ≥1 cm residual invasive cancer or positive lymph\\nnodes after neoadjuvant chemotherapy (NACT) [34]. One year of postoperative intravenous\\navelumab is currently being evaluated for its impact on survival in high-risk TNBC patients\\nin the A-Brave trial [35]. The results of these trials are eagerly anticipated and could provide\\nadditional options for the intensive treatment of patients with early-stage, high-risk TNBC\\n(Table 1).\\n5. Research Progress of PD-(L)1 Inhibitors in Combination with Chemotherapy\\nPreclinical and clinical studies have shown that in addition to direct toxicity to tumor\\ncells, some chemotherapeutic agents kill tumor cells through a pathway of immunogenic\\ncell death (ICD), which stimulates the recruitment and maturation of APCs, enhances the\\nantigen presentation process, and promotes the activation of T cells [36]. Chemotherapeutic\\nagents also increase the immunogenicity of tumors by exposing MHC molecules and\\nantigens on the surface of tumor cells [37]. The transient immunosuppression induced by\\nchemotherapy causes a massive release of cytokines and chemokines, which increases the\\ninﬁltration and activation of immune cells [38]. Furthermore, chemotherapeutic agents\\nreduce immunosuppressive cells such as Tregs and MDSCs [39]. These chemotherapy drugs\\ninclude anthracyclines, cyclophosphamide, and others commonly used for TNBC. Thus,\\ncombining PD-(L)1 inhibitors with chemotherapy is a promising approach to enhance\\nthe efﬁcacy of immunotherapy and facilitate synergistic anti-tumor activity. Based on\\nthis concept, a number of trials combining chemotherapy and immunotherapy are being\\nconducted in the clinic and some breakthroughs have been made (Table 2).\\nTable 2. Clinical trials of PD-(L)1 inhibitors in combination with chemotherapy.\\nClinical Trial\\nPhase\\nStatus\\nArms (n)\\nPopulation (n)\\nPD-L1 Status\\nMajor Outcomes\\nTrials in\\nadvanced\\nTNBC\\nKEYNOTE-355\\n(NCT02819518)\\nIII\\nOngoing\\nPemb + CT a (566) vs.\\nplacebo + CT (281)\\nFirst-line\\ntreatment in mTNBC\\n(847)\\nITT\\npopulation\\nmPFS: 7.5 vs. 5.6 months\\nmOS: 17.2 vs. 15.5 months\\n+(CPS b ≥1)\\nmPFS: 7.6 vs. 5.6 months\\nmOS: 17.6 vs. 16.0 months\\n+(CPS ≥10)\\nmPFS: 9.7 vs. 5.6 months\\nmOS: 23.0 vs. 16.1 months\\nCancers 2023, 15, 321\\n7 of 28\\nTable 2. Cont.\\nClinical Trial\\nPhase\\nStatus\\nArms (n)\\nPopulation (n)\\nPD-L1 Status\\nMajor Outcomes\\nKEYNOTE-150/\\nENHANCE 1\\n(NCT02513472)\\nIb/II\\nCompleted\\nPemb + eribulin mesylate\\n≤2 prior lines\\ntherapies in the\\nmetastatic setting\\n(167)\\nOverall\\nORR in total: 23.4%\\nstratum 1: 25.8%\\nstratum 2: 21.8%\\nmPFS in total: 4.1 months\\nstratum 1: 4.2 months\\nstratum 2: 4.1 months\\nmOS in total: 16.1 months\\nstratum 1: 17.4 months\\nstratum 2: 15.5 months\\n+(CPS ≥1)\\nORR in stratum 1: 34.5%\\nORR in stratum 2: 24.4%\\nmPFS in stratum 1: 6.1 months\\nmPFS in stratum 2: 4.1 months\\nmOS in stratum 1: 21.0 months\\nmOS in stratum 2: 14.0 months\\n−\\nORR in stratum 1: 16.1%\\nORR in stratum 2: 18.2%\\nmPFS in stratum 1: 3.5 months\\nmPFS in stratum 2: 3.9 months\\nmOS in stratum 1: 15.2 months\\nmOS in stratum 2: 15.5 months\\nTORCHLIGHT\\n(NCT04085276)\\nIII\\nRecruiting\\nTori + nab-P vs. placebo +\\nnab-P\\n≤1 line of CT\\nin the metastatic\\nsetting\\nNA\\nNCT04537286\\nII\\nRecruiting\\nCari + nab-P + Cp\\nFirst-line\\ntreatment in mTNBC\\nNA\\nNCT02755272\\nII\\nRecruiting\\nPemb + Cb + gemcitabine\\nvs. Cb + gemcitabine\\n>2 prior lines\\ntherapies\\nin the metastatic\\nsetting\\nNA\\nTONIC\\n(NCT02499367)\\nII\\nOngoing\\nA/C/Cp/\\nRT/no induction + Nivo\\n(70)\\nmTNBC (70)\\nORR in total: 20%\\nCp induction ORR: 23%\\nA induction ORR: 35%\\nmPFS in total: 1.9 months\\nTONIC-2\\n(NCT04159818)\\nII\\nRecruiting\\nCp/ low dose A/no\\ninduction\\n+ Nivo\\nMetastatic or\\nincurable locally\\nadvanced TNBC\\nNA\\nNCT01633970\\nIb\\nCompleted\\nAtez + nab-P\\n(33)\\n≤2 lines prior CT in\\nthe metastatic setting\\n(33)\\nORR: 39.4%\\nmPFS: 5.5 months\\nmOS: 14.7 months\\nIMpassion130\\n(NCT02425891)\\nIII\\nCompleted\\nAtez + nab-P (451) vs.\\nplacebo + nab-P (451)\\nFirst-line treatment in\\nmTNBC\\n(902)\\nITT\\npopulation\\nmPFS: 7.2 vs. 5.5 months\\nmOS: 21.0 vs. 18.7 months\\n+(≥1% IC c)\\nmPFS: 7.5 vs. 5.0 months\\nmOS: 25.4 vs. 17.9 months\\nIMpassion131\\n(NCT03125902)\\nIII\\nOngoing\\nAtez + P (431) vs. placebo +\\nP (220)\\nFirst-line treatment in\\nmTNBC (651)\\nITT\\npopulation\\nmPFS: 5.7 vs. 5.6 months\\nmOS: 19.2 vs. 22.8 months\\n+(≥1% IC)\\nmPFS: 6.0 vs. 5.7 months\\nmOS: 22.1 vs. 28.3 months\\nIMpassion132\\n(NCT03371017)\\nIII\\nRecruiting\\nAtez + CT d vs. placebo +\\nCT\\nFirst-line treatment\\nfor locally\\nadvanced inoperable\\nor mTNBC\\nNA\\nALICE\\n(NCT03164993)\\nII\\nOngoing\\nAtez + PLD + C vs. placebo\\n+ PLD + C\\n≤1 line previous\\nCT in the\\nmetastatic setting\\nNA\\nGIM25-CAPT\\n(NCT05266937)\\nII\\nRecruiting\\nAtez + nab-P + Cb\\nFirst-line therapy\\nin PD-L1-positive\\nmTNBC\\nNA\\nEL1SSAR\\n(NCT04148911)\\nIII\\nOngoing\\nAtez + nab-P\\nFirst-line therapy\\nin PD-L1-positive\\nmTNBC\\nNA\\nCancers 2023, 15, 321\\n8 of 28\\nTable 2. Cont.\\nClinical Trial\\nPhase\\nStatus\\nArms (n)\\nPopulation (n)\\nPD-L1 Status\\nMajor Outcomes\\nTrials in early-stage\\nTNBC as\\nneoadjuvant\\ntherapy\\nI-SPY2\\n(NCT01042379)\\nII\\nRecruiting\\nPemb + P→AC (29) vs.\\nP→AC\\n(85)\\nHER-2 negative, stage\\nII or\\nIII at high risk\\n(250, including 114\\nTNBC)\\npCR rates in TNBC:\\n60% vs. 22%\\nKEYNOTE-173\\n(NCT02622074)\\nIb\\nCompleted\\nPemb + (nab-P ± Cb→AC)\\n(60)\\nHigh-risk, early-stage\\nTNBC (60)\\nOverall pCR rate: 60%\\nKEYNOTE-522\\n(NCT03036488)\\nIII\\nOngoing\\nPemb + (PCb→AC/EC)\\n(784) vs. placebo +\\n(PCb→AC/EC) (390)\\n(→surgery→Pemb/placebo\\nfor up to 9 cycles)\\nStage II-III TNBC\\n(1174)\\nOverall\\npCR rates e:\\n64.8% vs. 51.2%\\n3-year EFS:\\n84.5% vs. 76.8%\\n+(CPS ≥1)\\npCR rates:\\n68.9% vs. 54.9%\\n−\\npCR rates:\\n45.3% vs. 30.3%\\nNeoPACT\\n(NCT03639948)\\nII\\nOngoing\\nPemb + Cb + docetaxel\\nEarly-stage TNBC\\nNA\\nNCT04613674\\nIII\\nRecruiting\\nCamr + CT vs. placebo + CT\\nEarly or Locally\\nAdvanced TNBC\\nNA\\nGeparNuevo\\n(NCT02685059)\\nII\\nCompleted\\nDurv×2w f→durv + (nab-P\\n→EC) (88) vs. placebo +\\n(nab-P →EC) (86)\\n(→surgery→physician’s\\nchoice)\\nPrimary, cT1b-cT4a-d\\ndisease, centrally\\nconﬁrmed TNBC\\n(174)\\nOverall pCR rates:\\n53.4% vs. 44.2%\\npCR rates in the window\\ncohort: 61.0% vs. 41.4%\\n3-year iDFS: 85.6% vs. 77.2%\\n3-year DDFS: 91.7% vs. 78.4%\\n3-year OS: 95.2% vs. 83.5%\\nNeoTRIPaPDL1\\n(NCT02620280)\\nIII\\nOngoing\\nAtez + nab-P + Cb (138) vs.\\nnab-P + Cb (142)\\n(→surgery→adjuvant\\nanthracycline regimen as\\nper investigator’s choice)\\nEarly high-risk and\\nlocally advanced\\nTNBC (280)\\nITT\\npopulation\\npCR rates: 48.6% vs. 44.4%\\n+(≥1% IC)\\npCR rates: 59.5% vs. 51.9%\\nIMpassion031\\n(NCT03197935)\\nIII\\nOngoing\\nAtez + (nab-P →AC) (165)\\nvs. placebo + (nab-P →AC)\\n(168)\\n(→surgery→\\nadjuvant Atez/placebo\\nfor up to 11 cycles)\\nStage II–III TNBC\\n(333)\\nOverall\\npCR rates: 58% vs. 41%\\n+(≥1% IC)\\npCR rates: 69% vs. 49%\\n−\\npCR rates: 48% vs. 34%\\nNSABP B-59\\n(NCT03281954)\\nIII\\nOngoing\\nAtez + (PCb→AC) vs.\\nplacebo + (PCb →AC)\\n(→surgery→adjuvant\\nAtez/placebo\\nuntil 1 year after the ﬁrst\\ndose)\\nStage II–III TNBC\\nNA\\nNCT02530489\\nII\\nOngoing\\nAtez + nab-P\\n(→surgery→adjuvant Atez\\nfor 4 cycles)\\nTNBC that were\\nnon-responders to\\ninitial AC\\nchemotherapy\\nNA\\nTrials in early-stage\\nTNBC as adjuvant\\ntherapy\\nNCT03487666\\nII\\nOngoing\\nNivo vs. capecitabine vs.\\nNivo + capecitabine\\nTNBC with ≥1 cm\\nRIC or LN (+) after\\nNACT\\nNA\\nIMpassion030\\n(NCT03498716)\\nIII\\nRecruiting\\nAtez + A/P-based CT vs.\\nCT\\nOperable-stage II-III\\nTNBC\\nNA\\nCancers 2023, 15, 321\\n9 of 28\\nTable 2. Cont.\\nClinical Trial\\nPhase\\nStatus\\nArms (n)\\nPopulation (n)\\nPD-L1 Status\\nMajor Outcomes\\nNCT03756298\\nII\\nRecruiting\\nAtez + capecitabine vs.\\ncapecitabine\\nTNBC with RIC after\\nNACT\\nNA\\nAbbreviations: mTNBC, metastatic triple-negative breast cancer; Pemb, pembrolizumab; Atez, atezolizumab; Durv.\\ndurvalumab; Cari, carilizumab; Tori, toripalimab; Nivo, nivolumab; Camr, camrelizumab; CT. chemotherapy;\\nRT, radiotherapy; Nab-P, nab-paclitaxel; P, paclitaxel; E, epirubicin; A, doxorubicin; C, cyclophosphamide; Cb,\\ncarboplatin; Cp, cisplatin; PLD, pegylated liposomal doxorubicin; mOS, median overall survival; mPFS, median\\nprogression-free survival; EFS, event-free survival; iDFS, invasive disease-free survival; DDFS, distant disease-\\nfree survival; ITT population, intention-to-treat population; ORR. objective response rate; pCR, pathological\\ncomplete remission; CPS, combined positive score; IC, immune cells; +, PD-L1 positive; −, PD-L1 negative;\\nRIC, residual invasive cancer; NA, not available. a In KEYNOTE-355, the chemotherapy regimens included\\nnab-paclitaxel; paclitaxel; or gem citabine plus carboplatin. b Immunohistochemistry 22C3 assay, CPS = PD-L1\\nstained cells (including tumor cells, lymphocytes, and macrophages) / the number of all viable tumor cells\\n× 100.\\nc The percentage of PD-L1 stained tumor-associated immune cells in the tumor area; immune cells\\nincluding lymphocytes, macrophages, dendritic cells, plasma cells, and granulocytes. d In the IMpassion132,\\nthe chemotherapy regimens include gemcitabine, capecitabine, and car boplatin. e In KEYNOTE-522, the ﬁrst\\ninterim pCR analysis was conducted on the ﬁrst 602 patients who underwent randomization (401 patients in\\npembrolizumab–chemotherapy group and 201 in placebo–chemotherapy group). f In the GeparNuevo study, 117\\npatients participated in the window phase.\\n5.1. In Advanced TNBC\\nAt present, a majority of clinical trials apply immunotherapy with chemotherapy\\nconcomitantly. The reason for this is that ICIs take time to work, while chemotherapy\\nagents kill tumor cells and modify the TIME during this waiting period.\\nKEYNOTE-355 is a phase III randomized controlled trial (RCT) assessing the efﬁ-\\ncacy and safety of pembrolizumab plus chemotherapy versus placebo plus chemother-\\napy as ﬁrst-line treatment for patients with advanced TNBC; chemotherapy regimens\\nwere based on the physician’s choice including nab-paclitaxel, paclitaxel, and gemc-\\nitabine/carboplatin. Initial results showed that the combination of pembrolizumab with\\nchemotherapy improved PFS in the intention-to-treat (ITT) population and in the com-\\nbined positive score (CPS) ≥1 subgroup (7.5 vs. 5.6 months, HR = 0.82, 95% CI: 0.69 to\\n0.97 and 7.6 vs. 5.6 months, HR = 0.74, 95% CI: 0.61 to 0.90, p = 0.0014, respectively); the\\nimprovement was particularly signiﬁcant in the CPS ≥10 subgroup (9.7 vs. 5.6 months,\\nHR = 0.65, 95% CI: 0.49 to 0.86, p = 0.0012) [40]. According to the latest release of follow-up\\ndata, OS was improved by almost 7 months in the CPS ≥10 subgroup after the addition\\nof pembrolizumab to chemotherapy (23.0 vs. 16.1 months, HR = 0.73, 95% CI: 0.55 to 0.95,\\np = 0.0185) and the adverse effects were manageable [41].\\nAnother single-arm phase Ib/II trial, KEYNOTE-150, used pembrolizumab in com-\\nbination with eribulin mesylate in patients with mTNBC who had received ≤2 lines of\\nprior therapy in the metastatic setting. Of the 167 patients enrolled, 40% had not received\\nprevious systemic therapies and were classiﬁed in stratum 1. The results showed that the\\nsurvival beneﬁt was most signiﬁcant in PD-L1-positive patients who had not received prior\\nsystemic therapy, which was consistent with previous studies. This study offers a new\\nimmuno–chemotherapy combination for the treatment of patients with mTNBC, although\\nfurther conﬁrmation is needed [42].\\nAfter a phase Ib trial (NCT01633970) demonstrated the safety and feasibility of ate-\\nzolizumab plus nab-paclitaxel in patients with locally recurrent or metastatic TNBC [43],\\nthe efﬁcacy of this immuno–chemotherapy combination for TNBC patients who did not\\nreceive systemic therapy in the metastatic setting was further validated by IMpassion130,\\nthe ﬁrst phase III RCT of immunotherapy for TNBC [44]. Preliminary results showed that a\\nPFS beneﬁt was observed with the addition of atezolizumab in both the ITT population\\n(7.2 vs. 5.5 months, HR = 0.80, 95% CI: 0.69 to 0.92, p = 0.002) and the PD-L1-positive pop-\\nulation (7.5 vs. 5.0 months, HR = 0.62, 95% CI: 0.49 to 0.78, p < 0.001). The second set of\\ninterim results indicated that atezolizumab signiﬁcantly improved OS from 18.0 months\\nto 25.0 months in the PD-L1-positive subgroup (HR = 0.71, 95% CI: 0.54 to 0.94), but the\\ndifference was not signiﬁcant in the ITT population (21.0 vs. 18.7 months, HR = 0.86, 95%\\nCancers 2023, 15, 321\\n10 of 28\\nCI: 0.72 to 1.02, p = 0.078) [45]. As a result, in March 2019, atezolizumab was granted accel-\\nerated approval by the Food and Drug Administration (FDA) to be used in combination\\nwith nab-paclitaxel as a ﬁrst-line treatment for late-stage TNBC patients. Additionally, the\\n7.5-month survival beneﬁt shown in the ﬁnal OS data further demonstrated the durable\\nefﬁcacy of this treatment combination for PD-L1-positive patients (25.4 vs. 17.9 months,\\nHR = 0.67, 95% CI: 0.53 to 0.86) [46].\\nHowever, these ﬁndings were contradicted when atezolizumab was combined with\\npaclitaxel and compared to placebo plus paclitaxel in the phase III clinical study IMpas-\\nsion131, which also investigated this as ﬁrst-line treatment for patients with advanced or\\nmetastatic TNBC. The study found no obvious differences in PFS between the two arms,\\nregardless of PD-L1 expression status (5.7 vs. 5.6 months, HR = 0.86, 95% CI: 0.70 to 1.05 for\\nthe ITT population and 6.0 vs. 5.7 months, HR = 0.82, 95% CI: 0.60 to 1.12, p = 0.20 for the\\nPD-L1-positive patients). With respect to OS, the atezolizumab arm appeared to be worse\\nbut not detrimental in the PD-L1-positive population (22.1 vs. 28.3 months, HR = 1.11, 95%\\nCI: 0.76 to 1.64) and in the ITT population (19.2 vs. 22.8 months, HR = 1.12, 95% CI: 0.88 to\\n1.43). Different chemotherapeutic agents, steroid pre-treatment with paclitaxel, and subtle\\ndifferences between study populations may explain the difference in results between IM-\\npassion130 and IMpassion131 [47]. In addition, levels of TILs, breast cancer susceptibility\\ngene (BRCA) mutational load, and the proportion of patients with residual disease after\\nNACT (which were unreported in the trial) may also have contributed to the unclear results\\nfrom IMpassion131 [48]. As the reason for this discrepancy remains undeﬁned, Roche has\\nvoluntarily withdrawn the indication for atezolizumab for the treatment of PD-L1 positive\\nadvanced TNBC. Recently, a small sample-based single-cell sequencing study suggested\\nthat paclitaxel may affect the efﬁcacy of atezolizumab by reducing key anti-tumor immune\\ncells in the TIME but enhancing immunosuppressive macrophages, yet this ﬁnding needs\\nto be further explored [49].\\nDespite some setbacks in the exploration of combination treatments with taxanes,\\natezolizumab is still being tested in different trials to investigate the safety and efﬁcacy of\\ncombination treatment with other chemotherapy agents in TNBC (Table 2).\\nBeyond concurrent chemotherapy, the induction use of small doses of chemothera-\\npeutic agents prior to immunotherapy is another strategy of the immuno–chemotherapy\\ncombination that is in the experimental phase. In the ﬁve cohorts of the phase II TONIC\\ntrial, patients with mTNBC received no induction or 2 weeks induction with low-dose\\ncyclophosphamide, cisplatin, doxorubicin, and hypofractionated irradiation, respectively,\\nall followed by the PD-1 blocking drug nivolumab. The total ORR was 20%, with a median\\nPFS (mPFS) of 1.9 months; a higher ORR occurred in the doxorubicin and carboplatin\\ncohorts at 35% and 23%, respectively. Analysis of patient samples suggested that short-\\nterm doxorubicin or cisplatin induction can convert the tumor microenvironment towards\\ninﬂammation and improve the response of nivolumab in TNBC. However, due to the limi-\\ntations of the trial itself, this conclusion needs further conﬁrmation [50]. The subsequent\\ntrial, TONIC-2, is currently recruiting (Table 2).\\n5.2. In Early-Stage TNBC\\nStudies based on transcriptomics and immunohistochemical techniques have revealed\\nthat mTNBC has signiﬁcantly reduced expression of immune activation genes as well\\nas immunotherapeutic targets, such as PD-L1, and a lower number of TILs compared to\\nprimary TNBC [51,52]. Thus, the TIME in the early-stage disease setting is more suitable\\nfor ICIs to function and to potentially achieve a true cure.\\nSeveral trials have indicated that the combination of pembrolizumab with chemother-\\napy can improve pathological complete remission (pCR) rates in early-stage TNBC. One of\\nthe cohorts in the I-SPY2 trial ﬁrst determined the feasibility of 4 cycles of pembrolizumab\\nin combination with paclitaxel- and anthracycline-based chemotherapy regimen in women\\nwith early-stage, high-risk HER-2-negative breast cancer. Compared to standard NACT regi-\\nmens, the addition of pembrolizumab increased the pCR rate for patients with TNBC by 38%\\nCancers 2023, 15, 321\\n11 of 28\\n(60% vs. 22% for pembrolizumab vs. control) [53]. Another phase Ib KEYNOTE-173 trial\\nwith a relatively small sample volume evaluated the safety and efﬁcacy of pembrolizumab\\nin combination with chemotherapy regimens, including different doses of nab-paclitaxel\\nwith or without carboplatin followed by doxorubicin and cyclophosphamide; the overall\\npCR rate was consistent with I-PSY2 at 60% [54].\\nIn the phase III trial KEYNOTE-522, 1174 patients with previously untreated early-\\nstage TNBC were randomized in a 2:1 ratio to either the pembrolizumab–chemotherapy arm\\nor the placebo–chemotherapy arm (chemotherapy backbone of 4 cycles of paclitaxel plus\\ncarboplatin, followed by 4 cycles of anthracycline plus cyclophosphamide every 3 weeks),\\nwith up to 9 cycles of adjuvant pembrolizumab or placebo after surgery. Preliminary results\\nbased on the ﬁrst 602 patients showed that the addition of pembrolizumab increased the\\npCR rate by 13.6% compared to the placebo–chemotherapy arm (64.8% vs. 51.2%, 95%\\nCI: 5.4% to 21.8%, p < 0.001). This beneﬁt was observed in most subgroups, including\\nPD-L1-negative patients [55]. Based on this undifferentiated beneﬁt, in July 2021, the\\nFDA approved pembrolizumab in combination with chemotherapy as a neoadjuvant\\ntreatment for early-stage, high-risk TNBC and for continued use as a single agent in the\\nadjuvant phase. Furthermore, recently updated follow-up data after 39.1 months showed\\nthat pembrolizumab treatment for almost 1 year reduced the risk of disease progression\\nby 37% (3-year event-free survival (EFS) of 84.5% vs. 76.8%, HR = 0.63, 95% CI: 0.48 to\\n0.82, p < 0.001). This EFS beneﬁt was independent of PD-L1 expression status, which is\\nconsistent with previous results and further demonstrates the long-term effectiveness of\\nthe perioperative addition of pembrolizumab. At the time of this analysis, data on OS were\\nimmature and further follow-up data are expected [56].\\nIn addition, the phase II NeoPACT trial is also ongoing, combining pembrolizumab\\nwith carboplatin and docetaxel as neoadjuvant therapy. The results of this study will\\ndemonstrate whether similar pCR rates and survival beneﬁts can be achieved by removing\\nanthracyclines from neoadjuvant chemotherapy regimens in early TNBC.\\nHowever, the situation becomes more complicated upon review of the results of\\nclinical trials with PD-L1 inhibitors.\\nThe phase II GeparNuevo study compared the efﬁcacy of receiving durvalumab or\\nplacebo every 4 weeks in addition to chemotherapy of nab-paclitaxel sequentially with\\nepirubicin and cyclophosphamide. A total of 174 patients with early TNBC were enrolled.\\nIt was noteworthy that 117 patients in this study received an additional, 2-week earlier\\nwindow treatment of durvalumab or placebo before the start of nab-paclitaxel, and 87% of\\n158 detected patients were PD-L1 positive. The intensive postoperative treatment regimen\\nfor patients enrolled in this trial was based on the physician’s choice. In the window cohort,\\nthe pCR rates were statistically increased by the addition of durvalumab (61.0% vs. 41.4%,\\nOR = 2.22, 95% CI: 1.06 to 4.64, p = 0.035), but not in the whole study population (53.4% vs.\\n44.2%, OR = 1.45, 95% CI: 0.80 to 2.63, p = 0.224). However, it remains uncertain whether this\\ndifference was due to one dose of durvalumab window treatment [57]. Surprisingly, after\\na median follow-up of 43.7 months, signiﬁcant improvements in 3-year invasive disease-\\nfree survival (iDFS), distant disease-free survival (DDFS), and OS were observed in the\\ndurvalumab group, even without the adjuvant durvalumab treatment, which contradicts\\nthe pCR results obtained initially (iDFS was 85.6% vs. 77.2%, HR = 0.48, 95% CI: 0.24 to\\n0.97, p = 0.036; DDFS was 91.7% vs. 78.4%, HR = 0.31, 95% CI: 0.13 to 0.74, p = 0.005; OS was\\n95.2% vs. 83.5%, HR = 0.24, 95% CI: 0.08 to 0.72, p = 0.006) [58]. More studies are needed to\\nelucidate this result and to explore the timing and sequence of ICIs when combined with\\nchemotherapy to treat early-stage TNBC.\\nThe efﬁcacy of 8 cycles of nab-paclitaxel and carboplatin with or without atezolizumab\\nin early-stage, high-risk TNBC was investigated in the NeoTRIPaPDL1 trial, with 4 cycles\\nof anthracycline regimen chemotherapy administered as adjuvant treatment. The pub-\\nlished results thus far have shown that the addition of atezolizumab to the neoadjuvant\\nsetting did not signiﬁcantly increase the pCR rate in the ITT population (48.6% vs. 44.4%,\\nOR = 1.18, 95% CI: 0.74 to 1.89, p = 0.48) or in the PD-L1-positive subgroup (59.5% vs.\\nCancers 2023, 15, 321\\n12 of 28\\n51.9%). Nevertheless, the primary endpoint of the study, the EFS data, still requires further\\nfollow-up [59].\\nOn the contrary, in the Impassion031 trial, a signiﬁcant increase in pCR rates was ob-\\nserved when atezolizumab was combined with a standard nab-paclitaxel- and doxorubicin-\\nbased chemotherapy regimen and applied in the adjuvant phase as a single agent (58% vs.\\n41%, rate difference 17%, 95% CI: 6% to 27%, p = 0.0044). The mature long-term survival\\nfollow-up data are not available at present. Similar to the KEYNOTE-522 results, the beneﬁt\\nof pCR was not signiﬁcantly related to PD-L1 expression status. Of note, platinum agents\\nwere removed from the NACT regimen in this trial [55,60].\\nFurthermore, it is noteworthy that anthracyclines were given preoperatively in both\\nthe KEYNOTE-522 and Impassion031 trials, whereas anthracyclines were applied postop-\\neratively in the NeoTRIPaPDL1 trial. This may be one reason why the difference in pCR\\nrates between the two arms in the NeoTRIPaPDL1 trial was not signiﬁcant.\\nThe safety and efﬁcacy of other combinations of PD-(L)1 inhibitors with chemotherapy\\ndrugs are also being tested in clinical trials. Last but not least, trials using ICIs plus\\nchemotherapy in the adjuvant phase of early-stage TNBC are underway and the results are\\nawaited with great interest (Table 2).\\n6. Research Progress of PD-(L)1 Inhibitors in Combination with Radiotherapy\\nSimilar to chemotherapy, radiotherapy (RT) has a dual role of mediating DNA damage-\\ninduced tumor cell death and immunomodulation, which can make the TIME more inﬂam-\\nmatory and facilitate the role of ICIs [61]. Whereas RT acts locally, the systemic side effects\\nare less severe and well tolerated.\\nA small single-arm phase II trial (NCT02730130) enrolled 17 unselected patients with\\nmTNBC with a median of 3 lines on prior systemic therapy. They received RT with\\n3000 centigrays (cGy) in ﬁve fractions over 5–7 days and pembrolizumab within 1 to 3 days\\nafter the ﬁrst fraction. The median follow-up was 34.5 weeks, with an ORR of 17.6%,\\nmPFS of 2.6 months, and median OS (mOS) of 8.25 months. Although the 3 patients who\\nexperienced complete remission were all PD-L1 positive, the analysis showed that PD-L1\\nstatus was not associated with therapeutic effects [62].\\nAnother phase II AZTEC trial enrolled 50 patients who had received less than 2 lines\\nof prior systemic therapy to receive RT combined with atezolizumab. Participants were\\nrandomly assigned to 20 Gy stereotactic ablative body RT (SABR) in one fraction or 24 Gy\\nSABR in three fractions to irradiate 1–4 lesions with at least one metastasis left unirradiated.\\nAtezolizumab was initiated within 5 days after the last part of RT. The median follow-up\\nwas 17 months, with mPFS of 3.1 months. No difference was observed in mPFS between the\\ntwo groups. PD-L1 expression status and TIL levels (5%) had little effect on the efﬁcacy [63].\\nIn these studies, the combination of pembrolizumab and RT showed modest but\\nencouraging clinical activity in unselected patients and was well tolerated, offering a new\\ntreatment idea for pre-treated patients with advanced TNBC. Additional trials are still\\nbeing explored (Table 3).\\n7. Research Progress of PD-(L)1 Inhibitors in Combination with Targeted Therapy\\n7.1. Combination with PARPi\\nPARPi are drugs that block the repair of single-strand DNA damage. These drugs\\nkill tumor cells through synthetic lethal effects that are formed by the accumulation of\\nhomologous recombination (HR) repair defects for DNA double-strand breaks due to\\nmutations in BRCA1/2. In addition to direct killing of tumor cells, previous in vitro studies\\nhave shown that PARPi can stimulate intrinsic immunity and upregulate interferon (IFN)\\nrelease by activating the cyclic GMP–AMP synthase-stimulator of interferon genes (cGAS-\\nSTING) signaling pathway, further upregulating tumor PD-L1 expression and inﬁltration\\nof CD8+ T cells [64–66]. In short, PARPi have the potential to turn cold tumors into hot\\ntumors and set the stage for the application of PD-(L)1 blockers.\\nCancers 2023, 15, 321\\n13 of 28\\nKEYNOTE-162 is a single-arm phase I/II trial evaluating the efﬁcacy and safety of\\npembrolizumab in combination with niraparib in 55 patients with advanced TNBC. The\\ntotal ORR was 21%, with ORR of 47% vs. 11% and 32% vs. 8% for the two subgroups,\\nrespectively, when considering tumor BRCA mutations as well as PD-L1 status [67]. Re-\\nmarkably, the mPFS in patients with BRCA mutations was 8.3 months, which was nearly\\n3 months longer than the mPFS of 5.6 months for olaparib reported in the OlympiAD trial\\nor 5.8 months for talazoparib reported in the TALA trial [68,69].\\nA cohort in the I-SPY2 trial studied the efﬁcacy of adding durvalumab and olaparib\\nto standard NACT regimens of paclitaxel compared to paclitaxel alone. In the TNBC\\nsubgroup analysis, although the addition of durvalumab and olaparib increased the pCR\\nrate in the experimental arm by 20% (47% vs. 27%), by comparison with related trials, the\\ninvestigators concluded that the contribution from olaparib to the increased pCR rate in\\nthe I-SPY2 experimental arm was relatively modest [70]. However, survival data from this\\nexperiment have not been published and a more reasonable random grouping should also\\nbe considered.\\nPD-(L)1 blockers combined with PARPi have shown initial efﬁcacy in both advanced\\nand early-stage TNBC patients, with more trials ongoing (Table 3).\\nTable 3. Clinical trials of PD-(L)1 inhibitors in combination with radiotherapy, targeted therapy, and\\nother immunotherapies.\\nClinical Trial\\nPhase\\nStatus\\nArms\\nPopulation\\nNCT02730130\\nII\\nOngoing\\nPemb + RT\\nmTNBC: a median of 3 lines\\nprior systemic therapy\\nAZTEC\\n(NCT03464942)\\nII\\nOngoing\\nAtez + RT\\nAdvanced TNBC:\\n<2 lines of prior\\nsystemic therapy\\nNCT03483012\\nII\\nOngoing\\nAtez + RT\\nmTNBC with brain metastases\\nKEYNOTE-162\\n(NCT02657889)\\nI/II\\nCompleted\\nPemb + niraparib\\nAdvanced TNBC: a median of 1 prior\\nline of therapy (range, 0–3)\\nin the metastatic setting\\nI-SPY2\\n(NCT01042379)\\nII\\nRecruiting\\nDurv + olaparib + paclitaxel\\nvs. paclitaxel\\nStage II-III TNBC: preoperative treatment\\nDORA\\n(NCT03167619)\\nII\\nOngoing\\nDurv + olaparib\\nPlatinum-treated mTNBC\\nKEYLYNK-009\\n(NCT04191135)\\nII/III\\nOngoing\\nPemb + olaparib vs. Pemb + Cb\\n+ gemcitabine\\nLocally recurrent inoperable\\nor metastatic TNBC: after induction\\nwith ﬁrst-line CT + Pemb\\nNCT03594396\\nI/II\\nOngoing\\nOlaparib + Durv\\nStage II/III TNBC or low ER\\nbreast cancer:\\npreoperative treatment\\nNCT03310957\\nIb/II\\nRecruiting\\nPemb + ladiratuzumab vedotin\\nUnresectable locally advanced\\nor metastatic TNBC:\\nﬁrst-line treatment\\nASCENT-04\\n(NCT05382286)\\nIII\\nRecruiting\\nPemb + SG vs. pemb + TPC\\nPreviously untreated, locally advanced\\ninoperable, or metastatic\\nPD-L1-positive TNBC\\nNCT04468061\\nII\\nRecruiting\\nPemb + SG vs. SG\\nPD-L1-negative mTNBC\\nASPRIA\\n(NCT04434040)\\nII\\nRecruiting\\nAtez + SG\\nEarly-stage TNBC with RIC after NACT\\nNCT03394287\\nII\\nCompleted\\nCamr + apatinib\\nAdvanced TNBC: <3 lines\\nof systemic therapy\\nCancers 2023, 15, 321\\n14 of 28\\nTable 3. Cont.\\nClinical Trial\\nPhase\\nStatus\\nArms\\nPopulation\\nNCT05447702\\nII\\nNot yet\\nrecruiting\\nCamr + apatinib + CT\\nNeoadjuvant therapy for stage II-III TNBC\\nNCT04303741\\nII\\nOngoing\\nCamr + apatinib + eribulin\\nUnresectable recurrent or mTNBC;\\npre-treated with anthracycline\\nand taxane\\nNCT04427293\\nI\\nRecruiting\\nPemb + Lenvatinib\\nEarly-stage TNBC: preoperative treatment\\nNCT04335006\\nIII\\nRecruiting\\nCare + nab-P + apatinib vs. Care\\n+ nab-P vs. nab-P\\nLocally advanced or metastatic TNBC:\\nﬁrst-line treatment\\nNCT03800836\\nIb\\nCompleted\\nAtez + ipatasertib + P/nab-P\\nmTNBC: ﬁrst-line treatment\\nBARBICAN\\n(NCT05498896)\\nII\\nOngoing\\nAtez + PAC + ipatasertib\\nvs. Atez + PAC\\nEarly-stage TNBC:\\npreoperative treatment\\nNCT04177108\\nIII\\nOngoing\\nAtez/placebo +\\nipatasertib/placebo + P\\nLocally advanced unresectable or metastatic\\nTNBC\\nCOLET\\n(NCT02322814)\\nII\\nCompleted\\nAtez + cobimetinib + P (cohorts\\nII)/Atez + cobimetinib + nab-P\\n(cohort III)\\nFirst-line treatment for mTNBC\\nNCT02536794\\nII\\nCompleted\\nDurv + tremelimumab\\nPre-treated mTNBC\\nNCT03872791\\nIb/II\\nOngoing\\nKN046 vs. KN046 + nab-P\\nmTNBC\\nSYNERGY\\n(NCT03616886)\\nIb/II\\nOngoing\\nDurv + oleclumab +PCb vs.\\nDurv + PCb\\nFirst-line treatment for mTNBC\\nNCT04584112\\nIb\\nOngoing\\nAtez + tiragolumab + CT\\nFirst-line treatment for PD-L1 (+) mTNBC\\nNCT05227664\\nII\\nRecruiting\\nAK117 + P/nab-P vs. AK112 +\\nP/nab-P vs. AK117+AK112 +\\nP/nab-P\\nFirst-line treatment for mTNBC\\nNCT03362060\\nI\\nOngoing\\nPemb + PVX-410 vaccine\\nPre-treated HLA-A2 (+) mTNBC\\nNCT02826434\\nI\\nOngoing\\nDurv + PVX-410\\nHLA-A2 (+) stage II or III TNBC\\nNCT03606967\\nII\\nRecruiting\\nCT →Durv + tremelimumab +\\nVaccine vs. CT →Durv +\\ntremelimumab\\nFirst-line treatment for\\nPD-L1-negative mTNBC\\nNCT03199040\\nI\\nOngoing\\nDurv + DNA vaccine vs. DNA\\nvaccine\\nEarly-stage TNBC\\nNSABP FB-14\\n(NCT04024800)\\nII\\nOngoing\\nAE37 peptide vaccine + Pemb\\nAdvanced TNBC: ≤1 line\\nof systemic therapy\\nNCT03387085\\nIb/II\\nOngoing\\nCombination of multiple\\ntreatments\\nmTNBC: ≥2 lines of prior therapy\\nNCT04445844\\nII\\nRecruiting\\nRetifanlimab + pelareorep\\nmTNBC: received 1–2 prior lines\\nof systemic therapy\\nNCT03004183\\nII\\nOngoing\\nADV/HSV-tk + RT + Pemb +\\nPre-treated mTNBC\\nNCT03256344\\nI\\nCompleted\\nAtez + talimogene laherparepvec\\nmTNBC with liver metastases\\nNCT05081492\\nI\\nRecruiting\\nCF33-hNIS-antiPDL1\\nmTNBC: ≥2 prior lines of therapy\\nfor metastatic disease\\nNCT04185311\\nI\\nOngoing\\nTalimogene laherparepvec +\\nnivolumab + ipilimumab\\nLocalized, palpable HER-2 negative\\nbreast cancer\\nAbbreviations: mTNBC, metastatic triple-negative breast cancer; Pemb, pembrolizumab; Camr, camrelizumab;\\nAtez. atezolizumab; Durv. durvalumab; Nivo, nivolumab; Care, carelizumab; CT, chemotherapy; RT, radiotherapy;\\nNab-P, nab-paclitaxel; P, paclitaxel; E, epirubicin; A, doxorubicin; C, cyclophosphamide; Cb, carboplatin; mOS,\\nmedian overall survival; mPFS, median progression-free survival; ORR, objective response rate; pCR, pathological\\ncomplete remission; DOR, median duration of response; SG, sacituzumab govitecan; TPC, treatment of physician’s\\nchoice; HLA, human leukocyte antigen; RIC, residual invasive cancer; NACT, neoadjuvant chemotherapy.\\nCancers 2023, 15, 321\\n15 of 28\\n7.2. Combination with ADCs\\nADCs consist of three components: mAb, linker, and cytotoxic payload. In addi-\\ntion to targeting antigen-expressing tumor cells for payload delivery, the mAb mediates\\nantibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated\\nphagocytosis (ADCP), and/or complement-dependent cytotoxicity (CDC), as well as the\\nunique bystander killing effect of ADCs to clear tumor cells [71,72]. The cytotoxic pay-\\nload, apart from directly killing tumor cells, also has immunomodulatory effects, as with\\nthe chemotherapeutic agents discussed above [73,74]. Furthermore, payload microtubule\\ninhibitors and topoisomerase inhibitors can directly activate DCs and promote their matu-\\nration [75,76]. Therefore, ADCs may create a more conducive TIME for the enhancement of\\nPD-(L)1 inhibitors and work synergistically with PD-(L)1 inhibitors to ﬁght against tumors.\\nSacituzumab govitecan, an ADC that targets the tumor cell surface antigen trop2 and\\nhas the irinotecan metabolite SN-38 as its payload, has been approved by the FDA for\\npatients with advanced TNBC who have received 2 or more lines treatments. Clinical trials\\nare currently underway to evaluate the potential of sacituzumab govitecan in combination\\nwith pembrolizumab as ﬁrst-line treatment for mTNBC.\\nLadiratuzumab vedotin is an ADC that targets the zinc transporter protein LIV-1\\nwith the microtubule inhibitor monomethyl auristatin E (MMAE) as a payload. A phase\\nIb/II trial (NCT03310957) evaluated the safety and efﬁcacy of its combination with pem-\\nbrolizumab as ﬁrst-line treatment for advanced TNBC. The initial 51 patients included\\nshowed moderate tolerability and a manageable safety proﬁle. Among the 26 patients\\nevaluable for efﬁcacy, the ORR was 54% [77]. This trial is currently underway and initial\\nresults are encouraging.\\nSeveral additional trials are testing the safety and efﬁcacy of PD-(L)1 inhibitors in\\ncombination with ADCs in both early-stage and advanced TNBC (Table 3).\\n7.3. Combination with Small Molecule Inhibitors\\nThe serine/threonine kinase AKT is a key component of the phosphatidylinositol-\\n3-kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways.\\nActivation of this pathway and its downstream pathways is associated with the growth,\\ninvasion, and drug resistance of a variety of tumors and is cross-linked with multiple\\nsignaling pathways, such as the mitogen-activated protein kinase (MAPK) pathway [78].\\nIt has been shown that activation of these two pathways is associated with an increase\\nin immunosuppressive cells and cytokines as well as a decrease in IFNγ, interleukin-2\\n(IL-2), and tumor necrosis factor α (TNFα) [79–81]. Therefore, a simultaneous blockade\\nof these pathways as well as PD-(L)1 would confer a better therapeutic effect. Results of\\na phase Ib trial (NCT03800836) combining the AKT inhibitors ipatasertib, atezolizumab,\\nand paclitaxel or nab-paclitaxel as a ﬁrst-line treatment for mTNBC showed an ORR of\\n54% and mPFS of 7.2 months in 114 patients. Subgroup analysis according to PD-L1 status,\\nPIK3CA/AKT1/phosphatase and tensin homolog (PTEN) alteration status, or taxane back-\\nbone showed no consistent trend across endpoints. Treatment was generally tolerable [82].\\nCobimetinib is a MAPK/extracellular signal-regulated kinase (MEK) inhibitor. In the phase\\nII COLET trial, a combination regimen of cobimetinib with atezolizumab and paclitaxel\\nor nab-paclitaxel as ﬁrst-line treatment failed to signiﬁcantly improve ORRs in mTNBC\\n(34.4% for the paclitaxel cohort and 29.0% for the nab-paclitaxel cohort) [83]. These ﬁndings\\nsuggest that more effort is still needed in the understanding of classical pathways and in\\nclinical translation.\\nAbnormal morphological and functional vascularity within solid tumors results in\\nhypoxia of tumor tissue and increased immunosuppressive TIME, as well as reduced and\\nsuppressed immune cell inﬁltration and activity [84,85]. Preclinical studies have shown\\nthat anti-vascular therapy increases immune cell inﬁltration and PD-L1 expression in tumor\\ntissues [86]. Thus, anti-tumor vascular therapy is a potential method to convert cold tumors\\ninto hot tumors. A phase II clinical trial (NCT03394287) combined camrelizumab with the\\nvascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor apatinib\\nCancers 2023, 15, 321\\n16 of 28\\nin patients with advanced TNBC with fewer than 3 lines of systemic therapy. Of the\\n40 patients included, 10 were treated intermittently with apatinib and 30 were treated\\ncontinuously. The ORR in the continuous dosing cohort was 43.3%, while no objective\\nresponse was observed in the intermittent dosing cohort. This trial demonstrated that the\\ncombination of the two drugs is safe and it shows a superior clinical response to single\\ndrug application [87].\\nMore trials on the combination of ICIs with small molecule inhibitors are underway\\n(Table 3).\\n8. Exploration of PD-(L)1 Inhibitors in Combination with Other Immunotherapies\\n8.1. Combination with Other ICIs\\nIn addition to PD-(L)1, immune checkpoints such as cytotoxic T-lymphocyte antigen-4\\n(CTLA-4), lymphocyte-activation gene 3 (LAG-3), and T cell immunoreceptor with Ig\\nand ITIM domains (TIGIT) are also signiﬁcantly upregulated in TNBC; their expression\\nlevels are further boosted by PD-(L)1 blockade, which may mediate acquired resistance\\nto PD-(L)1 blockade [88,89]. Therefore, to further reverse the tumor immunosuppressive\\nmicroenvironment and overcome PD-(L)1 inhibitor resistance, dual ICIs therapies have\\nbeen developed.\\nCTLA-4 is a co-suppressor molecule expressed by T cells. As a homologous receptor\\nof CD28, CTLA-4 can replace CD28 and bind to the B7 ligand on the surface of APCs,\\npreventing the activation and proliferation of T cells [90]. Anti-CTLA-4 antibodies en-\\nhance tumor cell killing by blocking the CTLA-4-B7 checkpoint pathway or by selectively\\ndepleting Treg cells, although this requires further validation [91]. In a small single-arm\\nstudy (NCT02536794), durvalumab in combination with tremelimumab demonstrated\\npreliminary efﬁcacy and a tolerable safety proﬁle in 7 patients with mTNBC, with an ORR\\nof 43% [92]. In particular, a combination regimen of KN046, a bispeciﬁc antibody that\\ntargets both PD-L1 and CTLA-4, with nab-paclitaxel for advanced TNBC showed initially\\npromising results in a phase Ib/II trial (NCT03872791), which may herald the coming of\\nthe era of bispeciﬁc antibodies [93].\\nNevertheless, the idea of combining ICIs for the treatment of TNBC met a waterloo in\\nthe SYNERGY trial. CD73, a metabolic immune checkpoint, is an ecto-5′-nucleotidase that\\nis expressed on a wide range of cells and works synergistically with CD39 to convert ATP\\ninto adenosine. Adenosine is a potent immunosuppressive molecule that suppresses the\\nfunction of a wide range of immune cells, especially T cells [94]. CD73 is highly expressed\\nin TNBC and is associated with poor prognosis [95]. The preliminary results at week 24\\nwere presented at the European Society for Medical Oncology (ESMO) 2022 and showed\\nthat the addition of the CD73 inhibitor oleclumab to chemotherapy and durvalumab did\\nnot improve clinical beneﬁts as a ﬁrst-line treatment for advanced TNBC (the clinical beneﬁt\\nrates were 42.9% vs. 43.3%, respectively) [96].\\nThe mixed results suggest that the functions and interactions of various immune\\ncheckpoints still need to be more thoroughly explored. Clinical trials on the effects of\\nPD-(L)1 inhibitors in combination with other ICIs, such as novel phagocytosis checkpoints,\\nare in full swing (Table 3).\\n8.2. TCVs and PD-(L)1 Inhibitors\\nThe practice of utilizing vaccines against breast tumors predates even ICI uses. How-\\never, due to limited efﬁcacy, this approach is not widely applied clinically. Personalized\\nTCVs based on neoantigens may beneﬁt speciﬁc patients via injection of tumor neoanti-\\ngens that were extracted from tumor tissues or human body ﬂuids along with adjuvants.\\nSuch therapy ampliﬁes the process of antigen capture and presentation, increases the\\nnumber of tumor-speciﬁc effector T cells, and establishes long-term memory to inhibit\\ntumor recurrence [97,98]. The major types currently in trials include: autologous cells,\\nwhole/genetically modiﬁed tumor cells, or DCs; cancer antigens, DNA/RNA/peptide\\nvaccines; and tumor cell products, such as exosomes [99].\\nCancers 2023, 15, 321\\n17 of 28\\nTCVs and PD-(L)1 inhibitors act in different steps of tumor elimination, and thus\\ncombination treatment will synergistically activate the entire immune system. Several\\nclinical trials are currently testing the safety and efﬁcacy of TCVs in combination with\\nPD-(L)1 inhibitors for the treatment of TNBC, in both early and advanced stages (Table 3).\\nNotably, a preclinical study showed that the sequence of PD-(L)1 inhibitors and vaccine\\ncombinations is critical to treatment efﬁcacy [100], which deserves special attention when\\nconducting clinical trials.\\n8.3. Oncolytic Virus (OVs) and PD-(L)1 Inhibitors\\nOVs immunotherapy utilizes natural or modiﬁed viruses to selectively infect tumor\\ncells and replicate in large numbers, thereby lysing tumor cells without harming normal\\ncells [101]. In addition to direct killing of tumor cells, OVs also enhance host anti-tumor\\nimmunity by mediating ICD, promoting the release of TAAs, increasing the recruitment and\\nmaturation of immune cells, and regulating the suppressive TIME, all together rapidly and\\neffectively transforming cold tumors into inﬂammatory tumors [102]. The efﬁcacy of OVs\\nalone or in combination with therapies such as ICIs has been demonstrated in preclinical\\ntumor models of TNBC [103]. While oncorine (H101) and talimogene laherparepvec (T-\\nVEC) have been approved by the Chinese Food and Drug Administration and the FDA\\nfor the treatment of head and neck cancer and melanoma, respectively, clinical studies\\nof OVs in TNBC are still in their infancy with few results published. A phase I trial\\n(NCT03256344) evaluated the safety of intrahepatic injection of T-VEC in combination\\nwith intravenous atezolizumab in patients with mTNBC or colorectal cancer, and no dose-\\nlimiting toxicity (DLT) was seen in the four TNBC patients who could be evaluated [104]. In\\naddition, scientists have developed chimeric oncolytic poxvirus that can express anti-PD-L1\\nantibodies and are currently in a phase I trial. Several trials combining PD-(L)1 blockade\\nand OVs are underway (Table 3).\\n8.4. ACT and PD-(L)1 Inhibitors\\nACT refers to a therapy in which immune-active cells are isolated from tumor patients,\\nexpanded, modiﬁed, and characterized in vitro, and then infused back for the purpose of\\ndirectly killing tumor cells or stimulating an immune response to kill tumor cells. Adoptive\\nTILs and genetically modiﬁed T cells expressing modiﬁed T cell receptors (TCR-T) or\\nchimeric antigen receptors (CAR-T) are currently the most studied, while therapies such\\nas adoptive NK cells and cytokine-induced killer cells (CIK) are also gaining attention.\\nHowever, in the ﬁeld of TNBC, this treatment is still in early phase trials. ACT can directly\\nincrease populations of immune killer cells in cold tumors, but its efﬁcacy may be greatly\\nreduced due to the presence of immune checkpoints. Therefore, combining ACT with\\nPD-(L)1 inhibitors is a promising approach to enhance anti-tumor efﬁcacy. A phase Ib/II\\ntrial (NCT03387085) ﬁrst demonstrated a safe and tolerable combination treatment of low-\\ndose chemoradiation, TCV, NK cells therapy, and a PD-L1 inhibitor as third- or greater-line\\ntherapy for mTNBC. The ORR was 56% and the disease control rate was 78% in the initial\\nenrollment of 9 patients [105] (Table 3). These preliminary encouraging results provide\\nideas for additional combination therapies. More outcomes are to be expected.\\n9. Potential Therapeutic Targets for Reversing Cold Tumors\\nAlthough considerable clinical trials have been conducted on TNBC patients with some\\nachievements, the mechanisms of tumor immunity are still being explored. Meanwhile,\\nsome potential therapeutic targets that can convert cold tumors have been identiﬁed.\\nAccording to a fundamental study, the mRNA N6-methyladenosine (m6A)-binding\\nprotein YTHDF1 can recognize and bind transcripts encoding lysosomal proteases, which\\nin turn increases the translation of lysosomal histone proteases in DCs, resulting in the\\nimpaired presentation of tumor neoantigens and T cell initiation. In addition, the anti-\\ntumor effect of PD-L1 blockade was enhanced in the YTHDF1-/- tumor-bearing mouse\\nmodels [106]. These suggest that the combination of ICIs and YTHDF1 depletion may be\\nCancers 2023, 15, 321\\n18 of 28\\na potential new therapeutic strategy. Research on innate immunity activation by STING\\nagonists are also proceeding in full swing.\\nTumor stromal ﬁbrosis is one mechanism by which T cell inﬁltration is restricted in\\ncold tumors. A recent study showed that discoidin domain receptor 1 (DDR1), a collagen\\nreceptor with tyrosine kinase activity, can enhance the collagen ﬁbril alignment and impede\\nimmune inﬁltration through the binding of its extracellular domain (ECD) to collagen.\\nConversely, ECD-neutralizing antibodies could disrupt this alignment, attenuate immune\\nrejection, and inhibit tumor growth [107]. This study suggests that disruption of tumor\\nstromal ﬁbrosis is one way to convert cold tumors and holds promise to improve anti-tumor\\nefﬁcacy in combination with ICIs in the future.\\nThere are also a growing number of studies focusing on the impact of the host nervous\\nsystem and commensal microbes on anti-tumor immunity. The effects of sympathetic-β-\\nadrenergic signaling on MDSCs’ survival, expression of immunosuppressive molecules\\nsuch as arginase-I and PD-L1, and proliferation and function of effector T cells in tumor\\ntissues have been revealed in mouse tumor models. A reduction of this signaling con-\\ntributed to the conversion of tumors to an immunoreactive tumor microenvironment, and\\nthis conversion signiﬁcantly improved the efﬁcacy of PD-1 ICI [108,109]. A multi-omics\\nanalysis of a TNBC cohort showed that genera under Clostridiales and the related metabo-\\nlite trimethylamine N-oxide (TMAO) were positively associated with the TIME activation\\nand immunotherapy efﬁcacy [110]. Although showing promising prospects for converting\\ncold tumors and improving the efﬁcacy of immunotherapy, these aspects of TNBC have\\nnot been studied sufﬁciently as of now, and more research is required.\\n10. Biomarkers for Predicting Immunological Response\\n10.1. PD-L1 Expression and TILs\\nThe predictive value of PD-L1 expression for the efﬁcacy of PD-(L)1 inhibitors in TNBC\\nhas been demonstrated in several trials [27,40,44]. However, there are still limitations re-\\nlated to choosing PD-L1 as a predictive marker. First, PD-L1 expression is spatiotemporally\\nvariable. It not only evolves over time with disease progression but also varies by metastatic\\nlocation, with the highest prevalence of positivity in lymph nodes and the lowest in the\\nliver [111]. Moreover, PD-L1 status was found to be less predictive of efﬁcacy in early-stage\\nTNBC compared to late-stage disease, as discussed previously [55,60]. Second, there are a\\nvariety of immunohistochemistry assays for PD-L1 expression status detection, but a lack\\nof standard test methods. The ﬁve mainstream assays commonly used from two companies\\nare the 22C3, 28-8, and 73-10 assays on the DAKO AutoStainer Link 48 platform and the\\nSP142 and SP263 assays on the Ventana Benchmark Ultra platform. These assays use differ-\\nent primary antibodies to assess PD-L1 expression in tumor cells and/or tumor-inﬁltrating\\nimmune cells with different scoring criteria and deﬁnitions of PD-L1 positivity [112,113].\\nThe 22C3 assay uses a combined positive score (CPS) based on both tumor cells and im-\\nmune cells (lymphocytes and macrophages) staining to determine PD-L1-positive tumors\\nin mTNBC patients for pembrolizumab, with a cutoff value of 10 in KEYNOTE-355. In\\ncontrast, the SP142 assay uses the percentage of stained tumor-inﬁltrating immune cells\\n(IC) to the tumor area to determine PD-L1-positive tumors for atezolizumab, with a cutoff\\nvalue of 1% in IMpassion130. Occasionally, in some trials, the percentage of tumor cells\\n(TC) stained is also used to assess PD-L1 expression [27,57]. It is worth noting that the three\\nscoring systems differ signiﬁcantly in terms of algorithms and the types of cells evaluated.\\nA comparative study analyzed the concordance between different PD-L1 assays and the\\nrelationship with patient clinical outcomes. The results showed poor equivalence between\\nthe different assays and they were not analytically interchangeable. SP142 assay (≥1%\\nIC) detected the least prevalence of PD-L1 positivity at 46.4% (74.9% for SP263 (≥1% IC)\\nand 80.9% for 22C3 (CPS ≥1)), with almost all of these patients captured by the other\\ntwo assays, and these patients had better clinical outcome improvement with the applica-\\ntion of atezolizumab [114]. In addition, tissue ﬁxation methods and subjective factors of\\npathologists may also affect PD-L1 results [115,116]. Finally, with the advent of some new\\nCancers 2023, 15, 321\\n19 of 28\\ntreatment combinations, some patients who are negative for PD-L1 can also proﬁt from ICIs,\\nsince some drugs upregulate PD-L1 expression during treatment, which is unpredictable\\nbefore therapy. Conclusively, the predictive value of PD-L1 expression for the efﬁcacy of\\nPD-(L)1 blockade is undeniable, but is not a determinant. Therefore, caution should be\\nexercised when making treatment decisions based on PD-L1 status.\\nTILs are a cell population consisting of T cells, B cells, and NK cells, including both\\ntumor-killing and immunosuppressive cells [117]. As with PD-L1 expression, TILs are\\nalso spatiotemporally variable [51,111]. In KEYNOTE-086, higher levels of TILs were\\nassociated with better ORR [118]. In a biomarker analysis of KEYNOTE-119, high TIL levels\\nwere related to better clinical outcomes with pembrolizumab, but not with chemotherapy.\\nPatients with TNBC and TILs ≥5% survived longer with pembrolizumab than with\\nchemotherapy, but this difference was not signiﬁcant [119]. In contrast, IMpassion130\\nshowed that stromal TIL (sTIL) levels were synergistic with PD-L1 expression; when\\nassessed independent of PD-L1, TILs failed to provide prognostic value [111]. A simple\\nmethod of section staining is recommended to quantify the extent of TIL inﬁltration [120].\\nTILs appear to be a promising biomarker for predicting the efﬁcacy of ICIs at a lower\\ncost, but more evidence is needed. Furthermore, in addition to the numerical level, the\\ncomposition ratio of cellular components, activation status, and spatial location distribution\\nof TILs are additional important factors that deserve further investigation when exploring\\nthe predictive effect of TILs on the efﬁcacy of immunotherapy.\\n10.2. TMB and Microsatellite Instability (MSI)/Mismatch Repair Deﬁciency (dMMR)\\nTumor mutational burden (TMB) is a measurement of the number of nonsynonymous\\nsomatic mutations in the genome of tumor cells [121]. When TMB > 10 mutations/Mb,\\nneoantigen production becomes common to tumor cells and can be recognized by TILs [121].\\nHigh TMB has been associated with efﬁcacy beneﬁts for ICIs in various tumors [122,123].\\nDespite being the highest TMB subtype of breast cancer, TNBC still has a low mutational\\nload compared to other tumors such as melanoma. One study showed that the median TMB\\nin breast cancer was 2.63 mut/Mb and only 5% of patients had high TMB (>10 mut/Mb),\\nwith metastatic tumors having higher TMB. Of these, the median mutational burden in\\nTNBC was 1.8 mut/Mb [124]. Data from 149 TNBC patients in the GeparNuevo trial\\nshowed a median TMB of 1.52 mut/Mb, and continuous TMB independently predicted\\npCR [125]. Data from 253 patients in the KEYNOTE-119 trial showed a positive correlation\\nbetween TMB and clinical response to pembrolizumab, but not to chemotherapy [126].\\nHowever, in another study, high TMB failed to predict response to ICIs. In the TNBC\\nsubgroup, 10 patients with high TMB (>10 mut/Mb) had an ORR of 0, compared to 20.5%\\nin patients with low TMB. The reason for the immaturity of TMB as a predictor for the\\nefﬁcacy of ICIs is mainly due to the fact that antigens generated by tumor mutations may\\nnot be immunogenic [127].\\nIn fact, MSI/dMMR is one possible cause of high TMB [128]. Although MSI-high/dMMR\\nhas been shown to be associated with immunotherapy efﬁcacy in a variety of tumors and\\nhas been approved by the FDA as a biomarker for the application of PD-1 blockers in\\nsolid tumors [129–131], its frequency is extremely low in TNBC, even in the high-level TIL\\nsubtype [132,133]. Based on the available evidence, MSI-high/dMMR is not a practical\\nbiomarker for screening TNBC patients who are or are not suitable for immunotherapy.\\nThe aforementioned biomarkers predict PD-(L)1 blockade responses either from the\\nperspective of the TIME or the tumor itself, but none of them are perfect. For now, the\\ncombination of several biomarkers to screen suitable patients may be more reliable. The\\nmost critical point in selecting immunotherapy-sensitive individuals and giving the most\\nappropriate therapy is to identify the immune deﬁciency at the tumor site; this is quite dif-\\nﬁcult, especially in patients with metastases, as many mechanisms of immune escape may\\nexist. However, with further understanding of tumor immune mechanisms, individualized\\nand precise immunotherapy becomes increasingly possible, especially with the inﬂux of\\nnovel genomics, single-cell sequencing, and artiﬁcial intelligence technologies.\\nCancers 2023, 15, 321\\n20 of 28\\n11. Pseudoprogression and Immune-Related Adverse Events\\nThe unique biological mechanisms of immunotherapy-ﬁghting tumors enable a long-\\nterm or even complete response. However, they also require a long response time, which\\nmay lead to the emergence of immune-related patterns of pseudoprogression, hyperpro-\\ngression, or a mixed response [134–137]. Pseudoprogression refers to an initial increase in\\ntumor size followed by a decrease of tumor burden, and is associated with immune cell\\ninﬁltration, edema, or necrosis due to immunotherapy [138]. Pseudoprogression after im-\\nmunotherapy for TNBC has been reported [139], but incidence rates based on large samples\\nare lacking. Previous data suggest that the incidence of pseudoprogression in solid tumors\\nis less than 10%, which implies that some patients who present with progression after\\ntreatment are likely to have true progression [140]. Although the immune-related response\\ncriteria (irRC), immune-related RECIST (irRECIST), and immune RECIST (iRECIST) have\\nbeen published to assist clinicians in evaluating response to immunotherapy, these are not\\nyet widely used in clinical practice [141–143]. Therefore, in patients presenting with tumor\\nprogression after initial immune-based therapy, clinicians must assess patients’ clinical\\nconditions and toxicity responses thoroughly before carefully deciding on subsequent\\ntreatments. This is especially important when immunotherapy is used in combination with\\nother therapies that have tumor-killing effects.\\nAlong with durable anti-tumor activity comes immune-related adverse events (irAEs)\\nthat are distinct from the toxicity of conventional chemotherapy. These irAEs vary according\\nto the type of immunotherapy, but there are some common features among ICIs [144].\\nFirst, irAEs are mostly organ-speciﬁc, occurring mainly in immune-related organs, with\\nrare cases reported involving multiple organ events at the same time [144,145]. Second,\\nwhile some irAEs occur rapidly, others are regularly delayed, even after treatment [144].\\nFinally, there is no clear relationship between irAEs and ICI dose [144,146]. These features\\nremind us that irAEs require long-term management that cannot be limited to the period of\\ndosing. Furthermore, the appearance of some toxicities often requires interruptions or even\\npermanent discontinuation of dosing. The most common irAEs in breast cancer patients are\\nrashes, followed by thyroid dysfunction (hypothyroidism > hyperthyroidism), and infusion\\nreactions [147]. Although these irAEs are not usually fatal, they often require high-dose\\ncorticosteroid treatment, which may lead to a reduced efﬁcacy of immunotherapy along\\nwith additional side effects. On the other hand, patients with permanent endocrine organ\\ndamage (such as the thyroid) are required to take therapeutic drugs for the rest of their\\nlife and their quality of life is therefore compromised. Notably, the current addition of\\nPD-(L)1 inhibitors to conventional therapies in TNBC patients has already increased the\\nincidence of associated irAEs, although severe incident rates are less than 10% [147–149].\\nLessons from other tumor types show us that some novel immunotherapies, as well as\\ncombination treatments with immunotherapies, can lead to a higher incidence of irAEs\\nand even severe cytokine release syndromes [150–152]. Therefore, the introduction of\\nnovel immunotherapies and new combination regimens is something that should be given\\nextra attention. Early identiﬁcation and management of irAEs is extremely important.\\nOf particular consideration is the impact of immunotherapy on fertility, as a signiﬁcant\\nproportion of patients with TNBC are younger than 40 years of age.\\n12. Conclusions\\nTNBC is the subtype of breast cancer with the worst prognosis. To date, although\\nseveral targeted drugs have been approved for the treatment of TNBC, the urgent need\\nfor improved survival has not been met. The practice of immunotherapy in TNBC is just\\nbeginning to take off. An advantage of the later start in this ﬁeld is that experience can be\\nlearned from other tumor types, both successful and failed. Although some progress has\\nbeen made with respect to ICIs for TNBC, many challenges remain. Clinical results show\\nthat only a small proportion of patients with TNBC actually beneﬁt from immunotherapy.\\nThus, identifying the target population and expanding the efﬁcacy is a top priority. Overall,\\ncombination treatment is the way forward, but the combination treatment mode, sequence,\\nCancers 2023, 15, 321\\n21 of 28\\ndosage, and duration require further exploration and careful attention should be focused\\non balancing economics and toxicity. As a growing number of preclinical and clinical\\nstudies are conducted in this ﬁeld, we expect to reach the ultimate goal: to select the most\\nsuitable patients for immunotherapy, to give the most appropriate immunotherapy or\\nimmune-combination therapy, to accurately assess the efﬁcacy of the treatment, and to\\nachieve optimal therapeutic results with minimal toxic damage.\\nAuthor Contributions: Conceptualization, L.L. and Z.F.; methodology, L.L.; software, L.L.; validation,\\nL.L., F.Z., and Z.L.; resources, L.L.; data curation, L.L. and F.Z.; writing—original draft preparation,\\nL.L.; writing—review and editing, L.L., F.Z., and Z.L.; visualization, L.L.; supervision, Z.F. All authors\\nhave read and agreed to the published version of the manuscript.\\nFunding: This research received no external funding.\\nConﬂicts of Interest: The authors declare no conﬂict of interest.\\nReferences\\n1.\\nLin, N.U.; Vanderplas, A.; Hughes, M.E.; Theriault, R.L.; Edge, S.B.; Wong, Y.N.; Blayney, D.W.; Niland, J.C.; Winer, E.P.; Weeks,\\nJ.C. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the\\nNational Comprehensive Cancer Network. Cancer 2012, 118, 5463–5472. [CrossRef] [PubMed]\\n2.\\nDent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A.\\nTriple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13, 4429–4434. [CrossRef]\\n3.\\nNedeljkovic, M.; Damjanovic, A. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to\\nthe Challenge. Cells 2019, 8, 957. [CrossRef]\\n4.\\nLehmann, B.D.; Jovanovic, B.; Chen, X.; Estrada, M.V.; Johnson, K.N.; Shyr, Y.; Moses, H.L.; Sanders, M.E.; Pietenpol, J.A.\\nReﬁnement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS\\nOne 2016, 11, e0157368. [CrossRef]\\n5.\\nBurstein, M.D.; Tsimelzon, A.; Poage, G.M.; Covington, K.R.; Contreras, A.; Fuqua, S.A.; Savage, M.I.; Osborne, C.K.; Hilsenbeck,\\nS.G.; Chang, J.C.; et al. Comprehensive genomic analysis identiﬁes novel subtypes and targets of triple-negative breast cancer.\\nClin. Cancer Res. 2015, 21, 1688–1698. [CrossRef]\\n6.\\nJiang, Y.Z.; Ma, D.; Suo, C.; Shi, J.; Xue, M.; Hu, X.; Xiao, Y.; Yu, K.D.; Liu, Y.R.; Yu, Y.; et al. Genomic and Transcriptomic\\nLandscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell 2019, 35, 428–440.e5. [CrossRef]\\n[PubMed]\\n7.\\nDe Melo Gagliato, D.; Cortes, J.; Curigliano, G.; Loi, S.; Denkert, C.; Perez-Garcia, J.; Holgado, E. Tumor-inﬁltrating lymphocytes\\nin Breast Cancer and implications for clinical practice. Biochim. Biophys. Acta. Rev. Cancer 2017, 1868, 527–537. [CrossRef]\\n[PubMed]\\n8.\\nMittendorf, E.A.; Philips, A.V.; Meric-Bernstam, F.; Qiao, N.; Wu, Y.; Harrington, S.; Su, X.; Wang, Y.; Gonzalez-Angulo, A.M.;\\nAkcakanat, A.; et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2014, 2, 361–370. [CrossRef]\\n[PubMed]\\n9.\\nKwa, M.J.; Adams, S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. Cancer 2018, 124,\\n2086–2103. [CrossRef]\\n10.\\nDunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape.\\nNat. Immunol. 2002, 3, 991–998. [CrossRef] [PubMed]\\n11.\\nChen, D.S.; Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013, 39, 1–10. [CrossRef]\\n12.\\nCampoli, M.; Ferrone, S. HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic signiﬁcance. Oncogene\\n2008, 27, 5869–5885. [CrossRef]\\n13.\\nSchreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion.\\nScience 2011, 331, 1565–1570. [CrossRef] [PubMed]\\n14.\\nKim, J.M.; Chen, D.S. Immune escape to PD-L1/PD-1 blockade: Seven steps to success (or failure). Ann. Oncol. 2016, 27,\\n1492–1504. [CrossRef] [PubMed]\\n15.\\nDou, A.; Fang, J. Heterogeneous Myeloid Cells in Tumors. Cancers 2021, 13, 3772. [CrossRef] [PubMed]\\n16.\\nSpranger, S. Mechanisms of tumor escape in the context of the T-cell-inﬂamed and the non-T-cell-inﬂamed tumor microenviron-\\nment. Int. Immunol. 2016, 28, 383–391. [CrossRef]\\n17.\\nDyck, L.; Mills, K.H.G. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur. J. Immunol. 2017, 47,\\n765–779. [CrossRef] [PubMed]\\n18.\\nFeng, M.; Jiang, W.; Kim, B.Y.S.; Zhang, C.C.; Fu, Y.X.; Weissman, I.L. Phagocytosis checkpoints as new targets for cancer\\nimmunotherapy. Nat. Rev. Cancer. 2019, 19, 568–586. [CrossRef]\\n19.\\nSanmamed, M.F.; Chen, L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 2018, 175,\\n313–326. [CrossRef]\\nCancers 2023, 15, 321\\n22 of 28\\n20.\\nChen, D.S.; Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 2017, 541, 321–330. [CrossRef]\\n21.\\nXiao, Y.; Ma, D.; Zhao, S.; Suo, C.; Shi, J.; Xue, M.Z.; Ruan, M.; Wang, H.; Zhao, J.; Li, Q.; et al. Multi-Omics Proﬁling Reveals\\nDistinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clin.\\nCancer Res. 2019, 25, 5002–5014. [CrossRef] [PubMed]\\n22.\\nGruosso, T.; Gigoux, M.; Manem, V.S.K.; Bertos, N.; Zuo, D.; Perlitch, I.; Saleh, S.M.I.; Zhao, H.; Souleimanova, M.; Johnson,\\nR.M.; et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J. Clin. Investig. 2019, 129,\\n1785–1800. [CrossRef] [PubMed]\\n23.\\nBareche, Y.; Buisseret, L.; Gruosso, T.; Girard, E.; Venet, D.; Dupont, F.; Desmedt, C.; Larsimont, D.; Park, M.; Rothe, F.; et al.\\nUnraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.\\nJ. Natl. Cancer Inst. 2020, 112, 708–719. [CrossRef] [PubMed]\\n24.\\nKeir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26,\\n677–704. [CrossRef] [PubMed]\\n25.\\nBalar, A.V.; Weber, J.S. PD-1 and PD-L1 antibodies in cancer: Current status and future directions. Cancer Immunol. Immunother.\\n2017, 66, 551–564. [CrossRef]\\n26.\\nSolinas, C.; Aiello, M.; Rozali, E.; Lambertini, M.; Willard-Gallo, K.; Migliori, E. Programmed cell death-ligand 2: A neglected but\\nimportant target in the immune response to cancer? Transl. Oncol. 2020, 13, 100811. [CrossRef]\\n27.\\nNanda, R.; Chow, L.Q.; Dees, E.C.; Berger, R.; Gupta, S.; Geva, R.; Pusztai, L.; Pathiraja, K.; Aktan, G.; Cheng, J.D.; et al.\\nPembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J. Clin. Oncol. 2016, 34,\\n2460–2467. [CrossRef]\\n28.\\nAdams, S.; Loi, S.; Toppmeyer, D.; Cescon, D.W.; De Laurentiis, M.; Nanda, R.; Winer, E.P.; Mukai, H.; Tamura, K.; Armstrong, A.;\\net al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B\\nof the phase II KEYNOTE-086 study. Ann. Oncol. 2019, 30, 405–411. [CrossRef]\\n29.\\nAdams, S.; Schmid, P.; Rugo, H.S.; Winer, E.P.; Loirat, D.; Awada, A.; Cescon, D.W.; Iwata, H.; Campone, M.; Nanda, R.;\\net al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II\\nKEYNOTE-086 study. Ann. Oncol. 2019, 30, 397–404. [CrossRef]\\n30.\\nWiner, E.P.; Lipatov, O.; Im, S.A.; Goncalves, A.; Munoz-Couselo, E.; Lee, K.S.; Schmid, P.; Tamura, K.; Testa, L.; Witzel, I.;\\net al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A\\nrandomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22, 499–511. [CrossRef]\\n31.\\nDirix, L.Y.; Takacs, I.; Jerusalem, G.; Nikolinakos, P.; Arkenau, H.T.; Forero-Torres, A.; Boccia, R.; Lippman, M.E.; Somer, R.;\\nSmakal, M.; et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b\\nJAVELIN Solid Tumor study. Breast. Cancer Res. Tr. 2018, 167, 671–686. [CrossRef] [PubMed]\\n32.\\nEmens, L.A.; Cruz, C.; Eder, J.P.; Braiteh, F.; Chung, C.; Tolaney, S.M.; Kuter, I.; Nanda, R.; Cassier, P.A.; Delord, J.P.; et al.\\nLong-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative\\nBreast Cancer A Phase 1 Study. Jama. Oncol. 2019, 5, 74–82. [CrossRef] [PubMed]\\n33.\\nBachelot, T.; Filleron, T.; Bieche, I.; Arnedos, M.; Campone, M.; Dalenc, F.; Coussy, F.; Sablin, M.P.; Debled, M.; Lefeuvre-\\nPlesse, C.; et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: The randomized phase II\\nSAFIR02-BREAST IMMUNO trial. Nat. Med. 2021, 27, 250–255. [CrossRef] [PubMed]\\n34.\\nPusztai, L.; Barlow, W.E.; Ganz, P.A.; Henry, N.L.; White, J.; Jagsi, R.; Mammen, J.M.V.; Lew, D.; Mejia, J.; Karantza, V.; et al.\\nSWOG S1418/NRG-BR006: A randomized, phase III trial to evaluate the efﬁcacy and safety of MK-3475 as adjuvant therapy for\\ntriple receptor-negative breast cancer with ≥1 cm residual invasive cancer or positive lymph nodes (> pN1mic) after neoadjuvant\\nchemotherapy. Cancer Res. 2018, 78 (Suppl. 4), OT1-02-04. [CrossRef]\\n35.\\nConte, P.F.; Dieci, M.V.; Bisagni, G.; De Laurentiis, M.; Tondini, C.A.; Schmid, P.; De Salvo, G.L.; Moratello, G.; Guarneri, V. Phase\\nIII randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer\\npatients: The A-BRAVE trial. J. Clin. Oncol. 2020, 38, TPS598. [CrossRef]\\n36.\\nGalluzzi, L.; Buque, A.; Kepp, O.; Zitvogel, L.; Kroemer, G. Immunological Effects of Conventional Chemotherapy and Targeted\\nAnticancer Agents. Cancer Cell 2015, 28, 690–714. [CrossRef]\\n37.\\nZitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat. Rev.\\nImmunol. 2006, 6, 715–727. [CrossRef]\\n38.\\nWu, J.; Waxman, D.J. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.\\nCancer Lett. 2018, 419, 210–221. [CrossRef]\\n39.\\nAhlmann, M.; Hempel, G. The effect of cyclophosphamide on the immune system: Implications for clinical cancer therapy. Cancer\\nChemoth. Pharm. 2016, 78, 661–671. [CrossRef]\\n40.\\nCortes, J.; Cescon, D.W.; Rugo, H.S.; Nowecki, Z.; Im, S.A.; Yusof, M.M.; Gallardo, C.; Lipatov, O.; Barrios, C.H.; Holgado, E.; et al.\\nPembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or\\nmetastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial.\\nLancet 2020, 396, 1817–1828. [CrossRef]\\n41.\\nCortes, J.; Rugo, H.S.; Cescon, D.W.; Im, S.A.; Yusof, M.M.; Gallardo, C.; Lipatov, O.; Barrios, C.H.; Perez-Garcia, J.; Iwata, H.; et al.\\nPembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N. Engl. J. Med. 2022, 387, 217–226. [CrossRef]\\n[PubMed]\\nCancers 2023, 15, 321\\n23 of 28\\n42.\\nTolaney, S.M.; Kalinsky, K.; Kaklamani, V.G.; D’Adamo, D.R.; Aktan, G.; Tsai, M.L.; O’Regan, R.M.; Kaufman, P.A.; Wilks, S.T.;\\nAndreopoulou, E.; et al. Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1):\\nA Phase Ib/II Study. Clin. Cancer Res. 2021, 27, 3061–3068. [CrossRef]\\n43.\\nAdams, S.; Diamond, J.R.; Hamilton, E.; Pohlmann, P.R.; Tolaney, S.M.; Chang, C.W.; Zhang, W.; Iizuka, K.; Foster, P.G.; Molinero,\\nL.; et al. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival\\nFollow-up: A Phase 1b Clinical Trial. Jama. Oncol. 2019, 5, 334–342. [CrossRef] [PubMed]\\n44.\\nSchmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Dieras, V.; Hegg, R.; Im, S.A.; Shaw Wright, G.; et al.\\nAtezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N. Engl. J. Med. 2018, 379, 2108–2121. [CrossRef]\\n[PubMed]\\n45.\\nSchmid, P.; Rugo, H.S.; Adams, S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Dieras, V.; Henschel, V.; Molinero, L.; Chui, S.Y.; et al.\\nAtezolizumab plus nab-paclitaxel as ﬁrst-line treatment for unresectable, locally advanced or metastatic triple-negative breast\\ncancer (IMpassion130): Updated efﬁcacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.\\n2020, 21, 44–59. [CrossRef]\\n46.\\nEmens, L.A.; Adams, S.; Barrios, C.H.; Dieras, V.; Iwata, H.; Loi, S.; Rugo, H.S.; Schneeweiss, A.; Winer, E.P.; Patel, S.; et al. First-\\nline atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130\\nﬁnal overall survival analysis. Ann. Oncol. 2021, 32, 983–993. [CrossRef]\\n47.\\nMiles, D.; Gligorov, J.; Andre, F.; Cameron, D.; Schneeweiss, A.; Barrios, C.; Xu, B.; Wardley, A.; Kaen, D.; Andrade, L.; et al.\\nPrimary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of ﬁrst-line paclitaxel with or\\nwithout atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann. Oncol. 2021, 32, 994–1004.\\n[CrossRef]\\n48.\\nFranzoi, M.A.; de Azambuja, E. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials-how to\\nexplain different results? ESMO Open 2020, 5, e001112. [CrossRef]\\n49.\\nZhang, Y.Y.; Chen, H.Y.; Mo, H.N.; Hu, X.D.; Gao, R.R.; Zhao, Y.H.; Liu, B.L.; Niu, L.J.; Sun, X.Y.; Yu, X.; et al. Single-cell analyses\\nreveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 2021, 39,\\n1578–1593.e8. [CrossRef]\\n50.\\nVoorwerk, L.; Slagter, M.; Horlings, H.M.; Sikorska, K.; van de Vijver, K.K.; de Maaker, M.; Nederlof, I.; Kluin, R.J.C.; Warren, S.;\\nOng, S.; et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade:\\nThe TONIC trial. Nat. Med. 2019, 25, 920–928. [CrossRef]\\n51.\\nHutchinson, K.E.; Yost, S.E.; Chang, C.W.; Johnson, R.M.; Carr, A.R.; McAdam, P.R.; Halligan, D.L.; Chang, C.C.; Schmolze, D.;\\nLiang, J.; et al. Comprehensive Proﬁling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals\\nImmune Phenotype Shifts. Clin. Cancer Res. 2020, 26, 657–668. [CrossRef]\\n52.\\nSzekely, B.; Bossuyt, V.; Li, X.; Wali, V.B.; Patwardhan, G.A.; Frederick, C.; Silber, A.; Park, T.; Harigopal, M.; Pelekanou, V.; et al.\\nImmunological differences between primary and metastatic breast cancer. Ann. Oncol. 2018, 29, 2232–2239. [CrossRef] [PubMed]\\n53.\\nNanda, R.; Liu, M.C.; Yau, C.; Shatsky, R.; Pusztai, L.; Wallace, A.; Chien, A.J.; Forero-Torres, A.; Ellis, E.; Han, H.; et al. Effect of\\nPembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer:\\nAn Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020, 6, 676–684. [CrossRef] [PubMed]\\n54.\\nSchmid, P.; Salgado, R.; Park, Y.H.; Munoz-Couselo, E.; Kim, S.B.; Sohn, J.; Im, S.A.; Foukakis, T.; Kuemmel, S.; Dent, R.; et al.\\nPembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from\\nthe phase 1b open-label, multicohort KEYNOTE-173 study. Ann. Oncol. 2020, 31, 569–581. [CrossRef] [PubMed]\\n55.\\nSchmid, P.; Cortes, J.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y.H.; Hui, R.; Harbeck, N.; et al.\\nPembrolizumab for Early Triple-Negative Breast Cancer. N. Engl. J. Med. 2020, 382, 810–821. [CrossRef]\\n56.\\nSchmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y.H.; Hui, R.; et al. Event-free\\nSurvival with Pembrolizumab in Early Triple-Negative Breast Cancer. N. Engl. J. Med. 2022, 386, 556–567. [CrossRef]\\n57.\\nLoibl, S.; Untch, M.; Burchardi, N.; Huober, J.; Sinn, B.V.; Blohmer, J.U.; Grischke, E.M.; Furlanetto, J.; Tesch, H.; Hanusch, C.; et al.\\nA randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in\\nearly triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol. 2019, 30, 1279–1288.\\n[CrossRef]\\n58.\\nLoibl, S.; Schneeweiss, A.; Huober, J.; Braun, M.; Rey, J.; Blohmer, J.U.; Furlanetto, J.; Zahm, D.M.; Hanusch, C.; Thomalla, J.;\\net al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete\\nresponse. Ann. Oncol. 2022, 33, 1149–1158. [CrossRef]\\n59.\\nGianni, L.; Huang, C.S.; Egle, D.; Bermejo, B.; Zamagni, C.; Thill, M.; Anton, A.; Zambelli, S.; Bianchini, G.; Russo, S.; et al.\\nPathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk\\nand locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann. Oncol. 2022, 33, 534–543. [CrossRef]\\n60.\\nMittendorf, E.A.; Zhang, H.; Barrios, C.H.; Saji, S.; Jung, K.H.; Hegg, R.; Koehler, A.; Sohn, J.; Iwata, H.; Telli, M.L.; et al.\\nNeoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo\\nand chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase\\n3 trial. Lancet 2020, 396, 1090–1100. [CrossRef]\\n61.\\nMcLaughlin, M.; Patin, E.C.; Pedersen, M.; Wilkins, A.; Dillon, M.T.; Melcher, A.A.; Harrington, K.J. Inﬂammatory microenviron-\\nment remodelling by tumour cells after radiotherapy. Nat. Rev. Cancer 2020, 20, 203–217. [CrossRef]\\nCancers 2023, 15, 321\\n24 of 28\\n62.\\nHo, A.Y.; Barker, C.A.; Arnold, B.B.; Powell, S.N.; Hu, Z.I.; Gucalp, A.; Lebron-Zapata, L.; Wen, H.Y.; Kallman, C.; D’Agnolo,\\nA.; et al. A phase 2 clinical trialassessing theefﬁcacy and safety of pembrolizumab and radiotherapy in patients with metastatic\\ntriple-negative breast cancer. Cancer 2020, 126, 850–860. [CrossRef] [PubMed]\\n63.\\nDavid, S.; Savas, P.; Siva, S.; White, M.; Neeson, M.W.; White, S.; Marx, G.; Cheuk, R.; Grogan, M.; Farrell, M.; et al. A randomised\\nphase II trial of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with atezolizumab in patients\\nwith advanced triple negative breast cancer (AZTEC trial). Cancer Res. 2022, 82, PD10–02. [CrossRef]\\n64.\\nPantelidou, C.; Sonzogni, O.; De Oliveria Taveira, M.; Mehta, A.K.; Kothari, A.; Wang, D.; Visal, T.; Li, M.K.; Pinto, J.; Castrillon,\\nJ.A.; et al. PARP Inhibitor Efﬁcacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in\\nBRCA-Deﬁcient Models of Triple-Negative Breast Cancer. Cancer Discov. 2019, 9, 722–737. [CrossRef] [PubMed]\\n65.\\nSen, T.; Rodriguez, B.L.; Chen, L.; Corte, C.M.D.; Morikawa, N.; Fujimoto, J.; Cristea, S.; Nguyen, T.; Diao, L.; Li, L.; et al. Targeting\\nDNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.\\nCancer Discov. 2019, 9, 646–661. [CrossRef] [PubMed]\\n66.\\nReislander, T.; Lombardi, E.P.; Groelly, F.J.; Miar, A.; Porru, M.; Di Vito, S.; Wright, B.; Lockstone, H.; Biroccio, A.; Harris, A.; et al.\\nBRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat. Commun. 2019, 10,\\n3143. [CrossRef]\\n67.\\nVinayak, S.; Tolaney, S.M.; Schwartzberg, L.; Mita, M.; McCann, G.; Tan, A.R.; Wahner-Hendrickson, A.E.; Forero, A.; Anders, C.;\\nWulf, G.M.; et al. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic\\nTriple-Negative Breast Cancer. JAMA Oncol. 2019, 5, 1132–1140. [CrossRef]\\n68.\\nSenkus-Konefka, E.; Domchek, S.M.; Im, S.A.; Xu, B.; Armstrong, A.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Conte, P.; et al.\\nSubgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients\\nwith HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Eur. J. Cancer 2018, 92, S19–S20.\\n[CrossRef]\\n69.\\nEiermann, W.; Rugo, H.S.; Diab, S.; Ettl, J.; Hurvitz, S.A.; Goncalves, A. Analysis of germline BRCA1/2 mutated (gBRCA(mut))\\nhormone receptor-positive (HR plus ) and triple negative breast cancer (TNBC) treated with talazoparib (TALA). J. Clin. Oncol.\\n2018, 36, 1070. [CrossRef]\\n70.\\nPusztai, L.; Yau, C.; Wolf, D.M.; Han, H.S.; Du, L.; Wallace, A.M.; String-Reasor, E.; Boughey, J.C.; Chien, A.J.; Elias, A.D.; et al.\\nDurvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively\\nrandomized I-SPY2 trial. Cancer Cell. 2021, 39, 989–998 e985. [CrossRef]\\n71.\\nYu, J.F.; Song, Y.P.; Tian, W.Z. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J. Hematol. Oncol.\\n2020, 13, 45. [CrossRef]\\n72.\\nLi, F.; Ulrich, M.; Jonas, M.; Stone, I.J.; Linares, G.; Zhang, X.Q.; Westendorf, L.; Benjamin, D.R.; Law, C.L. Tumor-Associated\\nMacrophages Can Contribute to Antitumor Activity through Fc gamma R-Mediated Processing of Antibody-Drug Conjugates.\\nMol. Cancer Ther. 2017, 16, 1347–1354. [CrossRef]\\n73.\\nCao, A.T.; Higgins, S.; Stevens, N.; Gardai, S.J.; Sussman, D. Additional mechanisms of action of ladiratuzumab vedotin contribute\\nto increased immune cell activation within the tumor. Cancer Res. 2018, 78, 2742. [CrossRef]\\n74.\\nBauzon, M.; Drake, P.M.; Barﬁeld, R.M.; Cornali, B.M.; Rupniewski, I.; Rabuka, D. Maytansine-bearing antibody-drug conjugates\\ninduce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. Oncoimmunology 2019, 8, e1565859.\\n[CrossRef]\\n75.\\nMuller, P.; Martin, K.; Theurich, S.; Schreiner, J.; Savic, S.; Terszowski, G.; Lardinois, D.; Heinzelmann-Schwarz, V.A.; Schlaak, M.;\\nKvasnicka, H.M.; et al. Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by\\nStimulation of Dendritic Cells. Cancer Immunol. Res. 2014, 2, 741–755. [CrossRef] [PubMed]\\n76.\\nMcKenzie, J.A.; Mbofung, R.M.; Malu, S.; Zhang, M.; Ashkin, E.; Devi, S.; Williams, L.; Tieu, T.; Peng, W.Y.; Pradeep, S.; et al.\\nThe Effect of Topoisomerase I Inhibitors on the Efﬁcacy of T-Cell-Based Cancer Immunotherapy. Jnci.-J. Natl. Cancer I 2018, 110,\\n777–786. [CrossRef] [PubMed]\\n77.\\nHan, H.; Diab, S.; Alemany, C.; Basho, R.; Brown-Glaberman, U.; Meisel, J.; Pluard, T.; Cortes, J.; Dillon, P.; Ettl, J.; et al. Open\\nlabel phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for ﬁrst-line treatment of patients with\\nunresectable locally-advanced or metastatic triple-negative breast cancer. Cancer Res. 2020, 80, PD1-06. [CrossRef]\\n78.\\nBergholz, J.S.; Zhao, J.J. How Compensatory Mechanisms and Adaptive Rewiring Have Shaped Our Understanding of Therapeutic\\nResistance in Cancer. Cancer Res. 2021, 81, 6074–6077. [CrossRef] [PubMed]\\n79.\\nZhang, Z.; Richmond, A.; Yan, C. Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition\\nAugment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2022, 23,\\n7353. [CrossRef]\\n80.\\nZhang, Z.; Richmond, A. The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune\\nCheckpoint Inhibitors. Front Mol. Biosci. 2021, 8, 648663. [CrossRef]\\n81.\\nHo, P.C.; Meeth, K.M.; Tsui, Y.C.; Srivastava, B.; Bosenberg, M.W.; Kaech, S.M. Immune-based antitumor effects of BRAF inhibitors\\nrely on signaling by CD40L and IFNgamma. Cancer Res. 2014, 74, 3205–3217. [CrossRef] [PubMed]\\n82.\\nSchmid, P.; Savas, P.; Espinosa, E.; Boni, V.; Italiano, A.; White, S.; Cheng, K.; Lam, L.; Robert, L.; Laliman, V.; et al. Phase\\n1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as ﬁrst-line therapy for locally\\nadvanced/metastatic triple-negative breast cancer (TNBC). Cancer Res. 2021, 81, PS12-28. [CrossRef]\\nCancers 2023, 15, 321\\n25 of 28\\n83.\\nBrufsky, A.; Kim, S.B.; Zvirbule, Z.; Eniu, A.; Mebis, J.; Sohn, J.H.; Wongchenko, M.; Chohan, S.; Amin, R.; Yan, Y.; et al. A phase II\\nrandomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as ﬁrst-line treatment for patients with locally\\nadvanced or metastatic triple-negative breast cancer (COLET): Primary analysis. Ann. Oncol. 2021, 32, 652–660. [CrossRef]\\n84.\\nLanitis, E.; Irving, M.; Coukos, G. Targeting the tumor vasculature to enhance T cell activity. Curr. Opin. Immunol. 2015, 33, 55–63.\\n[CrossRef]\\n85.\\nCorzo, C.A.; Condamine, T.; Lu, L.; Cotter, M.J.; Youn, J.I.; Cheng, P.; Cho, H.I.; Celis, E.; Quiceno, D.G.; Padhya, T.; et al. HIF-1α\\nregulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010, 207,\\n2439–2453. [CrossRef] [PubMed]\\n86.\\nLi, Q.; Wang, Y.; Jia, W.; Deng, H.; Li, G.; Deng, W.; Chen, J.; Kim, B.Y.S.; Jiang, W.; Liu, Q.; et al. Low-Dose Anti-Angiogenic\\nTherapy Sensitizes Breast Cancer to PD-1 Blockade. Clin. Cancer Res. 2020, 26, 1712–1724. [CrossRef] [PubMed]\\n87.\\nLiu, J.Q.; Liu, Q.; Li, Y.; Li, Q.; Su, F.X.; Yao, H.R.; Su, S.C.; Wang, Q.R.; Jin, L.; Wang, Y.; et al. Efﬁcacy and safety of camrelizumab\\ncombined with apatinib in advanced triple-negative breast cancer: An open-label phase II trial. J. Immunother. Cancer 2020, 8,\\ne000696. [CrossRef] [PubMed]\\n88.\\nLiu, Z.; Li, M.; Jiang, Z.; Wang, X. A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer. Transl. Oncol. 2018,\\n11, 311–329. [CrossRef] [PubMed]\\n89.\\nSaleh, R.; Toor, S.M.; Khalaf, S.; Elkord, E. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1,\\nCTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells. Vaccines 2019, 7, 149. [CrossRef] [PubMed]\\n90.\\nRowshanravan, B.; Halliday, N.; Sansom, D.M. CTLA-4: A moving target in immunotherapy. Blood 2018, 131, 58–67. [CrossRef]\\n91.\\nTang, F.; Du, X.; Liu, M.; Zheng, P.; Liu, Y. Anti-CTLA-4 antibodies in cancer immunotherapy: Selective depletion of intratumoral\\nregulatory T cells or checkpoint blockade? Cell Biosci. 2018, 8, 30. [CrossRef]\\n92.\\nSanta-Maria, C.A.; Kato, T.; Park, J.H.; Flaum, L.E.; Jain, S.; Tellez, C.; Stein, R.M.; Shah, A.N.; Gross, L.; Uthe, R.; et al. Durvalumab\\nand tremelimumab in metastatic breast cancer (MBC): Immunotherapy and immunopharmacogenomic dynamics. J. Clin. Oncol.\\n2017, 35, 3052. [CrossRef]\\n93.\\nXu, B.H.; Li, Q.; Zhang, Q.Y.; Zhang, Y.; Ouyang, Q.C.; Zhang, Y.; Liu, Q.; Sun, T.; Xu, J.; Yang, J.; et al. Preliminary safety\\ntolerability & efﬁcacy results of KN046 (an anti-PD-L1/CTLA-4 bispeciﬁc antibody) in combination with Nab-paclitaxel in\\npatients with metastatic triple-negative breast cancer (mTNBC). Cancer Res. 2021, 81, 1660.\\n94.\\nGhalamfarsa, G.; Kazemi, M.H.; Mohseni, S.R.; Masjedi, A.; Hojjat-Farsangi, M.; Azizi, G.; Youseﬁ, M.; Jadidi-Niaragh, F. CD73 as\\na potential opportunity for cancer immunotherapy. Expert. Opin. Ther. Tar. 2019, 23, 127–142. [CrossRef] [PubMed]\\n95.\\nLoi, S.; Pommey, S.; Haibe-Kains, B.; Beavis, P.A.; Darcy, P.K.; Smyth, M.J.; Stagg, J. CD73 promotes anthracycline resistance and\\npoor prognosis in triple negative breast cancer. Proc. Natl. Acad. Sci. USA 2013, 110, 11091–11096. [CrossRef]\\n96.\\nBuisseret, L.; Loirat, D.; Aftimos, P.G.; Punie, K.; Maurer, C.; Debien, V.; Goncalves, A.; Ghiringhelli, F.; Taylor, D.; Clatot, F.;\\net al. Primary endpoint results of SYNERGY, a randomized phase II trial, ﬁrst-line chemo-immunotherapy trial of durvalumab,\\npaclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-\\nnegative breast cancer (TNBC). Ann. Oncol. 2022, 33 (Suppl.7), S808–S869. [CrossRef]\\n97.\\nShemesh, C.S.; Hsu, J.C.; Hosseini, I.; Shen, B.Q.; Rotte, A.; Twomey, P.; Girish, S.; Wu, B. Personalized Cancer Vaccines: Clinical\\nLandscape, Challenges, and Opportunities. Mol. Ther. 2021, 29, 555–570. [CrossRef]\\n98.\\nSchumacher, T.N.; Scheper, W.; Kvistborg, P. Cancer Neoantigens. Annu. Rev. Immunol. 2019, 37, 173–200. [CrossRef]\\n99.\\nFritah, H.; Rovelli, R.; Chiang, C.L.; Kandalaft, L.E. The current clinical landscape of personalized cancer vaccines. Cancer Treat.\\nRev. 2022, 106, 102383. [CrossRef] [PubMed]\\n100. Verma, V.; Shrimali, R.K.; Ahmad, S.; Dai, W.; Wang, H.; Lu, S.; Nandre, R.; Gaur, P.; Lopez, J.; Sade-Feldman, M.; et al. PD-1\\nblockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat. Immunol. 2019, 20,\\n1231–1243. [CrossRef]\\n101. Hemminki, O.; dos Santos, J.M.; Hemminki, A. Oncolytic viruses for cancer immunotherapy. J. Hematol. Oncol. 2020, 13, 84.\\n[CrossRef] [PubMed]\\n102. Ylosmaki, E.; Cerullo, V. Design and application of oncolytic viruses for cancer immunotherapy. Curr. Opin. Biotech. 2020, 65,\\n25–36. [CrossRef]\\n103. Jin, S.; Wang, Q.; Wu, H.; Pang, D.; Xu, S. Oncolytic viruses for triple negative breast cancer and beyond. Biomark Res. 2021, 9, 71.\\n[CrossRef] [PubMed]\\n104. Hecht, J.R.; Chan, A.; Baurain, J.F.; Martin, M.; Longo-Munoz, F.; Kalinsky, K.; Raman, S.; Liu, C.X.; Cha, E.; Chan, E. Preliminary\\nsafety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer.\\nCancer Res. 2020, 80, P3-09. [CrossRef]\\n105. Kistler, M.; Nangia, C.; To, C.; Sender, L.; Lee, J.; Jones, F.; Jafari, O.; Seery, T.; Rabizadeh, S.; Niazi, K.; et al. Safety and efﬁcacy\\nfrom ﬁrst-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-afﬁnity CD16 NK cell line (haNK)\\nin patients with 2nd-line or greater metastatic triple-negative breast cancer (TNBC). Cancer Res. 2020, 80, P5-04-02. [CrossRef]\\n106. Han, D.; Liu, J.; Chen, C.; Dong, L.; Liu, Y.; Chang, R.; Huang, X.; Liu, Y.; Wang, J.; Dougherty, U.; et al. Anti-tumour immunity\\ncontrolled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature 2019, 566, 270–274. [CrossRef]\\n107. Sun, X.; Wu, B.; Chiang, H.C.; Deng, H.; Zhang, X.; Xiong, W.; Liu, J.; Rozeboom, A.M.; Harris, B.T.; Blommaert, E.; et al. Tumour\\nDDR1 promotes collagen ﬁbre alignment to instigate immune exclusion. Nature 2021, 599, 673–678. [CrossRef]\\nCancers 2023, 15, 321\\n26 of 28\\n108. Mohammadpour, H.; MacDonald, C.R.; Qiao, G.; Chen, M.; Dong, B.; Hylander, B.L.; McCarthy, P.L.; Abrams, S.I.; Repasky, E.A.\\nβ2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. J.\\nClin. Investig. 2019, 129, 5537–5552. [CrossRef]\\n109. Bucsek, M.J.; Qiao, G.; MacDonald, C.R.; Giridharan, T.; Evans, L.; Niedzwecki, B.; Liu, H.; Kokolus, K.M.; Eng, J.W.; Messmer,\\nM.N.; et al. β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8(+) T\\nCells and Undermines Checkpoint Inhibitor Therapy. Cancer Res. 2017, 77, 5639–5651. [CrossRef] [PubMed]\\n110. Wang, H.; Rong, X.; Zhao, G.; Zhou, Y.; Xiao, Y.; Ma, D.; Jin, X.; Wu, Y.; Yan, Y.; Yang, H.; et al. The microbial metabolite\\ntrimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metab. 2022, 34, 581–594 e588.\\n[CrossRef]\\n111. Emens, L.A.; Molinero, L.; Loi, S.; Rugo, H.S.; Schneeweiss, A.; Dieras, V.; Iwata, H.; Barrios, C.H.; Nechaeva, M.; Nguyen-Duc, A.;\\net al. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130\\nStudy. J. Natl. Cancer Inst. 2021, 113, 1005–1016. [CrossRef]\\n112. Badve, S.S.; Penault-Llorca, F.; Reis-Filho, J.S.; Deurloo, R.; Siziopikou, K.P.; D’Arrigo, C.; Viale, G. Determining PD-L1 Status\\nin Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. J. Natl. Cancer Inst. 2022, 114, 664–675.\\n[CrossRef]\\n113. Chebib, I.; Mino-Kenudson, M. PD-L1 immunohistochemistry: Clones, cutoffs, and controversies. APMIS 2022, 130, 295–313.\\n[CrossRef]\\n114. Rugo, H.S.; Loi, S.; Adams, S.; Schmid, P.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Dieras, V.; Winer, E.P.; Kockx, M.M.; et al.\\nPD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast\\nCancer. J. Natl. Cancer Inst. 2021, 113, 1733–1743. [CrossRef] [PubMed]\\n115. Ghebeh, H.; Mansour, F.A.; Colak, D.; Alfuraydi, A.A.; Al-Thubiti, A.A.; Monies, D.; Al-Alwan, M.; Al-Tweigeri, T.; Tulbah, A.\\nHigher PD-L1 Immunohistochemical Detection Signal in Frozen Compared to Matched Parafﬁn-Embedded Formalin-Fixed\\nTissues. Antibodies 2021, 10, 24. [CrossRef] [PubMed]\\n116. Reisenbichler, E.S.; Han, G.; Bellizzi, A.; Bossuyt, V.; Brock, J.; Cole, K.; Fadare, O.; Hameed, O.; Hanley, K.; Harrison, B.T.; et al.\\nProspective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast\\ncancer. Mod. Pathol. 2020, 33, 1746–1752. [CrossRef] [PubMed]\\n117. Paijens, S.T.; Vledder, A.; de Bruyn, M.; Nijman, H.W. Tumor-inﬁltrating lymphocytes in the immunotherapy era. Cell Mol.\\nImmunol. 2021, 18, 842–859. [CrossRef]\\n118. Loi, S.; Adams, S.; Schmid, P.; Cortes, J.; Cescon, D.W.; Winer, E.P.; Toppmeyer, D.L.; Rugo, H.S.; De Laurentiis, M.; Nanda, R.;\\net al. Relationship between tumor inﬁltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic\\ntriple-negative breast cancer (mTNBC): Results from KEYNOTE-086. Ann. Oncol. 2017, 28, v608. [CrossRef]\\n119. Loi, S.; Winer, E.; Lipatov, O.; Im, S.A.; Goncalves, A.; Cortes, J.; Lee, K.S.; Schmid, P.; Testa, L.; Witzel, I.; et al. Relationship\\nbetween tumor-inﬁltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy\\nfor previously treated metastatic triple-negative breast cancer (mTNBC). Cancer Res. 2020, 80, PD5-03. [CrossRef]\\n120. Loi, S.; Michiels, S.; Adams, S.; Loibl, S.; Budczies, J.; Denkert, C.; Salgado, R. The journey of tumor-inﬁltrating lymphocytes as a\\nbiomarker in breast cancer: Clinical utility in an era of checkpoint inhibition. Ann. Oncol. 2021, 32, 1236–1244. [CrossRef]\\n121. Schumacher, T.N.; Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 2015, 348, 69–74. [CrossRef]\\n122. Ott, P.A.; Bang, Y.J.; Piha-Paul, S.A.; Razak, A.R.A.; Bennouna, J.; Soria, J.C.; Rugo, H.S.; Cohen, R.B.; O’Neil, B.H.; Mehnert, J.M.;\\net al. T-Cell-Inﬂamed Gene-Expression Proﬁle, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict\\nEfﬁcacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J. Clin. Oncol. 2019, 37, 318–327. [CrossRef]\\n[PubMed]\\n123. Samstein, R.M.; Lee, C.H.; Shoushtari, A.N.; Hellmann, M.D.; Shen, R.; Janjigian, Y.Y.; Barron, D.A.; Zehir, A.; Jordan, E.J.; Omuro,\\nA.; et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 2019, 51,\\n202–206. [CrossRef] [PubMed]\\n124. Barroso-Sousa, R.; Jain, E.; Cohen, O.; Kim, D.; Buendia-Buendia, J.; Winer, E.; Lin, N.; Tolaney, S.M.; Wagle, N. Prevalence and\\nmutational determinants of high tumor mutation burden in breast cancer. Ann. Oncol. 2020, 31, 387–394. [CrossRef]\\n125. Karn, T.; Denkert, C.; Weber, K.E.; Holtrich, U.; Hanusch, C.; Sinn, B.V.; Higgs, B.W.; Jank, P.; Sinn, H.P.; Huober, J.; et al. Tumor\\nmutational burden and immune inﬁltration as independent predictors of response to neoadjuvant immune checkpoint inhibition\\nin early TNBC in GeparNuevo. Ann. Oncol. 2020, 31, 1216–1222. [CrossRef] [PubMed]\\n126. Winer, E.P.; Lipatov, O.; Im, S.A.; Goncalves, A.; Munoz-Couselo, E.; Lee, K.S.; Schmid, P.; Testa, L.; Witzel, I.; Ohtani, S.; et al.\\nAssociation of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy\\n(chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. J. Clin. Oncol. 2020, 38, 1013.\\n[CrossRef]\\n127. Jardim, D.L.; Goodman, A.; de Melo Gagliato, D.; Kurzrock, R. The Challenges of Tumor Mutational Burden as an Immunotherapy\\nBiomarker. Cancer Cell 2021, 39, 154–173. [CrossRef]\\n128. Chalmers, Z.R.; Connelly, C.F.; Fabrizio, D.; Gay, L.; Ali, S.M.; Ennis, R.; Schrock, A.; Campbell, B.; Shlien, A.; Chmielecki, J.;\\net al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017, 9, 34.\\n[CrossRef]\\nCancers 2023, 15, 321\\n27 of 28\\n129. Zhao, P.; Li, L.; Jiang, X.; Li, Q. Mismatch repair deﬁciency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1\\nimmunotherapy efﬁcacy. J. Hematol. Oncol. 2019, 12, 54. [CrossRef]\\n130. Prasad, V.; Kaestner, V.; Mailankody, S. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of\\nPembrolizumab for Mismatch Repair-Deﬁcient Solid Cancers. JAMA Oncol. 2018, 4, 157–158. [CrossRef]\\n131. Marcus, L.; Lemery, S.J.; Keegan, P.; Pazdur, R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite\\nInstability-High Solid Tumors. Clin. Cancer Res. 2019, 25, 3753–3758. [CrossRef]\\n132. Ren, X.Y.; Song, Y.; Wang, J.; Chen, L.Y.; Pang, J.Y.; Zhou, L.R.; Shen, S.J.; Cao, X.; Wang, Y.X.; Shao, M.M.; et al. Mismatch Repair\\nDeﬁciency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. Front Oncol.\\n2021, 11, 570623. [CrossRef]\\n133. Horimoto, Y.; Hlaing, M.T.; Saeki, H.; Kitano, S.; Nakai, K.; Sasaki, R.; Kurisaki-Arakawa, A.; Arakawa, A.; Otsuji, N.; Matsuoka,\\nS.; et al. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer. Cancer Sci.\\n2020, 111, 2647–2654. [CrossRef] [PubMed]\\n134. Schadendorf, D.; Hodi, F.S.; Robert, C.; Weber, J.S.; Margolin, K.; Hamid, O.; Patt, D.; Chen, T.T.; Berman, D.M.; Wolchok, J.D.\\nPooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic\\nMelanoma. J. Clin. Oncol. 2015, 33, 1889–1894. [CrossRef] [PubMed]\\n135. Wolchok, J.D.; Hamid, O.; Ribas, A.; Robert, C.; Kefford, R.; Hwu, W.J.; Weber, J.S.; Joshua, A.M.; Gangadhar, T.C.; Dronca,\\nR.S.; et al. Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in\\nKEYNOTE-001. J. Clin. Oncol. 2015, 33, 3000. [CrossRef]\\n136. Champiat, S.; Dercle, L.; Ammari, S.; Massard, C.; Hollebecque, A.; Postel-Vinay, S.; Chaput, N.; Eggermont, A.; Marabelle, A.;\\nSoria, J.C.; et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.\\nClinical. Cancer Res. 2017, 23, 1920–1928. [CrossRef]\\n137. Tazdait, M.; Mezquita, L.; Lahmar, J.; Ferrara, R.; Bidault, F.; Ammari, S.; Balleyguier, C.; Planchard, D.; Gazzah, A.; Soria, J.C.;\\net al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST\\nand iRECIST criteria. Eur. J. Cancer 2018, 88, 38–47. [CrossRef]\\n138. Chiou, V.L.; Burotto, M. Pseudoprogression and Immune-Related Response in Solid Tumors. J. Clin. Oncol. 2015, 33, 3541–3543.\\n[CrossRef]\\n139. Schmid, P.; Cruz, C.; Braiteh, F.S.; Eder, J.P.; Tolaney, S.; Kuter, I.; Nanda, R.; Chung, C.; Cassier, P.; Delord, J.P.; et al. Atezolizumab\\nin metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Cancer Res. 2017, 77, 2986. [CrossRef]\\n140. Borcoman, E.; Kanjanapan, Y.; Champiat, S.; Kato, S.; Servois, V.; Kurzrock, R.; Goel, S.; Bedard, P.; Le Tourneau, C. Novel patterns\\nof response under immunotherapy. Ann. Oncol. 2019, 30, 385–396. [CrossRef]\\n141. Wolchok, J.D.; Hoos, A.; O’Day, S.; Weber, J.S.; Hamid, O.; Lebbe, C.; Maio, M.; Binder, M.; Bohnsack, O.; Nichol, G.; et al.\\nGuidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res.\\n2009, 15, 7412–7420. [CrossRef] [PubMed]\\n142. Seymour, L.; Bogaerts, J.; Perrone, A.; Ford, R.; Schwartz, L.H.; Mandrekar, S.; Lin, N.U.; Litiere, S.; Dancey, J.; Chen, A.;\\net al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017, 18, E143–E152.\\n[CrossRef] [PubMed]\\n143. Nishino, M.; Giobbie-Hurder, A.; Gargano, M.; Suda, M.; Ramaiya, N.H.; Hodi, F.S. Developing a Common Language for Tumor\\nResponse to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements. Clin. Cancer Res. 2013,\\n19, 3936–3943. [CrossRef]\\n144. Majd, N.; de Groot, J. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblas-\\ntoma. Expert Opin Pharm. 2019, 20, 1609–1624. [CrossRef]\\n145. Yang, Y.; Wu, Q.; Chen, L.; Qian, K.; Xu, X. Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the\\ntreatment of triple-negative breast cancer: A case report. Ann. Transl. Med. 2022, 10, 424. [CrossRef]\\n146. Wang, P.F.; Chen, Y.; Song, S.Y.; Wang, T.J.; Ji, W.J.; Li, S.W.; Liu, N.; Yan, C.X. Immune-Related Adverse Events Associated with\\nAnti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharm. 2017, 8, 730. [CrossRef]\\n147. Balibegloo, M.; Nejadghaderi, S.A.; Sadeghalvad, M.; Soleymanitabar, A.; Nezamabadi, S.S.; Saghazadeh, A.; Rezaei, N. Adverse\\nevents associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis. Int.\\nImmunopharmacol. 2021, 96, 107796. [CrossRef] [PubMed]\\n148. Xin, Y.; Shen, G.; Zheng, Y.; Guan, Y.; Huo, X.; Li, J.; Ren, D.; Zhao, F.; Liu, Z.; Li, Z.; et al. Immune checkpoint inhibitors plus\\nneoadjuvant chemotherapy in early triple-negative breast cancer: A systematic review and meta-analysis. BMC Cancer 2021, 21,\\n1261. [CrossRef] [PubMed]\\n149. Villacampa, G.; Tolosa, P.; Salvador, F.; Sanchez-Bayona, R.; Villanueva, L.; Dienstmann, R.; Ciruelos, E.; Pascual, T. Addition of\\nimmune checkpoint inhibitors to chemotherapy versus chemotherapy alone in ﬁrst-line metastatic triple-negative breast cancer:\\nA systematic review and meta-analysis. Cancer Treat. Rev. 2022, 104, 102352. [CrossRef] [PubMed]\\n150. Wolchok, J.D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Wagstaff, J.; Schadendorf, D.;\\nFerrucci, P.F.; et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2017,\\n377, 1345–1356. [CrossRef]\\nCancers 2023, 15, 321\\n28 of 28\\n151. Ceschi, A.; Noseda, R.; Palin, K.; Verhamme, K. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of\\nWHO Global Pharmacovigilance Database. Front Pharmacol. 2020, 11, 557. [CrossRef] [PubMed]\\n152. Ciner, A.T.; Hochster, H.S.; August, D.A.; Carpizo, D.R.; Spencer, K.R. Delayed cytokine release syndrome after neoadjuvant\\nnivolumab: A case report and literature review. Immunotherapy 2021, 13, 1071–1078. [CrossRef] [PubMed]\\nDisclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual\\nauthor(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to\\npeople or property resulting from any ideas, methods, instructions or products referred to in the content.\\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\nAbstract. Triple‑negative breast cancer (TNBC) accounts for \\n10‑15% of all breast cancer cases. TNBCs lack estrogen and \\nprogesterone receptors and express low levels of HER2, and \\ntherefore do not respond to hormonal or anti‑HER2 therapies. \\nTNBC is a particularly aggressive form of breast cancer that \\ngenerally displays poorer prognosis compared to other breast \\ncancer subtypes. TNBC is chemotherapy sensitive, and this \\ntreatment remains the standard of care despite its limited benefit. \\nRecent advances with novel agents have been made for specific \\nsubgroups with PD‑L1+ tumors or germline Brca‑mutated \\ntumors. However, only a fraction of these patients responds to \\nimmune checkpoint or PARP inhibitors and even those who \\ndo respond often develop resistance and relapse. Various new \\nagents and combination strategies have been explored to further \\nunderstand molecular and immunological aspects of TNBC. \\nIn this review, we discuss clinical trials in the management of \\nTNBC as well as perspectives for potential future treatments.\\nContents\\n1.\\t Introduction\\n2.\\t Current treatment paradigm\\n3.\\t Investigational drugs\\n4.\\t New potential therapeutic strategies\\n5.\\t Conclusion\\n1. Introduction\\nBreast cancer is characterized by heterogeneity at the \\nmolecular and clinical levels. Several biomarkers including \\nestrogen receptor α (ERα), progesterone receptor (PR), and \\nhuman epidermal growth factor receptor‑2 (ERBB2/HER2) \\nhave been established, and the main breast cancer subtypes are \\nclassified according to their molecular profile\\xa0(1,2). Traditional \\nstaging of breast cancer is based on tumor size, lymph node \\ninvolvement, and presence of metastasis, and recently biologic \\nmarkers have been incorporated in the 8th edition of the \\nAmerican Joint Committee on Cancer (AJCC), improving the \\nprognostic discrimination over anatomic staging alone\\xa0(3).\\nTriple‑negative breast cancer (TNBC) is characterized as \\nhaving ≤1% cellular expression of ER and PR as determined \\nby immunohistochemistry (IHC), and having HER2 expres\\xad\\nsion of 0 to 1+ by IHC, or 2+ by IHC and fluorescence in\\xa0situ \\nhybridization (FISH) negative (i.e. not an amplified gene \\ncopy number), according to American Society of Clinical \\nOncology/College of American Pathologists (ASCO/CAP) \\nguidelines\\xa0(4,5). TNBCs are comprised of at least four distinct \\ntranscriptional subtypes: Two basal subtypes, BL1 and BL2; a \\nmesenchymal subtype M, which is devoid of immune cells; and \\na luminal androgen receptor (AR) subtype LAR\\xa0(1,2). TNBC is \\nalso subdivided into 6 different subgroups based on molecular \\nheterogeneity: Basal‑like; mesenchymal‑like; mesenchymal \\nstem‑like; luminal AR expression; immunomodulatory; and \\nunstable type\\xa0(6). TNBC represents approximately 15‑20% of \\nall newly diagnosed breast cancers and is generally a more \\naggressive disease with a poorer prognosis and higher grade \\nthan other types of breast cancer, accounting for 5% of all \\ncancer‑related deaths annually. The median overall survival \\n(OS) for the disease is 10.2\\xa0months with current therapies, with \\na 5‑year survival rate of ~65% for regional tumors and 11% for \\nthose that have spread to distant organs\\xa0(7,8).\\nIn this review, we discuss current TNBC treatments and \\nkey examples of improved clinical benefit, as well as new \\ntherapeutic strategies with which to treat the disease.\\n2. Current treatment paradigm\\nTNBC is chemotherapy sensitive, and this treatment remains \\nthe standard of care (SOC). Common chemotherapies \\ninclude anthracycline (e.g., DNA intercalating agent and \\ntopoisomerase II blocker doxorubicin), alkylating agents (e.g., \\ncyclophosamide), an anti‑microtubule agent taxane, and an \\nanti‑metabolite fluorouracil (5‑FU). The current SOC for newly \\nTriple‑negative breast cancer therapy: Current \\nand future perspectives (Review)\\nKWANG‑AI WON1,2  and  CHARLES SPRUCK3\\n1ConsultantCA, Moraga, CA 94556; 2Pin Pharmaceuticals, Inc., South San Francisco, CA 94080; \\n3Tumor Initiation and Maintenance Program, NCI‑Designated Cancer Center,\\nSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA\\nReceived July 14, 2020;  Accepted September 9, 2020\\nDOI: 10.3892/ijo.2020.5135\\nCorrespondence to: Dr Kwang‑Ai Won, ConsultantCA, 1988 Ascot \\nDrive, Unit A, Moraga, CA 94556, USA\\nE‑mail: wonk12pharm@yahoo.com\\nKey words: triple‑negative breast cancer, clinical studies, \\nimmunotherapy, \\nDNA‑damage \\nresponse, \\ntargeted \\ntherapy, \\ntherapeutic strategy\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1246\\ndiagnosed early TNBC consists of neoadjuvant chemotherapy, \\nfollowed by surgery. For patients with relapsed/refractory \\nTNBC, there is no standard chemotherapy regimen. Responses \\nto treatment are usually short in duration and followed by \\nrapid relapse, and visceral and brain metastases are common. \\nAvailable therapies for patients with advanced TNBC include \\nanti‑metabolites capecitabine and gemcitabine, non‑taxane \\nmicrotubule inhibitor eribulin, and DNA cross‑linker \\nplatinums. The median progression‑free survival (PFS) with \\nchemotherapy ranges from 1.7 to 3.7\\xa0months; the median OS \\nfrom the onset of metastasis is 10 to 13\\xa0months. In clinical \\ntrials, patients with advanced TNBC treated with single‑agent \\ntaxane‑ or platinum‑based chemotherapy had a median PFS \\nof 4 to 6\\xa0months and a median OS of 11 to 17\\xa0months\\xa0(9‑11).\\nNew treatment options for patients with advanced TNBC \\nhave recently emerged, especially in cases where surgery is \\nnot an option.\\nTNBC is more immunogenic than other breast cancer \\nsubtypes with tumor‑infiltrating lymphocytes (TILs) in its \\nmicroenvironment. However, TNBC also displays a high level \\nof programmed cell death‑ligand 1 (PD‑L1) expression\\xa0(12,13). \\nThus, immunotherapies targeting the programmed cell \\ndeath‑1 (PD‑1) receptor/PD‑L1 pathway that maintains immu\\xad\\nnosuppression in the tumor environment in TNBC have been \\nexplored and atezolizumab (anti‑PD‑L1 antibody) in combi\\xad\\nnation with nanoparticle albumin‑bound (nab)‑paclitaxel \\nwas approved as a first‑line therapy by the US Food and \\nDrug Administration (FDA) based on the IMpassion130 \\ntrial (NCT02425891) in 2019. This immuno‑chemotherapy \\nbecame SOC for patients with PD‑L1+, unresectable, locally \\nadvanced or metastatic TNBC. Note that the survival benefit \\nwas exclusively in PD‑L1+ TNBC patients. The threshold is \\n1% PD‑L1 expression on infiltrating immune cells by an \\napproved companion diagnostic SP142 IHC assay and 41% \\nof enrolled patients showed PD‑L1‑positive expression in \\nthe IMpassion130 trial. This is in contrast to studies in other \\ntypes of cancer which showed benefit for checkpoint inhibitor \\ntherapy even in patients with negative PD‑L1 expression. In \\nthe first interim analysis of IMpassion130, the median PFS \\nwas 7.5 vs. 5.0\\xa0months with chemotherapy and the median OS \\nwas 25.0 vs. 15.5\\xa0months with chemotherapy among patients \\nwith PD‑L1+ tumors\\xa0(14). In the pre‑specified second interim \\nanalysis (data cutoff January 2, 2019), the median OS was 25.0 \\nvs. 18.0\\xa0months with chemotherapy. Overall, the combination \\nwas well‑tolerated and immune‑related adverse events (AEs) \\nincluded rash, hypothyroidism, and pneumonitis\\xa0(15). Another \\nimmunotherapy, pembrolizumab (anti‑PD‑1 antibody), was \\napproved in 2017 as a histology agnostic immunotherapy in all \\nmicrosatellite instability‑high (MSI‑H) and/or mismatch repair \\ndeficient (dMMR) tumors. This is the first FDA‑approved \\ncancer treatment based on a tumor biomarker without regard \\nto the original location of the tumor. However, MSI‑H is rare \\nin breast cancer (<2%)\\xa0(16‑18).\\nBRCA1 and BRCA2‑deficient tumors exhibit impaired \\nhomologous recombination repair (HRR) and synthetic lethality \\nwith poly(ADP‑ribose) polymerase (PARP) inhibitors\\xa0(19,20). \\nThe FDA approved olaparib and talazoparib in 2018 to treat \\nadvanced‑stage HER2‑negative breast cancer in individuals \\nwith a Brca1 or Brca2 mutation. The FDA also approved the \\ncompanion diagnostic test to identify germline Brca‑mutated \\n(gBRCAm) breast cancer patients. Approximately 5% of patients \\nwith breast cancer carry a gBRCAm. Olaparib approval was \\nbased on data from the OlympiAD Phase\\xa0III (NCT02000622) \\ntrial comparing olaparib to physician's choice of chemotherapy \\n(capecitabine, vinorelbine or eribulin). Olaparib was associated \\nwith a 42% increase in median PFS as compared to the control \\ngroup (7 vs. 4\\xa0months) in gBRCAm HER2‑negative meta\\xad\\nstatic breast cancer patients with previous chemotherapy\\xa0(21). \\nThere was no statistically significant improvement in OS with \\nolaparib compared to the control group (19.3 vs. 17.1\\xa0months), \\nbut there was potential OS benefit among patients with no prior \\nchemotherapy for metastatic breast cancer (HR 0.51, 95%\\xa0CI \\n0.29‑0.90)\\xa0(22). Olaparib was generally well‑tolerated, with no \\nevidence of cumulative toxicity including the risk of developing \\nanemia during extended exposure. Talazoparib approval was \\nbased on data from the EMBRACA Phase\\xa0III (NCT01945775) \\ntrial comparing talazoparib to gemcitabine or to the same \\nphysician choice of standard therapy as the OlympiAD trial. \\nTalazoparib increased median PFS by 46% (8.6 vs. 5.6\\xa0months) \\nin gBRCAm HER2‑negative locally advanced or metastatic \\nbreast cancer patients with previous chemotherapy including an \\nanthracycline and/or taxane. Talazoparib presented with hema\\xad\\ntologic grade 3‑4 AEs (primarily anemia), which occurred in 55 \\nvs. 38% of the patients with standard therapy, and an improved \\nside‑effect profile in patient‑reported outcomes\\xa0(23).\\n3. Investigational drugs\\nTo improve therapeutic benefit in TNBC treatment, \\nvarious agents have been explored in clinical studies. They \\ninclude immuno‑ and targeted‑therapies in the networks of \\ntumor‑stroma, DNA damage response (DDR), cell surface or \\nintracellular receptors, and signaling pathways as well as cell \\nsurface markers for selective drug delivery, and antibody‑drug \\nconjugates (ADCs) (Fig.\\xa01). As of March 2020, 399 ongoing \\nstudies for TNBC have been listed on ClinicalTrials.gov and \\nselect Phase\\xa0III studies are listed in Table\\xa0I.\\nImmunotherapy: Immune checkpoint. TILs are frequent \\nin TNBC, correlate with increased pathologic complete \\nresponse (pCR) to neoadjuvant chemotherapy, and are predic\\xad\\ntive of disease‑free survival (DFS) and OS in early‑stage \\nTNBC\\xa0(24‑26). Expression of immune regulatory checkpoints \\nis an adaptive method of tumor resistance to infiltrating lympho\\xad\\ncytes within the tumor microenvironment. Multiple strategies \\nhave been used to enhance the response to PD‑1/PD‑L1 \\nblockade in pre‑clinical and early clinical studies, including \\nseveral intratumoral immune modulators and targeted \\nagents\\xa0(27). The activity of immunotherapy, such as immune \\ncheckpoint inhibitors, can be enhanced by chemotherapeutic \\nagents through the stimulation/release of antigens, thus leading \\nto promotion of immunogenic cell death. Currently, clinical \\ntrials investigating the use of immune checkpoint inhibitors \\nare ongoing either as a single agent or in various combinations \\nwith other agents beyond the metastatic setting and even in the \\nfirst‑line setting\\xa0(28).\\nNeoadjuvant treatment. Studies determining benefit from \\nneoadjuvant checkpoint inhibitor therapy have yielded mixed \\noutcomes. Neoadjuvant chemotherapy with pembrolizumab \\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1247\\nhave demonstrated manageable safety and promising anti\\xad\\ntumor activity for patients with early‑stage TNBC in the \\nKEYNOTE‑173 Phase 1b (NCT02622074)\\xa0(29) and I‑SPY2 \\nPhase\\xa0II (NCT01042379) trials\\xa0(30). The KEYNOTE‑522 \\nPhase\\xa0III trial (NCT03036488) further explored neoadjuvant \\nchemotherapy with or without pembrolizumab followed by \\nsurgery and pembrolizumab or placebo adjuvantly. The neoad\\xad\\njuvant combination showed a significantly higher pCR rate \\nthan the placebo‑chemotherapy group (65 vs. 51%). Note that \\na similar pCR benefit (~15%) in both the PD‑L‑positive and \\n‑negative subgroups was observed, suggesting that neoadju\\xad\\nvant pembrolizumab may benefit patients regardless of PD‑L1 \\nlevels. This is different from the advanced setting where only \\nthe PD‑L1‑positive patients benefit from atezolizumab. The \\ntoxicity profiles were as expected for each treatment, with \\nsimilar rates (78 vs. 73%) of grade ≥3 treatment‑related AEs \\n(TRAEs)\\xa0(31).\\nNeoTRIPaPDL1 Phase\\xa0 III (NCT02620280) trial also \\nexplored neoadjuvant chemotherapy with or without atezoli\\xad\\nzumab followed by surgery and four cycles of an anthracycline \\nregimen. However, in this trial for patients with early‑stage \\nhigh‑risk or locally advanced unilateral breast cancer there \\nwas no improvement in pCR with the combination therapy \\n(44 vs. 41% with the control arm)\\xa0(32). Note that the neoad\\xad\\njuvant chemo‑regimen was different from KEYNOTE‑522 \\nwhich included another round of chemotherapy following \\ncarboplatin and nab‑paclitaxel. The difference in the targets, \\nPD‑1 for pembrolizumab vs. PD‑L1 for atezolizumab, may \\nalso have contributed to the different outcomes. Another \\nPhase\\xa0III (NCT03197935) trial, IMpassion031 study also \\nexplored atezolizumab in combination with chemotherapy \\n(nab‑paclitaxel followed by doxorubicin and cyclophospha\\xad\\nmide) in comparison to placebo plus chemotherapy in the \\nneoadjuvant setting. Treatment with atezolizumab continued \\nadjuvantly for those in the combination arm of the study\\xa0(33). \\nThe primary endpoint was pCR.\\nIn the advanced setting. As a first‑line treatment option for \\npatients with locally recurrent, inoperable or metastatic TNBC, \\npembrolizumab was evaluated in combination with investiga\\xad\\ntor's choice of chemotherapy (i.e. nab‑paclitaxel, paclitaxel or \\ngemcitabine/carboplatin), compared to placebo plus chemo\\xad\\ntherapy (KEYNOTE‑355 Phase\\xa0 III trial, NCT02819518). \\nA significant PFS benefit with the pembrolizumab‑chemo \\ncombination in patients whose tumors expressed PD‑L1 \\n(CPS ≥10) was reported (9.7 vs. 5.6\\xa0months for chemotherapy \\nalone)\\xa0(34). The study is currently in progress to evaluate OS, \\nthe other primary endpoint of the trial.\\nIn contrast to other studies of immunotherapy combined \\nwith SOC chemotherapy, the Tonic trial (NCT02499367) \\nin metastatic TNBC was based on an adaptive trial design \\nthat explores a sequential treatment with anti‑PD‑1 antibody \\nnivolumab after 2\\xa0weeks of chemotherapy or radiotherapy. The \\nhypothesis is that short‑term treatment induces a more favor\\xad\\nable tumor microenvironment that would enhance sensitivity \\nto immune checkpoint blockade in TNBC. The highest overall \\nFigure 1. Immuno‑ and targeted‑therapies in key TNBC clinical studies. Various agents in the networks of TNBCs and immune cells have been explored, \\nas well as tumor‑stroma interactions in the tumor microenvironment (TME). Targets and agents relevant to immune checkpoint, cell surface or intracel\\xad\\nlular receptors, signaling pathways, DNA damage response, and cell cycle checkpoint are shown. Various chemotherapy agents are listed in the box. AS, \\nAdagloxad simolenin); LV, Ladiratuzumab vedotin; SG, Sacituzumab govitecan‑hziy; T‑DXd, tastuzumab deruxtecan; TNBC, triple‑negative breast cancer; \\nA2aR, adenosine 2A receptor; A2bR, 2B receptor; PD‑1, programmed cell death‑1; PD‑L1, programmed cell death‑ligand 1; VEGF‑A, vascular endothelial \\ngrowth factor A; RTKs, receptor tyrosine kinases; PARP, poly(ADP‑ribose) polymerase; CDK, cyclin‑dependent kinase; CD, cluster of differentiation; ATR, \\nataxia telangiectasia and Rad3‑related kinase; CHK1, checkpoint kinase 1; DNA‑PK, DNA‑dependent protein kinase; AR, androgen receptor; PI3K, phospha\\xad\\ntidylinositol 3‑kinase. \\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1248\\nTable I. Current phase III studies concerning TNBC.\\n\\t\\n\\t\\n\\t\\n\\t\\n\\t\\nStudy start; Primary\\n\\t\\n\\t\\n\\t\\n\\t\\nNo. of\\t\\ncompletion(month/\\t\\nClinicalTrials.gov\\nTherapeutic approach\\t\\nTreatment\\t\\nTNBC patient population\\t\\nRecruitment status\\t\\npatients\\t\\nday/year)\\t\\nIdentifier\\nNeoadjuvant therapy: \\t\\n(Carbo/nab‑pac) +/‑ atezolizumab.\\t\\nEarly high‑risk and\\t\\nActive, not recruiting\\t\\n278\\t\\n4/1/2016; May 2022\\t\\nNCT02620280\\nImmuno + chemotherapy \\t\\nThen, four cycles of AC, EC or\\t\\nlocally advanced\\n(NeoTRIPaPDL1)\\t\\nFEC as adjuvant chemotherapy\\nImmuno + chemotherapy\\t\\n(Pac/carbo, followed by AC or EC) \\t\\nLocally advanced\\t\\nActive, not recruiting\\t\\n1,174\\t\\n3/7/2017; 9/30/2025\\t\\nNCT03036488\\nas neoadjuvant therapy \\t\\n+/‑ pembrolizumab as neoadjuvant\\nand immunotherapy as \\t\\ntherapy prior to surgery. Then, \\nadjuvant therapy \\t\\npembrolizumab vs. placebo as\\n(KEYNOTE‑522)\\t\\nadjuvant therapy post‑surgery\\nNeoadjuvant therapy: \\t\\n(Nab‑pac +/‑ atezolizumab), \\t\\nEligible for surgery with\\t\\nActive, not recruiting\\t\\n324\\t\\n7/24/2017; 9/30/2020\\t\\nNCT03197935\\nImmuno + chemotherapy \\t\\nfollowed by AC\\t\\ninitial clinically assessed\\n(IMpassion031)\\t\\n\\t\\nprimary invasive (early\\n\\t\\n\\t\\nstage)\\nNeoadjuvant therapy: \\t\\n(Carbo/pac, then AC or EC) +/‑ \\t\\nNo metastatic disease\\t\\nRecruiting\\t\\n1,520\\t\\n12/19/2017; 12/31/2023\\t\\nNCT03281954\\nImmuno + chemotherapy\\t\\natezolizumab, followed after\\n\\t\\nsurgery by atezolizumab or placebo\\t\\nImmuno + chemotherapy\\t\\n(Nab‑pac/carbo, followed by AC\\t\\nPreviously untreated and\\t\\nNot yet recruiting\\t\\n522\\t\\n4/17/2020; 9/7/2022\\t\\nNCT04301739\\nas neoadjuvant therapy \\t\\nor EC) +/‑ HLX10 (anti‑PD‑1) as\\t\\npotentially resectable\\nand immunotherapy as \\t\\nneoadjuvant therapy prior to\\t\\npatients without distant\\nadjuvant therapy\\t\\nsurgery. Then, HLX10 vs. placebo\\t\\nmetastasis\\n\\t\\nas adjuvant therapy post‑surgery\\nImmunotherapy: Immune\\t\\nAdagloxad simolenin\\t\\nEarly stage at high risk for\\t\\nRecruiting\\t\\n668\\t\\n12/5/2018; 11/30/2025\\t\\nNCT03562637\\nstimulant following\\t\\n(OBI 822)/OBI‑821 vs. placebo\\t\\nrecurrence; defined as\\nneoadjuvant or adjuvant\\t\\n\\t\\nresidual invasive disease\\nchemotherapy\\t\\n\\t\\nfollowing neoadjuvant\\n\\t\\n\\t\\nchemotherapy or ≥4 positive\\n\\t\\n\\t\\naxillary nodes. The Globo\\t\\n\\t\\n\\t\\nH IHC assay for identifying\\n\\t\\n\\t\\neligible patient\\nPARP inhibitor + \\t\\n[(Veliparib/pac/carbo) vs. \\t\\nEarly stage\\t\\nActive, not recruiting\\t\\n634\\t\\n4/2/2014; 3/18/2016;\\t\\nNCT02032277\\nchemotherapy as\\t\\n(pac/carbo) vs. pac], \\t\\n\\t\\n\\t\\n\\t\\n(10/18/2020a)\\nneoadjuvant therapy \\t\\nfollowed by AC\\n(BrighTNess)\\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1249\\nTable I. Continued.\\n\\t\\n\\t\\n\\t\\n\\t\\n\\t\\nStudy start; Primary\\n\\t\\n\\t\\n\\t\\n\\t\\nNo. of\\t\\ncompletion(month/\\t\\nClinicalTrials.gov\\nTherapeutic approach\\t\\nTreatment\\t\\nTNBC patient population\\t\\nRecruitment status\\t\\npatients\\t\\nday/year)\\t\\nIdentifier\\nPARP inhibitor + \\t\\n(Pac/carbo) +/‑ olaparib\\t\\nTNBC and/or gBRCAm\\t\\nRecruiting\\t\\n527\\t\\n5/1/2016; January 2022\\t\\nNCT03150576\\nchemotherapy as\\t\\n\\t\\npositive breast cancer\\nneoadjuvant therapy\\n(PARTNER, Phase II/III)\\nAdjuvant therapy: \\t\\nAvelumab (anti‑PD‑L1) vs. \\t\\nHigh‑risk; completed\\t\\nRecruiting\\t\\n335\\t\\nJune 2016; June 2021\\t\\nNCT02926196\\nImmunotherapy\\t\\nobservation\\t\\ntreatment with curative\\n(A‑Brave)\\t\\n\\t\\nintent including surgery of\\n\\t\\n\\t\\nthe primary tumor, neo‑ or\\n\\t\\n\\t\\nadjuvant chemotherapy, and\\t\\n\\t\\n\\t\\n(if indicated) radiotherapy\\nAdjuvant therapy: \\t\\nPembrolizumab adjuvant therapy\\t\\nTNBC or low ER‑positive\\t\\nRecruiting\\t\\n1,000\\t\\n11/15/2016; 5/31/2026\\t\\nNCT02954874\\nImmunotherapy\\t\\nvs. no therapy\\t\\nand/or HER2 borderline\\n\\t\\n\\t\\nbreast cancer who have\\n\\t\\n\\t\\n≥1 cm residual invasive\\t\\n\\t\\n\\t\\nbreast cancer and/or positive\\n\\t\\n\\t\\nlymph nodes after\\n\\t\\n\\t\\nneoadjuvant chemotherapy\\nAdjuvant therapy: \\t\\nPac +/‑ atezolizumab, followed by\\t\\nStage II‑III operable\\t\\nRecruiting\\t\\n2,300\\t\\n8/2/2018; 1/15/2022\\t\\nNCT03498716\\nImmuno + chemotherapy\\t\\ndose‑dense AC or EC alone\\n(IMpassion030)\\nImmuno + chemotherapy\\t\\nNab‑pac +/‑ atezolizumab\\t\\nPreviously untreated locally\\t\\nActive, not recruiting\\t\\n900\\t\\n6/23/2015; 4/14/2020\\t\\nNCT02425891\\n(IMpassion130)\\t\\n\\t\\nadvanced or metastatic\\nSingle agent\\t\\nPembrolizumab vs. chemotherapy\\t\\nMetastatic (second/third\\t\\nActive, not recruiting\\t\\n622\\t\\n10/13/2015; 4/11/2019\\t\\nNCT02555657\\nimmunotherapy\\t\\n(cape, eribulin, gem, or vinorelbine)\\t\\nlines)\\n(KEYNOTE‑119)\\nImmuno + chemotherapy\\t\\n(Nab‑pac or pac or gem/carbo) +/‑ \\t\\nPreviously untreated locally\\t\\nActive, not recruiting\\t\\n882\\t\\n7/27/2016; 12/30/2019\\t\\nNCT02819518\\n(KEYNOTE‑355)\\t\\npembrolizumab\\t\\nrecurrent inoperable or\\n\\t\\n\\t\\nmetastatic\\t\\nImmuno + chemotherapy\\t\\nPac +/‑ atezolizumab\\t\\nPreviously untreated, \\t\\nRecruiting\\t\\n600\\t\\n8/25/2017; 11/15/2019\\t\\nNCT03125902\\n(IMpassion131)\\t\\n\\t\\ninoperable locally advanced\\n\\t\\n\\t\\nor metastatic\\t\\nImmuno + chemotherapy\\t\\n(Gem/cape/carbo) +/‑ atezolizumab\\t\\nEarly relapsing recurrent\\t\\nRecruiting\\t\\n540\\t\\n1/11/2018; 1/1/2023\\t\\nNCT03371017\\n(IMpassion132)\\t\\n\\t\\n(inoperable locally advanced\\n\\t\\n\\t\\nor metastatic)\\t\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1250\\nTable I. Continued.\\n\\t\\n\\t\\n\\t\\n\\t\\n\\t\\nStudy start; Primary\\n\\t\\n\\t\\n\\t\\n\\t\\nNo. of\\t\\ncompletion(month/\\t\\nClinicalTrials.gov\\nTherapeutic approach\\t\\nTreatment\\t\\nTNBC patient population\\t\\nRecruitment status\\t\\npatients\\t\\nday/year)\\t\\nIdentifier\\nImmuno + \\t\\nNab‑pac +/‑ toripalimab\\t\\nFirst/second‑line treatment\\t\\nRecruiting\\t\\n600\\t\\n12/21/2018; 2/28/2022\\t\\nNCT04085276\\nchemotherapy\\t\\n(anti‑PD‑1)\\t\\nof metastatic or recurrent\\t\\n(TORCHLIGHT)\\nImmuno + chemotherapy\\xa0 \\t Single arm: (Nab‑pac or pac) + \\t\\nPD‑L1‑positive\\t\\nRecruiting\\t\\n280\\t\\n12/17/2019; 6/28/2024\\t\\nNCT04148911\\n(EL1SSAR)\\t\\natezolizumab\\t\\nunresectable locally\\n\\t\\n\\t\\nadvanced or metastatic; not\\n\\t\\n\\t\\nreceived prior systemic\\n\\t\\n\\t\\ncytotoxic therapy\\nPARP inhibitor + \\xa0\\t\\nOlaparib + pembrolizumab vs. \\t\\nLocally recurrent inoperable\\t\\nRecruiting\\t\\n932\\t\\n12/19/2019; 1/26/2026\\t\\nNCT04191135\\nimmunotherapy as the\\t\\n(carbo/gem) + pembrolizumab after\\t or metastatic\\npost‑induction therapy\\t\\ninduction with first‑line\\n(KEYLYNK‑009, Phase\\t\\n(carbo/gem) + pembrolizumab\\nII/III)\\nAKT inhibitor + \\t\\nCohort 1 (PD‑L1 non‑positive): \\xa0\\t\\nLocally advanced\\t\\nRecruiting\\t\\n1,155\\t\\n11/25/2019; 10/10/2025\\t\\nNCT04177108\\nimmuno + chemotherapy\\t\\npaclitaxel (P)/ipatasertib\\t\\nunresectable or metastatic\\n\\t\\n(I)/atezolizumab (A) vs. P/I vs. P; \\n\\t\\nCohort 2 (PD‑L1 positive): P/I/A\\n\\t\\nvs. P/A\\nAKT inhibitor + \\t\\nPac +/‑ ipatasertib\\t\\nPIK3CA/AKT1/PTEN‑\\t\\nRecruiting\\t\\n450\\t\\n1/6/2018; 12/22/2021\\t\\nNCT03337724\\nchemotherapy\\xa0 \\t\\n\\t\\naltered, locally advanced or\\n(IPATunity130)\\t\\n\\t\\nmetastatic TNBC and locally\\n\\t\\n\\t\\nadvanced or metastatic\\n\\t\\n\\t\\nHR+/HER2‑breast\\n\\t\\n\\t\\nadenocarcinoma, not\\n\\t\\n\\t\\nsuitable for endocrine \\n\\t\\n\\t\\ntherapy\\nAKT inhibitor + \\t\\nPac +/‑ capivasertib\\t\\nLocally advanced\\t\\nRecruiting\\t\\n800\\t\\n6/25/2019; 9/1/2021\\t\\nNCT03997123\\nchemotherapy as first\\t\\n\\t\\n(inoperable) or metastatic\\t\\nline therapy \\n(CapItello290)\\nPI3K inhibitor + \\t\\nNab‑pac +/‑ alpelisib\\t\\nAdvanced; a PIK3CA\\t\\nNot yet recruiting\\t\\n566\\t\\n4/22/2020; 3/19/2024\\t\\nNCT04251533\\nchemotherapy\\t\\n\\t\\nmutation (Study Part A) or\\n(EPIK‑B3)\\t\\n\\t\\nPTEN loss without PIK3CA\\n\\t\\n\\t\\nmutation (Study Parts B1 and B2)\\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1251\\nresponse rate (ORR) was observed with doxorubicin induc\\xad\\ntion (35%) followed by nivolumab/doxorubicin. Doxorubicin \\ninduction also upregulated immune‑related genes as well \\nas inflammation, JAK‑STAT, and TNF‑α signaling‑related \\ngenes, suggesting a more favorable tumor microenvironment \\ninduced by these chemotherapies\\xa0(35). The InCITe Phase\\xa0II \\ntrial (NCT03971409) also includes a two‑week induction of \\nbinimetinib (MEK inhibitor), utomilumab (4‑1BB agonist), or \\nPF‑04518600 (anti‑OX40 antibody) which may help activate \\nthe immune system. The trial explores how well anti‑PD‑L1 \\nantibody avelumab might work with one of those agents after \\ninduction in stage\\xa0IV or unresectable and recurrent TNBC.\\nImmunotherapy: Adenosine pathway. Adenosine is catabo\\xad\\nlized from ATP and often overproduced and released by \\ntumor cells. It is also converted from extracellular nucleotides \\nby the plasma membrane protein, cluster of differentiation 73 \\n(CD73), which is upregulated in many cancer types\\xa0(36,37). \\nThe excess adenosine in the tumor microenvironment \\nactivates the adenosine 2A receptor (A2aR) and 2B receptor \\n(A2bR)\\xa0(38,39) which are highly expressed on the cell surfaces \\nof lymphocytes and myeloid cells, respectively, leading to \\nimmunosuppressive effects (Fig.\\xa02). Targeting these receptors \\nand enzymes could lead to reactivation of antitumor immunity \\nby abrogating the inhibitory effect on the immune system \\nand enhancing the cytotoxic T lymphocyte (CTL)‑mediated \\nimmune response\\xa0(40,41). \\nCombinations of adenosine pathway inhibitors and \\nimmune checkpoint inhibitors have been explored in clinical \\ntrials. NZV930 (SRF373) is an anti‑CD73 monoclonal \\nantibody that binds to CD73 on tumor cells, leading to \\ninternalization of CD73, thereby preventing CD73‑mediated \\nconversion of extracellular AMP to adenosine. A Phase\\xa0I/Ib \\nstudy (NCT03549000) is underway to evaluate NZV930 alone \\nand in combination with PD‑1 inhibitor PDR001 and/or A2aR \\nantagonist NIR178 in patients with advanced malignancies \\nincluding TNBC. NIR178 is an antagonist of A2aR, blocking \\nadenosine/A2aR‑mediated inhibition of T lymphocytes. A \\nPhase\\xa0II study (NCT03207867) is underway for NIR178 in \\ncombination with PD‑1 inhibitor spartalizumab in multiple \\nsolid tumors and diffuse large B‑cell lymphoma (DLBCL) \\nto assess if the addition of the adenosine antagonist improves \\nthe efficacy of PD‑1 inhibition. A dual adenosine A2aR/A2bR \\nreceptor antagonist, AB928, is currently being evaluated in a \\nPhase\\xa0I study (NCT03629756) in combination with the PD‑1 \\ninhibitor AB122 in patients with advanced malignancies. Early \\nresults show a favorable safety profile of AB928 combination \\ntherapy and predictable PK/PD correlation\\xa0(42). \\nDNA‑damage response: PARP. Approximately 60‑70% of \\nbreast cancer patients with an inherited Brca1/2 mutation \\nare TNBC subtype and 10‑30% of TNBC patients harbor \\na Brca pathogenic variant\\xa0(43,44). A condition defined as \\n‘BRCAness’\\xa0(45), which includes mutations in HRR genes \\nthrough genetic or epigenetic inactivation, leads to suscep\\xad\\ntibility to both platinum and PARP inhibitors. Various \\nPARP inhibitors (e.g. veliparib, niraparib, and rucaparib as \\nwell as olaparib and talazoparib) have been assessed in the \\nneoadjuvant and adjuvant settings and in combination with \\nother agents.\\nTable I. Continued.\\n\\t\\n\\t\\n\\t\\n\\t\\n\\t\\nStudy start; Primary\\n\\t\\n\\t\\n\\t\\n\\t\\nNo. of\\t\\ncompletion(month/\\t\\nClinicalTrials.gov\\nTherapeutic approach\\t\\nTreatment\\t\\nTNBC patient population\\t\\nRecruitment status\\t\\npatients\\t\\nday/year)\\t\\nIdentifier\\nAR antagonist as first\\t\\nBicalutamide vs. (docetaxel/cape\\t\\nAR‑positive metastatic\\t\\nRecruiting\\t\\n262\\t\\n12/1/2016; \\t\\nNCT03055312\\nline therapy\\t\\nor gem/docetaxel or gem/carbo)\\t\\n\\t\\n\\t\\n\\t\\nDecember 2020\\n(SYSUCC‑007)\\nAmino acid metabolism\\t\\n(Gem/carbo) +/‑ eryaspase\\xa0\\t\\nLocally recurrent or metastatic; \\t\\nRecruiting\\t\\n64\\t\\n6/13/2019; \\t\\nNCT03674242\\ntarget + chemotherapy as\\t\\n(L‑asparaginase encapsulated\\t\\nnot received prior systemic\\t\\n\\t\\n\\t\\nDecember 2020\\nfirst line therapy\\t\\ninside a donor‑derived red blood\\t\\ntherapy\\n(TRYbeCA‑2, \\t\\ncell)\\nPhase II/III)\\nAntibody‑drug conjugate\\t\\nSacituzumab Govitecan vs. \\t\\nRefractory/relapsed metastatic\\t\\nActive, not recruiting\\t\\n529\\t\\n11/3/2017; April 2020\\t\\nNCT02574455\\n(ASCENT)\\t\\n(eribulin, cape, gem, vinorelbine)\\nTNBC, triple‑negative breast cancer; AR, androgen receptor; A, doxorubicin; C, cyclophosphamide; Cape, capecitabine; Carbo, carboplatin; E, epirubicin; F, fluorouracil; Gem, gemcitabine; Nab‑pac, \\nNab‑paclitaxel); Pac, paclitaxel; gBRCAm, germline BRCA‑mutated. aEstimated Study Completion Date.\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1252\\nNeoadjuvant and adjuvant settings. A PARP inhibitor appears \\nto have efficacy for neoadjuvant treatment of patients with \\ngBRCAm TNBC. Talazoparib achieved encouraging pCR \\nin patients with gBRCAm breast cancer, including TNBC, \\nand HR+ breast cancer, as a neoadjuvant single‑agent without \\nthe addition of chemotherapy\\xa0(46). Currently a larger, multi\\xad\\ncenter, neoadjuvant Phase\\xa0II trial (NCT03499353) is ongoing. \\nHowever, the addition of a PARP inhibitor to standard neoad\\xad\\njuvant chemotherapy was found to be not beneficial. In the \\nBrighTNess Phase\\xa0III trial (NCT02032277) the addition of \\nPARP inhibitor veliparib to carboplatin and paclitaxel followed \\nby doxorubicin and cyclophosphamide did not improve pCR \\nwhereas the addition of veliparib and carboplatin to paclitaxel \\ndid. Therefore, the addition of carboplatin but not veliparib to \\npaclitaxel was proposed as a potential component of neoad\\xad\\njuvant chemotherapy for patients with high‑risk TNBC\\xa0(47). \\nPARP inhibitors have also been studied as an adju\\xad\\nvant single‑agent therapy. The OlympiA Phase\\xa0 III trial \\n(NCT02032823) was designed to assess olaparib in patients \\nwith gBRCAm and high‑risk HER2‑negative breast cancer \\nwho completed definitive local treatment and neoadjuvant or \\nadjuvant chemotherapy. The primary outcome measure will be \\ninvasive DFS with a time frame of up to 10\\xa0years.\\nIn combination with immunotherapy. A crosstalk exists \\nbetween PARP inhibition and the PD‑L1/PD‑1 immune \\ncheckpoint axis. PARP inhibitors upregulate PD‑L1 expres\\xad\\nsion on tumor cells by inhibiting glycogen synthase kinase 3 \\nbeta (GSK3β) and activating the cGAS‑STING pathway\\xa0(48). \\nThus, primary/acquired resistance to PARP inhibitors seems \\nto be associated with the development of immune evasion \\nmechanisms. Multiple clinical studies are underway to assess \\nsynergy between therapeutic strategies of PARP inhibition and \\nimmune checkpoint blockers.\\nIn platinum‑resistant, advanced, or metastatic \\nTNBC, niraparib combined with pembrolizumab \\n(TOPACIO/KEYNOTE‑162 Phase\\xa0II trial, NCT02657889) \\nshowed higher response rates in patients with tumor Brca muta\\xad\\ntions (tBRCAm): ORR of 28% in all (biomarker‑unselected) \\npatients vs. 60% for tBRCAm patients. The combination \\ntherapy was safe with a tolerable safety profile\\xa0(49). \\nIn MEDIOLA Phase\\xa0I/II trial (NCT02734004) the combi\\xad\\nnation of olaparib and durvalumab showed ORR of 63% in a \\ncohort of patients with gBRCAm metastatic breast cancer\\xa0(50). \\nIn the I‑SPY 2 Phase\\xa0II study (NCT01042379), adding the same \\ncombination to neoadjuvant paclitaxel led to improved pCR \\nrates in patients with high‑risk, HER2‑negative stage\\xa0II/III \\nbreast cancer compared with single‑agent paclitaxel. In those \\nwith TNBC, the pCR rate was 47 vs. 27% with paclitaxel alone. \\nAEs were consistent with the known safety profiles of each \\nagent alone\\xa0(51). In metastatic TNBC, the efficacy of induction \\ntreatment of olaparib followed by the combination treatment of \\nolaparib and durvalumab is being assessed in a Phase\\xa0II study \\n(NCT03801369)\\xa0(52). Patients with ≤2 prior chemotherapy \\nregimens for metastatic breast cancer are eligible, but patients \\nwith gBRCAm TNBC are excluded. The primary end point is \\nORR. \\nThe DORA Phase\\xa0 II trial (NCT03167619) is evalu\\xad\\nating olaparib as a maintenance therapy with or without \\ndurvalumab in patients with advanced TNBC who achieve at \\nleast stable disease after 3\\xa0cycles of platinum‑based chemo\\xad\\ntherapy. Another study of a PARP inhibitor as a maintenance \\ntherapy, KEYLYNK‑009 Phase\\xa0II/III trial (NCT04191135), \\nis underway in metastatic TNBC to assess the efficacy of \\nolaparib plus pembrolizumab vs. chemotherapy plus pembro\\xad\\nlizumab after induction with first‑line chemotherapy plus \\npembrolizumab\\xa0(53).\\nIn combination with DDR‑HRR pathway inhibitors. \\nResistance to PARP inhibitors can occur in certain cancer \\ncontexts by various mechanisms, including increased HRR \\ncapacity and decreased cell cycle progression and DNA \\nreplication stress. RAD51 overexpression has been observed \\nin a wide range of human cancers, particularly TNBCs and \\nserous ovarian cancers\\xa0(54,55). Upregulation of RAD51 in \\nBRCA1‑defective cells is also associated with resistance to \\nPARP inhibitor\\xa0(56,57). Inhibitors of key mediators of DNA \\nrepair and replication, such as ataxia telangiectasia mutated \\nkinase (ATM), ataxia telangiectasia and Rad3‑related kinase \\n(ATR), checkpoint kinase 1 (CHK1) and checkpoint kinase \\n2 (CHK2), DNA‑dependent protein kinase (DNA‑PK), and \\nWEE1 kinase (Fig.\\xa03) have been assessed to determine if they \\ncan sensitize tumor cells to treatment with PARP inhibitors, \\nas these inhibitors were found to prevent the accumulation of \\nRAD51 in TNBC\\xa0(58).\\nThe VIOLETTE Phase\\xa0 II study (NCT03330847) was \\nset up to assess the combinatory inhibition of PARP and a \\ncomponent of the ATR‑CHK1‑WEE1 axis. Olaparib with \\nDDR kinase ATR inhibitor AZD6738 was compared to \\nolaparib monotherapy in the second‑ or third‑line setting of \\nmetastatic TNBC. Patients were stratified by Brca and HRR \\ngene mutation status and the primary endpoint was PFS\\xa0(59). \\nThe study also included a combination arm of olaparib with \\nthe first‑in‑class WEE1 inhibitor adavosertib. WEE1 inhibitor \\nwas found to potentiate the activity of DNA‑damaging agents \\nin preclinical TNBC models\\xa0(60,61) and its potential clinical \\nFigure 2. ATP‑adenosine pathway. Adenosine is generated from ATP by \\nCD39 and CD73. It binds to A2 receptors on immune cells and blocks T cell \\npriming, expansion, and activation, natural killer (NK) cell degranulation, \\ndendritic cell (DC) maturation and activation, and tumor‑associated macro\\xad\\nphage (TAM) M1 polarization, thus leading to immunosuppression. ATP, \\nadenosine triphosphate; AMP, adenosine monophosphate; CD, cluster of \\ndifferentiation.\\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1253\\nvalue was observed in a Phase\\xa0I study in patients with Brca \\nmutations\\xa0(62). However, the combination treatment arm of \\nolaparib and adavosertib was discontinued in the VIOLETTE \\nstudy and patients were offered the opportunity to continue \\ntreatment on olaparib monotherapy. The CHK1 inhibitor \\nprexasertib in combination with olaparib was also explored in \\nearly clinical trials\\xa0(63), but development of prexasertib was \\ndiscontinued by the sponsor in 2019. \\nIntracellular signaling pathway targets\\nPI3K/AKT pathway. A wide range of malignancies including \\nTNBC show dysregulated phosphatase and tensin homolog \\n(PTEN)/phosphoinositide 3‑kinases (PI3K)/protein kinase B \\n(AKT)/mammalian target of rapamycin (mTOR) signaling \\ndue to mutations in multiple signaling components. Loss \\nof PTEN, a negative regulator of AKT, was found to be \\ncorrelated with decreased T‑cell infiltration at tumor \\nsites in patients, and inhibition of the PI3K‑AKT pathway \\nre‑sensitized to T‑cell‑mediated immunotherapy\\xa0(64). As the \\nPI3K/AKT pathway has emerged as a potential mechanism \\nof resistance to immunotherapy and chemotherapy, multiple \\nclinical trials have assessed inhibitors of the various pathway \\ncomponents.\\nAlpelisib is an oral PI3K inhibitor that selectively inhibits \\np110α. It showed efficacy in targeting Pik3ca‑mutated breast \\ncancer\\xa0(65) and was FDA approved in 2019 in combination \\nwith fulvestrant for postmenopausal women and men, with \\nHR+, HER2‑negative, Pik3ca‑mutated, advanced or metastatic \\nbreast cancer following progression on or after an endo\\xad\\ncrine‑based regimen. For patients with advanced TNBC, the \\nEPIK‑B3 Phase\\xa0III trial (NCT04251533) is planned with study \\nstart date of April 2020 to assess alpelisib in combination with \\nnab‑paclitaxel. Patients have Pik3ca mutations or PTEN loss \\nwith ≤1 prior line of therapy for metastatic disease.\\nIPI‑549 is a selective PI3K‑gamma inhibitor targeting \\nimmune‑suppressive tumor‑associated myeloid cells. The \\nMARIO‑3 Phase\\xa0II study (NCT03961698) was designed to \\nexplore the addition of IPI‑549 to the FDA approved regimen \\natezolizumab/nab‑paclitaxel in front‑line TNBC. Cohort A \\nwill be composed of patients with locally advanced, metastatic \\nTNBC, which will include two sub‑cohorts based on PD‑L1 \\nIHC status. The primary objective is CR rate.\\nIpatasertib and capivasertib are pan‑AKT inhibitors that \\nbind to all three isoforms of AKT. Both are now in Phase\\xa0III \\ntrials evaluating the efficacy of combination with paclitaxel \\nas first‑line therapy for locally advanced or metastatic TNBC. \\nIn the LOTUS Phase\\xa0II trial, adding ipatasertib to first‑line \\npaclitaxel improved PFS, particularly in patients with \\nPTEN/PI3K/AKT‑altered tumors (HR, 0.44)\\xa0(66). In this \\nsubgroup of patients, median OS was 23.1 vs. 16.2\\xa0months with \\nplacebo (HR, 0.65)\\xa0(67). To confirm the findings from LOTUS, \\nthe IPATunity130 Phase\\xa0III trial (NCT03337724) is evaluating \\nipatasertib + paclitaxel for PTEN/PI3K/AKT‑altered advanced \\nTNBC or HR+, HER2‑negative breast cancers. The primary \\nendpoint is PFS\\xa0(68). An independent trial also supported the \\npotential benefit for addition of AKT inhibitor to chemotherapy. \\nIn the PAKT Phase\\xa0II study (NCT02423603), addition of the \\noral AKT inhibitor capivasertib to first‑line paclitaxel resulted \\nin significantly longer PFS and OS in patients with advanced \\nTNBC, especially in patients with PTEN/PI3K/AKT‑altered \\ntumors. The median PFS duration was 5.9 vs. 4.2\\xa0months with \\nplacebo, meeting the predefined significance level, and better \\nbenefit in patients with PTEN/PI3K/AKT‑altered tumors with \\nmedian PFS of 9.3\\xa0months (HR, 0.30). The median OS was \\nprolonged by 6.5\\xa0months with capivasertib\\xa0(69). The most \\ncommon AEs of grade ≥3 were diarrhea, infection, rash, and \\nfatigue, similar to those observed with ipatasertib in the LOTUS \\ntrial. The CAPItello‑290 Phase\\xa0III trial (NCT03997123) is \\nunderway and the primary endpoints are PFS and OS\\xa0(70).\\nEfficacy of immunotherapy was also found to be \\nenhanced by AKT inhibitors as a first‑line therapy for locally \\nadvanced/metastatic TNBC. Phase\\xa0Ib study (NCT03800836) \\nwas designed to evaluate the triplet combination of ipatasertib \\n(I), atezolizumab (A), and paclitaxel or nab‑paclitaxel (P). \\nPreliminary efficacy and safety data up to January 5, 2019 \\nshowed that the triplet regimen had promising antitumor \\nFigure 3. DNA damage response pathways. Double‑strand breaks (DSB) or single‑strand breaks (SSB) activate DNA damage response (DDR) pathways, \\nleading to cell cycle arrest and DNA repair or cell death depending on cell context. PARP1 senses DNA breaks and is involved in SSB repair. Oncogenic \\npathways including RAS, PI3K, AR, and MYC signaling can affect HR repair activity and contribute to resistance to PARP inhibitor treatment. MRN, \\nMRE11-RAD50-NBS1 complex; ATRIP, ATP interacting protein; HR, homologous recombination; NHEJ, non\\xadhomologous end joining; H2AX, histone \\nH2AX; XRCC4, X‑ray repair cross‑complementing protein 4; ATR, ataxia telangiectasia and Rad3‑related protein; CHK1/2, checkpoint kinase 1/2; CDK1/2, \\ncyclin‑dependent kinase 1/2; DNA‑PK, DNA‑dependent protein kinase; AR, androgen receptor; PI3K, phosphatidylinositol 3‑kinase.\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1254\\nactivity (73% confirmed ORR), irrespective of biomarker \\nPD‑L1 status or PTEN/PI3K/AKT alteration status, and \\nmanageable toxicity\\xa0(71). In Phase\\xa0III trial (NCT04177108), \\npatients were enrolled in two cohorts according to PD‑L1 \\nstatus: Cohort 1 for PD‑L1‑negative tumors and cohort 2 for \\nPD‑L1‑positive tumors. Three arms, P + I + A vs. P + I vs. P, \\nwill be evaluated in cohort 1 and 2 arms, P + I + A vs. P + A, \\nwill be evaluated in cohort 2.\\nCDK4/6/Rb/E2F pathway. The G1‑S phase checkpoint of the \\ncell cycle is regulated by CDK4/6 activity which is controlled \\nby their binding partners D‑type cyclins and p16 INK4 inhib\\xad\\nitor. The active CDK4/6‑cyclin D complex phosphorylates the \\nretinoblastoma (Rb) protein, thereby activating E2F function \\nand transition from G1 to S phase of the cell cycle\\xa0(72). The \\nFDA approved CDK4/6 inhibitors palbociclib, ribociclib, and \\nabemaciclib based on improvements in PFS for the treatment \\nof ER+, HER2‑negative advanced or metastatic breast cancer \\nin combination with an endocrine therapy. TNBCs with a Rb+, \\np16 INK4‑negative profile might represent the subpopulation \\nof TNBC suitable for treatment with CDK4/6 inhibitors.\\nPreclinical combination studies of CDK4/6 inhibitors with \\nchemotherapy suggest that the timing and sequence of drug \\nexposure/drug delivery schedule might play a critical role in \\ndrug activity, and the evaluation of different schedules of treat\\xad\\nment may represent a new approach\\xa0(73,74). The hypothesis was \\nthat reversible G1 arrest of palbociclib could synchronize tumor \\ncells in the cell cycle and following their re‑entry later would \\nensure a higher fraction in mitosis (M) phase when exposed \\nto paclitaxel. In the first combination trial for palbociclib and \\npaclitaxel (NCT01320592) an alternative dosing schedule was \\nfeasible and safe, without evidence of additive toxicity in Rb+ \\nbreast cancer regardless of subtype\\xa0(75). Phase\\xa0I follow‑up \\ntrial (NCT02599363) of ribocilcib and weekly paclitaxel is in \\nprogress in patients with Rb+ advanced breast cancer. In this \\nstudy, pharmacodynamic, histologic, and imaging biomarkers \\nwill be utilized to confirm synchronization and schedule and \\nidentify a patient population that benefits from this treatment \\napproach.\\nThe standard chemotherapy regimen causes treat\\xad\\nment‑limiting cumulative myelosuppression that may \\ncompromise antitumor efficacy in TNBC. CDK4/6 inhibitors \\ninduce transient G1 arrest in immune cells and hematopoietic \\nstem and progenitor cells, potentially helping to preserve \\nT‑cell function and bone marrow. To test this hypothesis, an \\ninvestigational CDK4/6 inhibitor trilaciclib in combination \\nwith gemcitabine and carboplatin was explored to evaluate \\nbenefit for patients with ≤2 prior chemotherapy regimens in \\nmetastatic TNBC. Phase\\xa0II trial (NCT02978716) was negative \\nfor a safety‑related primary endpoint (i.e. no difference in the \\nfrequency or duration of severe grade 4 neutropenia). However, \\nthe median OS was improved by more than 60%, which was \\nlikely due to increased chemotherapy duration and exposure. \\nTrilaciclib‑treated patients also had a higher number of acti\\xad\\nvated CD8+ T cells over the first 5\\xa0cycles of chemotherapy, \\nwhich potentially enhanced antitumor immunity\\xa0(76).\\nMYC and CDK. Transcription factor c‑MYC triggers selective \\ngene expression to promote cell growth and proliferation. It is \\namplified in several different cancer types including TNBC, \\nfunctioning as a proto‑oncogene\\xa0(77). c‑MYC compensates for \\nBRCA loss by upregulating HRR through increased RAD51 \\nexpression\\xa0(55,78). TNBC patients with high c‑MYC and \\nRAD51 expression exhibit poor prognosis and less favorable \\nresponse to chemotherapy and PARP inhibitors\\xa0(55,57,79). \\nc‑MYC blockade in TNBC was found to be synthetic lethal \\nwith PARP inhibitors, independent of BRCA status\\xa0(80). \\nc‑MYC pathway activation in TNBC is also synthetic \\nlethal with CDK inhibition\\xa0(81). Dinaciclib is a pan‑CDK \\n(CDK1/2/5/9) inhibitor and the combination with PARP1 \\ninhibitor veliparib is currently being pursued in patients with \\nadvanced solid tumors for which no curative therapy exists \\n(Phase\\xa0I trial, NCT01434316). Dinaciclib induced immuno\\xad\\ngenic cell death (ICD) but also increased expression of PD1 \\non tumor‑infiltrating T cells and expression of PD‑L1 on \\ntumor cells, thus limiting its antitumor effect in preclinical \\nstudies. However, dinaciclib inhibits tumor growth in combi\\xad\\nnation with anti‑PD‑1\\xa0(82). Phase\\xa0Ib trial (NCT01676753) \\nwas designed to evaluate the efficacy of combined dinaciclib \\nand pembrolizumab in patients with metastatic or locally \\nadvanced and unresectable TNBC. Its clinical benefit rate was \\n47% in preliminary efficacy analysis and high c‑MYC expres\\xad\\nsion correlated significantly with clinical response, warranting \\nfurther validation of c‑MYC as a predicative biomarker of \\nresponse to CDK/checkpoint inhibitors\\xa0(83). \\nAR antagonists. The androgen receptor (AR) is an intracellular \\nsteroid receptor that dimerizes and translocates to the nucleus \\nafter binding androgen ligands. In the nucleus, AR binds to \\nandrogen response elements to promote target gene transcrip\\xad\\ntion in a tissue‑specific manner. AR can also be activated \\nin a ligand‑independent manner through crosstalk with key \\nsignaling pathways, including PI3K/AKT and ERK\\xa0(84). AR \\nis involved in cell cycle regulation and the epithelial‑to‑mesen\\xad\\nchymal transition (EMT)\\xa0(85,86). AR has emerged as a new \\nbiomarker and a potential therapeutic target in TNBC. AR is \\nexpressed in ≥40% of TNBCs and its expression level varies \\nconsiderably among TNBC molecular subtypes. It has been \\nassociated with favorable prognosis, with better DFS and \\nhigher OS in the LAR subtype\\xa0(87,88). However, patients \\nwith AR+ TNBCs have a decreased chance of achieving pCR \\nto neoadjuvant chemotherapy and the LAR subtype has been \\nlinked to poorer response to chemotherapy compared to other \\nTNBC patients\\xa0(89‑91). Multiple selective AR inhibitors have \\nbeen approved by the FDA for the treatment of prostate cancer \\nand are currently part of standard care\\xa0(92). The role of the AR \\nin signaling pathways in TNBC is still not clear and clinical \\nstudies are underway to provide more insight into the role of \\nthe AR as well as to assess whether AR targeting is a valuable \\ntherapeutic strategy in TNBC.\\nThe first proof‑of‑concept trial of AR‑targeted treatment \\nestablished activity of the first‑generation AR antagonist \\nbicalutamide in patients with advanced AR+ TNBC. The \\nTBCRC 011 Phase\\xa0II trial (NCT00468715) showed a modest \\nclinical benefit rate (CBR) of 19% at 6\\xa0months and a median \\nPFS duration of 12\\xa0weeks\\xa0(93).\\nAR+ TNBC expresses a luminal profile with intact Rb \\nprotein, the target of CDK4/6 activity. Thus, CDK4/6 inhibi\\xad\\ntors may increase the efficacy of AR antagonists in metastatic \\nAR+ TNBC. The single group Phase\\xa0I/II trial (NCT02605486) \\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1255\\nwas carried out to explore this hypothesis. The combination \\nof palbociclib and bicalutamide was well‑tolerated with no \\nunexpected toxicity\\xa0(94). It also met its prespecified efficacy \\nendpoint as measured by PFS with 11\\xa0patients (31 evaluable \\npatients) at 6\\xa0months\\xa0(95).\\nAs one of the second‑generation anti‑androgen thera\\xad\\npies, abiraterone is a steroidal CYP17 inhibitor with potent \\nhydroxylase activity, targeting androgen biosynthesis. The \\nFrench Breast Cancer Intergroup (UCBG) 12‑1 Phase\\xa0II trial \\n(NCT01842321) was designed to evaluate abiraterone acetate \\n(AA) with its requisite concomitant medication prednisone \\nin AR+ advanced or metastatic TNBC. Androgen deprivation \\nby AA resulted in 20% of the 6‑month CBR. This treatment \\nappeared to be beneficial for some patients with molecular \\napocrine tumors, a subtype that expresses AR but not ERα\\xa0(96). \\nConsidering that prednisone stimulates the glucocorticoid \\nreceptor (GR), which is expressed in approximately 25% of \\nTNBCs, GR activity might limit the efficacy of AA.\\nSeviteronel is an investigational lyase‑selective \\nnon‑steroidal CYP17 inhibitor that targets androgen and \\nestrogen production. The CLARITY‑01 Phase\\xa0 I/II trial \\n(NCT02580448) was set up to evaluate seviteronel in locally \\nadvanced or metastatic TNBC or ER+ breast cancer. It revealed \\nthat seviteronel was generally well‑tolerated and provided \\nclinical benefit. A total of 26 and 11% of patients reached at \\nleast a CBR at 4 and 6\\xa0months, respectively. Levels of circu\\xad\\nlating tumor cells (CTCs) also decreased\\xa0(97,98).\\nA second‑generation AR antagonist enzalutamide not only \\ncompetitively binds to the AR ligand‑binding domain, but also \\ninhibits nuclear translocation of AR, DNA binding, and coacti\\xad\\nvator recruitment. Phase\\xa0II single arm study (NCT01889238) \\nassessed the efficacy of enzalutamide in patients with locally \\nadvanced or metastatic, AR+ TNBC. The primary endpoint \\nwas CBR at 16\\xa0weeks, which was 25% in the intention‑to‑treat \\n(ITT) population and 33% in the evaluable subgroup whose \\ntumors expressed ≥10% nuclear AR. The only treatment‑related \\ngrade 3 or greater AE occurring in ≥2% of patients was \\nfatigue (3.4%)\\xa0(99). The randomized ENDEAR Phase\\xa0III study \\n(NCT02929576) comparing enzalutamide and paclitaxel to \\nplacebo and paclitaxel in advanced TNBC was in place\\xa0(100) \\nbut withdrawn in 2018, citing that further understanding about \\nthe role of androgen signaling in TNBC was required. The \\nTBCRC 032 Phase\\xa0Ib/II trial (NCT02457910) investigated the \\nsafety and efficacy of enzalutamide alone or in combination with \\nPI3K inhibitor taselisib in patients with metastatic AR+ TNBC. \\nPrimary endpoint of CBR at 16\\xa0weeks was 36% and median PFS \\nwas 3.4\\xa0months. The trial was not completed due to termination of \\nthe development of taselisib. Although this study was exploratory \\ndue to sample size limitation, it revealed subtype‑specific treat\\xad\\nment response (favorable trend for luminal over non‑luminal) and \\nidentified novel Fgfr2 gene fusions that likely activate the PI3K \\npathway and AR splice variants that may contribute to enzalu\\xad\\ntamide resistance. Therefore, an AR IHC score of ≥10% alone \\nmay not identify patients with AR‑dependent tumors, and LAR \\nsubtype and AR splice variants may help identify patients likely \\nto benefit from AR antagonists\\xa0(101).\\nCell surface targets\\nTumor‑associated carbohydrate antigens. The Globo H \\nantigen is a hexasaccharyl sphingolipid expressed on the \\nsurface of various cancer types and has been explored as a \\npotential target for vaccine therapy. Adagloxad simolenin (AS) \\nis an immune stimulant comprising the Globo H hexasac\\xad\\ncharide epitope linked to the carrier protein keyhole limpet \\nhemocyanin (KLH). KLH facilitates a more vigorous immune \\nresponse given the weak antigen, Globo H. As a first‑in‑class \\nactive immunotherapy in development for metastatic breast \\ncancer, AS with the saponin‑based adjuvant OBI‑821 induced \\nantibodies reactive with Globo H+ tumor cells that mediate \\nantibody‑dependent cell‑mediated cytotoxicity (ADCC) and \\ncomplement‑dependent cytotoxicity (CDC)\\xa0(102). Phase\\xa0II \\ntrial (NCT01516307) assessed low‑dose cyclophosphamide \\nwith or without active immunotherapy (AS + adjuvant) in \\npost‑treated metastatic breast cancer subjects with stable \\ndisease or response to treatment. Although it did not meet its \\nprimary efficacy endpoint of PFS, patients who developed an \\nimmune response to the vaccine showed significantly improved \\nPFS and OS\\xa0(103). Based on these subgroup data, Phase\\xa0III \\nstudy (NCT03562637) of AS with adjuvant vs. placebo treat\\xad\\nment is in progress for high‑risk early‑stage TNBC patients \\nfollowing neoadjuvant or adjuvant chemotherapy. Patients will \\nbe screened for Globo H expression (IHC H‑score ≥15) and \\nthe primary objective is improvement of invasive disease‑free \\nsurvival (IDFS) in the time frame of 5\\xa0years.\\nAntibody‑drug conjugates (ADCs). An ADC is designed to \\nbe stable in plasma, target a tumor cell surface antigen with \\na high affinity and specificity, and is internalized, cleaved, \\nand releases a payload drug which drives antitumor activity \\nthrough direct cytotoxic cell killing and induces ICD.\\nSacituzumab govitecan‑hziy (SG) targets a glycoprotein, \\nthe human trophoblast cell‑surface antigen 2 (TROP‑2), that \\nis expressed in more than 90% of TNBCs. Its payload is the \\nactive metabolite of irinotecan (SN‑38), which is conjugated \\nto the anti‑TROP‑2 antibody by a cleavable linker. Phase\\xa0I/II \\nsingle group study (NCT01631552) included 108\\xa0patients with \\nTNBC and 80% of patients had visceral metastases. The \\nmedian number of prior regimens was 3 (range, 2‑10), which \\nincluded chemotherapies and checkpoint inhibitors. Although \\nit did not include biomarker selection of patients, 57\\xa0patients \\nhad moderate (2+) to strong (3+) and 5\\xa0patients had weak \\nor absent TROP‑2 expression by IHC according to available \\ndata. The ORR was 33% and the median duration of response \\n(DOR) was 7.7\\xa0months. The median PFS was 5.5\\xa0months and \\nthe median OS was 13.0\\xa0months. Myelotoxic effects were the \\nmain adverse reactions and grade 3 or 4 AEs included anemia \\nand neutropenia\\xa0(104). The confirmatory ASCENT Phase\\xa0III \\nstudy (NCT02574455) of SG in comparison with treatment \\nof physician's choice for patients with metastatic TNBC \\nwas stopped due to compelling evidence of efficacy across \\nmultiple endpoints and SG was granted accelerated approval \\nby the FDA based on the results of the IMMU‑132‑01 Phase\\xa0II \\nclinical trial for the treatment of adult patients with metastatic \\nTNBC who have received ≥2 prior therapies for metastatic \\ndisease. It is the first ADC approved by the FDA specifically \\nfor relapsed or refractory metastatic TNBC as well as the first \\nFDA‑approved anti‑TROP‑2 ADC. \\nLadiratuzumab vedotin (LV) targets LIV‑1, which is \\nexpressed in >90% of breast tumors with limited expression \\nin normal tissues. LIV‑1 is a transmembrane protein with \\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1256\\nzinc transporter and metalloproteinase activity. The payload \\nof LV is the microtubule disrupting agent monomethyl \\nauristatin E (MMAE). Phase\\xa0I study (NCT01969643) in \\npatients with heavily pretreated metastatic TNBC showed \\n25% ORR and medium PFS of 11\\xa0weeks. Treatment was \\ngenerally well‑tolerated and related AEs were neutropenia, \\nanemia, and neuropathy\\xa0(105). LV was further explored \\nin combination studies and in earlier lines of treatment. \\nThe SGNLVA‑002 Phase\\xa0Ib/II trial (NCT03310957) was \\ndesigned to assess whether combining LV and pembroli\\xad\\nzumab results in synergistic activity through LV‑induced \\nICD that creates a microenvironment favorable for \\nenhanced anti‑PD‑L1 activity. It was for first‑line treatment \\nof patients with unresectable locally advanced or metastatic \\nTNBC. Initial dose‑finding studies revealed ORR of 35% \\nwith responses independent of PD‑L1 status and manage\\xad\\nable toxicity\\xa0(106).\\nADC has also been explored for HER2‑low or nega\\xad\\ntive breast cancer. The rationale is based on the bystander \\neffect, that is, the cleaved drug from an ADC may leak from \\nthe targeted tumor cell and affect cells in close proximity \\nregardless of their target antigen expression status. Thus, an \\nADC having a high drug‑to‑antibody ratio and high‑potency \\npayload would increase the killing of tumor cells even with \\nlow HER2 expression. Trastuzumab deruxtecan (T‑DXd) \\nis the first HER2‑targeted agent to demonstrate promising \\nclinical antitumor activity with a manageable safety profile \\nin patients considered to be HER2‑negative. T‑DXd delivers \\na potent topoisomerase I inhibitor payload (an exatecan \\nderivative) which is linked to a humanized anti‑HER2 anti\\xad\\nbody. In Phase\\xa0Ib (NCT02564900) trial of T‑DXd for heavily \\npretreated patients with advanced HER2‑low breast cancer, \\nORR was 37% with the median DOR being 10.4\\xa0months. \\nMost toxicities were gastrointestinal or hematologic‑related, \\nand interstitial lung disease (ILD) was an important \\nidentified risk\\xa0(107). The DESTINY‑Breast04 Phase\\xa0III \\n(NCT03734029) was initiated to compare the efficacy and \\nsafety of T‑DXd to physician's choice (capecitabine, eribulin, \\ngemcitabine, paclitaxel, or nab‑paclitaxel) in patients \\nwith HER2‑low, unresectable, and/or metastatic breast \\ncancer\\xa0(108).\\n4. New potential therapeutic strategies\\nConversion of TNBC: Access to endocrine therapy. Gene \\nexpression analysis and functional studies have revealed a high \\ndegree of plasticity and heterogeneity in luminal and basal‑like \\ntumors. Expression of ERα, FOXA1 or GATA3 can result \\nin transition from basal‑like breast cancer to luminal type \\nwhereas epigenetic reprogramming can result in a reverse tran\\xad\\nsition\\xa0(109‑111). The CDK2‑EZH2 axis in tumors with TNBC \\nphenotype (i.e. basal‑like breast cancer) has been explored for \\nconversion to the ERα+ subtype. Epigenetic enzyme EZH2, a \\nhistone‑lysine N‑methyltransferase that promotes histone H3 \\nlysine 27 mono‑, di‑ and tri‑methylation (H3K27me1/2/3), \\ndrives transcriptional repression\\xa0(112,113). EZH2 can be \\nphosphorylated at T416 (pT416‑EZH2) by cyclin E/CDK2 and \\n>80% of TNBC patient specimens exhibit high pT416‑EZH2 \\nlevels, which correlate with poorer survival\\xa0(114). In preclinical \\nstudies, transgenic expression of a phospho‑mimicking mutant \\nEZH2(T416D) in the mammary glands of mice reprogramed \\nthe committed luminal breast cancer cells into the basal‑like \\nTNBC phenotype. In this setting inhibition of the CDK2‑EZH2 \\naxis by EZH2 inhibitors reactivated ERα expression and thus \\ncombination with tamoxifen suppressed tumor growth and \\nimproved the survival of mice bearing tumors with the TNBC \\nphenotype\\xa0(115). Therefore, inhibitors of CDK2 or EZH2 \\ncombined with hormonal therapy may be a novel therapeutic \\nstrategy in TNBC with especially high pT416‑EZH2 levels. \\nAnother mechanism‑based therapy exploits the lack of \\nER expression due to hypermethylation of the ERα promoter. \\nA combination epigenetic therapy of a DNA methyltrans\\xad\\nferase (DNMT) inhibitor and a histone deacetylase (HDAC) \\ninhibitor led to re‑expression of genes including ERα and \\nrestored tamoxifen sensitivity in ER‑negative breast cancer \\nmodels\\xa0(116,117). However, Phase\\xa0II study (NCT01349959) \\nin patients with advanced hormone‑resistant breast cancer \\nor TNBC revealed that combination of DNMT inhibitor \\n5‑azacitidine and HDAC inhibitor entinostat did not induce \\nERα expression and primary endpoint ORR was not met\\xa0(118). \\nERα re‑expression induced by DNMT/HDAC inhibition might \\nbe attenuated by an active CDK2‑EZH2 axis, which affected \\noutcomes in this study.\\nThe conversion of basal‑like breast cancer into ERα+ is \\nalso under microenvironmental control. A paracrine signaling \\nnetwork involving platelet‑derived growth factor (PDGF)‑CC \\nand PDGF receptor‑α accelerated tumor growth through \\nrecruitment and activation of different subsets of cancer‑asso\\xad\\nciated fibroblasts\\xa0(119). In mouse models, impairing PDGF \\nsignaling was found to convert basal‑like breast cancers into \\nERα+, and thus enhanced sensitivity to tamoxifen in previously \\nresistant tumors\\xa0(120). Therefore, PDGF inhibitors combined \\nwith endocrine therapy may be a novel therapeutic strategy in \\nTNBC treatment.\\nAdaptive clinical studies: Molecular markers. Under the \\nmaster protocol framework, basket trials, where a targeted \\ntherapy is evaluated for multiple diseases that share common \\nmolecular alterations, and umbrella trials, where multiple \\ntargeted therapies are evaluated for a single disease that is \\nstratified into multiple subgroups based on different molecular \\nfactors, have been developed\\xa0(121). Recently there have been \\nmore adaptive, signal‑finding clinical trial designs coupled \\nwith correlative studies to investigate mechanisms of action. \\nThey also facilitate identifying active drug combinations as \\nwell as novel tumor indications. Patients are enrolled based on \\nmolecular markers from genetic profiling performed on their \\ntumors. Some examples are listed below.\\nIn the OLAPCO Phase\\xa0II trial (NCT02576444), PARP \\ninhibitor olaparib was assessed in combination with various \\nagents according to identified tumor mutations. It included \\nAKT inhibitor capivasertib for tumors with mutations in \\nthe PI3K‑AKT pathway, WEE1 inhibitor adavosertib for \\ntumors with tp53 or/and Kras mutations, and ATR inhibitor \\nceralasertib for tumors with mutations in HRR genes. Primary \\noutcome measure was ORR, and the trial also identified \\ngenetic determinants of response and resistance. Another \\nPhase\\xa0II trial (NCT03718091) evaluated ATR inhibitor M6620 \\nin selected solid tumors. Patients were enrolled in different \\ncohorts based on tumor mutation status, including truncating \\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1257\\nAtm mutations, germline Brca mutations, somatic Brca muta\\xad\\ntions or other HRR gene mutations, c‑MYC amplification, \\nFbxw7 mutations, cyclin E amplification, and Arid1a muta\\xad\\ntions. Primary outcome measures included disease control rate \\n(DCR) and changes in pCHK1 and γH2AX levels. The I‑SPY \\n2 Phase\\xa0II trial (NCT01042379) was a neoadjuvant breast \\ncancer trial using response‑adaptive randomization. It had \\nmultiple concurrent experimental arms with shared controls. \\nEach biomarker signature was established at trial entry. A new \\nregimen of combination with standard chemotherapy will be \\nmoved up to Phase\\xa0III trial if it shows a high probability of \\nimproved pCR over standard chemotherapy.\\n5. Conclusion\\nDeveloping novel treatments in both early and advanced \\nTNBC settings remains a significant unmet need. Recent \\nadvances with novel agents have been made for specific \\nsubgroups with PD‑L1+ tumors or gBRCAm tumors. However, \\nonly a fraction of those patients respond to immune check\\xad\\npoint or PARP inhibitors, and even those who do respond \\noften develop resistance and relapse. In diverse tumor \\nmicroenvironments, a given therapeutic agent shows vari\\xad\\nable responses, thus compromising the survival endpoints \\nespecially in an unselected TNBC population. Therefore, \\ndeveloping novel predictive biomarkers are crucial for \\nselecting patients that will benefit the most from a given \\ntherapy. Single cell technologies will provide additional \\ninsight on tumor‑stroma interactions and facilitate compel\\xad\\nling rationale for new treatments based on novel biomarkers. \\nA non‑invasive testing of plasma circulating tumor DNA \\n(ctDNA) and CTCs can potentially provide real‑time disease \\nmonitoring and even early therapy modification. However, \\ntheir prognostic value needs further evaluation. With recent \\nadvances in multiomic analyses of cancers, there appears to \\nbe genomic and molecular similarities between TNBC and \\nhigh‑grade serous ovarian carcinoma (HGSOC), suggesting \\nthat similar biological mechanisms drive some aspects of \\nboth cancer types. Therefore, treatment strategies for HGSOC \\ncan be explored in TNBC as well. The recent increase in the \\nnumber of clinical trials investigating various new agents \\nand combination strategies reflects further efforts to under\\xad\\nstand molecular and immunological aspects of TNBC. This \\nmay lead to more meaningful clinical benefits, including \\nevent‑free and overall survival. \\nAcknowledgements \\nThe authors would like to thank Professor Ian Collins of the \\nInstitute of Cancer Research, UK for valuable discussions on \\nthe DNA damage response pathways and checkpoint kinases.\\nFunding \\nNo funding was declared.\\nAvailability of data and materials \\nAll information provided in this review is documented with \\nrelevant and current references.\\nAuthors' contributions\\nKAW was responsible for conceptualization, design, interpre\\xad\\ntation and visualization. KAW and CS were responsible for \\nwriting, reviewing and editing. Both authors approved the final \\nmanuscript. \\nEthics approval and consent to participate \\nNot applicable. \\nPatient consent for publication \\nNot applicable. \\nCompeting interests \\nNo competing interests are declared. \\nReferences\\n\\u2002 1.\\tLehmann\\xa0BD, Bauer\\xa0JA, Chen\\xa0X, Sanders\\xa0ME, Chakravarthy\\xa0AB, \\nShyr\\xa0Y and Pietenpol\\xa0JA: Identification of human triple‑negative \\nbreast cancer subtypes and preclinical models for selection of \\ntargeted therapies. J\\xa0Clin Invest\\xa0121: 2750‑2767, 2011.\\n\\u2002 2.\\tLehmann\\xa0BD, Jovanović\\xa0B, Chen\\xa0X, Estrada\\xa0MV, Johnson\\xa0KN, \\nShyr\\xa0Y, Moses\\xa0HL, Sanders\\xa0ME and Pietenpol\\xa0JA: Refinement of \\ntriple‑negative breast cancer molecular subtypes: Implications for \\nneoadjuvant chemotherapy selection. PLoS One\\xa011: e0157368, 2016.\\n\\u2002 3.\\tGiuliano\\xa0AE, Connolly\\xa0JL, Edge\\xa0SB, Mittendorf\\xa0EA, Rugo\\xa0HS, \\nSolin\\xa0 LJ, Weaver\\xa0 DL, Winchester\\xa0 DJ and Hortobagyi\\xa0 GN: \\nBreast cancer‑major changes in the American Joint Committee \\non cancer eighth edition cancer staging manual. CA Cancer \\nJ\\xa0Clin\\xa067: 290‑303, 2017.\\n\\u2002 4.\\tWolff\\xa0AC, Hammond\\xa0MEH, Allison\\xa0KH, Harvey\\xa0BE, Mangu\\xa0PB, \\nBartlett\\xa0JMS, Bilous\\xa0M, Ellis\\xa0IO, Fitzgibbons\\xa0P, Hanna\\xa0W,\\xa0et\\xa0al: \\nHuman epidermal growth factor receptor 2 testing in breast \\ncancer: American Society of Clinical Oncology/College of \\nAmerican pathologists clinical practice guideline focused \\nupdate. J\\xa0Clin Oncol\\xa036: 2105‑2122, 2018.\\n\\u2002 5.\\tAllison\\xa0 KH, Hammond\\xa0 MEH, Dowsett\\xa0 M, McKernin\\xa0 SE, \\nCarey\\xa0 LA, Fitzgibbons\\xa0 PL, Hayes\\xa0 DF, Lakhani\\xa0 SR, \\nChavez‑MacGregor\\xa0M, Perlmutter\\xa0J,\\xa0et\\xa0al: Estrogen and proges\\xad\\nterone receptor testing in breast cancer: ASCO/CAP guideline \\nupdate. J\\xa0Clin Oncol\\xa038: 1346‑1366, 2020.\\n\\u2002 6.\\tYam\\xa0C, Mani\\xa0SA and Moulder\\xa0SL: Targeting the molecular \\nsubtypes of triple negative breast cancer: Understanding the \\ndiversity to progress the field. Oncologist\\xa022: 1086‑1093, 2017.\\n\\u2002 7.\\t Bonotto\\xa0M, Gerratana\\xa0L, Poletto\\xa0E, Driol\\xa0P, Giangreco\\xa0M, \\nRusso\\xa0S, Minisini\\xa0AM, Andreetta\\xa0C, Mansutti\\xa0M, Pisa\\xa0FE,\\xa0et\\xa0al: \\nMeasures of outcome in metastatic breast cancer: Insights from a \\nreal‑world scenario. Oncologist\\xa019: 608‑615, 2014.\\n\\u2002 8.\\tKohler\\xa0BA, Sherman\\xa0RL, Howlader\\xa0N, Jemal\\xa0A, Ryerson\\xa0AB, \\nHenry\\xa0KA, Boscoe\\xa0FP, Cronin\\xa0KA, Lake\\xa0A, Noone\\xa0AM,\\xa0et\\xa0al: \\nAnnual report to the nation on the status of cancer, 1975‑2011, \\nfeaturing incidence of breast cancer subtypes by race/ethnicity, \\npoverty, and state. J\\xa0Natl Cancer Inst\\xa0107: djv048, 2015.\\n\\u2002 9.\\tO'Shaughnessy\\xa0J, Schwartzberg\\xa0L, Danso\\xa0MA, Miller\\xa0 KD, \\nRugo\\xa0 HS, Neubauer\\xa0 M, Robert\\xa0 N, Hellerstedt\\xa0 B, Saleh\\xa0 M, \\nRichards\\xa0P,\\xa0et\\xa0al: Phase\\xa0III study of iniparib plus gemcitabine \\nand carboplatin versus gemcitabine and carboplatin in patients \\nwith metastatic triple‑negative breast cancer. J\\xa0Clin Oncol\\xa032: \\n3840‑3847, 2014.\\n10.\\tCaswell‑Jin\\xa0 JL, Plevritis\\xa0 SK, Tian\\xa0 L, Cadham\\xa0 CJ, Xu\\xa0 C, \\nStout\\xa0NK, Sledge\\xa0GW, Mandelblatt\\xa0JS and Kurian\\xa0AW: Change \\nin survival in metastatic breast cancer with treatment advances: \\nMeta‑analysis and systematic review. JNCI Cancer Spectr\\xa02: \\npky062, 2018.\\n11.\\t Plevritis\\xa0 SK, Munoz\\xa0 D, Kurian\\xa0 AW, Stout\\xa0 NK, Alagoz\\xa0 O, \\nNear\\xa0AM, Lee\\xa0SJ, van\\xa0den\\xa0Broek\\xa0JJ, Huang\\xa0X, Schechter\\xa0CB,\\xa0et\\xa0al: \\nAssociation of screening and treatment with breast cancer \\nmortality by molecular subtype in US women, 2000‑2012. \\nJAMA\\xa0319: 154‑164, 2018.\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1258\\n12.\\tStanton\\xa0SE, Adams\\xa0S and Disis\\xa0ML: Variation in the incidence \\nand magnitude of tumor‑infiltrating lymphocytes in breast cancer \\nsubtypes: A systematic review. JAMA Oncol\\xa02: 1354‑1360, 2016. \\n13.\\tSafonov\\xa0A, Jiang\\xa0T, Bianchini\\xa0G, Győrffy\\xa0B, Karn\\xa0T, Hatzis\\xa0C and \\nPusztai\\xa0L: Immune gene expression is associated with genomic \\naberrations in breast cancer. Cancer Res\\xa077: 3317‑3324, 2017.\\n14.\\t Schmid\\xa0P, Adams\\xa0S, Rugo\\xa0HS, Schneeweiss\\xa0A, Barrios\\xa0CH, \\nIwata\\xa0H, Diéras\\xa0V, Hegg\\xa0R, Im\\xa0SA, Shaw\\xa0Wright\\xa0G,\\xa0et\\xa0al: \\nAtezolizumab and Nab‑Paclitaxel in advanced triple‑negative \\nbreast cancer. N Engl J\\xa0Med\\xa0379: 2108‑2121, 2018. \\n15.\\tSchmid\\xa0P, Rugo\\xa0HS, Adams\\xa0S, Schneeweiss\\xa0A, Barrios\\xa0CH, \\nIwata\\xa0H, Diéras\\xa0V, Henschel\\xa0V, Molinero\\xa0L, Chui\\xa0SY,\\xa0et\\xa0al: \\nAtezolizumab plus nab‑paclitaxel as first‑line treatment for \\nunresectable, locally advanced or metastatic triple‑negative \\nbreast cancer (IMpassion130): Updated efficacy results from a \\nrandomised, double‑blind, placebo‑controlled, phase 3 trial. \\nLancet Oncol\\xa021: 44‑59, 2020. \\n16.\\tDudley\\xa0JC, Lin\\xa0MT, Le\\xa0DT and Eshleman\\xa0JR: Microsatellite \\ninstability as a biomarker for PD‑1 blockade. Clin Cancer Res\\xa022: \\n813‑820, 2016.\\n17.\\t Bonneville\\xa0 R, Krook\\xa0 MA, Kautto\\xa0 EA, Miya\\xa0 J, Wing\\xa0 MR, \\nChen\\xa0HZ, Reeser\\xa0JW, Yu\\xa0L and Roychowdhury\\xa0S: Landscape \\nof microsatellite instability across 39 cancer types. JCO Precis \\nOncol\\xa02017: PO.17.00073, 2017.\\n18.\\tKurata\\xa0K, Kubo\\xa0M, Mori\\xa0H, Kawaji\\xa0H, Motoyama\\xa0Y, Kuroki\\xa0L, \\nYamada\\xa0M, Kaneshiro\\xa0K, Kai\\xa0M and Nakamura\\xa0M: Microsatellite \\ninstability in triple negative breast cancers. In: Proceedings of \\nthe 2018 San Antonio Breast Cancer Symposium. Cancer Res\\xa079 \\n(Suppl\\xa04): Abstract nr P1-06-11. 2019.\\n19.\\t Bryant\\xa0HE, Schultz\\xa0N, Thomas\\xa0HD, Parker\\xa0KM, Flower\\xa0D, \\nLopez\\xa0 E, Kyle\\xa0 S, Meuth\\xa0 M, Curtin\\xa0 NJ and Helleday\\xa0 T: \\nSpecific killing of BRCA2‑deficient tumours with inhibitors of \\npoly(ADP‑ribose) polymerase. Nature\\xa0434: 913‑917, 2005.\\n20.\\tFarmer\\xa0 H, McCabe\\xa0 N, Lord\\xa0 CJ, Tutt\\xa0 AN, Johnson\\xa0 DA, \\nRichardson\\xa0 TB, Santarosa\\xa0 M, Dillon\\xa0 KJ, Hickson\\xa0 I, \\nKnights\\xa0C,\\xa0et\\xa0al: Targeting the DNA repair defect in BRCA \\nmutant cells as a therapeutic strategy. Nature\\xa0434: 917‑921, 2005.\\n21.\\t Robson\\xa0M, Im\\xa0SA, Senkus\\xa0E, Xu\\xa0B, Domchek\\xa0SM, Masuda\\xa0N, \\nDelaloge\\xa0S, Li\\xa0W, Tung\\xa0N, Armstrong\\xa0A,\\xa0et\\xa0al: Olaparib for meta\\xad\\nstatic breast cancer in patients with a germline BRCA mutation. \\nN Engl J\\xa0Med\\xa0377: 523‑533, 2017. \\n22.\\tRobson\\xa0ME, Tung\\xa0N, Conte\\xa0P, Im\\xa0SA, Senkus\\xa0E, Xu\\xa0B, Masuda\\xa0N, \\nDelaloge\\xa0S, Li\\xa0W, Armstrong\\xa0A,\\xa0et\\xa0al: OlympiAD final overall \\nsurvival and tolerability results: Olaparib versus chemotherapy \\ntreatment of physician's choice in patients with a germline BRCA \\nmutation and HER2‑negative metastatic breast cancer. Ann \\nOncol\\xa030: 558‑566, 2019. \\n23.\\tLitton\\xa0JK, Rugo\\xa0HS, Ettl\\xa0J, Hurvitz\\xa0SA, Gonçalves\\xa0A, Lee\\xa0KH, \\nFehrenbacher\\xa0L, Yerushalmi\\xa0R, Mina\\xa0LA, Martin\\xa0M,\\xa0et\\xa0al: \\nTalazoparib in patients with advanced breast cancer and a germ\\xad\\nline BRCA mutation. N Engl J\\xa0Med\\xa0379: 753‑763, 2018. \\n24.\\tDenkert\\xa0C, von\\xa0Minckwitz\\xa0G, Darb‑Esfahani\\xa0S, Lederer\\xa0B, \\nHeppner\\xa0BI, Weber\\xa0KE, Budczies\\xa0J, Huober\\xa0J, Klauschen\\xa0F, \\nFurlanetto\\xa0J,\\xa0et\\xa0al: Tumour‑infiltrating lymphocytes and prog\\xad\\nnosis in different subtypes of breast cancer: A pooled analysis of \\n3771\\xa0patients treated with neoadjuvant therapy. Lancet Oncol\\xa019: \\n40‑50, 2018. \\n25.\\tHida\\xa0AI, Watanabe\\xa0T, Sagara\\xa0Y, Kashiwaba\\xa0M, Sagara\\xa0Y, Aogi\\xa0K, \\nOhi\\xa0Y and Tanimoto\\xa0A: Diffuse distribution of tumor‑infiltrating \\nlymphocytes is a marker for better prognosis and chemo\\xad\\ntherapeutic effect in triple‑negative breast cancer. Breast Cancer \\nRes\\xa0Treat 178: 283‑294, 2019. \\n26.\\tLoi\\xa0 S, Drubay\\xa0 D, Adams\\xa0 S, Pruneri\\xa0 G, Francis\\xa0 PA, \\nLacroix‑Triki\\xa0M, Joensuu\\xa0H, Dieci\\xa0MV, Badve\\xa0S, Demaria\\xa0S,\\xa0et\\xa0al: \\nTumor‑infiltrating lymphocytes and prognosis: A pooled \\nindividual patient analysis of early‑stage triple‑negative breast \\ncancers. J\\xa0Clin Oncol\\xa037: 559‑569, 2019. \\n27.\\t Galon\\xa0J and Bruni\\xa0D: Approaches to treat immune hot, altered \\nand cold tumours with combination immunotherapies. Nat Rev \\nDrug Discov\\xa018: 197‑218, 2019. \\n28.\\tAdams\\xa0S, Gatti‑Mays\\xa0ME, Kalinsky\\xa0K, Korde\\xa0LA, Sharon\\xa0E, \\nAmiri‑Kordestani\\xa0 L, Bear\\xa0 H, McArthur\\xa0 HL, Frank\\xa0 E, \\nPerlmutter\\xa0J,\\xa0et\\xa0al: Current landscape of immunotherapy in breast \\ncancer: A review. JAMA Oncol: Apr 11, 2019 (Epub ahead of print).\\n29.\\tSchmid\\xa0P, Salgado\\xa0R, Park\\xa0YH, Muñoz‑Couselo\\xa0E, Kim\\xa0SB, \\nSohn\\xa0 J, Im\\xa0 S‑A, Foukakis\\xa0 T, Kuemmel\\xa0 S, Dent\\xa0 R,\\xa0 et\\xa0 al: \\nPembrolizumab plus chemotherapy as neoadjuvant treatment of \\nhigh‑risk, early‑stage triple‑negative breast cancer: Results from \\nthe phase 1b open‑label, multicohort KEYNOTE‑173 study. Ann \\nOncol\\xa031: 569‑581, 2020. \\n30.\\tNanda\\xa0R, Liu\\xa0MC, Yau\\xa0C, Shatsky\\xa0R, Pusztai\\xa0L, Wallace\\xa0A, \\nChien\\xa0AJ, Forero‑Torres\\xa0A, Ellis\\xa0E, Han\\xa0H,\\xa0et\\xa0al: Effect of \\npembrolizumab plus neoadjuvant chemotherapy on Pathologic \\ncomplete response in women with early‑stage breast cancer: An \\nanalysis of the ongoing phase 2 adaptively randomized I‑SPY2 \\ntrial. JAMA Oncol\\xa06: 1‑9, 2020.\\n31.\\t Schmid\\xa0P, Cortes\\xa0J, Pusztai\\xa0L, McArthur\\xa0H, Kümmel\\xa0S, Bergh\\xa0J, \\nDenkert\\xa0C, Park\\xa0YH, Hui\\xa0R, Harbeck\\xa0N,\\xa0et\\xa0al: Pembrolizumab for \\nearly triple‑negative breast cancer. N Engl J\\xa0Med\\xa0382: 810‑821, \\n2020. \\n32.\\tGianni\\xa0L, Huang\\xa0CS, Egle\\xa0D, Bermejo\\xa0B, Zamagni\\xa0C, Thill\\xa0M, \\nAnton\\xa0A, Zambelli\\xa0S, Bianchini\\xa0G, Russo\\xa0S and Ciruelos\\xa0E: \\nPathologic complete response (pCR) to neoadjvaunt treat\\xad\\nment with or without atezolizumab in triple negative, early \\nhigh‑risk and locally advanced breast cancer. NeoTRIPaPDL1 \\nMichelangelo randomized study. In: Proceedings of the 2019 San \\nAntonio Breast Cancer Symposium. Cancer Res 80 (Suppl\\xa04): \\nAbstract nr GS3-04, 2020. \\n33.\\tMittendorf\\xa0E, Barrios\\xa0CH, Harbeck\\xa0N, Miles\\xa0D, Saji\\xa0S, Zhang\\xa0H, \\nDuc\\xa0AN, Rafii\\xa0S and Lai\\xa0C: IMpassion031: A phase\\xa0III study \\ncomparing neoadjuvant atezolizumab vs placebo in combination \\nwith nab‑paclitaxel‑based chemotherapy in early triple‑negative \\nbreast cancer (TNBC). In: Proceedings of the 2017 San Antonio \\nBreast Cancer Symposium. Cancer Res\\xa078 (Suppl\\xa04): Abstract nr \\nOT2-07-03, 2018.\\n34.\\tCortes\\xa0J, Cescon\\xa0DW, Rugo\\xa0HS, Nowecki\\xa0Z, Im\\xa0SA, Yusof\\xa0MM, \\nGallardo\\xa0 C, Lipatov\\xa0 O, Barrios\\xa0 CH, Holgado\\xa0 E,\\xa0 et\\xa0 al: \\nKEYNOTE‑355: Randomized, double‑blind, phase\\xa0III study of \\npembrolizumab + chemotherapy versus placebo + chemotherapy \\nfor previously untreated locally recurrent inoperable or meta\\xad\\nstatic triple‑negative breast cancer. J\\xa0Clin Oncol\\xa038: (Suppl\\xa015): \\nS1000‑S1000, 2020.\\n35.\\tVoorwerk\\xa0 L, Slagter\\xa0 M, Horlings\\xa0 HM, Sikorska\\xa0 K, \\nvan\\xa0de\\xa0Vijver\\xa0KK, de\\xa0Maaker\\xa0M, Nederlof\\xa0I, Kluin\\xa0RJC, \\nWarren\\xa0S, Ong\\xa0S,\\xa0et\\xa0al: Immune induction strategies in meta\\xad\\nstatic triple‑negative breast cancer to enhance the sensitivity \\nto PD‑1 blockade: The TONIC trial. Nat Med\\xa025: 920‑928, \\n2019. \\n36.\\tAllard\\xa0B, Longhi\\xa0MS, Robson\\xa0SC and Stagg\\xa0J: The ectonucleo\\xad\\ntidases CD39 and CD73: Novel checkpoint inhibitor targets. \\nImmunol Rev\\xa0276: 121‑144, 2017. \\n37.\\t Ghalamfarsa\\xa0G, Kazemi\\xa0MH, Raoofi\\xa0Mohseni\\xa0S, Masjedi\\xa0A, \\nHojjat‑Farsangi\\xa0M, Azizi\\xa0G, Yousefi\\xa0M and Jadidi‑Niaragh\\xa0F: \\nCD73 as a potential opportunity for cancer immunotherapy. \\nExpert Opin Ther Targets\\xa023: 127‑142, 2019.\\n38.\\tDuhant\\xa0X, Schandené\\xa0L, Bruyns\\xa0C, Gonzalez\\xa0NS, Goldman\\xa0M, \\nBoeynaems\\xa0JM and Communi\\xa0D: Extracellular adenine nucleo\\xad\\ntides inhibit the activation of human CD4+ T lymphocytes. \\nJ\\xa0Immunol\\xa0169: 15‑21, 2002. \\n39.\\t Allard\\xa0B, Beavis\\xa0PA, Darcy\\xa0PK and Stagg\\xa0J: Immunosuppressive \\nactivities of adenosine in cancer. Curr Opin Pharmacol\\xa029: 7‑16, \\n2016. \\n40.\\tOhta\\xa0A: A metabolic immune checkpoint: Adenosine in tumor \\nmicroenvironment. Front Immunol\\xa07: 109, 2016. \\n41.\\t Buisseret\\xa0L, Pommey\\xa0S, Allard\\xa0B, Garaud\\xa0S, Bergeron\\xa0 M, \\nCousineau\\xa0I, Ameye\\xa0L, Bareche\\xa0Y, Paesmans\\xa0M, Crown\\xa0JPA,\\xa0et\\xa0al: \\nClinical significance of CD73 in triple‑negative breast cancer: \\nMultiplex analysis of a phase\\xa0III clinical trial. Ann Oncol\\xa029: \\n1056‑1062, 2018. \\n42.\\tPowderly\\xa0J, Spira\\xa0A, Gutierrez\\xa0R, DiRenzo\\xa0D, Udyavar\\xa0A, \\nKarakunnel\\xa0JJ, Rieger\\xa0A, Colabella\\xa0J, Lai\\xa0DW and de\\xa0Souza\\xa0P: \\nPhase\\xa01 evaluation of AB928, a novel dual adenosine receptor \\nantagonist, combined with chemotherapy or AB122 (anti‑PD‑1) \\nin patients with advanced malignancies. Ann Oncol\\xa030 (Suppl\\xa05): \\nv475‑v532, 2019.\\n43.\\tHartman\\xa0 AR, Kaldate\\xa0 RR, Sailer\\xa0 LM, Painter\\xa0 L, \\nGrier\\xa0CE, Endsley\\xa0RR, Griffin\\xa0M, Hamilton\\xa0SA, Frye\\xa0CA, \\nSilberman\\xa0 MA,\\xa0 et\\xa0 al: Prevalence of BRCA mutations in \\nan unselected population of triple‑negative breast cancer. \\nCancer\\xa0118: 2787‑2795, 2012. \\n44.\\tOkuma\\xa0 HS and Yonemori\\xa0 K: BRCA gene mutations and \\npoly(ADP‑Ribose) polymerase inhibitors in triple‑negative \\nbreast cancer. Adv Exp Med Biol\\xa01026: 271‑286, 2017. \\n45.\\tLord\\xa0 CJ and Ashworth\\xa0 A: BRCAness revisited. Nat Rev \\nCancer\\xa016: 110‑120, 2016.\\n46.\\tLitton\\xa0JK, Scoggins\\xa0ME, Hess\\xa0KR, Adrada\\xa0BE, Murthy\\xa0RK, \\nDamodaran\\xa0S, DeSnyder\\xa0SM, Brewster\\xa0AM, Barcenas\\xa0CH, \\nValero\\xa0V,\\xa0et\\xa0al: Neoadjuvant talazoparib for patients with oper\\xad\\nable breast cancer with a germline BRCA pathogenic variant. \\nJ\\xa0Clin Oncol\\xa038: 388‑394, 2020. \\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1259\\n47.\\t Loibl\\xa0S, O'Shaughnessy\\xa0J, Untch\\xa0M, Sikov\\xa0WM, Rugo\\xa0HS, \\nMcKee\\xa0 MD, Huober\\xa0 J, Golshan\\xa0 M, von\\xa0 Minckwitz\\xa0 G, \\nMaag\\xa0D,\\xa0et\\xa0al: Addition of the PARP inhibitor veliparib plus \\ncarboplatin or carboplatin alone to standard neoadjuvant \\nchemotherapy in triple‑negative breast cancer (BrighTNess): A \\nrandomised, phase\\xa03 trial. Lancet Oncol\\xa019: 497‑509, 2018. \\n48.\\tJiao\\xa0S, Xia\\xa0W, Yamaguchi\\xa0H, Wei\\xa0Y, Chen\\xa0MK, Hsu\\xa0JM, Hsu\\xa0JL, \\nYu\\xa0WH, Du\\xa0Y, Lee\\xa0HH,\\xa0et\\xa0al: PARP inhibitor upregulates PD‑L1 \\nexpression and enhances cancer‑associated immunosuppression. \\nClin Cancer Res\\xa023: 3711‑3720, 2017. \\n49.\\tVinayak\\xa0S, Tolaney\\xa0SM, Schwartzberg\\xa0L, Mita\\xa0M, McCann\\xa0G, \\nTan\\xa0 AR, Wahner‑Hendrickson\\xa0 AE, Forero\\xa0 A, Anders\\xa0 C, \\nWulf\\xa0 GM,\\xa0 et\\xa0 al: Open‑label clinical trial of niraparib \\ncombined with pembrolizumab for treatment of advanced \\nor metastatic triple‑negative breast cancer. JAMA Oncol\\xa05: \\n1132‑1140, 2019. \\n50.\\tDomchek\\xa0S, Postel‑Vinay\\xa0S, Im\\xa0S, Park\\xa0YH, Delord\\xa0J, Italiano\\xa0A, \\nAlexandre\\xa0J, You\\xa0B, Bastian\\xa0S, Krebs\\xa0MG,\\xa0et\\xa0al: Phase II study \\nof olaparib (o) and durvalumab (d) (MEDIOLA): Updated results \\nin patients (pts) with germline BRCA‑mutated (gBRCAm) meta\\xad\\nstatic breast cancer (mbc). Ann Oncol\\xa030 (Suppl\\xa05): v475‑v532, \\n2019.\\n51.\\t Pusztai\\xa0L, Han\\xa0HS, Yau\\xa0C, Wolf\\xa0D, Wallace\\xa0AM, Shatsky\\xa0R, \\nHelsten\\xa0T, Boughey JC, Haddad T, Stringer‑Reasor E,\\xa0et\\xa0al: \\nDurvalumab in combination with olaparib and paclitaxel in \\nhigh‑risk HER2 negative stage\\xa0II/III breast cancer: Results from \\nthe I‑SPY 2 trial. In: Proceedings of the Annual Meeting of the \\nAmerican Association for Cancer Research 2020. Cancer Res\\xa080 \\n(Suppl\\xa016): Abstract nr CT011, 2020.\\n52.\\tMitri\\xa0 ZI, Vuky\\xa0 J, Kemmer\\xa0 KA, Savin\\xa0 MA, Parmar\\xa0 S, \\nKolodzie\\xa0 AK, Johnson\\xa0 B, Williams‑Belizaire\\xa0 R, Gray\\xa0 JW \\nand Mills\\xa0GB: A phase\\xa0II trial of olaparib and durvalumab in \\nmetastatic BRCA wild type triple‑negative breast cancer. J\\xa0Clin \\nOncol\\xa037: TPS1111, 2019. \\n53.\\t Rugo\\xa0HS, Llombart‑Cussac\\xa0A, Andre\\xa0F, Robson\\xa0ME, Saji\\xa0S, \\nHarbeck\\xa0N, Schmid\\xa0P, Cescon\\xa0DW, Ahn\\xa0JS, Nanda\\xa0R,\\xa0et\\xa0al: \\nKEYLYNK‑009: A phase II/III, open‑label, randomized study \\nof pembrolizumab (pembro) plus olaparib vs pembro plus \\nchemotherapy after induction with first‑line pembro plus chemo\\xad\\ntherapy in patients with locally recurrent inoperable or metastatic \\ntriple‑negative breast cancer (TNBC). J\\xa0Clin Oncol\\xa038: TPS596, \\n2020.\\n54.\\tMaacke\\xa0 H, Opitz\\xa0 S, Jost\\xa0 K, Hamdorf\\xa0 W, Henning\\xa0 W, \\nKrüger\\xa0S, Feller\\xa0AC, Lopens\\xa0A, Diedrich\\xa0K, Schwinger\\xa0E and \\nStürzbecher\\xa0HW: Over‑expression of wild‑type Rad51 correlates \\nwith histological grading of invasive ductal breast cancer. Int \\nJ\\xa0Cancer\\xa088: 907‑913, 2000.\\n55.\\t Martin\\xa0RW, Orelli\\xa0BJ, Yamazoe\\xa0M, Minn\\xa0AJ, Takeda\\xa0S and \\nBishop\\xa0DK: RAD51 up‑regulation bypasses BRCA1 function \\nand is a common feature of BRCA1‑deficient breast tumors. \\nCancer Res\\xa067: 9658‑9665, 2007.\\n56.\\tWiegmans\\xa0AP, Yap\\xa0PY, Ward\\xa0A, Lim\\xa0YC and Khanna\\xa0KK: \\nDifferences in expression of key DNA damage repair genes after \\nepigenetic‑induced BRCAness dictate synthetic lethality with \\nPARP1 inhibition. Mol Cancer Ther\\xa014: 2321‑2331, 2015.\\n57.\\t Liu\\xa0Y, Burness\\xa0ML, Martin‑Trevino\\xa0R, Guy\\xa0J, Bai\\xa0S, Harouaka\\xa0R, \\nBrooks\\xa0MD, Shang\\xa0L, Fox\\xa0A, Luther\\xa0TK,\\xa0et\\xa0al: RAD51 mediates \\nresistance of cancer stem cells to PARP inhibition in triple‑nega\\xad\\ntive breast cancer. Clin Cancer Res\\xa023: 514‑522, 2017.\\n58.\\tMarzio\\xa0A, Puccini\\xa0J, Kwon\\xa0Y, Maverakis\\xa0NK, Arbini\\xa0A, Sung\\xa0P, \\nBar‑Sagi\\xa0 D and Pagano\\xa0 M: The F‑Box domain‑dependent \\nactivity of EMI1 regulates PARPi sensitivity in triple‑negative \\nbreast cancers. Mol Cell\\xa073: 224‑237.e6, 2019. \\n59.\\t Tutt\\xa0A, Stephens\\xa0C, Frewer\\xa0P, Pierce\\xa0A, Rhee\\xa0J, So\\xa0K, Ottesen\\xa0L, \\nDean\\xa0E and Hollingsworth\\xa0SJ: VIOLETTE: A randomized phase \\nII study to assess DNA damage response inhibitors in combina\\xad\\ntion with olaparib (Ola) vs. Ola monotherapy in patients (pts) with \\nmetastatic, triple‑negative breast cancer (TNBC) stratified by \\nalterations in homologous recombination repair (HRR)‑related \\ngenes. J\\xa0Clin Oncol\\xa036 (Suppl\\xa015): TPS1112, 2018. \\n60.\\tHirai\\xa0H, Arai\\xa0T, Okada\\xa0M, Nishibata\\xa0T, Kobayashi\\xa0M, Sakai\\xa0N, \\nImagaki\\xa0K, Ohtani\\xa0J, Sakai\\xa0T, Yoshizumi\\xa0T,\\xa0et\\xa0al: MK‑1775, a \\nsmall molecule Wee1 inhibitor, enhances anti‑tumor efficacy of \\nvarious DNA‑damaging agents, including 5‑fluorouracil. Cancer \\nBiol Ther\\xa09: 514‑522, 2010.\\n61.\\t Pitts\\xa0 TM, Simmons\\xa0 DM, Bagby\\xa0 SM, Hartman\\xa0 SJ, \\nYacob\\xa0BW, Gittleman\\xa0B, Tentler\\xa0JJ, Cittelly\\xa0D, Ormond\\xa0DR, \\nMessersmith\\xa0WA,\\xa0et\\xa0al: Wee1 inhibition enhances the anti‑tumor \\neffects of capecitabine in preclinical models of triple‑negative \\nbreast cancer. Cancers (Basel)\\xa012: 719, 2020. \\n62.\\t Do\\xa0K, Wilsker\\xa0D, Ji\\xa0J, Zlott\\xa0J, Freshwater\\xa0T, Kinders\\xa0RJ, Collins\\xa0J, \\nChen\\xa0AP, Doroshow\\xa0JH and Kummar\\xa0S: Phase I study of single‑agent \\nAZD1775 (MK‑1775), a Wee1 kinase inhibitor, in patients with \\nrefractory solid tumors. J\\xa0Clin Oncol\\xa033: 3409‑3415, 2015.\\n63.\\tDo\\xa0 KT, Hill\\xa0 SJ, Kochupurakkal\\xa0 B, Supko\\xa0 JG, Gannon\\xa0 C, \\nAnderson\\xa0 A, Muzikansky\\xa0 A, Wolanski\\xa0 A, Hedglin\\xa0 J, \\nParmar\\xa0K,\\xa0et\\xa0al: Abstract CT232: Phase I combination study \\nof the CHK1 inhibitor prexasertib (LY2606368) and olaparib \\nin patients with high‑grade serous ovarian cancer and other \\nadvanced solid tumors. In: Proceedings of the American \\nAssociation for Cancer Research Annual Meeting 2019. Cancer \\nRes\\xa079 (Suppl\\xa013): Abstract nr CT232, 2019. \\n64.\\tPeng\\xa0W, Chen\\xa0JQ, Liu\\xa0C, Malu\\xa0S, Creasy\\xa0C, Tetzlaff\\xa0MT, Xu\\xa0C, \\nMcKenzie\\xa0JA, Zhang\\xa0C, Liang\\xa0X,\\xa0et\\xa0al: Loss of PTEN promotes \\nresistance to T cell‑mediated immunotherapy. Cancer Discov\\xa06: \\n202‑216, 2016.\\n65.\\tAndré\\xa0 F, Ciruelos\\xa0 E, Rubovszky\\xa0 G, Campone\\xa0 M, Loibl\\xa0 S, \\nRugo\\xa0HS, Iwata\\xa0H, Conte\\xa0P, Mayer\\xa0IA, Kaufman\\xa0B,\\xa0et\\xa0al: Alpelisib \\nfor PIK3CA‑mutated, hormone receptor‑positive advanced breast \\ncancer. N Engl J\\xa0Med\\xa0380: 1929‑1940, 2019. \\n66.\\tKim\\xa0SB, Dent\\xa0R, Im\\xa0SA, Espié\\xa0M, Blau\\xa0S, Tan\\xa0AR, Isakoff\\xa0SJ, \\nOliveira\\xa0M, Saura\\xa0C, Wongchenko\\xa0MJ,\\xa0et\\xa0al: Ipatasertib plus \\npaclitaxel versus placebo plus paclitaxel as first‑line therapy for \\nmetastatic triple‑negative breast cancer (LOTUS): A multicentre, \\nrandomised, double‑blind, placebo‑controlled, phase 2 trial. \\nLancet Oncol\\xa018: 1360‑1372, 2017.\\n67.\\t Dent\\xa0R, Im\\xa0SA, Espie\\xa0M, Blau\\xa0S, Tan\\xa0AR, Isakoff\\xa0SJ, Oliveira\\xa0M, \\nSaura\\xa0C, Wongchenko\\xa0M, Kapp\\xa0AV,\\xa0et\\xa0al: Overall survival (OS) \\nupdate of the double‑blind placebo (PBO)‑controlled random\\xad\\nized phase 2 LOTUS trial of first‑line ipatasertib (IPAT) + \\npaclitaxel (PAC) for locally advanced/metastatic triple‑negative \\nbreast cancer (mTNBC). J\\xa0Clin Oncol\\xa036: 1008, 2018.\\n68.\\tDent\\xa0 R, Kim\\xa0 SB, Oliveira\\xa0 M, Isakoff\\xa0 SJ, Barrios\\xa0 CH, \\nO'Shaughnessy\\xa0 J, Lu\\xa0 X, Wongchenko\\xa0 M, Bradley\\xa0 D, \\nMani\\xa0 A,\\xa0 et\\xa0 al: IPATunity130: A pivotal randomized phase \\nIII trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for \\nPIK3CA/AKT1/PTEN‑altered advanced triple‑negative (TN) or \\nhormone receptor‑positive HER2‑negative (HR+/HER2‑) breast \\ncancer (BC). J\\xa0Clin Oncol\\xa036 (Suppl 15): TPS1117, 2018.\\n69.\\tSchmid\\xa0 P, Abraham\\xa0 J, Chan\\xa0 S, Wheatley\\xa0 D, Brunt\\xa0 AM, \\nNemsadze\\xa0G, Baird\\xa0RD, Park\\xa0YH, Hall\\xa0PS, Perren\\xa0T,\\xa0et\\xa0al: \\nCapivasertib plus paclitaxel versus placebo plus paclitaxel as \\nfirst‑line therapy for metastatic triple‑negative breast cancer: The \\nPAKT trial. J\\xa0Clin Oncol\\xa038: 423‑433, 2020. \\n70.\\tSchmid\\xa0P, Cortes\\xa0J, Robson\\xa0M, Iwata\\xa0H, Hegg\\xa0R, Verma\\xa0S, \\nNechaeva\\xa0M, Xu\\xa0B, Haddad\\xa0V, Imedio\\xa0RE,\\xa0et\\xa0al: Abstract \\nOT2‑08‑02: Capivasertib and paclitaxel in first‑line treatment of \\npatients with metastatic triple‑negative breast cancer: A phase III \\ntrial (CAPItello‑290). In: Proceedings of the 2019 San Antonio \\nBreast Cancer Symposium. Cancer Res\\xa080 (Suppl\\xa04): Abstract \\nnr\\xa0OT2-08-02, 2020. \\n71.\\tSchmid\\xa0P, Loirat\\xa0D, Savas\\xa0P, Espinosa\\xa0E, Boni\\xa0V, Italiano\\xa0A, \\nWhite\\xa0S, Singel\\xa0MS, Withana\\xa0N, Mani\\xa0A,\\xa0et\\xa0al: Phase Ib study \\nevaluating a triplet combination of ipatasertib (IPAT), atezoli\\xad\\nzumab (atezo), and paclitaxel (PAC) or nab‑PAC as first‑line \\n(1L) therapy for locally advanced/metastatic triple‑negative \\nbreast cancer (TNBC). In: Proceedings of the American \\nAssociation for Cancer Research Annual Meeting 2019. \\nCancer Res\\xa079 (Suppl\\xa013): Abstract nr CT049, 2019. \\n72.\\tHanahan\\xa0D and Weinberg\\xa0RA: Hallmarks of cancer: The next \\ngeneration. Cell\\xa0144: 646‑674, 2011.\\n73.\\tDean\\xa0JL, McClendon\\xa0AK and Knudsen\\xa0ES: Modification of the \\nDNA damage response by therapeutic CDK4/6 inhibition. J\\xa0Biol \\nChem\\xa0287: 29075‑29087, 2012.\\n74.\\t Cretella\\xa0D, Fumarola\\xa0C, Bonelli\\xa0M, Alfieri\\xa0R, La\\xa0Monica\\xa0S, \\nDigiacomo\\xa0G, Cavazzoni\\xa0A, Galetti\\xa0M, Generali\\xa0D and Petronini\\xa0PG: \\nPre‑treatment with the CDK4/6 inhibitor palbociclib improves the \\nefficacy of paclitaxel in TNBC cells. Sci Rep\\xa09: 13014, 2019. \\n75.\\t Clark\\xa0AS, McAndrew\\xa0NP, Troxel\\xa0A, Feldman\\xa0M, Lal\\xa0P, Rosen\\xa0M, \\nBurrell\\xa0 J, Redlinger\\xa0 C, Gallagher\\xa0 M, Bradbury\\xa0 AR,\\xa0 et\\xa0 al: \\nCombination paclitaxel and palbociclib: Results of a phase I trial \\nin advanced breast cancer. Clin Cancer Res\\xa025: 2072‑2079, 2019. \\n76.\\tTan\\xa0AR, Wright\\xa0GS, Thummala\\xa0AR, Danso\\xa0MA, Popovic\\xa0L, \\nPluard\\xa0TJ, Han\\xa0HS, Vojnović\\xa0Ž, Vasev\\xa0N, Ma\\xa0L,\\xa0et\\xa0al: Trilaciclib \\nplus chemotherapy versus chemotherapy alone in patients \\nwith metastatic triple‑negative breast cancer: A multicentre, \\nrandomised, open‑label, phase 2 trial. Lancet Oncol\\xa0 20: \\n1587‑1601, 2019. \\n77.\\t Stine\\xa0ZE, Walton\\xa0ZE, Altman\\xa0BJ, Hsieh\\xa0AL and Dang\\xa0CV: MYC, \\nmetabolism, and cancer. Cancer Discov\\xa05: 1024‑1039, 2015.\\nWON  and  SPRUCK:  TNBC THERAPY: CURRENT AND FUTURE PERSPECTIVES\\n1260\\n78.\\tAmbrosio\\xa0S, Amente\\xa0S, Napolitano\\xa0G, Di\\xa0Palo\\xa0G, Lania\\xa0L \\nand Majello\\xa0B: MYC impairs resolution of site‑specific DNA \\ndouble‑strand breaks repair. Mutat Res\\xa0774: 6‑13, 2015. \\n79.\\t Wiegmans\\xa0 AP, Al‑Ejeh\\xa0 F, Chee\\xa0 N, Yap\\xa0 PY, Gorski\\xa0 JJ, \\nDa\\xa0Silva\\xa0L, Bolderson\\xa0E, Chenevix‑Trench\\xa0G, Anderson\\xa0R, \\nSimpson\\xa0PT,\\xa0et\\xa0al: Rad51 supports triple negative breast cancer \\nmetastasis. Oncotarget\\xa05: 3261‑3272, 2014.\\n80.\\tCarey\\xa0JPW, Karakas\\xa0C, Bui\\xa0T, Chen\\xa0X, Vijayaraghavan\\xa0S, Zhao\\xa0Y, \\nWang\\xa0J, Mikule\\xa0K, Litton\\xa0JK, Hunt\\xa0KK and Keyomarsi\\xa0K: \\nSynthetic lethality of PARP inhibitors in combination with MYC \\nblockade is independent of BRCA status in triple negative breast \\ncancer. Cancer Res\\xa078: 742‑757, 2018. \\n81.\\t Horiuchi\\xa0D, Kusdra\\xa0L, Huskey\\xa0NE, Chandriani\\xa0S, Lenburg\\xa0ME, \\nGonzalez‑Angulo\\xa0AM, Creasman\\xa0KJ, Bazarov\\xa0AV, Smyth\\xa0JW, \\nDavis\\xa0SE,\\xa0et\\xa0al: MYC pathway activation in triple‑negative breast \\ncancer is synthetic lethal with CDK inhibition. J\\xa0Exp Med\\xa0209: \\n679‑696, 2012.\\n82.\\tHossain\\xa0DMS, Javaid\\xa0S, Cai\\xa0M, Zhang\\xa0C, Sawant\\xa0A, Hinton\\xa0M, \\nSathe\\xa0 M, Grein\\xa0 J, Blumenschein\\xa0 W, Pinheiro\\xa0 EM and \\nChackerian\\xa0 A: Dinaciclib induces immunogenic cell death \\nand enhances anti‑PD1‑mediated tumor suppression. J\\xa0Clin \\nInvest\\xa0128: 644‑654, 2018. \\n83.\\tChien\\xa0AJ, Gliwa\\xa0AS, Rahmaputri\\xa0S, Dittrich\\xa0HF, Majure\\xa0MC, \\nRugo\\xa0HS, Melisko\\xa0ME, Munster\\xa0PN, Park\\xa0JW, Moasser\\xa0MM,\\xa0et\\xa0al: \\nA phase Ib trial of the cyclin‑dependent kinase inhibitor dinaci\\xad\\nclib (dina) in combination with pembrolizumab (P) in patients \\nwith advanced triple‑negative breast cancer (TNBC) and \\nresponse correlation with MYC‑overexpression. J\\xa0Clin Oncol\\xa038: \\n1076, 2020\\n84.\\tKono\\xa0M, Fujii\\xa0T, Lim\\xa0B, Karuturi\\xa0MS, Tripathy\\xa0D and Ueno\\xa0NT: \\nAndrogen receptor function and androgen receptor‑targeted thera\\xad\\npies in breast cancer: A Review. JAMA Oncol\\xa03: 1266‑1273, 2017. \\n85.\\tGerratana\\xa0L, Basile\\xa0D, Buono\\xa0G, De\\xa0Placido\\xa0S, Giuliano\\xa0M, \\nMinichillo\\xa0 S, Coinu\\xa0 A, Martorana\\xa0 F, De\\xa0 Santo\\xa0 I, \\nDel\\xa0Mastro\\xa0L,\\xa0et\\xa0al: Androgen receptor in triple negative breast \\ncancer: A potential target for the targetless subtype. Cancer Treat \\nRev\\xa068: 102‑110, 2018. \\n86.\\tAnestis\\xa0 A, Zoi\\xa0 I, Papavassiliou\\xa0 AG and Karamouzis\\xa0 MV: \\nAndrogen receptor in breast cancer‑clinical and preclinical \\nresearch insights. Molecules\\xa025: 358, 2020 \\n87.\\t Masuda\\xa0H, Baggerly\\xa0KA, Wang\\xa0Y, Zhang\\xa0Y, Gonzalez‑Angulo\\xa0AM, \\nMeric‑Bernstam\\xa0 F, Valero\\xa0 V, Lehmann\\xa0 BD, Pietenpol\\xa0 JA, \\nHortobagyi\\xa0GN,\\xa0et\\xa0al: Differential response to neoadjuvant \\nchemotherapy among 7 triple‑negative breast cancer molecular \\nsubtypes. Clin Cancer Res\\xa019: 5533‑5540, 2013.\\n88.\\tThike\\xa0 AA, Yong‑Zheng Chong\\xa0 L, Cheok\\xa0 PY, Li\\xa0 HH, \\nWai‑Cheong\\xa0Yip\\xa0G, Huat\\xa0Bay\\xa0B, Tse\\xa0GM, Iqbal\\xa0J and Tan\\xa0PH: \\nLoss of androgen receptor expression predicts early recurrence \\nin triple‑negative and basal‑like breast cancer. Mod Pathol\\xa027: \\n352‑360, 2014.\\n89.\\tEchavarria\\xa0I, Lopez‑Tarruella\\xa0S, Picornell\\xa0A, García‑Saenz\\xa0JA, \\nJerez\\xa0Y, Hoadley\\xa0K, Gómez\\xa0HL, Moreno\\xa0F, Monte‑Millan\\xa0MD, \\nMárquez‑Rodas\\xa0I,\\xa0et\\xa0al: Pathological response in a triple‑negative \\nbreast cancer cohort treated with neoadjuvant carboplatin and \\ndocetaxel according to Lehmann's refined classification. Clin \\nCancer Res\\xa024: 1845‑1852, 2018.\\n90.\\tSantonja\\xa0A, Sánchez‑Muñoz\\xa0A, Lluch\\xa0A, Chica‑Parrado\\xa0MR, \\nAlbanell\\xa0 J, Chacón\\xa0 JI, Antolín\\xa0 S, Jerez\\xa0 JM, de\\xa0 la\\xa0 Haba\\xa0 J, \\nde\\xa0Luque\\xa0V,\\xa0et\\xa0al: Triple negative breast cancer subtypes and \\npathologic complete response rate to neoadjuvant chemotherapy. \\nOncotarget\\xa09: 26406‑26416, 2018.\\n91.\\t Venema\\xa0 CM, Bense\\xa0 RD, Steenbruggen\\xa0 TG, Nienhuis\\xa0 HH, \\nQiu\\xa0SQ, van\\xa0Kruchten\\xa0M, Brown\\xa0M, Tamimi\\xa0RM, Hospers\\xa0GAP, \\nSchröder\\xa0CP,\\xa0et\\xa0al: Consideration of breast cancer subtype in \\ntargeting the androgen receptor. Pharmacol Ther\\xa0200: 135‑147, 2019. \\n92.\\tRice\\xa0MA, Malhotra\\xa0SV and Stoyanova\\xa0T: Second‑generation \\nantiandrogens: From discovery to standard of care in castration \\nresistant prostate cancer. Front Oncol\\xa09: 801, 2019. \\n93.\\tGucalp\\xa0A, Tolaney\\xa0S, Isakoff\\xa0SJ, Ingle\\xa0JN, Liu\\xa0MC, Carey\\xa0LA, \\nBlackwell\\xa0K, Rugo\\xa0H, Nabell\\xa0L, Forero\\xa0A,\\xa0et\\xa0al: Phase II trial \\nof bicalutamide in patients with androgen receptor‑positive, \\nestrogen receptor‑negative metastatic breast cancer. Clin Cancer \\nRes\\xa019: 5505‑5512, 2013.\\n94.\\tGucalp\\xa0A, Edelweiss\\xa0M, Patil\\xa0S, Gounder\\xa0MM, Feigin\\xa0KN, \\nCorben\\xa0 A, Arumov\\xa0 A and Traina\\xa0 TA: Abstract P3‑11‑04: \\nPhase\\xa0I/II trial of palbociclib in combination with bicalutamide \\nfor the treatment of androgen receptor (AR)+ metastatic breast \\ncancer (MBC). In: Proceedings of the 2017 San Antonio Breast \\nCancer Symposium. Cancer Res 2018;78 (Suppl\\xa04): Abstract \\nnr\\xa0P3-11-04, 2018. \\n\\u2002 95.\\tGucalp\\xa0A, Boyle\\xa0LA, Alano\\xa0T, Arumov\\xa0A, Gounder\\xa0MM, \\nPatil\\xa0S, Feigin\\xa0K, Edelweiss\\xa0M, D'Andrea\\xa0G, Bromberg\\xa0J,\\xa0et\\xa0al: \\nPhase II trial of bicalutamide in combination with palbociclib \\nfor the treatment of androgen receptor (+) metastatic breast \\ncancer. J\\xa0Clin Oncol\\xa038, 2020.\\n\\u2002 96.\\tBonnefoi\\xa0H, Grellety\\xa0T, Tredan\\xa0O, Saghatchian\\xa0M, Dalenc\\xa0F, \\nMailliez\\xa0 A, L'Haridon\\xa0 T, Cottu\\xa0 P, Abadie‑Lacourtoisie\\xa0 S, \\nYou\\xa0B,\\xa0et\\xa0al: A phase II trial of abiraterone acetate plus predni\\xad\\nsone in patients with triple‑negative androgen receptor positive \\nlocally advanced or metastatic breast cancer (UCBG 12‑1). Ann \\nOncol\\xa027: 812‑818, 2016. \\n\\u2002 97.\\tGucalp\\xa0A, Danso\\xa0MA, Elias\\xa0AD, Bardia\\xa0A, Ali\\xa0HY, Potter\\xa0D, \\nGabrail\\xa0NY, Haley\\xa0BB, Khong\\xa0HT, Riley\\xa0EC,\\xa0et\\xa0al: Phase \\n(Ph) 2 stage 1 clinical activity of seviteronel, a selective \\nCYP17‑lyase and androgen receptor (AR) inhibitor, in women \\nwith advanced AR+ triple‑negative breast cancer (TNBC) or \\nestrogen receptor (ER)+ BC: CLARITY‑01. J\\xa0Clin Oncol\\xa035: \\n1102, 2017.\\n\\u2002 98.\\tBardia\\xa0A, Gucalp\\xa0A, DaCosta\\xa0N, Gabrail\\xa0N, Danso\\xa0M, Ali\\xa0H, \\nBlackwell\\xa0 KL, Carey\\xa0 LA, Eisner\\xa0 JR, Baskin‑Bey\\xa0 ES and \\nTraina\\xa0TA: Phase 1 study of seviteronel, a selective CYP17 \\nlyase and androgen receptor inhibitor, in women with estrogen \\nreceptor‑positive or triple‑negative breast cancer. Breast Cancer \\nRes Treat.\\xa0171: 111‑120, 2018. \\n\\u2002 99.\\tTraina\\xa0TA, Miller\\xa0K, Yardley\\xa0DA, Eakle\\xa0J, Schwartzberg\\xa0LS, \\nO'Shaughnessy\\xa0 J, Gradishar\\xa0 W, Schmid\\xa0 P, Winer\\xa0 E, \\nKelly\\xa0C,\\xa0et\\xa0al: Enzalutamide for the treatment of androgen \\nreceptor‑expressing triple‑negative breast cancer. J\\xa0 Clin \\nOncol\\xa036: 884‑890, 2018. \\n100.\\tDent\\xa0R, Schmid\\xa0P, Cortes\\xa0J, Kim\\xa0SB, Andre\\xa0F, Abramson\\xa0V, \\nCardoso\\xa0F, Colleoni\\xa0M, Morris\\xa0P, Steinberg\\xa0J,\\xa0et\\xa0al: Abstract \\nOT3‑02‑02: ENDEAR: A randomized international phase \\n3 study comparing the efficacy and safety of enzalutamide \\nin combination with paclitaxel chemotherapy or as mono\\xad\\ntherapy vs placebo with paclitaxel in patients with advanced \\ndiagnostic‑positive triple‑negative breast cancer. Cancer Res\\xa077: \\nAbstract OT3‑02‑02, 2017. \\n101.\\tLehmann\\xa0 BD, Abramson\\xa0 VG, Sanders\\xa0 ME, Mayer\\xa0 EL, \\nHaddad\\xa0TC, Nanda\\xa0R, Van\\xa0Poznak\\xa0C, Storniolo\\xa0AM, Nangia\\xa0JR, \\nGonzalez‑Ericsson\\xa0PI,\\xa0et\\xa0al: TBCRC 032 IB/II multicenter \\nstudy: Molecular insights to AR antagonist and PI3K inhibitor \\nefficacy in patients with AR+ metastatic triple‑negative breast \\ncancer. Clin Cancer Res\\xa026: 2111‑2123, 2020.\\n102.\\tGilewski\\xa0T, Ragupathi\\xa0G, Bhuta\\xa0S, Williams\\xa0LJ, Musselli\\xa0C, \\nZhang\\xa0 XF, Bornmann\\xa0 WG, Spassova\\xa0 M, Bencsath\\xa0 KP, \\nPanageas\\xa0KS,\\xa0et\\xa0al: Immunization of metastatic breast cancer \\npatients with a fully synthetic globo H conjugate: A phase I trial. \\nProc Natl Acad Sci USA\\xa098: 3270‑3275, 2001.\\n103.\\tHuang\\xa0 CS, Yu\\xa0 AL, Tseng\\xa0 LM, Chow\\xa0 LWC, Hou\\xa0 MF, \\nHurvitz\\xa0SA, Schwab\\xa0RB, Wong\\xa0CH, Murray\\xa0JL, Chang\\xa0SC,\\xa0et\\xa0al: \\nRandomized phase II/III trial of active immunotherapy with \\nOPT‑822/OPT‑821 in patients with metastatic breast cancer. \\nJ\\xa0Clin Oncol\\xa034 (Suppl\\xa015): S1003, 2016. \\n104.\\tBardia\\xa0 A, Mayer\\xa0 IA, Vahdat\\xa0 LT, Tolaney\\xa0 SM, Isakoff\\xa0 SJ, \\nDiamond\\xa0 JR, O'Shaughnessy\\xa0 J, Moroose\\xa0 RL, Santin\\xa0 AD, \\nAbramson\\xa0VG,\\xa0et\\xa0al: Sacituzumab govitecan‑hziy in refrac\\xad\\ntory metastatic triple‑negative breast cancer. N Eng J\\xa0Med\\xa0380: \\n741‑751, 2019. \\n105.\\tModi\\xa0S, Pusztai\\xa0L, Forero\\xa0A, Mita\\xa0M, Miller\\xa0KD, Weise\\xa0A, \\nBurris\\xa0H\\xa0III, Kalinsky\\xa0K, Tsai\\xa0M, Liu\\xa0MC,\\xa0et\\xa0al: Abstract PD3‑14: \\nPhase 1 study of the antibody‑drug conjugate SGN‑LIV1A in \\npatients with heavily pretreated triple‑negative metastatic breast \\ncancer. Cancer Res\\xa078, 2018. \\n106.\\tHan\\xa0 HS, Alemany\\xa0 CA, Brown‑Glaberman\\xa0 UA, Pluard\\xa0 TJ, \\nSinha\\xa0 R, Sterrenberg\\xa0 D, Albain\\xa0 KS, Basho\\xa0 RK, Biggs\\xa0 D, \\nBoni\\xa0V,\\xa0et\\xa0al: SGNLVA‑002: Single‑arm, open label phase \\nIb/II study of ladiratuzumab vedotin (LV) in combination with \\npembrolizumab for first‑line treatment of patients with unresect\\xad\\nable locally advanced or metastatic triple‑negative breast cancer. \\nJ\\xa0Clin Oncol\\xa037 (Suppl\\xa015): TPS1110, 2019. \\n107.\\tModi\\xa0S, Park\\xa0H, Murthy\\xa0RK, Iwata\\xa0H, Tamura\\xa0K, Tsurutani\\xa0J, \\nMoreno‑Aspitia\\xa0A, Doi\\xa0T, Sagara\\xa0Y, Redfern\\xa0C,\\xa0et\\xa0al: Antitumor \\nactivity and safety of trastuzumab Deruxtecan in patients with \\nHER2‑low‑expressing advanced breast cancer: Results from a \\nphase Ib study. J\\xa0Clin Oncol\\xa038: 1887‑1896, 2020.\\n108.\\tModi\\xa0S, Ohtani\\xa0S, Lee\\xa0CC, Wang\\xa0K, Saxena\\xa0K and Cameron\\xa0DA: \\nA phase III, multicenter, randomized, open label trial of [fam‑] \\ntrastuzumab deruxtecan (DS‑8201a) versus investigator's \\nchoice in HER2‑low breast cancer. J\\xa0Clin Oncol\\xa037: (Suppl\\xa015): \\nTPS1102, 2019.\\nINTERNATIONAL JOURNAL OF ONCOLOGY  57:  1245-1261,  2020\\n1261\\n109.\\t Molyneux\\xa0G, Geyer\\xa0FC, Magnay\\xa0FA, McCarthy\\xa0A, Kendrick\\xa0H, \\nNatrajan\\xa0R, Mackay\\xa0A, Grigoriadis\\xa0A, Tutt\\xa0A, Ashworth\\xa0A,\\xa0et\\xa0al: BRCA1 \\nbasal‑like breast cancers originate from luminal epithelial progenitors \\nand not from basal stem cells. Cell Stem Cell\\xa07: 403‑417, 2010.\\n110.\\tBernardo\\xa0GM, Bebek\\xa0G, Ginther\\xa0CL, Sizemore\\xa0ST, Lozada\\xa0KL, \\nMiedler\\xa0JD, Anderson\\xa0LA, Godwin\\xa0AK, Abdul‑Karim\\xa0FW, \\nSlamon\\xa0DJ and Keri\\xa0RA: FOXA1 represses the molecular pheno\\xad\\ntype of basal breast cancer cells. Oncogene 32: 554‑563, 2013.\\n111.\\tSu\\xa0Y, Subedee\\xa0A, Bloushtain‑Qimron\\xa0N, Savova\\xa0V, Krzystanek\\xa0M, \\nLi\\xa0L, Marusyk\\xa0A, Tabassum\\xa0DP, Zak\\xa0A, Flacker\\xa0MJ,\\xa0et\\xa0al: \\nSomatic cell fusions reveal extensive heterogeneity in basal‑like \\nbreast cancer. Cell Rep\\xa011: 1549‑1563, 2015.\\n112.\\tCao\\xa0R, Wang\\xa0L, Wang\\xa0H, Xia\\xa0L, Erdjument‑Bromage\\xa0H, Tempst\\xa0P, \\nJones\\xa0RS and Zhang\\xa0Y: Role of histone H3 lysine 27 methylation \\nin Polycomb‑group silencing. Science\\xa0298: 1039‑1043, 2002.\\n113.\\tYamagishi\\xa0M and Uchimaru\\xa0K: Targeting EZH2 in Cancer \\nTherapy. Curr Opin Oncol\\xa029: 375‑381, 2017.\\n114.\\tYang\\xa0CC, LaBaff\\xa0A, Wei\\xa0Y, Nie\\xa0L, Xia\\xa0W, Huo\\xa0L, Yamaguchi\\xa0H, \\nHsu\\xa0YH, Hsu\\xa0JL, Liu\\xa0D,\\xa0et\\xa0al: Phosphorylation of EZH2 at T416 \\nby CDK2 contributes to the malignancy of triple negative breast \\ncancers. Am J\\xa0Transl Res\\xa07: 1009‑1020, 2015.\\n115.\\tNie\\xa0L, Wei\\xa0Y, Zhang\\xa0F, Hsu\\xa0YH, Chan\\xa0LC, Xia\\xa0W, Ke\\xa0B, Zhu\\xa0C, \\nDeng\\xa0R, Tang\\xa0J,\\xa0 et\\xa0al: CDK2‑mediated site‑specific phos\\xad\\nphorylation of EZH2 drives and maintains triple‑negative breast \\ncancer. Nat Commun\\xa010: 5114, 2019. \\n116.\\tYang\\xa0X, Phillips\\xa0DL, Ferguson\\xa0AT, Nelson\\xa0WG, Herman\\xa0JG \\nand Davidson\\xa0NE: Synergistic activation of functional estrogen \\nreceptor (ER)‑alpha by DNA methyltransferase and histone \\ndeacetylase inhibition in human ER‑alpha‑negative breast \\ncancer cells. Cancer Res\\xa061: 7025‑7029, 2001.\\n117.\\tSharma\\xa0D, Saxena\\xa0NK, Davidson\\xa0NE and Vertino\\xa0PM: Restoration \\nof tamoxifen sensitivity in estrogen receptor‑negative breast \\ncancer cells: Tamoxifen‑bound reactivated ER recruits distinctive \\ncorepressor complexes. Cancer Res\\xa066: 6370‑6378, 2006.\\n118.\\tConnolly\\xa0RM, Li\\xa0H, Jankowitz\\xa0RC, Zhang\\xa0Z, Rudek\\xa0MA, Jeter\\xa0SC, \\nSlater\\xa0SA, Powers\\xa0P, Wolff\\xa0AC, Fetting\\xa0JH,\\xa0et\\xa0al: Combination \\nepigenetic therapy in advanced breast cancer with 5‑azacitidine \\nand entinostat: A phase II National Cancer Institute/Stand up to \\ncancer study. Clin Cancer Res\\xa023: 2691‑2701, 2017. \\n119.\\tAnderberg\\xa0C, Li\\xa0H, Fredriksson\\xa0L, Andrae\\xa0J, Betsholtz\\xa0C, Li\\xa0X, \\nEriksson\\xa0U and Pietras\\xa0K: Paracrine signaling by platelet‑derived \\ngrowth factor‑CC promotes tumor growth by recruitment of \\ncancer‑associated fibroblasts. Cancer Res\\xa069: 369‑378, 2009. \\n120.\\tRoswall\\xa0P, Bocci\\xa0M, Bartoschek\\xa0M, Li\\xa0H, Kristiansen\\xa0G, Jansson\\xa0S, \\nLehn\\xa0S, Sjölund\\xa0J, Reid\\xa0S, Larsson\\xa0C,\\xa0et\\xa0al: Microenvironmental control \\nof breast cancer subtype elicited through paracrine platelet‑derived \\ngrowth factor‑CC signaling. Nat Med\\xa024: 463‑473, 2018. \\n121.\\tPark\\xa0JJH, Hsu\\xa0G, Siden\\xa0EG, Thorlund\\xa0K and Mills\\xa0EJ: An \\noverview of precision oncology basket and umbrella trials for \\nclinicians. CA Cancer J\\xa0Clin\\xa070: 125‑137, 2020.\\nThis work is licensed under a Creative Commons \\nAttribution-NonCommercial-NoDerivatives 4.0 \\nInternational (CC BY-NC-ND 4.0) License.\\n\""
      ]
     },
     "execution_count": 96,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "document"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "id": "1fd2e744-682d-47f7-9dd8-3d10ded60d1a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2955 senteneces were found\n"
     ]
    }
   ],
   "source": [
    "\n",
    "import re\n",
    "\n",
    "# Splitting the essay on '.', '?', and '!'\n",
    "single_sentences_list = re.split(r'(?<=[.?!])\\s+', document)\n",
    "print (f\"{len(single_sentences_list)} senteneces were found\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "id": "65c108b5-f01e-41db-a6c1-0adf2ceaabd2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'sentence': 'Explor Target Antitumor Ther.', 'index': 0},\n",
       " {'sentence': '2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 232\\n© The Author(s) 2024.',\n",
       "  'index': 1},\n",
       " {'sentence': 'This is an Open Access article licensed under a Creative Commons Attribution 4.0 International \\nLicense (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution \\nand reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the \\noriginal author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.',\n",
       "  'index': 2}]"
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "sentences = [{'sentence': x, 'index' : i} for i, x in enumerate(single_sentences_list)]\n",
    "sentences[:3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "id": "9677d779-8eec-4710-b59a-f30b91ce99a7",
   "metadata": {},
   "outputs": [],
   "source": [
    "def combine_sentences(sentences, buffer_size=1):\n",
    "    # Go through each sentence dict\n",
    "    for i in range(len(sentences)):\n",
    "\n",
    "        # Create a string that will hold the sentences which are joined\n",
    "        combined_sentence = ''\n",
    "\n",
    "        # Add sentences before the current one, based on the buffer size.\n",
    "        for j in range(i - buffer_size, i):\n",
    "            # Check if the index j is not negative (to avoid index out of range like on the first one)\n",
    "            if j >= 0:\n",
    "                # Add the sentence at index j to the combined_sentence string\n",
    "                combined_sentence += sentences[j]['sentence'] + ' '\n",
    "\n",
    "        # Add the current sentence\n",
    "        combined_sentence += sentences[i]['sentence']\n",
    "\n",
    "        # Add sentences after the current one, based on the buffer size\n",
    "        for j in range(i + 1, i + 1 + buffer_size):\n",
    "            # Check if the index j is within the range of the sentences list\n",
    "            if j < len(sentences):\n",
    "                # Add the sentence at index j to the combined_sentence string\n",
    "                combined_sentence += ' ' + sentences[j]['sentence']\n",
    "\n",
    "        # Then add the whole thing to your dict\n",
    "        # Store the combined sentence in the current sentence dict\n",
    "        sentences[i]['combined_sentence'] = combined_sentence\n",
    "\n",
    "    return sentences\n",
    "\n",
    "sentences = combine_sentences(sentences)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "id": "84343603-b4c1-433f-89da-6146967c5ab8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'sentence': 'Explor Target Antitumor Ther.',\n",
       "  'index': 0,\n",
       "  'combined_sentence': 'Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 232\\n© The Author(s) 2024.'},\n",
       " {'sentence': '2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 232\\n© The Author(s) 2024.',\n",
       "  'index': 1,\n",
       "  'combined_sentence': 'Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 232\\n© The Author(s) 2024. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International \\nLicense (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution \\nand reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the \\noriginal author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.'},\n",
       " {'sentence': 'This is an Open Access article licensed under a Creative Commons Attribution 4.0 International \\nLicense (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution \\nand reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the \\noriginal author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.',\n",
       "  'index': 2,\n",
       "  'combined_sentence': '2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\\nPage 232\\n© The Author(s) 2024. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International \\nLicense (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution \\nand reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the \\noriginal author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Exploration of Targeted Anti-tumor Therapy\\nOpen Access\\nReview\\nEarly-stage triple negative breast cancer: the therapeutic role of \\nimmunotherapy and the prognostic value of pathological complete \\nresponse\\nPierluigi De Santis1, Martina Perrone1, Chiara Guarini1, Anna Natalizia Santoro1, Carmelo Laface1, \\nDaniela Carrozzo1, Gaia Rachele Oliva2, Palma Fedele1*\\n1Oncology Unit, Francavilla Fontana Ceglie Messapica Hospital District, 72021 Francavilla Fontana, Italy\\n2Department of Medicine and Translational Surgery, Università Cattolica del Sacro Cuore, 00168 Roma, Italy\\n*Correspondence: Palma Fedele, Oncology Unit, Francavilla Fontana Ceglie Messapica Hospital District, 72021 Francavilla \\nFontana, Italy.'}]"
      ]
     },
     "execution_count": 101,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "sentences[:3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "id": "33fdda8e-8e35-42ab-b253-fb3a25d80d72",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sentence_transformers import SentenceTransformer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "id": "5582282a-8457-4f89-8d1b-d4911b39903e",
   "metadata": {},
   "outputs": [],
   "source": [
    "model = SentenceTransformer('all-MiniLM-L6-v2')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "id": "fdd0d041-85e5-4041-a930-300f54df73f3",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# Get the list of sentences to embed\n",
    "texts_to_embed = [x['combined_sentence'] for x in sentences]\n",
    "\n",
    "# Generate embeddings\n",
    "embeddings = model.encode(texts_to_embed)\n",
    "\n",
    "# Attach embeddings back to each sentence dict\n",
    "for i, sentence in enumerate(sentences):\n",
    "    sentence['combined_sentence_embedding'] = embeddings[i]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "id": "dfb8bd5a-13b3-42cf-ac0b-2871ad55927a",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "def calculate_cosine_distances(sentences):\n",
    "    distances = []\n",
    "    for i in range(len(sentences) - 1):\n",
    "        embedding_current = sentences[i]['combined_sentence_embedding']\n",
    "        embedding_next = sentences[i + 1]['combined_sentence_embedding']\n",
    "        \n",
    "        # Calculate cosine similarity\n",
    "        similarity = cosine_similarity([embedding_current], [embedding_next])[0][0]\n",
    "        \n",
    "        # Convert to cosine distance\n",
    "        distance = 1 - similarity\n",
    "\n",
    "        # Append cosine distance to the list\n",
    "        distances.append(distance)\n",
    "\n",
    "        # Store distance in the dictionary\n",
    "        sentences[i]['distance_to_next'] = distance\n",
    "\n",
    "    # Optionally handle the last sentence\n",
    "    # sentences[-1]['distance_to_next'] = None  # or a default value\n",
    "\n",
    "    return distances, sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "id": "3988944e-32f0-48e4-83ef-6622b506ca79",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "distances, sentences = calculate_cosine_distances(sentences)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "id": "4bf1657f-d22a-40ca-a360-1aa65bf05aba",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[np.float32(0.13247752), np.float32(0.50575906), np.float32(0.04913175)]"
      ]
     },
     "execution_count": 107,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "distances[:3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "id": "180434d8-a484-46bc-bd99-2482b1c6bbf2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "plt.plot(distances);"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "id": "d3bea6ed-1b2e-463f-a55e-de4ed4aea40f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import numpy as np\n",
    "\n",
    "plt.plot(distances);\n",
    "\n",
    "y_upper_bound = .9\n",
    "plt.ylim(0, y_upper_bound)\n",
    "plt.xlim(0, len(distances))\n",
    "\n",
    "# We need to get the distance threshold that we'll consider an outlier\n",
    "# We'll use numpy .percentile() for this\n",
    "breakpoint_percentile_threshold = 95\n",
    "breakpoint_distance_threshold = np.percentile(distances, breakpoint_percentile_threshold) # If you want more chunks, lower the percentile cutoff\n",
    "plt.axhline(y=breakpoint_distance_threshold, color='r', linestyle='-');\n",
    "\n",
    "# Then we'll see how many distances are actually above this one\n",
    "num_distances_above_theshold = len([x for x in distances if x > breakpoint_distance_threshold]) # The amount of distances above your threshold\n",
    "plt.text(x=(len(distances)*.01), y=y_upper_bound/50, s=f\"{num_distances_above_theshold + 1} Chunks\");\n",
    "\n",
    "# Then we'll get the index of the distances that are above the threshold. This will tell us where we should split our text\n",
    "indices_above_thresh = [i for i, x in enumerate(distances) if x > breakpoint_distance_threshold] # The indices of those breakpoints on your list\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "id": "0123a82a-d5be-4325-9128-f443d4c42180",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Initialize the start index\n",
    "start_index = 0\n",
    "\n",
    "# Create a list to hold the grouped sentences\n",
    "chunks = []\n",
    "\n",
    "# Iterate through the breakpoints to slice the sentences\n",
    "for index in indices_above_thresh:\n",
    "    # The end index is the current breakpoint\n",
    "    end_index = index\n",
    "\n",
    "    # Slice the sentence_dicts from the current start index to the end index\n",
    "    group = sentences[start_index:end_index + 1]\n",
    "    combined_text = ' '.join([d['sentence'] for d in group])\n",
    "    chunks.append(combined_text)\n",
    "    \n",
    "    # Update the start index for the next group\n",
    "    start_index = index + 1\n",
    "\n",
    "# The last group, if any sentences remain\n",
    "if start_index < len(sentences):\n",
    "    combined_text = ' '.join([d['sentence'] for d in sentences[start_index:]])\n",
    "    chunks.append(combined_text)\n",
    "\n",
    "# grouped_sentences now contains the chunked sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "id": "ebd35ea8-0645-4ec0-b913-28c26b729580",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Chunk #0\n",
      "Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.org/10.37349/etat.2024.00215\n",
      "Page 232\n",
      "© The Author(s) 2024. This is an Open Access article licensed under a Creative Commons Attribution 4.0 I\n",
      "...\n",
      "zation, Investigation, Writing—original draft, Writing—review & editing, Validation, \n",
      "Supervision. MP, CG, and GRO: Conceptualization, Investigation, Writing—original draft, Writing—review & \n",
      "editing.\n",
      "\n",
      "\n",
      "Chunk #1\n",
      "ANS, PF, and CL: Validation, Writing—review & editing, Supervision. DC: Investigation. All authors \n",
      "read and approved the submitted version. Explor Target Antitumor Ther. 2024;5:232–50 | https://doi.o\n",
      "...\n",
      "Not applicable. Consent to participate\n",
      "Not applicable. Consent to publication\n",
      "Not applicable. Availability of data and materials\n",
      "Not applicable. Funding\n",
      "Not applicable. Copyright\n",
      "© The Author(s) 2024.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for i, chunk in enumerate(chunks[:2]):\n",
    "    buffer = 200\n",
    "    \n",
    "    print (f\"Chunk #{i}\")\n",
    "    print (chunk[:buffer].strip())\n",
    "    print (\"...\")\n",
    "    print (chunk[-buffer:].strip())\n",
    "    print (\"\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b80f5618-7fe2-45e6-8bde-e34d083e69e5",
   "metadata": {},
   "source": [
    "# Level 5: Agentic Chunking"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "88d83b21-afb2-4410-997f-cb88c1761b26",
   "metadata": {},
   "source": [
    "Taking level 4 even further - can we instruct an LLM to do this task like a human would?\n",
    "\n",
    "How does a human even go about chunking in the first place?\n",
    "\n",
    "Well...let me think, how would I go about chunking a document into its discrete parts such that the results were semantically similar?\n",
    "\n",
    "I would get myself a scratch piece of paper or notepad\n",
    "I'd start at the top of the essay and assume the first part will be a chunk (since we don't have any yet)\n",
    "Then I would keep going down the essay and evaluate if a new sentence or piece of the essay should be a part of the first chunk, if not, then create a new one\n",
    "Then keep doing that all the way down the essay until we got to the end."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "384f789f-cc9c-4608-beb0-8f5125c5980d",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\YELISETTY RAHUL\\Music\\aiml\\env\\Lib\\site-packages\\IPython\\core\\interactiveshell.py:3577: LangChainDeprecationWarning: As of langchain-core 0.3.0, LangChain uses pydantic v2 internally. The langchain_core.pydantic_v1 module was a compatibility shim for pydantic v1, and should no longer be used. Please update the code to import from Pydantic directly.\n",
      "\n",
      "For example, replace imports like: `from langchain_core.pydantic_v1 import BaseModel`\n",
      "with: `from pydantic import BaseModel`\n",
      "or the v1 compatibility namespace if you are working in a code base that has not been fully upgraded to pydantic 2 yet. \tfrom pydantic.v1 import BaseModel\n",
      "\n",
      "  exec(code_obj, self.user_global_ns, self.user_ns)\n"
     ]
    }
   ],
   "source": [
    "\n",
    "from langchain.output_parsers.openai_tools import JsonOutputToolsParser\n",
    "from langchain_community.chat_models import ChatOpenAI\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "from langchain_core.runnables import RunnableLambda\n",
    "from langchain.chains import create_extraction_chain\n",
    "from typing import Optional, List\n",
    "from langchain.chains import create_extraction_chain_pydantic\n",
    "from langchain_core.pydantic_v1 import BaseModel\n",
    "from langchain import hub"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "40c33047-ef2e-4de3-91cd-a91bd16f9abc",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
